FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Lu, PY
Kottyan, LC
Pinney, SM
James, JA
Xie, CC
Buckholz, JM
Harley, JB
AF Lu, Pai-Yue
Kottyan, Leah C.
Pinney, Susan M.
James, Judith A.
Xie, Changchun
Buckholz, Jeanette M.
Harley, John B.
TI Identifying a Link Between Uranium Exposure and Systemic Lupus
Erythematosus in a Community Living near a Uranium Plant.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Lu, Pai-Yue; Kottyan, Leah C.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
[Pinney, Susan M.; Xie, Changchun; Buckholz, Jeanette M.] Univ Cincinnati, Cincinnati, OH USA.
[James, Judith A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 1606
BP S686
EP S686
PG 1
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748303327
ER
PT J
AU Mountz, JD
Wang, JH
New, JS
Yang, P
Wu, Q
Luo, B
Li, J
Druey, KM
Hsu, HC
AF Mountz, John D.
Wang, John H.
New, James S.
Yang, PingAr
Wu, Qi
Luo, Bao
Li, Jun
Druey, Kirk M.
Hsu, Hui-Chen
TI Inhibition of Pathogenic Autoantibodies by Accelerating the Exit of
Germinal Center B Cells Via Manipulation of Regulator of G-Protein
Signaling
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Mountz, John D.; New, James S.; Yang, PingAr; Wu, Qi; Luo, Bao; Li, Jun; Hsu, Hui-Chen] Univ Alabama Birmingham, Birmingham, AL USA.
[Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Wang, John H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Druey, Kirk M.] NIAID, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 2575
BP S1090
EP S1090
PG 1
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748306085
ER
PT J
AU Quinzanos, I
Hirsh, JM
Caplan, L
AF Quinzanos, Itziar
Hirsh, Joel M.
Caplan, Liron
TI Correlations of Single Item Health Literacy Screening Questions with
Established Measures of Health Literacy in Subjects with Rheumatoid
Arthritis.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Quinzanos, Itziar; Hirsh, Joel M.] Denver Hlth Med Ctr, Denver, CO USA.
[Caplan, Liron] Denver VAMC, Aurora, CO USA.
[Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 91
BP S41
EP S41
PG 1
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748300092
ER
PT J
AU Rasmussen, A
Ice, JA
Li, H
Grundahl, K
Kelly, JA
Radfar, L
Hefner, KS
Stone, DU
Anaya, JM
Rohrer, M
Houston, GD
Lewis, DM
Chodosh, J
Harley, JB
Hughes, P
Maier-Moore, JS
Montgomery, CG
Rhodus, NL
Farris, AD
Segal, BM
Lessard, CJ
Scofield, RH
Sivils, KM
AF Rasmussen, Astrid
Ice, John A.
Li, He
Grundahl, Kiely
Kelly, Jennifer A.
Radfar, Lida
Hefner, Kimberly S.
Stone, Donald U.
Anaya, Juan-Manuel
Rohrer, Michael
Houston, Glen D.
Lewis, David M.
Chodosh, James
Harley, John B.
Hughes, Pamela
Maier-Moore, Jacen S.
Montgomery, Courtney G.
Rhodus, Nelson L.
Farris, A. Darise
Segal, Barbara M.
Lessard, Christopher J.
Scofield, R. Hal
Sivils, Kathy Moser
TI Effects of Reclassification Using the American College of Rheumatology
Criteria On a Large cohort Sjogren's Syndrome Patients.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Rasmussen, Astrid; Ice, John A.; Li, He; Grundahl, Kiely; Kelly, Jennifer A.; Montgomery, Courtney G.; Lessard, Christopher J.; Sivils, Kathy Moser] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Radfar, Lida; Stone, Donald U.; Houston, Glen D.; Lewis, David M.; Maier-Moore, Jacen S.; Lessard, Christopher J.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Hefner, Kimberly S.] Hefner Eye Care & Opt Ctr, Oklahoma City, OK USA.
[Anaya, Juan-Manuel] Univ Nacl Rosario, Corp Invest Biol, Bogota, Colombia.
[Rohrer, Michael; Hughes, Pamela; Rhodus, Nelson L.] Univ Minnesota, Minneapolis, MN USA.
[Chodosh, James] Harvard Clin & Translat Sci Ctr, Boston, MA USA.
[Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
[Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
[Segal, Barbara M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
[Farris, A. Darise; Scofield, R. Hal] Oklahoma Med Res Foun, Oklahoma City, OK USA.
RI Anaya, Juan-Manuel/J-1960-2016
OI Anaya, Juan-Manuel/0000-0002-6444-1249
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 2203
BP S931
EP S931
PG 1
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748305123
ER
PT J
AU Schmajuk, G
Miao, YH
Yazdany, J
Margaretten, M
Steinman, M
AF Schmajuk, Gabriela
Miao, Yinghui
Yazdany, Jinoos
Margaretten, Mary
Steinman, Michael
TI Liver Toxicity Monitoring and Its Impact On Methotrexate Discontinuation
in a National Cohort of Veterans
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Schmajuk, Gabriela; Margaretten, Mary] UCSF, San Francisco, CA USA.
[Miao, Yinghui; Steinman, Michael] San Francisco VA Med Ctr, San Francisco, CA USA.
[Yazdany, Jinoos] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 1822
BP S775
EP S775
PG 1
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748304099
ER
PT J
AU Sekine, H
Machida, T
Sakamoto, N
Suzuki, E
Zhang, X
Reilly, C
Gilkeson, GS
AF Sekine, Hidemaru
Machida, Takeshi
Sakamoto, Natsumi
Suzuki, Eiji
Zhang, Xian
Reilly, Christopher
Gilkeson, Gary S.
TI IRF-1 Deficient Lupus-Prone MRL/Lpr Mice Show Reduced Glomerulonephritis
but Develop Severe Interstitial Nephritis, Renal Vasculitis and
Pulmonary Granulomas with Propensity for Th2 Polarity.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Sekine, Hidemaru; Machida, Takeshi; Sakamoto, Natsumi] Fukushima Med Univ, Fukushima, Japan.
[Suzuki, Eiji; Zhang, Xian; Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Zhang, Xian] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Reilly, Christopher] Virginia Tech, Blacksburg, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 1442
BP S619
EP S620
PG 2
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748303163
ER
PT J
AU Tjarnlund, A
Bottai, M
Rider, LG
Werth, VP
Pilkington, CA
de Visser, M
Alfredsson, L
Amato, AA
Barohn, RJ
Liang, MH
Singh, JA
Miller, FW
Lundberg, IE
AF Tjarnlund, Anna
Bottai, Matteo
Rider, Lisa G.
Werth, Victoria P.
Pilkington, Clarissa A.
de Visser, Marianne
Alfredsson, Lars
Amato, Anthony A.
Barohn, Richard J.
Liang, Matthew H.
Singh, Jasvinder A.
Miller, Frederick W.
Lundberg, Ingrid E.
CA Int Myositis Classification Criter
TI Progress Report On Development of Classification Criteria for Adult and
Juvenile Idiopathic Inflammatory Myopathies.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Tjarnlund, Anna] Karolinska Univ Hosp, Dept Med, Rheumatol Unit, Solna, Sweden.
[Bottai, Matteo; Alfredsson, Lars] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden.
[Rider, Lisa G.; Miller, Frederick W.] NIEHS, NIH, Bethesda, MD USA.
[Werth, Victoria P.] Univ Penn, Philadelphia, PA 19104 USA.
[Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Pilkington, Clarissa A.] Great Ormond St Hosp Sick Children, London WC1N 3JH, England.
[de Visser, Marianne] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands.
[Amato, Anthony A.; Liang, Matthew H.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Amato, Anthony A.] Harvard Univ, Sch Med, Boston, MA USA.
[Barohn, Richard J.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, MO USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 4
Z9 4
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 753
BP S323
EP S324
PG 2
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748301290
ER
PT J
AU Verma, SM
Okawa, J
Propert, K
Werth, VP
AF Verma, Saroj M.
Okawa, Joyce
Propert, Kathleen
Werth, Victoria P.
TI The Impact of Dyspigmentation and Scarring in Cutaneous Lupus On Quality
of Life.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Okawa, Joyce] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Okawa, Joyce; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 947
BP S411
EP S411
PG 1
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748302023
ER
PT J
AU Yomogida, K
Chou, YK
Chu, CQ
AF Yomogida, Kentaro
Chou, Yuan K.
Chu, Cong-Qiu
TI Superantigen Induces IL-17 Production From Extremely Polarized Th1
Clones
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Yomogida, Kentaro; Chou, Yuan K.; Chu, Cong-Qiu] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Chu, Cong-Qiu] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 2320
BP S980
EP S980
PG 1
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748305240
ER
PT J
AU Chang, MH
Gordon, LA
Fung, HB
AF Chang, Mei H.
Gordon, Lori A.
Fung, Horatio B.
TI Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C
SO CLINICAL THERAPEUTICS
LA English
DT Review
DE boceprevir; direct-acting antiviral agent; nonstructural protein 3
serine protease inhibitor; SCH 503034
ID DIRECT-ACTING ANTIVIRALS; GENOTYPE 1 INFECTION; VIRUS NS3 PROTEASE;
RESISTANCE MUTATIONS; VIRAL-HEPATITIS; POLYMERASE INHIBITORS; NAIVE
PATIENTS; TELAPREVIR; THERAPY; DRUGS
AB Background: Boceprevir is a protease inhibitor indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in combination with peginterferon and ribavirin for treatment-naive patients and those who previously failed to improve with interferon and ribavirin treatment.
Objective: This article provides an overview of the mechanism of action, pharmacologic and pharmacokinetic properties, clinical efficacy, and tolerability of boceprevir.
Methods: Relevant information was identified through a search of PubMed (1990 July 2012), EMBASE (1990 July 2012), International Pharmaceutical Abstracts (1970-July 2012), and Google Scholar using the key words boceprevir, SCH 503034, non-structural protein 3 (NS3) serine protease inhibitor, and direct-acting antiviral agent (DAA). Additional information was obtained from the US Food and Drug Administration's Web site, review of the reference lists of identified articles, and posters and abstracts from scientific meetings.
Results: Clinical efficacy of boceprevir was assessed in 2 Phase III trials, Serine Protease Inhibitor Therapy-2 (SPRINT-2) for treatment-naive patients and Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 (RESPOND-2) for treatment-experienced patients. In SPRINT-2, patients were randomized to receive peginterferon + ribavirin (PR) or peginterferon + ribavirin + boceprevir (PRB); duration of boceprevir therapy varied from 24, 32, to 44 weeks on the basis of HCV RNA results. The primary endpoint was achievement of sustained virologic response (SVR; lower limit of detection, 9.3 IU/mL). The addition of boceprevir was shown to be superior, with overall SVR rates ranging from 63% to 66% compared with 38% with PR (P < 0.001). Results of SVR in SPRINT-2 were also reorganized to monitor SVRs in black and non-black patients. Treatment-experienced patients were assessed in RESPOND-2; however, null responders were excluded. Patients were again randomized to PR or PRB; duration of boceprevir therapy varied from 32 to 44 weeks on the basis of HCV RNA results. SVR was significantly higher in patients receiving boceprevir (59%-66% vs 21% with PR; P < 0.001). This benefit was seen in both previous nonresponders (SVR, 40%-52% vs 7% with PR), as well as previous relapsers (SVR, 69%-75% vs 29% with PR). Importantly, SVR could be attained with a shortened course of therapy in almost one half of all treated patients in SPRINT-2 (44%) and RESPOND-2 (46%).
Conclusions: Boceprevir was well tolerated in clinical trials and a welcomed addition to our HCV armamentarium. (Clin Ther. 2012;34:2021-2038) Published by Elsevier HS Journals, Inc.
C1 [Chang, Mei H.; Gordon, Lori A.; Fung, Horatio B.] James J Peters Vet Affairs Med Ctr, Serv Pharm, Bronx, NY 10468 USA.
RP Chang, MH (reprint author), James J Peters Vet Affairs Med Ctr, Serv Pharm, 130 W Kings Bridge Rd,119, Bronx, NY 10468 USA.
EM Mei.Chang2@va.gov
NR 78
TC 13
Z9 14
U1 1
U2 12
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
J9 CLIN THER
JI Clin. Ther.
PD OCT
PY 2012
VL 34
IS 10
BP 2021
EP 2038
DI 10.1016/j.clinthera.2012.08.009
PG 18
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 029JE
UT WOS:000310490600001
PM 22975763
ER
PT J
AU Jacobson, AF
Friedman, NC
Matsuoka, DT
AF Jacobson, A. F.
Friedman, N. C.
Matsuoka, D. T.
TI Assessing the Relative Contribution of Free and Bound Radioiodine to
Thyroid Visualization in I-123-MIBG Imaging
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Meeting Abstract
CT 25th Annual Congress of the European-Association-of-Nuclear-Medicine
(EANM)
CY OCT 27-31, 2012
CL Milan, ITALY
SP European Assoc Nucl Med (EANM)
C1 [Jacobson, A. F.; Matsuoka, D. T.] GE Healthcare, Princeton, NJ USA.
[Friedman, N. C.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD OCT
PY 2012
VL 39
SU 2
MA P1070
BP S595
EP S596
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 019GW
UT WOS:000309726603397
ER
PT J
AU Gold, JI
Douglas, MK
Thomas, ML
Elliott, JE
Rao, SM
Miaskowski, C
AF Gold, Jeffrey I.
Douglas, Marilyn 'Marty' K.
Thomas, Mary Laudon
Elliott, Janette E.
Rao, Stephen M.
Miaskowski, Christine
TI The Relationship Between Posttraumatic Stress Disorder, Mood States,
Functional Status, and Quality of Life in Oncology Outpatients
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Cancer; posttraumatic stress disorder (PTSD); mood states; functional
status; quality of life
ID KARNOFSKY PERFORMANCE STATUS; CANCER PAIN MANAGEMENT;
NON-HODGKINS-LYMPHOMA; BREAST-CANCER; PTSD SYMPTOMS; SURVIVORS;
VETERANS; THERAPY; ADJUSTMENT; DEPRESSION
AB Context. Oncology patients are at risk for developing posttraumatic stress disorder (PTSD) and other comorbid mood states, which are associated with decreases in functional status and quality of life (QOL). However, few studies have investigated the relationship between PTSD, other mood states, functional status, and QOL in oncology outpatients.
Objectives. This study had four aims: 1) determine the percentages of patients with PTSD and partial PTSD; 2) evaluate for differences in demographic and clinical characteristics among patients with PTSD, partial PTSD, and no PTSD; 3) evaluate for differences in mood states, functional status, and QOL among the three PTSD groups; and 4) evaluate whether demographic and disease characteristics were predictors of PTSD.
Methods. As part of a larger clinical trial that evaluated the effects of a cognitive-behavioral intervention on cancer pain management, 289 adult oncology patients (M-age = 61.3, SD = 11.6) completed self-report measures that assessed PTSD, other mood states, functional status, and QOL.
Results. Forty-five percent of the sample met the diagnostic criteria for PTSD (n = 78) and partial PTSD (n = 53) and were younger than those with no PTSD. Patients with PTSD had a significantly lower Karnofsky Performance Status, shorter time since diagnosis, higher ratings of mood disturbance, lower ratings of functional status, and lower QOL than patients with no PTSD. A lower Karnofsky Performance Status, fewer months since diagnosis, and presence of bone metastases predicted a higher likelihood of being classified as having PTSD.
Conclusion. Early identification and interventions may mediate the onset of psychological distress and improve health outcomes. J Pain Symptom Manage 2012;44:520-531. (C) 2012 U. S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Gold, Jeffrey I.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA.
Childrens Hosp Los Angeles, Pain Management & Palliat Care Program, Dept Anesthesiol Crit Care Med, Los Angeles, CA 90027 USA.
[Douglas, Marilyn 'Marty' K.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Douglas, Marilyn 'Marty' K.; Thomas, Mary Laudon; Elliott, Janette E.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Rao, Stephen M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Miaskowski, Christine] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA USA.
RP Gold, JI (reprint author), Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, 4650 Sunset Blvd,MS 12, Los Angeles, CA 90027 USA.
EM jgold@chla.usc.edu
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service [NRI-97026]
FX This research was supported by the Department of Veterans Affairs,
Veterans Health Administration, Health Services Research and Development
Service (project no. NRI-97026). The views expressed in this article are
those of the authors and do not necessarily represent the views of the
Department of Veterans Affairs. The authors declare no conflicts of
interest.
NR 49
TC 6
Z9 7
U1 3
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD OCT
PY 2012
VL 44
IS 4
BP 520
EP 531
DI 10.1016/j.jpainsymman.2011.10.014
PG 12
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 029QY
UT WOS:000310511800007
PM 22743157
ER
PT J
AU Habib, SL
Yadav, M
Tizani, S
Bhandari, B
Valente, AJ
AF Habib, Samy L.
Yadav, Mukesh
Tizani, Shaza
Bhandari, Basant
Valente, Anthony J.
TI Tuberin Inhibits Production of the Matrix Protein Fibronectin in
Diabetes
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID REPAIR ENZYME OGG1; MAMMALIAN TARGET; CELL-GROWTH; 3-KINASE/AKT PATHWAY;
EPITHELIAL-CELLS; PROXIMAL TUBULE; HIGH GLUCOSE; SCLEROSIS; GENE;
RAPAMYCIN
AB Exposure of proximal tubular epithelial cells to high glucose contributes to the accumulation of tubulointerstitial and matrix proteins in diabetic nephropathy, but how this occurs is not well understood. We investigated the effect of the signaling molecule tuberin, which modulates the mammalian target of rapamycin pathway, on renal hypertrophy and fibronectin expression. We found that the kidney mass was significantly greater in partially tuberin-deficient (TSC2(+/-)) diabetic rats than wild-type diabetic rats. Furthermore, TSC2(+/-) rats exhibited significant increases in the basal levels of phospho-tuberin and fibronectin expression in the kidney cortex. Increased levels of phosphorylated tuberin associated with an increase in fibronectin expression in both wild-type and TSC2(+/-) diabetic rats. Treatment with insulin abrogated the diabetes-induced increase in fibronectin expression. In vitro, high glucose enhanced fibronectin expression in TSC2(+/-) primary proximal tubular epithelial cells; both inhibition of Akt and inhibition of the mammalian target of rapamycin could prevent this effect of glucose. In addition, forced expression of tuberin in tuberin-null cells abolished the expression of fibronectin protein. Taken together, these data suggest that tuberin plays a central role in the development of renal hypertrophy and in modulating the production of the matrix protein fibronectin in diabetes.
C1 [Habib, Samy L.; Yadav, Mukesh; Tizani, Shaza] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Habib, Samy L.; Bhandari, Basant; Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Habib, Samy L.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Habib, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM habib@uthscsa.edu
FU American Heart Association; South Texas Veterans Healthcare System
FX This work was supported in part by grants from the American Heart
Association and a Merit Review Award from the South Texas Veterans
Healthcare System (to S.L.H.).
NR 32
TC 13
Z9 15
U1 1
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD OCT
PY 2012
VL 23
IS 10
BP 1652
EP 1662
DI 10.1681/ASN.2012030285
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA 019JO
UT WOS:000309736000011
PM 22904348
ER
PT J
AU Park, M
Hsu, CY
Li, YM
Mishra, RK
Keane, M
Rosas, SE
Dries, D
Xie, DW
Chen, J
He, J
Anderson, A
Go, AS
Shlipak, MG
AF Park, Meyeon
Hsu, Chi-yuan
Li, Yongmei
Mishra, Rakesh K.
Keane, Martin
Rosas, Sylvia E.
Dries, Daniel
Xie, Dawei
Chen, Jing
He, Jiang
Anderson, Amanda
Go, Alan S.
Shlipak, Michael G.
CA Chronic Renal Insufficiency Cohort
TI Associations between Kidney Function and Subclinical Cardiac
Abnormalities in CKD
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID LEFT-VENTRICULAR HYPERTROPHY; CHRONIC RENAL-INSUFFICIENCY;
CONGESTIVE-HEART-FAILURE; CYSTATIN-C; DIASTOLIC FUNCTION; EJECTION
FRACTION; UREMIC CARDIOMYOPATHY; SYSTOLIC FUNCTION; DISEASE PATIENTS;
RISK-FACTOR
AB Heart failure is a common consequence of CKD, and it portends high risk for mortality. However, among patients without known heart failure, the associations of different stages of estimated GFR (eGFR) with changes in cardiac structure and function are not well described. Here, we performed a cross-sectional analysis to study these associations among 3487 participants of the Chronic Renal Insufficiency Cohort Study. We estimated GFR using cystatin C. The prevalence of left ventricular hypertrophy (LVH) assessed by echocardiography was 32%, 48%, 57%, and 75% for eGFR categories >= 60, 45-59, 30-44, and <30 ml/min per 1.73 m(2.), respectively. In fully adjusted multivariable analyses, subjects with eGFR levels of <30 ml/min per 1.73 m(2) had twofold higher odds of LVH (OR=2.20, 95% CI=1.40-3.40; P<0.001) relative to subjects with eGFR >= 60 ml/min per 1.73 m(2). This reduction in kidney function also significantly associated with abnormal LV geometry but not diastolic or systolic dysfunction. An eGFR of 30-44 ml/min per 1.73 m(2) also significantly associated with LVH and abnormal LV geometry compared with eGFR >= 60 ml/min per 1.73 m(2). In summary, in this large CKD cohort, reduced kidney function associated with abnormal cardiac structure. We did not detect significant associations between kidney function and systolic or diastolic function after adjusting for potential confounding variables.
C1 [Park, Meyeon; Hsu, Chi-yuan] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Li, Yongmei; Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA.
[Mishra, Rakesh K.] San Francisco VA Med Ctr, Div Cardiol, San Francisco, CA USA.
[Keane, Martin; Dries, Daniel] Univ Penn, Sch Med, Div Cardiovasc, Philadelphia, PA 19104 USA.
[Rosas, Sylvia E.] Univ Penn, Sch Med, Div Renal, Philadelphia, PA 19104 USA.
[Xie, Dawei; Anderson, Amanda] Univ Penn, Dept Epidemiol, Philadelphia, PA 19104 USA.
[Chen, Jing] Tulane Sch Med, Sect Nephrol & Hypertens, New Orleans, LA USA.
[He, Jiang] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA.
[Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Go, Alan S.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Go, Alan S.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Go, Alan S.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
RP Park, M (reprint author), Univ Calif San Francisco, Div Nephrol, 521 Parnassus Ave,C443,Box 0532, San Francisco, CA 94143 USA.
EM meyeon.park@ucsf.edu
FU American Heart Association Western Affiliates Fellowship Grant; National
Institutes of Health National Research Service Award [F32 DK093231];
Chronic Renal Insufficiency Cohort General Clinical Research Center;
University of Pennsylvania [UL1 RR-024134]; Johns Hopkins University
[UL1 RR-025005]; University of Maryland [M01 RR-16500]; Case Western
Reserve University [UL1 RR-024989]; University of Michigan [M01
RR-000042, UL1 RR-024986]; University of Illinois at Chicago [UL1
RR-029879]; [K24 DK92291]; [R01 DK066488]
FX M.P. was supported by an American Heart Association Western Affiliates
Fellowship Grant and is currently supported by National Institutes of
Health National Research Service Award Grant F32 DK093231. C.-y.H. was
partially funded by Grant K24 DK92291. This project was supported by
Grant R01 DK066488 (to M.G.S.). In addition, we would like to
acknowledge the Chronic Renal Insufficiency Cohort General Clinical
Research Center and Clinical and Translational Science Awards:
University of Pennsylvania Grant UL1 RR-024134, Johns Hopkins University
Grant UL1 RR-025005, University of Maryland Grant M01 RR-16500, Case
Western Reserve University Grant UL1 RR-024989, University of Michigan
Grants M01 RR-000042 and UL1 RR-024986, and University of Illinois at
Chicago Grant UL1 RR-029879.
NR 38
TC 68
Z9 75
U1 1
U2 2
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD OCT
PY 2012
VL 23
IS 10
BP 1725
EP 1734
DI 10.1681/ASN.2012020145
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 019JO
UT WOS:000309736000018
PM 22935481
ER
PT J
AU Harb, GC
Thompson, R
Ross, RJ
Cook, JM
AF Harb, Gerlinde C.
Thompson, Richard
Ross, Richard J.
Cook, Joan M.
TI Combat-Related PTSD Nightmares and Imagery Rehearsal: Nightmare
Characteristics and Relation to Treatment Outcome
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; SEXUAL
ASSAULT SURVIVORS; SLEEP DISTURBANCE; EXPOSURE THERAPY; DREAM CONTENT;
VETERANS; SYMPTOM; TRAUMA
AB The characteristics of nightmares of 48 male U.S. Vietnam war veterans with combat-related posttraumatic stress disorder (PTSD), as well as revised dream scripts developed in the course of Imagery Rehearsal therapy, were examined in relation to pretreatment symptomatology and treatment outcome. Features, content, and themes of nightmares and rescripted dreams were coded by 2 independent raters. Nightmares were replete with scenes of death and violence and were predominantly replays of actual combat events in which the veteran was under attack and feared for his life. Although addressing or resolving the nightmare theme with rescripting was associated with a reduction in sleep disturbance, references to violence in the rescripted dream were related to poorer treatment outcome in nightmare frequency; B = 5.69 (SE = 1.14). The experience of olfactory sensations in nightmares, a possible index of nightmare intensity, was also related to poorer treatment response; B = 2.95 (SE = 1.06). Imagery rehearsal for individuals with severe, chronic PTSD and fairly replicative nightmares may be most effective when the rescripted dream incorporates a resolution of the nightmare theme and excludes violent details.
C1 [Thompson, Richard] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA.
[Ross, Richard J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Cook, Joan M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Cook, Joan M.] Natl Ctr PTSD, Evaluat Div, West Haven, CT USA.
[Harb, Gerlinde C.; Ross, Richard J.] Philadelphia VA Med Ctr, Behav Hlth Serv Res, Philadelphia, PA USA.
RP Cook, JM (reprint author), Yale Univ, Sch Med, NEPEC 182,950 Campbell Ave, West Haven, CT 06516 USA.
EM Joan.Cook@yale.edu
NR 37
TC 6
Z9 6
U1 4
U2 22
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD OCT
PY 2012
VL 25
IS 5
BP 511
EP 518
DI 10.1002/jts.21748
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 026CV
UT WOS:000310251500004
PM 23047646
ER
PT J
AU Hellmuth, JC
Stappenbeck, CA
Hoerster, KD
Jakupcak, M
AF Hellmuth, Julianne C.
Stappenbeck, Cynthia A.
Hoerster, Katherine D.
Jakupcak, Matthew
TI Modeling PTSD Symptom Clusters, Alcohol Misuse, Anger, and Depression as
They Relate to Aggression and Suicidality in Returning US Veterans
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; AFGHANISTAN WAR VETERANS;
COGNITIVE-BEHAVIORAL THERAPY; VIETNAM COMBAT VETERANS; PRIMARY-CARE;
MILITARY VETERANS; IRAQ; IDEATION; VIOLENCE; RISK
AB Suicidal ideation and aggression are common correlates of posttraumatic stress disorder (PTSD) among U.S. Iraq and Afghanistan war veterans. The existing literature has established a strong link between these factors, but a more nuanced understanding of how PTSD influences them is needed. The current study examined the direct and indirect relationships between PTSD symptom clusters and suicidal ideation in general aggression (without a specified target) regarding depression, alcohol misuse, and trait anger. Participants were 359 (92% male) U.S. Iraq/Afghanistan war veterans. Path analysis results suggested that the PTSD numbing cluster was directly (beta= .28, p< .01) and indirectly (beta= .17, p= .001) related through depression. The PTSD hyperarousal cluster was indirectly related to suicidal ideation through depression (beta= .13, p< .001). The PTSD reexperiencing cluster was directly related to aggression (beta= .17, p< .05), whereas the PTSD numbing and hyperarousal clusters were indirectly related to aggression through trait anger (beta= .05, p< .05; beta= .20, p< .001). These findings indicate that adjunct treatments aimed at stabilizing anger, depression, and alcohol misuse may help clinicians ameliorate the maladaptive patterns often observed in veterans. These results also point to specific manifestations of PTSD and co-occurring conditions that may inform clinicians in their attempts to identify at risk veterans and facilitate preventative interventions.
C1 [Hoerster, Katherine D.; Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA.
RP Hellmuth, JC (reprint author), Dept Psychiat, Div Prevent & Community Res, 389 Whitney Ave, New Haven, CT 06511 USA.
EM Julianne.Hellmuth@yale.edu
FU NIDA NIH HHS [T32 DA019426, T32DA019426]
NR 52
TC 33
Z9 33
U1 2
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD OCT
PY 2012
VL 25
IS 5
BP 527
EP 534
DI 10.1002/jts.21732
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 026CV
UT WOS:000310251500006
PM 23073972
ER
PT J
AU Estevez, AO
Mueller, CL
Morgan, KL
Szewczyk, NJ
Teece, L
Miranda-Vizuete, A
Estevez, M
AF Estevez, Annette O.
Mueller, Catherine L.
Morgan, Kathleen L.
Szewczyk, Nathaniel J.
Teece, Luke
Miranda-Vizuete, Antonio
Estevez, Miguel
TI Selenium induces cholinergic motor neuron degeneration in Caenorhabditis
elegans
SO NEUROTOXICOLOGY
LA English
DT Article
DE Cholinergic; Glutathione; Neurodegeneration; Oxidative stress; Selenium
ID AMYOTROPHIC-LATERAL-SCLEROSIS; VESICULAR ACETYLCHOLINE TRANSPORTER;
EGG-LAYING BEHAVIOR; SYNAPTIC-TRANSMISSION; C-ELEGANS;
NEUROMUSCULAR-JUNCTION; PARKINSONS-DISEASE; SODIUM SELENATE;
NERVOUS-SYSTEM; RAT MODEL
AB Selenium is an essential micronutrient required for cellular antioxidant systems, yet at higher doses it induces oxidative stress. Additionally, in vertebrates environmental exposures to toxic levels of selenium can cause paralysis and death. Here we show that selenium-induced oxidative stress leads to decreased cholinergic signaling and degeneration of cholinergic neurons required for movement and egg-laying in Caenorhabditis elegans. Exposure to high levels of selenium leads to proteolysis of a soluble muscle protein through mechanisms suppressible by two pharmacological agents, levamisole and aldicarb which enhance cholinergic signaling in muscle. In addition, animals with reduction-of-function mutations in genes encoding post-synaptic levamisole-sensitive acetylcholine receptor subunits or the vesicular acetylcholine transporter developed impaired forward movement faster during selenium-exposure than normal animals, again confirming that selenium reduces cholinergic signaling. Finally, the antioxidant reduced glutathione, inhibits selenium-induced reductions in egg-laying through a cellular protective mechanism dependent on the C. elegans glutaredoxin, GLRX-21. These studies provide evidence that the environmental toxicant selenium induces neurodegeneration of cholinergic neurons through depletion of glutathione, a mechanism linked to the neuropathology of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Estevez, Annette O.; Mueller, Catherine L.; Teece, Luke; Estevez, Miguel] Univ Arizona, Dept Neurol, Tucson, AZ 85724 USA.
[Morgan, Kathleen L.] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev 151U, Pittsburgh, PA 15240 USA.
[Szewczyk, Nathaniel J.] Univ Nottingham, MRC, Arthrit Res UK Ctr Musculoskeletal Ageing Res, Sch Grad Entry Med & Hlth, Derby DE22 3DT, England.
[Miranda-Vizuete, Antonio] Univ Seville, Inst Biomed Sevilla, Hosp Univ Virgen Rocio, CSIC, Seville 41013, Spain.
[Teece, Luke] Brandeis Univ, Dept Biol, Waltham, MA 02453 USA.
[Teece, Luke] Brandeis Univ, Dept Math, Waltham, MA 02453 USA.
[Teece, Luke] Brandeis Univ, Dept Psychol, Waltham, MA 02453 USA.
RP Estevez, M (reprint author), Univ Arizona, Dept Neurol, 1501N Campbell Ave, Tucson, AZ 85724 USA.
EM aestevez@email.arizona.edu; clm58@email.arizona.edu;
kathleen@immunetrics.com; Nathaniel.Szewczyk@nottingham.ac.uk;
lteece89@brandeis.edu; amiranda-ibis@us.es; estevezm@email.arizona.edu
RI Miranda-Vizuete, Antonio/D-6927-2012; IBIS, FISIOLOGIA/O-9485-2015
OI Miranda-Vizuete, Antonio/0000-0002-6856-5396; Szewczyk,
Nathaniel/0000-0003-4425-9746
FU Jim Himelic Foundation; Southern Arizona Foundation; Keatings Institute;
National Institute of Environmental Health Sciences [R21-ES012305];
National Institute of Arthritis and Musculoskeletal and Skin Diseases
[R01-AR054342]; Instituto de Salud Carlos III [PI050065, PI080557];
Fondo Social Europeo, FEDER; Junta de Andalucia [CVI-3629, CVI-2697];
NIH National Center for Research Resources (NCRR)
FX We would like to thank LA. Jacobson and D. Miller for providing strains
PJ727 and NC571, respectively. This research was supported by grants
from the Jim Himelic Foundation (AE and ME), Southern Arizona Foundation
(ME), Keatings Institute (ME), National Institutes of Environmental
Health Sciences [R21-ES012305 to AE and ME], Arthritis and
Musculoskeletal and Skin Diseases [R01-AR054342 to NJS], Instituto de
Salud Carlos III [Projects PI050065 and PI080557, co-financed by Fondo
Social Europeo, FEDER to AMV] and Junta de Andalucia [Projects CVI-3629
and CVI-2697 to AMV]. Some nematode strains used in this work were
provided by the Caenorhabditis Genetics Center, which is funded by the
NIH National Center for Research Resources (NCRR).
NR 66
TC 26
Z9 26
U1 0
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0161-813X
J9 NEUROTOXICOLOGY
JI Neurotoxicology
PD OCT
PY 2012
VL 33
IS 5
BP 1021
EP 1032
DI 10.1016/j.neuro.2012.04.019
PG 12
WC Neurosciences; Pharmacology & Pharmacy; Toxicology
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology
GA 028BA
UT WOS:000310396600006
PM 22560997
ER
PT J
AU Alford, MD
McGregor, JC
Singh, H
AF Alford, Mariah D.
McGregor, Jessina C.
Singh, Harleen
TI The effects of universal fibrate discontinuation on management of
dyslipidemia at the Portland Veterans Affairs Medical Center (PVAMC)
SO PHARMACOTHERAPY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP)
CY OCT 21-24, 2012
CL Hollywood, FL
SP Amer Coll Clin Pharm (ACCP)
C1 [Alford, Mariah D.] Portland VA Med Ctr, Portland, OR USA.
[McGregor, Jessina C.; Singh, Harleen] Oregon Hlth & Sci Univ, Coll Pharm, Oregon State Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD OCT
PY 2012
VL 32
IS 10
MA 36
BP E188
EP E188
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 015NH
UT WOS:000309452700037
ER
PT J
AU Patel, K
Alsip, D
Raval, R
Lee, T
AF Patel, Khyati
Alsip, Danielle
Raval, Roshani
Lee, Todd
TI Comparing change in hemoglobin A1C of patients in pharmacist managed
telehealth clinic versus in-person clinic
SO PHARMACOTHERAPY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP)
CY OCT 21-24, 2012
CL Hollywood, FL
SP Amer Coll Clin Pharm (ACCP)
C1 [Patel, Khyati; Alsip, Danielle; Raval, Roshani] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
[Lee, Todd] Univ Illinois, Coll Pharm, Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD OCT
PY 2012
VL 32
IS 10
MA 254
BP E253
EP E253
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 015NH
UT WOS:000309452700254
ER
PT J
AU Moshiri, M
Chapman, T
Fechner, PY
Dubinsky, TJ
Shnorhavorian, M
Osman, S
Bhargava, P
Katz, DS
AF Moshiri, Mariam
Chapman, Teresa
Fechner, Patricia Y.
Dubinsky, Theodore J.
Shnorhavorian, Margarett
Osman, Sherif
Bhargava, Puneet
Katz, Douglas S.
TI Evaluation and Management of Disorders of Sex Development:
Multidisciplinary Approach to a Complex Diagnosis
SO RADIOGRAPHICS
LA English
DT Article
ID CONGENITAL ADRENAL-HYPERPLASIA; AMBIGUOUS GENITALIA; CONSENSUS
STATEMENT; INTERSEX DISORDERS; GENDER DYSPHORIA; DEVELOPMENT DSD;
PERINEOSCROTAL HYPOSPADIAS; INITIAL MANAGEMENT; 46,XY DISORDERS;
DIFFERENTIATION
AB Various disorders of sex development (DSD) result in abnormal development of genitalia, which may be recognized at prenatal ultrasonography, immediately after birth, or later in life. Current methods for diagnosing DSD include a thorough physical examination, laboratory tests to determine hormone levels and identify chromosomal abnormalities, and radiologic imaging of the genitourinary tract and adjacent organs. Because of the complex nature of DSD, the participation of a multidisciplinary team is required to address the patient's medical needs as well as any psychosocial issues that the patient or the family may encounter after the diagnosis. The first step in the management of DSD is sex assignment, which is based on factors such as the genotype; the presence, location, and appearance of reproductive organs; the potential for fertility; and the cultural background and beliefs of the patient's family. The primary goal of sex assignment is to achieve the greatest possible consistency between the patient's assigned sex and his or her gender identity. Once the sex is assigned, the next step in management might be surgery, hormone therapy, or no intervention at all. Patients with ovotesticular DSD and gonadal dysgenesis may require a gonadectomy, followed by reconstructive surgery. Some patients may need hormone replacement therapy during puberty. An understanding of the immediacy of families' need for sex assignment and clinicians' need for reliable diagnostic imaging results will help radiologists participate effectively in the prenatal and postnatal assessment of patients with DSD. (C)RSNA, 2012 . radiographics.rsna.org
C1 [Moshiri, Mariam; Chapman, Teresa; Fechner, Patricia Y.; Dubinsky, Theodore J.; Osman, Sherif; Bhargava, Puneet] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA.
[Chapman, Teresa] Seattle Childrens Hosp, Dept Radiol, Seattle, WA USA.
[Fechner, Patricia Y.] Seattle Childrens Hosp, Dept Endocrinol, Seattle, WA USA.
[Shnorhavorian, Margarett] Seattle Childrens Hosp, Dept Urol, Seattle, WA USA.
[Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA USA.
[Katz, Douglas S.] Winthrop Univ Hosp, Dept Radiol, Mineola, NY 11501 USA.
RP Moshiri, M (reprint author), Univ Washington, Sch Med, Dept Radiol, Box 357115,1959 NE Pacific St, Seattle, WA 98195 USA.
EM moshiri@uw.edu
OI Bhargava, Puneet/0000-0002-3849-9666
NR 45
TC 7
Z9 14
U1 1
U2 15
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD OCT
PY 2012
VL 32
IS 6
SI SI
BP 1599
EP 1618
DI 10.1148/rg.326125507
PG 20
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 025PF
UT WOS:000310202800006
PM 23065160
ER
PT J
AU Strate, LL
Modi, R
Cohen, E
Spiegel, BMR
AF Strate, Lisa L.
Modi, Rusha
Cohen, Erica
Spiegel, Brennan M. R.
TI Diverticular Disease as a Chronic Illness: Evolving Epidemiologic and
Clinical Insights
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
ID IRRITABLE-BOWEL-SYNDROME; SIGMOID DIVERTICULITIS; COLONIC
DIVERTICULOSIS; PRACTICE PARAMETERS; DIGESTIVE DISEASES; SEGMENTAL
COLITIS; DIETARY FIBER; UNITED-STATES; RISK-FACTORS; BURDEN
AB Diverticular disease imposes a significant burden on Western and industrialized societies. The traditional pathogenesis model posits that low dietary fiber predisposes to diverticulosis, and fecalith obstruction prompts acute diverticulitis that is managed with broad-spectrum antibiotics or surgery. However, a growing body of knowledge is shifting the paradigm of diverticular disease from an acute surgical illness to a chronic bowel disorder composed of recurrent abdominal symptoms and considerable psychosocial impact. New research implicates a role for low-grade inflammation, sensory-motor nerve damage, and dysbiosis in a clinical picture that mimics irritable bowel syndrome (IBS) and even inflammatory bowel disease (IBD). Far from being an isolated event, acute diverticulitis may be the catalyst for chronic symptoms including abdominal pain, cramping, bloating, diarrhea, constipation, and "post-diverticulitis IBS." In addition, studies reveal lower health-related quality of life in patients with chronic diverticular disease vs. controls. Health-care providers should maintain a high index of suspicion for the multifaceted presentations of diverticular disease, and remain aware that it might contribute to long-term emotional distress beyond traditional diverticulitis attacks. These developments are prompting a shift in therapeutic approaches from widespread antimicrobials and supportive care to the use of probiotics, mesalamine, and gut-directed antibiotics. This review addresses the emerging literature regarding epidemiology, pathophysiology, and management of chronic, symptomatic diverticular disease, and provides current answers to common clinical questions.
C1 [Strate, Lisa L.] Univ Washington, Harborview Med Ctr, Sch Med, Div Gastroenterol,Dept Med, Seattle, WA 98104 USA.
[Modi, Rusha; Spiegel, Brennan M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA.
[Cohen, Erica; Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Gastroenterol, Los Angeles, CA USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Dept Med, Los Angeles, CA 90095 USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
RP Spiegel, BMR (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ucla.edu
FU Amgen; Ironwood Pharmaceuticals; Shire Pharmaceuticals
FX Brennan Spiegel has served as an advisor for Prometheus and Ironwood
Pharmaceuticals, and has received research support from Amgen, Ironwood
Pharmaceuticals, and Shire Pharmaceuticals. Lisa Strate has served as an
advisor for Shire Pharmaceuticals.
NR 69
TC 84
Z9 85
U1 1
U2 32
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
IS 10
BP 1486
EP 1493
DI 10.1038/ajg.2012.194
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 018XK
UT WOS:000309701000007
PM 22777341
ER
PT J
AU Kanwal, F
Hoang, T
Kramer, J
Chrusciel, T
El-Serag, H
Dominitz, JA
Asch, SM
AF Kanwal, Fasiha
Tuyen Hoang
Kramer, Jennifer
Chrusciel, Timothy
El-Serag, Hashem
Dominitz, Jason A.
Asch, Steven M.
TI The Performance of Process Measures in Hepatitis C
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID VIRUS-INFECTION; ANTIVIRAL THERAPY; LIVER-DISEASE; UNITED-STATES; US
VETERANS; RIBAVIRIN; VACCINATION; PREDICTORS; MANAGEMENT
AB OBJECTIVES: Previous evaluations regarding the extent to which standard chronic hepatitis C virus (HCV) care processes are delivered during routine clinical care are scant and have primarily relied on automated data-the validity of which is unknown.
METHODS: We examined adherence to 24 explicit modified Delphi panel-derived HCV-specific process measures in a cohort of 122,744 patients enrolled in the automated Veterans Administration HCV Clinical Case Registry between 2000 and 2006. We reviewed medical charts of 717 patients to compare the agreement between Registry and charts. We also estimated the effect of justifiable exceptions on measured performance in HCV by determining the proportion of patients who failed a measure but met a valid exception (i.e., patient refusal, outside care, or treatment contraindications).
RESULTS: The percentage of patients who met the individual measures varied. For example, 74% of patients received HCV genotype testing, 23% received antiviral treatment, 28% received liver biopsy, and 16% received hepatitis A vaccination. We found excellent agreement between the Registry and charts in all measures (agreement coefficients >0.75). However, exceptions to indicated care documented in charts were common for genotype testing, liver biopsy, and antiviral treatment. After accounting for these exceptions, the measure rates increased from 75 to 93% for genotype testing, 31 to 50% for liver biopsy, and from 26 to 64% for antiviral treatment. Treatment contraindications were the most common reasons for not meeting indicated care.
CONCLUSIONS: Automated data missed several exceptions to care that are documented only in providers' notes, thus underestimating process of care. These results have implications for future quality assessment initiatives-most of which will likely rely on automated data for process-based quality reporting. After accounting for automated data and medical record reviews, vaccinations and antiviral treatment rates in the Veterans Administration left room for improvement.
C1 [Kanwal, Fasiha; Chrusciel, Timothy] St Louis Univ, John Cochran VA Med Ctr, Dept Gastroenterol & Hepatol, St Louis, MO 63103 USA.
[Kanwal, Fasiha] St Louis Univ, Sch Med, St Louis, MO USA.
[Tuyen Hoang; Asch, Steven M.] Greater Los Angeles VA Healthcare Syst, Dept Med, Los Angeles, CA USA.
[Kanwal, Fasiha; Kramer, Jennifer; El-Serag, Hashem] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston VA HSR&D Ctr Excellence, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA.
[Kramer, Jennifer; El-Serag, Hashem] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Kramer, Jennifer; El-Serag, Hashem] Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA.
[Dominitz, Jason A.] VA Puget Healthcare Syst, NW VA Hepatitis Resource Ctr C, Seattle, WA USA.
[Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
RP Kanwal, F (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston VA HSR&D Ctr Excellence, Hlth Serv Res & Dev Serv, 2002 Holcombe Blvd 152, Houston, TX 77030 USA.
EM fasiha.kanwal@va.gov
OI Dominitz, Jason/0000-0002-8070-7086
FU Health Services Research and Development Service, Office of Research and
Development, Department of Veterans Affairs [IIR-07-111]
FX This material is based on work supported part by Health Services
Research and Development Service, Office of Research and Development,
Department of Veterans Affairs, grant IIR-07-111 to Dr Kanwal. We are
indebted to the Hepatitis C Clinical Case Registry for the data used in
this study. The authors declare no conflict of interest.
NR 26
TC 12
Z9 12
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
IS 10
BP 1512
EP 1521
DI 10.1038/ajg.2012.201
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 018XK
UT WOS:000309701000010
PM 22777337
ER
PT J
AU Laine, L
Jensen, DM
McQuaid, KR
AF Laine, Loren
Jensen, Dennis M.
McQuaid, Kenneth R.
TI Is Injecting Absolute Alcohol a Safe and Effective Therapy for Bleeding
Ulcers? Response
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
C1 [Laine, Loren] Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT 06520 USA.
[Laine, Loren] VA Connecticut Healthcare Syst, New Haven, CT USA.
[Jensen, Dennis M.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[McQuaid, Kenneth R.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
RP Laine, L (reprint author), Yale Univ, Sch Med, Sect Digest Dis, 333 Cedar St,1080 LMP, New Haven, CT 06520 USA.
EM loren.laine@yale.edu
NR 2
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
IS 10
BP 1591
EP 1591
DI 10.1038/ajg.2012.258
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 018XK
UT WOS:000309701000026
ER
PT J
AU Ku, JH
Ali, A
Suhler, EB
Choi, D
Rosenbaum, JT
AF Ku, Jennifer H.
Ali, Amro
Suhler, Eric B.
Choi, Dongseok
Rosenbaum, James T.
TI Characteristics and Visual Outcome of Patients With Retinal Vasculitis
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID UVEITIS
AB Objective: To examine the characteristics and visual outcome in 207 patients with retinal vasculitis.
Methods: Demographic and visual outcome data were collected retrospectively from the ophthalmologic records of 207 cases (321 affected eyes). Descriptive analysis was performed on all cases and visual outcome analysis was performed for the 114 cases with visual acuity recorded at 2 or more visits. The Kaplan-Meier method and Cox regression were used to examine visual outcome and predictors for prognosis.
Results: Patients in our series had a roughly even distribution of sex, were predominantly non-Hispanic white (77.8%), and had bilateral disease (75.7%). The annualized mean visual acuity change for the 203 eyes (114 patients) with some follow-up was 0.01 logMAR unit per year. Although 75 eyes (36.9%) had 20/25 or better visual acuity at baseline, 33.6% of the remaining eyes experienced visual acuity improvement of at least 2 lines on the Snellen chart during follow-up and some continued to improve more than 9 years after the initial evaluation. Cox multivariate analysis demonstrated that patients who were nonwhite, had worse visual acuity at baseline, or who had an ocular infection were more likely to experience improvement by this definition.
Conclusions: We believe that this is the first US case series to investigate visual outcome in patients with this diagnosis. Although many patients in our series worsened despite therapy, a subset experienced substantial improvement.
C1 [Ku, Jennifer H.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA.
[Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
[Ku, Jennifer H.; Suhler, Eric B.; Choi, Dongseok] Oregon Hlth & Sci Univ, Dept Publ Hlth, Portland, OR 97239 USA.
[Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
RP Ku, JH (reprint author), Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, 3181 Sam Jackson Pk Rd SW, Portland, OR 97239 USA.
EM kuj@ohsu.edu
FU Research to Prevent Blindness; National Eye Institute; Stan and Madelle
Rosenfeld Family Trust; William and Mary Bauman Foundation; William C.
Kuzell Foundation
FX This work was supported by Research to Prevent Blindness, a core grant
from the National Eye Institute, and funds from the Stan and Madelle
Rosenfeld Family Trust, the William and Mary Bauman Foundation, and the
William C. Kuzell Foundation.
NR 16
TC 3
Z9 3
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2012
VL 130
IS 10
BP 1261
EP 1266
DI 10.1001/archophthalmol.2012.1596
PG 6
WC Ophthalmology
SC Ophthalmology
GA 016TX
UT WOS:000309543500002
PM 22688383
ER
PT J
AU Butler, NJ
Suhler, EB
AF Butler, Nicholas J.
Suhler, Eric B.
TI Levofloxacin-Associated Panuveitis With Chorioretinal Lesions
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Letter
C1 [Butler, Nicholas J.] Johns Hopkins Univ, Sch Med, Div Ocular Immunol, Wilmer Eye Inst, Baltimore, MD 21287 USA.
[Suhler, Eric B.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
[Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
RP Butler, NJ (reprint author), Johns Hopkins Univ, Sch Med, Div Ocular Immunol, Wilmer Eye Inst, 1800 Orleans St,Woods Bldg,Room 472, Baltimore, MD 21287 USA.
EM nbutle10@jhmi.edu
NR 4
TC 3
Z9 3
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2012
VL 130
IS 10
BP 1342
EP 1344
PG 4
WC Ophthalmology
SC Ophthalmology
GA 016TX
UT WOS:000309543500021
PM 23044958
ER
PT J
AU Ersek, M
Polissar, N
Du Pen, A
Jablonski, A
Herr, K
Neradilek, MB
AF Ersek, Mary
Polissar, Nayak
Du Pen, Anna
Jablonski, Anita
Herr, Keela
Neradilek, Moni B.
TI Addressing methodological challenges in implementing the nursing home
pain management algorithm randomized controlled trial
SO CLINICAL TRIALS
LA English
DT Article
ID OF-LIFE CARE; ADVANCED DEMENTIA; HIP FRACTURE; PHARMACOLOGICAL
MANAGEMENT; IMMPACT RECOMMENDATIONS; COGNITIVE IMPAIRMENT; FAMILY
PERSPECTIVES; ASSESSMENT TOOLS; CLINICAL-TRIALS; PERSISTENT PAIN
AB Background Unrelieved pain among nursing home (NH) residents is a well-documented problem. Attempts have been made to enhance pain management for older adults, including those in NHs. Several evidence-based clinical guidelines have been published to assist providers in assessing and managing acute and chronic pain in older adults. Despite the proliferation and dissemination of these practice guidelines, research has shown that intensive systems-level implementation strategies are necessary to change clinical practice and patient outcomes within a health-care setting. One promising approach is the embedding of guidelines into explicit protocols and algorithms to enhance decision making.
Purpose The goal of the article is to describe several issues that arose in the design and conduct of a study that compared the effectiveness of pain management algorithms coupled with a comprehensive adoption program versus the effectiveness of education alone in improving evidence-based pain assessment and management practices, decreasing pain and depressive symptoms, and enhancing mobility among NH residents.
Methods The study used a cluster-randomized controlled trial (RCT) design in which the individual NH was the unit of randomization. The Roger's Diffusion of Innovations theory provided the framework for the intervention. Outcome measures were surrogate-reported usual pain, self-reported usual and worst pain, and self-reported pain-related interference with activities, depression, and mobility.
Results The final sample consisted of 485 NH residents from 27 NHs. The investigators were able to use a staggered enrollment strategy to recruit and retain facilities. The adaptive randomization procedures were successful in balancing intervention and control sites on key NH characteristics. Several strategies were successfully implemented to enhance the adoption of the algorithm.
Limitations/Lessons The investigators encountered several methodological challenges that were inherent to both the design and implementation of the study. The most problematic issue concerned the measurement of outcomes in persons with moderate to severe cognitive impairment. It was difficult to identify valid, reliable, and sensitive outcome measures that could be applied to all NH residents regardless of the ability to self-report. Another challenge was the inability to incorporate advances in implementation science into the ongoing study
Conclusions Methodological challenges are inevitable in the conduct of an RCT. The need to optimize internal validity by adhering to the study protocol is compromised by the emergent logistical issues that arise during the course of the study. Clinical Trials 2012; 9: 634-644. http://ctj.sagepub.com
C1 [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Ersek, Mary; Neradilek, Moni B.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Polissar, Nayak] Mt Whisper Light Stat, Seattle, WA USA.
[Du Pen, Anna] Univ Washington, Sch Med, Dept Family Med, Seattle, WA 98195 USA.
[Jablonski, Anita] Seattle Univ, Coll Nursing, Seattle, WA 98122 USA.
[Herr, Keela] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA.
RP Ersek, M (reprint author), Univ Penn, Sch Nursing, 418 Curie Blvd,Room 329, Philadelphia, PA 19104 USA.
EM ersekm@nursing.upenn.edu
FU National Institute of Nursing Research [R01NR009100]; Swedish Medical
Center, Seattle, WA; University of Pennsylvania School of Nursing;
Philadelphia VA Medical Center
FX The project described was supported by Award Number R01NR009100 from the
National Institute of Nursing Research.; This material is the result of
work supported with resources and the use of facilities at the Swedish
Medical Center, Seattle, WA; the University of Pennsylvania School of
Nursing; and the Philadelphia VA Medical Center. Mary Ersek conceived
the study, procured funding, served as principal investigator of the
project, and drafted the manuscript. Nayak Polissar and Moni B Neradilek
developed, described, and implemented the randomization procedures,
power calculations, and statistical analyses. Anna Du Pen and Keela Herr
participated in the study design. Anna Du Pen and Anita Jablonski
assisted in coordinating the study and refining the methods. All authors
assisted in drafting the manuscript and approved the final manuscript.
Clinical trials registration: NCT01399567, Swedish Medical Center,
Seattle, WA.
NR 73
TC 7
Z9 7
U1 3
U2 19
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
J9 CLIN TRIALS
JI Clin. Trials
PD OCT
PY 2012
VL 9
IS 5
BP 634
EP 644
DI 10.1177/1740774512454243
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 019HX
UT WOS:000309730200012
PM 22879574
ER
PT J
AU Hanlon, CA
Jones, EM
Li, XB
Hartwell, KJ
Brady, KT
George, MS
AF Hanlon, Colleen A.
Jones, E. Morgan
Li, Xingbao
Hartwell, Karen J.
Brady, Kathleen T.
George, Mark S.
TI Individual variability in the locus of prefrontal craving for nicotine:
Implications for brain stimulation studies and treatments
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Nicotine; Craving; Functional MRI; Transcranial magnetic stimulation
ID TRANSCRANIAL MAGNETIC STIMULATION; SMOKING; CORTEX; ABSTINENCE;
DEPENDENCE; RELAPSE; FMRI; RTMS; CUES; TMS
AB Background: Attenuation of cue-elicited craving with brain stimulation techniques is a growing area of attention in addiction research. This investigation aims to guide these studies by assessing individual variability in the location of peak cortical activity during cue-elicited craving.
Method: Twenty-six nicotine-dependent individuals performed a cue-elicited craving task in a 3T MRI scanner while BOLD signal data was collected. The task included epochs of smoking cues, neutral cues, and rest. The location of peak activity during smoking cues relative to neutral cues ('hot spot') was isolated for each individual. The spatial dispersion of the 26 cue-elicited hot spots (1 per participant) was quantified via hierarchical clustering.
Results: When viewing nicotine cues all 26 participants had at least one cluster of significant prefrontal cortex activity (p < 0.05, cluster corrected). Only 62% had peak activity in the medial prefrontal cortex cluster (including 100% of the men). In 15% of the participants peak activity was located in either the left lateral prefrontal cortex or left insula cluster. Peak activity in the remaining 23% was dispersed throughout the prefrontal cortex.
Conclusion: There is considerable individual variability in the location of the cue-elicited 'hot spot' as measured by BOLD activity. Men appear to have a more uniform location of peak BOLD response to cues than women. Consequently, acquiring individual functional imaging data may be advantageous for either tailoring treatment to the individual or filtering participants before enrollment in treatment. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Hanlon, Colleen A.; Jones, E. Morgan; Li, Xingbao; Hartwell, Karen J.; Brady, Kathleen T.; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Hartwell, Karen J.; Brady, Kathleen T.; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
RP Hanlon, CA (reprint author), Med Univ S Carolina, Dept Psychiat, Ctr Adv Imaging Res, Charleston, SC 29425 USA.
EM hanlon@musc.edu
FU NIDA [K01DA027756]; NICHD [K12HD055885]; MUSC's CTSA from the National
Center for Research Resources [UL1 RR029882]
FX Funding was provided by NIDA K01DA027756 (Hanlon), NICHD K12HD055885
(Hartwell), and MUSC's CTSA UL1 RR029882 from the National Center for
Research Resources. The funding source had no further role in study
design, collection, analysis, interpretation or in the decision to
submit the paper for publication.
NR 25
TC 6
Z9 7
U1 2
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD OCT 1
PY 2012
VL 125
IS 3
BP 239
EP 243
DI 10.1016/j.drugalcdep.2012.02.019
PG 5
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 024NL
UT WOS:000310115800008
PM 22459915
ER
PT J
AU Goodlin, SJ
Wingate, S
Albert, NM
Pressler, SJ
Houser, J
Kwon, J
Chiong, J
Storey, CP
Quill, T
Teerlink, JR
AF Goodlin, Sarah J.
Wingate, Sue
Albert, Nancy M.
Pressler, Susan J.
Houser, Janet
Kwon, Jennifer
Chiong, Jun
Storey, C. Porter
Quill, Timothy
Teerlink, John R.
CA PAIN-HF Investigators
TI Investigating Pain in Heart Failure Patients: The Pain Assessment,
Incidence, and Nature in Heart Failure (PAIN-HF) Study
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Heart failure; pain; symptoms; arthritis shortness of breath; opioids
ID DEPRESSION; PREVALENCE; VALIDATION; EXERCISE; QUALITY; LIFE; CARE
AB Background: Patients with advanced heart failure (HF) have high rates of pain and other symptoms that diminish quality of life. We know little about the characteristics and correlates of pain in patients with advanced HF.
Methods and Results: We identified pain prevalence, location, character, severity, frequency, and correlates in 347 outpatients with advanced HF enrolled from hospices and clinics. We evaluated the correlation of pain with HF-related quality of life, mortality, symptoms and health problems, and current treatments for pain. Pain at any site was reported by 293 patients (84.4%), and 138 (39.5%) reported pain at more than one site. The most common site of pain was the legs below the knees (32.3% of subjects). Pain interfered with activity for 70% of patients. Pain was "severe" or "very severe" for 28.6% of subjects with chest pain, and for 38.9% of those with other sites of pain. The only medication reported to provide pain relief was opioids, prescribed for 34.1% of subjects (P = .001). The strongest predictors of pain were degenerative joint disease (DJD) (odds ratio [OR] 14.95, 95% confidence interval [CI] 3.9-56.0; P < .001), other arthritis (OR 2.8, 95% CI 1.20-6.62; P = .017), shortness of breath (OR 3.27, 95% CI 1.47-7.28; P = .004), and angina pectoris (OR 3.38, 95% CI 1.30-8.81; P = .013).
Conclusions: Pain occurred at multiple sites in patients with advanced HF. Pain correlated with DJD or other arthritis, shortness of breath, and angina. Only opioid analgesics provided relief of pain. Future research should evaluate the etiology of and interventions to manage pain in patients with HF. (J Cardiac Fail 2012;18:776-783)
C1 [Goodlin, Sarah J.] Patient Ctr Educ & Res, Salt Lake City, UT 84103 USA.
[Goodlin, Sarah J.] Portland VA Med Ctr, Portland, OR USA.
[Wingate, Sue] Midatlantic States Kaiser Permanente, Silver Spring, MD USA.
[Albert, Nancy M.] Cleveland Clin, RN Nursing Inst, Cleveland, OH 44106 USA.
[Albert, Nancy M.] Cleveland Clin, Kaufman Ctr Heart Failure, Cleveland, OH 44106 USA.
[Pressler, Susan J.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Houser, Janet] Regis Univ, Denver, CO USA.
[Chiong, Jun] Loma Linda Univ, Med Ctr, Loma Linda, CA 92350 USA.
[Storey, C. Porter] Kaiser Permanente, Denver, CO USA.
[Quill, Timothy] Univ Rochester, Rochester, NY USA.
[Teerlink, John R.] UCSF VAMC San Francisco, San Francisco, CA USA.
RP Goodlin, SJ (reprint author), Patient Ctr Educ & Res, Salt Lake City, UT 84103 USA.
EM sgoodlin@patient-centered.org
FU Mayday Fund, New York, New York
FX The Mayday Fund, New York, New York.
NR 23
TC 20
Z9 21
U1 0
U2 5
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD OCT
PY 2012
VL 18
IS 10
BP 776
EP 783
DI 10.1016/j.cardfail.2012.07.007
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025HS
UT WOS:000310179900005
PM 23040113
ER
PT J
AU Ramasubbu, K
Deswal, A
Chan, WY
Aguilar, D
Bozkurt, B
AF Ramasubbu, Kumudha
Deswal, Anita
Chan, Wenyaw
Aguilar, David
Bozkurt, Biykem
TI Echocardiographic Changes During Treatment of Acute Decompensated Heart
Failure: Insights From the ESCAPE Trial
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Heart failure; echocardiography; acute echocardiographic changes; ESCAPE
trial
ID IDIOPATHIC DILATED CARDIOMYOPATHY; ARTERY CATHETERIZATION EFFECTIVENESS;
VENTRICULAR SYSTOLIC DYSFUNCTION; NATRIURETIC PEPTIDE;
DOPPLER-ECHOCARDIOGRAPHY; DIASTOLIC PRESSURE; EJECTION FRACTION;
SECONDARY; SURVIVAL; EXERCISE
AB Background: Long-term heart failure (HF) treatment has been shown to result in reverse chamber remodeling. However, it is unknown whether sizes of cardiac chambers acutely change during HF therapy and whether these changes are associated with favorable clinical outcomes.
Methods and Results: Using the Evaluation Study of Congestive Heart Failure and Pulsmonary Artery Catheterization Effectiveness (ESCAPE) trial database, echocardiographic parameters at baseline and discharge, changes from baseline to discharge, and their association with the combined endpoint of death or HF rehospitalization (HFH) at 6 months were evaluated in patients admitted with acute decompensated HF (ADHF). Also, the correlation between changes in invasive hemodynamic parameters compared with changes in echocardiographic parameters was analyzed. During the treatment of ADHF, right atrium, right ventricle, and inferior vena cava (IVC) sizes decreased acutely. Mitral regurgitation severity and mitral inflow parameters also improved significantly. However, the majority of acute changes in echocardiographic parameters did not have an impact on clinical outcome, except for the reduction in left ventricular (LV) end-diastolic and end-systolic volumes, which was associated with a reduction in the combined outcome of HFH or death. The change in invasive hemodynamics that best correlated with change in echocardiographic parameters was change in pulmonary capillary wedge pressure with change in IVC diameter and IVC collapsibility.
Conclusions: This is the first study to identify the echocardiographic parameters that change during the treatment of ADHF and the echocardiographic parameters that most reliably correlate with invasive hemodynamic changes. Most changes in echocardiographic parameters were not associated with clinical outcomes, except for the reduction in LV volume, which was associated with a reduction in HFH or death. (J Cardiac Fail 2012;18:792-798)
C1 [Ramasubbu, Kumudha; Deswal, Anita; Bozkurt, Biykem] Michael E DeBakey Vet Adm Med Ctr, Dept Cardiol, Baylor Coll Med, Houston, TX USA.
[Chan, Wenyaw] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Houston, TX USA.
RP Ramasubbu, K (reprint author), Michael E DeBakey VA Med Ctr, Dept Cardiol 3C 300A, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM kumudhar@bcm.tmc.edu
NR 29
TC 10
Z9 10
U1 0
U2 2
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD OCT
PY 2012
VL 18
IS 10
BP 792
EP 798
DI 10.1016/j.cardfail.2012.08.358
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025HS
UT WOS:000310179900007
PM 23040115
ER
PT J
AU Scremin, OU
Norman, KM
Roch, M
Holschneider, DP
Scremin, AME
AF Scremin, Oscar U.
Norman, Keith M.
Roch, Margareth
Holschneider, Daniel P.
Scremin, A. M. Erika
TI Acetylcholinesterase Inhibition Interacts with Training To Reverse
Spatial Learning Deficits after Cortical Impact Injury
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE acetylcholinesterase; cholinergic; neurorehabilitation; traumatic brain
injury; spatial learning
ID TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; RAT MODEL; CHOLINERGIC
MARKERS; CONTUSION INJURY; WORKING MEMORY; MESSENGER-RNA; LONG-TERM;
DONEPEZIL; NEURONS
AB Cholinergic mechanisms are known to play a key role in cognitive functions that are profoundly altered in traumatic brain injury (TBI). The present investigation was designed to test the ability of continuous administration, starting at the time of injury, of physostigmine (PHY), an acetylcholinesterase (AChE) inhibitor that crosses the blood-brain barrier (BBB), to ameliorate the alterations of learning and memory induced by cerebral cortex impact injury in rats under isoflurane anesthesia. Learning and memory were assessed with the Morris water maze implemented during days 7-11 (WM1), and days 21-25 post-TBI (WM2), with four trials per day for 3 days, followed by target reversal and 2 additional days of training. These groups of Sprague-Dawley male rats were used: TBI treated with PHY at 3.2 mu mol/kg/day (TBI-PHY3.2), or 6.4 mu mol/kg/day (TBI-PHY6.4), by subcutaneous osmotic pumps, or TBI and no injury (Sham) treated with saline. AChE activity was measured in brain tissue samples of non-traumatized animals that received PHY at the doses used in the TBI animals. In WM1 tests, PHY3.2 improved learning within sessions, but not between sessions, in the recall of the target position, while PHY6.4 had no significant effects. In WM2 tests, PHY improved within- and between-sessions performance at both dose levels. We found that continuous AChE inhibition interacted with repeated training on the water maze task to completely reverse the deficits seen in learning and memory induced by TBI. The PHY treatment also reduced the amount of brain tissue loss as measured using cresyl violet staining.
C1 [Scremin, Oscar U.; Norman, Keith M.; Roch, Margareth] Vet Affairs Greater Los Angeles Healthcare Syst, Res, Los Angeles, CA 90073 USA.
[Scremin, A. M. Erika] Vet Affairs Greater Los Angeles Healthcare Syst, Phys Med & Rehabil Serv, Los Angeles, CA 90073 USA.
[Scremin, Oscar U.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
[Scremin, A. M. Erika] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Holschneider, Daniel P.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA.
[Holschneider, Daniel P.] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA.
[Holschneider, Daniel P.] Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA.
RP Scremin, OU (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res, 11301 Wilshire Blvd,Bldg 115,Room 319, Los Angeles, CA 90073 USA.
EM oscremin@ucla.edu
FU Department of Veterans Affairs Rehabilitation Research & Development
Merit Review (VA RRD) [B5089R]; VA RR&D Research Career Scientist award
FX This work was supported by Department of Veterans Affairs Rehabilitation
Research & Development Merit Review (VA RR&D) #B5089R, and a VA RR&D
Research Career Scientist award (to O.U.S.).
NR 58
TC 6
Z9 6
U1 1
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD OCT
PY 2012
VL 29
IS 15
BP 2457
EP 2464
DI 10.1089/neu.2012.2465
PG 8
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 022NY
UT WOS:000309967300003
PM 22738336
ER
PT J
AU Steinman, MA
Lee, SJ
Boscardin, WJ
Miao, YH
Fung, KZ
Moore, KL
Schwartz, JB
AF Steinman, Michael A.
Lee, Sei J.
Boscardin, W. John
Miao, Yinghui
Fung, Kathy Z.
Moore, Kelly L.
Schwartz, Janice B.
TI Patterns of Multimorbidity in Elderly Veterans
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE multimorbidity; aged; veterans; age effects
ID MULTIPLE CHRONIC CONDITIONS; QUALITY-OF-CARE; CHRONIC DISEASES;
PREVALENCE; COMORBIDITY; POPULATION; MANAGEMENT; CONSEQUENCES;
PERFORMANCE; COMPLEXITY
AB Objectives To determine patterns of co-occurring diseases in older adults and the extent to which these patterns vary between the young-old and the old-old. Design Observational study. Setting Department of Veterans Affairs. Participants Veterans aged 65 years and older (1.9 million male, mean age 76 +/- 7; 39,000 female, mean age 77 +/- 8) with two or more visits to Department of Veterans Affairs (VA) or Medicare settings in 2007 and 2008. Measurements The presence of 23 common conditions was assessed using hospital discharge diagnoses and outpatient encounter diagnoses from the VA and Medicare. Results The mean number of chronic conditions (out of 23 possible) was 5.5 +/- 2.6 for men and 5.1 +/- 2.6 for women. The prevalence of most conditions increased with advancing age, although diabetes mellitus and hyperlipidemia were 11% to 13% less prevalent in men and women aged 85 and older than in those aged 65 to 74 (P < .001 for each). In men, the most common three-way combination of conditions was hypertension, hyperlipidemia, and coronary heart disease, which together were present in 37% of men. For women, the most common combination was hypertension, hyperlipidemia, and arthritis, which co-occurred in 25% of women. Reflecting their high population prevalence, hypertension and hyperlipidemia were both present in 9 of the 15 most common three-way disease combinations in men and in 11 of the 15 most common combinations in women. The prevalence of many disease combinations varied substantially between young-old and old-old adults. Conclusions Specific combinations of diseases are highly prevalent in older adults and inform the development of guidelines that account for the simultaneous presence of multiple chronic conditions.
C1 [Steinman, Michael A.; Lee, Sei J.; Boscardin, W. John; Miao, Yinghui; Fung, Kathy Z.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Schwartz, Janice B.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Steinman, Michael A.; Lee, Sei J.; Boscardin, W. John; Miao, Yinghui; Fung, Kathy Z.] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA.
[Moore, Kelly L.; Schwartz, Janice B.] Jewish Home San Francisco, San Francisco, CA USA.
RP Steinman, MA (reprint author), 4150 Clement St,SFVAMC Box 181G, San Francisco, CA 94121 USA.
EM Mike.steinman@ucsf.edu
FU National Institute on Aging (NIA) [RC1-AG036377]; University of
California at San Francisco; NIA; American Federation for Aging Research
[1K23-AG030999, K23AG040779]; San Francisco VA Medical Center
FX This work was presented at the national meeting of the American
Geriatrics Society, National Harbor, Maryland, 2011. Any opinions
expressed in this work do not represent the official position of the VA.
This work was supported National Institute on Aging (NIA) Grant
RC1-AG036377, the University of California at San Francisco KL2 Career
Development Program, Paul B. Beeson Career Development Awards from the
NIA and the American Federation for Aging Research (1K23-AG030999 and
K23AG040779), and the Health Services Research and Development Research
Enhancement Award Program at the San Francisco VA Medical Center.
NR 37
TC 46
Z9 46
U1 2
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD OCT
PY 2012
VL 60
IS 10
BP 1872
EP 1880
DI 10.1111/j.1532-5415.2012.04158.x
PG 9
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 019LF
UT WOS:000309740400010
PM 23035702
ER
PT J
AU Morley, JF
Duda, JE
AF Morley, James F.
Duda, John E.
TI Parkinson's disease and the risk of cerebrovascular pathology
SO MOVEMENT DISORDERS
LA English
DT Editorial Material
ID STROKE; LESIONS; HOMOCYSTEINE; PREVALENCE; POSTMORTEM
C1 Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
Univ Penn, Perelman Sch Med, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP Duda, JE (reprint author), Univ Penn, Sch Med, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
EM john.duda@med.va.gov
NR 27
TC 5
Z9 5
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD OCT
PY 2012
VL 27
IS 12
BP 1471
EP 1472
DI 10.1002/mds.25179
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 023VL
UT WOS:000310064800001
PM 23033113
ER
PT J
AU Wise, SK
Schlosser, RJ
AF Wise, Sarah K.
Schlosser, Rodney J.
TI Evidence-Based Practice Sublingual Immunotherapy for Allergic Rhinitis
SO OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Sublingual immunotherapy; Allergic rhinitis; Allergy; Antigen; Allergen;
Safety; Efficacy; Anaphylaxis
ID INHALANT ALLERGY; FATAL REACTIONS; EFFICACY; SAFETY;
RHINOCONJUNCTIVITIS; METAANALYSIS; ANTIBODIES; INJECTIONS; DIAGNOSIS;
TABLETS
AB In this article, the authors review the current evidence regarding the public health and economic impact of allergic rhinitis. Diagnostic methods for allergic disease are discussed as well as certain nuances of allergy skin testing protocols. In addition, the evidence supporting sublingual immunotherapy (SLIT) for allergic rhinitis is reviewed, with subsequent attention to certain subgroups, such as adults and children, seasonal versus perennial allergens, and SLIT efficacy for individual antigens. The authors consider the evidence supporting appropriate SLIT dosing as well as the existing data on SLIT safety.
C1 [Schlosser, Rodney J.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
[Wise, Sarah K.] Emory Univ, Atlanta, GA 30308 USA.
RP Schlosser, RJ (reprint author), Med Univ S Carolina, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA.
EM schlossr@musc.edu
NR 36
TC 2
Z9 2
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0030-6665
J9 OTOLARYNG CLIN N AM
JI Otolaryngol. Clin. N. Am.
PD OCT
PY 2012
VL 45
IS 5
BP 1045
EP +
DI 10.1016/j.otc.2012.06.008
PG 12
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 020DG
UT WOS:000309788300010
PM 22980684
ER
PT J
AU Mylopoulos, M
Lohfeld, L
Norman, GR
Dhaliwal, G
Eva, KW
AF Mylopoulos, Maria
Lohfeld, Lynne
Norman, Geoffrey R.
Dhaliwal, Gurpreet
Eva, Kevin W.
TI Renowned Physicians' Perceptions of Expert Diagnostic Practice
SO ACADEMIC MEDICINE
LA English
DT Article
AB Purpose
To further the development of a substantive theory of expert diagnostic practice, the authors explored the ways in which exceptional physicians, nominated by their peers, conceptualized their own diagnostic expertise specifically and diagnostic excellence generally.
Method
In this grounded theory, interview-based study, physicians at six North American research sites were nominated by their peers as exceptional diagnosticians and exceptional professionals and invited to participate in the study. A saturation sample included 34 participants, 20 exceptional diagnosticians, and 14 exceptional professionals. Using a constant comparative approach, the authors conducted one-on-one interviews with participants, transcribed the audiotapes of those interviews, and analyzed them for emergent themes. They developed a stable thematic structure and applied it to the entire data set.
Results
Four interconnected themes emerged that inform the community's understanding of how physicians conceptualize expert diagnostic practice: (1) possession of extensive knowledge built through purposeful, continuous engagement in clinical practice, (2) possession of the skills to effectively gather patient stories, (3) reflective integration of that knowledge and those patient stories during diagnosis, and (4) continuous learning through clinical practice.
Conclusions
Exploring these results within the context of current discourses in medical education brings to the forefront two key features of physicians' construction of diagnostic excellence: (1) the integrated nature of the medical competencies that underpin the diagnostic process and (2) the optimally adaptive nature of the diagnostic process. These findings can inform the development of practical and effective pedagogical strategies to guide trainees, clinicians, and medical educators who strive for excellence.
C1 [Mylopoulos, Maria] Univ Toronto, Fac Med, Toronto, ON, Canada.
[Mylopoulos, Maria] Hosp Sick Children, Learning Inst, Toronto, ON M5G 1X8, Canada.
[Lohfeld, Lynne; Norman, Geoffrey R.] McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
[Norman, Geoffrey R.] McMaster Univ, Fac Hlth Sci, Programme Educ Res & Dev, Hamilton, ON, Canada.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA.
[Eva, Kevin W.] Univ British Columbia, Fac Med, Ctr Hlth Educ Scholarship, Vancouver, BC, Canada.
[Eva, Kevin W.] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC, Canada.
RP Mylopoulos, M (reprint author), SickKids Learning Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM maria.mylopoulos@utoronto.ca
FU Social Sciences and Humanities Research Council
FX This project was funded by a grant from the Social Sciences and
Humanities Research Council.
NR 13
TC 18
Z9 18
U1 1
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD OCT
PY 2012
VL 87
IS 10
BP 1413
EP 1417
DI 10.1097/ACM.0b013e31826735fc
PG 5
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 016UC
UT WOS:000309544000027
PM 22914510
ER
PT J
AU Lehavot, K
AF Lehavot, Keren
TI Coping Strategies and Health in a National Sample of Sexual Minority
Women
SO AMERICAN JOURNAL OF ORTHOPSYCHIATRY
LA English
DT Article
DE sexual minority women; lesbians; bisexual women; adaptive coping
strategies; maladaptive coping strategies; depression; somatic symptoms;
social support
ID QUALITY-OF-LIFE; PERCEIVED SOCIAL SUPPORT; YOUNG AUSTRALIAN WOMEN;
MENTAL-HEALTH; PSYCHOLOGICAL DISTRESS; PHYSICAL HEALTH; GAY MEN;
SOCIOECONOMIC-STATUS; DEPRESSIVE SYMPTOMS; COLLEGE-STUDENTS
AB Coping strategies have been shown to significantly influence mental and physical health among heterosexual and medically ill populations. These associations have not been thoroughly examined among sexual minority women, who are known to shoulder a high burden of disease. This study assesses the impact of adaptive and maladaptive coping on mental and physical health among 1,381 lesbian and bisexual women and examines the potential mediating role of maladaptive coping in explaining bisexual womens poorer health relative to lesbians. Participants completed a web-based survey that assessed demographic characteristics, social support, adaptive and maladaptive coping strategies, and mental and physical health. Maladaptive coping strategies, especially behavioral disengagement and self-blame, were significantly associated with mental and physical health. Coping was more strongly predictive of mental health than physical health, and maladaptive coping more strongly predictive of health outcomes than demographics, social support, and adaptive coping. Interactions between social support and coping were generally not significant. Additionally, bisexual women reported more adverse mental and physical health outcomes than lesbians, and maladaptive coping significantly mediated these relationships. Providers working with sexual minority women may wish to pay particular attention to maladaptive coping strategies, countering these with adaptive, empowerment-based interventions.
C1 [Lehavot, Keren] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
RP Lehavot, K (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM klehavot@uw.edu
FU Centers for Disease Control Grant for Public Health Research
Dissertation [R36 CD000996]
FX The research on which this article is based was supported by Centers for
Disease Control Grant for Public Health Research Dissertation (R36
CD000996) awarded to Keren Lehavot when she was a graduate student in
the Department of Psychology, University of Washington. The author
thanks Jane Simoni, her graduate school advisor.
NR 85
TC 14
Z9 14
U1 4
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-9432
J9 AM J ORTHOPSYCHIAT
JI Am. J. Orthopsychiatr.
PD OCT
PY 2012
VL 82
IS 4
BP 494
EP 504
DI 10.1111/j.1939-0025.2012.01178.x
PG 11
WC Psychiatry; Social Work
SC Psychiatry; Social Work
GA 017MX
UT WOS:000309595200005
PM 23039347
ER
PT J
AU Wright, S
Armeson, K
Hill, EG
Streck, C
Leddy, L
Cole, D
Esnaola, N
Camp, ER
AF Wright, Sharee
Armeson, Kent
Hill, Elizabeth G.
Streck, Christian
Leddy, Lee
Cole, David
Esnaola, Nestor
Camp, E. Ramsay
TI The role of sentinel lymph node biopsy in select sarcoma patients: a
meta-analysis
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Sarcoma; Sentinel; Lymph node
ID CLEAR-CELL SARCOMA; SOFT-TISSUE SARCOMA; EXTREMITY RHABDOMYOSARCOMA;
PEDIATRIC-PATIENTS; MELANOMA; METASTASIS; EXPERIENCE; MANAGEMENT;
CANCER; ADULTS
AB BACKGROUND: Sentinel lymph node (SLN) biopsy is a staging technique for occult lymph node disease. SLN biopsy has been applied to select patients with sarcoma, although the clinical utility remains uncertain.
METHODS: A PubMed/MEDLINE literature search was performed, and SLN biopsy outcomes were analyzed using a Bayesian meta-analytic approach to obtain point and interval estimates of rates of interest.
RESULTS: Sixteen studies involving SLN biopsy in patients with sarcoma were identified. Of 114 patients reported, 14 patients had positive SLNs (crude estimate, 12%; meta-analysis estimate, 17%). The meta-analysis false-negative rate was 29% (95% credible interval, 5%-59%). Recurrence and death rates in the SLN-positive group were higher than in the SLN-negative group.
CONCLUSIONS: This investigation highlights the current role of SLN biopsy in select patients with sarcoma for tumor staging. Questions regarding the high false-negative rate and management of micrometastatic lymphatic disease in patients with sarcoma still exist. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Camp, E. Ramsay] Med Univ S Carolina, Dept Surg, Div Surg Oncol, Charleston, SC 29425 USA.
Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, Div Surg Oncol, Charleston, SC 29425 USA.
EM campe@musc.edu
NR 31
TC 7
Z9 7
U1 0
U2 1
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
J9 AM J SURG
JI Am. J. Surg.
PD OCT
PY 2012
VL 204
IS 4
BP 428
EP 433
DI 10.1016/j.amjsurg.2011.12.019
PG 6
WC Surgery
SC Surgery
GA 020JT
UT WOS:000309805500004
PM 22578407
ER
PT J
AU Gabayan, GZ
Asch, SM
Sun, BC
AF Gabayan, G. Z.
Asch, S. M.
Sun, B. C.
TI Short-Term Readmission Following Discharge From California Emergency
Departments
SO ANNALS OF EMERGENCY MEDICINE
LA English
DT Meeting Abstract
CT Research Forum of the American-College-of-Emergency-Physicians (ACEP)
CY OCT 08-09, 2012
CL Denver, CO
SP Amer Coll Emergency Phys (ACEP)
C1 [Gabayan, G. Z.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Gabayan, G. Z.] W Los Angeles VA, Los Angeles, CA USA.
Vet Affairs Palo Alto Hlth Ctr, Palo Alto, CA USA.
Oregon Hlth & Sci Univ, Portland, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-0644
J9 ANN EMERG MED
JI Ann. Emerg. Med.
PD OCT
PY 2012
VL 60
IS 4
SU S
BP S73
EP S74
PG 2
WC Emergency Medicine
SC Emergency Medicine
GA 018BX
UT WOS:000309636100203
ER
PT J
AU Gabayan, GZ
Sun, BC
Asch, SM
Timmermans, S
Hoffman, JR
Derose, SF
AF Gabayan, G. Z.
Sun, B. C.
Asch, S. M.
Timmermans, S.
Hoffman, J. R.
Derose, S. F.
TI A Qualitative Analysis of the Factors Associated With Unanticipated
Short-Term Death Following Emergency Department Discharge
SO ANNALS OF EMERGENCY MEDICINE
LA English
DT Meeting Abstract
CT Research Forum of the American-College-of-Emergency-Physicians (ACEP)
CY OCT 08-09, 2012
CL Denver, CO
SP Amer Coll Emergency Phys (ACEP)
C1 [Gabayan, G. Z.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Gabayan, G. Z.] W Los Angeles VA, Los Angeles, CA USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
Univ So Calif, Los Angeles, CA USA.
Kaiser Permanente So Calif, Pasadena, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-0644
J9 ANN EMERG MED
JI Ann. Emerg. Med.
PD OCT
PY 2012
VL 60
IS 4
SU S
BP S74
EP S74
PG 1
WC Emergency Medicine
SC Emergency Medicine
GA 018BX
UT WOS:000309636100204
ER
PT J
AU Lewin-Smith, M
Kalasinsky, V
Shilo, K
Tomashefski, J
Cropp, A
AF Lewin-Smith, Michael
Kalasinsky, Victor
Shilo, Konstantin
Tomashefski, Joseph
Cropp, Alan
TI Detection of Silicone in Lung Tissue
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Letter
C1 [Lewin-Smith, Michael] Joint Pathol Ctr, Silver Spring, MD 20910 USA.
[Kalasinsky, Victor] US Dept Vet Affairs, Vet Hlth Adm, Off Res & Dev, Washington, DC 20420 USA.
[Shilo, Konstantin] Ohio State Univ, Med Ctr, Dept Pathol, Columbus, OH 43210 USA.
[Tomashefski, Joseph] Case Western Reserve Univ, Sch Med, Dept Pathol, MetroHlth Med Ctr, Cleveland, OH 44109 USA.
[Cropp, Alan] Pulm Med Consultants, Youngstown, OH 44512 USA.
RP Lewin-Smith, M (reprint author), Joint Pathol Ctr, Silver Spring, MD 20910 USA.
RI Shilo, Konstantin/E-4084-2011
OI Shilo, K/0000-0002-6702-3130
NR 5
TC 2
Z9 2
U1 0
U2 0
PU COLL AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD OCT
PY 2012
VL 136
IS 10
BP 1179
EP 1180
DI 10.5858/arpa.2012-0143-LE
PG 2
WC Medical Laboratory Technology; Medicine, Research & Experimental;
Pathology
SC Medical Laboratory Technology; Research & Experimental Medicine;
Pathology
GA 020PH
UT WOS:000309824900001
PM 23020716
ER
PT J
AU Mandal, CC
Ghosh-Choudhury, T
Dey, N
Choudhury, GG
Ghosh-Choudhury, N
AF Mandal, Chandi Charan
Ghosh-Choudhury, Triparna
Dey, Nirmalya
Choudhury, Goutam Ghosh
Ghosh-Choudhury, Nandini
TI miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate
breast tumor CSF-1 expression
SO CARCINOGENESIS
LA English
DT Article
ID COLONY-STIMULATING FACTOR; CANCER CELLS; FACTOR-I; GENE-EXPRESSION;
GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMARY-GLAND; PTEN;
MICRORNAS; RECEPTOR
AB Increasing evidence shows the beneficial effects of fish oil on breast cancer growth and invasion in vitro and in animal models. Expression of CSF-1 (colony stimulating factor-1) by breast cancer cells acts as potent activator of malignancy and metastasis. In this report, we used two human breast cancer cell lines, MDA-MB-231 and MCF-7, to show that the bioactive fish oil component DHA (docosahexaenoic acid) inhibits expression of CSF-1 and its secretion from these cancer cells. We found that the tumor suppressor protein PTEN regulates CSF-1 expression through PI 3 kinase/Akt signaling via a transcriptional mechanism. The enhanced abundance of microRNA-21 (miR-21) in breast cancer cells contributes to the growth and metastasis. Interestingly, DHA significantly inhibited expression of miR-21. miR-21 Sponge, which derepresses the miR-21 targets, markedly decreased expression of CSF-1 and its secretion. Furthermore, miR-21-induced upregulation of CSF-1 mRNA and its transcription were prevented by expression of PTEN mRNA lacking 3-untranslated region (UTR) and miR-21 recognition sequence. Strikingly, miR-21 reversed DHA-forced reduction of CSF-1 expression and secretion. Finally, we found that expression of miR-21 as well as CSF-1 was significantly attenuated in breast tumors of mice receiving a diet supplemented with fish oil. Our results reveal a novel mechanism for the therapeutic function of fish oil diet that blocks miR-21, thereby increasing PTEN levels to prevent expression of CSF-1 in breast cancer.
C1 [Mandal, Chandi Charan; Ghosh-Choudhury, Triparna; Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Choudhury, Goutam Ghosh; Ghosh-Choudhury, Nandini] S Texas Vet Hlth Care Syst, VA Res, San Antonio, TX USA.
[Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
[Dey, Nirmalya; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
RP Ghosh-Choudhury, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
EM choudhuryg@uthscsa.edu; choudhury@uthscsa.edu
FU National Institutes of Health [RO1 AR52425, RO1 DK50190]; Cancer Therapy
and Research Center; VA Merit review grants; VA Senior Research Career
Scientist Award; VA Research Service Merit Review grant; Juvenile
Diabetes Research Foundation [1-2008-185]; Cancer Prevention Research
Institute of Texas post-doctoral fellowship
FX National Institutes of Health (RO1 AR52425), Ronald Williams Orthopedic
Award from the Cancer Therapy and Research Center, and VA Merit review
grants to N.G.C. supported this work. Part of the work was supported by
National Institutes of Health (RO1 DK50190) grant (to G.G.C.).; We thank
Dr Anthony Valente, Associate Professor, Department of Medicine,
University of Texas Health Science Center, San Antonio, TX, USA, for
critically reading the manuscript. G. G. C. is a recipient of VA Senior
Research Career Scientist Award and is supported by VA Research Service
Merit Review grant and Juvenile Diabetes Research Foundation 1-2008-185
grant. C. C. M. is a recipient of Cancer Prevention Research Institute
of Texas post-doctoral fellowship.
NR 57
TC 33
Z9 35
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2012
VL 33
IS 10
BP 1897
EP 1908
DI 10.1093/carcin/bgs198
PG 12
WC Oncology
SC Oncology
GA 018XJ
UT WOS:000309700900009
PM 22678116
ER
PT J
AU Golden-Mason, L
Stone, AE
Bambha, KM
Cheng, LL
Rosen, HR
AF Golden-Mason, Lucy
Stone, Amy E. L.
Bambha, Kiran M.
Cheng, Linling
Rosen, Hugo R.
TI Race- and gender-related variation in natural killer p46 expression
associated with differential anti-hepatitis c virus immunity
SO HEPATOLOGY
LA English
DT Article
ID HUMAN NK CELLS; TOLL-LIKE RECEPTORS; DENDRITIC CELLS; CYTOTOXICITY
RECEPTORS; INFLUENZA INFECTION; MEDIATED CYTOLYSIS; SURFACE EXPRESSION;
VIRAL-INFECTIONS; HCV INFECTION; NKP46
AB Major racial and gender differences have been documented in the natural history and treatment responses of chronic hepatitis C virus (HCV) infection; however, distinct mechanisms have remained enigmatic. We hypothesized that racial- and gender-related differences in natural killer (NK) cell populations may explain altered natural history and treatment responses. Our study cohort consisted of 29 African-American (AA; 55% male) and 29 Caucasian-American (CA; 48% male) healthy uninfected control subjects. Multiparameter flow cytometric analysis was used to characterize levels, phenotype with respect to 14 NK receptors, and lymphokine-activated killing (LAK) function. Gene expression was assessed by real-time reverse-transcriptase polymerase chain reaction after 6-hour in vitro stimulation with Toll-like receptor (TLR) ligands. The ability to control HCV infection was assessed in the Huh-7.5/JFH-1 coculture system. NK expression of natural cytotoxicity receptor NKp46 was strongly associated with CA race and female gender and correlated positively with LAK activity (P = 0.0054). NKp46high NKs were more efficient at controlling HCV than their NKp46low counterparts (P < 0.001). Similarly, ligation of NKp46 on isolated NK cells resulted in a significant reduction in the HCV copy number detected in Huh-7.5/JFH-1 coculture (multiplicity of infection: 0.01) at an effector:target ratio of 5:1 (P < 0.005). After TLR stimulation, genes involved in cytotoxicity, but not cytokine genes, were significantly up-regulated in NKp46high NKs. Cytokine stimulation (interleukin [IL]-12 and IL-15) demonstrated that NKp46high NK cells have significantly higher interferon-gamma production than NKp46low cells. TLR stimulation significantly induced degranulation as well as tumor necrosis factor alpha (TNF-a)-related apoptosis-inducing ligand, Fas, and TNF-a protein expression in NKp46high NKs. NKp46 ligand was induced on HCV-infected hepatocytes. Conclusions: NKp46 expression may contribute to differential HCV responses. NKp46 expression correlates with anti-HCV activity in vitro and thus may prove to be a useful therapeutic target. (HEPATOLOGY 2012)
C1 [Golden-Mason, Lucy; Stone, Amy E. L.; Bambha, Kiran M.; Cheng, Linling; Rosen, Hugo R.] Univ Colorado Denver, Div Gastroenterol & Hepatol, Hepatitis Ctr C, Dept Med, Aurora, CO 80045 USA.
[Golden-Mason, Lucy; Stone, Amy E. L.; Rosen, Hugo R.] Univ Colorado, Integrated Program Immunol, Denver, CO 80202 USA.
[Golden-Mason, Lucy; Stone, Amy E. L.; Rosen, Hugo R.] Natl Jewish Hosp, Denver, CO USA.
[Rosen, Hugo R.] Denver VA Med Ctr, Denver, CO USA.
RP Rosen, HR (reprint author), Univ Colorado Denver, Div Gastroenterol & Hepatol, Hepatitis Ctr C, Dept Med, B-158,Acad Off Bldg 1,12631 E 17th Ave,Room 7614,, Aurora, CO 80045 USA.
EM Hugo.Rosen@UCDENVER.edu
FU VA Merit Review Grant; NIH [U19 AI 1066328, K24AI083742]
FX This work was supported by VA Merit Review Grant, and NIH grants U19 AI
1066328 and K24AI083742. The authors thank Dr. Takaji Wakita (National
Institute of Infectious Diseases) for kindly providing the JFH-1
plasmid. The authors thank the Colorado Center for AIDS Research
Laboratory Core for access to FACS sorting.
NR 31
TC 28
Z9 28
U1 0
U2 28
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
IS 4
BP 1214
EP 1222
DI 10.1002/hep.25771
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 018PJ
UT WOS:000309673500005
PM 22505144
ER
PT J
AU Schafer, AL
Sellmeyer, DE
Palermo, L
Hietpas, J
Eastell, R
Shoback, DM
Black, DM
AF Schafer, Anne L.
Sellmeyer, Deborah E.
Palermo, Lisa
Hietpas, Jean
Eastell, Richard
Shoback, Dolores M.
Black, Dennis M.
TI Six Months of Parathyroid Hormone (1-84) Administered Concurrently
Versus Sequentially with Monthly Ibandronate Over Two Years: The PTH and
Ibandronate Combination Study (PICS) Randomized Trial
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; ALENDRONATE;
TERIPARATIDE; THERAPY; TURNOVER; MARKERS; MEN
AB Context: PTH therapy improves bone mineral density (BMD) and decreases fractures in postmenopausal osteoporosis, but cost and the burden of daily injections limit its use.
Objective: We evaluated two novel approaches to the use of 6 months of PTH therapy over 2 yr.
Design, Setting, Participants, and Interventions: We conducted a randomized, double-blinded trial of two combinations of daily PTH(1-84) and monthly ibandronate in 44 postmenopausal women with low bone mass. Participants received either 6 months of concurrent PTH and ibandronate, followed by 18 months of ibandronate (concurrent) or two sequential courses of 3 months of PTH followed by 9 months of ibandronate (sequential) over 2 yr.
Main Outcome Measures: Bone turnover markers were measured. Areal and volumetric BMD were assessed by dual-energy x-ray absorptiometry and quantitative computed tomography, respectively.
Results: Over 2 yr, areal BMD at the spine and hip increased similarly in both groups, with 7.5 and 8.2% increases in spine BMD in the concurrent and sequential arms, respectively (difference -0.6%, 95% confidence interval = -3.4-2.1%). Volumetric BMD also increased similarly between groups. With concurrent therapy, mean N-propeptide of type I collagen increased 75% between baseline and month 1 and then declined. With sequential therapy, the second 3-month PTH course increased N-propeptide of type I collagen markedly (209%), although to a lesser absolute degree than the first.
Conclusions: Six months of PTH(1-84), used over 2 yr with a bisphosphonate in either of our dosing regimens increased BMD substantially. Short PTH courses may provide the benefits of anabolic osteoporosis therapy with reduced burden for patients. (J Clin Endocrinol Metab 97: 3522-3529, 2012)
C1 [Schafer, Anne L.; Shoback, Dolores M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Palermo, Lisa; Hietpas, Jean; Black, Dennis M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Schafer, Anne L.; Shoback, Dolores M.] San Francisco VA Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA.
[Sellmeyer, Deborah E.] Johns Hopkins Univ, Dept Med, Baltimore, MD 21224 USA.
[Eastell, Richard] Univ Sheffield, Dept Human Metab, Sheffield S10 2RX, S Yorkshire, England.
RP Schafer, AL (reprint author), 4150 Clement St,111N, San Francisco, CA 94121 USA.
EM anne.schafer@ucsf.edu
FU Genentech, Inc.; Amgen; Novartis; Lilly; Warner Chilcott; AstraZeneca;
Merck; Roche
FX The PICS trial was supported by an investigator-initiated grant (to D.
M. B.) from Genentech, Inc., a member of the Roche group. The sponsor
was involved in study design and the decision to approve the final
article, but it was not involved in the collection, analysis, or
interpretation of data or in the writing of the article. Study drugs
were supplied by NPS Pharmaceuticals, Inc. [PTH(1-84)], Genentech
(ibandronate), and Bayer (calcium citrate and D3). Reagents
for bone turnover marker assays were provided by Roche Diagnostics. The
authors have full control of all primary data. Additional support was
provided by the Department of Veterans Affairs, through the Research
Enhancement Award Program (to A. L. S. and D. M. S.) and a Career
Development Award (to A. L. S.).; A. L. S. and J.H. have nothing to
disclose. D. E. S. has received research support from Amgen and
Novartis. L. P. has consulted for NPS and Nycomed. R. E. has received
research support from Amgen, Lilly, Warner Chilcott, and AstraZeneca and
has consulted for Amgen, AstraZeneca, GSK, Medtronics, Nastech, Nestle,
Fonterra Brands, Novartis, Ono Pharma, Osteologix, Pfizer, Lilly, Sanofi
Aventis, Tethys, Unilever, Unipath, and Inverness Medical. D. M. S. has
received research support from NPS and has consulted for Lilly. D. M. B.
has received research support from Amgen, Merck, Novartis, and Roche and
has consulted for Nycomed.
NR 20
TC 17
Z9 17
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD OCT 1
PY 2012
VL 97
IS 10
BP 3522
EP 3529
DI 10.1210/jc.2012-1844
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 018MH
UT WOS:000309664400046
PM 22791766
ER
PT J
AU Moin, T
Bergsneider, M
Vespa, P
Heaney, AP
AF Moin, Tannaz
Bergsneider, Marvin
Vespa, Paul
Heaney, Anthony P.
TI Pituitary Function in Patients with Normal Pressure Hydrocephalus before
and after Neurosurgical Correction
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID HYPOPITUITARISM; CHILDREN
AB Introduction: Little is known about pituitary function in patients with normal pressure hydrocephalus (NPH). This study evaluated pituitary function in a large series of patients awaiting neurosurgical correction for NPH. We also sought to ascertain whether surgical correction of hydrocephalus would result in improvement of any noted pituitary dysfunction.
Methods: Patients with NPH referred for neurosurgical evaluation between February 2010 and January 2011 were eligible for recruitment. Pituitary endocrine evaluation including serum prolactin, free thyroid hormone, TSH, IGF-I, FSH, LH, estradiol, testosterone, cortisol, and ACTH was preformed at baseline and 1 and 3 months after surgery.
Results: Of the 63 patients referred for possible NPH, 32 met study criteria, 20 could provide informed consent, and laboratory evaluation was obtainable in 16. The mean age of these patients was 62 +/- 14 yr, and 75% were men. The overall incidence of NPH-associated pituitary dysfunction was 31% (five of 16 patients) at baseline laboratory assessment. Hypogonadism was the most common type of pituitary dysfunction detected.
Conclusion: NPH is associated with pituitary dysfunction, observed in a significant proportion (31%) of patients. As such, we recommend that pituitary screening should be considered in all NPH patients. In two patients with hypogonadism, surgical correction of NPH was associated with improved testosterone levels. Therefore, not all patients with NPH-associated pituitary dysfunction will require hormone replacement therapy because surgical correction may correct pituitary deficiencies in some instances. (J Clin Endocrinol Metab 97: 3545-3549, 2012)
C1 [Moin, Tannaz] Vet Affairs Greater Los Angeles, Dept Med, Los Angeles, CA 90073 USA.
[Moin, Tannaz] Vet Affairs Greater Los Angeles, Hlth Serv Res & Dev Ctr Excellence, Study Healthcare Provider Behav, Los Angeles, CA 90073 USA.
[Moin, Tannaz; Heaney, Anthony P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Bergsneider, Marvin; Vespa, Paul; Heaney, Anthony P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA.
RP Heaney, AP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
EM aheaney@mednet.ucla.edu
FU VA Office of Academic Affiliations, Health Services Research and
Development through the Health Services Fellowship Training Program, VA
Greater Los Angeles [TPM 65-000]
FX T.M. was an endocrinology fellow in the UCLA Department of Medicine,
Division of Endocrinology, Diabetes, and Hypertension during data
collection and initial analysis of this study. She completed manuscript
preparation and submission as a health services research fellow
supported by VA Office of Academic Affiliations, Health Services
Research and Development through the Health Services Fellowship Training
Program (TPM 65-000), VA Greater Los Angeles.
NR 11
TC 4
Z9 4
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD OCT 1
PY 2012
VL 97
IS 10
BP 3545
EP 3549
DI 10.1210/jc.2012-1978
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 018MH
UT WOS:000309664400049
PM 22821894
ER
PT J
AU Blackstock, OJ
Beach, MC
Korthuis, PT
Cohn, JA
Sharp, VL
Moore, RD
Saha, S
AF Blackstock, Oni J.
Beach, Mary Catherine
Korthuis, P. Todd
Cohn, Jonathan A.
Sharp, Victoria L.
Moore, Richard D.
Saha, Somnath
TI HIV Providers' Perceptions of and Attitudes Toward Female Versus Male
Patients
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID INFECTED DRUG-USERS; ANTIRETROVIRAL THERAPY; UNITED-STATES; PHYSICIANS
PERCEPTIONS; GENDER-DIFFERENCES; PROTEASE INHIBITORS; CARE; ADHERENCE;
DISPARITIES; WOMEN
AB As a first step in understanding the role that health care providers may play in observed gender disparities in HIV care in the United States, we sought to examine whether HIV providers' perceptions of and attitudes toward female and male patients differ. We used data from the Enhancing Communication to Improve HIV Outcomes (ECHO) study, a multisite, cross-sectional study focused on the role of the patient-provider relationship in disparities in HIV care conducted from October 2006 to June 2007. Using separate scales, we assessed HIV providers' perceptions about their patients (e.g., intelligence, compliance, responsibility) as well as providers' attitudes toward their patients (e.g., like, respect, frustrate). We used multivariable linear regression with generalized estimating equations to compare provider scores for female and male patients. Our sample comprised 37 HIV providers and 317 patients. Compared with male patients, HIV-infected females were less likely to be highly educated or employed, and more likely to report nonadherence to antiretroviral medications and depressive symptoms. In unadjusted and adjusted analyses, there was a significant difference in providers' perceptions of female and male patients, with providers having more negative perceptions of female patients. However, there was no significant difference in HIV providers' attitudes toward female and male patients in unadjusted or adjusted analyses. Further study is needed to elucidate the role of providers' perceptions and attitudes about female and male patients in observed gender disparities in HIV care.
C1 [Blackstock, Oni J.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, Dept Med, Bronx, NY 10467 USA.
[Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA.
[Korthuis, P. Todd; Saha, Somnath] Oregon Hlth & Sci Univ, Dept Med, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA.
[Cohn, Jonathan A.] Wayne State Univ, Sch Med, Dept Med, Div Infect Dis, Detroit, MI 48201 USA.
[Sharp, Victoria L.] Columbia Univ, St Lukes Roosevelt Hosp Ctr, Ctr Comprehens Care, New York, NY USA.
[Moore, Richard D.] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis & Clin Pharmacol, Baltimore, MD 21205 USA.
[Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA.
RP Blackstock, OJ (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, Dept Med, 3514 Dekalb Ave, Bronx, NY 10467 USA.
EM oblackst@montefiore.org
FU Health Resources Service Administration; Agency for Healthcare Research
and Quality (AHRQ) [290-01-0012]; Department of Veterans Affairs; Agency
for Healthcare Research and Quality [K08 HS013903-05]; Robert Wood
Johnson Generalist Physician Faculty Scholars Awards; National
Institutes of Health, National Institute on Drug Abuse [K23DA019809];
NIH [K24DA00432, R01DA11602, R01AA16893]
FX This research was supported by a contract from the Health Resources
Service Administration and the Agency for Healthcare Research and
Quality (AHRQ 290-01-0012). Dr. Saha is supported by the Department of
Veterans Affairs. Dr. Beach was supported by the Agency for Healthcare
Research and Quality (K08 HS013903-05) and both Drs. Beach and Saha were
supported by Robert Wood Johnson Generalist Physician Faculty Scholars
Awards. Dr. Korthius was supported by the National Institutes of Health,
National Institute on Drug Abuse (K23DA019809). Dr. Moore was supported
by NIH (K24DA00432, R01DA11602, R01AA16893). The views expressed in this
article are those of the authors, and no official endorsement by the
Agency for Healthcare Research and Quality or the US Department of
Health and Human Services is intended or should be inferred.
NR 32
TC 4
Z9 4
U1 2
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD OCT
PY 2012
VL 26
IS 10
BP 582
EP 588
DI 10.1089/apc.2012.0159
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 015XF
UT WOS:000309479000003
PM 22978375
ER
PT J
AU Thames, AD
Moizel, J
Panos, SE
Patel, SM
Byrd, DA
Myers, HF
Wyatt, GE
Hinkin, CH
AF Thames, April D.
Moizel, Jennifer
Panos, Stella E.
Patel, Sapna M.
Byrd, Desiree A.
Myers, Hector F.
Wyatt, Gail E.
Hinkin, Charles H.
TI Differential Predictors of Medication Adherence in HIV: Findings from a
Sample of African American and Caucasian HIV-Positive Drug-Using Adults
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; HEALTH-CARE-SYSTEM; COGNITIVE IMPAIRMENT;
RACIAL-DIFFERENCES; INFECTED ADULTS; SOCIAL SUPPORT; SELF-EFFICACY;
UNITED-STATES; VIRAL LOAD; HIV/AIDS
AB Modest or even occasional nonadherence to combined antiretroviral therapy (cART) can result in adverse clinical outcomes. African Americans demonstrate lower rates of adherence than Caucasians or Latinos. Identifying factors that influence medication adherence among African Americans is a critical step toward reducing HIV/ AIDS disease progression and mortality. In a sample of 181 African American (n = 144) and Caucasian (n = 37) HIV-positive drug-using individuals [age (M = 42.31; SD = 6.6) education (M = 13.41; SD = 2.1)], we examined the influence of baseline drug use, literacy, neurocognition, depression, treatment-specific social support, and patient satisfaction with health care provider on medication adherence averaged over the course of 6 months (study dates 2002-2006). Our findings suggest differential baseline predictors of medication adherence for African Americans and Caucasians, such that patient satisfaction with provider was the strongest predictor of follow-up medication adherence for African Americans whereas for Caucasians depressive symptoms and treatment-specific social support were predictive of medication adherence (after controlling for duration of drug use).
C1 [Thames, April D.; Panos, Stella E.; Patel, Sapna M.; Myers, Hector F.; Wyatt, Gail E.; Hinkin, Charles H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Myers, Hector F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.
[Moizel, Jennifer] Alliant Int Univ Angeles, Dept Clin Psychol, Los Angeles, CA USA.
[Byrd, Desiree A.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA.
[Thames, April D.; Panos, Stella E.; Patel, Sapna M.; Hinkin, Charles H.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
RP Thames, AD (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,C8-746, Los Angeles, CA 90095 USA.
EM athames@mednet.ucla.edu
RI Thames, April/K-1964-2014
OI Thames, April/0000-0001-8414-7189
FU National Institute of Mental Health [RO1 MH58552, T32 19535]
FX This study was funded by the National Institute of Mental Health (RO1
MH58552) awarded to Charles Hinkin, Ph.D. Dr. Thames is supported under
a National Institute of Mental Health training grant (T32 19535; PI: C.
Hinkin).
NR 61
TC 21
Z9 21
U1 5
U2 16
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD OCT
PY 2012
VL 26
IS 10
BP 621
EP 630
DI 10.1089/apc.2012.0157
PG 10
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 015XF
UT WOS:000309479000007
PM 22889235
ER
PT J
AU Bandeali, SJ
Kayani, WT
Lee, VV
Pan, W
Elayda, MAA
Nambi, V
Jneid, HM
Alam, M
Wilson, JM
Birnbaum, Y
Ballantyne, CM
Virani, SS
AF Bandeali, Salman J.
Kayani, Waleed T.
Lee, Vei-Vei
Pan, Wei
Elayda, Mac Arthur A.
Nambi, Vijay
Jneid, Hani M.
Alam, Mahboob
Wilson, James M.
Birnbaum, Yochai
Ballantyne, Christie M.
Virani, Salim S.
TI Outcomes of Preoperative Angiotensin-Converting Enzyme Inhibitor Therapy
in Patients Undergoing Isolated Coronary Artery Bypass Grafting
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ATRIAL-FIBRILLATION; CARDIAC-SURGERY; CARDIOVASCULAR-SURGERY;
MYOCARDIAL-INFARCTION; RISK PATIENTS; EVENTS; SYSTEM; TRIAL;
METAANALYSIS; PREVENTION
AB The association between preoperative use of angiotensin-converting enzyme (ACE) inhibitors and outcomes after coronary artery bypass grafting (CABG) remain controversial. Our aim was to study in-hospital outcomes after isolated CABG in patients on preoperative ACE inhibitors. A retrospective analysis of 8,889 patients who underwent isolated CABG from 2000 through 2011 was conducted. The primary outcome of interest was the incidence of major adverse events (MAEs) defined as a composite of mortality, postoperative renal dysfunction, myocardial infarction, stroke, and atrial fibrillation during index hospitalization. The secondary outcome was the incidence of individual outcomes included in MAEs. Logistic regression analyses were performed. Of 8,889 patients, 3,983 (45%) were on preoperative ACE inhibitors and 4,906 (55%) were not. Overall incidence of MAEs was 38.1% (n = 1,518) in the ACE inhibitor group compared to 33.6% (n = 1,649) in the no-ACE inhibitor group. Preoperative use of ACE inhibitors was independently associated with MAEs (odds ratio 1.13, 95% confidence interval 1.03 to 1.24), most of which was driven by a statistically significant increase in postoperative renal dysfunction (odds ratio 1.18, 95% confidence interval 1.03 to 1.36) and atrial fibrillation (odds ratio 1.15, 95% confidence interval 1.05 to 1.27). In-hospital mortality, postoperative myocardial infarction, and stroke were not significantly associated with preoperative ACE inhibitor use. Analyses performed after excluding patients with low ejection fractions yielded similar results. In conclusion, preoperative ACE inhibitor use was associated with an increased risk of MAEs after CABG, in particular postoperative renal dysfunction and atrial fibrillation. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;110:919-923)
C1 [Bandeali, Salman J.; Nambi, Vijay; Jneid, Hani M.; Birnbaum, Yochai; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA.
[Virani, Salim S.] Hlth Serv Res & Dev Ctr Excellence, Hlth Policy & Qual Program, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Lee, Vei-Vei; Elayda, Mac Arthur A.] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Epidemiol & Biostat, Houston, TX USA.
[Wilson, James M.] St Lukes Episcopal Hosp, Texas Heart Inst, Cardiol Sect, Houston, TX USA.
[Pan, Wei] Texas Heart Inst, Dept Cardiovasc Anesthesiol, Houston, TX 77025 USA.
[Nambi, Vijay; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA.
[Nambi, Vijay; Ballantyne, Christie M.; Virani, Salim S.] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX USA.
[Jneid, Hani M.; Virani, Salim S.] Michael E DeBakey VA Med Ctr, Cardiol Sect, Dept Med, Houston, TX USA.
[Alam, Mahboob] Memphis Vet Affairs Med Ctr, Cardiol Sect, Dept Med, Memphis, TN USA.
RP Bandeali, SJ (reprint author), Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA.
EM bandeali@bcm.edu
OI Virani, Salim/0000-0001-9541-6954
FU Department of Veterans Affairs Health Services Research and Development
Service Career Development Award
FX Dr. Virani is supported by a Department of Veterans Affairs Health
Services Research and Development Service Career Development Award.
NR 28
TC 17
Z9 17
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD OCT 1
PY 2012
VL 110
IS 7
BP 919
EP 923
DI 10.1016/j.amjcard.2012.05.021
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 015ZO
UT WOS:000309487100001
PM 22727178
ER
PT J
AU Tran, TT
Beyda, ND
Biehle, LR
Cottreau, JE
Echevarria, K
Musick, WL
Perez, KK
Schilling, AN
AF Tran, Truc T.
Beyda, Nicholas D.
Biehle, Lauren R.
Cottreau, Jessica E.
Echevarria, Kelly
Musick, William L.
Perez, Katherine K.
Schilling, Amy N.
CA Houston Infect Dis Network
TI Significant publications on infectious diseases pharmacotherapy in 2011
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; CLOSTRIDIUM-DIFFICILE INFECTION;
HEPATITIS-C VIRUS; CLINICAL-PRACTICE GUIDELINES; MINIMUM INHIBITORY
CONCENTRATION; BLOOD-STREAM INFECTIONS; GENOTYPE 1 INFECTION; ACUTE
OTITIS-MEDIA; DOUBLE-BLIND; NAIVE ADULTS
AB Purpose. Important articles on topics pertinent to infectious diseases (ID) pharmacotherapy published in prominent peer-reviewed journals in 2011 are summarized.
Summary. Pharmacists, physicians, and researchers from the Houston Infectious Diseases Network were asked to nominate articles published in 2011 that they perceived as having a significant impact on the field of ID pharmacotherapy. The resulting list, comprising 10 articles related to human immunodeficiency virus (HIV) disease or acquired immune deficiency syndrome (AIDS) and 38 articles on a broad range of other ID-related topics, was sent to members of the Society of Infectious Diseases Pharmacists (SIDP) for evaluation via an Internet survey. The survey participants were asked to select 10 articles from the list of general ID articles and 1 article from the HIV- or AIDS-related articles that they viewed as having the most impact on the field. Of the 328 SIDP members surveyed, 120 (37%) ranked the non-HIV-related papers and 55 (17%) ranked the HIV-related papers. The 12 highest-ranked items-including 3 guidelines-are summarized here.
Conclusion. Due to the increasing number of articles published each year, it is difficult to maintain a current knowledge of significant publications in the field of ID pharmacotherapy. This review of the key articles in 2011 may be helpful to the nonspecialist clinician by lessening this burden. Am J Health-Syst Pharm. 2012; 69:1671-81
C1 [Musick, William L.; Perez, Katherine K.] Methodist Hosp, Dept Pharm, Houston, TX 77030 USA.
[Tran, Truc T.; Beyda, Nicholas D.; Biehle, Lauren R.; Cottreau, Jessica E.] Univ Houston, Coll Pharm, Dept Clin Sci & Adm, Houston, TX 77030 USA.
[Biehle, Lauren R.] Cardinal Hlth, Houston, TX USA.
[Echevarria, Kelly] S Texas Vet Hlth Care Syst, Dept Pharm, San Antonio, TX USA.
[Schilling, Amy N.] Univ Texas Galveston, Med Branch, Galveston, TX 77550 USA.
RP Musick, WL (reprint author), Methodist Hosp, Dept Pharm, 6565 Fannin St,MB1-09, Houston, TX 77030 USA.
EM wmusick@tmhs.org
NR 78
TC 2
Z9 2
U1 0
U2 2
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD OCT 1
PY 2012
VL 69
IS 19
BP 1671
EP 1681
DI 10.2146/ajhp120151
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 015ZF
UT WOS:000309486200015
PM 22997121
ER
PT J
AU Ravenell, RL
Kamen, DL
Spence, JD
Hollis, BW
Fleury, TJ
Janech, MG
Almeida, JS
Shaftman, SR
Oates, JC
AF Ravenell, Roneka L.
Kamen, Diane L.
Spence, J. David
Hollis, Bruce W.
Fleury, Thomas J.
Janech, Michael G.
Almeida, Jonas S.
Shaftman, Stephanie R.
Oates, Jim C.
TI Premature Atherosclerosis Is Associated With Hypovitaminosis D and
Angiotensin-Converting Enzyme Inhibitor Non-use in Lupus Patients
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Systemic lupus erythematosus; Atherosclerosis; Vitamin D deficiency;
Angiotensin-converting enzyme inhibitors; Hypercholesterolemia
ID CORONARY-ARTERY-DISEASE; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION;
CAROTID PLAQUE; RISK-FACTORS; VITAMIN-D; ERYTHEMATOSUS;
25-HYDROXYVITAMIN-D; PREVALENCE; ULTRASOUND
AB The ultimate goal is to identify and target modifiable risk factors that will reduce major cardiovascular events in African American lupus patients. As a first step toward achieving this goal, this study was designed to explore risk factor models of preclinical atherosclerosis in a predominantly African American group of patients with systemic lupus erythematosus (SLE) using variables historically associated with endothelial function in nonlupus populations. Fifty-one subjects with SLE but without a history of clinical cardiovascular events were enrolled. At entry, a Framingham risk factor history and medication list were recorded. Sera and plasma samples were analyzed for lipids, lupus activity markers and total 25-hydroxyvitamin D (25 (OH)D levels. Carotid ultrasound measurements were performed to determine total plaque area (TPA) in both carotids. Cases had TPA values above age-matched controls from a vascular prevention clinic population. Logistic regression and machine learning analyses were performed to create predictive models. 25(OH) D levels were significantly lower, and SLE disease duration was significantly higher in cases. 25(OH) D levels inversely correlated with age-adjusted TPA. Angiotensin-converting enzyme (ACE) inhibitor nonuse associated with case status. Logistic regression models containing ACE inhibitor use, 25(OH) D levels and low-density lipoprotein levels had a diagnostic accuracy of 84% for predicting accelerated atherosclerosis. Similar results were obtained with machine learning models, but hydroxychloroquine use associated with controls in these models. This is the first study to demonstrate an association between atherosclerotic burden and 25(OH) D insufficiency or ACE inhibitor nonuse in lupus patients. These findings provide strong rationale for the study of ACE inhibitors and vitamin D replenishment as preventive therapies in this high-risk population.
C1 [Ravenell, Roneka L.; Kamen, Diane L.; Fleury, Thomas J.; Oates, Jim C.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA.
[Spence, J. David] Univ Western Ontario, Robarts Res Inst, Stroke Prevent & Atherosclerosis Res Ctr, London, ON, Canada.
[Hollis, Bruce W.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Janech, Michael G.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Almeida, Jonas S.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
[Shaftman, Stephanie R.] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Oates, Jim C.] Ralph H Johnson VA Med Ctr, Med Serv, Charleston, SC USA.
RP Oates, JC (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol, Clin Sci Bldg,Suite 912,MSC 637, Charleston, SC 29425 USA.
EM oatesjc@musc.edu
RI Spence, J. David/K-6396-2013
OI Spence, J. David/0000-0001-7478-1098; Janech,
Michael/0000-0002-3202-4811
FU NIH/NCRR MUSC-SCTR [UL1 RR029882]; NIH/NIAMS [K23 AR052364]; MUSC
General and Clinical Research Center [M01RR001070]; VA Research
Enhancement Award Program; Lupus Foundation
FX This study was supported by NIH/NCRR MUSC-SCTR grant number UL1
RR029882, NIH/NIAMS grant number K23 AR052364 and the MUSC General and
Clinical Research Center (M01RR001070). This study was also supported by
an award from the VA Research Enhancement Award Program and a grant from
the Lupus Foundation.
NR 31
TC 25
Z9 25
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD OCT
PY 2012
VL 344
IS 4
BP 268
EP 273
DI 10.1097/MAJ.0b013e31823fa7d9
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 016UL
UT WOS:000309544900004
PM 22222338
ER
PT J
AU Jun, G
Vardarajan, BN
Buros, J
Yu, CE
Hawk, MV
Dombroski, BA
Crane, PK
Larson, EB
Mayeux, R
Haines, JL
Lunetta, KL
Pericak-Vance, MA
Schellenberg, GD
Farrer, LA
AF Jun, Gyungah
Vardarajan, Badri N.
Buros, Jacqueline
Yu, Chang-En
Hawk, Michele V.
Dombroski, Beth A.
Crane, Paul K.
Larson, Eric B.
Mayeux, Richard
Haines, Jonathan L.
Lunetta, Kathryn L.
Pericak-Vance, Margaret A.
Schellenberg, Gerard D.
Farrer, Lindsay A.
CA Alzheimers Dis Genetics Consortium
TI Comprehensive Search for Alzheimer Disease Susceptibility Loci in the
APOE Region
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; GENOME-WIDE ASSOCIATION; HUMAN
APOLIPOPROTEIN-E; GENETIC ASSOCIATION; COMMON VARIANTS; TOMM40; ALLELE;
RISK; AGE; METAANALYSIS
AB Objective: To evaluate the association of risk and age at onset (AAO) of Alzheimer disease (AD) with single-nucleotide polymorphisms (SNPs) in the chromosome 19 region including apolipoprotein E (APOE) and a repeat-length polymorphism in TOMM40 (poly-T, rs10524523).
Design: Conditional logistic regression models and survival analysis.
Setting: Fifteen genome-wide association study data sets assembled by the Alzheimer's Disease Genetics Consortium.
Participants: Eleven thousand eight hundred forty AD cases and 10 931 cognitively normal elderly controls.
Main Outcome Measures: Association of AD risk and AAO with genotyped and imputed SNPs located in an 800-Mb region including APOE in the entire Alzheimer's Disease Genetics Consortium data set and with the TOMM40 poly-T marker genotyped in a subset of 1256 cases and 1605 controls.
Results: In models adjusting for APOE epsilon 4, no SNPs in the entire region were significantly associated with AAO at P < .001. Rs10524523 was not significantly associated with AD or AAO in models adjusting for APOE genotype or within the subset of epsilon 3/epsilon 3 subjects.
Conclusions: APOE alleles epsilon 2, epsilon 3, and epsilon 4 account for essentially all the inherited risk of AD associated with this region. Other variants including a poly-T track in TOMM40 are not independent risk or AAO loci.
C1 [Jun, Gyungah; Vardarajan, Badri N.; Buros, Jacqueline; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA.
[Jun, Gyungah; Lunetta, Kathryn L.; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA.
[Jun, Gyungah; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02118 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Jun, Gyungah; Vardarajan, Badri N.; Buros, Jacqueline; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Med Biomed Genet, Boston, MA USA.
[Jun, Gyungah; Lunetta, Kathryn L.; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Jun, Gyungah; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA USA.
[Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA USA.
[Yu, Chang-En; Crane, Paul K.; Larson, Eric B.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Yu, Chang-En] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Larson, Eric B.] Grp Hlth, Grp Hlth Res Inst, Seattle, WA USA.
[Hawk, Michele V.; Dombroski, Beth A.; Schellenberg, Gerard D.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Mayeux, Richard] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA.
[Mayeux, Richard] Columbia Univ, Dept Neurol, Taub Inst Alzheimers Dis & Aging Brain, New York, NY USA.
[Haines, Jonathan L.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
[Haines, Jonathan L.] Vanderbilt Univ, Vanderbilt Ctr Human Genet Res, Nashville, TN USA.
[Pericak-Vance, Margaret A.] Univ Miami, John P Hussman Inst Human Genom, Miami, FL USA.
[Pericak-Vance, Margaret A.] Univ Miami, Dr John T Macdonald Fdn, Dept Human Genet, Miami, FL USA.
RP Farrer, LA (reprint author), 72 E Concord St, Boston, MA 02118 USA.
EM farrer@bu.edu
RI ; Haines, Jonathan/C-3374-2012; Myers, Amanda/B-1796-2010; Kowall,
Neil/G-6364-2012; Saykin, Andrew/A-1318-2007; Crane, Paul/C-8623-2014;
Tsuang, Debby/L-7234-2016
OI Farrer, Lindsay/0000-0001-5533-4225; Myers, Amanda/0000-0002-3100-9396;
Kowall, Neil/0000-0002-6624-0213; Saykin, Andrew/0000-0002-1376-8532;
Tsuang, Debby/0000-0002-4716-1894; Valladares, Otto/0000-0001-8055-2187;
Reisberg, Barry/0000-0002-9104-7423; Buros,
Jacqueline/0000-0001-9588-4889; Crane, Paul/0000-0003-4278-7465; Ferris,
Steven/0000-0001-8641-6223
FU GlaxoSmithKline; Kronos Science; Northern California Institute for
Research and Education; Abbott; AstraZeneca AB; Bayer Schering Pharma
AG; Bristol-Myers Squibb; Eisai Global Clinical Development; Elan
Corporation; Genentech; GE Healthcare; Innogenetics; Johnson Johnson;
Eli Lilly and Co; Medpace Inc; Merck and Co Inc; Novartis AG; Pfizer
Inc; F. Hoffman-La Roche; Schering-Plough; Synarc Inc.; National
Institutes of Health NIA; National Institutes of Health NIA through ADGC
[U01 AG032984, RC2 AG036528]; National Institutes of Health NIA through
National Alzheimer's Coordinating Center [U01 AG016976]; National
Institutes of Health NIA through National Cell Repository for
Alzheimer's Disease [U24 AG021886]; National Institutes of Health NIA
through NIA Late-Onset Alzheimer's Disease Study [U24 AG026395, U24
AG026390]; National Institutes of Health NIA through Banner Sun Health
Research Institute [P30 AG019610]; National Institutes of Health NIA
through Boston University [P30 AG013846, U01 AG10483, R01 CA129769, R01
MH080295, R01 AG017173, R01 AG025259, R01 AG33193]; National Institutes
of Health NIA through Columbia University [P50 AG008702, R37 AG015473];
National Institutes of Health NIA through Duke University [P30 AG028377,
R01 AG05128, R01 NS39764, R01 MH60451]; National Institutes of Health
NIA through Emory University [AG025688]; National Institutes of Health
NIA through Group Health Research Institute [UO1 AG06781, UO1 HG004610];
National Institutes of Health NIA through Indiana University [P30
AG10133]; National Institutes of Health NIA through Johns Hopkins
University [P50 AG005146, R01 AG020688]; National Institutes of Health
NIA through Massachusetts General Hospital [P50 AG005134]; National
Institutes of Health NIA through Mayo Clinic [P50 AG016574]; National
Institutes of Health NIA through Mount Sinai School of Medicine [P50
AG005138, P01 AG002219]; National Institutes of Health NIA through New
York University [P30 AG08051, MO1 RR00096, UL1 RR029893]; National
Institutes of Health NIA through Northwestern University [P30 AG013854];
National Institutes of Health NIA through Oregon Health & Science
University [P30 AG008017, R01 AG026916]; National Institutes of Health
NIA through Rush University [P30 AG010161, R01 AG019085, R01 AG15819,
R01 AG17917, R01 AG30146]; National Institutes of Health NIA through
Translational Genomics Research Institute [R01 NS059873, R01 AG034504];
National Institutes of Health NIA through University of Alabama at
Birmingham [P50 AG016582, UL1 RR02777]; National Institutes of Health
NIA through University of Arizona [R01 AG031581]; National Institutes of
Health NIA through University of California, Davis [P30 AG010129];
National Institutes of Health NIA through University of California,
Irvine [P50 AG016573, P50 AG016575, P50 AG016576, P50 AG016577];
National Institutes of Health NIA through University of California, Los
Angeles [P50 AG016570]; National Institutes of Health NIA through
University of California, San Diego [P50 AG005131]; National Institutes
of Health NIA through University of California, San Francisco [P50
AG023501, P01 AG019724]; National Institutes of Health NIA through
University of Kentucky [P30 AG028383, AG05144]; National Institutes of
Health NIA through University of Michigan [P50 AG008671]; National
Institutes of Health NIA through University of Pennsylvania [P30
AG010124]; National Institutes of Health NIA through University of
Pittsburgh [P50 AG005133, AG030653]; National Institutes of Health NIA
through University of Southern California [P50 AG005142]; National
Institutes of Health NIA through University of Texas Southwestern [P30
AG012300]; National Institutes of Health NIA through University of Miami
[R01 AG027944, AG010491, AG027944, AG021547, AG019757]; National
Institutes of Health NIA through University of Washington [P50
AG005136]; National Institutes of Health NIA through Vanderbilt
University [R01 AG019085]; National Institutes of Health NIA through
Washington University [P50 AG005681, P01 AG03991]; NIA [U24 AG21886, U01
AG024904, RC2 AG036535, K01 AG030514]; Banner Alzheimer's Foundation;
Johnnie B. Byrd Sr Alzheimer's Center & Research Institute; Medical
Research Council; state of Arizona; local National Health Service
trusts; Newcastle University; Higher Education Funding Council for
England; Alzheimer's Research Trust; BRACE; North Bristol NHS Trust
Research and Innovation Department; DeNDRoN; Stichting MS Research;
BrainNet Europe; Hersenstichting Nederland Breinbrekend Werk;
International Parkinson Fonds; Internationale Stiching Alzheimer
Onderzoek; Alzheimer's Association; Alzheimer's Drug Discovery
Foundation; Dana Foundation; National Institute of Biomedical Imaging
and Bioengineering; Alzheimer's Association [IIRG-08-89720,
IIRG-05-14147]; US Department of Veterans Affairs Administration; Office
of Research and Development; Biomedical Laboratory Research Program;
Wellcome Trust; Howard Hughes Medical Institute; Canadian Institute of
Health Research
FX The Kathleen Price Bryan Brain Bank at Duke University Medical Center is
funded by GlaxoSmithKline. Genotyping of the Translational Genomics
Research Institute series 2 cohort was supported by Kronos Science.
Funding for ADNI is through the Northern California Institute for
Research and Education by grants from Abbott, AstraZeneca AB, Bayer
Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical
Development, Elan Corporation, Genentech, GE Healthcare,
GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly and Co,
Medpace Inc, Merck and Co Inc, Novartis AG, Pfizer Inc, F. Hoffman-La
Roche, Schering-Plough, and Synarc Inc.; The National Institutes of
Health NIA supported this work through the following grants: ADGC, U01
AG032984 and RC2 AG036528; National Alzheimer's Coordinating Center, U01
AG016976; National Cell Repository for Alzheimer's Disease, U24
AG021886; NIA Late-Onset Alzheimer's Disease Study, U24 AG026395 and U24
AG026390; Banner Sun Health Research Institute, P30 AG019610; Boston
University, P30 AG013846, U01 AG10483, R01 CA129769, R01 MH080295, R01
AG017173, R01 AG025259, and R01 AG33193; Columbia University, P50
AG008702 and R37 AG015473; Duke University, P30 AG028377, R01 AG05128,
R01 NS39764, and R01 MH60451; Emory University, AG025688; Group Health
Research Institute, UO1 AG06781 and UO1 HG004610; Indiana University,
P30 AG10133; Johns Hopkins University, P50 AG005146 and R01 AG020688;
Massachusetts General Hospital, P50 AG005134; Mayo Clinic, P50 AG016574;
Mount Sinai School of Medicine, P50 AG005138 and P01 AG002219; New York
University, P30 AG08051, MO1 RR00096, and UL1 RR029893; Northwestern
University, P30 AG013854; Oregon Health & Science University, P30
AG008017 and R01 AG026916; Rush University, P30 AG010161, R01 AG019085,
R01 AG15819, R01 AG17917, and R01 AG30146; Translational Genomics
Research Institute, R01 NS059873 and R01 AG034504; University of Alabama
at Birmingham, P50 AG016582 and UL1 RR02777; University of Arizona, R01
AG031581; University of California, Davis, P30 AG010129; University of
California, Irvine, P50 AG016573, P50 AG016575, P50 AG016576, and P50
AG016577; University of California, Los Angeles, P50 AG016570;
University of California, San Diego, P50 AG005131; University of
California, San Francisco, P50 AG023501 and P01 AG019724; University of
Kentucky, P30 AG028383 and AG05144; University of Michigan, P50
AG008671; University of Pennsylvania, P30 AG010124; University of
Pittsburgh, P50 AG005133 and AG030653; University of Southern
California, P50 AG005142; University of Texas Southwestern, P30
AG012300; University of Miami, R01 AG027944, AG010491, AG027944,
AG021547, and AG019757; University of Washington, P50 AG005136;
Vanderbilt University, R01 AG019085; and Washington University, P50
AG005681 and P01 AG03991. Samples from the National Cell Repository for
Alzheimer's Disease, which receives government support under cooperative
agreement grant U24 AG21886 awarded by the NIA, were used in this study.
The Translational Genomics Research Institute series was also funded by
the Banner Alzheimer's Foundation, the Johnnie B. Byrd Sr Alzheimer's
Center & Research Institute, the Medical Research Council, and the state
of Arizona and also includes samples from the following sites: Newcastle
Brain Tissue Resource (funding via the Medical Research Council, local
National Health Service trusts, and Newcastle University), MRC London
Brain Bank for Neurodegenerative Diseases (funding via the Medical
Research Council), South West Dementia Brain Bank (funding via numerous
sources including the Higher Education Funding Council for England,
Alzheimer's Research Trust, and BRACE as well as North Bristol NHS Trust
Research and Innovation Department and DeNDRoN), the Netherlands Brain
Bank (funding via numerous sources including Stichting MS Research,
BrainNet Europe, Hersenstichting Nederland Breinbrekend Werk,
International Parkinson Fonds, and Internationale Stiching Alzheimer
Onderzoek), Institut de Neuropatologia, Servei Anatomia Patologica, and
Universitat de Barcelona.; Funding for ADNI is through the Northern
California Institute for Research and Education by grants from the
Alzheimer's Association, Alzheimer's Drug Discovery Foundation, the Dana
Foundation, and the National Institute of Biomedical Imaging and
Bioengineering and NIA grants U01 AG024904, RC2 AG036535, and K01
AG030514. Support was also from Alzheimer's Association grants
IIRG-08-89720 (Dr Farrer) and IIRG-05-14147 (Dr Pericak-Vance) and the
US Department of Veterans Affairs Administration, Office of Research and
Development, Biomedical Laboratory Research Program. Dr St George-Hyslop
is supported by Wellcome Trust, Howard Hughes Medical Institute, and the
Canadian Institute of Health Research.
NR 37
TC 31
Z9 31
U1 0
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD OCT
PY 2012
VL 69
IS 10
BP 1270
EP 1279
DI 10.1001/archneurol.2012.2052
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 016TC
UT WOS:000309541400005
PM 22869155
ER
PT J
AU Phipps, AI
Buchanan, DD
Makar, KW
Burnett-Hartman, AN
Coghill, AE
Passarelli, MN
Baron, JA
Ahnen, DJ
Win, AK
Potter, JD
Newcomb, PA
AF Phipps, Amanda I.
Buchanan, Daniel D.
Makar, Karen W.
Burnett-Hartman, Andrea N.
Coghill, Anna E.
Passarelli, Michael N.
Baron, John A.
Ahnen, Dennis J.
Win, Aung Ko
Potter, John D.
Newcomb, Polly A.
TI BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis
According to Patient and Tumor Characteristics
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; MICROSATELLITE INSTABILITY; COLON-CANCER;
MISMATCH REPAIR; V600E MUTATION; POOR SURVIVAL; MOLECULAR-FEATURES;
STAGE-II; RISK; IMMUNOHISTOCHEMISTRY
AB Background: BRAF mutations in colorectal cancer (CRC) are disproportionately observed in tumors exhibiting microsatellite instability (MSI) and are associated with other prognostic factors. The independent association between BRAF mutation status and CRC survival, however, remains unclear.
Methods: We evaluated the association between the BRAF c.1799T>A (p.V600E) mutation and survival in individuals with incident invasive CRC diagnosed between 1997 and 2007 in Western Washington State. Tumor specimens were tested for this BRAF mutation and MSI status. We used Cox regression to estimate HRs and 95% confidence intervals (CI) for the association between BRAF mutation status and disease-specific and overall survival. Stratified analyses were conducted by age, sex, tumor site, stage, and MSI status.
Results: Among 1,980 cases tested, 12% were BRAF c.1799T>A(p.V600E) mutation-positive (n = 247). BRAF-mutated CRC was associated with poorer disease-specific survival adjusting for age, sex, time from diagnosis to enrollment, stage, and MSI status (HR, 1.43; 95% CI, 1.05-1.95). This association was limited to cases diagnosed at ages <50 (HR, 3.06; 95% CI, 1.70-5.52) and was not evident in cases with MSI-high tumors (HR, 0.94; 95% CI, 0.44-2.03). Associations with overall survival were similar.
Conclusions: Our results show that the prevalence of BRAF mutations in CRC differs by patient and tumor characteristics and suggest that the association between BRAF status and CRC survival may differ by some of these factors.
Impact: The presence of a BRAF c.1799T>A (p.V600E) mutation is associated with significantly poorer prognosis after CRC diagnosis among subgroups of patients. Cancer Epidemiol Biomarkers Prev; 21(10); 1792-8. (c) 2012 AACR.
C1 [Phipps, Amanda I.; Makar, Karen W.; Burnett-Hartman, Andrea N.; Coghill, Anna E.; Passarelli, Michael N.; Potter, John D.; Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Buchanan, Daniel D.] Queensland Inst Med Res, Familial Canc Lab, Brisbane, Qld 4006, Australia.
[Baron, John A.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
[Ahnen, Dennis J.] Univ Colorado, Sch Med, Denver Vet Affairs Med Ctr, Denver, CO USA.
[Win, Aung Ko] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3052, Australia.
[Potter, John D.] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand.
RP Phipps, AI (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,M4-B402, Seattle, WA 98109 USA.
EM aphipps@fhcrc.org
OI Potter, John/0000-0001-5439-1500; Win, Aung Ko/0000-0002-2794-5261;
Buchanan, Daniel/0000-0003-2225-6675
FU National Cancer Institute (NCI), NIH [U01CA74794, R01CA076366]; NCI
[R25-CA94880, K05 CA152715]
FX This work was supported by the National Cancer Institute (NCI), NIH
(U01CA74794, R01CA076366), and through cooperative agreements with
members of the Colon Cancer Family Registry and Principal Investigators.
This publication was also supported by the NCI grant R25-CA94880 and NCI
grant K05 CA152715.
NR 48
TC 55
Z9 56
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD OCT
PY 2012
VL 21
IS 10
BP 1792
EP 1798
DI 10.1158/1055-9965.EPI-12-0674
PG 7
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 017FS
UT WOS:000309576100023
PM 22899730
ER
PT J
AU Chan, JM
Litwack-Harrison, S
Bauer, SR
Daniels, NA
Wilt, TJ
Shannon, J
Bauer, DC
AF Chan, June M.
Litwack-Harrison, Stephanie
Bauer, Scott R.
Daniels, Nicholas A.
Wilt, Timothy J.
Shannon, Jackilen
Bauer, Douglas C.
TI Statin Use and Risk of Prostate Cancer in the Prospective Osteoporotic
Fractures in Men (MrOS) Study
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID POPULATION
AB Background: Statins are a common medication for cholesterol control that may also have effects on cancer-related pathways. The evidence of an association between statins and prostate cancer risk remains ambiguous.
Methods: We examined statin use in a prospective cohort of 5,069 elderly U.S. men and the risk of incident total, low/high stage, and low/high grade prostate cancer diagnosed between 2000 and 2008. We used multivariate logistic regression models to estimate relative risks and 95% confidence intervals, adjusting for demographic and lifestyle characteristics.
Results: There was no evidence of an association between statin use and any of the prostate cancer endpoints (total, low/high stage, low/high grade prostate cancer), adjusting for age, study site, race, body mass index, marital status, family history of prostate cancer, number of comorbidities, physical activity, and smoking history.
Conclusions and Impact: In this study of elderly U. S. men, we observed a null association between statin use and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev; 21(10); 1886-8. (c) 2012 AACR.
C1 [Chan, June M.; Bauer, Scott R.; Wilt, Timothy J.; Bauer, Douglas C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA.
[Chan, June M.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94158 USA.
[Litwack-Harrison, Stephanie; Daniels, Nicholas A.; Bauer, Douglas C.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA.
[Shannon, Jackilen] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Shannon, Jackilen] Portland VA Med Ctr, Portland, OR USA.
RP Chan, JM (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 1450 3rd St,MC 3110, San Francisco, CA 94158 USA.
EM june.chan@ucsf.edu
FU National Institutes of Health; National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging
(NIA); National Center for Research Resources (NCRR); NIH Roadmap for
Medical Research [U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647,
U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, UL1 RR024140];
Prostate Cancer Foundation; Steven & Christine Burd-Safeway Endowment
FX The MrOS Study is supported by National Institutes of Health funding.
The following institutes provide support: the National Institute of
Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National
Institute on Aging (NIA), the National Center for Research Resources
(NCRR), and NIH Roadmap for Medical Research under the following grant
numbers: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01
AR45654, U01 AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140. Dr.
Chan and Mr. S. Bauer also receive support from the Prostate Cancer
Foundation and the Steven & Christine Burd-Safeway Endowment.
NR 8
TC 5
Z9 5
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD OCT
PY 2012
VL 21
IS 10
BP 1886
EP 1888
DI 10.1158/1055-9965.EPI-12-0816
PG 3
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 017FS
UT WOS:000309576100034
PM 22879205
ER
PT J
AU Mendez, E
AF Mendez, Eduardo
TI Biomarkers of HPV Infection in Oropharyngeal Carcinomas: Can We Find
Simplicity in the Puzzle of Complexity?
SO CANCER RESEARCH
LA English
DT Review
ID SQUAMOUS-CELL CARCINOMA; ONCOGENIC HUMAN-PAPILLOMAVIRUS; UNITED-STATES;
COPY NUMBER; NECK-CANCER; ORAL-CAVITY; HEAD; SURVIVAL; P16(INK4A);
PREVALENCE
C1 [Mendez, Eduardo] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98109 USA.
[Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA.
[Mendez, Eduardo] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
RP Mendez, E (reprint author), Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Otolaryngol Head & Neck Surg, 1100 Fairview Ave N,Mail Stop D5-390, Seattle, WA 98109 USA.
EM edmendez@uw.edu
NR 22
TC 3
Z9 3
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD OCT 1
PY 2012
VL 72
IS 19
BP 4896
EP 4898
DI 10.1158/0008-5472.CAN-12-3285
PG 3
WC Oncology
SC Oncology
GA 016LY
UT WOS:000309521200004
PM 22991303
ER
PT J
AU Seepersaud, R
Bensing, BA
Yen, YT
Sullam, PM
AF Seepersaud, Ravin
Bensing, Barbara A.
Yen, Yihfen T.
Sullam, Paul M.
TI The Accessory Sec Protein Asp2 Modulates GlcNAc Deposition onto the
Serine-Rich Repeat Glycoprotein GspB
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article
ID STREPTOCOCCUS-GORDONII; STRUCTURE PREDICTION; SURFACE PROTEIN; HUMAN
PLATELETS; BINDING; GLYCOSYLATION; SYSTEM; EXPORT; ADHESIN; BIOGENESIS
AB The accessory Sec system is a specialized transport system that exports serine-rich repeat (SRR) glycoproteins of Gram-positive bacteria. This system contains two homologues of the general secretory (Sec) pathway (SecA2 and SecY2) and several other essential proteins (Asp1 to Asp5) that share no homology to proteins of known function. In Streptococcus gordonii, Asp2 is required for the transport of the SRR adhesin GspB, but its role in export is unknown. Tertiary structure predictions suggest that the carboxyl terminus of Asp2 resembles the catalytic region of numerous enzymes that function through a Ser-Asp-His catalytic triad. Sequence alignment of all Asp2 homologues identified a highly conserved pentapeptide motif (Gly-X-Ser(362)-X-Gly) typical of most Ser-Asp-His catalytic triads, where Ser forms the reactive residue. Site-directed mutagenesis of residues comprising the predicted catalytic triad of Asp2 of S. gordonii had no effect upon GspB transport but did result in a marked change in the electrophoretic mobility of the protein. Lectin-binding studies and monosaccharide content analysis of this altered glycoform revealed an increase in glucosamine deposition. Random mutagenesis of the Asp2 region containing this catalytic domain also disrupted GspB transport. Collectively, our findings suggest that Asp2 is a bifunctional protein that is essential for both GspB transport and correct glycosylation. The catalytic domain may be responsible for controlling the glycosylation of GspB, while other surrounding regions are functionally required for glycoprotein transport.
C1 [Sullam, Paul M.] San Francisco VA Med Ctr, San Francisco, CA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Sullam, PM (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.
EM paul.sullam@ucsf.edu
FU U.S. Department of Veteran Affairs; Northern California Institute for
Research and Education; National Institutes of Health [R01 AI41513, R01
AI057433]
FX This study was supported by the U.S. Department of Veteran Affairs, the
Northern California Institute for Research and Education, and grants R01
AI41513 and R01 AI057433 from the National Institutes of Health.
NR 47
TC 9
Z9 9
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD OCT
PY 2012
VL 194
IS 20
BP 5564
EP 5575
DI 10.1128/JB.01000-12
PG 12
WC Microbiology
SC Microbiology
GA 016AV
UT WOS:000309490600009
PM 22885294
ER
PT J
AU Xu, YP
Simon, JE
Ferruzzi, MG
Ho, L
Pasinetti, GM
Wu, QL
AF Xu, Yanping
Simon, James E.
Ferruzzi, Mario G.
Ho, Lap
Pasinetti, Giulio Maria
Wu, Qingli
TI Quantification of anthocyanidins in the grapes and grape juice products
with acid assisted hydrolysis using LC/MS
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Grape; LC-MS; Polyphenols; Anthocyanins; Anthocyanidins; Acidic
hydrolysis
ID ANTIOXIDANT ACTIVITY; RED WINES; CAPACITY; IDENTIFICATION; STRESS
AB A simple and precise acid-assisted hydrolysis method was established for the quantification of anthocyanidins in 15 grape juice samples, four grape berries and four grape skins using LC/MS. Under optimized conditions, five major anthocyanidins including delphinidin, cyanidin, petunidin, peonidin and malvidin in the hydrolyzed grape extracts were successfully separated within 25 mm and quantified individually. The results revealed that the total concentration of anthocyanidins was not symmetrically distributed in the different grape juice products. While quantitative distribution of anthocyanidins in grape berries and skins are quite similar, anthocyanidin concentration in grape skins was found to be four to eight times higher than their corresponding berries. The precision of this method was validated by recovery percentages of five anthocyanidins, ranging from 98.59% to 103.20% with the relative standard deviation (RSD) less than 5.03%. This quantitative method provides a rapid and accurate tool to quantitatively study individual anthocyanidins in grapes or grape juice samples for quality control and to facilitate the evaluation and comparison of new commercial grapes or grape juices products in the market. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Xu, Yanping; Simon, James E.; Wu, Qingli] Rutgers State Univ, Dept Plant Biol & Pathol, New Use Agr & Nat Plant Prod Program, New Brunswick, NJ 08901 USA.
[Xu, Yanping; Simon, James E.; Wu, Qingli] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Med Chem, Piscataway, NJ 08854 USA.
[Ferruzzi, Mario G.] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA.
[Ho, Lap; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY 10468 USA.
RP Wu, QL (reprint author), Rutgers State Univ, Dept Plant Biol & Pathol, New Use Agr & Nat Plant Prod Program, 59 Dudley Rd, New Brunswick, NJ 08901 USA.
EM qlwu@aesop.rutgers.edu
FU New Use Agriculture and Natural Plant Products Program; NIH [1 PO1
AT004511-01]
FX This work was supported by the New Use Agriculture and Natural Plant
Products Program and was conducted as part of the Core B Research
Program in CERC with funds provided by NIH Award 1 PO1 AT004511-01. Many
thanks to Stephen T. Talcott, Texas A&M University for isolating juice
polyphenolic preparations; JoLynne Wrightman, Welch's Inc., for
providing the Concord Grape Juice and their helpful discussions.
NR 22
TC 11
Z9 12
U1 3
U2 54
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD OCT
PY 2012
VL 4
IS 4
BP 710
EP 717
DI 10.1016/j.jff.2012.04.010
PG 8
WC Food Science & Technology
SC Food Science & Technology
GA 017CZ
UT WOS:000309569000002
ER
PT J
AU Joshi, A
Ringman, JM
Lee, AS
Juarez, KO
Mendez, MF
AF Joshi, Aditi
Ringman, John M.
Lee, Albert S.
Juarez, Kevin O.
Mendez, Mario F.
TI Comparison of clinical characteristics between familial and non-familial
early onset Alzheimer's disease
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE Dementia; Early onset Alzheimer's disease; Familial Alzheimer's disease;
PSEN1 gene
ID PRESENILIN-1 MUTATION CARRIERS; POSTERIOR CORTICAL ATROPHY; AMYLOID
DEPOSITION; DIAGNOSIS; PATHOLOGY; SEIZURES; FEATURES; PLAQUES; VARIANT;
RISK
AB Although familial Alzheimer's disease (FAD) is an early onset AD (EAD), most patients with EAD do not have a familial disorder. Recent guidelines recommend testing for genes causing FAD only in those EAD patients with two first-degree relatives. However, some patients with FAD may lack a known family history or other indications for suspecting FAD but might nonetheless be carriers of FAD mutations. The study was aimed to identify clinical features that distinguish FAD from non-familial EAD (NF-EAD). A retrospective review of a university-based cohort of 32 FAD patients with PSEN1-related AD and 81 with NF-EAD was conducted. The PSEN1 patients, compared to the NF-EAD patients, had an earlier age of disease onset (41.8 +/- A 5.2 vs. 55.9 +/- A 4.8 years) and, at initial assessment, a longer disease duration (5.1 +/- A 3.4 vs. 3.3 +/- A 2.6 years) and lower MMSE scores (10.74 +/- A 8.0 vs. 20.95 +/- A 5.8). Patients with NF-EAD were more likely to present with non-memory deficits, particularly visuospatial symptoms, than were FAD patients. When age, disease duration, and MMSE scores were controlled in a logistical regression model, FAD patients were more likely to have significant headaches, myoclonus, gait abnormality, and pseudobulbar affect than those with NF-EAD. In addition to a much younger age of onset, FAD patients with PSEN1 mutations differed from those with NF-EAD by a history of headaches and pseudobulbar affect, as well as myoclonus and gait abnormality on examination. These may represent differences in pathophysiology between FAD and NF-EAD and in some contexts such findings should lead to genetic counseling and appropriate recommendations for genetic testing for FAD.
C1 [Joshi, Aditi; Juarez, Kevin O.; Mendez, Mario F.] VA Greater Los Angeles Healthcare Ctr, Neurol Sect, Neurobehav Unit 691 116AF, Los Angeles, CA 90073 USA.
[Joshi, Aditi; Ringman, John M.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Ringman, John M.; Mendez, Mario F.] Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Dis Res, Los Angeles, CA USA.
[Lee, Albert S.; Mendez, Mario F.] Western Univ Hlth Sci, Pomona, CA USA.
RP Joshi, A (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurol Sect, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM aditijoshi@mednet.ucla.edu
FU VA Merit Review; Alzheimer's Disease Research Center [NIA P50 AG-16570];
PHS [K08 AG-22228]; California DHS [04-35522]; California Alzheimer's
Disease Center [09-11408]; Easton Consortium for Alzheimer's Disease
Drug Discovery and Biomarkers; [R01AG034499-03]
FX This work was supported by grant #R01AG034499-03 and a VA Merit Review
(A. Joshi, A. Lee, K. O. Juarez, and M. F. Mendez), Alzheimer's Disease
Research Center Grant NIA P50 AG-16570 ( M. F. Mendez, J.M. Ringman).
Dr. Ringman receives additional support from PHS K08 AG-22228,
California DHS #04-35522, California Alzheimer's Disease Center Grant
09-11408, and the Easton Consortium for Alzheimer's Disease Drug
Discovery and Biomarkers.
NR 39
TC 13
Z9 14
U1 2
U2 23
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
J9 J NEUROL
JI J. Neurol.
PD OCT
PY 2012
VL 259
IS 10
BP 2182
EP 2188
DI 10.1007/s00415-012-6481-y
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 017BD
UT WOS:000309562800022
PM 22460587
ER
PT J
AU Beadell, NC
Thompson, EM
Delashaw, JB
Cetas, JS
AF Beadell, Noah C.
Thompson, Eric M.
Delashaw, Johnny B.
Cetas, Justin S.
TI The deleterious effects of methamphetamine use on initial presentation
and clinical outcomes in aneurysmal subarachnoid hemorrhage
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE methamphetamine; subarachnoid hemorrhage; aneurysm; outcome; vascular
disorders; vasospasm
ID INTRACEREBRAL HEMORRHAGE; YOUNG-ADULTS; CEREBRAL VASOSPASM; ORAL
AMPHETAMINE; ISCHEMIC-STROKE; ABUSE; COCAINE; COMPLICATIONS; INHALATION;
ANGIITIS
AB Object. The objective of this study was to retrospectively look at methamphetamine (MA) use in patients with aneurysmal subarachnoid hemorrhage (SAH) to determine if MA use affects clinical presentation and outcomes after aneurysmal SAH.
Methods. A retrospective review of patients admitted to the Oregon Health & Science University neurosurgical service with aneurysmal SAH during the past 6 years was undertaken. Variables analyzed included MA use, age, sex, cigarette use, Hunt and Hess grade, Fisher grade, admission blood pressure, aneurysm characteristics, occurrence of vasospasm, hospital length of stay (LOS), cerebral infarction, aneurysm treatment, and Glasgow Outcome Scale (GOS) score. Data differences between MA users and nonusers were statistically analyzed using multivariate logistic regression analysis. A separate comparison with randomly selected age-matched nonuser controls was also performed.
Results. Twenty-eight (7%) of 374 patients with aneurysmal SAH were identified as MA users. Methamphetamine users were younger than nonusers (45.2 vs 55.9 years, respectively; p < 0.001). Despite a younger age, MA users had significantly higher Hunt and Hess grades than nonusers (3.0 vs 2.5, respectively; p < 0.020) and age-matched controls (3.0 vs 2.0, respectively; p < 0.001). Earliest available mean arterial pressure was significantly higher in MA users (122.1 vs 109.7, respectively; p = 0.005) than all nonusers but not age-matched controls. Methamphetamine users had significantly higher vasospasm rates than nonusers (92.9% vs 71.1%, respectively; p = 0.008) but similar rates as age-matched controls (92.9% vs 89.3%, respectively; p = 0.500). Glasgow Outcome Scale score did not differ significantly between users and nonusers (3 vs 4, respectively; p = 0.170), but users had significantly lower GOS scores than age-matched controls (3 vs 5, respectively; p < 0.001). There was no statistically significant difference in the LOS between users and nonusers (18 days vs 16 days, respectively; p = 0.431) or users and age-matched controls (18 days vs 14 days, respectively; p = 0.250). In the multivariate analysis, MA use (OR 3.777, p = 0.018), age (p < 0.001), Fisher grade (p = 0.011), Hunt and Hess grade (p < 0.001), and cerebral infarction (p < 0.001) were predictors of poor GOS score. The only predictor of vasospasm was age (p < 0.001), although a strong predictive trend in MA use (p = 0.149) was found. Predictors of a hospital LOS > 15 days included age (p = 0.002), Fisher grade (p = 0.002), Hunt and Hess grade (p < 0.001). and cerebral infarction (p < 0.001). Predictors of cerebral infarction include male sex (p = 0.022) and Hunt and Hess grade (p = 0.006), with vasospasm demonstrating a strong trend (p = 0.056).
Conclusions. A history of MA use may predict poorer outcomes in patients who present with aneurysmal SAH. Methamphetamine users have significantly worse presentations and outcomes when compared with age-matched controls. (http://thejns.org/doi/abs/10.3171/2012.7.JNS12396)
C1 [Thompson, Eric M.; Delashaw, Johnny B.; Cetas, Justin S.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA.
[Beadell, Noah C.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Cetas, Justin S.] Portland VA Med Ctr, Portland, OR USA.
RP Cetas, JS (reprint author), Oregon Hlth & Sci Univ, Dept Neurol Surg, Mail Code L472,3303 Bond Ave SW, Portland, OR 97239 USA.
EM cetasj@ohsu.edu
NR 38
TC 4
Z9 4
U1 0
U2 1
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD OCT
PY 2012
VL 117
IS 4
BP 781
EP 786
DI 10.3171/2012.7.JNS12396
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 015YZ
UT WOS:000309485600033
PM 22920957
ER
PT J
AU Cheng, G
Alavi, A
AF Cheng, Gang
Alavi, Abass
TI The Value of F-18-FDG PET/CT in the Assessment of Cardiac Malignancy
Remains to Be Defined
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Letter
ID LOW-CARBOHYDRATE-DIET; HIGH-FAT; MYOCARDIAL UPTAKE; FDG UPTAKE;
SUPPRESSION; DIAGNOSIS; HEART
C1 [Cheng, Gang] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP Cheng, G (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM gangcheng99@yahoo.com
NR 8
TC 1
Z9 1
U1 0
U2 2
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
J9 J NUCL MED
JI J. Nucl. Med.
PD OCT
PY 2012
VL 53
IS 10
BP 1657
EP 1657
DI 10.2967/jnumed.112.109611
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 015FS
UT WOS:000309432400027
PM 22915158
ER
PT J
AU Eagan, MJ
Zuk, PA
Zhao, KW
Bluth, BE
Brinkmann, EJ
Wu, BM
McAllister, DR
AF Eagan, Michael J.
Zuk, Patricia A.
Zhao, Ke-Wei
Bluth, Benjamin E.
Brinkmann, Elyse J.
Wu, Benjamin M.
McAllister, David R.
TI The suitability of human adipose-derived stem cells for the engineering
of ligament tissue
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE ASCs; adipose-derived stem cells; ligament engineering; collagen type 1;
tissue engineering; adult stem cells
ID ANTERIOR CRUCIATE LIGAMENT; MEDIAL COLLATERAL LIGAMENT; MARROW STROMAL
CELLS; GROWTH-FACTORS; TENASCIN-C; IN-VITRO; MATRIX SYNTHESIS; PATELLAR
TENDON; SILK SCAFFOLD; RABBIT MODEL
AB Rupture of the anterior cruciate ligament (ACL) is the one of the most common sports-related injuries. With its poor healing capacity, surgical reconstruction using either autografts or allografts is currently required to restore function. However, serious complications are associated with graft reconstructions and the number of such reconstructions has steadily risen over the years, necessitating the search for an alternative approach to ACL repair. Such an approach may likely be tissue engineering. Recent engineering approaches using ligament-derived fibroblasts have been promising, but the slow growth rate of such fibroblasts in vitro may limit their practical application. More promising results are being achieved using bone marrow mesenchymal stem cells (MSCs). The adipose-derived stem cell (ASC) is often proposed as an alternative choice to the MSC and, as such, may be a suitable stem cell for ligament engineering. However, the use of ASCs in ligament engineering still remains relatively unexplored. Therefore, in this study, the potential use of human ASCs in ligament tissue engineering was initially explored by examining their ability to express several ligament markers under growth factor treatment. ASC populations treated for up to 4?weeks with TGF beta 1 or IGF1 did not show any significant and consistent upregulation in the expression of collagen types 1 and 3, tenascin C and scleraxis. While treatment with EGF or bFGF resulted in increased tenascin C expression, increased expression of collagens 1 and 3 were never observed. Therefore, simple in vitro treatment of human ASC populations with growth factors may not stimulate their ligament differentiative potential. Copyright (c) 2011 John Wiley & Sons, Ltd.
C1 [Zhao, Ke-Wei; McAllister, David R.] VA Greater Los Angeles Healthcare Syst, Orthoped Tissue Engn Lab, W Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA.
[Eagan, Michael J.; McAllister, David R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthoped Surg, Ctr Hlth Sci, Los Angeles, CA 90095 USA.
[Zuk, Patricia A.; Bluth, Benjamin E.] Univ Calif Los Angeles, David Geffen Sch Med, Div Plast Surg, Dept Surg,Ctr Hlth Sci, Los Angeles, CA 90095 USA.
[Brinkmann, Elyse J.; Wu, Benjamin M.] Univ Calif Los Angeles, Dept Biomed Engn, Henry Samueli Sch Engn & Appl Sci, Los Angeles, CA 90095 USA.
RP McAllister, DR (reprint author), VA Greater Los Angeles Healthcare Syst, Orthoped Tissue Engn Lab, W Los Angeles Healthcare Ctr, Room E3-201,Bldg 304,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM pzuk@mednet.ucla.edu
FU VA Rehabilitation RRD grant
FX This study was supported by a VA Rehabilitation RR&D grant.
NR 63
TC 10
Z9 10
U1 4
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1932-6254
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD OCT
PY 2012
VL 6
IS 9
BP 702
EP 709
DI 10.1002/term.474
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology; Engineering, Biomedical
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA 015QH
UT WOS:000309460500004
PM 21953999
ER
PT J
AU Wong, ES
Wang, BCM
Alfonso-Cristancho, R
Flum, DR
Sullivan, SD
Garrison, LP
Arterburn, DE
AF Wong, Edwin S.
Wang, Bruce C. M.
Alfonso-Cristancho, Rafael
Flum, David R.
Sullivan, Sean D.
Garrison, Louis P.
Arterburn, David E.
TI BMI Trajectories Among the Severely Obese: Results From an Electronic
Medical Record Population
SO OBESITY
LA English
DT Article
ID UNITED-STATES; CHILDHOOD OBESITY; SOCIOECONOMIC POSITION; OVERWEIGHT
PREVALENCE; WEIGHT-GAIN; TRENDS; ADULTS; RACE/ETHNICITY; DISPARITIES;
EPIDEMIC
AB Epidemiological studies have documented the growing prevalence of severe obesity during the past three decades. The primary goal of this study was to estimate the trajectory of BMI change over 5+ years in a cohort of subjects identified as severely obese (BMI >= 35). We conducted a retrospective cohort study among adults enrolled in Group Health (GH) in Washington State. We tracked 11,735 subjects with at least one BMI measure of 35 or greater in the calendar year 2005 through April 2010. Population averaged BMI trajectories were estimated as a quadratic function of time using a marginal regression model, adjusting for gender and baseline BMI and age. For the average male in GH, the estimated BMI trajectory exhibited a slightly inverted U-shaped pattern and a 0.17 increase in BMI over the sample period. For the average female, the BMI trajectory was slightly U-shaped with BMI decreasing 0.03 units over the sample period. We found a high degree of heterogeneity in the shape of estimated trajectories across baseline characteristics with larger 5-year BMI increases among younger subjects with a lower initial BMI. We conclude that BMI changes over 5 years among individuals classified as severely obese are generally small and consistent with studies documenting BMI changes for individuals in other lower BMI categories. Our results also suggest that once the 35 BMI threshold is reached, individuals will continue to remain severely obese, especially at younger ages.
C1 [Wong, Edwin S.; Wang, Bruce C. M.; Alfonso-Cristancho, Rafael; Sullivan, Sean D.; Garrison, Louis P.] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA.
[Wong, Edwin S.] VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA USA.
[Flum, David R.] Univ Washington, Surg Outcomes Res Ctr, Seattle, WA 98195 USA.
[Arterburn, David E.] Grp Hlth Res Inst, Seattle, WA USA.
RP Wong, ES (reprint author), Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA.
EM eswong@uw.edu
FU HQ Air Force [FA7014-08-2-0002]; Department of Veterans Affairs, Health
Services Research, and Development Post-Doctoral Fellowship [TPP 61-024]
FX This paper was written for the Bariatric Obesity Outcome Modeling
Collaborative. Members are listed in Supplementary Appendix online. This
work was supported by the HQ Air Force Surgeon General under Award No.
FA7014-08-2-0002. Opinions, interpretations, conclusions, and
recommendations are those of the author and are not necessarily endorsed
by the U. S. Air Force. E. S. W. was supported by the Department of
Veterans Affairs, Health Services Research, and Development
Post-Doctoral Fellowship TPP 61-024. The authors thank Sebastien
Haneuse, Matthew Maciejewski, Andy Bogart, Valerie Smith, Maren Olsen,
Allyson Littman for their valuable input and suggestions.
NR 24
TC 2
Z9 2
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
J9 OBESITY
JI Obesity
PD OCT
PY 2012
VL 20
IS 10
BP 2107
EP 2112
DI 10.1038/oby.2012.29
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 016IH
UT WOS:000309510700020
PM 22314622
ER
PT J
AU Parameswaran, S
Spaeth-Rublee, B
Huynh, PT
Pincus, HA
AF Parameswaran, Sharat
Spaeth-Rublee, Brigitta
Phuong Trang Huynh
Pincus, Harold Alan
TI Comparison of National Mental Health Quality Assessment Programs Across
the Globe
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID OUTCOME MEASUREMENT; IMPROVEMENT; CARE; PREVALENCE; DISORDERS
AB Objective: This study by the International Initiative for Mental Health Leadership Clinical Leaders Project sought to describe ongoing or soon-to-be-established national-level mental health quality measurement programs in 12 participating countries, in order to understand the nature and structure of these programs. Methods: A survey was distributed to representatives from the participating countries (Australia, Canada, England, Germany, Ireland, Japan, the Netherlands, New Zealand, Norway, Scotland, Taiwan, and the United States). Data included descriptions of qualifying programs and the organizations responsible for them, quality indicators used, entities assessed, sources and means of the programs' data collection, the level at which data are reported, and how the data are used. Participants were asked to identify which quality domains and subdomains were represented by indicators in each program. Results were analyzed with descriptive statistics. Results: Thirty-eight programs were identified. Most programs were administered by governmental organizations, focused on hospital care, and used encounter or utilization databases as sources of information. Programs used different methods to identify indicators. Program data were used for various purposes. A wide range of domains of quality were represented in the programs reported, although most commonality was seen in domains associated with high-acuity care, with fewer programs assessing recovery-related domains. Conclusions: This study found wide variation among established quality assessment programs, which may reflect a focus on local priorities. The goal of this project is to work toward establishing an international framework for mental health quality assessment and thus a means to compare key measures of performance across countries. (Psychiatric Services 63:982,988, 2012; doi: 10.1176/appi.ps.201100382)
C1 [Parameswaran, Sharat] Univ Calif Los Angeles, Robert Wood Johnson Fdn Clin Scholars, Los Angeles, CA 90024 USA.
[Parameswaran, Sharat] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Clin Psychiat, Los Angeles, CA USA.
[Spaeth-Rublee, Brigitta; Phuong Trang Huynh] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Pincus, Harold Alan] Columbia Univ, Dept Psychiat, New York, NY USA.
RP Parameswaran, S (reprint author), Univ Calif Los Angeles, Robert Wood Johnson Fdn Clin Scholars, 10940 Wilshire Blvd,Suite 710-18, Los Angeles, CA 90024 USA.
EM sharu@ucla.edu
OI Iyer, Sharat/0000-0002-8576-7010
FU National Institute of Mental Health [R25 MH086466]; American Psychiatric
Press
FX Funding was provided by grant R25 MH086466 from the National Institute
of Mental Health. Additional funding came from government and
nongovernment organizations of the countries participating in the IIMHL
project (Australia, Canada, England, Germany, Ireland, japan, the
Netherlands, New Zealand, Norway, Scotland, Taiwan, and the United
States). The authors thank the members of the IIMHL for their assistance
with this project. Dr. Parameswaran is the recipient of an unrestricted
educational grant from the American Psychiatric Institute for Research
and Education and Janssen Pharmaceuticals.; Dr. Pincus receives travel
support as a consultant for Value Options and publication royalties from
the American Psychiatric Press and from Lippincott, Williams and
Wilkins. The other authors report no competing interests.
NR 21
TC 5
Z9 5
U1 5
U2 15
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD OCT
PY 2012
VL 63
IS 10
BP 982
EP 988
DI 10.1176/appi.ps.201100382
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 015ZX
UT WOS:000309488100006
ER
PT J
AU Colman, RJ
Beasley, TM
Allison, DB
Weindruch, R
AF Colman, Ricki J.
Beasley, T. Mark
Allison, David B.
Weindruch, Richard
TI Skeletal effects of long-term caloric restriction in rhesus monkeys
SO AGE
LA English
DT Article
DE Caloric restriction; Bone; Aging; Osteoporosis; Dietary restriction;
Dual-energy x-ray absorptiometry
ID BONE-MINERAL DENSITY; DIETARY RESTRICTION; FOOD RESTRICTION;
BODY-COMPOSITION; MACACA-MULATTA; TENNIS PLAYERS; ADULT MALE; WOMEN;
AGE; OSTEOPOROSIS
AB Age-related bone loss is well established in humans and is known to occur in nonhuman primates. There is little information, however, on the effect of dietary interventions, such as caloric restriction (CR), on age-related bone loss. This study examined the effects of long-term, moderate CR on skeletal parameters in rhesus monkeys. Thirty adult male rhesus monkeys were subjected to either a restricted (R, n = 15) or control (C, n = 15) diet for 20 years and examined throughout for body composition and biochemical markers of bone turnover. Total body, spine, and radius bone mass and density were assessed by dual-energy X-ray absorptiometry. Assessment of biochemical markers of bone turnover included circulating serum levels of osteocalcin, carboxyterminal telopeptide of type I collagen, cross-linked aminoterminal telopeptide of type I collagen, parathyroid hormone, and 25(OH)vitamin D. Overall, we found that bone mass and density declined over time with generally higher levels in C compared to R animals. Circulating serum markers of bone turnover were not different between C and R with nonsignficant diet-by-time interactions. We believe the lower bone mass in R animals reflects the smaller body size and not pathological osteopenia.
C1 [Colman, Ricki J.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.
[Beasley, T. Mark; Allison, David B.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
[Weindruch, Richard] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA.
[Weindruch, Richard] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA.
RP Colman, RJ (reprint author), Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.
EM rcolman@primate.wisc.edu
OI Allison, David/0000-0003-3566-9399
FU National Institutes of Health [P01 AG-11915, P51 RR000167]; Research
Facilities Improvement Program [RR15459-01, RR020141-01]
FX We acknowledge the excellent technical assistance provided by S. Baum,
J. Christensen, J. A. Adriansjach, C. E. Armstrong, and the Animal Care
and Veterinary Staff of the WNPRC. This work was supported by National
Institutes of Health grants P01 AG-11915 and P51 RR000167. This research
was conducted in part at the WNPRC, which received support from Research
Facilities Improvement Program grant numbers RR15459-01 and RR020141-01.
This research was supported in part by facilities and resources at the
Wm. S. Middleton Memorial Veterans Hospital.
NR 70
TC 6
Z9 6
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0161-9152
J9 AGE
JI Age
PD OCT
PY 2012
VL 34
IS 5
BP 1133
EP 1143
DI 10.1007/s11357-011-9354-x
PG 11
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 011NB
UT WOS:000309170600007
PM 22189911
ER
PT J
AU Liu, JR
Zhang, W
Chuang, GC
Hill, HS
Tian, L
Fu, YC
Moellering, DR
Garvey, WT
AF Liu, Jiarong
Zhang, Wei
Chuang, Gin C.
Hill, Helliner S.
Tian, Ling
Fu, Yuchang
Moellering, Douglas R.
Garvey, W. Timothy
TI Role of TRIB3 in regulation of insulin sensitivity and nutrient
metabolism during short-term fasting and nutrient excess
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE tribbles 3; glucose oxidation; nutrient sensor; skeletal muscle; adipose
tissue; adipocyte; mitochondria; glucose transport; glucose oxidation
ID SKELETAL-MUSCLE; GENE-EXPRESSION; MITOCHONDRIAL BIOGENESIS; OXIDATIVE
STRESS; DIABETIC COMPLICATIONS; TRIBBLES HOMOLOG; MESSENGER-RNA;
CELL-FUNCTION; TRB3; INDUCTION
AB Liu J, Zhang W, Chuang GC, Hill HS, Tian L, Fu Y, Moellering DR, Garvey WT. Role of TRIB3 in regulation of insulin sensitivity and nutrient metabolism during short-term fasting and nutrient excess. Am J Physiol Endocrinol Metab 303: E908-E916, 2012. First published July 31, 2012; doi:10.1152/ajpendo.00663.2011.-We have suggested previously that Tribbles homolog 3 (TRIB3), a negative regulator of Akt activity in insulin-sensitive tissues, could mediate glucose-induced insulin resistance in muscle under conditions of chronic hyperglycemia (Liu J, Wu X, Franklin JL, Messina JL, Hill HS, Moellering DR, Walton RG, Martin M, Garvey WT. Am J Physiol Endocrinol Metab 298: E565-E576, 2010). In the current study, we have assessed short-term physiological regulation of TRIB3 in skeletal muscle and adipose tissues by nutrient excess and fasting as well as TRIB3's ability to modulate glucose transport and mitochondrial oxidation. In Sprague-Dawley rats, we found that short-term fasting enhanced insulin sensitivity concomitantly with decrements in TRIB3 mRNA (66%, P < 0.05) and protein (81%, P < 0.05) in muscle and increments in TRIB3 mRNA (96%, P < 0.05) and protein (similar to 10-fold, P < 0.05) in adipose tissue compared with nonfasted controls. On the other hand, rats fed a Western diet for 7 days became insulin resistant concomitantly with increments in TRIB3 mRNA (155%, P < 0.05) and protein (69%, P = 0.0567) in muscle and a decrease in the mRNA (76%, P < 0.05) and protein (70%, P < 0.05) in adipose. In glucose transport and mitochondria oxidation studies using skeletal muscle cells, we found that stable TRIB3 overexpression impaired insulin-stimulated glucose uptake without affecting basal glucose transport and increased both basal glucose oxidation and the maximal uncoupled oxygen consumption rate. With stable knockdown of TRIB3, basal and insulin-stimulated glucose transport rates were increased, whereas basal glucose oxidation and the maximal uncoupled oxygen consumption rate were decreased. In conclusion, TRIB3 impacts glucose uptake and oxidation oppositely in muscle and fat according to levels of nutrient availability. The above data for the first time implicate TRIB3 as a potent physiological regulator of insulin sensitivity and mitochondrial glucose oxidation under conditions of nutrient deprivation and excess.
C1 [Zhang, Wei; Tian, Ling; Moellering, Douglas R.; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Liu, Jiarong; Chuang, Gin C.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Chuang, Gin C.; Moellering, Douglas R.] Univ Alabama Birmingham, Comprehens Diabet Ctr, Diabet Res & Training Ctr, Birmingham, AL USA.
[Chuang, Gin C.; Moellering, Douglas R.] Univ Alabama Birmingham, Bioanalyt Redox Biol Core, Birmingham, AL USA.
[Hill, Helliner S.] Novo Nordisk, Field Med Affairs Diabet, Princeton, NJ USA.
[Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, 1675 Univ Blvd, Birmingham, AL 35294 USA.
EM garveyt@uab.edu
RI Chuang, Gin/J-6510-2012
OI Chuang, Gin/0000-0003-3919-1820
FU National Institute of Diabetes and Digestive and Kidney Diseases
[DK-038765, DK-083562]; Merit Review Program of the Department of
Veterans Affairs; University of Alabama at Birmingham Diabetes Research
and Training Center [P60 DK-079626]
FX This work was supported by grants from the National Institute of
Diabetes and Digestive and Kidney Diseases (DK-038765, DK-083562) and by
the Merit Review Program of the Department of Veterans Affairs.; We
acknowledge support from core facilities of the University of Alabama at
Birmingham Diabetes Research and Training Center (P60 DK-079626).
NR 50
TC 9
Z9 9
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
EI 1522-1555
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD OCT
PY 2012
VL 303
IS 7
BP E908
EP E916
DI 10.1152/ajpendo.00663.2011
PG 9
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 016HF
UT WOS:000309507700011
PM 22850683
ER
PT J
AU Inoue, T
Wang, JH
Higashiyama, M
Rudenkyy, S
Higuchi, K
Guth, PH
Engel, E
Kaunitz, JD
Akiba, Y
AF Inoue, Takuya
Wang, Joon-Ho
Higashiyama, Masaaki
Rudenkyy, Sergiy
Higuchi, Kazuhide
Guth, Paul H.
Engel, Eli
Kaunitz, Jonathan D.
Akiba, Yasutada
TI Dipeptidyl peptidase IV inhibition potentiates amino acid- and bile
acid-induced bicarbonate secretion in rat duodenum
SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
LA English
DT Article
DE glucagon-like peptide-2; L cells; TGR5; monosodium glutamate; taste
receptor
ID GLUCAGON-LIKE PEPTIDE-1; L CELLS; ABSORPTION; RECEPTORS; INTESTINE;
PROTEIN; MUCOSA; EPAC; RAP1; PIGS
AB Inoue T, Wang JH, Higashiyama M, Rudenkyy S, Higuchi K, Guth PH, Engel E, Kaunitz JD, Akiba Y. Dipeptidyl peptidase IV inhibition potentiates amino acid-and bile acid-induced bicarbonate secretion in rat duodenum. Am J Physiol Gastrointest Liver Physiol 303: G810-G816, 2012. First published July 19, 2012; doi:10.1152/ajpgi.00195.2012.-Intestinal endocrine cells release gut hormones, including glucagon-like peptides (GLPs), in response to luminal nutrients. Luminal L-glutamate (L-Glu) and 5'-inosine monophosphate (IMP) synergistically increases duodenal HCO3- secretion via GLP-2 release. Since L cells express the bile acid receptor TGR5 and dipeptidyl peptidase (DPP) IV rapidly degrades GLPs, we hypothesized that luminal amino acids or bile acids stimulate duodenal HCO3- secretion via GLP-2 release, which is enhanced by DPPIV inhibition. We measured HCO3- secretion with pH and CO2 electrodes using a perfused rat duodenal loop under isoflurane anesthesia. L-Glu (10 mM) and IMP (0.1 mM) were luminally coperfused with or without luminal perfusion (0.1 mM) or intravenous (iv) injection (3 mu mol/kg) of the DPPIV inhibitor NVP728. The loop was also perfused with a selective TGR5 agonist betulinic acid (BTA, 10 mu M) or the non-bile acid type TGR5 agonist 3-(2-chlorophenyl)-N-(4-chlorophenyl)-N,5-dimethylisoxazole-4-carboxamide (CCDC; 10 mu M). DPPIV activity visualized by use of the fluorogenic substrate was present on the duodenal brush border and submucosal layer, both abolished by the incubation with NVP728 (0.1 mM). An iv injection of NVP728 enhanced L-Glu/IMP-induced HCO3- secretion, whereas luminal perfusion of NVP728 had no effect. BTA or CCDC had little effect on HCO3- secretion, whereas NVP728 iv markedly enhanced BTA- or CCDC-induced HCO3- secretion, the effects inhibited by a GLP-2 receptor antagonist. Coperfusion of the TGR5 agonist enhanced L-Glu/IMP-induced HCO3 secretion with the enhanced GLP-2 release, suggesting that TGR5 activation amplifies nutrient sensing signals. DPPIV inhibition potentiated luminal L-Glu/IMP-induced and TGR5 agonist-induced HCO3- secretion via a GLP-2 pathway, suggesting that the modulation of the local concentration of the endogenous secretagogue GLP-2 by luminal compounds and DPPIV inhibition helps regulate protective duodenal HCO3- secretion.
C1 [Rudenkyy, Sergiy; Guth, Paul H.; Kaunitz, Jonathan D.; Akiba, Yasutada] Univ Calif Los Angeles, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
[Inoue, Takuya; Wang, Joon-Ho; Higashiyama, Masaaki; Kaunitz, Jonathan D.; Akiba, Yasutada] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA.
[Kaunitz, Jonathan D.; Akiba, Yasutada] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA USA.
[Kaunitz, Jonathan D.; Akiba, Yasutada] Brentwood Biomed Res Inst, Los Angeles, CA USA.
[Inoue, Takuya; Higuchi, Kazuhide] Osaka Med Coll, Dept Internal Med 2, Osaka, Japan.
RP Akiba, Y (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM yakiba@mednet.ucla.edu
FU Ajinomoto, Japan; Department of Veterans Affairs Merit Review Award;
NIH-NIDDK [R01 DK54221, P30 DK0413]
FX This research was supported by a research grant from Ajinomoto, Japan
(Y. Akiba), Department of Veterans Affairs Merit Review Award, NIH-NIDDK
R01 DK54221 (J. Kaunitz), and the animal core of NIH-NIDDK P30 DK0413
(J. E. Rozengurt).
NR 40
TC 12
Z9 12
U1 0
U2 13
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1857
J9 AM J PHYSIOL-GASTR L
JI Am. J. Physiol.-Gastroint. Liver Physiol.
PD OCT
PY 2012
VL 303
IS 7
BP G810
EP G816
DI 10.1152/ajpgi.00195.2012
PG 7
WC Gastroenterology & Hepatology; Physiology
SC Gastroenterology & Hepatology; Physiology
GA 016HJ
UT WOS:000309508100004
PM 22821947
ER
PT J
AU Weaver, TE
Mancini, C
Maislin, G
Cater, J
Staley, B
Landis, JR
Ferguson, KA
George, CFP
Schulman, DA
Greenberg, H
Rapoport, DM
Walsleben, JA
Lee-Chiong, T
Gurubhagavatula, I
Kuna, ST
AF Weaver, Terri E.
Mancini, Cristina
Maislin, Greg
Cater, Jacqueline
Staley, Bethany
Landis, J. Richard
Ferguson, Kathleen A.
George, Charles F. P.
Schulman, David A.
Greenberg, Harly
Rapoport, David M.
Walsleben, Joyce A.
Lee-Chiong, Teofilo
Gurubhagavatula, Indira
Kuna, Samuel T.
TI Continuous Positive Airway Pressure Treatment of Sleepy Patients with
Milder Obstructive Sleep Apnea Results of the CPAP Apnea Trial North
American Program (CATNAP) Randomized Clinical Trial
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE continuous positive airway pressure; obstructive sleep apnea; daytime
sleepiness; randomized clinical trial; functional status
ID BREATHING DISORDERS; DAYTIME SLEEPINESS; PRACTICE PARAMETERS; PLACEBO;
HEALTH; ADULTS; PERFORMANCE; POPULATION; MODAFINIL; THERAPY
AB Rationale: Twenty-eight percent of people with mild to moderate obstructive sleep apnea experience daytime sleepiness, which interferes with daily functioning. It remains unclear whether treatment with continuous positive airway pressure improves daytime function in these patients.
Objectives: To evaluate the efficacy of continuous positive airway pressure treatment to improve functional status in sleepy patients with mild and moderate obstructive sleep apnea.
Methods: Patients with self-reported daytime sleepiness (Epworth Sleepiness Scale score >10) and an apnea-hypopnea index with 3% desaturation and from 5 to 30 events per hour were randomized to 8 weeks of active or sham continuous positive airway pressure treatment. After the 8-week intervention, participants in the sham arm received 8 weeks of active continuous positive airway pressure treatment.
Measurements and Main Results: The Total score on the Functional Outcomes of Sleep Questionnaire was the primary outcome measure. intervention was 0.89 for the active group (n = 113) and 0.06 for the placebo group (n = 110) (P= 0.006). The group difference in mean change corresponded to an effect size of 0.41 (95% confidence interval, 0.14-0.67). The mean (SD) improvement in Functional Outcomes of Sleep Questionnaire Total score from the beginning to the end of the crossover phase (n = 91) was 1.73 +/- 2.50 (t[90] = 6.59; P < 0.00001) with an effect size of 0.69.
Conclusions: Continuous positive airway pressure treatment improves the functional outcome of sleepy patients with mild and moderate obstructive sleep apnea. Clinical trial registered with www.clinicaltrials.gov (NCT 00127348).
C1 [Weaver, Terri E.] Univ Illinois, Coll Nursing, Dept Biobehav Hlth Sci, Chicago, IL 60612 USA.
[Weaver, Terri E.; Mancini, Cristina] Univ Penn, Sch Nursing, Biobehav & Hlth Sci Div, Philadelphia, PA 19104 USA.
[Weaver, Terri E.; Maislin, Greg; Cater, Jacqueline; Staley, Bethany; Gurubhagavatula, Indira; Kuna, Samuel T.] Univ Penn, Sch Med, Ctr Sleep & Circadian Neurobiol, Div Sleep Med,Dept Med, Philadelphia, PA 19104 USA.
[Maislin, Greg; Cater, Jacqueline] Biostat Consulting, Wynnewood, PA USA.
[Landis, J. Richard] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Ferguson, Kathleen A.; George, Charles F. P.] Univ Western Ontario, Schulich Sch Med & Dent, Div Respirol, London, ON, Canada.
[Schulman, David A.] Emory Univ, Emory Univ Hosp, Div Pulm Allergy & Crit Care Med, Atlanta, GA 30322 USA.
[Greenberg, Harly] N Shore Long Isl Jewish Hlth Syst, Div Pulm Crit Care & Sleep Med, New Hyde Pk, NY USA.
[Rapoport, David M.; Walsleben, Joyce A.] NYU, Sleep Disorder Ctr, Sch Med, Dept Med,Div Pulm & Crit Care & Sleep Med, New York, NY USA.
[Lee-Chiong, Teofilo] Natl Jewish Hlth, Dept Med, Denver, CO USA.
[Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Weaver, TE (reprint author), Univ Illinois, Coll Nursing, Dept Biobehav Hlth Sci, 845 S Damen Ave MC 802, Chicago, IL 60612 USA.
EM teweaver@uic.edu
OI Rapoport, David/0000-0002-4855-2600
FU National Institutes for Health National Heart, Lung, and Blood Institute
[R01 HL076101]; Sleep Medicine Education and Research Foundation
(American Academy of Sleep Medicine); Respironics Sleep and Respiratory
Research Foundation; Cephalon, Inc.
FX Supported by National Institutes for Health National Heart, Lung, and
Blood Institute, R01 HL076101 (T.E.W., C.M., B.S., J.R.L., K.A.F.,
C.F.P.G., D.A.S., H.G., D.M.R., JAW., S.T.K.); Sleep Medicine Education
and Research Foundation (American Academy of Sleep Medicine) (T.E.W.);
Respironics Sleep and Respiratory Research Foundation (T.E.W.); and
Cephalon, Inc. (T.E.W., CM.). Equipment provided by Philips Respironics,
Inc., ProTech Services, Inc., and Embla.
NR 32
TC 67
Z9 68
U1 1
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD OCT 1
PY 2012
VL 186
IS 7
BP 677
EP 683
DI 10.1164/rccm.201202-0200OC
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 014NV
UT WOS:000309383600019
PM 22837377
ER
PT J
AU Byers, AL
Vittinghoff, E
Lui, LY
Hoang, T
Blazer, DG
Covinsky, KE
Ensrud, KE
Cauley, JA
Hillier, TA
Fredman, L
Yaffe, K
AF Byers, Amy L.
Vittinghoff, Eric
Lui, Li-Yung
Hoang, Tina
Blazer, Dan G.
Covinsky, Kenneth E.
Ensrud, Kristine E.
Cauley, Jane A.
Hillier, Teresa A.
Fredman, Lisa
Yaffe, Kristine
TI Twenty-Year Depressive Trajectories Among Older Women
SO ARCHIVES OF GENERAL PSYCHIATRY
LA English
DT Article
ID LATE-LIFE DEPRESSION; NATIONAL-COMORBIDITY-SURVEY; PRIMARY-CARE
PATIENTS; LATENT CLASS ANALYSIS; PHYSICAL-ACTIVITY; MAJOR DEPRESSION;
COMMUNITY SAMPLE; FUTURE-RESEARCH; SYMPTOMS; ADULTS
AB Context: Despite the frequent occurrence of depressive symptoms among older adults, especially women, little is known about the long-term course of late-life depressive symptoms.
Objective: To characterize the natural course of depressive symptoms among older women (from the young old to the oldest old) followed up for almost 20 years.
Design: Using latent-class growth-curve analysis, we analyzed women enrolled in an ongoing prospective cohort study (1988 through 2009).
Setting: Clinic sites in Baltimore, Maryland; Minneapolis, Minnesota; the Monongahela Valley near Pittsburgh, Pennsylvania; and Portland, Oregon.
Participants: We studied 7240 community-dwelling women 65 years or older.
Main Outcome Measure: The Geriatric Depression Scale short form (score range, 0-15) was used to routinely assess depressive symptoms during the follow-up period.
Results: Among older women, we identified 4 latent classes during 20 years, with the predicted probabilities of group membership totaling 27.8% with minimal depressive symptoms, 54.0% with persistently low depressive symptoms, 14.8% with increasing depressive symptoms, and 3.4% with persistently high depressive symptoms. In an adjusted model for latent class membership, odds ratios (ORs) for belonging in the increasing depressive symptoms and persistently high depressive symptoms classes, respectively, compared with a group having minimal depressive symptoms were substantially and significantly (P < .05) elevated for the following variables: baseline smoking (ORs, 4.69 and 7.97), physical inactivity (ORs, 2.11 and 2.78), small social network (ORs, 3.24 and 6.75), physical impairment (ORs, 8.11 and 16.43), myocardial infarction (ORs, 2.09 and 2.41), diabetes mellitus (ORs, 2.98 and 3.03), and obesity (ORs, 1.86 and 2.90).
Conclusions: During 20 years, almost 20% of older women experienced persistently high depressive symptoms or increasing depressive symptoms. In addition, these women had more comorbidities, physical impairment, and negative lifestyle factors at baseline. These associations support the need for intervention and prevention strategies to reduce depressive symptoms into the oldest-old years. Arch Gen Psychiatry. 2012;69(10):1073-1079
C1 [Byers, Amy L.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Vittinghoff, Eric; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, Dept ofMedicine, San Francisco, CA 94121 USA.
[Byers, Amy L.; Hoang, Tina; Covinsky, Kenneth E.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Lui, Li-Yung] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Blazer, Dan G.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA.
[Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Ensrud, Kristine E.] Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA.
[Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
[Fredman, Lisa] Boston Univ, Dept Epidemiol, Boston, MA 02215 USA.
RP Byers, AL (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,Mail Code 116H, San Francisco, CA 94121 USA.
EM Amy.Byers@ucsf.edu
OI Cauley, Jane A/0000-0003-0752-4408
FU National Institute of Mental Health [R01 MH086498, MH079093]; National
Institute on Aging [AG031155]; Public Health Service from the National
Institute of Arthritis and Musculoskeletal and Skin Diseases [2 R01
AG027574-22A1, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1,
AG05407, AG05394, AR35582, AR35583, AR35584, AG026720, R01 AG18037, R01
AG028144-01A1]; National Institute on Aging
FX This work was supported by grants R01 MH086498 from the National
Institute of Mental Health (Dr Yaffe), which was administered by the
Northern California Institute for Research and Education and with
resources of the San Francisco Veterans Affairs Medical Center, K01
Career Development Award MH079093 from the National Institute of Mental
Health (Dr Byers), and K24 Midcareer Investigator Award AG031155 from
the National Institute on Aging (Dr Yaffe). The Study of Osteoporotic
Fractures was supported by Public Health Service grants 2 R01
AG027574-22A1, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1,
AG05407, AG05394, AR35582, AR35583, AR35584, AG026720, R01 AG18037, and
R01 AG028144-01A1 from the National Institute of Arthritis and
Musculoskeletal and Skin Diseases and the National Institute on Aging.
NR 48
TC 44
Z9 46
U1 4
U2 17
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-990X
J9 ARCH GEN PSYCHIAT
JI Arch. Gen. Psychiatry
PD OCT
PY 2012
VL 69
IS 10
BP 1073
EP 1079
PG 7
WC Psychiatry
SC Psychiatry
GA 014YV
UT WOS:000309412800010
PM 23026957
ER
PT J
AU Schumacher, HR
Evans, RR
Saag, KG
Clower, J
Jennings, W
Weinstein, SP
Yancopoulos, GD
Wang, J
Terkeltaub, R
AF Schumacher, H. Ralph, Jr.
Evans, Robert R.
Saag, Kenneth G.
Clower, James
Jennings, William
Weinstein, Steven P.
Yancopoulos, George D.
Wang, Jian
Terkeltaub, Robert
TI Rilonacept (interleukin-1 trap) for prevention of gout flares during
initiation of uric acid-lowering therapy: Results from a phase III
randomized, double-blind, placebo-controlled, confirmatory efficacy
study
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID HEALTH-CARE UTILIZATION; IL-1 INHIBITION; RENAL-DISEASE; ARTHRITIS;
MANAGEMENT; ANAKINRA; INFLAMMATION; ALLOPURINOL; PREVALENCE; ADHERENCE
AB Objective To evaluate the efficacy and safety of the interleukin-1 inhibitor rilonacept (interleukin-1 Trap) for gout flare prevention during initiation of uric acidlowering therapy (ULT). Methods In total, 241 adult patients with gout, =2 gout flares within the past year, and a serum urate level =7.5 mg/dl were initiated on allopurinol 300 mg daily and randomly allocated in a 1:1:1 ratio to receive 16 once-weekly subcutaneous injections of placebo, rilonacept 80 mg, or rilonacept 160 mg, with a double (loading) dose on day 1. Allopurinol was titrated to achieve a serum urate level of <6.0 mg/dl. The study was powered for the primary efficacy end point, the number of gout flares per patient through week 16. Results More patients in the rilonacept groups (80.0% in the rilonacept 80 mg group, 86.4% in the rilonacept 160 mg group) completed the study than in the placebo group (72.5%; P < 0.05 for the rilonacept 160 mg group versus the placebo group). Over 16 weeks, the mean number of gout flares per patient was significantly reduced by rilonacept treatment (placebo: 1.06, rilonacept 80 mg: 0.29 [P < 0.001], rilonacept 160 mg: 0.21 [P < 0.001]). Significantly lower proportions of patients reported =1 gout flares with rilonacept 80 mg (18.8%) and rilonacept 160 mg (16.3%) relative to placebo (46.8%; P < 0.001 for both). Except for injection site reactions (1.3% in the placebo group versus 8.8% in the rilonacept 80 mg group [P = 0.0635, post hoc analysis] and 19.8% in the rilonacept 160 mg group [P = 0.0001, post hoc analysis]), the incidence of adverse events was generally balanced among the treatment groups. Conclusion Rilonacept markedly reduced the occurrence of gout flares associated with the initiation of ULT. The efficacy and safety profile suggests that rilonacept may have the potential to improve long-term disease control for some patients by improving adherence to ULT by reducing flares during the first months after ULT initiation.
C1 [Schumacher, H. Ralph, Jr.] Univ Penn, Philadelphia, PA 19104 USA.
[Schumacher, H. Ralph, Jr.] VA Med Ctr, Philadelphia, PA USA.
[Evans, Robert R.; Weinstein, Steven P.; Yancopoulos, George D.; Wang, Jian] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
[Clower, James] Westside Ctr Clin Res & Baptist Primary Care, Jacksonville, FL USA.
[Jennings, William] Radiant Res, San Antonio, TX USA.
[Terkeltaub, Robert] Univ Calif San Diego, San Diego, CA 92103 USA.
[Terkeltaub, Robert] VA Healthcare Syst San Diego, San Diego, CA USA.
[Saag, Kenneth G.] Univ Alabama Birmingham, Birmingham, AL USA.
RP Schumacher, HR (reprint author), Philadelphia VA Med Ctr, 151K,Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM schumacr@mail.med.upenn.edu
FU Regeneron Pharmaceuticals; Regeneron; Takeda; Novartis; Ardea; Pfizer;
Savient; URL
FX Supported by Regeneron Pharmaceuticals.; Dr. Schumacher has received
consultancy fees, speaking fees, and/or honoraria (less than $10,000
each) from Regeneron, Takeda, Novartis, Ardea, and Pfizer. Dr. Evans
owns stock or stock options in Regeneron. Dr. Saag has received
consultancy fees, speaking fees, and/or honoraria (less than $10,000
each) from Takeda, Novartis, Ardea, and Savient. Dr. Weinstein owns
stock or stock options in Regeneron and holds a patent licensed to
Regeneron for Arcalyst (rilonacept). Dr. Yancopoulos owns stock or stock
options in Regeneron and holds a patent licensed to Regeneron for
Arcalyst (rilonacept). Dr. Wang owns stock or stock options in
Regeneron. Dr. Terkeltaub has received consultancy fees, speaking fees,
and/or honoraria (less than $10,000 each) from Regeneron, Novartis, URL,
Takeda, Ardea, and Pfizer, and has served as a paid consultant to
Leerink Swann Investment Banking Group.
NR 48
TC 43
Z9 44
U1 2
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD OCT
PY 2012
VL 64
IS 10
BP 1462
EP 1470
DI 10.1002/acr.21690
PG 9
WC Rheumatology
SC Rheumatology
GA 014QV
UT WOS:000309391700003
PM 22549879
ER
PT J
AU Young, P
Kim, B
Malin, JL
AF Young, Patricia
Kim, Benjamin
Malin, Jennifer L.
TI Preoperative breast MRI in early-stage breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Magnetic resonance imaging, Functional; Decision
analysis; Technology; Assessment
ID RANDOMIZED CONTROLLED-TRIAL; 20-YEAR FOLLOW-UP; COST-EFFECTIVENESS;
RADIATION-THERAPY; CONSERVATIVE SURGERY; SURGICAL-MANAGEMENT; CONSERVING
SURGERY; MASTECTOMY; IMPACT; CARCINOMA
AB Rapid uptake of new imaging technology is a major contributor to rising healthcare costs. Preoperative breast magnetic resonance imaging (MRI) for patients with early-stage breast cancer has dramatically increased in use without the evidence of improved outcomes compared to standard assessment and is associated with higher rates of mastectomy. A decision analytic model was developed to evaluate the impact of adding breast MRI to the preoperative evaluation of women with early-stage breast cancer who were candidates for breast-conserving therapy on patient outcomes measured in quality-adjusted life years (QALYs). Model inputs, including survival, recurrence rates, and health utilities, were obtained from a comprehensive literature review. One-way sensitivity analyses were performed to estimate threshold values for key parameters at which adding MRI would become the optimal imaging strategy over standard assessment. Preoperative MRI resulted in 17.77 QALYs compared to 17.86 QALYs with standard assessment, a decrease of 0.09 QALYs or 34 days. In sensitivity analyses, standard assessment was associated with better patient outcomes than preoperative breast MRI across all plausible probabilities for mastectomy, local recurrence, and health utilities. For routine preoperative breast MRI to become the optimal strategy, the conversion rate to mastectomy after preoperative MRI would need to be < 1 % (versus the range of 3.6-33 % reported in the literature). Routine preoperative breast MRI appears to confer no advantage over the standard diagnostic evaluations for early-stage breast cancer and may lead to worse patient outcomes.
C1 [Young, Patricia] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Young, Patricia; Malin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Kim, Benjamin] UCSF Sch Med, Div Hematol Oncol, Dept Med, San Francisco, CA USA.
[Kim, Benjamin; Malin, Jennifer L.] RAND Corp, Santa Monica, CA USA.
[Malin, Jennifer L.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
[Malin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Young, P (reprint author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Suite 5512, Los Angeles, CA 90048 USA.
EM pyoung@mednet.ucla.edu
NR 42
TC 7
Z9 8
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD OCT
PY 2012
VL 135
IS 3
BP 907
EP 912
DI 10.1007/s10549-012-2207-1
PG 6
WC Oncology
SC Oncology
GA 003ZB
UT WOS:000308648800028
PM 22923237
ER
PT J
AU Holmgren, SC
Goren, EM
Wood, BL
Becker, PS
Taylor, JA
AF Holmgren, Sigrid C.
Goren, Emily M.
Wood, Brent L.
Becker, Pamela S.
Taylor, Jason A.
TI Immune defects in a mouse model of Fanconi anaemia
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Letter
DE Fanconi anaemia; vaccination; immune defects; human papillomavirus
ID HEAD
C1 [Holmgren, Sigrid C.; Goren, Emily M.; Taylor, Jason A.] Portland VA Med Ctr, Portland, OR USA.
[Wood, Brent L.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
[Wood, Brent L.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Becker, Pamela S.] Univ Washington, Div Hematol, Seattle, WA 98195 USA.
[Taylor, Jason A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Holmgren, SC (reprint author), Portland VA Med Ctr, Portland, OR USA.
EM taylojas@ohsu.edu
NR 9
TC 2
Z9 2
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD OCT
PY 2012
VL 159
IS 2
BP 246
EP 250
DI 10.1111/bjh.12012
PG 5
WC Hematology
SC Hematology
GA 012NC
UT WOS:000309242000018
PM 22897682
ER
PT J
AU Smith, MA
Schnellmann, RG
AF Smith, Matthew A.
Schnellmann, Rick G.
TI Calpains, mitochondria, and apoptosis
SO CARDIOVASCULAR RESEARCH
LA English
DT Review
DE Calpains; Apoptosis; Mitochondria; Cardiovascular system
ID RENAL-CELL DEATH; MYOFIBRILLAR PROTEIN TURNOVER; CALCIUM-DEPENDENT
PROTEASE; REDUCES INFARCT SIZE; MU-CALPAIN; ENDOTHELIAL-CELLS;
PERMEABILITY TRANSITION; SKELETAL-MUSCLE; CA-2&-ACTIVATED PROTEASE;
SIGNALING PATHWAYS
AB Mitochondrial activity is critical for efficient function of the cardiovascular system. In response to cardiovascular injury, mitochondrial dysfunction occurs and can lead to apoptosis and necrosis. Calpains are a 15-member family of Ca-2-activated cysteine proteases localized to the cytosol and mitochondria, and several have been shown to regulate apoptosis and necrosis. For example, in endothelial cells, Ca-2 overload causes mitochondrial calpain 1 cleavage of the Na/Ca-2 exchanger leading to mitochondrial Ca-2 accumulation. Also, activated calpain 1 cleaves Bid, inducing cytochrome c release and apoptosis. In renal cells, calpains 1 and 2 promote apoptosis and necrosis by cleaving cytoskeletal proteins, which increases plasma membrane permeability and cleavage of caspases. Calpain 10 cleaves electron transport chain proteins, causing decreased mitochondrial respiration and excessive activation, or inhibition of calpain 10 activity induces mitochondrial dysfunction and apoptosis. In cardiomyocytes, calpain 1 activates caspase 3 and poly-ADP ribose polymerase during tumour necrosis factor--induced apoptosis, and calpain 1 cleaves apoptosis-inducing factor after Ca-2 overload. Many of these observations have been elucidated with calpain inhibitors, but most calpain inhibitors are not specific for calpains or a specific calpain family member, creating more questions. The following review will discuss how calpains affect mitochondrial function and apoptosis within the cardiovascular system.
C1 [Smith, Matthew A.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, Charleston, SC 29425 USA.
[Schnellmann, Rick G.] Ralph Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, 280 Calhoun St,MSC140, Charleston, SC 29425 USA.
EM schnell@musc.edu
FU NIH [GM 084147, ES-012239, C06 RR-015455]; NIH/NIEHS Training Program in
Environmental Stress Signaling [T32ES012878-05]; Biomedical Laboratory
Research and Development Program of the Department of Veterans Affairs
FX This study was supported by NIH Grant (GM 084147), the NIH Grant
(ES-012239), the NIH/NIEHS Training Program in Environmental Stress
Signaling (T32ES012878-05), and by the Biomedical Laboratory Research
and Development Program of the Department of Veterans Affairs. Animal
facilities were funded by NIH grant (C06 RR-015455).
NR 113
TC 76
Z9 83
U1 0
U2 68
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0008-6363
J9 CARDIOVASC RES
JI Cardiovasc. Res.
PD OCT 1
PY 2012
VL 96
IS 1
BP 32
EP 37
DI 10.1093/cvr/cvs163
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 010CS
UT WOS:000309072700007
PM 22581845
ER
PT J
AU Mantovani, A
Pavlicova, M
Avery, D
Nahas, Z
McDonald, WM
Wajdik, CD
Holtzheimer, PE
George, MS
Sackeim, HA
Lisanby, SH
AF Mantovani, Antonio
Pavlicova, Martina
Avery, David
Nahas, Ziad
McDonald, William M.
Wajdik, Chandra D.
Holtzheimer, Paul E., III
George, Mark S.
Sackeim, Harold A.
Lisanby, Sarah H.
TI LONG-TERM EFFICACY OF REPEATED DAILY PREFRONTAL TRANSCRANIAL MAGNETIC
STIMULATION (TMS) IN TREATMNT-RESISTANT DEPRESSION
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE transcranial magnetic stimulation; efficacy; follow-up;
treatment-resistant; depression
ID MAJOR DEPRESSION; OPEN-LABEL; ELECTROCONVULSIVE-THERAPY; ANTIDEPRESSANT
EFFICACY; RELAPSE; METAANALYSIS; MULTISITE; TRIAL; RTMS; PHARMACOTHERAPY
AB Background A few studies have examined the durability of transcranial magnetic stimulation (TMS) antidepressant benefit once patients remitted. This study examined the long-term durability of clinical benefit from TMS using a protocol-specified TMS taper and either continuation pharmacotherapy or naturalistic follow-up. Methods Patients were remitters from an acute double-blind sham-controlled trial of TMS (n=18), or from an open-label extension in patients who did not respond to the acute trial (n=43). Long-term durability of TMS acute effect was examined in remitters over a 12-week follow-up. Relapse, defined as 24-item Hamilton Depression Rating Scale (HDRS-24) =20, was the primary outcome. Results Of 61 remitters in the acute trial, five entered naturalistic follow-up and 50 entered the TMS taper. Thirty-two patients completed TMS taper and 1-, 2-, and 3-month follow-up. At 3-month visit, 29 of 50 (58%) were classified as in remission (HDRS-24 =10), two of 50 (4%) as partial responders (30%= HDRS-24 reduction <50% from baseline), and one of 50 (2%) met criteria for relapse. During the entire 3-month follow-up, five of the 37 patients relapsed (relapse rate=13.5%), but four of them regained remission by the end of the study. The average time to relapse in these five patients was 7.2 +/- 3.3 weeks. Patients who relapsed had higher depression scores at 1 month. Conclusions While one third of the sample was lost to follow-up, our results demonstrate that most patients contributing to observations experienced persistence of benefit from TMS followed by pharmacotherapy or no medication. Longer follow-up and more rigorous studies are needed to explore the true long-term durability of remission produced by TMS.
C1 [Mantovani, Antonio] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Div Expt Therapeut, Dept Psychiat, New York, NY 10032 USA.
[Mantovani, Antonio] Univ Siena, Div Psychiat, Dept Neurosci, I-53100 Siena, Italy.
[Avery, David; Wajdik, Chandra D.] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA.
[Nahas, Ziad] Amer Univ Beirut, Dept Psychiat, Beirut, Lebanon.
[McDonald, William M.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
[Holtzheimer, Paul E., III] Dartmouth Hitchcock Med Ctr, Dept Psychiat, Lebanon, NH 03766 USA.
[George, Mark S.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Lisanby, Sarah H.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA.
RP Mantovani, A (reprint author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Div Expt Therapeut, Dept Psychiat, 1051 Riverside Dr,Unit 21, New York, NY 10032 USA.
EM am2518@columbia.edu
RI Holtzheimer, Paul/B-6212-2015
OI Holtzheimer, Paul/0000-0002-3552-3296
FU National Institute of Mental Health [5R01MH069929, 5R01MH069887,
5R01MH069896, 5R01MH069895, 5R01MH069886]; Eli Lilly and Company; Forest
Pharmaceuticals; Northstar Neuroscience; Neuronetics Inc; Performance
Plus; Takeda; Avanir Pharmaceutical; Aventis Pharmaceutical; Cyberonics
Inc; Hope for Depression Research Foundation; Integra; Medtronic Inc;
National Alliance of Research on Schizophrenia and Depression; National
Institute of Mental Health; Neuropace; Neuronetics; St. Jude Medical
Neuromodulation
FX We thank the following, who were either compensated or uncompensated
(u): Minnie Dobbins, MEd, MUSC (general administrative support), Judith
E. Kiersky, Ph.D., Columbia University (external expert rater), and
Elaine M. Dillingham, B. A., Columbia University (coordinated the expert
rater tapes/ratings and the neuropsychological administration and
scoring); Wenle Zhao, Ph.D. and Catherine Dillon from the MUSC Data
Coordinating Center; data and safety monitoring board members: Scott L.
Rauch, M. D., chairman, McLean Hospital, Belmont, Massachusetts; Eric
Wassermann, M. D.(u), National Institute of Neurological Disorders and
Stroke, Bethesda, Maryland; Cynthia Wainscott, Robert G. Robinson, M.
D., The University of Iowa; and Hongbin Gu, Ph.D., University of North
Carolina, Chapel Hill; MUSC site investigators, raters, and
coordinators, including Xingbao Li, M. D., Samet Kose, M. D., Jeffrey J.
Borckardt, Ph.D., Kevin Johnson, RN, Ph.D.; Columbia University site
investigators, raters, and coordinators, including Linda Fitzsimons, M.
S., R.N.C., Nancy Turret, L. C. S. W., Seth Disner, B. A., Austin
Harrison, B. A., Matthew Truesdale, B. S., and Teresa Ngyuen, B. S.;
Emory University site investigators, raters, and coordinators, including
Sinead Quinn, Mustafa A. Mufti, M. D., Adriana P. Hermida, M. D., Boadie
Dunlop, M. D., Charles M. Epstein, M. D., Ronald Chismar, R.N., Kimberly
McWhorter, J. D., MPH, and Halima N. Garba; and University of Washington
site investigators, raters, and coordinators, including Daniel Krashin,
M. D., Tobias Dang, M. D., Chul Jin Shin, M. D., Rita Navarro, M. D.,
Wang-Ku Rho, M. D., Susan Bentley, M. D., David R. Haynor, M. D., Emily
Rosenberger, B. A., Angela Ghesquiere, M. S. W., and Peter Roy-Byrne, M.
D. This study was presented in abstract form at the American Psychiatric
Association annual meeting, May 23, 2010; New Orleans, Louisiana. This
study was supported by the National Institute of Mental Health funded
Optimization of TMS for the Treatment of Depression Study (OPT-TMS)
study involving grants 5R01MH069929 (Dr. Avery), 5R01MH069887 (Dr.
George), 5R01MH069896 (Dr. George), 5R01MH069895 (Dr. Lisanby), and
5R01MH069886 (Dr. McDonald). Following a competitive bid and request
involving all TMS manufacturers at the time of trial initiation,
Neuronetics Inc. was selected and loaned the TMS devices, head holders,
and coils for the trial and allowed use of the safety Investigational
Device Exemption for their device.; Drs. Mantovani and Pavlikova have no
financial interest to disclose. Dr. Avery reports research grants,
speaking fees, or advisory board work with Eli Lilly and Company, Forest
Pharmaceuticals, Northstar Neuroscience, Neuronetics Inc, Performance
Plus, and Takeda. Dr. Nahas reports past and current research grants,
speaking fees, or consulting work with Avanir Pharmaceutical, Aventis
Pharmaceutical, Cyberonics Inc, Eli Lilly and Company, Hope for
Depression Research Foundation, Integra, Medtronic Inc, National
Alliance of Research on Schizophrenia and Depression, National Institute
of Mental Health, Neuronetics Inc, and Neuropace (unpaid consultant).
Dr. McDonald has received past research funding from Neuronetics. Dr.
McDonald is also an unpaid consultant for NeuroStim. Dr. McDonald is on
the faculty at Emory University which holds a patent on a TMS device. He
receives no payment or royalties on this device. Chandra Wajdik has no
financial interest to disclose. Dr. Holtzheimer has received consulting
fees from St. Jude Medical Neuromodulation. Dr. George has been an
unpaid advisor to Brainsonix, Brainsway, Neuronetics, Neostim and
Neosync (as they make products related to TMS), and a paid advisor to
Puretech ventures. The full amount of his advisory income has never been
more than 10% of his university salary. MUSC has two patent applications
in Dr. George's name on combining TMS with MRI imaging. He has no equity
investment in any device or pharmaceutical company. Dr. Sackeim has
served as a consultant to Cyberonics, Inc., Magstim Inc., MECTA Corp.,
and Neuronetics, Inc. Dr. Lisanby has served as PI on industry-sponsored
research grants to Columbia/RFMH or Duke (Neuronetics (past), Brainsway,
ANS/St. Jude, Cyberonics (past)); equipment loans to Columbia or Duke
(Magstim, MagVenture); is co-inventor on a patent application for TMS
technology not the topic of study here; and has no consultancies,
speakers bureau memberships, board affiliations, or equity holdings in
related industries.
NR 29
TC 18
Z9 19
U1 3
U2 24
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD OCT
PY 2012
VL 29
IS 10
BP 883
EP 890
DI 10.1002/da.21967
PG 8
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 014RY
UT WOS:000309394600007
PM 22689290
ER
PT J
AU Steidtmann, D
Manber, R
Arnow, BA
Klein, DN
Markowitz, JC
Rothbaum, BO
Thase, ME
Kocsis, JH
AF Steidtmann, Dana
Manber, Rachel
Arnow, Bruce A.
Klein, Daniel N.
Markowitz, John C.
Rothbaum, Barbara O.
Thase, Michael E.
Kocsis, James H.
TI PATIENT TREATMENT PREFERENCE AS A PREDICTOR OF RESPONSE AND ATTRITION IN
TREATMENT FOR CHRONIC DEPRESSION
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE treatment outcome; treatment engagement
ID BEHAVIORAL ANALYSIS SYSTEM; PRIMARY-CARE; MAJOR DEPRESSION; CHRONIC
FORMS; PSYCHOTHERAPY; DISORDER; TRIAL; SYMPTOMATOLOGY
AB Background Findings regarding the relationship between patient treatment preference and treatment outcome are mixed. This is a secondary data analysis investigating the relationship between treatment preference, and symptom outcome and attrition in a large two-phase depression treatment trial. Methods Patients met DSM-IV criteria for chronic forms of depression. Phase I was a 12-week, nonrandomized, open-label trial in which all participants (n = 785) received antidepressant medication(s) (ADM). Phase I nonremitters were randomized to Phase II, in which they received 12 weeks of either cognitive-behavioral system of psychotherapy (CBASP) + ADM (n = 193), brief supportive psychotherapy (BSP) + ADM (n = 187), or ADM only (n = 93). Participants indicated their treatment preference (medication only, combined treatment or no preference) at study entry. Symptoms were measured at 2-week intervals with the 24-item Hamilton Rating Scale for Depression (HAM-D). Results A large majority of patients reported a preference for combined treatment. Patients who preferred medication only were more likely to endorse a chemical imbalance explanation for depression, whereas those desiring combined treatment were more likely to attribute their depression to stressful experiences. In Phase I, patients who expressed no treatment preference showed greater rates of HAM-D symptom reduction than those with any preference, and patients with a preference for medication showed higher attrition than those preferring combined treatment. In Phase II, baseline treatment preference was not associated with symptom reduction or attrition. Conclusions Treatment preferences may moderate treatment response and attrition in unexpected ways. Research identifying factors associated with differing preferences may enable improved treatment retention and response.
C1 [Steidtmann, Dana; Manber, Rachel; Arnow, Bruce A.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA.
[Klein, Daniel N.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA.
[Markowitz, John C.] Columbia Univ, New York State Psychiat Inst, New York, NY USA.
[Rothbaum, Barbara O.] Emory Univ, Sch Med, Atlanta, GA USA.
[Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Kocsis, James H.] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA.
RP Steidtmann, D (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, 401 Quarry Rd, Stanford, CA 94305 USA.
EM dsteidt@stanford.edu
FU NIMH [UO1 MH62475, UO1 MH61587, UO1 MH62546, UO1 MH61562, UO1 MH63481,
U01 MH62465, UO1 MH61590, UO1 MH61504, T32 MH019938, U01 MH62491,
5T32MH019938-18]
FX Contract grant sponsor: NIMH; Contract grant numbers: UO1 MH62475 (James
H. Kocsis), UO1 MH61587 (Michael E. Thase), UO1 MH62546 (Daniel N.
Klein), UO1 MH61562 (Madhukar Trivedi), UO1 MH63481 (Philip Ninan and
Barbara O. Rothbaum), U01 MH62465 (Alan J. Gelenberg), UO1 MH61590
(Martin B. Keller), UO1 MH61504 and T32 MH019938 (Alan F. Schatzberg),
U01 MH62491 (James P. McCullough, Jr.); This work was supported by NIMH
grants to Cornell University (UO1 MH62475; James H. Kocsis); University
of Pittsburgh (UO1 MH61587; Michael E. Thase); Stony Brook University
(UO1 MH62546; Daniel N. Klein); University of Texas Southwestern Medical
Center (UO1 MH61562; Madhukar Trivedi); Emory University (UO1 MH63481;
Philip Ninan and Barbara O. Rothbaum); University of Arizona (U01
MH62465; Alan J. Gelenberg); BrownUniversity (UO1 MH61590; Martin B.
Keller); Stanford University (UO1 MH61504 and 5T32MH019938-18; Alan F.
Schatzberg); and Virginia Commonwealth University (U01 MH62491; James P.
McCullough, Jr.). All medications for this study were donated by Forest
Laboratories, GlaxoSmithKline, Organon Pharmaceuticals Inc., Pfizer
Inc., and Wyeth Pharmaceuticals.
NR 32
TC 19
Z9 22
U1 1
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD OCT
PY 2012
VL 29
IS 10
BP 896
EP 905
DI 10.1002/da.21977
PG 10
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 014RY
UT WOS:000309394600009
PM 22767424
ER
PT J
AU Raina, A
Papachristou, GI
AF Raina, Amit
Papachristou, Georgios I.
TI A Rare Cause of Anemia
SO GASTROENTEROLOGY
LA English
DT Editorial Material
ID PANCREATITIS
C1 [Raina, Amit] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA.
Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA.
RP Raina, A (reprint author), Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA.
NR 3
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD OCT
PY 2012
VL 143
IS 4
BP E1
EP E2
DI 10.1053/j.gastro.2012.03.004
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 014FY
UT WOS:000309361800001
PM 22921527
ER
PT J
AU Merlin, JS
Westfall, AO
Raper, JL
Zinski, A
Norton, WE
Willig, JH
Gross, R
Ritchie, CS
Saag, MS
Mugavero, MJ
AF Merlin, Jessica S.
Westfall, Andrew O.
Raper, James L.
Zinski, Anne
Norton, Wynne E.
Willig, James H.
Gross, Robert
Ritchie, Christine S.
Saag, Michael S.
Mugavero, Michael J.
TI Pain, Mood, and Substance Abuse in HIV: Implications for Clinic Visit
Utilization, Antiretroviral Therapy Adherence, and Virologic Failure
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; pain; psychiatric illness; substance abuse; ART adherence; health
care utilization
ID OPIOID-PRESCRIBING PRACTICES; HUMAN-IMMUNODEFICIENCY-VIRUS;
PATIENT-REPORTED OUTCOMES; PRIMARY-CARE; VIRAL LOAD;
PSYCHIATRIC-DISORDERS; DISEASE PROGRESSION; INFECTED PATIENTS;
MENTAL-HEALTH; PREVALENCE
AB Background: Cooccurring pain, mood disorders, and substance abuse are common in HIV-infected patients. Our objective was to investigate the relationship between pain, alone and in the context of mood disorders and substance abuse, on clinic utilization, antiretroviral therapy adherence, and virologic suppression.
Methods: Pain, mood disorders, and substance abuse were assessed at the first visit. No-show and urgent visits were measured over a 1-year period. Models were adjusted for age, race, sex, insurance status, CD4(+) T-lymphocyte count, and HIV risk factor.
Results: Among 1521 participants, 509 (34%) reported pain, 239 (16%) had pain alone, 189 (13%) had pain and a mood disorder, and 30 (2%) had pain and substance abuse. In univariate models, participants with pain, mood disorders, and substance abuse had higher odds of a no-show visit than those without these conditions [odds ratio (OR), 1.4; 95% confidence interval (CI), 1.1-1.8; OR, 1.5; 95% CI, 1.2-1.9; OR, 2.0; 95% CI, 1.4-2.8, respectively]. In the multivariable model, pain increased the odds of a no-show visit only in participants without substance abuse (OR, 1.5; 95% CI, 1.1-1.9) and pain reduced the odds of a no-show visit in participants with substance abuse (OR, 0.5; 95% CI, 0.2-0.9; P for interaction = 0.0022).
Conclusions: In this study, pain increased the odds of no-show visits but only for participants without substance abuse. Because pain, mood disorders, and substance abuse are highly prevalent in HIV-infected patients, our findings have implications for HIV treatment success. Interventions that incorporate pain management may be important for improving health outcomes in patients living with HIV infection.
C1 [Merlin, Jessica S.; Westfall, Andrew O.; Raper, James L.; Zinski, Anne; Willig, James H.; Saag, Michael S.; Mugavero, Michael J.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA.
[Merlin, Jessica S.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA.
[Westfall, Andrew O.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA.
[Norton, Wynne E.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL 35294 USA.
[Gross, Robert] Univ Penn, Dept Med, Div Infect Dis, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Gross, Robert] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Ritchie, Christine S.] Univ Calif San Francisco, Dept Med, Div Geriatr, Jewish Home San Francisco Ctr Res Aging, San Francisco, CA USA.
RP Merlin, JS (reprint author), BBRB 222,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM jmerlin@uab.edu
OI Westfall, Andrew/0000-0002-0468-4695
FU Definicaire LLC.; Penn Center for AIDS Research (CFAR) [P30 AI 045008];
NIA [7K07AG031779]; Merck Foundation; Bristol-Myers Squibb; Gilead
Sciences; Tibotec Therapeutics; Pfizer, Inc; Definicare, LLC.;
[K23MH082641]
FX A. O. Westfall has received consulting fees from Definicaire LLC. R.
Gross is supported by the Penn Center for AIDS Research (CFAR) (P30 AI
045008). C. S. Ritchie is supported by 7K07AG031779 (NIA). M. J.
Mugavero is supported by K23MH082641 and has received consulting fees
(advisory board) from Merck Foundation, Bristol-Myers Squibb, and Gilead
Sciences, and grant support to UAB from Tibotec Therapeutics, Pfizer,
Inc, Bristol-Myers Squibb, and Definicare, LLC. For the remaining
authors, no conflicts of interest were disclosed.
NR 62
TC 31
Z9 31
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2012
VL 61
IS 2
BP 164
EP 170
DI 10.1097/QAI.0b013e3182662215
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 012EQ
UT WOS:000309218700013
PM 22766967
ER
PT J
AU Korthuis, PT
Fiellin, DA
McGinnis, KA
Skanderson, M
Justice, AC
Gordon, AJ
Doebler, DA
Asch, SM
Fiellin, LE
Bryant, K
Gibert, CL
Crystal, S
Goetz, MB
Rimland, D
Rodriguez-Barradas, MC
Kraemer, KL
AF Korthuis, P. Todd
Fiellin, David A.
McGinnis, Kathleen A.
Skanderson, Melissa
Justice, Amy C.
Gordon, Adam J.
Doebler, Donna Almario
Asch, Steven M.
Fiellin, Lynn E.
Bryant, Kendall
Gibert, Cynthia L.
Crystal, Stephen
Goetz, Matthew Bidwell
Rimland, David
Rodriguez-Barradas, Maria C.
Kraemer, Kevin L.
TI Unhealthy Alcohol and Illicit Drug Use Are Associated With Decreased
Quality of HIV Care
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE alcohol; quality of health care; HIV; quality indicators; health care;
opioid-related disorders
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUBSTANCE-ABUSE TREATMENT; ACTIVE
ANTIRETROVIRAL THERAPY; HEALTH-CARE; UNITED-STATES; OF-CARE; TREATMENT
OUTCOMES; PERFORMANCE-MEASURES; INFECTED PERSONS; MEDICAL-CARE
AB Background: HIV-infected patients with substance use experience suboptimal health outcomes, possibly because of variations in care.
Objectives: To assess the association between substance use and the quality of HIV care (QOC) received.
Research Design: Retrospective cohort study.
Subjects: HIV-infected patients enrolled in the Veterans Aging Cohort Study.
Measures: We collected self-report substance use data and abstracted 9 HIV quality indicators (QIs) from medical records. Independent variables were unhealthy alcohol use (AUDIT-C score >= 4) and illicit drug use (self-report of stimulants, opioids, or injection drug use in past year). Main outcome was the percentage of QIs received, if eligible. We estimated associations between substance use and QOC using multivariable linear regression.
Results: The majority of the 3410 patients were male (97.4%) and black (67.0%) with a mean age of 49.1 years (SD = 8.8). Overall, 25.8% reported unhealthy alcohol use, 22% illicit drug use, and participants received 81.5% (SD - 18.9) of QIs. The mean percentage of QIs received was lower for those with unhealthy alcohol use versus not (59.3% vs. 70.0%, P < 0.001) and those using illicit drugs vs. not (57.8% vs. 70.7%, P < 0.001). In multivariable models, unhealthy alcohol use (adjusted beta -2.74; 95% confidence interval: -4.23 to -1.25) and illicit drug use (adjusted beta -3.51; 95% CI: -4.99 to -2.02) remained inversely associated with the percentage of QIs received.
Conclusions: Although the overall QOC for these HIV-infected Veteran patients was high, gaps persist for those with unhealthy alcohol and illicit drug use. Interventions that address substance use in HIV-infected patients may improve the QOC received.
C1 [Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
[Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
[Fiellin, David A.; Justice, Amy C.; Fiellin, Lynn E.] Yale Univ, Sch Med, Dept Gen Med, New Haven, CT USA.
[Fiellin, David A.; Justice, Amy C.; Fiellin, Lynn E.] Yale Univ, Sch Med, Dept Publ Hlth, Div Gen Internal Med, New Haven, CT 06510 USA.
[Fiellin, David A.; Justice, Amy C.; Fiellin, Lynn E.] Yale Univ, Sch Med, Ctr Interdisciplinary Res AIDS, New Haven, CT USA.
[McGinnis, Kathleen A.; Skanderson, Melissa; Gordon, Adam J.; Doebler, Donna Almario] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
[Justice, Amy C.] VA Connecticut Healthcare Syst, Vet Aging Cohort Study Coordinating Ctr, Dept Gen Med, West Haven, CT USA.
[Justice, Amy C.] VA Connecticut Healthcare Syst, Vet Aging Cohort Study Coordinating Ctr, Dept Publ Hlth, West Haven, CT USA.
[Gordon, Adam J.; Doebler, Donna Almario; Kraemer, Kevin L.] Univ Pittsburgh, Dept Med, Ctr Res Hlth Care, Pittsburgh, PA USA.
[Asch, Steven M.] Stanford Univ, VA Greater Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA.
[Bryant, Kendall] NIAAA, HIV AIDS Res, Rockville, MD 20852 USA.
[Gibert, Cynthia L.] VA Med Ctr, Washington, DC USA.
[Gibert, Cynthia L.] George Washington Univ, Med Ctr, Washington, DC 20037 USA.
[Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90095 USA.
[Rimland, David] VA Med Ctr, Dept Med, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Dept Med, Infect Dis Sect, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA.
RP Korthuis, PT (reprint author), Oregon Hlth & Sci Univ, Dept Med, 3181 SW Sam Jackson Pk Rd,Mail Code L-475, Portland, OR 97239 USA.
EM korthuis@ohsu.edu
OI Goetz, Matthew/0000-0003-4542-992X; Fiellin, David/0000-0002-4006-010X
FU National Institutes of Health, National Institute on Alcohol Abuse and
Alcoholism [U10AA013566]; National Institutes of Health, National
Institute on Drug Abuse [K23 DA019809]
FX Supported by the National Institutes of Health, National Institute on
Alcohol Abuse and Alcoholism Grant U10AA013566; National Institutes of
Health, National Institute on Drug Abuse Grant K23 DA019809 (to Dr
Korthuis).
NR 53
TC 12
Z9 12
U1 3
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2012
VL 61
IS 2
BP 171
EP 178
DI 10.1097/QAI.0b013e31826741aa
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 012EQ
UT WOS:000309218700014
PM 22820808
ER
PT J
AU Winter, L
Parks, SM
AF Winter, Laraine
Parks, Susan M.
TI Elders' Preferences for Life-Prolonging Treatment and Their Proxies'
Substituted Judgment: Influence of the Elders' Current Health
SO JOURNAL OF AGING AND HEALTH
LA English
DT Article
DE end of life; families; physical function
ID SURROGATE DECISION-MAKING; SUSTAINING MEDICAL TREATMENTS; OF-LIFE;
ADVANCE DIRECTIVES; PROSPECT-THEORY; OLDER-ADULTS; GENDER-DIFFERENCES;
END; ACCURACY; CARE
AB Objectives: People in poor health tend to view life-prolonging treatments (e.g., tube feeding) as more acceptable than do healthier people. Do proxies' substituted judgments reveal a similar tendency, showing greater acceptance when the elder is in worse health? Method: In a cross-sectional telephone-based survey of 202 elderly individuals and their proxies, preferences for 4 life-prolonging treatments in 7 health prospects were examined in relation to the elder's current health status, operationalized as number of deficits in activities of daily living. Results: Stronger preferences for life-prolonging treatments in worse-health prospects were expressed by both elders and proxies when the elders' current health was relatively poor. The interaction effect was at least as pronounced for proxies' substituted judgment as for elders' own preferences. Discussion: Findings provide important insight into proxy decision making and have particular implications for proxy decision making on behalf of elders with dementia or other causes of decisional incapacity.
C1 [Winter, Laraine; Parks, Susan M.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
RP Winter, L (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave,Room B904, Philadelphia, PA 19104 USA.
EM laraine.winter@gmail.com
FU NINR NIH HHS [R21NR010263]
NR 55
TC 3
Z9 3
U1 7
U2 16
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0898-2643
J9 J AGING HEALTH
JI J. Aging Health
PD OCT
PY 2012
VL 24
IS 7
BP 1157
EP 1178
DI 10.1177/0898264312454572
PG 22
WC Gerontology; Health Policy & Services
SC Geriatrics & Gerontology; Health Care Sciences & Services
GA 007IV
UT WOS:000308882900004
PM 22869900
ER
PT J
AU Baliram, R
Sun, L
Cao, J
Li, JH
Latif, R
Huber, AK
Yuen, T
Blair, HC
Zaidi, M
Davies, TF
AF Baliram, Ramkumarie
Sun, Li
Cao, Jay
Li, Jianhua
Latif, Rauf
Huber, Amanda K.
Yuen, Tony
Blair, Harry C.
Zaidi, Mone
Davies, Terry F.
TI Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH
signaling
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID THYROID-STIMULATING HORMONE; BONE-MINERAL DENSITY; SERUM TSH;
POSTMENOPAUSAL WOMEN; THYROXINE THERAPY; RECOMBINANT TSH;
OSTEOPROTEGERIN; POLYMORPHISM; FRACTURES; REGULATOR
AB The osteoporosis associated with human hyperthyroidism has traditionally been attributed to elevated thyroid hormone levels. There is evidence, however, that thyroid-stimulating hormone (TSH), which is low in most hyperthyroid states, directly affects the skeleton. Importantly, Tshr-knockout mice are osteopenic. In order to determine whether low TSH levels contribute to bone loss in hyperthyroidism, we compared the skeletal phenotypes of wild-type and Tshr-knockout mice that were rendered hyperthyroid. We found that hyperthyroid mice lacking TSHR had greater bone loss and resorption than hyperthyroid wild-type mice, thereby demonstrating that the absence of TSH signaling contributes to bone loss. Further, we identified a TSH-like factor that may confer osteoprotection. These studies suggest that therapeutic suppression of TSH to very low levels may contribute to bone loss in people.
C1 [Sun, Li; Li, Jianhua; Yuen, Tony; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, Dept Med, New York, NY 10029 USA.
[Sun, Li; Li, Jianhua; Yuen, Tony; Zaidi, Mone] James J Peters VA Med Ctr, New York, NY USA.
[Baliram, Ramkumarie; Latif, Rauf; Huber, Amanda K.; Davies, Terry F.] Mt Sinai Sch Med, Thyroid Res Unit, New York, NY 10029 USA.
[Cao, Jay] ARS, USDA, Human Nutr Res Ctr, Grand Forks, ND USA.
[Blair, Harry C.] Univ Pittsburgh, Dept Pathol & Cell Biol, Pittsburgh, PA USA.
[Blair, Harry C.] Pittsburgh VA Med Ctr, Pittsburgh, PA USA.
RP Zaidi, M (reprint author), Mt Sinai Sch Med, Mt Sinai Bone Program, Dept Med, Box 1050,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM mone.zaidi@mssm.edu
FU NIH [DK080459, DK069713, DK052464, AG23186, DK70526]; VA Merit Review
Program; USDA ARS CRIS Program [5450-51000-046-00D]
FX This work was supported in part by DK080459 (to M. Zaidi, L. Sun, and
T.F. Davies), DK069713 and DK052464 (to T.F. Davies), and AG23186 and
DK70526 (to M. Zaidi) from the NIH and by the VA Merit Review Program
(to T.F. Davies and H.C. Blair). J. Cao is supported by the USDA ARS
CRIS Program (5450-51000-046-00D).
NR 32
TC 32
Z9 34
U1 2
U2 10
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD OCT
PY 2012
VL 122
IS 10
BP 3737
EP 3741
DI 10.1172/JCI63948
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 013VK
UT WOS:000309333800042
PM 22996689
ER
PT J
AU Karlin, BE
Brown, GK
Trockel, M
Cunning, D
Zeiss, AM
Taylor, CB
AF Karlin, Bradley E.
Brown, Gregory K.
Trockel, Mickey
Cunning, Darby
Zeiss, Antonette M.
Taylor, C. Barr
TI National Dissemination of Cognitive Behavioral Therapy for Depression in
the Department of Veterans Affairs Health Care System: Therapist and
Patient-Level Outcomes
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE dissemination; cognitive behavioral therapy; depression; psychotherapy
training; veterans
ID POSTTRAUMATIC-STRESS-DISORDER; WORKING ALLIANCE INVENTORY; PSYCHOMETRIC
PROPERTIES; ANTIDEPRESSANT MEDICATION; PSYCHOLOGICAL TREATMENTS; MOOD
DISORDERS; COMPETENCE; TRIAL; COMORBIDITY; SCALE
AB Objective: The Department of Veterans Affairs (VA) health care system is nationally disseminating and implementing cognitive behavioral therapy for depression (CBT-D). The current article evaluates therapist and patient-level outcomes associated with national training in and implementation of CBT-D in the VA health care system. Method: Therapist competencies were assessed with the Cognitive Therapy Rating Scale (CTRS). Patient outcomes were assessed with the Beck Depression Inventory-II and the World Health Organization Quality of Life-BREF. Therapeutic alliance was assessed with the Working Alliance Inventory -Short Revised. Two-hundred twenty-one therapists have received training, and 356 veteran patients have received treatment through the VA CBT-D Training Program. Results: Of therapists who have participated in the program, 182 (82%) completed all training requirements and achieved competency, reflected by a score of 40 on the CTRS. Of 356 patients, nearly 70% completed 10 or more sessions or improved sufficiently to stop therapy before the 10th session. Mean depression scores decreased by approximately 40% from initial to later treatment phase. Effect sizes of changes ranged from d = 0.39 to d = 0.74 for quality of life and from d = 0.47 to d = 0.66 for therapeutic alliance measures. Conclusion: National training in and implementation of CBT-D within the VA health care system is associated with significant, positive therapist training outcomes, as evidenced by increases in CBT core competencies. The implementation of the protocol by newly trained CBT-D therapists is associated with significantly improved patient outcomes, as evidenced by large decreases in depression and improvements in quality of life.
C1 [Karlin, Bradley E.; Zeiss, Antonette M.] US Dept Vet Affairs Cent Off, Off Mental Hlth Serv, Washington, DC 20420 USA.
[Brown, Gregory K.] Philadelphia Vet Affairs Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA.
[Brown, Gregory K.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Trockel, Mickey; Cunning, Darby; Taylor, C. Barr] Stanford Univ, Med Ctr, Dept Psychiat, Palo Alto, CA 94304 USA.
[Trockel, Mickey; Cunning, Darby; Taylor, C. Barr] Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Palo Alto, CA USA.
RP Karlin, BE (reprint author), US Dept Vet Affairs Cent Off, Off Mental Hlth Serv 10P4M, 810 Vermont Ave NW, Washington, DC 20420 USA.
EM bradley.karlin2@va.gov
NR 71
TC 39
Z9 39
U1 1
U2 18
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD OCT
PY 2012
VL 80
IS 5
BP 707
EP 718
DI 10.1037/a0029328
PG 12
WC Psychology, Clinical
SC Psychology
GA 013NP
UT WOS:000309312400001
PM 22823859
ER
PT J
AU Morgenstern, J
Kuerbis, AN
Chen, AC
Kahler, CW
Bux, DA
Kranzler, HR
AF Morgenstern, Jon
Kuerbis, Alexis N.
Chen, Andrew C.
Kahler, Christopher W.
Bux, Donald A., Jr.
Kranzler, Henry R.
TI A Randomized Clinical Trial of Naltrexone and Behavioral Therapy for
Problem Drinking Men Who Have Sex With Men
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE problem drinkers; men who have sex with men; naltrexone;
cognitive-behavior therapy; moderation
ID PLACEBO-CONTROLLED TRIAL; SUBSTANCE USE DISORDERS; ALCOHOL DEPENDENCE;
PROBLEM DRINKERS; MOTIVATIONAL ENHANCEMENT; TARGETED NALTREXONE; ABUSE
TREATMENT; HIV-INFECTION; DOUBLE-BLIND; DRUG-USE
AB Objective: This study tested the comparative effectiveness of modified behavioral self-control therapy (MBSCT) and naltrexone (NIX), as well as the added benefit of combining the 2, in problem drinking men who have sex with men (MSM) seeking to reduce but not quit drinking. Method: Participants (N = 200) were recruited and urn randomized to 1 of 2 medication conditions, NTX or placebo (PBO), and either MSBCT or no behavioral intervention, yielding 4 conditions: PBO, NTX, MSBCT, and NIX + MSBCT. In addition, all participants received a brief medication compliance intervention. Participants were treated for 12 weeks and assessed 1 week after treatment completion. Two primary outcomes-sum of standard drinks and number of heavy drinking days and 1 secondary outcome percentage of those drinking in a nonhazardous manner (NoH)-were selected a priori. Results: There was a significant main effect for MBSCT (all ps < .01) but not NTX on all 3 outcomes. In addition, the combination of NTX and MBSCT was not more effective than either MSCBT or PBO. There was a significant interaction effect on NoH, such that NIX significantly increased the likelihood (odds ratio = 3.3) of achieving a nonhazardous drinking outcome relative to PBO. In addition, NIX was significantly more effective than PBO on a descriptive outcome: negative consequences of drinking. Conclusions: There was no advantage to adding NIX to MBSCT. In addition, MBSCT showed stronger evidence of efficacy than NIX. At the same time, NIX delivered in the context of a minimal medication compliance intervention was significantly more effective than PBO on an important clinical indicator. Results provide new information to guide the treatment of problem drinking, including in primary care settings.
C1 [Morgenstern, Jon; Kuerbis, Alexis N.; Chen, Andrew C.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA.
[Kahler, Christopher W.] Brown Univ, Dept Behav & Social Sci, Providence, RI 02912 USA.
[Kahler, Christopher W.] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA.
[Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA.
RP Morgenstern, J (reprint author), Columbia Univ, Coll Phys & Surg, Dept Psychiat, 180 Ft Washington Ave,HP-240, New York, NY 10032 USA.
EM jm977@columbia.edu
FU NIAAA NIH HHS [5 RO1 AA015553, K23 AA018696, K24 AA013736, R01 AA015553]
NR 65
TC 14
Z9 14
U1 4
U2 9
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD OCT
PY 2012
VL 80
IS 5
BP 863
EP 875
DI 10.1037/a0028615
PG 13
WC Psychology, Clinical
SC Psychology
GA 013NP
UT WOS:000309312400015
PM 22612306
ER
PT J
AU Sherwood, M
Hage, FG
Heo, J
Shaw, LJ
Cerqueira, MD
Iskandrian, AE
AF Sherwood, Melody
Hage, Fadi G.
Heo, Jack
Shaw, Leslee J.
Cerqueira, Manuel D.
Iskandrian, Ami E.
TI SPECT myocardial perfusion imaging as an endpoint
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Editorial Material
ID QUANTITATIVE-ANALYSIS; NUCLEAR CARDIOLOGY; QUANTIFICATION; IMAGES; TRIAL
C1 [Sherwood, Melody; Heo, Jack; Iskandrian, Ami E.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Shaw, Leslee J.] Emory Univ, Sch Med, Atlanta, GA USA.
[Cerqueira, Manuel D.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
RP Iskandrian, AE (reprint author), Univ Alabama Birmingham, 318 LHRB, Birmingham, AL 35294 USA.
EM aiskand@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
NR 15
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD OCT
PY 2012
VL 19
IS 5
BP 891
EP 894
DI 10.1007/s12350-012-9583-0
PG 4
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 014AV
UT WOS:000309348300005
PM 22669737
ER
PT J
AU Shaw, LJ
Hage, FG
Berman, DS
Hachamovitch, R
Iskandrian, A
AF Shaw, Leslee J.
Hage, Fadi G.
Berman, Daniel S.
Hachamovitch, Rory
Iskandrian, Ami
TI Prognosis in the era of comparative effectiveness research: Where is
nuclear cardiology now and where should it be?
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY;
MYOCARDIAL-PERFUSION SPECT; HEART-RATE RESPONSE;
CARDIOVASCULAR-MAGNETIC-RESONANCE; LEFT-VENTRICULAR DYSFUNCTION; ACUTE
CHEST-PAIN; RANDOMIZED CONTROLLED-TRIAL; ALL-CAUSE MORTALITY; OPTIMAL
MEDICAL THERAPY
C1 [Shaw, Leslee J.] Emory Univ, Sch Med, Emory Clin Cardiovasc Res Inst, Atlanta, GA 30324 USA.
[Hage, Fadi G.; Iskandrian, Ami] Univ Alabama Birmingham, Birmingham, AL USA.
[Hage, Fadi G.; Iskandrian, Ami] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Berman, Daniel S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Hachamovitch, Rory] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
RP Shaw, LJ (reprint author), Emory Univ, Sch Med, Emory Clin Cardiovasc Res Inst, 1462 Clifton Rd NE,Room529, Atlanta, GA 30324 USA.
EM lshaw3@emory.edu
NR 159
TC 61
Z9 61
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD OCT
PY 2012
VL 19
IS 5
BP 1026
EP 1043
DI 10.1007/s12350-012-9593-y
PG 18
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 014AV
UT WOS:000309348300020
PM 22760523
ER
PT J
AU Shaw, LJ
Hage, FG
Berman, DS
Hachamovitch, R
Iskandrian, A
AF Shaw, Leslee J.
Hage, Fadi G.
Berman, Daniel S.
Hachamovitch, Rory
Iskandrian, Ami
TI Prognosis in the era of comparative effectiveness research: Where is
nuclear cardiology now and where should it be? (vol 19, pg 1026, 2012)
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Correction
ID CORONARY FLOW RESERVE
C1 [Shaw, Leslee J.] Emory Univ, Sch Med, Emory Clin Cardiovasc Res Inst, Atlanta, GA 30324 USA.
[Hage, Fadi G.; Iskandrian, Ami] Univ Alabama Birmingham, Birmingham, AL USA.
[Hage, Fadi G.; Iskandrian, Ami] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Berman, Daniel S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Hachamovitch, Rory] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
RP Shaw, LJ (reprint author), Emory Univ, Sch Med, Emory Clin Cardiovasc Res Inst, 1462 Clifton Rd NE,Room 529, Atlanta, GA 30324 USA.
EM lshaw3@emory.edu
NR 3
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD OCT
PY 2012
VL 19
IS 5
BP 1092
EP 1093
DI 10.1007/s12350-012-9605-y
PG 2
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 014AV
UT WOS:000309348300028
ER
PT J
AU Simon, J
AF Simon, Jack
TI Very early MS - insights from MRI
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Review
DE Clinically isolated syndrome; multiple sclerosis; magnetic resonance
imaging; atrophy; gray matter
ID CLINICALLY ISOLATED SYNDROMES; GRAY-MATTER ATROPHY; RADIOLOGICALLY
ISOLATED SYNDROME; EARLY MULTIPLE-SCLEROSIS; GREY-MATTER;
DIAGNOSTIC-CRITERIA; WHITE-MATTER; FOLLOW-UP; LESIONS; CONVERSION
AB Magnetic resonance imaging (MRI) is likely to play an increasing role in efforts to understand the earliest changes in multiple sclerosis (MS) and narrowing the gap to new insights provided by the recent pathology literature showing early meningeal and cortical inflammatory disease and cortical gray matter demyelination. Much of the insight into early MS already comes from MRI as it evaluates patients at the time of a clinically isolated syndrome (CIS). Series show transition of tissue from normal to abnormal, and now often reveal gray matter more so than white matter pathology, deep gray more than cortical gray, and quantitative MRI changes preceding atrophy in early MS. But the CIS population is heterogeneous, likely including patients with many years' duration, as well as relatively recent onset disease. Efforts to evaluate earlier disease, possibly sub-populations of CIS, patients at risk for MS with strict criteria for a radiologically isolated syndrome, and tumefactive MS, combined with advanced MRI technology, may bring us closer to in vivo insight into truly early or earliest MS.
C1 Portland VA Med Ctr, Portland, OR 97239 USA.
RP Simon, J (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM jack.simon3@va.gov
NR 29
TC 6
Z9 6
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD OCT
PY 2012
VL 18
IS 10
BP 1372
EP 1376
DI 10.1177/1352458512452925
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 014EW
UT WOS:000309359000002
PM 22760097
ER
PT J
AU Jang, YC
Liu, YH
Hayworth, CR
Bhattacharya, A
Lustgarten, MS
Muller, FL
Chaudhuri, A
Qi, WB
Li, Y
Huang, JY
Verdin, E
Richardson, A
Van Remmen, H
AF Jang, Young C.
Liu, Yuhong
Hayworth, Christopher R.
Bhattacharya, Arunabh
Lustgarten, Michael S.
Muller, Florian L.
Chaudhuri, Asish
Qi, Wenbo
Li, Yan
Huang, Jing-Yi
Verdin, Eric
Richardson, Arlan
Van Remmen, Holly
TI Dietary restriction attenuates age-associated muscle atrophy by lowering
oxidative stress in mice even in complete absence of CuZnSOD
SO AGING CELL
LA English
DT Article
DE Aging; calorie restriction; mice; mitochondria; oxidative stress;
reactive oxygen species; sarcopenia; skeletal muscle
ID RAT SKELETAL-MUSCLE; CALORIC RESTRICTION; NEUROMUSCULAR-JUNCTION;
MITOCHONDRIAL-FUNCTION; SUPEROXIDE-DISMUTASE; MOTOR-NEURONS; PROTON
LEAK; SARCOPENIA; DEGENERATION; ACETYLATION
AB Age-related loss of muscle mass and function, sarcopenia, has a major impact on the quality of life in the elderly. Among the proposed causes of sarcopenia are mitochondrial dysfunction and accumulated oxidative damage during aging. Dietary restriction (DR), a robust dietary intervention that extends lifespan and modulates age-related pathology in a variety of species, has been shown to protect from sarcopenia in rodents. Although the mechanism(s) by which DR modulates aging are still not defined, one potential mechanism is through modulation of oxidative stress and mitochondrial dysfunction. To directly test the protective effect of DR against oxidative stressinduced muscle atrophy in vivo, we subjected mice lacking a key antioxidant enzyme, CuZnSOD (Sod1) to DR (60% of ad libitum fed diet). We have previously shown that the Sod1-/- mice exhibit an acceleration of sarcopenia associated with high oxidative stress, mitochondrial dysfunction, and severe neuromuscular innervation defects. Despite the dramatic atrophy phenotype in the Sod1-/- mice, DR led to a reversal or attenuation of reduced muscle function, loss of innervation, and muscle atrophy in these mice. DR improves mitochondrial function as evidenced by enhanced Ca2+ regulation and reduction of mitochondrial reactive oxygen species (ROS). Furthermore, we show upregulation of SIRT3 and MnSOD in DR animals, consistent with reduced mitochondrial oxidative stress and reduced oxidative damage in muscle tissue measured as F2-isoprostanes. Collectively, our results demonstrate that DR is a powerful mediator of mitochondrial function, mitochondrial ROS production, and oxidative damage, providing a solid protection against oxidative stressinduced neuromuscular defects and muscle atrophy in vivo even under conditions of high oxidative stress.
C1 [Jang, Young C.; Liu, Yuhong; Bhattacharya, Arunabh; Muller, Florian L.; Qi, Wenbo; Li, Yan; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Jang, Young C.; Liu, Yuhong; Bhattacharya, Arunabh; Lustgarten, Michael S.; Muller, Florian L.; Chaudhuri, Asish; Qi, Wenbo; Li, Yan; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Hayworth, Christopher R.] Univ Texas Austin, Neurobiol Sect, Austin, TX 78712 USA.
[Hayworth, Christopher R.] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA.
[Lustgarten, Michael S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Chaudhuri, Asish; Qi, Wenbo; Li, Yan; Richardson, Arlan; Van Remmen, Holly] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78229 USA.
[Huang, Jing-Yi; Verdin, Eric] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM vanremmen@uthscsa.edu
OI Verdin, Eric/0000-0003-3703-3183
FU UTHSCSA; NIH-NCI [P30 CA54174]; NIH-NIA [P01AG19316]; American
Federation for Aging Research; [P01AG020591]
FX We would like to thank Dr. Ting Ting Huang for providing Sod1 null
breeders, Dr. Noah Weisleder and Dr. Pei Lin for their help with in vivo
electroporation, and Marian Sabia, Amanda Jernigan, Barbara Hunter,
Vivian Diaz, Jimmy Wewer, and Dr. Victoria Frohlich for their technical
support. Some of the images were generated in the Core Optical Imaging
Facility and EM Facility, which are supported by UTHSCSA, NIH-NCI P30
CA54174 (CTRC at UTHSCSA), and NIH-NIA P01AG19316. Also supported by
P01AG020591 (HVR, AR) and a Julie Martin Mid-Career grant from the
American Federation for Aging Research (HVR).
NR 41
TC 27
Z9 27
U1 0
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
J9 AGING CELL
JI Aging Cell
PD OCT
PY 2012
VL 11
IS 5
BP 770
EP 782
DI 10.1111/j.1474-9726.2012.00843.x
PG 13
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 007EK
UT WOS:000308871400006
PM 22672615
ER
PT J
AU Maguilnik, I
Neumann, WL
Sonnenberg, A
Genta, RM
AF Maguilnik, I.
Neumann, W. L.
Sonnenberg, A.
Genta, R. M.
TI Reactive gastropathy is associated with inflammatory conditions
throughout the gastrointestinal tract
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLLAGENOUS COLITIS; BILE REFLUX;
LYMPHOCYTIC COLITIS; GASTRIC-MUCOSA; DIFFERENTIAL-DIAGNOSIS;
CLINICAL-SIGNIFICANCE; OPERATED STOMACH; PEPTIC-ULCER; FEATURES
AB Background The epidemiology of reactive gastropathy and its relationship with other conditions of the gastrointestinal tract associated with NSAID use have not been evaluated. Aims To test the hypothesis that if reactive gastropathy shares common aetiological factors with these conditions, the analysis of a large cohort would unveil associations. Methods We queried a national pathology database for subjects with a diagnosis of reactive gastropathy; controls were patients with normal gastric biopsies. We also extracted diagnoses of H. pylori infection, intestinal metaplasia, duodenal lymphocytosis, duodenitis, ileitis, microscopic colitis and focal colitis. Results Of 504 011 patients with gastric biopsies, 69 101 had oesophageal, 166 134 duodenal, 13 010 ileal and 83 334 colonic biopsies. Reactive gastropathy was diagnosed in 15.6% of patients, H. pylori infection in 10.3% and normal gastric mucosa in 16.3%. Reactive gastropathy was evenly distributed across the US and increased from 2.0% in the first decade of life to >20% in octogenarians. Compared with controls, reactive gastropathy was significantly associated with Barrett's mucosa (OR 1.21 95% CI 1.16129); duodenitis (OR 1.36; 95% CI 1.281.44); duodenal intraepithelial lymphocytosis (OR 1.25; 95% CI 1.131.39); active ileitis (OR 1.88; 95% CI 1.472.40); focal active colitis (OR 1.57; 95% CI 1.331.86); and collagenous colitis (OR 1.50; 95% CI 1.122.03). Conclusions Reactive gastropathy, a common histopathological feature of the stomach, shows an age-dependent rise and is associated with changes of the digestive tract believed to be caused by NSAID use or duodenogastric reflux. However, a large fraction of reactive gastropathy remains unexplained; its frequent occurrence merits further efforts at elucidating its aetiology.
C1 [Maguilnik, I.] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil.
[Neumann, W. L.; Genta, R. M.] Miraca Life Sci, Miraca Res Inst, Irving, TX 75039 USA.
[Neumann, W. L.; Genta, R. M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Sonnenberg, A.] Portland VA Med Ctr, Portland, OR USA.
[Genta, R. M.] Dallas VA Med Ctr, Dallas, TX USA.
RP Genta, RM (reprint author), Miraca Life Sci, Miraca Res Inst, 6655 N MacArthur Blvd, Irving, TX 75039 USA.
EM robert.genta@utsouthwestern.edu
FU Miraca Life Sciences, Irving TX
FX Dr Neumann's gastrointestinal pathology fellowship was partially funded
by Miraca Life Sciences, Irving TX. Dr Genta is an employee of Miraca
Life Sciences, Irving TX.
NR 38
TC 7
Z9 7
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD OCT
PY 2012
VL 36
IS 8
BP 736
EP 743
DI 10.1111/apt.12031
PG 8
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 007KT
UT WOS:000308887900005
PM 22928604
ER
PT J
AU Felsenfeld, AJ
Levine, BS
AF Felsenfeld, Arnold J.
Levine, Barton S.
TI Approach to Treatment of Hypophosphatemia
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Hypophosphatemia; adenosine triphosphate (ATP); 2,3-diphosphoglycerate
(2,3-DPG); fibroblast growth factor 23 (FGF-23)
ID INTENSIVE-CARE-UNIT; INTRAVENOUS PHOSPHORUS THERAPY; KIDNEY-TRANSPLANT
RECIPIENTS; ACUTE RESPIRATORY-FAILURE; ADENOSINE-TRIPHOSPHATE;
MYOCARDIAL PERFORMANCE; SERUM PHOSPHORUS; PHOSPHATE; REPLACEMENT;
2,3-DIPHOSPHOGLYCERATE
AB Hypophosphatemia can be acute or chronic. Acute hypophosphatemia with phosphate depletion is common in the hospital setting and results in significant morbidity and mortality. Chronic hypophosphatemia, often associated with genetic or acquired renal phosphate-wasting disorders, usually produces abnormal growth and rickets in children and osteomalacia in adults. Acute hypophosphatemia may be mild (phosphorus level, 2-2.5 mg/dL), moderate (1-1.9 mg/dL), or severe (<1 mg/dL) and commonly occurs in clinical settings such as refeeding, alcoholism, diabetic ketoacidosis, malnutrition/starvation, and after surgery (particularly after partial hepatectomy) and in the intensive care unit. Phosphate replacement can be given either orally, intravenously, intradialytically, or in total parenteral nutrition solutions. The rate and amount of replacement are empirically determined, and several algorithms are available. Treatment is tailored to symptoms, severity, anticipated duration of illness, and presence of comorbid conditions, such as kidney failure, volume overload, hypo-or hypercalcemia, hypo- or hyperkalemia, and acid-base status. Mild/moderate acute hypophosphatemia usually can be corrected with increased dietary phosphate or oral supplementation, but intravenous replacement generally is needed when significant comorbid conditions or severe hypophosphatemia with phosphate depletion exist. In chronic hypophosphatemia, standard treatment includes oral phosphate supplementation and active vitamin D. Future treatment for specific disorders associated with chronic hypophosphatemia may include cinacalcet, calcitonin, or dypyrimadole. Am J Kidney Dis. 60(4):655-661. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
C1 VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Levine, BS (reprint author), Nephrol Sect 111L, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM blevine@ucla.edu
NR 43
TC 11
Z9 12
U1 0
U2 32
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD OCT
PY 2012
VL 60
IS 4
BP 655
EP 661
DI 10.1053/j.ajkd.2012.03.024
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 010QO
UT WOS:000309109400024
PM 22863286
ER
PT J
AU Bekris, LM
Millard, S
Lutz, F
Li, G
Galasko, DR
Farlow, MR
Quinn, JF
Kaye, JA
Leverenz, JB
Tsuang, DW
Yu, CE
Peskind, ER
AF Bekris, Lynn M.
Millard, Steve
Lutz, Franziska
Li, Gail
Galasko, Doug R.
Farlow, Martin R.
Quinn, Joseph F.
Kaye, Jeffrey A.
Leverenz, James B.
Tsuang, Debby W.
Yu, Chang-En
Peskind, Elaine R.
TI Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in
Alzheimer's disease
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE FYN; PPP2R4; MAPT; AD; CSF
ID PROTEIN-TYROSINE KINASE; FYN KINASE; COGNITIVE IMPAIRMENTS;
POLYMORPHISMS; ASSOCIATION; DIAGNOSIS; PATHOLOGY; BIOMARKER; PP2A
AB Alzheimer's disease (AD) is characterized by the presence in the brain of amyloid plaques, consisting predominately of the amyloid beta peptide (A beta), and neurofibrillary tangles, consisting primarily of tau. Hyper-phosphorylated-tau (p-tau) contributes to neuronal damage, and both p-tau and total-tau (t-tau) levels are elevated in AD cerebrospinal fluid (CSF) compared to cognitively normal controls. Our hypothesis was that increased ratios of CSF phosphorylated-tau levels relative to total-tau levels correlate with regulatory region genetic variation of kinase or phosphatase genes biologically associated with the phosphorylation status of tau. Eighteen SNPs located within 5' and 3' regions of 5 kinase and 4 phosphatase genes, as well as two SNPs within regulatory regions of the MAPT gene were chosen for this analysis. The study sample consisted of 101 AD patients and 169 cognitively normal controls. Rs7768046 in the FYN kinase gene and rs913275 in the PPP2R4 phosphatase gene were both associated with CSF p-tau and t-tau levels in AD. These SNPs were also differentially associated with either CSF t-tau (rs7768046) or CSF p-tau (rs913275) relative to t-tau levels in AD compared to controls. These results suggest that rs7768046 and rs913275 both influence CSF tau levels in an AD-associated manner. (c) 2012 Wiley Periodicals, Inc.
C1 [Bekris, Lynn M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA.
[Bekris, Lynn M.; Lutz, Franziska; Yu, Chang-En] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
[Millard, Steve; Leverenz, James B.; Tsuang, Debby W.; Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, NW Network VISN Mental Illness Res Educ & Clin Ct, Seattle, WA USA.
[Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98108 USA.
[Galasko, Doug R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Galasko, Doug R.] VA Med Ctr San Diego, San Diego, CA USA.
[Farlow, Martin R.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA.
[Quinn, Joseph F.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Quinn, Joseph F.; Kaye, Jeffrey A.] Portland VA Med Ctr, Portland, OR USA.
[Leverenz, James B.] Parkinsons Dis Res Educ & Clin Ctr PADRECC, NW Network VISN 20, Roseburg, OR USA.
RP Bekris, LM (reprint author), Univ Washington, Dept Med, Div Gerontol & Geriatr Med, VAPSHCS GRECC S182B,1660 S Columbian Way, Seattle, WA 98108 USA.
EM lbekris@u.washington.edu
RI Tsuang, Debby/L-7234-2016
OI Tsuang, Debby/0000-0002-4716-1894; Kaye, Jeffrey/0000-0002-9971-3478
FU U.S. Department of Veterans Affairs, Office of Research and Development
Clinical Research and Development Program; Biomedical Laboratory
Research Program; NIH [2P50AG005136-27, 1P50NS062684-01A1,
K99AG034214-02]; University of Washington Alzheimer's Disease Research
Center NIH [P50-AB005136]; University of California San Diego
Alzheimer's Disease Research Center [AGO 5131]
FX Grant sponsor: U.S. Department of Veterans Affairs, Office of Research
and Development Clinical Research and Development Program; Grant
sponsor: Biomedical Laboratory Research Program; Grant sponsor: NIH;
Grant numbers: 2P50AG005136-27, 1P50NS062684-01A1, K99AG034214-02; Grant
sponsor: University of Washington Alzheimer's Disease Research Center
NIH; Grant number: P50-AB005136; Grant sponsor: University of California
San Diego Alzheimer's Disease Research Center; Grant number: AGO 5131.
NR 40
TC 8
Z9 8
U1 1
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD OCT
PY 2012
VL 159B
IS 7
BP 874
EP 883
DI 10.1002/ajmg.b.32094
PG 10
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA 007HR
UT WOS:000308879900015
PM 22927204
ER
PT J
AU Ito, T
Hiramatsu, K
Tomasz, A
de Lencastre, H
Perreten, V
Holden, MTG
Coleman, DC
Goering, R
Giffard, PM
Skov, RL
Zhang, KY
Westh, H
O'Brien, F
Tenover, FC
Oliveira, DC
Boyle-Vavra, S
Laurent, F
Kearns, AM
Kreiswirth, B
Ko, KS
Grundmann, H
Sollid, JE
John, JF
Daum, R
Soderquist, B
Buist, G
AF Ito, Teruyo
Hiramatsu, Keiichi
Tomasz, Alexander
de Lencastre, Herminia
Perreten, Vincent
Holden, Matthew T. G.
Coleman, David C.
Goering, Richard
Giffard, Philip M.
Skov, Robert L.
Zhang, Kunyan
Westh, Henrik
O'Brien, Frances
Tenover, Fred C.
Oliveira, Duarte C.
Boyle-Vavra, Susan
Laurent, Frederic
Kearns, Angela M.
Kreiswirth, Barry
Ko, Kwan Soo
Grundmann, Hajo
Sollid, Johanna E.
John, Joseph F., Jr.
Daum, Robert
Soderquist, Bo
Buist, Girbe
CA Int Working Grp Classification Sta
TI Guidelines for Reporting Novel mecA Gene Homologues
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Editorial Material
ID RESISTANT STAPHYLOCOCCUS-AUREUS; PENICILLIN-BINDING PROTEIN;
METHICILLIN-RESISTANT; SEQUENCE ALIGNMENT; MOLECULAR-CLONING; SCIURI;
DETERMINANTS; NOMENCLATURE; EVOLUTION; STRAINS
C1 [Ito, Teruyo; Hiramatsu, Keiichi] Juntendo Univ, Dept Bacteriol, Tokyo, Japan.
[Tomasz, Alexander; de Lencastre, Herminia] Rockefeller Univ, New York, NY 10021 USA.
[de Lencastre, Herminia; Oliveira, Duarte C.] Univ Nova Lisboa, Inst Tecnol Quim & Biol, Oeiras, Portugal.
[Perreten, Vincent] Univ Bern, Inst Vet Bacteriol, Bern, Switzerland.
[Holden, Matthew T. G.] Wellcome Trust Sanger Inst, Hinxton, Cambs, England.
[Coleman, David C.] Univ Dublin, Dublin Dent Univ Hosp, Trinity Coll Dublin, Dublin, Ireland.
[Goering, Richard] Creighton Univ, Med Ctr, Omaha, NE USA.
[Giffard, Philip M.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia.
[Skov, Robert L.] Statens Serum Inst, DK-2300 Copenhagen, Denmark.
[Zhang, Kunyan] Univ Calgary, Calgary, AB, Canada.
[Westh, Henrik] Univ Copenhagen, Fac Hlth, Copenhagen, Denmark.
[Westh, Henrik] Univ Copenhagen, Hvidovre Hosp, Copenhagen, Denmark.
[O'Brien, Frances] Curtin Univ Technol, Perth, WA, Australia.
[Tenover, Fred C.] Cepheid, Sunnyvale, CA USA.
[Oliveira, Duarte C.] Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Life Sci, CREM, Caparica, Portugal.
[Boyle-Vavra, Susan; Daum, Robert] Univ Chicago, Chicago, IL 60637 USA.
[Laurent, Frederic] Hosp Civils Lyon, French Natl Reference Ctr Staphylococci, Lyon, France.
[Kearns, Angela M.] Hlth Protect Agcy, Staphylococcus Reference Unit, London, England.
[Kreiswirth, Barry] Publ Hlth Res Inst, New York, NY USA.
[Ko, Kwan Soo] Sungkyunkwan Univ, Sch Med, Seoul, South Korea.
[Grundmann, Hajo] Natl Inst Publ Hlth & Environm, Utrecht, Netherlands.
[Sollid, Johanna E.] Univ Tromso, Tromso, Norway.
[John, Joseph F., Jr.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Soderquist, Bo] Orebro Univ Hosp, Orebro, Sweden.
[Buist, Girbe] Univ Groningen, Groningen, Netherlands.
[Buist, Girbe] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
RP Ito, T (reprint author), Juntendo Univ, Dept Bacteriol, Tokyo, Japan.
EM teruybac@juntendo.ac.jp
RI ; Coleman, David/C-2008-2009; Giffard, Philip/N-2293-2013; Staves,
Peter/C-8219-2014; Laurent, Frederic/M-4719-2014; Holden,
Matthew/K-6449-2014
OI Ko, Kwan Soo/0000-0002-0978-1937; Tomasz, Alexander/0000-0003-1520-1983;
Coleman, David/0000-0003-1797-2888; Holden, Matthew/0000-0002-4958-2166;
de Lencastre, Herminia/0000-0001-6816-8932; Westh,
Henrik/0000-0001-5681-647X; Oliveira, Duarte/0000-0002-9591-1039;
Goering, Richard/0000-0001-7502-7185
FU NIAID NIH HHS [R01 AI045738]
NR 21
TC 67
Z9 72
U1 1
U2 18
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD OCT
PY 2012
VL 56
IS 10
BP 4997
EP 4999
DI 10.1128/AAC.01199-12
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 006GQ
UT WOS:000308807900001
PM 22869575
ER
PT J
AU Erickson, MA
Hansen, K
Banks, WA
AF Erickson, Michelle A.
Hansen, Kim
Banks, William A.
TI Inflammation-induced dysfunction of the low-density lipoprotein
receptor-related protein-1 at the blood-brain barrier: Protection by the
antioxidant N-acetylcysteine
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Amyloid beta; Alzheimer's disease; Neuroinflammation; Oxidative stress;
Lipopolysaccharide; LRP-1; Pgp; N-acetylcysteine
ID AMYLOID-BETA-PEPTIDE; MICROVASCULAR ENDOTHELIAL-CELLS; MILD COGNITIVE
IMPAIRMENT; P-GLYCOPROTEIN FUNCTION; NECROSIS-FACTOR-ALPHA;
ACETYL-L-CYSTEINE; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; METABOLIC
SYNDROME; SYSTEMIC INFLAMMATION
AB Impairment in two blood-brain barrier (BBB) efflux transporters, p-glycoprotein (Pgp) and low-density lipoprotein receptor-related protein-1 (LRP-1) are thought to contribute to the progression of Alzheimer's disease (AD) by resulting in the brain accumulation of their substrate amyloid beta peptide (A beta). The initial cause of impaired efflux, however, is unknown. We have shown that induction of systemic inflammation by intraperitoneal administration of lipopolysaccharide impairs the efflux of A beta from the brain, suggesting that systemic inflammation could be one such initiator. In this study, we determined whether pre-administration of the antioxidant N-aceytlcysteine (Nac) has a protective effect against LPS-induced A beta transporter dysfunction. Our findings were that Nac protected against LPS-induced A beta transport dysfunction at the BBB through an LRP-1-dependent and Pgp-independent mechanism. This was associated with Nac exerting antioxidant effects in the periphery but not the brain, despite an increased rate of entry of Nac into the brain following LPS. We also found that Nac pre-administration resulted in lower blood levels of the cytokines and chemokines interferon-gamma, interleukin-10, CCL2, CCL4, and CCL5, but only lowered CCL4 in the cerebral cortex and hippocampus. Finally, we observed that hippocampal cytokine responses to LPS were decreased compared to cortex. These findings demonstrate a novel mechanism by which antioxidants prevent A beta accumulation in the brain caused by inflammation, and therefore protect against AD. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Erickson, Michelle A.] St Louis Univ, Dept Physiol & Pharmacol, St Louis, MO 63103 USA.
[Erickson, Michelle A.; Hansen, Kim; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
[Hansen, Kim; Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
RP Banks, WA (reprint author), Bldg 1,Rm 810A,1660 Columbian Way, Seattle, WA 98108 USA.
EM mericks9@slu.edu; nesnah@washington.edu; wabanks1@uw.edu
FU NIA NIH HHS [R01 AG029839]
NR 73
TC 30
Z9 31
U1 3
U2 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD OCT
PY 2012
VL 26
IS 7
BP 1085
EP 1094
DI 10.1016/j.bbi.2012.07.003
PG 10
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 007PC
UT WOS:000308899600011
PM 22809665
ER
PT J
AU Young, MR
AF Young, M. Rita
TI Endothelial cells in the eyes of an immunologist
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Review
DE Endothelial cells; Cancer; Immunoregulation; Immune trafficking
ID T-CELLS; VIRUS-INFECTION; EXPRESSION; ACTIVATION; SECRETION; IMMUNITY;
PROLIFERATION; MACROPHAGES; RECRUITMENT; RESPONSES
AB Endothelial cell activation in the process of tumor angiogenesis and in various aspects of vascular biology has been extensively studied. However, endothelial cells also function in other capacities, including in immune regulation. Compared to the more traditional immune regulatory populations (Th1, Th2, Treg, etc.), endothelial cells have received far less credit as being immune regulators. Their regulatory capacity is multifaceted. They are critical in both limiting and facilitating the trafficking of various immune cell populations, including T cells and dendritic cells, out of the vasculature and into tissue. They also can be induced to stimulate immune reactivity or to be immune inhibitory. In each of these parameters (trafficking, immune stimulation and immune inhibition), their role can be physiological, whereby they have an active role in maintaining health. Alternatively, their role can be pathological, whereby they contribute to disease. In theory, endothelial cells are in an ideal location to recruit cells that can mediate immune reactivity to tumor tissue. Furthermore, they can activate the immune cells as they transmigrate across the endothelium into the tumor. However, what is seen is the absence of these protective effects of endothelial cells and, instead, the endothelial cells succumb to the defense mechanisms of the tumor, resulting in their acquisition of a tumor-protective role. To understand the immune regulatory potential of endothelial cells in protecting the host versus the tumor, it is useful to better understand the other circumstances in which endothelial cells modulate immune reactivities. Which of the multitude of immune regulatory roles that endothelial cells can take on seems to rely on the type of stimulus that they are encountering. It also depends on the extent to which they can be manipulated by potential dangers to succumb and contribute toward attack on the host. This review will explore the physiological and pathological roles of endothelial cells as they regulate immune trafficking, immune stimulation and immune inhibition in a variety of conditions and will then apply this information to their role in the tumor environment. Strategies to harness the immune regulatory potential of endothelial cells are starting to emerge in the non-tumor setting. Results from such efforts are expected to be applicable to being able to skew endothelial cells from having a tumor-protective role to a host-protective role.
C1 [Young, M. Rita] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
[Young, M. Rita] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29401 USA.
[Young, M. Rita] Med Univ S Carolina, Dept Med, Charleston, SC 29401 USA.
RP Young, MR (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
EM rita.young@va.gov
FU Department of Veterans Affairs [CX000100]; National Institutes of Health
[RO1 CA128837, RO1 DE018268]
FX This work was supported by the Department of Veterans Affairs through a
Clinical Sciences Research & Development award (CX000100) and a Senior
Research Career Scientist award, and by grants RO1 CA128837 and RO1
DE018268 from the National Institutes of Health.
NR 38
TC 5
Z9 5
U1 2
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7004
EI 1432-0851
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD OCT
PY 2012
VL 61
IS 10
BP 1609
EP 1616
DI 10.1007/s00262-012-1335-0
PG 8
WC Oncology; Immunology
SC Oncology; Immunology
GA 010CO
UT WOS:000309072300001
PM 22903347
ER
PT J
AU Isvilanonda, V
Dengler, E
Iaquinto, JM
Sangeorzan, BJ
Ledoux, WR
AF Isvilanonda, Vara
Dengler, Evan
Iaquinto, Joseph M.
Sangeorzan, Bruce J.
Ledoux, William R.
TI Finite element analysis of the foot: Model validation and comparison
between two common treatments of the clawed hallux deformity
SO CLINICAL BIOMECHANICS
LA English
DT Article
DE Modified Jones; FHL tendon transfer; Foot; Finite element analysis;
Clawed hallux deformity
ID MEDIAL LONGITUDINAL-ARCH; METATARSOPHALANGEAL JOINT; DIABETIC-PATIENTS;
JONES PROCEDURE; TENDON TRANSFER; TOE DEFORMITY; PLANTAR; CARTILAGE;
PRESSURE; FORCE
AB Background: Clawed hallux is defined by first metatarsophalangeal joint extension and first interphalangeal joint flexion: it can increase plantar pressures and ulceration risk. We investigated two corrective surgical techniques, the modified Jones and flexor hallucis longus tendon transfer.
Methods: A finite element foot model was modified to generate muscle overpulls, including extensor hallucis longus, flexor hallucis longus and peroneus longus. Both corrective procedures were simulated, predicting joint angle and plantar pressure changes.
Findings: The clawed hallux deformity was generated by overpulling: 1) extensor hallucis longus, 2) peroneus longus + extensor hallucis longus, 3) extensor hallucis longus + flexor hallucis longus and 4) all three together. The modified Jones reduced metatarsophalangeal joint angles, but acceptable hallux pressure was found only when there was no flexor hallucis longus overpull. The flexor hallucis longus tendon transfer reduced deformity at the metatarsophalangeal and interphalangeal joints but may extended the hallux due to the unopposed extensor hallucis longus. Additionally, metatarsal head pressure increased with overpulling of the extensor hallucis longus + flexor hallucis longus, and all three muscles together.
Interpretation: The modified Jones was effective in correcting clawed hallux deformity involving extensor hallucis longus overpull without flexor hallucis longus overpull. The flexor hallucis longus tendon transfer was effective in correcting clawed hallux deformity resulting from the combined overpull of both extensor and flexor hallucis longus, but not with isolated extensor hallucis longus overpull. An additional procedure to reduce the metatarsal head pressure may be required concomitant to the flexor hallucis longus tendon transfer. However this procedure avoids interphalangeal joint fusion. Published by Elsevier Ltd
C1 [Isvilanonda, Vara; Dengler, Evan; Iaquinto, Joseph M.; Sangeorzan, Bruce J.; Ledoux, William R.] US Dept Vet Affairs, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA USA.
[Isvilanonda, Vara; Dengler, Evan; Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA.
[Sangeorzan, Bruce J.; Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA.
RP Ledoux, WR (reprint author), VA Puget Sound, Ms 151,1660 S Columbian Way, Seattle, WA 98108 USA.
EM wrledoux@u.washington.edu
RI Ledoux, William/K-6815-2015
OI Ledoux, William/0000-0003-4982-7714
FU VA Grants [A0806C, A2661C, A4843C, A6973R]
FX This work is supported by the VA Grants A0806C, A2661C, A4843C and
A6973R. The study sponsors played no role in the study design; in the
collection, analysis and interpretation of data; in the writing of the
manuscript: and in the decision to submit the manuscript for
publication. The authors would also like to thank Daniel L A. Camacho
and Joanna J. Blevins for their work on early versions of the foot
model.
NR 59
TC 16
Z9 16
U1 0
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0268-0033
J9 CLIN BIOMECH
JI Clin. Biomech.
PD OCT
PY 2012
VL 27
IS 8
BP 837
EP 844
DI 10.1016/j.clinbiomech.2012.05.005
PG 8
WC Engineering, Biomedical; Orthopedics; Sport Sciences
SC Engineering; Orthopedics; Sport Sciences
GA 006WP
UT WOS:000308850800016
PM 22694884
ER
PT J
AU Kasckow, J
Appelt, C
Haas, GL
Huegel, S
Fox, L
Gurklis, J
Zickmund, S
Daley, D
AF Kasckow, J.
Appelt, C.
Haas, G. L.
Huegel, S.
Fox, L.
Gurklis, J.
Zickmund, S.
Daley, D.
TI Development of a Recovery Manual for Suicidal Patients with
Schizophrenia: Consumer Feedback
SO COMMUNITY MENTAL HEALTH JOURNAL
LA English
DT Article
DE Schizophrenia; Suicide; Manual; Prevention; Recovery; Qualitative
research
ID HEALTH
AB A recovery-oriented manual was developed for patients with schizophrenia and suicidality. It included psychoeducational information, vignettes, "workbook" sections and was reviewed by experts in suicidology, recovery, patient education, manual development and psychosocial interventions. The revised version was tested in 22 consumers with schizophrenia and a history of suicidality. Consumer-based focus groups yielded five key themes which were used to further refine the manual. A satisfaction survey indicated that 85% stated the manual was 'somewhat easy', 'easy' or 'very easy to read.' All stated it was 'very useful', 'useful' or 'somewhat useful. Thus, the manual appears to be acceptable and useful.
C1 [Kasckow, J.; Haas, G. L.; Daley, D.] UPMC, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA.
[Kasckow, J.] VA Pittsburgh Hlth Care Syst MIRECC, Behav Hlth, Pittsburgh, PA 15206 USA.
[Kasckow, J.; Zickmund, S.] Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Huegel, S.; Gurklis, J.] VA Pittsburgh Hlth Care Syst, Behav Hlth, Pittsburgh, PA 15206 USA.
[Zickmund, S.] UPMC, Dept Med, Pittsburgh, PA 15213 USA.
RP Kasckow, J (reprint author), UPMC, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA.
EM Kasckowjw@upmc.edu
FU NIMH NIH HHS [T32 MH15169, T32 MH015169]
NR 15
TC 0
Z9 0
U1 1
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0010-3853
J9 COMMUNITY MENT HLT J
JI Community Ment. Health J.
PD OCT
PY 2012
VL 48
IS 5
BP 564
EP 567
DI 10.1007/s10597-011-9477-7
PG 4
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 013XK
UT WOS:000309339200004
PM 22187086
ER
PT J
AU Kaunitz, JD
AF Kaunitz, Jonathan D.
TI From Bedside to Bench: Reverse Engineering Medical Progress
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Editorial Material
ID HISTAMINE
C1 [Kaunitz, Jonathan D.] W Los Angeles VAMC, Los Angeles, CA 90073 USA.
[Kaunitz, Jonathan D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA.
RP Kaunitz, JD (reprint author), W Los Angeles VAMC, Bldg 114,Room 217E, Los Angeles, CA 90073 USA.
EM jdkaunitz@gmail.com
FU BLRD VA [I01 BX001245]; NIDDK NIH HHS [R01 DK054221]
NR 8
TC 0
Z9 0
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD OCT
PY 2012
VL 57
IS 10
BP 2481
EP 2483
DI 10.1007/s10620-012-2386-y
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 012HQ
UT WOS:000309227300001
PM 22983560
ER
PT J
AU Saunders, GH
Forsline, A
AF Saunders, Gabrielle H.
Forsline, Anna
TI Hearing-aid counseling: Comparison of single-session informational
counseling with single-session performance-perceptual counseling
SO INTERNATIONAL JOURNAL OF AUDIOLOGY
LA English
DT Article
DE Hearing aids; rehabilitation of hearing impaired; counseling
ID MEDICAL INFORMATION; REPORTED HANDICAP; OLDER-PEOPLE; ADULTS; USERS;
IMPAIRMENT; OUTCOMES; PROGRAM; MEMORY; INVENTORY
AB Objective: Hearing-aid counseling can improve outcome but programs are often too resource-intensive to be clinically practical. Here we examined the effectiveness of single-session informational counseling with single-session performance-perceptual counseling. Design: Two forms of counseling were compared: informational counseling (IC) and performance-perceptual counseling (PPC). IC focused on discussing communication strategies and tips for hearing-aid use. PPC addressed the discrepancy between measured and perceived ability to understand speech. Outcomes were measured eight-to-ten weeks post-counseling using quantitative and qualitative measures: Hearing handicap inventory, abbreviated profile of hearing aid benefit, psychosocial impact of assistive devices scale (PIADS), international outcome inventory for hearing aids, and a semi-structured exit interview. Study sample: Seventy-four hearing aid-users with symmetrical sensorineural hearing loss participated. Results: Scores on the hearing questionnaires showed no change following either form of counseling. Scores on the PIADS improved for participants as a whole, and the semi-structured interview revealed increased hearing-aid use, better understanding and acceptance of hearing loss, increased use of communication strategies, and improved ability to explain hearing difficulties to others. Conclusions: A single session of hearing-aid counseling can improve hearing-aid use and satisfaction. Open-ended interview and/or quality of life measures are more sensitive to these benefits than hearing questionnaires.
C1 [Saunders, Gabrielle H.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA.
[Forsline, Anna] Portland VA Med Ctr, Dept Audiol & Speech Pathol, Portland, OR 97239 USA.
RP Saunders, GH (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM gabrielle.saunders@va.gov
FU Department of Veterans Affairs Health Administration, Rehabilitation
Research and Development Grant [C3951R]; National Center for
Rehabilitative Auditory Research, Portland VA Medical Center, Portland,
Oregon
FX The research reported here was supported by the Department of Veterans
Affairs Health Administration, Rehabilitation Research and Development
Grant # C3951R and the National Center for Rehabilitative Auditory
Research, Portland VA Medical Center, Portland, Oregon. We thank Mark
Caldwell and ShienPei Silverman for their participation with data
collection and administrative support. Data from this work have been
presented at the 2008 International Hearing Aid Research Conference
(IHCON), Lake Tahoe, USA August 13-15, 2008; and at the 5th
International Adult Aural Rehabilitation Conference, Tampa Florida, USA,
March 16-19, 2009.
NR 45
TC 7
Z9 7
U1 0
U2 12
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1499-2027
J9 INT J AUDIOL
JI Int. J. Audiol.
PD OCT
PY 2012
VL 51
IS 10
BP 754
EP 764
DI 10.3109/14992027.2012.699200
PG 11
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 010NZ
UT WOS:000309102500007
PM 22812927
ER
PT J
AU Ellis, C
Grubaugh, AL
Egede, LE
AF Ellis, Charles
Grubaugh, Anouk L.
Egede, Leonard E.
TI The association between major depression, health behaviors, and quality
of life in adults with stroke
SO INTERNATIONAL JOURNAL OF STROKE
LA English
DT Article
DE depression; quality of life; stroke
ID RISK-FACTOR SURVEY; POSTSTROKE DEPRESSION; FOLLOW-UP; SURVIVORS;
SATISFACTION; SYMPTOMS; CAREGIVERS; REHABILITATION; RELIABILITY;
POPULATION
AB Aim The study aims to examine the association between major depression, healthcare behaviors, and quality of life indices among adults with stroke. Methods Data from 5869 participants with stroke in the 2006 Behavioral Risk Factor Surveillance Survey were examined. Multiple logistic regression was used to assess the independent association between depression status, self-care and preventive health behaviors, and quality of life indices, after accounting for relevant covariates. Results In multivariate models, individuals with major depression were less likely to engage in physical activity (odds ratio 0.41; 95% confidence interval 0.29, 0.56) than those without major depression. Women with major depression were also less likely to have received a mammogram in the past two-years (odds ratio 0.61; 95% confidence interval 0.40, 0.96 for women?=?age 40 and odds ratio 0.58; 95% confidence interval 0.36, 0.72 for women?=?age 50) and a pap smear in the past three-years (odds ratio 0.40; 95% CI 0.22, 0.72). In comparisons of quality of life, individuals with major depression were less likely to perceive their health as excellent/very good/good (odds ratio 0.36; 95% confidence interval 0.25, 0.53), to report being satisfied with life (odds ratio 0.13; 95% confidence interval 0.08, 0.20), and to report receiving needed social support (odds ratio 0.42; 95% confidence interval 0.28, 0.63). Individuals who were depressed were also more likely to report one or more poor physical and poor mental health days in the past 30 days (odds ratio 4.56; 95% confidence interval 3.08, 6.76 and odds ratio 10.97; 95% confidence interval 7.75, 15.52, respectively). Conclusions In adults with stroke, major depression is associated with decreased engagement in stroke-specific and gender-specific self-care and preventive health behaviors, as well as a broad range of quality of life indices.
C1 [Ellis, Charles] Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Ellis, Charles; Grubaugh, Anouk L.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, VA Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC USA.
[Grubaugh, Anouk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
RP Ellis, C (reprint author), Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA.
EM ellisc@musc.edu
FU Charleston, SC HSR& D Funded Center for Disease Prevention and Health
Interventions for Diverse Populations [REA 08-261]; Veterans Health
Administration Health Services Research and Development program
[07-012-3, 07-015-2]
FX (1) This work represents work supported by the use of facilities at the
Charleston, SC HSR& D Funded Center for Disease Prevention and Health
Interventions for Diverse Populations (REA 08-261).; (2) Dr Ellis is
supported by a career development award (CDA# 07-012-3) from the
Veterans Health Administration Health Services Research and Development
program.; (3) Dr Grubaugh is supported by a career development award
(CDA2 # 07-015-2) from the Veterans Health Administration Health
Services Research and Development program.
NR 40
TC 4
Z9 5
U1 1
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-4930
J9 INT J STROKE
JI Int. J. Stroke
PD OCT
PY 2012
VL 7
IS 7
BP 536
EP 543
DI 10.1111/j.1747-4949.2011.00708.x
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 008PD
UT WOS:000308968100011
PM 22151696
ER
PT J
AU Severson, EP
Singh, JA
Browne, JA
Trousdale, RT
Sarr, MG
Lewallen, DG
AF Severson, Erik P.
Singh, Jasvinder A.
Browne, James A.
Trousdale, Robert T.
Sarr, Michael G.
Lewallen, David G.
TI Total Knee Arthroplasty in Morbidly Obese Patients Treated With
Bariatric Surgery A Comparative Study
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article
DE total knee arthroplasty; morbidly obese; bariatric surgery; outcomes
ID TOTAL JOINT ARTHROPLASTY; WEIGHT-LOSS; GASTRIC BYPASS; BONE TURNOVER;
TOTAL HIP; COMPLICATIONS; REPLACEMENT; MECHANISMS; MARKERS
AB Our objective was to compare outcomes (anesthesia time, total operative time, tourniquet time, duration of hospital stay, 90-day complication rate, and transfusion rates) of patients with total knee arthroplasty (TKA) who underwent bariatric surgery before or after TKA. One hundred twenty-five patients were included: TKA before bariatric surgery (group 1; n = 39), TKA within 2 years of bariatric surgery (group 2; n = 25), and TKA more than 2 years after bariatric surgery (group 3; n = 61). Patients with TKA more than 2 years after bariatric surgery had shorter anesthesia and total operative and tourniquet times than other groups; differences were significant between groups. Ninety-day complication and transfusion rates approached but did not meet statistical significance. Ninety-day complication rates and duration of hospital stay did not differ significantly between the 3 groups. The level of evidence was level II (cohort study).
C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Fac Off, Sch Publ Hlth, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Severson, Erik P.] Minnesota Ctr Orthopaed, Crosby, MN USA.
[Severson, Erik P.; Singh, Jasvinder A.; Trousdale, Robert T.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, C SMART, Birmingham, AL USA.
[Browne, James A.] Univ Virginia, Dept Orthopaed Surg, Charlottesville, VA USA.
[Sarr, Michael G.] Mayo Clin, Coll Med, Dept Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off, Sch Publ Hlth, Dept Med, Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
OI singh, jasvinder/0000-0003-3485-0006
FU NCRR NIH HHS [KL2 RR024151, KL2 RR024151-01]
NR 28
TC 27
Z9 27
U1 2
U2 7
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD OCT
PY 2012
VL 27
IS 9
BP 1696
EP 1700
DI 10.1016/j.arth.2012.03.005
PG 5
WC Orthopedics
SC Orthopedics
GA 013WA
UT WOS:000309335400019
PM 22554730
ER
PT J
AU Nielson, CM
Klein, RF
Orwoll, ES
AF Nielson, Carrie M.
Klein, Robert F.
Orwoll, Eric S.
TI Sex and the single nucleotide polymorphism: Exploring the genetic causes
of skeletal sex differences
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
ID BONE-MINERAL DENSITY; ESTROGEN-RECEPTOR-ALPHA; EXPRESSION; DIMORPHISM;
GENDER; MASS; OSTEOPOROSIS; METAANALYSIS; OSTEOCLASTS; STRENGTH
C1 [Klein, Robert F.; Orwoll, Eric S.] Oregon Hlth & Sci Univ, Dept Med, Bone & Mineral Unit, Portland, OR 97239 USA.
[Klein, Robert F.] Portland VA Med Ctr, Portland, OR USA.
RP Orwoll, ES (reprint author), Oregon Hlth & Sci Univ, Bone & Mineral Unit CR 113, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM orwoll@ohsu.edu
OI Orwoll, Eric/0000-0002-8520-7355
FU NIAMS NIH HHS [K01 AR062655]
NR 32
TC 1
Z9 2
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD OCT
PY 2012
VL 27
IS 10
BP 2047
EP 2050
DI 10.1002/jbmr.1723
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 007ZB
UT WOS:000308925800002
PM 22991137
ER
PT J
AU Smith, AK
Lo, B
AF Smith, Alexander K.
Lo, Bernard
TI The Problem with Actually Tattooing DNR across Your Chest
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
ID PREFERENCES
C1 [Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94941 USA.
[Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Lo, Bernard] Greenwall Fdn, New York, NY USA.
[Lo, Bernard] Univ Calif San Francisco, Div Gen Internal Med, Dept Med, San Francisco, CA 94941 USA.
RP Smith, AK (reprint author), Univ Calif San Francisco, Div Geriatr, Dept Med, 4150 Clement St 181 G, San Francisco, CA 94941 USA.
EM aksmith@ucsf.edu
NR 7
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2012
VL 27
IS 10
BP 1238
EP 1239
DI 10.1007/s11606-012-2134-1
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 008PL
UT WOS:000308968900004
PM 22810355
ER
PT J
AU Zhang, YT
Gellad, WF
Zhou, L
Lin, YJ
Lave, JR
AF Zhang, Yuting
Gellad, Walid F.
Zhou, Lei
Lin, Yi-Jen
Lave, Judith R.
TI Access to and Use of $4 Generic Programs in Medicare
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE Medicare; low-cost generic drugs; pharmaceuticals
ID QUALITY
AB Although four-dollar programs ($4 per 30-day supply for selected generic drugs) have become important options for seniors to obtain affordable medications, little is known about access to these programs and the characteristics of those who use them.
We quantify access to $4 programs based on driving distance; evaluate factors affecting the program use and potential cost-savings associated with switching to $4 programs in Medicare.
Observational study.
US Medicare Part D data, 5% random sample, 2007
347,653 elderly beneficiaries without Medicaid coverage or low-income subsidies.
We evaluated how use of $4 programs was affected by driving distance to the store and the beneficiary's demographic and socioeconomic status, insurance coverage, health status, comorbidities, and medication use. For those who did not use the $4 programs, we calculated potential savings from switching to $4 generics.
Eighty percent of seniors in Medicare Part D filled prescriptions for generic drugs that were commonly available at $4 programs. Among them, only 16.3% filled drugs through $4 programs. Beneficiaries who lived in poor areas, had less insurance, more co-morbidities, and used more drugs and lived closer to $4 generic retail pharmacies, were more likely to use these programs. Blacks were less likely to use the program relative to Whites (15.0% vs. 16.4%; OR = 0.75, 95% CI 0.71-0.80). While 53.2% of nonusers would save by switching to $4 program after incorporating travelling costs, 58% of those who could save would have net annual out-of-pocket savings of less than $20.
The take-up rate of $4 programs was low in 2007 among Medicare beneficiaries. As more stores offer $4 programs and increasing numbers of drugs become generic, more beneficiaries could potentially benefit, as could the Medicare program.
C1 [Zhang, Yuting; Zhou, Lei; Lave, Judith R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA.
[Gellad, Walid F.] Univ Pittsburgh, Sch Med, Div Gen Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.
[Gellad, Walid F.] RAND Corp, Pittsburgh, PA USA.
[Zhou, Lei] PharmaNet i3, Indianapolis, IN USA.
[Lin, Yi-Jen] Univ Pittsburgh, Grad Sch Publ & Int Affairs, Pittsburgh, PA 15261 USA.
RP Zhang, YT (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA.
EM ytzhang@pitt.edu
OI Zhang, Yuting/0000-0002-6460-6779
FU RAND-University of Pittsburgh Health Institute (RUPHI); University of
Pittsburgh School of the Health Sciences; National Center for Research
Resources, National Institutes of Health (NIH) [UL1 RR024153]; NIH
Roadmap for Medical Research; NIMH [RC1 MH088510]; AHRQ [R01 HS018657];
Highmark Inc.
FX The RAND University of Pittsburgh Health Institute and the Clinical and
Translational Science Institute: Translating Research into Practice
Program. This project was supported in part by the RAND-University of
Pittsburgh Health Institute (RUPHI), a formal collaboration between the
RAND Corporation, RAND Health, and the University of Pittsburgh School
of the Health Sciences. This publication was made possible by grant UL1
RR024153 from the National Center for Research Resources, a component of
the National Institutes of Health (NIH), and NIH Roadmap for Medical
Research. During the study period, Dr. Zhang was also supported by NIMH
RC1 MH088510 and AHRQ R01 HS018657.; Dr. Gellad has received an
honorarium from Vindico Medical Education for preparation of a
continuing medical education (CME) activity focused on improving
medication adherence. Drs. Zhang and Lave were investigators for a
contact (2008-2009) to evaluate the effects of high-deductible health
plans funded by Highmark Inc., which sells Part D plans.
NR 13
TC 15
Z9 15
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2012
VL 27
IS 10
BP 1251
EP 1257
DI 10.1007/s11606-012-1993-9
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 008PL
UT WOS:000308968900009
PM 22311333
ER
PT J
AU Lin, OS
Kozarek, RA
Gluck, M
Jiranek, GC
Koch, J
Kowdley, KV
Irani, S
Nguyen, M
Dominitz, JA
AF Lin, Otto S.
Kozarek, Richard A.
Gluck, Michael
Jiranek, Geoffrey C.
Koch, Johannes
Kowdley, Kris V.
Irani, Shayan
Nguyen, Matthew
Dominitz, Jason A.
TI Preference for Colonoscopy Versus Computerized Tomographic Colonography:
A Systematic Review and Meta-analysis of Observational Studies
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Review
DE colorectal cancer; adenoma; screening; colonoscopy; computerized
tomographic colonography
ID LIMITED BOWEL PREPARATION; CANCER SCREENING COMPLIANCE; PRIMARY-CARE
PATIENTS; CT COLONOGRAPHY; COLORECTAL-CANCER; PATIENT ACCEPTANCE;
CONVENTIONAL COLONOSCOPY; VIRTUAL COLONOSCOPY; MR COLONOGRAPHY; OPTICAL
COLONOSCOPY
AB In recent years, colorectal cancer (CRC) screening using computerized tomographic colonography (CTC) has attracted considerable attention. In order to better understand patient preferences for CTC versus colonoscopy, we performed a systematic review and meta-analysis of the available literature. Data sources included published studies, abstracts and book chapters, in any language, with publication dates from 1995 through February 2012, and with prospective or retrospective enrollment of diagnostic or screening patients who had undergone both procedures and explicit assessment of their preference for colonoscopy versus CTC. A predefined algorithm identified eligible studies using computer and hand searches performed by two independent investigators. We used a mixed effects model to pool preference differences (defined as the proportion of subjects who preferred CTC minus the proportion who preferred colonoscopy for each study). Twenty-three studies met inclusion criteria, totaling 5616 subjects. In 16 of these studies, patients preferred CTC over colonoscopy, while colonoscopy was preferred in three studies. Due to the high degree of heterogeneity, an overall pooled preference difference was not calculated. Stratified analysis revealed that studies published in radiology journals (preference difference 0.590 [95 % CI 0.485, 0.694]) seemed more likely than studies in gastroenterology (0.218 [-0.015-0.451]) or general medicine journals (-0.158 [-0.389-0.072]) to report preference for CTC (p < 0.001). Studies by radiology authors showed a trend towards stronger preference for CTC compared with studies by gastroenterology authors. Symptomatic patients expressed no preference, but screening patients preferred CTC. There was no difference in preferences between studies using "masked" and "unmasked" preference ascertainment methods. Three studies featuring limited bowel preparations for CTC reported marked preference for CTC. There was no evidence of publication bias, while cumulative and exclusion analysis did not show any temporal trend or dominant study. Limitations included data heterogeneity and preference ascertainment limitations. In conclusion, most included studies reported preference for CTC. On stratified analysis, screening patients preferred CTC while diagnostic patients showed no preference. Studies published in radiology journals showed significantly stronger preference for CTC compared with studies in gastroenterology or general medicine journals.
C1 [Lin, Otto S.; Kozarek, Richard A.; Gluck, Michael; Jiranek, Geoffrey C.; Koch, Johannes; Kowdley, Kris V.; Irani, Shayan; Nguyen, Matthew] Virginia Mason Med Ctr, Gastroenterol Sect, Seattle, WA 98101 USA.
[Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA USA.
[Dominitz, Jason A.] Univ Washington, Seattle, WA 98195 USA.
RP Lin, OS (reprint author), Virginia Mason Med Ctr, Gastroenterol Sect, 1100 9th Ave, Seattle, WA 98101 USA.
EM otto.lin@vmmc.org
OI Dominitz, Jason/0000-0002-8070-7086
FU Cumberland Pharmaceuticals
FX None of the authors have any financial conflicts of interest to report,
with the following exceptions: 1) A research grant from Cumberland
Pharmaceuticals to Dr. Otto Lin, for a pilot study assessing the
efficacy and safety of crystalline lactulose as a colonoscopy bowel
preparation agent; 2) Consultancies for Epigenomics Inc. and Salix
Pharmaceuticals for Dr. Jason Dominitz.
NR 72
TC 17
Z9 18
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2012
VL 27
IS 10
BP 1349
EP 1360
DI 10.1007/s11606-012-2115-4
PG 12
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 008PL
UT WOS:000308968900021
PM 22700393
ER
PT J
AU Pierce, JMR
Estrada, CA
Mathews, RE
AF Pierce, J. Matthew R.
Estrada, Carlos A.
Mathews, Ronnie E., Jr.
TI Buyers Beware: Lead Poisoning due to Ayurvedic Medicine
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE dietary supplements; lead; India; medicine; Ayurvedic; Phytotherapy;
plant extracts/chemistry
AB A 29-year-old man, who recently emigrated from India, presented with a 2-week history of abdominal pain, as well as nausea, constipation, and fatigue. He underwent removal of a parathyroid adenoma 6 weeks prior to admission and received a locally made Indian traditional medicine (Ayurveda) for pain control; however, this information was not initially available. He was instructed to take approximately 15 g/day. Initial evaluation revealed a normocytic anemia, but other workup including imaging and endoscopy was unrevealing. Given his recent use of Ayurvedic medicines, we tested for lead poisoning and found a blood lead level of 72 mcg/dl. We sent his medicine for analysis and found it had a high lead concentration of 36,000 mcg/g, which is over 25,000 times the maximum daily dose. He improved with cessation of the medicine and treatment with succimer. Lead poisoning can present with a variety of nonspecific signs and symptoms, including abdominal pain and anemia. Ayurvedic medicines, as well as traditional medicines from other cultures, may be a source of lead or other heavy metals. It is essential for physicians to be aware of adverse effects of Ayurvedic medicines as they are easily available and increasing in popularity.
C1 [Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
[Estrada, Carlos A.] Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA.
RP Estrada, CA (reprint author), Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, FOT 732,510 20th St S, Birmingham, AL 35294 USA.
EM cestrada@uab.edu
NR 12
TC 1
Z9 1
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2012
VL 27
IS 10
BP 1384
EP 1386
DI 10.1007/s11606-012-2048-y
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 008PL
UT WOS:000308968900026
PM 22476953
ER
PT J
AU Hoggatt, KJ
Flores, M
Solorio, R
Wilhelm, M
Ritz, B
AF Hoggatt, Katherine J.
Flores, Marie
Solorio, Rosa
Wilhelm, Michelle
Ritz, Beate
TI The "Latina Epidemiologic Paradox" Revisited: The Role of Birthplace and
Acculturation in Predicting Infant Low Birth Weight for Latinas in Los
Angeles, CA
SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH
LA English
DT Article
DE Low birth weight; Latina, Hispanic; US-born, foreign-born;
Acculturation; Two-phase analysis
ID UNITED-STATES; PREGNANCY OUTCOMES; MORTALITY DIFFERENTIALS;
MEXICAN-AMERICANS; PERINATAL HEALTH; PRETERM BIRTH; WOMEN; POPULATION;
CALIFORNIA; ETHNICITY
AB The "Latina epidemiologic paradox" refers to the observation that despite socioeconomic disadvantages, Latina mothers in the United States (US) have a similar or lower risk for delivering an infant with low birth weight (LBW) compared to non-Latina White mothers. An analogous paradox may exist between foreign-born (FB) and US-born (USB) Latinas. Our goal was to assess differences in LBW in USB Latinas, FB Latinas, and non-Latina Whites in Los Angeles County in 2003 using birth records and survey data. Using logistic regression, we estimated associations between LBW and birthplace/ethnicity in a birth cohort and nested survey responder group and between LBW and acculturation in responders to a follow-up survey. USB Latinas and FB Latinas had a higher prevalence of LBW infants compared to Whites (odds ratio [OR] = 1.34, 95% confidence interval [CI] = (1.17, 1.53) and OR = 1.32, 95% CI = (1.18, 1.49), respectively); when we adjusted for additional maternal risk factors these point estimates were attenuated, and interval estimates were consistent with a modest positive or inverse association. Among Latinas only, LBW was more common for high-acculturated FB and USB Latinas compared to low-acculturated FB Latinas, and there was limited evidence that environmental or behavior risk factors had less impact in low-acculturated Latinas. In summary, adjusting only for demographics, Latinas in our study were more likely to have LBW infants compared to Whites, in contrast to the Latina paradox hypothesis. Furthermore, adjusting for environmental or behavioral factors attenuated the positive association, but there was little evidence that Latinas had a lower prevalence of LBW regardless of the variables included in the models. Finally, among Latinas, there was limited evidence that associations between known risk factors and LBW were modified by acculturation.
C1 [Hoggatt, Katherine J.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA.
[Hoggatt, Katherine J.] VA Greater Los Angeles, HSR&D Ctr Excellence, Study Healthcare Provider Behav, Los Angeles, CA 91343 USA.
[Flores, Marie] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Solorio, Rosa] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Wilhelm, Michelle; Ritz, Beate] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
RP Hoggatt, KJ (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Box 951772, Los Angeles, CA 90095 USA.
EM khoggatt@ucla.edu
RI Ritz, Beate/E-3043-2015
FU NIEHS NIH HHS [P30 ES007048, R01 ES010960, 5 P30 ES07048]; NINR NIH HHS
[R21 NR010856]
NR 40
TC 11
Z9 11
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1912
J9 J IMMIGR MINOR HEALT
JI J. Immigr. Minor. Health
PD OCT
PY 2012
VL 14
IS 5
BP 875
EP 884
DI 10.1007/s10903-011-9556-4
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 004BX
UT WOS:000308656200019
PM 22160842
ER
PT J
AU Korrapati, MC
Shaner, BE
Neely, BA
Alge, JL
Arthur, JM
Schnellmann, RG
AF Korrapati, Midhun C.
Shaner, Brooke E.
Neely, Benjamin A.
Alge, Joseph L.
Arthur, John M.
Schnellmann, Rick G.
TI Diabetes-Induced Renal Injury in Rats Is Attenuated by Suramin
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID GELATINASE-ASSOCIATED LIPOCALIN; KAPPA-B ACTIVATION; TGF-BETA;
OBSTRUCTIVE NEPHROPATHY; PROTEOMIC ANALYSIS; SIGNALING PATHWAY;
STATISTICAL-MODEL; GENE-EXPRESSION; EARLY BIOMARKER; KIDNEY-DISEASE
AB Progression of hyperglycemia-induced renal injury is a contributing factor for diabetic nephropathy (DN)-induced end-stage renal disease (ESRD), and development of novel therapeutic strategies that act early to prevent progression of DN and ESRD are important. We examined the efficacy and mechanism(s) of suramin on hyperglycemia-induced renal injury before development of overt histological damage. Two groups of male Sprague-Dawley rats received streptozotocin (STZ) and one group received saline. Three weeks later, one STZ group received suramin (10 mg/kg). All animals were euthanized 1 week later (4 weeks). Although there was a decrease in creatinine clearance between control and STZ +/- suramin rats, there was no difference in creatinine clearance between STZ rats +/- suramin intervention. Liquid chromatography-tandem mass spectroscopy-based analysis revealed increases in urinary proteins that are early indicators of DN (e.g., cystatin C, clusterin, cathepsin B, retinol binding protein 4, and peroxiredoxin-1) in the STZ group, which were blocked by suramin. Endothelial intracellular adhesion molecule-1 (ICAM-1) activation, leukocyte infiltration, and inflammation; transforming growth factor-beta 1 (TGF-beta 1) signaling; TGF-beta 1/SMAD-3-activated fibrogenic markers fibronectin-1, alpha-smooth muscle actin, and collagen 1A2; activation of proinflammatory and profibrotic transcription factors nuclear factor-kappa B (NF-kappa B) and signal transducer and activator of transcription factor-3 (STAT-3), respectively, were all increased in STZ rats and suramin blocked these changes. In conclusion, delayed administration of suramin attenuated 1) urinary markers of DN, 2) inflammation by blocking NF-kappa B activation and ICAM-1-mediated leukocyte infiltration, and 3) fibrosis by blocking STAT-3 and TGF-beta 1/SMAD-3 signaling. These results support the potential use of suramin in DN.
C1 [Korrapati, Midhun C.; Shaner, Brooke E.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Div Nephrol, Charleston, SC 29425 USA.
[Neely, Benjamin A.; Alge, Joseph L.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Arthur, John M.; Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Div Nephrol, 280 Calhoun St,MSC140, Charleston, SC 29425 USA.
EM schnell@musc.edu
OI Neely, Benjamin/0000-0001-6120-7695; Alge, Joseph/0000-0002-2491-1066
FU National Institutes of Health National Institute of General Medical
Sciences [GM084147]; National Institutes of Health National Center for
Research Resources [UL1-RR029882, C06-RR015455]; Biomedical Laboratory
Research and Development Program of the Department of Veterans Affairs;
South Carolina Clinical and Translational Research Institute; Medical
University of South Carolina
FX This work was supported by the National Institutes of Health National
Institute of General Medical Sciences [Grant GM084147]; the National
Institutes of Health National Center for Research Resources [Grant
UL1-RR029882]; the Biomedical Laboratory Research and Development
Program of the Department of Veterans Affairs; the South Carolina
Clinical and Translational Research Institute, with an academic home at
the Medical University of South Carolina. Animal facilities were funded
by National Institutes of Health National Center for Research Resources
[Grant C06-RR015455].
NR 61
TC 9
Z9 9
U1 1
U2 2
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD OCT
PY 2012
VL 343
IS 1
BP 34
EP 43
DI 10.1124/jpet.112.196964
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 009AK
UT WOS:000308997500004
PM 22736507
ER
PT J
AU Sher, L
Grunebaum, MF
Sullivan, GM
Burke, AK
Cooper, TB
Mann, JJ
Oquendo, MA
AF Sher, Leo
Grunebaum, Michael F.
Sullivan, Gregory M.
Burke, Ainsley K.
Cooper, Thomas B.
Mann, J. John
Oquendo, Maria A.
TI Testosterone levels in suicide attempters with bipolar disorder
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Testosterone; Bipolar disorder; Depression; Suicide; Smoking
ID GENDER-DIFFERENCES; PERSONALITY DIMENSIONS; AGGRESSIVE-BEHAVIOR; PLASMA
TESTOSTERONE; DEPRESSED-PATIENTS; VIOLENT OFFENDERS; ADOLESCENT MALES;
CONTROLLED-TRIAL; DOUBLE-BLIND; STEROID USE
AB Objective: The best known neurobehavioral effects of testosterone are on sexual function and aggression. However, testosterone and other androgens may be involved in the pathophysiology of mood disorders and suicidal behavior. This is the first study to examine whether there is a relation between testosterone levels and clinical parameters in bipolar suicide attempters.
Methods: Patients with a DSM-IV diagnosis of a bipolar disorder (16 males and 51 females), in a depressive or mixed episode with at least one past suicide attempt were enrolled. Demographic and clinical parameters, including lifetime suicidal behavior, were assessed and recorded. Plasma testosterone was assayed using a double antibody radioimmunoassay procedure.
Results: The number of major depressive episodes, the maximum lethality of suicide attempts, and the testosterone levels were higher in men compared to women. Current suicidal ideation scores were higher in women compared to men. Controlling for sex, we found that testosterone levels positively correlated with the number of manic episodes and the number of suicide attempts.
Conclusion: Our findings are consistent with previous observations of the association between testosterone levels and parameters of mood and behavior. This study suggests that testosterone levels may be related to the course of bipolar disorder and suicidal behavior. Further studies of the role of testosterone in the neurobiology of mood disorders and suicidal behavior are merited. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA.
[Sher, Leo; Grunebaum, Michael F.; Sullivan, Gregory M.; Burke, Ainsley K.; Cooper, Thomas B.; Mann, J. John; Oquendo, Maria A.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Sher, Leo; Grunebaum, Michael F.; Sullivan, Gregory M.; Burke, Ainsley K.; Cooper, Thomas B.; Mann, J. John; Oquendo, Maria A.] Columbia Univ, Coll Phys & Surg, New York, NY USA.
[Sher, Leo] Mt Sinai Sch Med, New York, NY USA.
RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Leo.Sher@mssm.edu
FU NIH [R01 MH59710, P50 MH62185, R01 MH48514]
FX This research study supported by grants R01 MH59710, P50 MH62185, and
R01 MH48514 from the NIH. The NIH had no further role in study design;
in the collection, analysis, and interpretation of the data; in the
writing of the report; and in the decision to submit the paper for
publication.
NR 62
TC 18
Z9 19
U1 1
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD OCT
PY 2012
VL 46
IS 10
BP 1267
EP 1271
DI 10.1016/j.jpsychires.2012.06.016
PG 5
WC Psychiatry
SC Psychiatry
GA 013GU
UT WOS:000309294700003
PM 22858352
ER
PT J
AU Jahshan, C
Wynn, JK
Breitmeyer, BG
Green, MF
AF Jahshan, Carol
Wynn, Jonathan K.
Breitmeyer, Bruno G.
Green, Michael F.
TI Nonconscious and conscious color priming in schizophrenia
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Schizophrenia; Visual processing; Color priming; Nonconscious; Feed
forward
ID PSYCHIATRIC RATING-SCALE; VISUAL BACKWARD-MASKING; PARVOCELLULAR
CONTRIBUTIONS; CONTRAST SENSITIVITY; QUALITY-ASSURANCE; ATTENTION; FORM;
DYSFUNCTION; POTENTIALS; TRANSIENT
AB Deficits in visual processing are well established in schizophrenia. However, there is conflicting evidence about whether these deficits start before the formation of percepts because visual processing studies in schizophrenia have typically examined the processing of consciously registered stimuli. In this study, we used nonconscious color priming to evaluate the very early visual processing stages in schizophrenia. Nonconscious and conscious color priming was assessed in 148 schizophrenia patients and 54 healthy control subjects. In both conditions, subjects identified the color of a ring preceded by a disk (prime) in the same color (congruent) or a different color (incongruent). The ring rendered the disk invisible in the nonconscious condition (SOA of 62.5 ms) or did not mask the disk (SOA of 200 ms) in the conscious condition. Schizophrenia patients exhibited a color priming effect (longer reaction times in the incongruent vs. congruent trials) that was similar to healthy controls in both the nonconscious and conscious priming conditions. Healthy controls had a significantly larger priming effect in the nonconscious vs. conscious condition, but patients did not show a significant difference in priming effects between the two conditions. Our results indicate that schizophrenia patients do not have deficits at the nonconscious, pre-perceptual stages of visual processing, suggesting that the feed forward sweep of information processing (from retina to V1) might be intact in schizophrenia. These results imply that the welldocumented visual processing deficits in this illness likely occur at later, percept-dependent stages of processing. Published by Elsevier Ltd.
C1 [Jahshan, Carol; Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 22, Los Angeles, CA 90073 USA.
[Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
[Breitmeyer, Bruno G.] Univ Houston, Dept Psychol, Houston, TX USA.
[Breitmeyer, Bruno G.] Univ Houston, Ctr Neuroengn & Cognit Sci, Houston, TX USA.
RP Jahshan, C (reprint author), VA Greater Los Angeles Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 22, Bldg 210,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM caroljahshan@hotmail.com
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
FU NIH [MH043292, MH065707]
FX Funding for this study was provided by NIH Grants MH043292 and MH065707
(MFG). The NIH had no further role in study design; in the collection,
analysis, and interpretation of data; in the writing of the report; and
in the decision to submit the paper for publication.
NR 47
TC 8
Z9 10
U1 2
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD OCT
PY 2012
VL 46
IS 10
BP 1312
EP 1317
DI 10.1016/j.jpsychires.2012.06.009
PG 6
WC Psychiatry
SC Psychiatry
GA 013GU
UT WOS:000309294700010
PM 22785333
ER
PT J
AU Brasky, TM
Baik, CS
Slatore, CG
Alvarado, M
White, E
AF Brasky, Theodore M.
Baik, Christina S.
Slatore, Christopher G.
Alvarado, Mariela
White, Emily
TI Prediagnostic Nonsteroidal Anti-Inflammatory Drug Use and Lung Cancer
Survival in the VITAL Study
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Aspirin; Ibuprofen; Nonsteroidal anti-inflammatory drugs; Lung Cancer;
Histology; Survival
ID C-REACTIVE PROTEIN; LOW-DOSE ASPIRIN; COLORECTAL-CANCER; WOMENS HEALTH;
LARGE COHORT; RISK; TRIAL; INFLAMMATION; CELECOXIB; CHEMOTHERAPY
AB Introduction: Inflammation is important for lung oncogenesis. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to improve colorectal cancer survival. However, few studies have examined the association in lung cancer patients.
Methods: The VITamins And Lifestyle (VITAL) cohort includes Washington State residents, aged 50 to 76 years, who completed a baseline questionnaire between 2000 and 2002. Participants responded on the frequency and duration of use of individual NSAIDs in the previous 10 years. Subjects of this study were 785 members of the cohort, who were identified with incident lung cancer from baseline through 2007 through linkage to a population-based cancer registry. Participants were followed for lung cancer death through linkage to state records of death through 2009. Adjusted proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association between NSAIDs and lung cancer death.
Results: Five hundred and twenty-two participants (66%) died from lung cancer. Relative to nonuse, high (>= 4 days/week and >= 4 years) prediagnostic use of regular-strength or low-dose aspirin (HR 0.99, 95% CI: 0.74-1.33 and HR 0.89, 95% CI: 0.67-1.17, respectively) or total nonaspirin NSAIDs (HR 1.20, 95% CI: 0.79-1.83) did not reduce lung cancer death. However, high use of ibuprofen was associated with a 62% increased risk of lung cancer death (HR 1.62, 95% CI: 1.01-2.58).
Conclusions: Long-term, prediagnostic NSAID use does not improve lung cancer survival overall. Use of ibuprofen may reduce survival from lung cancer. Our results underscore the need for further study of the mechanisms of action for individual NSAIDs with regard to cancer survival.
C1 [Brasky, Theodore M.] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Canc Prevent & Control,Coll Med, Columbus, OH 43201 USA.
[Brasky, Theodore M.; Baik, Christina S.; White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA.
[Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR USA.
[Slatore, Christopher G.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
[Alvarado, Mariela] Bastyr Univ, Dept Nat Med, Kenmore, WA USA.
RP Brasky, TM (reprint author), Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Canc Prevent & Control,Coll Med, 1590 N High St,Suite 525, Columbus, OH 43201 USA.
EM theodore.brasky@osumc.edu
OI Slatore, Christopher/0000-0003-0958-8122
FU National Institutes of Health [R25-CA094880, K05-CA154337]; VA HSRD
Career Development Award
FX This work was supported by National Institutes of Health grants
R25-CA094880 (National Cancer Institute) and K05-CA154337 (National
Cancer Institute and Office of Dietary Supplements). Dr. Slatore is a
recipient of a VA HSRD Career Development Award and is supported by
resources from the Portland VA Medical Center. The Department of
Veterans Affairs did not have a role in the conduct of the study, in the
collection, management, analysis, or interpretation of data, or in the
preparation of the article. The views expressed in this article are
those of the authors and do not necessarily represent the views of the
Department of Veterans Affairs or the US Government.
NR 39
TC 6
Z9 6
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD OCT
PY 2012
VL 7
IS 10
BP 1503
EP 1512
DI 10.1097/JTO.0b013e3182641bdc
PG 10
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 007WP
UT WOS:000308919400010
PM 22982651
ER
PT J
AU Shih, YYI
Li, G
Muir, ER
De La Garza, BH
Kiel, JW
Duong, TQ
AF Shih, Yen-Yu I.
Li, Guang
Muir, Eric R.
De La Garza, Bryan H.
Kiel, Jeffrey W.
Duong, Timothy Q.
TI Pharmacological MRI of the choroid and retina: Blood flow and BOLD
responses during nitroprusside infusion
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE pharmacological MRI; retina; blood flow; blood oxygenation level
dependent; pO2; nitroprusside; nitric oxide
ID MANGANESE-ENHANCED MRI; NITRIC-OXIDE; SODIUM-NITROPRUSSIDE; FUNCTIONAL
MRI; OXYGEN-TENSION; INTRAOCULAR-PRESSURE; INDUCED HYPOTENSION; RAT
RETINA; AUTOREGULATION; MICROCIRCULATION
AB Nitroprusside, a vasodilatory nitric oxide donor, is clinically used during vascular surgery and to lower blood pressure in acute hypertension. This article reports a novel application of blood flow (BF) and blood oxygenation level dependent (BOLD) MRI on an 11.7T scanner to image the rat chorioretinal BF and BOLD changes associated with graded nitroprusside infusion. At low doses (1 or 2 mu g/kg/min), nitroprusside increased BF as expected but decreased BOLD signals, showing an intriguing BFBOLD uncoupling. At high doses (3-5 mu g/kg/min), nitroprusside decreased BF and markedly decreased BOLD signals. To our knowledge, this is the first pharmacological MRI application of the retina. This approach has potential to open up new avenues to study the drug-related hemodynamic functions and to evaluate the effects of novel therapeutic interventions on BOLD and BF in the normal and diseased retinas. Magn Reson Med, 2012. (c) 2011 Wiley Periodicals, Inc.
C1 [Shih, Yen-Yu I.; Li, Guang; Muir, Eric R.; De La Garza, Bryan H.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Kiel, Jeffrey W.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Shih, YYI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM shihy@uthscsa.edu; duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Li, Guang/C-9539-2011; Muir,
Eric/H-8830-2013
OI Li, Guang/0000-0002-7648-0464; Shih, Yen-Yu Ian/0000-0001-6529-911X
FU NIH/NEI; Department of Veterans Affairs; San Antonio Life Science
Institute; American Heart Association; Clinical Translational Science
Award (CTSA); San Antonio Area Foundation; NIH/NEI [R01 EY009702,
EY014211, EY018855]; American Heart Association [10POST4290091];
Clinical Translational Science Award (CTSA) [UL1RR025767]
FX YYIS and GL were contributed equally to this study. This work was
supported in part by the NIH/NEI, MERIT Award from the Department of
Veterans Affairs, and San Antonio Life Science Institute to TQD and
American Heart Association, Clinical Translational Science Award (CTSA),
and San Antonio Area Foundation to YYIS.; Grant sponsor: NIH/NEI; Grant
numbers: R01 EY009702, EY014211, EY018855; Grant sponsor: American Heart
Association; Grant number: 10POST4290091; Grant sponsor: Clinical
Translational Science Award (CTSA); Grant number: UL1RR025767; Grant
sponsor: Department of Veterans Affairs; Grant sponsor: San Antonio Life
Science Institute; Grant sponsor: San Antonio Area Foundation.
NR 58
TC 12
Z9 12
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0740-3194
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD OCT
PY 2012
VL 68
IS 4
BP 1273
EP 1278
DI 10.1002/mrm.24112
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 011YY
UT WOS:000309203500031
PM 22183830
ER
PT J
AU Friedlander, AH
Chang, TI
Chantra, PK
Aghazadehsanai, N
Harada, ND
Garrett, NR
AF Friedlander, Arthur H.
Chang, Tina I.
Chantra, Prem K.
Aghazadehsanai, Nona
Harada, Nancy D.
Garrett, Neal R.
TI Do carotid atheromas on panoramic images prognosticate arterial
calcifications on mammograms: acknowledged markers of future adverse
cardiovascular events?
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; SCREENING MAMMOGRAPHY; VASCULAR CALCIFICATIONS;
INCREASED RISK; WOMEN; ASSOCIATION; RADIOGRAPHY; ATHEROSCLEROSIS;
POPULATION; PREVALENCE
AB Objective. The aim of this study was to evaluate the relationship between calcified carotid artery plaque (CCAP) on panoramic images and breast arterial calcifications (BAC) on mammograms, a validated independent risk indicator of fatal myocardial infarctions and strokes.
Materials and Methods. Women >= 55 years old having CCAP diagnosed by their dentists had their mammograms evaluated for BAC by a physician. Other study variables were age, ethnicity, body mass index, and medications for hypertension, diabetes, and dyslipidemia. Descriptive and bivariate statistics and logistic regression were computed.
Results. Researchers identified 40 women (mean age 62.2 +/- 6.2 years old) with CCAP, of whom 9 (prevalence rate 22.5%) also had BAC. The women with BAC tended to be older (65.1 vs 61.3 years old), more frequently hypertensive (100% vs 80.6%), and more frequently black than those without BAC, although these differences were not statistically significant (P > 0.10).
Conclusions. CCAP on panoramic images of women is unrelated to the presence of BAC on mammograms. (Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:526-532)
C1 [Friedlander, Arthur H.; Chang, Tina I.; Chantra, Prem K.; Aghazadehsanai, Nona] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Friedlander, Arthur H.; Chang, Tina I.; Garrett, Neal R.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
[Chantra, Prem K.; Harada, Nancy D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM arthur.friedlander@va.gov
FU National Center for Research Resources, National Institutes of Health
[CO6 Rr-14529-01]; Department of Veterans Affairs; University of
California
FX Elements of this investigation were conducted in a faciligy constructed
with support from Research Facilities Improvement Program grant no. CO6
Rr-14529-01 from the National Center for Research Resources, National
Institutes of Health.; None of the authors reports commercial
associations with products and services described in this publication
that might pose a potential, perceived, or real conflict of interest.
All authors are full-time, salaried employees of either the Department
of Veterans Affairs or the University of California.
NR 36
TC 0
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-4403
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD OCT
PY 2012
VL 114
IS 4
BP 526
EP 532
DI 10.1016/j.oooo.2012.05.008
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 012AT
UT WOS:000309208500028
PM 22986249
ER
PT J
AU Luo, YC
Dallaglio, K
Chen, Y
Robinson, WA
Robinson, SE
McCarter, MD
Wang, JB
Gonzalez, R
Thompson, DC
Norris, DA
Roop, DR
Vasiliou, V
Fujita, M
AF Luo, Yuchun
Dallaglio, Katiuscia
Chen, Ying
Robinson, William A.
Robinson, Steven E.
McCarter, Martin D.
Wang, Jianbin
Gonzalez, Rene
Thompson, David C.
Norris, David A.
Roop, Dennis R.
Vasiliou, Vasilis
Fujita, Mayumi
TI ALDH1A Isozymes are Markers of Human Melanoma Stem Cells and Potential
Therapeutic Targets
SO STEM CELLS
LA English
DT Article
DE Melanoma; Cancer stem cells; Tumor-initiating cells; Aldehyde
dehydrogenase; Microarray analysis; Molecular targeted therapy
ID ALDEHYDE DEHYDROGENASE-ACTIVITY; INITIATING CELLS; PHASE-II; METASTATIC
MELANOMA; FUNCTIONAL MARKER; BREAST-CANCER; LUNG-CANCER; IDENTIFICATION;
CD133; CHEMOTHERAPY
AB Although the concept of cancer stem cells (CSCs) is well-accepted for many tumors, the existence of such cells in human melanoma has been the subject of debate. In this study, we demonstrate the existence of human melanoma cells that fulfill the criteria for CSCs (self-renewal and differentiation) by serially xenotransplanting cells into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. These cells possess high aldehyde dehydrogenase (ALDH) activity with ALDH1A1 and ALDH1A3 being the predominant ALDH isozymes. ALDH-positive melanoma cells are more tumorigenic than ALDH-negative cells in both NOD/SCID mice and NSG mice. Biological analyses of the ALDH-positive melanoma cells reveal the ALDH isozymes to be key molecules regulating the function of these cells. Silencing ALDH1A by siRNA or shRNA leads to cell cycle arrest, apoptosis, decreased cell viability in vitro, and reduced tumorigenesis in vivo. ALDH-positive melanoma cells are more resistant to chemotherapeutic agents and silencing ALDH1A by siRNA sensitizes melanoma cells to drug-induced cell death. Furthermore, we, for the first time, examined the molecular signatures of ALDH-positive CSCs from patient-derived tumor specimens. The signatures of melanoma CSCs include retinoic acid (RA)-driven target genes with RA response elements and genes associated with stem cell function. These findings implicate that ALDH isozymes are not only biomarkers of CSCs but also attractive therapeutic targets for human melanoma. Further investigation of these isozymes and genes will enhance our understanding of the molecular mechanisms governing CSCs and reveal new molecular targets for therapeutic intervention of cancer. STEM Cells2012;30:21002113
C1 [Luo, Yuchun; Dallaglio, Katiuscia; Norris, David A.; Roop, Dennis R.; Fujita, Mayumi] Univ Colorado Denver, Dept Dermatol, Aurora, CO 80045 USA.
[Dallaglio, Katiuscia; Roop, Dennis R.; Fujita, Mayumi] Univ Colorado Denver, Charles C Gates Ctr Regenerat Med & Stem Cell Bio, Aurora, CO 80045 USA.
[Chen, Ying; Vasiliou, Vasilis] Univ Colorado Denver, Dept Pharmaceut Sci, Aurora, CO 80045 USA.
[Robinson, William A.; Robinson, Steven E.; Gonzalez, Rene] Univ Colorado Denver, Div Med Oncol, Dept Med, Aurora, CO 80045 USA.
[McCarter, Martin D.] Univ Colorado Denver, Dept Surg, Aurora, CO 80045 USA.
[Wang, Jianbin] Univ Colorado Denver, Dept Biochem & Mol Genet, Aurora, CO 80045 USA.
[Norris, David A.; Fujita, Mayumi] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Fujita, M (reprint author), Univ Colorado Denver, Dept Dermatol, Mail Stop 8127,12801 E 17th Ave,Rm 4124, Aurora, CO 80045 USA.
EM mayumi.fujita@ucdenver.edu
RI Luo, Yuchun/B-8683-2014; Wang, Jianbin/B-8973-2016
OI Wang, Jianbin/0000-0003-3155-894X
FU NIH [CA125833]; Veterans Affairs Merit Review Award; UCCC; Wendy Will
Case Cancer Fund; Tadamitsu Cancer Research Fund; NEI [EY11490, EY17963]
FX We thank the University of Colorado Denver melanoma tissue bank for
providing human melanoma samples, the University of Colorado Cancer
Center (UCCC) flow core (Alistaire S. Acosta and Karen Helm) for helping
with FACS sorting, the Mind Research Network from New Mexico (Marilee
Morgan and Kent Hutchison) for helping with microarray analysis, and
Garrick Talmage for assisting with experiments. We also thank Miki
Tanioka, M. D., Ph.D. (Department of Dermatology, Kyoto University) and
J Daniel Jensen, M. D. (Sacred Heart Medical Center from Spokane, WA)
for critically reviewing the manuscript. This work was supported by an
NIH Grant CA125833 (to M. F.), Veterans Affairs Merit Review Award (to
M. F.), a grant from the UCCC (to M. F.), Wendy Will Case Cancer Fund
(to M. F.), Tadamitsu Cancer Research Fund (to M. F.), and NEI Grants
EY17963 and EY11490 (to V.V.).
NR 53
TC 87
Z9 88
U1 4
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
J9 STEM CELLS
JI Stem Cells
PD OCT
PY 2012
VL 30
IS 10
BP 2100
EP 2113
DI 10.1002/stem.1193
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
Oncology; Cell Biology; Hematology
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 008AA
UT WOS:000308928300004
PM 22887839
ER
PT J
AU Janoff, EN
Gustafson, C
Frank, DN
AF Janoff, Edward N.
Gustafson, Claire
Frank, Daniel N.
TI The world within: living with our microbial guests and guides
SO TRANSLATIONAL RESEARCH
LA English
DT Editorial Material
ID INFLAMMATORY-BOWEL-DISEASE; INTESTINAL MICROBIOTA; GUT MICROBIOTA;
COMMENSAL BACTERIA; IMMUNE-RESPONSES; DENDRITIC CELLS; INDUCTION; IGA;
ENVIRONMENT; MICROFLORA
C1 [Janoff, Edward N.] Univ Colorado Denver, Sch Med, Div Infect Dis, Dept Med, Aurora, CO 80045 USA.
Denver Vet Affairs Med Ctr, Denver, CO USA.
Univ Colorado Denver, Sch Med, Microbiome Res Consortium, Aurora, CO USA.
RP Janoff, EN (reprint author), Univ Colorado Denver, Sch Med, Div Infect Dis, Dept Med, 12700 E 19th Ave,Box B-168, Aurora, CO 80045 USA.
EM Edward.Janoff@ucdenver.edu
FU NHGRI NIH HHS [R21HG005964]; NIAID NIH HHS [R21 AI083615, R21AI083615];
NICHD NIH HHS [R01 HD059527, R01HD059527]
NR 47
TC 6
Z9 6
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1931-5244
J9 TRANSL RES
JI Transl. Res.
PD OCT
PY 2012
VL 160
IS 4
BP 239
EP 245
DI 10.1016/j.trsl.2012.05.005
PG 7
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
Research & Experimental
SC Medical Laboratory Technology; General & Internal Medicine; Research &
Experimental Medicine
GA 013IM
UT WOS:000309299100001
PM 22732305
ER
PT J
AU Baker, JF
Mehta, NN
Baker, DG
Toedter, G
Shults, J
Von Feldt, JM
Leonard, MB
AF Baker, Joshua F.
Mehta, Nehal N.
Baker, Daniel G.
Toedter, Gary
Shults, Justine
Von Feldt, Joan Marie
Leonard, Mary B.
TI Vitamin D, Metabolic Dyslipidemia, and Metabolic Syndrome in Rheumatoid
Arthritis
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Lipoproteins; Metabolic syndrome; Rheumatoid arthritis; Triglycerides;
Vitamin D
ID BETA-CELL DYSFUNCTION; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; D
DEFICIENCY; 25-HYDROXYVITAMIN D; HYPOVITAMINOSIS-D; RISK; ASSOCIATION;
CHOLESTEROL; PREVALENCE
AB PURPOSE: Vitamin D deficiency is a potential risk factor for cardiometabolic disease. We investigated the associations between vitamin D and dyslipidemia and the metabolic syndrome in patients with rheumatoid arthritis, a group at high risk for cardiovascular disease.
METHODS: Serum 25(OH) vitamin D and lipoprotein levels were measured at baseline in a random sample of 499 participants, ages 18-85 years, enrolled in a randomized trial of golimumab (GOlimumab Before Employing methotrexate as the First-line Option in the treatment of Rheumatoid arthritis of Early onset or GO-BEFORE Trial). Participants had rheumatoid arthritis with active disease, and were naive to methotrexate and biologic therapies. Multivariable linear regression was performed to assess associations between vitamin D levels and lipoprotein fractions. Multivariable logistic regression was performed to determine the odds of hyperlipidemia and the metabolic syndrome in participants with vitamin D deficiency (<20 ng/mL).
RESULTS: In multivariable linear regression, vitamin D levels (per 10 ng/mL) were associated inversely with low-density lipoprotein (beta: -0.029 [-0.049, -0.0091], P = .004) and triglyceride (beta: -0.094 [-0.15, -0.039] P = .001) levels, adjusted for demographic, cardiovascular, and disease-specific variables. Vitamin D and high-density lipoprotein levels were not associated in univariate or multivariate analyses. Vitamin D deficiency was associated independently with an increased odds of hyperlipidemia (odds ratio 1.72; 95% confidence interval, 1.10-2.45; P = .014) and metabolic syndrome (odds ratio 3.45; 95% confidence interval, 1.75-6.80; P < .001) in adjusted models.
CONCLUSIONS: In conclusion, vitamin D deficiency was associated with the metabolic syndrome and dyslipidemia in rheumatoid arthritis, suggesting a potential role in cardiovascular disease risk. Large-scale, prospective studies are needed to determine if vitamin D supplementation improves lipoprotein levels and reduces cardiovascular risk in rheumatoid arthritis. (C) 2012 Elsevier Inc. All rights reserved. The American Journal of Medicine (2012) 125, 1036.e9-1036.e15
C1 [Baker, Joshua F.] Univ Penn, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA.
[Mehta, Nehal N.; Shults, Justine; Leonard, Mary B.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Mehta, Nehal N.] Univ Penn, Dept Med, Div Cardiovasc Med, Philadelphia, PA 19104 USA.
[Baker, Daniel G.] Centocor Res & Dev, Clin Immunol, Malvern, PA USA.
[Toedter, Gary] Centocor Res & Dev, Biomarker, Malvern, PA USA.
[Von Feldt, Joan Marie] Vet Affairs Med Ctr, Div Rheumatol, Philadelphia, PA USA.
[Leonard, Mary B.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA.
RP Baker, JF (reprint author), Hosp Univ Penn, Dept Med, Div Rheumatol, 8 Penn Tower Bldg,1 Convent Ctr Blvd, Philadelphia, PA 19104 USA.
EM bakerjo@uphs.upenn.edu
NR 36
TC 6
Z9 6
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD OCT
PY 2012
VL 125
IS 10
AR 1036.e9
DI 10.1016/j.amjmed.2012.01.025
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 010UR
UT WOS:000309120400036
PM 22800875
ER
PT J
AU White, DL
Tavakoli-Tabasi, S
Kuzniarek, J
Ramsey, DJ
El-Serag, HB
AF White, Donna L.
Tavakoli-Tabasi, Shahriar
Kuzniarek, Jill
Ramsey, David J.
El-Serag, Hashem B.
TI Racial Differences in the Association Between Adiposity Measures and the
Risk of Hepatitis C-related Liver Disease
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE epidemiology; veterans; infectious diseases; anthropometry; insulin
resistance; cirrhosis; obesity; hepatology
ID BIOELECTRICAL-IMPEDANCE ANALYSIS; APPENDICULAR BODY-COMPOSITION;
NONALCOHOLIC FATTY LIVER; AFRICAN-AMERICANS; BIOCHEMICAL MARKERS;
INSULIN-RESISTANCE; VIRUS-INFECTION; PROSPECTIVE MULTICENTER;
INTERETHNIC DIFFERENCES; BIOIMPEDANCE ANALYSIS
AB Background: African Americans have lower reported likelihood of hepatitis C virus-related cirrhosis than whites. It is unknown whether relative differences in the distribution of adipose tissue, lean mass, and other anthropometric measurements may explain these observed interethnic differences in disease risk.
Aim: To evaluate the association between anthropometric measurements and advanced liver disease in a cross-sectional study of African American and white male veterans.
Methods: We used the validated FibroSURE-ActiTest to assess hepatic pathology, and direct segmental multichannel bioelectric impedance analysis for anthropometric measurements. Race-stratified logistic regression was employed to evaluate risk of high fibrosis progression rate (FPR) and advanced inflammation (A2 to A3).
Results: Among 330 eligible males (59% African American), there were 43 white and 57 African American males with high FPR, and 70 African American and 59 white with advanced inflammation. Percentage body fat (%BF) was a stronger predictor of high FPR risk than was a high body mass index in African Americans [odds ratio (OR)(adj) = 2.08; 95% confidence interval (CI), 0.83-5.23 for highest %BF vs. lowest tertile and ORadj = 1.50; 95% CI, 0.60-3.75 for obese vs. normal body mass index, respectively], but not in whites. Highest lean leg mass was associated with a nonsignificant increased risk of both high FPR and advanced inflammation in African Americans (ORhighFPRadj = 1.73; 95% CI, 0.73-4.10; ORAdvancedinflammationAdj = 1.65; 95% CI, 0.76-3.56) versus a decreased risk of both in whites (ORhighFPRadj = 0.62; 95% CI, 0.21-1.79; ORAdvancedinflammationAdj = 0.58; 95% CI, 0.22-1.48).
Conclusions: Interethnic differences in nontraditional anthropometric measurements like %BF suggests their potential role in understanding interethnic differences in hepatitis C virus-related liver disease risk in males.
C1 [White, Donna L.; Kuzniarek, Jill; Ramsey, David J.; El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Clin Epidemiol & Outcomes Program, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA.
[White, Donna L.; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
[White, Donna L.; Kuzniarek, Jill; Ramsey, David J.; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Michael E DeBakey Vet Med Ctr, Houston, TX 77030 USA.
[Tavakoli-Tabasi, Shahriar] Baylor Coll Med, Dept Med, Sect Infect Dis, Michael E DeBakey Vet Med Ctr, Houston, TX 77030 USA.
[Tavakoli-Tabasi, Shahriar] Michael E DeBakey VA Med Ctr, Hepatitis Clin C, Infect Dis Sect, Houston, TX USA.
RP White, DL (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,MS 152, Houston, TX 77030 USA.
EM dwhite1@bcm.edu
FU VA Clinical Research and Development Merit Review Award [H-22934];
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
[K24 DK081736-01, K01 DK078154-03]; Texas Medical Center Digestive
Disease Center [P30 DK56338]; Houston VA HSR&D Center of Excellence
FX Supported in part by a VA Clinical Research and Development Merit Review
Award (H-22934, PI: H.B.E.-S.), the NIH/National Institute of Diabetes
and Digestive and Kidney Diseases (K24 DK081736-01, K01 DK078154-03,
PIs, El-Serag and White, respectively), Texas Medical Center Digestive
Disease Center (P30 DK56338), and the Houston VA HSR&D Center of
Excellence.
NR 49
TC 0
Z9 0
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0192-0790
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD OCT
PY 2012
VL 46
IS 9
BP 779
EP 788
DI 10.1097/MCG.0b013e318266f6eb
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 004TD
UT WOS:000308703100013
PM 22955261
ER
PT J
AU Zhu, AL
Sonnenberg, A
AF Zhu, Amy L.
Sonnenberg, Amnon
TI Is Gastric Cancer Again Rising?
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Letter
ID HELICOBACTER-PYLORI; TRENDS
C1 [Zhu, Amy L.] Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Portland, OR USA.
RP Zhu, AL (reprint author), Portland VA Med Ctr, Portland, OR USA.
NR 6
TC 10
Z9 10
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0192-0790
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD OCT
PY 2012
VL 46
IS 9
BP 804
EP 806
DI 10.1097/MCG.0b013e3182604254
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 004TD
UT WOS:000308703100018
PM 22914346
ER
PT J
AU Collins, EG
Halabi, S
Langston, M
Schnell, T
Tobin, MJ
Laghi, F
AF Collins, Eileen G.
Halabi, Sahar
Langston, Mathew
Schnell, Timothy
Tobin, Martin J.
Laghi, Franco
TI Sexual Dysfunction in Men with COPD: Impact on Quality of Life and
Survival
SO LUNG
LA English
DT Article
DE Endocrine; Erectile dysfunction; Testosterone; Sexuality; Aging; Outcome
ID OBSTRUCTIVE PULMONARY-DISEASE; ERECTILE DYSFUNCTION; DEPRESSIVE
SYMPTOMS; INTERNATIONAL INDEX; CARDIOVASCULAR-DISEASE; TOTAL
TESTOSTERONE; PENILE ERECTION; PREVALENCE; IMPOTENCE; VALIDATION
AB Most patients with chronic obstructive pulmonary disease (COPD) are middle-aged or older, and by definition all have a chronic illness. Aging and chronic illness decrease sexual interest, sexual function, and testosterone levels. To date, researchers have not simultaneously explored prevalence, risk factors, and impact of sexual dysfunctions on quality of life and survival in men with COPD. We tested three hypotheses: First, sexual dysfunctions, including erectile dysfunction, are highly prevalent and impact negatively the quality of life of those with COPD. Second, gonadal state is a predictor of erectile dysfunction. Third, erectile dysfunction, a potential maker of systemic atherosclerosis, is a risk factor for mortality in men with COPD.
In this prospective study, sexuality was assessed in 90 men with moderate-to-severe COPD (40 hypogonadal) by questionnaire. Testosterone levels, comorbidities, dyspnea, depressive symptoms, and survival (4.8 years median follow-up) were recorded.
Seventy-four percent of patients had at least one sexual dysfunction, with erectile dysfunction being the most common (72 %). Most were dissatisfied with their current and expected sexual function. Severity of COPD was equivalent in patients with and without erectile dysfunction. Low testosterone, depressive symptoms, and presence of partner were independently associated with erectile dysfunction. Severity of lung disease and comorbidities, but not erectile dysfunction, were independently associated with mortality (p = 0.006).
Sexual dysfunctions, including erectile dysfunction, were highly prevalent and had a negative impact on quality of life in men with COPD. In addition, gonadal state was an independent predictor of erectile dysfunction. Finally, erectile dysfunction was not associated with all-cause mortality.
C1 [Halabi, Sahar; Langston, Mathew; Schnell, Timothy; Tobin, Martin J.; Laghi, Franco] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA.
[Collins, Eileen G.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA.
[Collins, Eileen G.] Univ Illinois, Coll Nursing, Chicago, IL USA.
[Langston, Mathew; Schnell, Timothy; Tobin, Martin J.; Laghi, Franco] Loyola Univ, Div Pulm & Crit Care Med, Maywood, IL 60153 USA.
RP Laghi, F (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, 111 N 5th Ave & Roosevelt Rd, Hines, IL 60141 USA.
EM flaghi@lumc.edu
FU AMVETS; Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development Rehabilitation Research and
Development Service
FX This work was supported in part by grants from AMVETS and the Department
of Veterans Affairs, Veterans Health Administration, Office of Research
and Development Rehabilitation Research and Development Service.
NR 64
TC 13
Z9 15
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2040
J9 LUNG
JI Lung
PD OCT
PY 2012
VL 190
IS 5
BP 545
EP 556
DI 10.1007/s00408-012-9398-4
PG 12
WC Respiratory System
SC Respiratory System
GA 008PG
UT WOS:000308968400010
PM 22752718
ER
PT J
AU Hansen, L
Press, N
Rosenkranz, SJ
Baggs, JG
Kendall, J
Kerber, A
Williamson, A
Chesnutt, MS
AF Hansen, Lissi
Press, Nancy
Rosenkranz, Susan J.
Baggs, Judith Gedney
Kendall, Judith
Kerber, Amanda
Williamson, Angel
Chesnutt, Mark S.
TI Life-sustaining treatment decisions in the ICU for patients with ESLD: A
prospective investigation
SO RESEARCH IN NURSING & HEALTH
LA English
DT Article
DE intensive care; qualitative research; decision-making; liver diseases;
life support care
ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL; QUALITATIVE DESCRIPTION; FAMILY
SATISFACTION; PALLIATIVE CARE; END; SUPPORT; WITHDRAWAL; COMMUNICATION;
PERSPECTIVES
AB We conducted a prospective study in the ICU of life-sustaining treatment and comfort care decisions over time in patients with end-stage liver disease (ESLD) from the perspectives of patients, family members, and healthcare professionals. Six patients with ESLD, 19 family members, and 122 professionals participated. The overarching theme describing the decision-making process was on the train. Four sub-themes positioned patients and family members as passengers with limited control, unable to fully understand the decision-making process. Findings suggest that including patients and family members in non-immediate life-saving decisions and verifying early on their understanding may help to improve the decision-making process. (c) 2012 Wiley Periodicals, Inc. Res Nurs Health 35:518532, 2012
C1 [Hansen, Lissi; Press, Nancy; Rosenkranz, Susan J.; Baggs, Judith Gedney; Kendall, Judith; Kerber, Amanda; Williamson, Angel; Chesnutt, Mark S.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Chesnutt, Mark S.] Portland VA Med Ctr, Portland, OR USA.
RP Hansen, L (reprint author), Oregon Hlth & Sci Univ, SN 6S,3455 SWUS Vet Hosp Rd, Portland, OR 97239 USA.
FU National Institute of Nursing Research [R21 NR009845]; Portland VA
Medical Center, Portland, Oregon
FX The study was funded by grant R21 NR009845 from the National Institute
of Nursing Research, Lissi Hansen (PI). This study is the result of work
supported by resources from the Portland VA Medical Center, Portland,
Oregon. Neither the NIH nor the Department of Veterans Affairs had a
role in the conduct of the study, in the collection, management,
analysis, or interpretation of data, or in the preparation of the
manuscript. The views expressed in this article are those of the authors
and do not necessarily represent the views of the Department of Veterans
Affairs or the U.S. Government. The authors thank the patients, family
members, and healthcare professionals for participating in the study and
sharing their perspectives and the different specialties for their
support of the study.
NR 58
TC 3
Z9 3
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-6891
J9 RES NURS HEALTH
JI Res. Nurs. Health
PD OCT
PY 2012
VL 35
IS 5
BP 518
EP 532
DI 10.1002/nur.21488
PG 15
WC Nursing
SC Nursing
GA 004YO
UT WOS:000308717600008
PM 22581585
ER
PT J
AU Zhang, XY
Chen, DC
Xiu, MH
Hui, L
Liu, HB
Luo, XG
Zuo, LJ
Zhang, HP
Kosten, TA
Kosten, TR
AF Zhang, Xiang Yang
Chen, Da Chun
Xiu, Mei Hong
Hui, Li
Liu, Haibo
Luo, Xingguang
Zuo, Lingjun
Zhang, Huiping
Kosten, Therese A.
Kosten, Thomas R.
TI Association of functional dopamine-beta-hydroxylase (DBH) 19 bp
insertion/deletion polymorphism with smoking severity in male
schizophrenic smokers
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Dopamine beta-hydroxylase; Smoking; Nicotine; Genotype;
Association
ID YOUNG-WOMEN SMOKE; TOBACCO SMOKING; GENE DBH; PSYCHOLOGICAL
CHARACTERISTICS; NICOTINE DEPENDENCE; METABOLIC ENZYMES; CONSUMPTION;
BEHAVIOR; LINKAGE; VARIANT
AB Recent evidence suggests that a dopamine beta-hydroxylase (DBH) polymorphism may play a role in determining an individual's predisposition to developing nicotine dependence. The mechanism for such an association may reflect nicotine's mediation of drug reward in the brain through actions on dopamine, a key mediator of drug reward. Because schizophrenia patients have usually high rates of nicotine use, they are a model group to study such an association. In this study, we hypothesized that the functional polymorphism of DBH (D beta H5'-Ins/Del) was associated with smoking in patients with schizophrenia. This polymorphism was genotyped in 636 chronic male schizophrenia (smoker/nonsmoker=490/146) and 396 male controls (smoker/nonsmoker=231/165) using a case-control design. The cigarettes smoked per day (CPD) and smoking behaviors were evaluated by clinician-administered questionnaires and the Fagerstrom Test for Nicotine Dependence (FTND). The results showed no significant differences in DBH 5'-Ins/Del genotype and allele distributions between the patients and healthy controls or between smokers and nonsmokers in either patients or healthy controls alone. However, schizophrenic smokers with the Del allele smoked fewer cigarettes each day and had lower FTND score than those with Ins/Ins genotype. These results suggest that the DBH 5'-Ins/Del polymorphism may influence smoking severity among schizophrenic smokers. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zhang, Xiang Yang] Chinese Acad Sci, Inst Psychol, Beijing 100101, Peoples R China.
[Zhang, Xiang Yang; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Zhang, Xiang Yang; Chen, Da Chun; Xiu, Mei Hong; Hui, Li; Liu, Haibo; Kosten, Thomas R.] Peking Univ, Ctr Biol Psychiat, Beijing HuiLongGuan Hosp, Beijing 100871, Peoples R China.
[Luo, Xingguang; Zuo, Lingjun; Zhang, Huiping] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu; kosten@bcm.edu
FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of
Veterans Affairs [VISN 16]; Mental Illness Research, Education and
Clinical Center (MIRECC); United States National Institute of Health
[P50-DA18827, K05-DA0454, U01-MH79639]
FX Funding for this study was provided by grants from the Stanley Medical
Research Institute (03T-459 and 05T-726), and the Department of Veterans
Affairs, VISN 16, Mental Illness Research, Education and Clinical Center
(MIRECC), United States National Institute of Health K05-DA0454,
P50-DA18827 and U01-MH79639. These sources had no further role in study
design; in the collection, analysis and interpretation of data; in the
writing of the report; and in the decision to submit the paper for
publication.
NR 47
TC 5
Z9 6
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD OCT
PY 2012
VL 141
IS 1
BP 48
EP 53
DI 10.1016/j.schres.2012.07.011
PG 6
WC Psychiatry
SC Psychiatry
GA 004VK
UT WOS:000308709100009
PM 22871345
ER
PT J
AU Tarbox, SI
Brown, LH
Haas, GL
AF Tarbox, Sarah I.
Brown, Leslie H.
Haas, Gretchen L.
TI Diagnostic specificity of poor premorbid adjustment: Comparison of
schizophrenia, schizoaffective disorder, and mood disorder with
psychotic features
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Development; First-episode; Prediction; Psychosis;
Schizophrenia-spectrum; Social functioning
ID 1ST-EPISODE SCHIZOPHRENIA; VALIDITY; SCALE
AB Individuals with schizophrenia have significant deficits in premorbid social and academic adjustment compared to individuals with non-psychotic diagnoses. However, it is unclear how severity and developmental trajectory of premorbid maladjustment compare across psychotic disorders. This study examined the association between premorbid functioning (in childhood, early adolescence, and late adolescence) and psychotic disorder diagnosis in a first-episode sample of 105 individuals: schizophrenia (n = 68), schizoaffective disorder (n = 22), and mood disorder with psychotic features (n = 15). Social and academic maladjustment was assessed using the Cannon-Spoor Premorbid Adjustment Scale. Worse social functioning in late adolescence was associated with higher odds of schizophrenia compared to odds of either schizoaffective disorder or mood disorder with psychotic features, independently of child and early adolescent maladjustment. Greater social dysfunction in childhood was associated with higher odds of schizoaffective disorder compared to odds of schizophrenia. Premorbid decline in academic adjustment was observed for all groups, but did not predict diagnosis at any stage of development. Results suggest that social functioning is disrupted in the premorbid phase of both schizophrenia and schizoaffective disorder, but remains fairly stable in mood disorders with psychotic features. Disparities in the onset and time course of social dysfunction suggest important developmental differences between schizophrenia and schizoaffective disorder. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Tarbox, Sarah I.; Brown, Leslie H.; Haas, Gretchen L.] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA.
[Haas, Gretchen L.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC VISN4, Pittsburgh, PA USA.
RP Tarbox, SI (reprint author), Connecticut Mental Hlth Ctr, PRIME Res Clin, 34 Pk St,B-38, New Haven, CT 06519 USA.
EM sarah.tarbox@yale.edu
FU NIH/NCRR/GCRC [M01 RR00056]; [MH45156]; [MH84053]; [MH48492]; [c UL1
RR024153]
FX This work was supported by MH45156 and MH84053 (PI: D. Lewis), MH48492
(PI: G. L. Haas), and the c UL1 RR024153 and NIH/NCRR/GCRC Grant M01
RR00056. We thank Drs. Raymond Cho, MD, Gretchen Haas PhD, and Konasale
Prasad, MD, and the clinical core staff of the Center for the
Neuroscience of Mental Disorders (MH45156, MH084053, David Lewis, MD,
Director) for their assistance in diagnostic, psychosocial, and
psychopathological assessments. We thank James Luther, MA, and Barbara
Hanusa, PhD, for their statistical consultation and assistance with
parameter estimation for the logistic regression models. The contents do
not represent the views of the Department of Veterans Affairs or the
United States Government.
NR 21
TC 10
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD OCT
PY 2012
VL 141
IS 1
BP 91
EP 97
DI 10.1016/j.schres.2012.07.008
PG 7
WC Psychiatry
SC Psychiatry
GA 004VK
UT WOS:000308709100016
PM 22858353
ER
PT J
AU Yagi, M
Sobel, M
AF Yagi, Mayumi
Sobel, Michael
TI Response to: Heparin and platelet activation, Jagroop-Dearing &
Mikhailidis
SO THROMBOSIS RESEARCH
LA English
DT Letter
C1 [Yagi, Mayumi; Sobel, Michael] VA Puget Sound HCS, Seattle, WA 98108 USA.
RP Yagi, M (reprint author), VA Puget Sound HCS, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM myagi@uw.edu
NR 5
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
J9 THROMB RES
JI Thromb. Res.
PD OCT
PY 2012
VL 130
IS 4
BP 686
EP 686
DI 10.1016/j.thromres.2012.07.015
PG 1
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 007WQ
UT WOS:000308919500031
ER
PT J
AU Tafti, BA
Shaba, W
Li, YX
Yevdayev, E
Berenji, GR
AF Tafti, Bashir Akhavan
Shaba, Wisam
Li, Yuxin
Yevdayev, Ella
Berenji, Gholam Reza
TI Staging and Follow-up of Lacrimal Gland Carcinomas by F-18-FDG PET/CT
Imaging
SO CLINICAL NUCLEAR MEDICINE
LA English
DT Editorial Material
DE PET/CT; lacrimal gland; transitional cell carcinoma; tumor staging
ID POSITRON-EMISSION-TOMOGRAPHY; NECK-CANCER; HEAD; MANAGEMENT; PATIENT;
TUMORS
C1 [Tafti, Bashir Akhavan; Shaba, Wisam; Li, Yuxin; Yevdayev, Ella; Berenji, Gholam Reza] Vet Adm Greater Los Angeles Hlth Care Syst, Dept Nucl Med, Los Angeles, CA 90073 USA.
RP Berenji, GR (reprint author), Vet Adm Greater Los Angeles Hlth Care Syst, Dept Nucl Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM gholam.berenji@va.gov
NR 13
TC 3
Z9 3
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0363-9762
J9 CLIN NUCL MED
JI Clin. Nucl. Med.
PD OCT
PY 2012
VL 37
IS 10
BP E249
EP E252
DI 10.1097/RLU.0b013e31825ae11b
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 007BW
UT WOS:000308864800003
PM 22899198
ER
PT J
AU Overs, S
Hughes, CM
Haselkorn, JK
Turner, AP
AF Overs, Shannon
Hughes, Christina M.
Haselkorn, Jodie K.
Turner, Aaron P.
TI Modifiable Comorbidities and Disability in Multiple Sclerosis
SO CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
LA English
DT Review
DE Multiple sclerosis; Comorbid; Chronic illness; Hypertension; Diabetes;
Obesity; Smoking; Clinical trials; Clinical care
ID LIFE-STYLE FACTORS; CIGARETTE-SMOKING; COGNITIVE IMPAIRMENT;
ORAL-CONTRACEPTIVES; DISEASE PROGRESSION; ALCOHOL-CONSUMPTION;
INSULIN-RESISTANCE; CHRONIC ILLNESS; PRIMARY-CARE; RISK-FACTOR
AB Multiple sclerosis is a common neurological disease that results in disability in early adulthood that may progress through a relatively normal lifespan. Other comorbid health conditions can increase the likelihood of progression of MS and independently contribute to limitations in activities and social participation. We examine common modifiable health conditions and behaviors, including hypertension, obesity, diabetes mellitus, alcohol, and smoking to determine their impacts on MS and disability. Appropriate identification and treatment can improve health status, diminish disability, and improve quality of life.
C1 [Hughes, Christina M.; Haselkorn, Jodie K.; Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S RCS 117, Seattle, WA 98108 USA.
[Overs, Shannon] Portland VA Med Ctr, Dept Neurol, Portland, OR 97239 USA.
[Hughes, Christina M.; Haselkorn, Jodie K.; Turner, Aaron P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98105 USA.
[Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98105 USA.
RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S RCS 117, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM Aaron.Turner@va.gov
OI Turner, Aaron/0000-0001-6897-8003
NR 87
TC 8
Z9 9
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1528-4042
EI 1534-6293
J9 CURR NEUROL NEUROSCI
JI Curr. Neurol. Neurosci. Rep.
PD OCT
PY 2012
VL 12
IS 5
BP 610
EP 617
DI 10.1007/s11910-012-0293-4
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 001DG
UT WOS:000308439700014
PM 22791240
ER
PT J
AU Greyson, CR
AF Greyson, Clifford R.
TI Right heart failure in the intensive care unit
SO CURRENT OPINION IN CRITICAL CARE
LA English
DT Review
DE cor pulmonale; pulmonary hypertension; right ventricle; ventricular
assist device
ID RIGHT-VENTRICULAR FAILURE; PULMONARY ARTERIAL-HYPERTENSION;
RESPIRATORY-DISTRESS-SYNDROME; JUGULAR VENOUS DISTENSION;
PRESSURE-OVERLOAD; ASSIST DEVICE; ATRIAL SEPTOSTOMY; SYSTOLIC FUNCTION;
DYSFUNCTION; FLOW
AB Purpose of review
This review summarizes the approach to and recent developments in the evaluation and treatment of acute right heart failure in the ICU. Right heart failure, defined as failure of the right ventricle to provide sufficient blood flow through the pulmonary circulation at normal central venous pressure, is a common problem caused by a combination of increased right-ventricular afterload and right-ventricular contractile dysfunction.
Recent findings
Management of acute right heart failure continues to be challenging because of insufficient understanding of its pathophysiology, a lack of guidelines, and few available tools. Recent research has contributed to an improved understanding of its mechanisms, helping to guide therapy and suggest future options. Right-ventricular assist devices are emerging as a promising approach to treatment when optimization of hemodynamics and conventional medical therapy fail.
Summary
Right heart failure causes venous congestion and systemic hypoperfusion. Once right heart failure is identified, the primary goal is to alleviate any reversible cause of excessive load or right-ventricular contractile failure. When the underlying abnormalities cannot be alleviated, trials of diuretic, vasodilator, or inotropic therapy may be required. Invasive monitoring helps guide therapy. Medically refractory right heart failure may potentially be treated with right-ventricular assist devices.
C1 [Greyson, Clifford R.] Dept Vet Affairs Med Ctr, Denver, CO USA.
[Greyson, Clifford R.] Univ Colorado, Sch Med, Denver, CO USA.
RP Greyson, CR (reprint author), Denver VAMC, 1055 Clermont St, Denver, CO 80220 USA.
EM Clifford.Greyson@UCDenver.edu
FU Department of Veterans Affairs Medical Research Service
FX Supported by the Department of Veterans Affairs Medical Research
Service.
NR 46
TC 6
Z9 7
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1070-5295
J9 CURR OPIN CRIT CARE
JI Curr. Opin. Crit. Care
PD OCT
PY 2012
VL 18
IS 5
BP 424
EP 431
DI 10.1097/MCC.0b013e3283577070
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 004HF
UT WOS:000308671400003
PM 22889868
ER
PT J
AU Bartzokis, G
Lu, P
Couvrette, A
Raven, E
DeTore, N
Altshuler, L
Mintz, J
Ventura, J
Casaus, L
Luo, J
Subotnik, K
Nuechterlein, K
AF Bartzokis, George
Lu, Po
Couvrette, Alexander
Raven, Erika
DeTore, Nicole
Altshuler, Lori
Mintz, Jim
Ventura, Joseph
Casaus, Laurie
Luo, John
Subotnik, Kenneth
Nuechterlein, Keith
TI The mechanism of action of antipsychotics and intracortical myelination
in schizophrenia
SO EARLY INTERVENTION IN PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Bartzokis, George; Lu, Po; Couvrette, Alexander; Raven, Erika; DeTore, Nicole; Altshuler, Lori; Ventura, Joseph; Casaus, Laurie; Luo, John; Subotnik, Kenneth; Nuechterlein, Keith] Univ Calif Los Angeles, Los Angeles, CA USA.
[Bartzokis, George] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
[Mintz, Jim] Univ Texas Hlth Sci Ctr, San Antonio, TX USA.
RI Bartzokis, George/K-2409-2013; Mintz, Jim/N-7385-2014
OI Mintz, Jim/0000-0002-8299-5851
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-7885
J9 EARLY INTERV PSYCHIA
JI Early Interv. Psychiatry
PD OCT
PY 2012
VL 6
SU 1
SI SI
BP 8
EP 8
PG 1
WC Psychiatry
SC Psychiatry
GA 003AI
UT WOS:000308580100030
ER
PT J
AU Mathalon, DH
AF Mathalon, Daniel H.
CA NAPLS Consortium
TI Neurophysiological abnormalities during processing of stimulus deviance
in youth at clinical high risk for psychosis: an interim analysis of the
NAPLS-2 data
SO EARLY INTERVENTION IN PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-7885
J9 EARLY INTERV PSYCHIA
JI Early Interv. Psychiatry
PD OCT
PY 2012
VL 6
SU 1
SI SI
BP 9
EP 9
PG 1
WC Psychiatry
SC Psychiatry
GA 003AI
UT WOS:000308580100036
ER
PT J
AU Loewy, RL
Pearson, R
Schlosser, D
Stuart, B
Mathalon, D
Vinogradov, S
AF Loewy, Rachel L.
Pearson, Rahel
Schlosser, Danielle
Stuart, Barbara
Mathalon, Daniel
Vinogradov, Sophia
TI Childhood trauma, cortisol secretion and risk for psychosis
SO EARLY INTERVENTION IN PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Loewy, Rachel L.; Pearson, Rahel; Schlosser, Danielle; Stuart, Barbara; Mathalon, Daniel; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Mathalon, Daniel; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 3
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-7885
J9 EARLY INTERV PSYCHIA
JI Early Interv. Psychiatry
PD OCT
PY 2012
VL 6
SU 1
SI SI
BP 12
EP 12
PG 1
WC Psychiatry
SC Psychiatry
GA 003AI
UT WOS:000308580100048
ER
PT J
AU Fulford, D
Niendam, T
Floyd, E
Miskovich, T
Carter, C
Mathalon, D
Vinogradov, S
Loewy, R
AF Fulford, Daniel
Niendam, Tara
Floyd, Erin
Miskovich, Tara
Carter, Cameron
Mathalon, Daniel
Vinogradov, Sophia
Loewy, Rachel
TI Symptom dimensions in early psychosis: examining the unique
contributions of depression and anxiety on functional outcomes
SO EARLY INTERVENTION IN PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Fulford, Daniel; Mathalon, Daniel; Vinogradov, Sophia; Loewy, Rachel] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Niendam, Tara; Floyd, Erin; Miskovich, Tara; Carter, Cameron] Univ Calif Davis, Davis, CA 95616 USA.
[Mathalon, Daniel; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-7885
J9 EARLY INTERV PSYCHIA
JI Early Interv. Psychiatry
PD OCT
PY 2012
VL 6
SU 1
SI SI
BP 33
EP 33
PG 1
WC Psychiatry
SC Psychiatry
GA 003AI
UT WOS:000308580100121
ER
PT J
AU Yohannes, S
Fulford, D
Hardy, K
Mathalon, D
Vinogradov, S
Loewy, R
AF Yohannes, Seghel
Fulford, Daniel
Hardy, Kate
Mathalon, Daniel
Vinogradov, Sophia
Loewy, Rachel
TI Exploring the relationship between ethnicity and interviewer-rated
symptom severity in early psychosis
SO EARLY INTERVENTION IN PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Yohannes, Seghel; Fulford, Daniel; Hardy, Kate; Mathalon, Daniel; Vinogradov, Sophia; Loewy, Rachel] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Fulford, Daniel; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-7885
J9 EARLY INTERV PSYCHIA
JI Early Interv. Psychiatry
PD OCT
PY 2012
VL 6
SU 1
SI SI
BP 81
EP 81
PG 1
WC Psychiatry
SC Psychiatry
GA 003AI
UT WOS:000308580100300
ER
PT J
AU Amano, JE
Subotnik, KL
Ventura, J
Gretchen-Doorly, D
Casaus, LR
Luo, JS
Marder, SR
Hellemann, GS
Dunn, W
Nuechterlein, KH
AF Amano, Joshua E.
Subotnik, Kenneth L.
Ventura, Joseph
Gretchen-Doorly, Denise
Casaus, Laurie R.
Luo, John S.
Marder, Stephen R.
Hellemann, Gerhard S.
Dunn, Walter
Nuechterlein, Keith H.
TI Oral and long-acting injectable risperidone: Relationships among
medication plasma levels, adherence, and clinical outcome in
schizophrenia patients shortly after the initial psychotic episode
SO EARLY INTERVENTION IN PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Subotnik, Kenneth L.; Ventura, Joseph; Gretchen-Doorly, Denise; Casaus, Laurie R.; Luo, John S.; Marder, Stephen R.; Hellemann, Gerhard S.; Dunn, Walter; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Amano, Joshua E.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Los Angeles UCLA, Los Angeles, CA 90024 USA.
[Marder, Stephen R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-7885
J9 EARLY INTERV PSYCHIA
JI Early Interv. Psychiatry
PD OCT
PY 2012
VL 6
SU 1
SI SI
BP 101
EP 101
PG 1
WC Psychiatry
SC Psychiatry
GA 003AI
UT WOS:000308580100380
ER
PT J
AU Stuart, BK
Fulford, D
Vertinski, M
McPherson, M
Vinogradov, S
Loewy, RL
AF Stuart, Barbara K.
Fulford, Daniel
Vertinski, Mary
McPherson, Meagan
Vinogradov, Sophia
Loewy, Rachel L.
TI The discrepancy between the experience and expression of emotion as a
risk marker for conversion to psychotic disorder
SO EARLY INTERVENTION IN PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Stuart, Barbara K.; Fulford, Daniel; Vinogradov, Sophia; Loewy, Rachel L.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Vertinski, Mary] Univ Nevada, Las Vegas, NV 89154 USA.
[Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-7885
J9 EARLY INTERV PSYCHIA
JI Early Interv. Psychiatry
PD OCT
PY 2012
VL 6
SU 1
SI SI
BP 122
EP 122
PG 1
WC Psychiatry
SC Psychiatry
GA 003AI
UT WOS:000308580100464
ER
PT J
AU Kranzler, HR
McKay, JR
AF Kranzler, Henry R.
McKay, James R.
TI Personalized Treatment of Alcohol Dependence
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Article
DE Substance use; Alcohol dependence; Pharmacogenetics; OPRM1; Asn40Asp;
A118G; Naltrexone; Nalmefene; Genetic moderation; 5-HTTLPR; Ondansetron;
Sertraline; Adaptive trial designs; Adaptive protocol; Stepped care;
Treatment algorithm
ID MU-OPIOID RECEPTOR; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED
MULTICENTER; HEAVY DRINKERS; STEPPED-CARE; NALTREXONE TREATMENT;
CONTINUING CARE; DOUBLE-BLIND; GENE OPRM1; FUNCTIONAL POLYMORPHISM
AB Pharmacogenetic and adaptive treatment approaches can be used to personalize care for alcohol-dependent patients. Preliminary evidence shows that variation in the gene encoding the mu-opioid receptor moderates the response to naltrexone when used to treat alcohol dependence. Studies have also shown moderating effects of variation in the gene encoding the serotonin transporter on response to serotonergic treatment of alcohol dependence. Adaptive algorithms that modify alcohol treatment based on patients' progress have also shown promise. Initial response to outpatient treatment appears to be a particularly important in the selection of optimal continuing care interventions. In addition, stepped-care algorithms can reduce the cost and burden of treatment while maintaining good outcomes. Finally, matching treatment to specific problems present at intake or that emerge during treatment can also improve outcomes. Although all of these effects require replication and further refinement, the future of personalized care for alcohol dependence appears bright.
C1 [Kranzler, Henry R.; McKay, James R.] Univ Penn, Perelman Sch Med, Dept Psychiat, Ctr Studies Addict, Philadelphia, PA 19104 USA.
[Kranzler, Henry R.; McKay, James R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Kranzler, HR (reprint author), Univ Penn, Perelman Sch Med, Dept Psychiat, Ctr Studies Addict, 3900 Chestnut St, Philadelphia, PA 19104 USA.
EM kranzler@mail.med.upenn.edu; jimrache@mail.med.upenn.edu
FU National Institutes of Health [K24 AA13736, K24 DA029062, P01 AA016821];
Alkermes; Gilead; GlaxoSmithKline; Lilly; Lundbeck; Pfizer; Roche;
Sanofi-Aventis; Solvay; Merck; Janssen; Schering Plough; Abbott; Johnson
Johnson; Human Service Center
FX Related work by the authors is supported by grants K24 AA13736 (to HRK)
and K24 DA029062 and P01 AA016821 (to JRM) from the National Institutes
of Health.; H. R. Kranzler: consulting fees from Alkermes, Gilead,
GlaxoSmithKline, Lilly, Lundbeck, Pfizer, Roche, Sanofi-Aventis, and
Solvay; research support from Merck; and honoraria from the American
College of Neuropsychopharmacology's Alcohol Clinical Trials Initiative
(ACTIVE), which was supported by Lilly, Janssen, Schering Plough,
Lundbeck, Alkermes, GlaxoSmithKline, Abbott, and Johnson & Johnson; J.
R. McKay: consulting fees from Human Service Center.
NR 65
TC 24
Z9 25
U1 3
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD OCT
PY 2012
VL 14
IS 5
BP 486
EP 493
DI 10.1007/s11920-012-0296-5
PG 8
WC Psychiatry
SC Psychiatry
GA 999XK
UT WOS:000308348800007
PM 22810115
ER
PT J
AU Kaisey, M
Mittman, B
Pearson, M
Connor, KI
Chodosh, J
Vassar, SD
Nguyen, FT
Vickrey, BG
AF Kaisey, Marwa
Mittman, Brian
Pearson, Marjorie
Connor, Karen I.
Chodosh, Joshua
Vassar, Stefanie D.
Nguyen, France T.
Vickrey, Barbara G.
TI Predictors of acceptance of offered care management intervention
services in a quality improvement trial for dementia
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE dementia; care management; intervention participation
ID RANDOMIZED CONTROLLED-TRIAL; FAMILY CAREGIVERS; COLLABORATIVE CARE;
ALZHEIMER-DISEASE; PEOPLE; PARTICIPATION; DEPRESSION; OUTCOMES; RECEIPT;
SUPPORT
AB Objective Care management approaches have been proven to improve outcomes for patients with dementia and their family caregivers (dyads). However, acceptance of services in these programs is incomplete, impacting effectiveness. Acceptance may be related to dyad as well as healthcare system characteristics, but knowledge about factors associated with program acceptance is lacking. This study investigates patient, caregiver, and healthcare system characteristics associated with acceptance of offered care management services. Methods This study analyzed data from the intervention arm of a cluster randomized controlled trial of a comprehensive dementia care management intervention. There were 408 patientcaregiver dyads enrolled in the study, of which 238 dyads were randomized to the intervention. Caregiver, patient, and health system factors associated with participation in offered care management services were assessed through bivariate and multivariate regression analyses. Results Out of the 238 dyads, 9 were ineligible for this analysis, leaving data of 229 dyads in this sample. Of these, 185 dyads accepted offered care management services, and 44 dyads did not. Multivariate analyses showed that higher likelihood of acceptance of care management services was uniquely associated with cohabitation of caregiver and patient (p?0.001), lesser severity of dementia (p?=?0.03), and higher patient comorbidity (p?=?0.03); it also varied across healthcare organization sites. Conclusions Understanding factors that influence care management participation could result in increased adoption of successful programs to improve quality of care. Using these factors to revise both program design as well as program promotion may also benefit external validity of future quality improvement research trials. Copyright (c) 2011 John Wiley & Sons, Ltd.
C1 [Pearson, Marjorie; Vickrey, Barbara G.] RAND Corp, Santa Monica, CA USA.
[Kaisey, Marwa] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Mittman, Brian] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Serv HSR&D Sepulveda Ctr Exce, Sepulveda, CA USA.
[Connor, Karen I.; Vassar, Stefanie D.; Nguyen, France T.; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Connor, Karen I.; Vassar, Stefanie D.; Vickrey, Barbara G.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA.
[Chodosh, Joshua] VA Greater Los Angeles Healthcare Syst, GRECC, Sepulveda, CA USA.
[Chodosh, Joshua] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA.
RP Vickrey, BG (reprint author), RAND Corp, Santa Monica, CA USA.
EM bvickrey@ucla.edu
OI Mittman, Brian/0000-0003-3589-9178; Chodosh, Joshua/0000-0001-7784-4306
FU California Department of Public Health [06-55314]; Alzheimer's Disease
Research Center of California; SCAN Foundation
FX This analysis was supported by the California Department of Public
Health (contract 06-55314) for the Alzheimer's Disease Research Center
of California.; Drs. Mittman, Connor, Pearson, and Nguyen-Grozavu, and
Ms. Kaisey and Vassar have no conflicts of interest to report. Dr.
Chodosh received a grant from the SCAN Foundation. Dr. Vickrey serves as
a consultant for EMD Serono Canada, Inc.
NR 26
TC 0
Z9 0
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-6230
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD OCT
PY 2012
VL 27
IS 10
BP 1078
EP 1085
DI 10.1002/gps.2830
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 999JH
UT WOS:000308305500011
PM 22190354
ER
PT J
AU Luo, YC
Ellis, LZ
Dallaglio, K
Takeda, M
Robinson, WA
Robinson, SE
Liu, WM
Lewis, KD
McCarter, MD
Gonzalez, R
Norris, DA
Roop, DR
Spritz, RA
Ahn, NG
Fujita, M
AF Luo, Yuchun
Ellis, Lixia Z.
Dallaglio, Katiuscia
Takeda, Moe
Robinson, William A.
Robinson, Steven E.
Liu, Weimin
Lewis, Karl D.
McCarter, Martin D.
Gonzalez, Rene
Norris, David A.
Roop, Dennis R.
Spritz, Richard A.
Ahn, Natalie G.
Fujita, Mayumi
TI Side Population Cells from Human Melanoma Tumors Reveal Diverse
Mechanisms for Chemoresistance
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID OVARIAN-CANCER CELLS; STEM-LIKE CELLS; DRUG-RESISTANCE; ABC
TRANSPORTERS; MULTIDRUG-RESISTANCE; METASTATIC MELANOMA;
MALIGNANT-MELANOMA; MDR1 EXPRESSION; IN-VIVO; MODULATION
AB Side population (SP) cells are identified as cells capable of excluding the fluorescent Hoechst dye and anticancer drugs, and it represents hematopoietic stem cells and chemoresistant cells from several solid tumors. In this study, we confirmed the presence of SP cells in tumors from melanoma patients. Melanoma SP cells overexpressed ATP-binding-cassette (ABC) transporters, ABCB1 and ABCB5. We generated a direct in vivo xenograft model, and demonstrated that SP cells were resistant to paclitaxel, a substrate of ABCB1, both in vitro and in vivo. However, melanoma SP cells were also resistant to temozolomide, which is not a substrate for ABC transporters, through IL-8 upregulation. In addition, gene profiling studies identified three signaling pathways (NF-kappa B, alpha 6-beta 4-integrin, and IL-1) as differentially upregulated in melanoma SP cells, and there was a significant increase of PCDHB11 and decrease of FUK and TBX2 in these cells. Therefore, we provide evidence that SP is an enriched source of chemoresistant cells in human melanomas, and suggest that the selected genes and signaling pathways of SP cells may be a potential target for effective melanoma therapies. To our knowledge, this is a previously unreported study to isolate SP cells from melanoma patients and to investigate the gene expression profiling of these cells.
C1 [Luo, Yuchun; Ellis, Lixia Z.; Dallaglio, Katiuscia; Takeda, Moe; Liu, Weimin; Norris, David A.; Roop, Dennis R.; Fujita, Mayumi] Univ Colorado Denver, Dept Dermatol, Aurora, CO USA.
[Dallaglio, Katiuscia; Roop, Dennis R.; Fujita, Mayumi] Univ Colorado Denver, Charles C Gates Regenerat Med & Stem Cell Biol, Aurora, CO USA.
[Robinson, William A.; Robinson, Steven E.; Lewis, Karl D.; Gonzalez, Rene] Univ Colorado Denver, Div Med Oncol, Dept Med, Aurora, CO USA.
[McCarter, Martin D.] Univ Colorado Denver, Dept Surg, Aurora, CO USA.
[Norris, David A.; Fujita, Mayumi] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Spritz, Richard A.] Univ Colorado Denver, Human Med Genet Program, Aurora, CO USA.
[Ahn, Natalie G.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA.
RP Fujita, M (reprint author), Univ Colorado, Dept Dermatol, Mail Stop 8127,12801 E 17th Ave,Room 4124, Aurora, CO 80045 USA.
EM mayumi.fujita@ucdenver.edu
RI Luo, Yuchun/B-8683-2014
FU US National Institutes of Health [P30CA046934, R03CA125833,
P30AR057212]; Wendy Will Case Cancer Fund; Tadamitsu Cancer Research
Fund
FX We thank the University of Colorado Denver (UCD) melanoma tissue bank
for providing human melanoma samples, the Flow Core of the University of
Colorado Cancer Center (UCCC) and the Skin Disease Research Center
(SDRC) (Alistaire S. Acosta and Karen Helm) for helping with FACS
sorting, the Molecular Genetics Core from the SDRC and microarray core
from UCD for helping with copy number analysis, and the Mind Research
Network from New Mexico (Marilee Morgan and Kent Hutchison) for helping
with microarray analysis. We thank Garrick Talmage, Tracey Ferrara, and
Katherine Gowan for assisting experiments. This work was supported by
the US National Institutes of Health grants P30CA046934 (to NGA and MF
and the Flow Core of the UCCC), R03CA125833 (to MF), and P30AR057212
(Flow Core and the Molecular Genetics Core of the SDRC), Wendy Will Case
Cancer Fund (to MF), and the Tadamitsu Cancer Research Fund (to MF).
NR 42
TC 31
Z9 37
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD OCT
PY 2012
VL 132
IS 10
BP 2440
EP 2450
DI 10.1038/jid.2012.161
PG 11
WC Dermatology
SC Dermatology
GA 007SY
UT WOS:000308909700019
PM 22622430
ER
PT J
AU Basu, P
Shah, N
Farhat, S
Lynn, A
Win, S
Siriki, R
Rahman, M
Mittimani, K
AF Basu, Patrick
Shah, N.
Farhat, S.
Lynn, A.
Win, Sandar
Siriki, R.
Rahman, Md
Mittimani, K.
TI AnoRectal Dysfunction (ARD) in Functional Bowel Disorders (FBD): A
Systematic Bio Mechanical Evaluation: Clinical Pilot Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Basu, Patrick] Columbia Sch Phys & Surg, New York, NY USA.
[Farhat, S.; Lynn, A.; Win, Sandar; Siriki, R.; Rahman, Md; Mittimani, K.] North Shore Forest Hills Hosp, Hofstra Med Sch, New York, NY USA.
[Shah, N.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 1728
BP S701
EP S701
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839703015
ER
PT J
AU Basu, P
Shah, N
Farhat, S
Mittimani, K
Gheewala, R
Polepalle, A
Lynn, A
Win, S
Rahman, M
Siriki, R
AF Basu, Patrick
Shah, N.
Farhat, S.
Mittimani, K.
Gheewala, Rachana
Polepalle, A.
Lynn, A.
Win, Sandar
Rahman, Md
Siriki, R.
TI Serum Anti-Sacromyces Cervecedes Antibody IgA (ASCA IgA) is a Novel
Surrogate Marker for Small Intestinal Bacterial Overgrowth (SIBO): An
Open Label Control Clinical Trial
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Basu, Patrick; Gheewala, Rachana; Polepalle, A.] Columbia Sch Phys & Surg, New York, NY USA.
[Farhat, S.; Mittimani, K.; Lynn, A.; Win, Sandar; Rahman, Md; Siriki, R.] North Shore Forest Hills Hosp, Hofstra Med Sch NY, New York, NY USA.
[Shah, N.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 1717
BP S696
EP S696
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839703004
ER
PT J
AU Basu, P
Shah, N
Farhat, S
Rahman, M
Siriki, R
Win, S
Lynn, A
Mittimani, K
AF Basu, Patrick
Shah, N.
Farhat, S.
Rahman, Md
Siriki, R.
Win, Sandar
Lynn, A.
Mittimani, K.
TI Unrevealing a Novel Association of Cholesterol Ester Storage Disease
(CESD) And Non Alcoholic Fatty Liver Disease (NAFLD) - A Similar
Clinical Spectrum With Different Etiology: A Prospective Clinical Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Basu, Patrick] Columbia Sch Phys & Surg, New York, NY USA.
[Farhat, S.; Rahman, Md; Siriki, R.; Win, Sandar; Lynn, A.; Mittimani, K.] North Shore Forest Hills Hosp, Hofstra Med Sch, New York, NY USA.
[Shah, N.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 333
BP S143
EP S143
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839700334
ER
PT J
AU Basu, P
Shah, N
Farhat, S
Siriki, R
Rahman, M
Win, S
Lynn, A
Mittimani, K
AF Basu, Patrick
Shah, N.
Farhat, S.
Siriki, R.
Rahman, Md
Win, Sandar
Lynn, A.
Mittimani, K.
TI Heat Shock Protein-70 (HSP-70) A Novel Surrogate Marker for Hypoxia
Induced Liver Injury (HILI): A Prospective Open Label Control Clinical
Pilot Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Basu, Patrick] Columbia Sch Phys & Surg, New York, NY USA.
[Farhat, S.; Siriki, R.; Rahman, Md; Win, Sandar; Lynn, A.; Mittimani, K.] North Shore Forest Hills Hosp, Hofstra Med Sch, New York, NY USA.
[Shah, N.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 332
BP S142
EP S143
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839700333
ER
PT J
AU Basu, P
Shah, N
Farhat, S
Mittimani, K
Siriki, R
Rahman, M
Lynn, A
Win, S
Brown, R
AF Basu, Patrick
Shah, N.
Farhat, S.
Mittimani, K.
Siriki, R.
Rahman, Md
Lynn, A.
Win, Sandar
Brown, Robert, Jr.
TI Ratio of IL 10 over IL 12 is a Novel Surrogate to Evaluate the Severity
of Non Alcoholic Steatohepatitis (NASH) - A Prospective Clinical Pilot
Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Basu, Patrick; Brown, Robert, Jr.] Columbia Sch Phys & Surg, New York, NY USA.
[Farhat, S.; Mittimani, K.; Siriki, R.; Rahman, Md; Lynn, A.; Win, Sandar] North Shore Forest Hills Hosp, Hofstra Med Sch, New York, NY USA.
[Shah, N.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 364
BP S155
EP S155
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839700365
ER
PT J
AU Basu, P
Shah, N
Farhat, S
Siriki, R
Rahman, M
Lynn, A
Win, S
Mittimani, K
Brown, R
AF Basu, Patrick
Shah, N.
Farhat, S.
Siriki, R.
Rahman, Md
Lynn, A.
Win, Sandar
Mittimani, K.
Brown, Robert, Jr.
TI Pegylated Interferon Alfa, Nitazoxanide, Telaprevir, Ribavirin, in
Genotype 1 Undergoing Prior Experienced Chronic Hepatitis C Patients - A
Randomized Placebo Control Clinical Pilot Trial (INTRIGUE - C)
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Basu, Patrick; Brown, Robert, Jr.] Columbia Sch Phys & Surg, New York, NY USA.
[Farhat, S.; Siriki, R.; Rahman, Md; Lynn, A.; Win, Sandar; Mittimani, K.] North Shore Forest Hills Hosp, Hofstra Med Sch, New York, NY USA.
[Shah, N.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 363
BP S154
EP S154
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839700364
ER
PT J
AU Basu, P
Shah, N
Farhat, S
Mittimani, K
Siriki, R
Rahman, M
Win, S
Lynn, A
AF Basu, Patrick
Shah, N.
Farhat, S.
Mittimani, K.
Siriki, R.
Rahman, Md
Win, Sandar
Lynn, A.
TI Prevalence of Recurrence of Helicobacter pylori (HP) Infection in a
Special Population in the Community. HERROIC Study: Helicobacter pylori
Recurrence Resistance or Re-infections in a Special Population Base
Community: An Observational Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Basu, Patrick] Columbia Sch Phys & Surg, New York, NY USA.
[Farhat, S.; Mittimani, K.; Siriki, R.; Rahman, Md; Win, Sandar; Lynn, A.] Hofstra Med Sch NY, North Shore Forest Hills Hosp, New York, NY USA.
[Shah, N.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 117
BP S49
EP S50
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839700118
ER
PT J
AU Boardman, C
Sonnenberg, A
AF Boardman, Charles
Sonnenberg, Amnon
TI Management of Incidentally Detected Barrett's in a Young Person: a
Markov Process Cost-Utility Analysis
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Boardman, Charles] Portland VA Med Ctr, Portland, OR USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 1520
BP S607
EP S608
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839702404
ER
PT J
AU Go, M
Hatton-Ward, S
Rushton, P
Sonnenberg, A
AF Go, M.
Hatton-Ward, S.
Rushton, P.
Sonnenberg, Amnon
TI Risk of H. pylori Infection among Mormon Missionaries to Developing
Countries
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Go, M.; Hatton-Ward, S.] VA SLC Hlth Care Syst, Salt Lake City, UT USA.
[Rushton, P.] Brigham Young Univ, Provo, UT 84602 USA.
[Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 118
BP S50
EP S50
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839700119
ER
PT J
AU Ocampo, L
Kunkel, D
Tan, CR
Leung, J
Leung, F
AF Ocampo, Luis
Kunkel, David
Tan, Carlyn Rose
Leung, Joseph
Leung, Felix
TI Underwater Snare Cautery Polypectomy Can Be Safely Executed During Water
Exchange Colonoscopy
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Ocampo, Luis; Tan, Carlyn Rose; Leung, Felix] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Kunkel, David] UCLA Training Program Digest Dis, Los Angeles, CA USA.
[Leung, Joseph] Sacramento Vet Affairs Med Ctr, Sacramento, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 1339
BP S531
EP S531
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839702223
ER
PT J
AU Qureshi, W
Patel, R
Shaib, Y
AF Qureshi, Waqar
Patel, Ruchir
Shaib, Yasser
TI Outcomes of Office Based Hemorrhoid Treatment
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Qureshi, Waqar; Patel, Ruchir] Baylor Coll Med, Houston, TX 77030 USA.
[Shaib, Yasser] VA Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 535
BP S222
EP S222
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839700536
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI The Long-Term Time Trends of Mortality from Colorectal Cancer Are Shaped
by an Underlying Birth-Cohort Pattern
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 1975
BP S805
EP S806
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839703262
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI How to Catch a Suspicious Mucosal Lesion in the Act of Bleeding
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 1858
BP S757
EP S757
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839703145
ER
PT J
AU Takatori, N
Pisegna, J
Oh, D
Ohning, G
AF Takatori, Nanae
Pisegna, Joseph
Oh, David
Ohning, Gordon
TI Factors Influencing Compliance with ACG Surveillance Colonoscopy
Guidelines in a VA Patient Population
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Takatori, Nanae] Stanford Hosp, Palo Alto, CA USA.
[Pisegna, Joseph; Oh, David; Ohning, Gordon] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 1485
BP S594
EP S594
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839702369
ER
PT J
AU Tan, CR
Kunkel, D
Ocampo, L
Sanmiguel, C
Karsan, S
Cohen, H
Leung, F
AF Tan, Carlyn Rose
Kunkel, David
Ocampo, Luis
Sanmiguel, Claudia
Karsan, Sundip
Cohen, Hartley
Leung, Felix
TI The Water Exchange Method Is Effective and Safe in Reducing Sigmoid
Volvulus: A Case Series
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 [Tan, Carlyn Rose; Ocampo, Luis; Cohen, Hartley; Leung, Felix] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Kunkel, David; Sanmiguel, Claudia; Karsan, Sundip] UCLA Training Program Digest Dis, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2012
VL 107
SU 1
MA 1352
BP S536
EP S537
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V30UA
UT WOS:000208839702236
ER
PT J
AU La Hoz, RM
Baddley, JW
AF La Hoz, Ricardo M.
Baddley, John W.
TI Subcutaneous Fungal Infections
SO CURRENT INFECTIOUS DISEASE REPORTS
LA English
DT Article
DE Subcutaneous mycoses; Chromoblastomycosis Fonsecaea pedrosoi; Fonsecaea;
Cladophialophora carrionii; Cladophialophora; Phialophora; Eumycetoma;
Madurella mycetomatis; Leptosphaeria senegalensis; Madurella grisea;
Pseudallescheria boydii; Scedosporium apiospermum; Sporotrichosis;
Sporothrix schenckii species complex; Nodular lymphangitis
AB Subcutaneous mycoses are common in tropical and subtropical regions of the world. These infections have multiple features in common, including similar epidemiology, mode of transmission, indolent chronic presentation with low potential for dissemination in immunocompetent hosts, and pyogranulomatous lesions on histopathology. Herein, we provide up-to-date epidemiologic, clinical, diagnostic, and therapeutic data for three important subcutaneous mycoses: chromoblastomycosis, mycetoma, and sporotrichosis.
C1 [La Hoz, Ricardo M.; Baddley, John W.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA.
[Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA.
RP Baddley, JW (reprint author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, 1900 Univ Blvd,Tinsley Harrison Tower 229, Birmingham, AL 35294 USA.
EM jbaddley@uab.edu
FU Pfizer
FX J. Baddley has been a consultant for Merck, Abbott, and Pfizer. His
institution has received grant support from Pfizer. R. La Hoz reported
no potential conflicts of interest relevant to this article.
NR 134
TC 5
Z9 6
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3847
EI 1534-3146
J9 CURR INFECT DIS REP
JI Curr. Infect. Dis. Rep.
PD OCT
PY 2012
VL 14
IS 5
BP 530
EP 539
DI 10.1007/s11908-012-0275-3
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA V32XH
UT WOS:000208983400009
PM 22811027
ER
PT J
AU Li, J
Hsu, HC
Mountz, JD
AF Li, Jun
Hsu, Hui-Chen
Mountz, John D.
TI Managing Macrophages in Rheumatoid Arthritis by Reform or Removal
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Macrophage; Polarization; Rheumatoid arthritis; Therapy; Management;
Reform; Removal; Joint recruitment; Inflammation; Depletion; TRAIL
ID TUMOR-NECROSIS-FACTOR; COLLAGEN-INDUCED ARTHRITIS; COLONY-STIMULATING
FACTORS; SCAVENGER RECEPTOR CD163; SYNOVIAL FIBROBLASTS; GM-CSF;
MEDIATES APOPTOSIS; MOUSE MODEL; TNF-ALPHA; T-CELLS
AB Macrophages play a central role in the pathogenesis of rheumatoid arthritis (RA). There is an imbalance of inflammatory and antiinflammatory macrophages in RA synovium. Although the polarization and heterogeneity of macrophages in RA have not been fully uncovered, the identity of macrophages in RA can potentially be defined by their products, including the co-stimulatory molecules, scavenger receptors, different cytokines/chemokines and receptors, and transcription factors. In the last decade, efforts to understand the polarization, apoptosis regulation, and novel signaling pathways in macrophages, as well as how distinct activated macrophages influence disease progression, have led to strategies that target macrophages with varied specificity and selectivity. Major targets that are related to macrophage development and apoptosis include TNF-alpha, IL-1, IL-6, GM-CSF, M-CSF, death receptor 5 (DR5), Fas, and others, as listed in Table 1. Combined data from clinical, preclinical, and animal studies of inhibitors of these targets have provided valuable insights into their roles in the disease progression and, subsequently, have led to the evolving therapeutic paradigms in RA. In this review, we propose that reestablishment of macrophage equilibrium by inhibiting the development of, and/or eliminating, the proinflammatory macrophages will be an effective therapeutic approach for RA and other autoimmune diseases.
C1 [Li, Jun; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Hsu, Hui-Chen; Mountz, John D.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL 35233 USA.
RP Mountz, JD (reprint author), Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, SHEL Bldg,Suite 307,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM junliuab@uab.edu; rheu078@uab.edu; jdmountz@uab.edu
FU American College of Rheumatology (ACR) Research and Education
Foundation; Lupus Research Institute (LRI); Arthritis Foundation; NIH [1
R01 AI083705, RO1 AI071110-01A1, VA 1I01BX000600]; ACR; Daiichi-Sankyo
Co Ltd.
FX Funding for this research was made possible by the American College of
Rheumatology (ACR) Research and Education Foundation and the Lupus
Research Institute (LRI). Dr. Li has received grant support (Fellowship
Award) from the Arthritis Foundation. Dr. Hsu has received grant support
from the LRI and NIH 1 R01 AI083705. Dr. Mountz has received grant
support from the ACR, NIH RO1 AI071110-01A1, VA 1I01BX000600, and
Daiichi-Sankyo Co Ltd.
NR 54
TC 47
Z9 47
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3774
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD OCT
PY 2012
VL 14
IS 5
BP 445
EP 454
DI 10.1007/s11926-012-0272-4
PG 10
WC Rheumatology
SC Rheumatology
GA 225VE
UT WOS:000324991600010
PM 22855296
ER
PT J
AU McBurney, CA
Vina, ER
AF McBurney, Christine A.
Vina, Ernest R.
TI Racial and Ethnic Disparities in Rheumatoid Arthritis
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Rheumatoid arthritis; Health disparities; Race; Ethnicity; Socioeconomic
status; Patient-provider communication; Health literacy; Depression;
Treatment; Adherence
ID MODIFYING ANTIRHEUMATIC DRUGS; OF-THE-LITERATURE; SINGLE-NUCLEOTIDE
POLYMORPHISMS; PATIENT-PHYSICIAN COMMUNICATION;
SYSTEMIC-LUPUS-ERYTHEMATOSUS; AFRICAN-AMERICANS; WORK DISABILITY;
ANTIRETROVIRAL THERAPY; DISADVANTAGED PATIENTS; TREATMENT PREFERENCES
AB Racial and ethnic health disparities are a national health issue. They are well described in other chronic diseases, but in rheumatoid arthritis (RA), research into their causes, outcomes, and elimination is in its early stages. Health disparities occur in a complex milieu, with system-level, provider-level, and individual-level factors playing roles. Dissecting the overlapping aspects of race/ethnicity, socioeconomic variables, and how their individual components combine to explain the magnitude of disparities in RA can be challenging. Recent research has focused on the extent to which treatment preferences, adherence, trust in physicians, patient-physician communication, health literacy, and depression have contributed to observed disparities in RA. Practicing evidence-based medicine, improving patient-physician communication skills, reducing language and literacy barriers, improving adherence to therapies, raising awareness of racial/ethnic disparities, and recognizing comorbidities such as depression are steps clinicians may take to help eliminate racial/ethnic disparities in RA.
C1 [McBurney, Christine A.; Vina, Ernest R.] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15261 USA.
[Vina, Ernest R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
RP Vina, ER (reprint author), Arthrit Res Ctr, 3347 Forbes Ave,Ste 220, Pittsburgh, PA 15213 USA.
EM mcburneyca@upmc.edu; evina1@pitt.edu
OI Vina, Ernest/0000-0001-8135-1731
NR 79
TC 8
Z9 8
U1 2
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3774
EI 1534-6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD OCT
PY 2012
VL 14
IS 5
BP 463
EP 471
DI 10.1007/s11926-012-0276-0
PG 9
WC Rheumatology
SC Rheumatology
GA 225VE
UT WOS:000324991600012
PM 22773376
ER
PT J
AU Leutwyler, H
Hubbard, EM
Vinogradov, S
Dowling, GA
AF Leutwyler, Heather
Hubbard, Erin M.
Vinogradov, Sophia
Dowling, Glenna A.
TI Videogames to Promote Physical Activity in Older Adults with
Schizophrenia
SO GAMES FOR HEALTH JOURNAL
LA English
DT Article
AB Older adults with schizophrenia need physical activity interventions to improve their physical health. The purpose of this report is to describe the preliminary acceptability of a videogame-based physical activity program using the Kinect (TM) for Xbox 360 game system (Microsoft, Redmond, WA) in older adults with schizophrenia.
C1 [Leutwyler, Heather; Hubbard, Erin M.; Dowling, Glenna A.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA.
[Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA.
[Dowling, Glenna A.] Res Ctr, Inst Aging, San Francisco, CA USA.
RP Leutwyler, H (reprint author), Univ Calif San Francisco, Dept Physiol Nursing, 2 Koret Way,N631A,Box 0610, San Francisco, CA 94143 USA.
EM heather.leutwyler@nursing.ucsf.edu
NR 15
TC 4
Z9 4
U1 2
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2161-783X
EI 2161-7856
J9 GAMES HEALTH J
JI Games Health J.
PD OCT
PY 2012
VL 1
IS 5
BP 381
EP 383
DI 10.1089/g4h.2012.0051
PG 3
WC Health Policy & Services; Public, Environmental & Occupational Health;
Rehabilitation
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Rehabilitation
GA V40YR
UT WOS:000209514400012
ER
PT J
AU Hull, RL
Johnson, PY
Braun, KR
Day, AJ
Wight, TN
AF Hull, Rebecca L.
Johnson, Pamela Y.
Braun, Kathleen R.
Day, Anthony J.
Wight, Thomas N.
TI Hyaluronan and Hyaluronan Binding Proteins Are Normal Components of
Mouse Pancreatic Islets and Are Differentially Expressed by Islet
Endocrine Cell Types
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE extracellular matrix; hyaluronan; islet; proteoglycan
ID ALPHA-TRYPSIN INHIBITOR; HEPARAN-SULFATE PROTEOGLYCANS;
SMOOTH-MUSCLE-CELLS; BETA-CELLS; EXTRACELLULAR-MATRIX;
INSULIN-SECRETION; BASEMENT-MEMBRANE; GROWTH-FACTOR; HEAVY-CHAINS; NOD
MICE
AB The pancreatic islet comprises endocrine, vascular, and neuronal cells. Signaling among these cell types is critical for islet function. The extracellular matrix (ECM) is a key regulator of cell-cell signals, and while some islet ECM components have been identified, much remains unknown regarding its composition. We investigated whether hyaluronan, a common ECM component that may mediate inflammatory events, and molecules that bind hyaluronan such as versican, tumor necrosis factor-stimulated gene 6 (TSG-6), and components of inter-a-trypsin inhibitor (I alpha I), heavy chains 1 and 2 (ITIH1/ITIH2), and bikunin, are normally produced in the pancreatic islet. Mouse pancreata and isolated islets were obtained for microscopy (with both paraformaldehyde and Carnoy's fixation) and mRNA. Hyaluronan was present predominantly in the peri-islet ECM, and hyaluronan synthase isoforms 1 and 3 were also expressed in islets. Versican was produced in alpha cells; TSG-6 in alpha and beta cells; bikunin in alpha, beta, and delta cells; and ITIH1/ITIH2 predominantly in beta cells. Our findings demonstrate that hyaluronan, versican, TSG-6, and IaI are normal islet components and that different islet endocrine cell types contribute these ECM components. Thus, dysfunction of either alpha or beta cells likely alters islet ECM composition and could thereby further disrupt islet function. (J Histochem Cytochem 60:749-760, 2012)
C1 [Hull, Rebecca L.] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
[Hull, Rebecca L.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Johnson, Pamela Y.; Braun, Kathleen R.; Wight, Thomas N.] Benaroya Res Inst Virginia Mason, Hope Heart Matrix Biol Program, Seattle, WA USA.
[Day, Anthony J.] Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Manchester, Lancs, England.
[Wight, Thomas N.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
RP Hull, RL (reprint author), Vet Affairs Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM rhull@u.washington.edu
RI Day, Anthony/O-1658-2015
OI Day, Anthony/0000-0002-1415-3134; Hull, Rebecca/0000-0001-9690-4087
FU Department of Veterans Affairs, Veterans Affairs Puget Sound Health Care
System (Seattle, WA), National Institutes of Health [DK088082,
DK017047]; Juvenile Diabetes Research Foundation [nPOD 25-2010-648]
FX The authors received the following financial support for the research,
authorship, and/or publication of this article: This work was supported
by the Department of Veterans Affairs, Veterans Affairs Puget Sound
Health Care System (Seattle, WA), National Institutes of Health grants
DK088082 (RLH) and DK017047 (University of Washington Diabetes Research
Center), and the Juvenile Diabetes Research Foundation (nPOD 25-2010-648
[TNW]).
NR 72
TC 13
Z9 13
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022-1554
EI 1551-5044
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD OCT
PY 2012
VL 60
IS 10
BP 749
EP 760
DI 10.1369/0022155412457048
PG 12
WC Cell Biology
SC Cell Biology
GA 010XF
UT WOS:000309127100003
PM 22821669
ER
PT J
AU Spain, R
Mancini, M
St George, R
Bourdette, D
Horak, F
AF Spain, R.
Mancini, M.
St George, R.
Bourdette, D.
Horak, F.
TI Longitudinal measures of instrumented gait and balance in multiple
sclerosis over 18 months
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Meeting Abstract
CT 28th Congress of the
European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis
CY OCT 10-13, 2012
CL Lyon, FRANCE
SP European Comm Treatment & Res Multiple Sclerosis
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD OCT
PY 2012
VL 18
SU 4
BP 330
EP 331
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 275UC
UT WOS:000328702202105
ER
PT J
AU Bollyky, PL
Bogdani, M
Bollyky, JB
Hull, RL
Wight, TN
AF Bollyky, Paul L.
Bogdani, Marika
Bollyky, Jennifer B.
Hull, Rebecca L.
Wight, Thomas N.
TI The Role of Hyaluronan and the Extracellular Matrix in Islet
Inflammation and Immune Regulation
SO CURRENT DIABETES REPORTS
LA English
DT Article
DE Hyaluronan; TSG-6; CD44; TLR2; TLR4; Toll-like receptors; Foxp3;
Regulatory T-cells; TR1; Treg; IL-10; TGF-beta; Extracellular matrix;
Diabetes; Islets; Islet inflammation; Immune regulation
ID NONOBESE DIABETIC MICE; BETA-CELL DESTRUCTION; T-CELLS;
PANCREATIC-ISLETS; BASEMENT-MEMBRANE; DENDRITIC CELLS; CROSS-LINKING;
NOD MICE; EXPERIMENTAL ARTHRITIS; AUTOIMMUNE-DISEASE
AB Type 1 diabetes (T1D) is a disease that in most individuals results from autoimmune attack of a single tissue type, the pancreatic islet. A fundamental, unanswered question in T1D pathogenesis is how the islet tissue environment influences immune regulation. This crosstalk is likely to be communicated through the extracellular matrix (ECM). Here, we review what is known about the ECM in insulitis and examine how the tissue environment is synchronized with immune regulation. In particular, we focus on the role of hyaluronan (HA) and its interactions with Foxp3+ regulatory T-cells (Treg). We propose that HA is a "keystone molecule" in the inflammatory milieu and that HA, together with its associated binding proteins and receptors, is an appropriate point of entry for investigations into how ECM influences immune regulation in the islet.
C1 [Bollyky, Paul L.; Bollyky, Jennifer B.; Wight, Thomas N.] Benaroya Res Inst Virginia Mason, Seattle, WA 98101 USA.
[Bogdani, Marika] Pacific NW Diabet Res Inst, Seattle, WA USA.
[Hull, Rebecca L.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Hull, Rebecca L.] Univ Washington, Seattle, WA 98195 USA.
RP Bollyky, PL (reprint author), Benaroya Res Inst Virginia Mason, 1201 9th Ave, Seattle, WA 98101 USA.
EM pbollyky@benaroyaresearch.org
OI Hull, Rebecca/0000-0001-9690-4087
FU National Institutes of Health [DK046635, DK080178, DK089128,
U01AI101984, HL018645]; BIRT supplement [AR037296]; Juvenile Diabetes
Research Foundation [nPOD 25-2010-648]; Center for Translational
Research at BRI
FX This work was supported by National Institutes of Health grants DK046635
(to G.T.N.); DK080178, DK089128 and U01AI101984 (to P. L. B.); and
HL018645 and a BIRT supplement AR037296 (to T.N.W.). This work was also
supported by grants from the Juvenile Diabetes Research Foundation (nPOD
25-2010-648 (to T.N.W.), and The Center for Translational Research at
BRI (to G.T.N.).
NR 99
TC 27
Z9 27
U1 1
U2 22
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1534-4827
J9 CURR DIABETES REP
JI Curr. Diabetes Rep.
PD OCT
PY 2012
VL 12
IS 5
BP 471
EP 480
DI 10.1007/s11892-012-0297-0
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 999CJ
UT WOS:000308286400004
PM 22810951
ER
PT J
AU Wortzel, HS
Arciniegas, DB
AF Wortzel, Hal S.
Arciniegas, David B.
TI Treatment of Post-Traumatic Cognitive Impairments
SO CURRENT TREATMENT OPTIONS IN NEUROLOGY
LA English
DT Review
DE Traumatic brain injury; Cognitive disorders; Rehabilitation; Drug
therapy; Post-traumatic cognitive impairments; Treatment
ID TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED
TRIAL; LONG-TERM DISABILITY; OF-THE-LITERATURE; EFNS TASK-FORCE;
A-META-ANALYSIS; CDP-CHOLINE; HEAD-INJURY; UNITED-STATES
AB aEuro cent Cognitive impairment is a common consequence of traumatic brain injury (TBI) and a substantial source of disability. Across all levels of TBI severity, attention, processing speed, episodic memory, and executive function are most commonly affected.
aEuro cent The differential diagnosis for post-traumatic cognitive impairments is broad, and includes emotional, behavioral, and physical problems as well as substance use disorders, medical conditions, prescribed and self-administered medications, and symptom elaboration. Thorough neuropsychiatric assessment for such problems is a prerequisite to treatments specifically targeting cognitive impairments.
aEuro cent First-line treatments for post-traumatic cognitive impairments are nonpharmacologic, including education, realistic expectation setting, environmental and lifestyle modifications, and cognitive rehabilitation.
aEuro cent Pharmacotherapies for post-traumatic cognitive impairments include uncompetitive N-methyl-D-aspartate receptor (NMDA) antagonists, medications that directly or indirectly augment cerebral catecholaminergic or acetylcholinergic function, or agents with combinations of these properties.
aEuro cent In the immediate post-injury period, treatment with uncompetitive NMDA receptor antagonists reduces duration of unconsciousness. The mechanism for this effect may involve attenuation of neurotrauma-induced glutamate-mediated excitotoxicity and/or stabilization of glutamate signaling in the injured brain.
aEuro cent During the subacute or late post-injury periods, medications that augment cerebral acetylcholinergic function may improve declarative memory. Among responders to this treatment, secondary benefits on attention, processing speed, and executive function impairments as well as neuropsychiatric disturbances may be observed. During these post-injury periods, medications that augment cerebral catecholaminergic function may improve hypoarousal, processing speed, attention, and/or executive function as well as comorbid depression or apathy.
aEuro cent When medications are used, a "start-low, go-slow, but go" approach is encouraged, coupled with frequent reassessment of benefits and side effects as well as monitoring for drug-drug interactions. Titration to either beneficial effect or medication intolerance should be completed before discontinuing a treatment or augmenting partial responses with additional medications.
C1 [Wortzel, Hal S.] Denver Vet Affairs Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 19, Denver, CO 80220 USA.
[Wortzel, Hal S.; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Psychiat, Neurobehav Disorders Program, Aurora, CO USA.
[Wortzel, Hal S.; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Aurora, CO USA.
RP Wortzel, HS (reprint author), Denver Vet Affairs Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 19, 1055 Clermont St, Denver, CO 80220 USA.
EM hal.wortzel@ucdenver.edu
FU Department of Veterans Affairs VISN 19 Mental Illness Research,
Education, and Clinical Center; National Institute of Child Health &
Human Development [5R01 HD047242, 5R01 HD047242-S1]
FX This work was supported in part by the Department of Veterans Affairs
VISN 19 Mental Illness Research, Education, and Clinical Center as well
as the National Institute of Child Health & Human Development grants
5R01 HD047242 and 5R01 HD047242-S1. Dr. Wortzel is an employee of the
Department of Veterans Affairs, and Dr. Arciniegas is President of the
International Brain Injury Association and a civilian contractor for the
United States Army Medical Research and Materiel Command-Telemedicine &
Advanced Technology Research Center. The opinions expressed and
information presented in this work do not necessarily reflect the views
of these organizations and are not expressly endorsed by them.
NR 88
TC 12
Z9 14
U1 3
U2 24
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1092-8480
J9 CURR TREAT OPTION NE
JI Curr. Treat. Options Neurol.
PD OCT
PY 2012
VL 14
IS 5
BP 493
EP 508
DI 10.1007/s11940-012-0193-6
PG 16
WC Clinical Neurology
SC Neurosciences & Neurology
GA 999ZG
UT WOS:000308354400006
PM 22865461
ER
PT J
AU Kahn, SE
Suvag, S
Wright, LA
Utzschneider, KM
AF Kahn, S. E.
Suvag, S.
Wright, L. A.
Utzschneider, K. M.
TI Interactions between genetic background, insulin resistance and
beta-cell function
SO DIABETES OBESITY & METABOLISM
LA English
DT Review
DE ABCC8; glucokinase; incretins; insulin secretion; insulin sensitivity;
islet; KCNJ11; proinsulin; SLC30A8; TCF7L2; zinc
ID GENOME-WIDE ASSOCIATION; DIABETES PREVENTION PROGRAM; LARGE-SCALE
ASSOCIATION; ZINC TRANSPORTER ZNT8; BODY-MASS INDEX; GLUCOSE-TOLERANCE;
FTO GENE; TCF7L2 POLYMORPHISMS; SUSCEPTIBILITY LOCI; PROINSULIN LEVELS
AB An interaction between genes and the environment is a critical component underlying the pathogenesis of the hyperglycaemia of type 2 diabetes. The development of more sophisticated techniques for studying gene variants and for analysing genetic data has led to the discovery of some 40 genes associated with type 2 diabetes. Most of these genes are related to changes in beta-cell function, with a few associated with decreased insulin sensitivity and obesity. Interestingly, using quantitative traits based on continuous measures rather than dichotomous ones, it has become evident that not all genes associated with changes in fasting or post-prandial glucose are also associated with a diagnosis of type 2 diabetes. Identification of these gene variants has provided novel insights into the physiology and pathophysiology of the beta-cell, including the identification of molecules involved in beta-cell function that were not previously recognized as playing a role in this critical cell.
C1 [Kahn, S. E.; Suvag, S.; Wright, L. A.; Utzschneider, K. M.] Univ Washington, Dept Med, Seattle, WA USA.
[Kahn, S. E.; Suvag, S.; Wright, L. A.; Utzschneider, K. M.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM skahn@u.washington.edu
OI Kahn, Steven/0000-0001-7307-9002
FU United States Department of Veterans Affairs; National Institutes of
Health [DK-017047, DK-007247]
FX This work was supported by the United States Department of Veterans
Affairs and National Institutes of Health Grants DK-017047 and
DK-007247.
NR 74
TC 6
Z9 6
U1 0
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD OCT
PY 2012
VL 14
SU 3
BP 46
EP 56
DI 10.1111/j.1463-1326.2012.01650.x
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 995UJ
UT WOS:000308038300007
PM 22928564
ER
PT J
AU Stevens, RJ
Ali, R
Bankhead, CR
Bethel, MA
Cairns, BJ
Camisasca, RP
Crowe, FL
Farmer, AJ
Harrison, S
Hirst, JA
Home, P
Kahn, SE
McLellan, JH
Perera, R
Pluddemann, A
Ramachandran, A
Roberts, NW
Rose, PW
Schweizer, A
Viberti, G
Holman, RR
AF Stevens, R. J.
Ali, R.
Bankhead, C. R.
Bethel, M. A.
Cairns, B. J.
Camisasca, R. P.
Crowe, F. L.
Farmer, A. J.
Harrison, S.
Hirst, J. A.
Home, P.
Kahn, S. E.
McLellan, J. H.
Perera, R.
Plueddemann, A.
Ramachandran, A.
Roberts, N. W.
Rose, P. W.
Schweizer, A.
Viberti, G.
Holman, R. R.
TI Cancer outcomes and all-cause mortality in adults allocated to
metformin: systematic review and collaborative meta-analysis of
randomised clinical trials
SO DIABETOLOGIA
LA English
DT Article
DE Meta-analysis; Metformin; Neoplasms; Systematic review
ID INITIAL COMBINATION THERAPY; TYPE-2 DIABETES-MELLITUS; GLYCEMIC CONTROL;
INCIDENT CANCER; DOUBLE-BLIND; RISK; GLUCOSE; COHORT; ROSIGLITAZONE;
PIOGLITAZONE
AB Observational studies suggest that metformin may reduce cancer risk by approximately one-third. We examined cancer outcomes and all-cause mortality in published randomised controlled trials (RCTs).
RCTs comparing metformin with active glucose-lowering therapy or placebo/usual care, with minimum 500 participants and 1-year follow-up, were identified by systematic review. Data on cancer incidence and all-cause mortality were obtained from publications or by contacting investigators. For two trials, cancer incidence data were not available; cancer mortality was used as a surrogate. Summary RRs, 95% CIs and I (2)statistics for heterogeneity were calculated by fixed effects meta-analysis.
Of 4,039 abstracts identified, 94 publications described 14 eligible studies. RRs for cancer were available from 11 RCTs with 398 cancers during 51,681 person-years. RRs for all-cause mortality were available from 13 RCTs with 552 deaths during 66,447 person-years. Summary RRs for cancer outcomes in people randomised to metformin compared with any comparator were 1.02 (95% CI 0.82, 1.26) across all trials, 0.98 (95% CI 0.77, 1.23) in a subgroup analysis of active-comparator trials and 1.36 (95% CI 0.74, 2.49) in a subgroup analysis of placebo/usual care comparator trials. The summary RR for all-cause mortality was 0.94 (95% CI 0.79, 1.12) across all trials.
Meta-analysis of currently available RCT data does not support the hypothesis that metformin lowers cancer risk by one-third. Eligible trials also showed no significant effect of metformin on all-cause mortality. However, limitations include heterogeneous comparator types, absent cancer data from two trials, and short follow-up, especially for mortality.
C1 [Stevens, R. J.; Bankhead, C. R.; Farmer, A. J.; Harrison, S.; Hirst, J. A.; McLellan, J. H.; Perera, R.; Plueddemann, A.; Roberts, N. W.; Rose, P. W.] Univ Oxford, Dept Primary Care Hlth Sci, Oxford OX2 6GG, England.
[Ali, R.; Cairns, B. J.; Crowe, F. L.] Univ Oxford, Canc Epidemiol Unit, Oxford OX2 6GG, England.
[Bethel, M. A.; Holman, R. R.] Univ Oxford, Diabet Trials Unit, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX2 6GG, England.
[Camisasca, R. P.] Takeda Pharmaceut Co, TGRD Europe, London, England.
[Home, P.] Newcastle Univ, Sch Med, ICM Diabet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Kahn, S. E.] Univ Washington, Seattle, WA 98195 USA.
[Kahn, S. E.] Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA.
[Ramachandran, A.] Dr A Ramachandrans Diabet Hosp, India Diabet Res Fdn, Chennai, Tamil Nadu, India.
[Schweizer, A.] Novartis Pharmaceut, Basel, Switzerland.
[Viberti, G.] Kings Coll London, Sch Med, Metab Med Unit, London WC2R 2LS, England.
RP Stevens, RJ (reprint author), Univ Oxford, Dept Primary Care Hlth Sci, Woodstock Rd, Oxford OX2 6GG, England.
EM richard.stevens@phc.ox.ac.uk
OI McLellan, Julie/0000-0002-2868-8631; Cairns,
Benjamin/0000-0001-7994-8213; Hirst, Jennifer/0000-0002-8416-2159; Kahn,
Steven/0000-0001-7307-9002
FU Diabetes UK [10/00040002]; GlaxoSmithKline; sanofi-aventis; Novartis;
Bayer; Merck; Lilly; Amylin; Pfizer; Daiichi Sankyo; Speedel; Novo
Nordisk
FX The funding for the individual studies has been listed previously.
Administrative support for the systematic review was funded by Diabetes
UK (grant number 10/00040002).; R. Ali has received grants and honoraria
from GlaxoSmithKline and sanofi-aventis for research and educational
activities in relation to cancer.; M. A. Bethel receives research
funding from Novartis and Bayer. Her department receives funding in
support of research from Merck, Lilly and Amylin.; A. J. Farmer has
received funding for travel to meetings in the past 12 months from
Pfizer and sanofi-aventis, and his department has received funding from
sanofi-aventis and Pfizer in payment for consultancy, but he has no
personal interest in this funding.; G. Viberti has, in the past,
received consulting fees, grant support and lecture fees from, and has
an equity interest in, GlaxoSmithKline; received consulting fees, grant
support and lecture fees from Novartis; received consulting and lecture
fees from Daiichi Sankyo and Speedel; and received grant support from
Pfizer. He is now retired and as such no longer has any conflicts of
interest.; R. R. Holman has, in the last 12 months, received research
support from Amylin, Bayer, Merck and Novartis; attended advisory boards
with Amylin, Lilly, Merck, Novartis and Novo Nordisk; and given lectures
supported by Bayer, Lilly, Merck and Novo Nordisk.
NR 46
TC 78
Z9 80
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD OCT
PY 2012
VL 55
IS 10
BP 2593
EP 2603
DI 10.1007/s00125-012-2653-7
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 999ZH
UT WOS:000308354600007
PM 22875195
ER
PT J
AU Prisciandaro, JJ
Korte, JE
McRae-Clark, AL
Brady, KT
AF Prisciandaro, James J.
Korte, Jeffrey E.
McRae-Clark, Aimee L.
Brady, Kathleen T.
TI Associations between behavioral disinhibition and cocaine use history in
individuals with cocaine dependence
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Cocaine dependence; Impulsivity; Novelty seeking; Cocaine use; Age of
onset
ID HIGH IMPULSIVITY; EARLY-ONSET; ALCOHOL-USE; TEMPERAMENT; PERSONALITY;
CHARACTER; GENDER; MODEL; TASK; MEN
AB Background: Behavioral disinhibition has been suggested as both a cause and consequence of substance use disorders. Many studies examining associations between behavioral disinhibition and substance use history have focused on individuals with alcohol dependence or non-dependent college students. In the present study, the relationship between behavioral disinhibition and cocaine use history in individuals with cocaine dependence is examined.
Methods: Forty-six non-treatment-seeking cocaine-dependent men and women completed impulsivity (Barratt Impulsiveness Scale; BIS) and novelty seeking (Temperament and Character Inventory; TCI) questionnaires at the baseline visit of an ongoing study. Unadjusted, and adjusted for gender and age, Pearson correlations were calculated between BIS, TCI, and cocaine use variables from the Structured Clinical Interview for DSM-IV and Timeline Follow-back (age of onset, quantity/frequency of past 30 day cocaine use).
Results: As expected, elevated motor impulsivity and novelty seeking were each associated with younger age of dependence onset. Also, individuals with lower levels of persistence on the TCI reported more days of co-caine use over the previous month. Unexpectedly, increased novelty seeking and attentional impulsivity were associated with fewer days of cocaine use and less money spent on cocaine, respectively. Controlling for age and gender did not substantially change the pattern of observed associations.
Conclusions: The present study provides preliminary evidence for associations between behavioral disinhibition and cocaine use history in cocaine-dependent individuals. Given our relatively small sample size and the correlational nature of our findings, further research is needed to replicate and extend our results. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Prisciandaro, James J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, Charleston, SC 29425 USA.
[Brady, Kathleen T.] Ralph H Johnson VAMC, Charleston, SC USA.
RP Prisciandaro, JJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 67 President St,MSC861, Charleston, SC 29425 USA.
EM priscian@musc.edu
RI McRae-Clark, Aimee/I-3341-2013
OI McRae-Clark, Aimee/0000-0002-9774-318X
FU NIH [P50DA016511, U10DA013727]; NIDA [F32 DA032250]
FX Funding for this study was provided by NIH grants P50DA016511 (Brady)
and U10DA013727 (Brady); the NIH had no further role in study design; in
the collection, analysis and interpretation of data: in the writing of
the report; and in the decision to submit the paper for publication. Dr.
Prisciandaro was supported by NIDA F32 DA032250.
NR 32
TC 9
Z9 9
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
J9 ADDICT BEHAV
JI Addict. Behav.
PD OCT
PY 2012
VL 37
IS 10
BP 1185
EP 1188
DI 10.1016/j.addbeh.2012.05.015
PG 4
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 984QD
UT WOS:000307205200019
PM 22710029
ER
PT J
AU Hoffman, WH
Shacka, JJ
Andjelkovic, AV
AF Hoffman, William H.
Shacka, John J.
Andjelkovic, Anuska V.
TI Autophagy in the brains of young patients with poorly controlled T1DM
and fatal diabetic ketoacidosis
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Review
DE Autophagic gene-4; Cleaved caspase-3; Diabetic encephalopathy; Diabetic
ketoacidosis; Glucose-regulated protein78; Light chain-3; Oxidative
stress
ID ENDOPLASMIC-RETICULUM STRESS; CHAPERONE-MEDIATED AUTOPHAGY; UNFOLDED
PROTEIN RESPONSE; MAGNETIC-RESONANCE SPECTROSCOPY; POLYUNSATURATED
FATTY-ACIDS; HEAT-SHOCK-PROTEIN; GROWTH-FACTOR-I; OXIDATIVE STRESS;
CELL-DEATH; LIPID-PEROXIDATION
AB Semi-quantitative neuroradiologic studies, quantitative neuron density studies and immunocytochemistry markers of oxidative stress and neuroinflammation indicate neuronal injury and deficits in young patients with chronic poorly controlled type 1 diabetes mellitus (T1DM). Present data suggest that pathogenesis of the neuronal deficits in young patients, who die as the result of diabetic ketoacidosis (DKA) and brain edema (BE), does not involve apoptosis, a prominent form of regulated cell death in many disease states. To further address this we studied mediators of macroautophagy, endoplasmic reticulum (ER) stress and apoptosis. In all areas studied we demonstrated increased levels of macroautophagy-associated proteins including light chain-3 (LC3) and autophagy related protein-4 (Atg4), as well as increased levels of the ER-associated glucose-regulated protein78/binding immunoglobulin protein (GRP78/BiP) in T1DM. In contrast, cleaved caspase-3 was rarely detected in any T1DM brain regions. These results suggest that chronic metabolic instability and oxidative stress may cause alterations in the autophagy-lysosomal pathway but not apoptosis, and macroautophagy-associated molecules may serve as useful candidates for further study in the pathogenesis of early neuronal deficits in T1DM. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Hoffman, William H.] Georgia Hlth Sci Univ, Dept Pediat, Sect Pediat Endocrinol, Augusta, GA USA.
[Shacka, John J.] Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA.
[Shacka, John J.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Andjelkovic, Anuska V.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
[Andjelkovic, Anuska V.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.
RP Hoffman, WH (reprint author), Georgia Hlth Sci Univ, Dept Pediat, Sect Pediat Endocrinol, Augusta, GA USA.
EM whoffman@georgiahealth.edu
FU NIH [RO1 NS 062853]; VA Merit Review Award [1 101 BX000957-01]
FX Dr. Andjelkovic is supported by grant (AVA) NIH RO1 NS 062853. Dr.
Shacka is supported by a VA Merit Review Award (1 101 BX000957-01) and
acknowledges the Neuroscience Molecular Detection Core (P30 NS47466;
Kevin Roth, MD, PhD, Director). The authors also acknowledge the
critical review of Dr. M.P. Casanova.
NR 113
TC 9
Z9 9
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD OCT
PY 2012
VL 93
IS 2
BP 273
EP 280
DI 10.1016/j.yexmp.2011.10.007
PG 8
WC Pathology
SC Pathology
GA 990DL
UT WOS:000307611100014
PM 22079479
ER
PT J
AU Chen, BJ
Yi, GY
Cook, RJ
Zhou, XH
AF Chen, Baojiang
Yi, Grace Y.
Cook, Richard J.
Zhou, Xiao-Hua
TI Marginal methods for clustered longitudinal binary data with incomplete
covariates
SO JOURNAL OF STATISTICAL PLANNING AND INFERENCE
LA English
DT Article
DE Association; Generalized estimating equation; Longitudinal data; Missing
covariates
ID REGRESSION-MODELS; SMOKING PREVENTION; CAUTIONARY NOTE; MISSING DATA;
RESPONSES; OUTCOMES; PROGRAM; DISEASE; RISK
AB Many analyses for incomplete longitudinal data are directed to examining the impact of covariates on the marginal mean responses. We consider the setting in which longitudinal responses are collected from individuals nested within clusters. We discuss methods for assessing covariate effects on the mean and association parameters when covariates are incompletely observed. Weighted first and second order estimating equations are constructed to obtain consistent estimates of mean and association parameters when covariates are missing at random. Empirical studies demonstrate that estimators from the proposed method have negligible finite sample biases in moderate samples. An application to the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS) demonstrates the utility of the proposed method. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Chen, Baojiang] Univ Nebraska, Med Ctr, Dept Biostat, Omaha, NE 68198 USA.
[Yi, Grace Y.; Cook, Richard J.] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada.
[Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Biostat Unit, Seattle, WA 98101 USA.
RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
EM baojiang.chen@unmc.edu; azhou@u.washington.edu
FU Natural Sciences and Engineering Research Council of Canada; Canadian
Institutes for Health Research; U.S. Department of Veterans Affairs;
Veterans Affairs Health Administration; National Science Foundation of
China [NSFC 30728019]; National Institute on Aging [U01AG016976]; HSR&D
Grants (VA Research Career Scientist Award) [RCS 05-196]
FX This research was supported by Grants from the Natural Sciences and
Engineering Research Council of Canada (G.Y. Yi and R.J. Cook) and the
Canadian Institutes for Health Research (R.J. Cook). R.J. Cook is Canada
Research Chair in Statistical Methods for Health Research. Dr. Xiao-Hua
Zhou, Ph.D., is presently a Core Investigator and Biostatistics Unit
Director at the Northwest HSR&D Center of Excellence, Department of
Veterans Affairs Medical Center, Seattle, WA, Dr. Zhou's work was
supported in part by U.S. Department of Veterans Affairs, Veterans
Affairs Health Administration, HSR&D Grants (VA Research Career
Scientist Award RCS 05-196), and the National Science Foundation of
China (NSFC 30728019). Both Drs. Zhou and Chen were supported in part by
National Institute on Aging Grant U01AG016976 to the National
Alzheimer's Coordinating Center.
NR 32
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-3758
J9 J STAT PLAN INFER
JI J. Stat. Plan. Infer.
PD OCT
PY 2012
VL 142
IS 10
BP 2819
EP 2831
DI 10.1016/j.jspi.2012.04.006
PG 13
WC Statistics & Probability
SC Mathematics
GA 964BH
UT WOS:000305668200007
PM 23805025
ER
PT J
AU Koenigsberg, HW
Yuan, PX
Diaz, GA
Guerreri, S
Dorantes, C
Mayson, S
Zamfirescu, C
New, AS
Goodman, M
Manji, HK
Siever, LJ
AF Koenigsberg, Harold W.
Yuan, Peixiong
Diaz, George A.
Guerreri, Stephanie
Dorantes, Christine
Mayson, Sarahjo
Zamfirescu, Constantin
New, Antonia S.
Goodman, Marianne
Manji, Husseini K.
Siever, Larry J.
TI Platelet protein kinase C and brain-derived neurotrophic factor levels
in borderline personality disorder patients
SO PSYCHIATRY RESEARCH
LA English
DT Article; Proceedings Paper
CT 66th Annual Meeting of the Society-of-Biological-Psychiatry
CY MAY 12-14, 2011
CL San Francisco, CA
SP Soc Biol Psychiat
DE PKC; BDNF; Neurotrophic factors; Second messengers; Personality
disorders; Borderline personality disorder
ID BIPOLAR AFFECTIVE-DISORDER; TEENAGE SUICIDE VICTIMS; POSTMORTEM BRAIN;
DEPRESSED-PATIENTS; MAJOR DEPRESSION; MOOD DISORDERS; EXPRESSION;
TRANSLOCATION; TRANSDUCTION; COMORBIDITY
AB Borderline personality disorder (BPD) is a prevalent and difficult to treat psychiatric condition characterized by abrupt mood swings, intense anger and depression, unstable interpersonal relationships, impulsive self-destructive behavior and a suicide rate of approximately 10%. Possible underlying molecular dysregulations in BPD have not been well explored. Protein kinase C (PKC) and brain-derived neurotrophic factor (BDNF) have both been implicated in affective disorders, but their role in BPD has not been examined. Platelets were isolated from blood obtained from 24 medication-free BPD patients and 18 healthy control subjects. PKC-alpha, phosphorylated-PKC-alpha (p-PKC alpha), PKC-beta II, and BDNF were measured in platelet homogenates by immunoblotting. In the males, platelet BDNF and PKC-alpha levels were lower in patients than controls. p-PKC-alpha and PKC-beta II were lower at trend levels. In the entire sample, platelet p-PKC alpha and PKC-alpha activity were lower, at a trend level, in patients compared to controls. This is the first report to our knowledge of PKC and BDNF activity in BPD and calls for replication. These findings are consistent with altered PKC and BDNF activity in a range of neuropsychiatric conditions including bipolar disorder, depression and suicide. Published by Elsevier Ireland Ltd.
C1 [Koenigsberg, Harold W.; Diaz, George A.; Guerreri, Stephanie; Dorantes, Christine; Mayson, Sarahjo; Zamfirescu, Constantin; New, Antonia S.; Goodman, Marianne; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Koenigsberg, Harold W.; New, Antonia S.; Goodman, Marianne; Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Yuan, Peixiong] NIMH, Bethesda, MD 20892 USA.
[Manji, Husseini K.] Johnson & Johnson Pharmaceut, New Brunswick, NJ USA.
RP Koenigsberg, HW (reprint author), Mental Hlth Patient Care Ctr, James J Peters VA Med Ctr, Mt Sinai Sch Med, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM HWarrenK@nyc.rr.com
FU Intramural NIH HHS; NCRR NIH HHS [5MO1RR00071, M01 RR000071]
NR 41
TC 7
Z9 7
U1 2
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD SEP 30
PY 2012
VL 199
IS 2
BP 92
EP 97
DI 10.1016/j.psychres.2012.04.026
PG 6
WC Psychiatry
SC Psychiatry
GA 056SC
UT WOS:000312510700003
PM 22633012
ER
PT J
AU McDermott, K
Maynard, C
Trivedi, R
Lowy, E
Fihn, S
AF McDermott, Kelly
Maynard, Charles
Trivedi, Ranak
Lowy, Elliott
Fihn, Stephan
TI Factors associated with presenting > 12 hours after symptom onset of
acute myocardial infarction among Veteran men
SO BMC CARDIOVASCULAR DISORDERS
LA English
DT Article
DE Veterans; Acute myocardial infarction; Time from symptom onset; Delayed
presentation
ID REPERFUSION THERAPY; HOSPITAL PRESENTATION; MISSED OPPORTUNITIES; TIME;
ANGIOPLASTY; IMPROVE; TRIAL; ARTERY; STEMI; DELAY
AB Background: Approximately 2/3 of Veterans admitting to Veterans Health Administration (VHA) facilities present >12 hours after symptom onset of acute myocardial infarction (AMI) ("late presenters"). Veterans admitted to VHA facilities with AMI may delay hospital presentation for different reasons compared to their general population counter parts. Despite the large descriptive literature on factors associated with delayed presentation in the general population, the literature describing these factors among the Veteran AMI population is limited. The purpose of this analysis is to identify predictors of late presentation in the Veteran population presenting with AMI to VHA facilities. Identifying predictors will help inform and target interventions for Veterans at a high risk of late presentation.
Methods: In our cross-sectional study, we analyzed a cohort of 335 male Veterans from nine VHA facilities with physician diagnosed AMI between April 2005 and December 2006. We compared demographics, presentation characteristics, medical history, perceptions of health, and access to health care between early and late presenting Veterans. We used standard descriptive statistics for bivariate comparisons and multivariate logistic regression to identify independent predictors of late presentation.
Results: Our cohort was an average of 64 +/- 10 years old and was 88% white. Sixty-eight percent of our cohort were late presenters. Bivariate comparisons found that fewer late presenters had attended at least some college or vocational school (late 53% vs. early 66%, p = 0.02). Multivariate analysis showed that presentation with ST-elevation myocardial infarction (STEMI) was associated with early presentation (OR = 0.4 95%CI [0.2, 0.9]) and >= 2 angina episodes in the prior 24 hours (versus 0-1 episode) was associated with late presentation (OR = 7.5 95%CI [3.6,15.6]).
Conclusions: A significant majority of Veterans presenting to VHA facilities with AMI were late presenters. We found few differences between early and late presenters. Having a STEMI was independently associated with early presentation and reporting >= 2 angina episodes in the 24 hours prior to hospital admission was independently associated with late presentation. These independent predictors of early and late presentation are similar to what has been reported for the general population. Despite these similarities to the general population, there may be untapped opportunities for patient education within the VHA to decrease late presentation.
C1 [McDermott, Kelly] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94115 USA.
[Maynard, Charles; Trivedi, Ranak; Lowy, Elliott; Fihn, Stephan] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev NW Ctr Excellence, Seattle, WA 98101 USA.
RP McDermott, K (reprint author), Univ Calif San Francisco, Osher Ctr Integrat Med, 1545 Divisadero St,3rd Floor,Box 1726, San Francisco, CA 94115 USA.
EM mcdermottk@ocim.ucsf.edu
RI Maynard, Charles/N-3906-2015
OI Maynard, Charles/0000-0002-1644-7814
FU AHRQ
FX This work was funded in part by an AHRQ dissertation grant awarded to
Dr. McDermott. The views expressed in this article are those of the
authors and do not necessarily represent the views of the Department of
Veterans Affairs
NR 25
TC 2
Z9 2
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2261
J9 BMC CARDIOVASC DISOR
JI BMC Cardiovasc. Disord.
PD SEP 28
PY 2012
VL 12
AR 82
DI 10.1186/1471-2261-12-82
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 044FJ
UT WOS:000311604500001
PM 23020779
ER
PT J
AU Lohavanichbutr, P
Houck, J
Doody, DR
Wang, P
Mendez, E
Futran, N
Upton, MP
Holsinger, FC
Schwartz, SM
Chen, C
AF Lohavanichbutr, Pawadee
Houck, John
Doody, David R.
Wang, Pei
Mendez, Eduardo
Futran, Neal
Upton, Melissa P.
Holsinger, F. Christopher
Schwartz, Stephen M.
Chen, Chu
TI Gene Expression in Uninvolved Oral Mucosa of OSCC Patients Facilitates
Identification of Markers Predictive of OSCC Outcomes
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; NECK-CANCER PATIENTS; CLINICAL-IMPLICATIONS;
HUMAN-PAPILLOMAVIRUS; FIELD CANCERIZATION; PROTEOMIC ANALYSIS;
RISK-ASSESSMENT; HEAD; HETEROZYGOSITY; SURVIVAL
AB Oral and oropharyngeal squamous cell carcinomas (OSCC) are among the most common cancers worldwide, with approximately 60% 5-yr survival rate. To identify potential markers for disease progression, we used Affymetrix U133 plus 2.0 arrays to examine the gene expression profiles of 167 primary tumor samples from OSCC patients, 58 uninvolved oral mucosae from OSCC patients and 45 normal oral mucosae from patients without oral cancer, all enrolled at one of the three University of Washington-affiliated medical centers between 2003 to 2008. We found 2,596 probe sets differentially expressed between 167 tumor samples and 45 normal samples. Among 2,596 probe sets, 71 were significantly and consistently up-or down-regulated in the comparison between normal samples and uninvolved oral samples and between uninvolved oral samples and tumor samples. Cox regression analyses showed that 20 of the 71 probe sets were significantly associated with progression-free survival. The risk score for each patient was calculated from coefficients of a Cox model incorporating these 20 probe sets. The hazard ratio (HR) associated with each unit change in the risk score adjusting for age, gender, tumor stage, and high-risk HPV status was 2.7 (95% CI: 2.0-3.8, p = 8.8E-10). The risk scores in an independent dataset of 74 OSCC patients from the MD Anderson Cancer Center was also significantly associated with progression-free survival independent of age, gender, and tumor stage (HR 1.6, 95% CI: 1.1-2.2, p = 0.008). Gene Set Enrichment Analysis showed that the most prominent biological pathway represented by the 71 probe sets was the Integrin cell surface interactions pathway. In conclusion, we identified 71 probe sets in which dysregulation occurred in both uninvolved oral mucosal and cancer samples. Dysregulation of 20 of the 71 probe sets was associated with progression-free survival and was validated in an independent dataset.
C1 [Lohavanichbutr, Pawadee; Houck, John; Doody, David R.; Schwartz, Stephen M.; Chen, Chu] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98104 USA.
[Wang, Pei] Fred Hutchinson Canc Res Ctr, Program Biostat & Biomath, Seattle, WA 98104 USA.
[Mendez, Eduardo; Futran, Neal; Chen, Chu] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.
[Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA.
[Mendez, Eduardo] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Upton, Melissa P.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Holsinger, F. Christopher] Univ Texas MD Anderson Canc Ctr, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA.
[Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98104 USA.
EM cchen@fhcrc.org
OI Schwartz, Stephen/0000-0001-7499-8502
FU National Institutes of Health, National Cancer Institute [NIH/NCI 5R01
CA095419]; Fred Hutchinson Cancer Research Center; Cancer Center Support
Core Grant [CA16672]; National Cancer Institute [P50 CA97007];
"Clinician Investigator Program in Translational Research" [K12
CA88084]; NIH Loan Repayment Program; Clinical Research Program [2 L30
CA117652-02A1]; THANC Foundation Young Investigator Award in Head and
Neck Cancer
FX The study was supported by grants from the National Institutes of
Health, National Cancer Institute (NIH/NCI 5R01 CA095419), and by
institutional funds from the Fred Hutchinson Cancer Research Center. The
study at the MD Anderson Cancer Center was supported by Cancer Center
Support Core Grant CA16672 (Affymetrix Microarray Core Facility; the
Bioinformatics Core), Specialized Program of Research Excellence in Head
and Neck Cancer Grant P50 CA97007 from the National Cancer Institute,
"Clinician Investigator Program in Translational Research" K12 CA88084,
NIH Loan Repayment Program, Clinical Research Program 2 L30
CA117652-02A1, and THANC Foundation Young Investigator Award in Head and
Neck Cancer. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 63
TC 11
Z9 11
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 28
PY 2012
VL 7
IS 9
AR e46575
DI 10.1371/journal.pone.0046575
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 022PZ
UT WOS:000309973900186
PM 23029552
ER
PT J
AU Siegel, JM
AF Siegel, Jerome M.
TI Suppression of Sleep for Mating
SO SCIENCE
LA English
DT Editorial Material
ID PERFORMANCE; DEPRIVATION
C1 [Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 91343 USA.
[Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 91343 USA.
RP Siegel, JM (reprint author), Univ Calif Los Angeles, Dept Psychiat, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 91343 USA.
EM jsiegel@ucla.edu
NR 14
TC 2
Z9 2
U1 0
U2 19
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD SEP 28
PY 2012
VL 337
IS 6102
BP 1610
EP 1611
DI 10.1126/science.1228466
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 012DJ
UT WOS:000309215400028
PM 23019635
ER
PT J
AU Graves, SS
Mathes, DW
Georges, GE
Kuhr, CS
Chang, J
Butts, TM
Storb, R
AF Graves, Scott S.
Mathes, David W.
Georges, George E.
Kuhr, Christian S.
Chang, Jeff
Butts, Tiffany M.
Storb, Rainer
TI Long-Term Tolerance to Kidney Allografts After Induced Rejection of
Donor Hematopoietic Chimerism in a Preclinical Canine Model
SO TRANSPLANTATION
LA English
DT Article
DE Dog; Nonmyeloablative conditioning regimen; Mixed hematopoietic
chimerism; Kidney allograft; Recipient lymphocyte infusion; Tolerance
ID TOTAL-BODY IRRADIATION; BONE-MARROW-TRANSPLANTATION; CELL
TRANSPLANTATION; HEMATOLOGIC MALIGNANCIES; MIXED CHIMERISM;
PHARMACOLOGICAL IMMUNOSUPPRESSION; OLDER PATIENTS; DLA; GRAFTS;
CYCLOSPORINE
AB Background. Allogeneic hematopoietic cell transplantation provides a reliable method for inducing tolerance toward solid organ grafts. However, this procedure can result in graft-versus-host disease, thereby limiting its application. Here, we test the hypothesis that mixed chimerism can be intentionally reverted to host hematopoiesis without rejection of a kidney graft.
Methods. Recipient dogs were given 2-Gy total-body irradiation (TBI) before and a short course of immunosuppression after marrow infusion from dog leukocyte antigen-identical littermates. All dogs achieved stable mixed chimerism. After a mean of 20 weeks, one cohort of dogs received kidney transplants from their respective marrow donors. Subsequently, recipients were reconditioned with 2-Gy TBI and given autologous granulocyte colony-stimulating factor-mobilized leukocytes (recipient leukocyte infusion [RLI]) that had been collected before marrow transplantation.
Results. Dogs receiving a second TBI and RLI without a kidney transplant rejected their donor hematopoietic graft within 3 weeks. Dogs that received kidney grafts, followed by a second TBI and RLI, rejected their marrow graft without rejecting their transplanted kidneys for periods greater than 1 year.
Conclusion. Mixed chimerism may be clinically reverted to 100% recipient without rejection of a kidney allograft. This finding may have application toward minimizing the risk of graft-versus-host disease in solid organ transplantation patients given hematopoietic cell transplantation from human leukocyte antigen-identical donors.
C1 [Graves, Scott S.; Mathes, David W.; Georges, George E.; Chang, Jeff; Butts, Tiffany M.; Storb, Rainer] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
[Graves, Scott S.; Georges, George E.; Storb, Rainer] Univ Washington, Dept Med, Seattle, WA USA.
[Mathes, David W.; Chang, Jeff] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
[Mathes, David W.] VA Puget Sound Hlth Care Syst, Plast Surg Serv, Seattle, WA USA.
[Kuhr, Christian S.] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
RP Graves, SS (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, POB 19024,D1-100, Seattle, WA 98109 USA.
EM sgraves@fhcrc.org
FU National Institutes of Health, Bethesda, MD [P01CA078902, P30CA015704];
National Endowment for Plastic Surgery Grant from the Plastic Surgery
Educational Foundation
FX This work was supported by grant numbers P01CA078902 and P30CA015704
from the National Institutes of Health, Bethesda, MD, and a National
Endowment for Plastic Surgery Grant from the Plastic Surgery Educational
Foundation (to D.W.M.).
NR 31
TC 9
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD SEP 27
PY 2012
VL 94
IS 6
BP 562
EP 568
DI 10.1097/TP.0b013e3182646bf1
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 012GD
UT WOS:000309223100008
PM 22929594
ER
PT J
AU Prasad, R
Katiyar, SK
AF Prasad, Ram
Katiyar, Santosh K.
TI Bioactive Phytochemical Proanthocyanidins Inhibit Growth of Head and
Neck Squamous Cell Carcinoma Cells by Targeting Multiple Signaling
Molecules
SO PLOS ONE
LA English
DT Article
ID FACTOR RECEPTOR; DEPENDENT KINASES; INDUCE APOPTOSIS; INK4 INHIBITORS;
CYCLE CONTROL; BCL-2 FAMILY; HUMAN CANCER; ORAL-CANCER; GRAPE SEEDS;
THERAPY
AB Despite advances in surgical and medical therapies, approximate 50% survival rate of head and neck squamous cell carcinoma (HNSCC) has had marginal improvement in the last 30 years. Therefore, alternative strategies are required for the management of HNSCC. Here, we report the chemotherapeutic effect of proanthocyanidins on HNSCC cells using in vitro and in vivo models. Treatment of human HNSCC cell lines from different sub-sites, such as oral cavity (SCC1), larynx (SCC5), tongue (OSC19) and pharynx (FaDu), with grape seed proanthocyanidins (GSPs) reduced their cell viability and induced cell death in a dose-and time-dependent manner. GSPs induced inhibition of cell viability was associated with: (i) G1-phase arrest, (ii) inhibition of expressions of cyclins (cyclin D1 and Cyclin D2) and cyclin-dependent kinases (Cdk), (iii) increased expression of the Cdk inhibitory proteins (Cip1/p21, Kip1/p27), enhanced binding of Cdk inhibitors to Cdks, and downregulation of E2F transcription factor. GSPs significantly (P<0.05-0.001) increased apoptosis of SCC1 and OSC19 cells with induction of Bax, reduced expression of Bcl-2, and activation of caspase-3. GSPs also reduced the expression of epidermal growth factor receptor (EGFR), and treatment of SCC1 cells with erlotinib, an EGFR-targeting small molecule tyrosine kinase inhibitor, significantly (P<0.05-0.001) reduced cell viability and increased cell death. Dietary administration of GSPs (0.5%, w/w) in supplementation with AIN76A control diet inhibited the growth of SCC1 tumor xenografts in athymic nude mice, which was associated with: (i) inhibition of cell proliferation, (ii) induction of apoptosis of tumor xenograft cells, (iii) decreased expression of cyclins and Cdks, (iv) decreased expression of EGFR, and (v) increased expression of Cip1/p21 and Kip1/p27 proteins and their increased binding to Cdks in tumor xenograft samples. Together, these results suggest that GSPs may be a promising candidate for head and neck squamous cell carcinoma therapy.
C1 [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
EM skatiyar@uab.edu
FU Veterans Administration
FX This work was supported by funds from the Veterans Administration Merit
Review Award (SKK). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 45
TC 15
Z9 15
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 26
PY 2012
VL 7
IS 9
AR e46404
DI 10.1371/journal.pone.0046404
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 016KP
UT WOS:000309517300115
PM 23050025
ER
PT J
AU Waxman, DA
AF Waxman, Daniel A.
TI Worlds Apart
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
C1 [Waxman, Daniel A.] RAND Corp, Pardee RAND Grad Sch, Santa Monica, CA 90406 USA.
[Waxman, Daniel A.] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
RP Waxman, DA (reprint author), RAND Corp, Pardee RAND Grad Sch, Santa Monica, CA 90406 USA.
EM dwaxman@rand.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD SEP 26
PY 2012
VL 308
IS 12
BP 1219
EP 1220
DI 10.1001/jama.2012.9980
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 010OK
UT WOS:000309103600024
PM 23011711
ER
PT J
AU Lipsky, BA
Moran, GJ
Napolitano, LM
Vo, L
Nicholson, S
Kim, M
AF Lipsky, Benjamin A.
Moran, Gregory J.
Napolitano, Lena M.
Vo, Lien
Nicholson, Susan
Kim, Myoung
TI A prospective, multicenter, observational study of complicated skin and
soft tissue infections in hospitalized patients: clinical
characteristics, medical treatment, and outcomes
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Complicated skin and soft tissue infections; Prospective observational
study; Diabetic foot infection; Abscess; Surgical site infection;
Cellulitis
ID RESISTANT STAPHYLOCOCCUS-AUREUS; DIABETIC FOOT ULCERS; ACUTE BACTERIAL
SKIN; ANTIMICROBIAL THERAPY; WOUND SCORE; TRIAL; VANCOMYCIN; MORTALITY;
PEXIGANAN; SIDESTEP
AB Background: Complicated skin and soft tissue infections (cSSTIs) occur frequently, but limited data do not allow any consensus on an optimal treatment strategy. We designed this prospective, multicenter, observational study to to explore the current epidemiology, treatment, and resulting clinical outcomes of cSSTIs to help develop strategies to potentially improve outcomes.
Methods: From June 2008 to December 2009 we enrolled a pre-specified number of adults treated in 56 U.S. hospitals with intravenous antibiotic(s) for any of the following cSSTIs: diabetic foot infection (DFI); surgical site infection (SSI); deep soft tissue abscess (DSTA); or, cellulitis. Investigators treated all patients per their usual practice during the study and collected data on a standardized form.
Results: We enrolled 1,033 patients (DFI 27%; SSI 32%; DSTA 14%; cellulitis 27%; mean age 54 years; 54% male), of which 74% had healthcare-associated risk factors. At presentation, 89% of patients received initial empiric therapy with intravenous antibiotics; similar to 20% of these patients had this empiric regimen changed or discontinued based on culture and sensitivity results. Vancomycin was the most frequently used initial intravenous antibiotic, ordered in 61% of cases. During their stay 44% of patients underwent a surgical procedure related to the study infection, usually incision and drainage or debridement. The mean length of stay was 7.1 days, ranging from 5.8 (DSTA) to 8.1 (SSI).
Conclusion: Our findings from this large prospective observational study that characterized patients with cSSTIs from diverse US inpatient populations provide useful information on the current epidemiology, clinical management practices and outcomes of this common infection.
C1 [Lipsky, Benjamin A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Lipsky, Benjamin A.] Univ Washington, Seattle, WA 98195 USA.
[Lipsky, Benjamin A.] VA Puget Sound HCS S GMS 123, Seattle, WA 98108 USA.
[Moran, Gregory J.] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA.
[Napolitano, Lena M.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Vo, Lien; Nicholson, Susan; Kim, Myoung] LLC, Janssen Sci Affairs, Raritan, NJ USA.
[Lipsky, Benjamin A.] 79 Stone Meadow, Oxford OX2 6TD, England.
RP Lipsky, BA (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA.
EM dblipsky@hotmail.com
OI Lipsky, Benjamin A./0000-0001-9886-5114
FU Janssen Scientific Affairs, LLC, Raritan, NJ, USA
FX The work was supported by Janssen Scientific Affairs, LLC, Raritan, NJ,
USA.
NR 27
TC 14
Z9 14
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD SEP 25
PY 2012
VL 12
AR 227
DI 10.1186/1471-2334-12-227
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 060KI
UT WOS:000312776100001
PM 23009247
ER
PT J
AU Selby, VN
Scherzer, R
Barnett, CF
MacGregor, JS
Morelli, J
Donovan, C
Deeks, SG
Martin, JN
Hsue, PY
AF Selby, Van N.
Scherzer, Rebecca
Barnett, Christopher F.
MacGregor, John S.
Morelli, Juliana
Donovan, Catherine
Deeks, Steven G.
Martin, Jeffrey N.
Hsue, Priscilla Y.
TI Doppler echocardiography does not accurately estimate pulmonary artery
systolic pressure in HIV-infected patients
SO AIDS
LA English
DT Article
ID HYPERTENSION; DIAGNOSIS
AB Doppler echocardiography is used to screen for HIV-related pulmonary arterial hypertension (HRPAH). We studied patients with HIV infection to determine the accuracy of Doppler echocardiography-estimated pulmonary artery systolic pressure (PASP) compared with PASP measured during right heart catheterization. Doppler echocardiography-estimated PASP was inaccurate in 19.7% of cases. Using Doppler echocardiography-estimated PASP, one in three patients with HRPAH was missed. Doppler echocardiography estimates of PASP are not accurate in patients with HIV.
C1 [Selby, Van N.; Barnett, Christopher F.; MacGregor, John S.; Morelli, Juliana; Donovan, Catherine; Hsue, Priscilla Y.] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA.
[Deeks, Steven G.; Martin, Jeffrey N.] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA.
[Deeks, Steven G.; Martin, Jeffrey N.] San Francisco Gen Hosp, Posit Hlth Program, Dept Med, San Francisco, CA 94110 USA.
[Martin, Jeffrey N.] Univ Calif San Francisco, Dept Biostat & Epidemiol, San Francisco, CA 94143 USA.
[Scherzer, Rebecca] San Francisco VA Med Ctr, Div Endocrinol & Metab, San Francisco, CA USA.
RP Hsue, PY (reprint author), San Francisco Gen Hosp, Div Cardiol, Room 5G1,1001 Potrero Ave, San Francisco, CA 94110 USA.
EM phsue@medsfgh.ucsf.edu
FU NIH [R01HL091526, R01 AI052745, R01 CA119903, P30 AI27763, MO1
RR000083]; Actelion; Gilead
FX The work was supported in part by grants from the NIH (R01HL091526, R01
AI052745, R01 CA119903, P30 AI27763 and MO1 RR000083), and Actelion.
Registration site: www.clinicaltrials.gov, study number: NCT00845013.;
P.Y.H. has been the recipient of an investigator-initiated award from
Actelion and consulting fees from Gilead. There are no other conflicts
of interest.
NR 8
TC 15
Z9 16
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD SEP 24
PY 2012
VL 26
IS 15
BP 1967
EP 1969
DI 10.1097/QAD.0b013e3283579653
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 012GN
UT WOS:000309224100014
PM 22781217
ER
PT J
AU Berkowitz, SA
Johansen, KL
AF Berkowitz, Seth A.
Johansen, Kirsten L.
TI Behavioral Medicine Trial Design: Time for a Change reply
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Berkowitz, Seth A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA.
RP Berkowitz, SA (reprint author), Univ Calif San Francisco, Dept Med, 1545 Divisidero St,POB 0320, San Francisco, CA 94143 USA.
EM Seth.Berkowitz@ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD SEP 24
PY 2012
VL 172
IS 17
BP 1351
EP 1351
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 010FE
UT WOS:000309079300019
ER
PT J
AU Srinivasan, S
Simms, JA
Nielsen, CK
Lieske, SP
Bito-Onon, JJ
Yi, H
Hopf, FW
Bonci, A
Bartlett, SE
AF Srinivasan, Subhashini
Simms, Jeffrey A.
Nielsen, Carsten K.
Lieske, Steven P.
Bito-Onon, Jade J.
Yi, Henry
Hopf, Frederic Woodward
Bonci, Antonello
Bartlett, Selena E.
TI The Dual Orexin/Hypocretin Receptor Antagonist, Almorexant, in the
Ventral Tegmental Area Attenuates Ethanol Self-Administration
SO PLOS ONE
LA English
DT Article
ID LONG-EVANS RATS; ALCOHOL DEPENDENCE; INDUCED REINSTATEMENT; OREXIN-A;
MESOLIMBIC DOPAMINE; NALTREXONE RESPONSE; REWARD-SEEKING; FOOD-INTAKE;
NEURONS; INVOLVEMENT
AB Recent studies have implicated the hypocretin/orexinergic system in reward-seeking behavior. Almorexant, a dual orexin/hypocretin R-1 and R-2 receptor antagonist, has proven effective in preclinical studies in promoting sleep in animal models and was in Phase III clinical trials for sleep disorders. The present study combines behavioral assays with in vitro biochemical and electrophysiological techniques to elucidate the role of almorexant in ethanol and sucrose intake. Using an operant self-administration paradigm, we demonstrate that systemic administration of almorexant decreased operant self-administration of both 20% ethanol and 5% sucrose. We further demonstrate that intra-ventral tegmental area (VTA) infusions, but not intra-substantia nigra infusions, of almorexant reduced ethanol self-administration. Extracellular recordings performed in VTA neurons revealed that orexin-A increased firing and this enhancement of firing was blocked by almorexant. The results demonstrate that orexin/hypocretin receptors in distinct brain regions regulate ethanol and sucrose mediated behaviors.
C1 [Srinivasan, Subhashini; Simms, Jeffrey A.; Nielsen, Carsten K.; Lieske, Steven P.; Bito-Onon, Jade J.; Yi, Henry; Hopf, Frederic Woodward; Bartlett, Selena E.] Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Emeryville, CA USA.
[Bartlett, Selena E.] Queensland Univ Technol, Translat Res Inst, Brisbane, Qld 4001, Australia.
[Bonci, Antonello] NIDA, Intramural Res Program, Baltimore, MD USA.
[Bonci, Antonello] Univ Calif San Francisco, Dept Neurol, Emeryville, CA USA.
[Bonci, Antonello] Johns Hopkins Univ, Solomon Snyder Dept Neurosci, Baltimore, MD USA.
[Lieske, Steven P.] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA.
RP Bartlett, SE (reprint author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Emeryville, CA USA.
EM selena.bartlett@qut.edu.au
RI Bartlett, Selena/J-1345-2012
OI Bartlett, Selena/0000-0002-1741-3958
FU Department of Defense, TATRC grant [W81XWH-10-1-0247]; state funding for
medical research through UCSF
FX The research was carried out with the help of Department of Defense,
TATRC grant W81XWH-10-1-0247 (www.tatrc.org) awarded to S. E. B. and A.
B. and the state funding for medical research through UCSF to S. E. B.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 60
TC 19
Z9 20
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 21
PY 2012
VL 7
IS 9
AR e44726
DI 10.1371/journal.pone.0044726
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 014RG
UT WOS:000309392800013
PM 23028593
ER
PT J
AU Xiong, GX
Zhang, L
Mojsilovic-Petrovic, J
Arroyo, E
Elkind, J
Kundu, S
Johnson, B
Smith, CJ
Cohen, NA
Grady, SM
Cohen, AS
AF Xiong, Guoxiang
Zhang, Lei
Mojsilovic-Petrovic, Jelena
Arroyo, Edguardo
Elkind, Jaclynn
Kundu, Suhali
Johnson, Brian
Smith, Colin J.
Cohen, Noam A.
Grady, Sean M.
Cohen, Akiva S.
TI GABA and glutamate are not colocalized in mossy fiber terminals of
developing rodent hippocampus
SO BRAIN RESEARCH
LA English
DT Article
DE Granule cell; Vesicular glutamate transporter; Vesicular GABA
transporter; Immunofluorescence; Synaptic button
ID GRANULE CELLS; DENTATE GYRUS; RAT HIPPOCAMPUS; GABAERGIC PHENOTYPE;
IMMUNOHISTOCHEMICAL LOCALIZATION; VESICULAR GLUTAMATE; TRANSPORTER
EAAC1; MESSENGER-RNA; DECARBOXYLASE; EXPRESSION
AB It has been hypothesized that, in the developing rodent hippocampus, mossy fiber terminals release GABA together with glutamate. Here, we used transgenic glutamic acid decarboxylase-67 (GAD67)-GFP expressing mice and multi-label immunohistochemistry to address whether glutamatergic and GABAergic markers are colocalized. We demonstrate that in the dentate gyrus, interneurons positive for GABA/GAD are sparsely distributed along the edge of the hilus, in a different pattern from that of the densely packed granule cells. Co-staining for synaptophysin and vesicular glutamate transporter1 (VGLUT1) in postnatal day 14 brain sections from both mice and rats showed mossy fiber terminals as a group of large (2-5 mu m in diameter) VGLUT1-positive excitatory presynaptic terminals in the stratum lucidum of area CA3a/b. Furthermore, co-staining for synaptophysin and vesicular GABA transporter (VGAT) revealed a group of small-sized (similar to 0.5 mu m in diameter) inhibitory presynaptic terminals in the same area where identified mossy fiber terminals were present. The two types of terminals appeared to be mutually exclusive, and showed no colocalization. Thus, our results do not support the hypothesis that GABA is released as a neurotransmitter from mossy fiber terminals during development. Published by Elsevier B.V.
C1 [Xiong, Guoxiang] Childrens Hosp Philadelphia, Dept Neurol, Div Neurol, Philadelphia, PA 19104 USA.
[Arroyo, Edguardo; Grady, Sean M.; Cohen, Akiva S.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.
[Cohen, Akiva S.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Xiong, GX (reprint author), Childrens Hosp Philadelphia, Dept Neurol, Div Neurol, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM xiong@email.chop.edu
OI Cohen, Noam/0000-0002-9462-3932
FU National Institutes of Health [HD059288, NS069629]
FX The authors thank Dr. Michael Schell for his invaluable suggestions on
the manuscript. This work was supported by grants from the National
Institutes of Health (HD059288 and NS069629 to A.S.C.).
NR 36
TC 5
Z9 7
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD SEP 20
PY 2012
VL 1474
BP 40
EP 49
DI 10.1016/j.brainres.2012.07.042
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 011FL
UT WOS:000309150300005
PM 22842523
ER
PT J
AU Koul, S
Khandrika, L
Meacham, RB
Koul, HK
AF Koul, Sweaty
Khandrika, Lakshmipathi
Meacham, Randall B.
Koul, Hari K.
TI Genome Wide Analysis of Differentially Expressed Genes in HK-2 Cells, a
Line of Human Kidney Epithelial Cells in Response to Oxalate
SO PLOS ONE
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; CALCIUM-OXALATE; LLC-PK1 CELLS; DNA-SYNTHESIS;
CRYSTAL RETENTION; MICROARRAY DATA; TRANSPORT; PATHWAYS; EXPOSURE;
PROLIFERATION
AB Nephrolithiasis is a multi-factorial disease which, in the majority of cases, involves the renal deposition of calcium oxalate. Oxalate is a metabolic end product excreted primarily by the kidney. Previous studies have shown that elevated levels of oxalate are detrimental to the renal epithelial cells; however, oxalate renal epithelial cell interactions are not completely understood. In this study, we utilized an unbiased approach of gene expression profiling using Affymetrix HG_U133_plus2 gene chips to understand the global gene expression changes in human renal epithelial cells [HK-2] after exposure to oxalate. We analyzed the expression of 47,000 transcripts and variants, including 38,500 well characterized human genes, in the HK2 cells after 4 hours and 24 hours of oxalate exposure. Gene expression was compared among replicates as per the Affymetrix statistical program. Gene expression among various groups was compared using various analytical tools, and differentially expressed genes were classified according to the Gene Ontology Functional Category. The results from this study show that oxalate exposure induces significant expression changes in many genes. We show for the first time that oxalate exposure induces as well as shuts off genes differentially. We found 750 up-regulated and 2276 down-regulated genes which have not been reported before. Our results also show that renal cells exposed to oxalate results in the regulation of genes that are associated with specific molecular function, biological processes, and other cellular components. In addition we have identified a set of 20 genes that is differentially regulated by oxalate irrespective of duration of exposure and may be useful in monitoring oxalate nephrotoxicity. Taken together our studies profile global gene expression changes and provide a unique insight into oxalate renal cell interactions and oxalate nephrotoxicity.
C1 [Koul, Sweaty; Khandrika, Lakshmipathi; Meacham, Randall B.; Koul, Hari K.] Univ Colorado, Signal Transduct & Mol Urol Lab, Sch Med, Div Urol,Dept Surg,Program Urosci, Aurora, CO USA.
[Koul, Hari K.] Univ Colorado, Ctr Comprehens Canc, Sch Med, Aurora, CO USA.
[Koul, Hari K.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Koul, HK (reprint author), Univ Colorado, Signal Transduct & Mol Urol Lab, Sch Med, Div Urol,Dept Surg,Program Urosci, Aurora, CO USA.
EM hari.koul@uchsc.edu
FU National Institutes of Health (NIH) [NIH-DK-RO1-54084]; Department of
Surgery Academic Enrichment Funds; VA Merit Award [01BX001258];
NIH/National Cancer Institute [R01CA161880]
FX This work was supported in part by a research grant to Hari K. Koul from
the National Institutes of Health (NIH) (NIH-DK-RO1-54084) and
Department of Surgery Academic Enrichment Funds (HKK). HKK is also
supported in part by VA Merit Award-01BX001258 and NIH/National Cancer
Institute R01CA161880 grants. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 34
TC 6
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2012
VL 7
IS 9
AR e43886
DI 10.1371/journal.pone.0043886
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 014PP
UT WOS:000309388400013
PM 23028475
ER
PT J
AU Kaddurah-Daouk, R
Yuan, PX
Boyle, SH
Matson, W
Wang, Z
Zeng, ZB
Zhu, HJ
Dougherty, GG
Yao, JK
Chen, G
Guitart, X
Carlson, PJ
Neumeister, A
Zarate, C
Krishnan, RR
Manji, HK
Drevets, W
AF Kaddurah-Daouk, Rima
Yuan, Peixiong
Boyle, Stephen H.
Matson, Wayne
Wang, Zhi
Zeng, Zhao Bang
Zhu, Hongjie
Dougherty, George G.
Yao, Jeffrey K.
Chen, Guang
Guitart, Xavier
Carlson, Paul J.
Neumeister, Alexander
Zarate, Carlos
Krishnan, Ranga R.
Manji, Husseini K.
Drevets, Wayne
TI Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a
Unique Metabolic Profile
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MAJOR DEPRESSIVE DISORDER; GLOBAL BIOCHEMICAL APPROACH; CSF MONOAMINE
METABOLITES; PARKINSONS-DISEASE; OXIDATIVE STRESS; ANTIDEPRESSANT
TREATMENT; PSYCHIATRIC-DISORDERS; SEROTONIN TRANSPORTER;
S-ADENOSYLMETHIONINE; BIPOLAR DISORDER
AB Targeted metabolomics provides an approach to quantify metabolites involved in specific molecular pathways. We applied an electrochemistry-based, targeted metabolomics platform to define changes in tryptophan, tyrosine, purine and related pathways in the depressed and remitted phases of major depressive disorder (MDD). Biochemical profiles in the cerebrospinal fluid of unmedicated depressed (n=14; dMDD) or remitted MDD subjects (n=14; rMDD) were compared against those in healthy controls (n=18; HC). The rMDD group showed differences in tryptophan and tyrosine metabolism relative to the other groups. The rMDD group also had higher methionine levels and larger methionine-to-glutathione ratios than the other groups, implicating methylation and oxidative stress pathways. The dMDD sample showed nonsignificant differences in the same direction in several of the metabolic branches assessed. The reductions in metabolites associated with tryptophan and tyrosine pathways in rMDD may relate to the vulnerability this population shows for developing depressive symptoms under tryptophan or catecholamine depletion.
C1 [Kaddurah-Daouk, Rima; Boyle, Stephen H.; Krishnan, Ranga R.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC 27710 USA.
[Yuan, Peixiong; Chen, Guang; Guitart, Xavier; Carlson, Paul J.; Neumeister, Alexander; Zarate, Carlos; Manji, Husseini K.; Drevets, Wayne] NIMH, NIH, Intramural Res Program, Bethesda, MD 20892 USA.
[Matson, Wayne] Bedford VA Med Ctr, Dept Syst Biochem, Bedford, MA USA.
[Wang, Zhi; Zeng, Zhao Bang; Zhu, Hongjie] N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA.
[Wang, Zhi; Zeng, Zhao Bang; Zhu, Hongjie] N Carolina State Univ, Bioinformat Res Ctr, Raleigh, NC 27695 USA.
[Dougherty, George G.; Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Dougherty, George G.; Yao, Jeffrey K.] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Krishnan, Ranga R.] Duke NUS Grad Med Sch, Singapore, Singapore.
[Drevets, Wayne] Univ Oklahoma, Laureate Inst Brain Res, Tulsa, OK USA.
[Drevets, Wayne] Univ Oklahoma, Dept Psychiat, Tulsa, OK USA.
RP Kaddurah-Daouk, R (reprint author), Duke Univ, Dept Psychiat & Behav Sci, Durham, NC 27710 USA.
EM Kaddu001@mc.duke.edu
RI yuan, tao/Q-3137-2016; Chen, Guang/A-2570-2017
OI yuan, tao/0000-0002-0904-9770;
FU NIH [R24 GM078233]; Department of Veterans Affairs Senior Research
Scientist Award; Amgen; Bristol-Myers Squibb; CeNeRx; Corcept;
GlaxoSmithKline; Johnson Johnson; Lundbeck; Merck; Organon; Pfizer;
Sepracor; Wyeth; Rules Based Medicine; Eisai; Abbott
FX This research was supported in part by funding from NIH R24 GM078233,
"The Metabolomics Research Network" (R.K.-D.) and the Department of
Veterans Affairs Senior Research Scientist Award (JKY). Earle Bain, M.D.
performed many of the lumbar punctures. Michele Drevets, Ruth Tinsley
and other clinical staff at Mood and Anxiety Disorder Program of NIMH
assisted with patient recruitment and evaluation, and contributed to
collecting and storing the CSF samples. The contents of this article do
not represent the views of the Department of VeteransAffairs or the
United States Government.; Rima Kaddurah-Daouk is equity holder in
Metabolon Inc., a biotechnology company in the metabolomics domain, and
also an inventor on patents in the metabolomics field. She has received
funding or consultancy fees for BMS, Pfizer Inc., AstraZeneca and
Lundbeck. George G. Dougherty owns shares of Pfizer and Merck. Carlos
Zarate is listed as a co-inventor on a patent for the use of ketamine in
major depression. Dr. Zarate has assigned his patent rights on ketamine
to the U.S. government. Ranga R Krishnan has received consultancy fees
from Amgen, Bristol-Myers Squibb, CeNeRx, Corcept, GlaxoSmithKline,
Johnson & Johnson, Lundbeck, Merck, Organon, Pfizer, Sepracor, and
Wyeth. Wayne Drevets has received consultancy fees from Pfizer, Rules
Based Medicine, Eisai, Abbott, and Johnson & Johnson, and has a use
patent filed on scopolamine in the treatment of depression. Peixiong
Yuan, Stephen H. Boyle, Wayne Matson, Zhi Wang, Zhao-bang Zeng, Hongjie
Zhu, Jeffrey Yao, Guang Chen, Xavier Guitart, Paul J. Carlson, Alexander
Neumeister, and Husseini K. Manji have no relevant financial interests
to disclose.
NR 79
TC 17
Z9 18
U1 1
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 19
PY 2012
VL 2
AR 667
DI 10.1038/srep00667
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 007BI
UT WOS:000308863400001
PM 22993692
ER
PT J
AU Prochazka, AV
Caverly, TJ
AF Prochazka, Allan V.
Caverly, T. J.
TI Review: Varenicline is better than bupropion but not nicotine patch for
smoking abstinence in adults
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID METAANALYSIS; CESSATION; RISK
RP Prochazka, AV (reprint author), Denver VA Med Ctr, Denver, CO USA.
NR 4
TC 1
Z9 1
U1 1
U2 2
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD SEP 18
PY 2012
VL 157
IS 6
AR JC3-7
DI 10.7326/0003-4819-157-6-201209180-02007
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 007UB
UT WOS:000308912800006
PM 22986399
ER
PT J
AU Lee, HJ
Feliers, D
Mariappan, M
Sataranatarajan, K
Choudhury, GG
Kasinath, B
AF Lee, Hak Joo
Feliers, Denis
Mariappan, Meenalakshmi
Sataranatarajan, Kavithalakshmi
Choudhury, Goutam Ghosh
Kasinath, Balakuntalam
TI The vascular effect of zofenopril, a sulfhydrylated ACE inhibitor,
involves L-cys/H2S pathway
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Meeting Abstract
CT 2nd International Conference on H2S Biology and Medicine
CY SEP 20-22, 2012
CL Atlanta, GA
SP Emory Univ Hosp, Carlyle Fraser Heart Crt, Sulfagenix, Inc, McMaster Univ, Farncombe Family Digest Hlth Res Inst, Fondazione Ricerca Sci Termale (FoRST), Chugai Pharmaceut Co., Ltd, Taiyo Instruments, Inc, Daiichi-Sankyo Pharmaceut, Amer Heart Assoc Basic Cardiovasc Sci, Merck
C1 [Lee, Hak Joo; Feliers, Denis; Mariappan, Meenalakshmi; Sataranatarajan, Kavithalakshmi; Choudhury, Goutam Ghosh; Kasinath, Balakuntalam] Univ Texas Hlth Sci Ctr, San Antonio, TX 78229 USA.
[Lee, Hak Joo; Mariappan, Meenalakshmi; Choudhury, Goutam Ghosh; Kasinath, Balakuntalam] S Texas Vet Healthcare Syst, Med, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD SEP 15
PY 2012
VL 27
SU 2
MA P16
BP S18
EP S19
DI 10.1016/j.niox.2012.08.017
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 018WA
UT WOS:000309696300017
ER
PT J
AU Huber, AK
Finkelman, FD
Li, CW
Concepcion, E
Smith, E
Jacobson, E
Latif, R
Keddache, M
Zhang, W
Tomer, Y
AF Huber, Amanda K.
Finkelman, Fred D.
Li, Cheuk Wun
Concepcion, Erlinda
Smith, Eric
Jacobson, Eric
Latif, Rauf
Keddache, Mehdi
Zhang, Weijia
Tomer, Yaron
TI Genetically Driven Target Tissue Overexpression of CD40: A Novel
Mechanism in Autoimmune Disease
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SINGLE-NUCLEOTIDE POLYMORPHISM; RHEUMATOID SYNOVIAL FIBROBLASTS;
GRAVES-DISEASE; THYROTROPIN RECEPTOR; 5'-UNTRANSLATED REGION; CYTOKINE
SECRETION; C/T POLYMORPHISM; CELLS; EXPRESSION; GENE
AB The CD40 gene, an important immune regulatory gene, is also expressed and functional on nonmyeloid-derived cells, many of which are targets for tissue-specific autoimmune diseases, including beta cells in type 1 diabetes, intestinal epithelial cells in Crohn's disease, and thyroid follicular cells in Graves' disease (GD). Whether target tissue CD40 expression plays a role in autoimmune disease etiology has yet to be determined. In this study, we show that target tissue overexpression of CD40 plays a key role in the etiology of autoimmunity. Using a murine model of GD, we demonstrated that thyroidal CD40 overexpression augmented the production of thyroid-specific Abs, resulting in more severe experimental autoimmune GD (EAGD), whereas deletion of thyroidal CD40 suppressed disease. Using transcriptome and immune-pathway analyses, we showed that in both EAGD mouse thyroids and human primary thyrocytes, CD40 mediates this effect by activating downstream cytokines and chemokines, most notably IL-6. To translate these findings into therapy, we blocked IL-6 during EAGD induction in the setting of thyroidal CD40 overexpression and showed decreased levels of thyroid stimulating hormone receptor-stimulating Abs and frequency of disease. We conclude that target tissue overexpression of CD40 plays a key role in the etiology of organ-specific autoimmune disease. The Journal of Immunology, 2012, 189:3043-3053.
C1 [Huber, Amanda K.; Li, Cheuk Wun; Concepcion, Erlinda; Zhang, Weijia; Tomer, Yaron] Mt Sinai Sch Med, Div Endocrinol, New York, NY 10029 USA.
[Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH 45220 USA.
[Smith, Eric; Jacobson, Eric] Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH 45267 USA.
[Latif, Rauf] Bronx Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Keddache, Mehdi] Cincinnati Childrens Hosp, Med Ctr, Genome Ctr, Cincinnati, OH 45229 USA.
RP Huber, AK (reprint author), Taubman Biomedical Sci Res Bldg,Room 4248,109 Zin, Ann Arbor, MI 48109 USA.
EM hubera@umich.edu
FU National Institutes of Health [DK61659, DK067555, DK073681]; Department
of Veterans Affairs funds
FX This work was supported in part by Grants DK61659, DK067555, and
DK073681 from the National Institutes of Health and by Department of
Veterans Affairs funds (to Y.T.).
NR 46
TC 18
Z9 20
U1 1
U2 9
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD SEP 15
PY 2012
VL 189
IS 6
BP 3043
EP 3053
DI 10.4049/jimmunol.1200311
PG 11
WC Immunology
SC Immunology
GA 004RK
UT WOS:000308698600040
PM 22888137
ER
PT J
AU Tattevin, P
Schwartz, BS
Graber, CJ
Volinski, J
Bhukhen, A
Bhukhen, A
Mai, TT
Vo, NH
Dang, DN
Phan, TH
Basuino, L
Perdreau-Remington, F
Chambers, HF
Diep, BA
AF Tattevin, Pierre
Schwartz, Brian S.
Graber, Christopher J.
Volinski, Joann
Bhukhen, Akta
Bhukhen, Arti
Mai, Thuy T.
Vo, Nhung H.
Dang, Denise N.
Tiffany HaiVan Phan
Basuino, Li
Perdreau-Remington, Francoise
Chambers, Henry F.
Binh An Diep
TI Concurrent Epidemics of Skin and Soft Tissue Infection and Bloodstream
Infection Due to Community-Associated Methicillin-Resistant
Staphylococcus aureus
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID UNITED-STATES; MOLECULAR EPIDEMIOLOGY; CHANGING EPIDEMIOLOGY;
SAN-FRANCISCO; CLONE USA300; BACTEREMIA; EMERGENCE; HOSPITALS; SEQUENCE;
STRAINS
AB Background. Since its emergence in 2000, epidemic spread of the methicillin-resistant Staphylococcus aureus (MRSA) clone USA300 has led to a high burden of skin and soft tissue infections (SSTIs) in the United States, yet its impact on MRSA bloodstream infections (BSIs) is poorly characterized.
Methods. To assess clonality of the MRSA isolates causing SSTI and BSI during the epidemic period, a stratified, random sample of 1350 unique infection isolates (from a total of 7252) recovered at the Community Health Network of San Francisco from 2000 to 2008 were selected for genotyping. Risk factors and outcomes for 549 BSI cases caused by the USA300 epidemic clone and non-USA300 MRSA clones were assessed by retrospective review of patient medical records.
Results. From 2000 to 2008, secular trends of USA300 SSTI and USA300 BSI were strongly correlated (Pearson r = 0.953). USA300 accounted for 55% (304/549) of BSIs as it was the predominant MRSA clone that caused community-associated (115/160), healthcare-associated community-onset (125/207), and hospital-onset (64/182) BSIs. Length of hospitalization after BSI diagnosis and mortality rates for USA300 and non-USA300 were similar. Two independent risk factors for USA300 BSI were identified: concurrent SSTI (adjusted relative risk, 1.4 [95% confidence interval {CI}, 1.2-1.6]) and anti-MRSA antimicrobial use in the preceding 30 days (0.7 [95% CI, .6-.8]). Isolates from concurrent SSTI were indistinguishable genotypically from the USA300 isolates that caused BSI.
Conclusions. USA300 SSTIs serve as a source for BSI. Strategies to control the USA300 SSTI epidemic may lessen the severity of the concurrent USA300 BSI epidemic.
C1 [Tattevin, Pierre; Schwartz, Brian S.; Volinski, Joann; Bhukhen, Akta; Bhukhen, Arti; Mai, Thuy T.; Vo, Nhung H.; Dang, Denise N.; Tiffany HaiVan Phan; Basuino, Li; Perdreau-Remington, Francoise; Chambers, Henry F.; Binh An Diep] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94110 USA.
[Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA.
[Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Diep, BA (reprint author), Univ Calif San Francisco, Dept Med, Div Infect Dis, 1001 Potrero Ave,Bldg 30,Rm 3300, San Francisco, CA 94110 USA.
EM bdiep@medsfgh.ucsf.edu
FU Association pour la Formation et la Recherche en Reanimation et en
Infectiologie; Pontchaillou University Hospital, Rennes, France; US
Public Health Service grants National Institute of Health (NIH) National
Institute of Allergy and Infectious Diseases (NIAID) [R01 AI070289]; NIH
NIAID [R01 AI087674]
FX This work was supported by a grant from the Association pour la
Formation et la Recherche en Reanimation et en Infectiologie and by the
Pontchaillou University Hospital, Rennes, France (to P. T.), and US
Public Health Service grants National Institute of Health (NIH) National
Institute of Allergy and Infectious Diseases (NIAID) R01 AI070289 (to H.
F. C.) and NIH NIAID R01 AI087674 (to B. A. D.).
NR 35
TC 33
Z9 33
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 15
PY 2012
VL 55
IS 6
BP 781
EP 788
DI 10.1093/cid/cis527
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 995LF
UT WOS:000308008900008
PM 22670044
ER
PT J
AU Hazlett, EA
Zhang, J
New, AS
Zelmanova, Y
Goldstein, KE
Haznedar, MM
Meyerson, D
Goodman, M
Siever, LJ
Chu, KW
AF Hazlett, Erin A.
Zhang, Jing
New, Antonia S.
Zelmanova, Yuliya
Goldstein, Kim E.
Haznedar, M. Mehmet
Meyerson, David
Goodman, Marianne
Siever, Larry J.
Chu, King-Wai
TI Potentiated Amygdala Response to Repeated Emotional Pictures in
Borderline Personality Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Amygdala; arousal; borderline personality disorder; emotion; fMRI;
schizotypal personality disorder; valence
ID DIALECTICAL BEHAVIOR-THERAPY; MENTALIZATION-BASED TREATMENT; AFFECTIVE
DYSREGULATION; SOCIAL COGNITION; CONDITIONED FEAR; EMPIRICAL-BASIS;
FOLLOW-UP; FMRI; HABITUATION; COMORBIDITY
AB Background: Borderline personality disorder (BPD) is characterized by an inability to regulate emotional responses. The amygdala is important in learning about the valence (goodness and badness) of stimuli and functions abnormally in BPD.
Methods: Event-related functional magnetic resonance imaging (MRI) was employed in three groups: unmedicated BPD (n = 33) and schizotypal personality disorder (n = 28) participants and healthy control subjects (n = 32) during a task involving an intermixed series of unpleasant, neutral, and pleasant pictures each presented twice within their respective trial block/run. The amygdala was hand-traced on each participant's structural MRI scan and co-registered to their MRI scan. Amygdala responses were examined with a mixed-model multivariate analysis of variance.
Results: Compared with both control groups, BPD patients showed greater amygdala activation, particularly to the repeated emotional but not neutral pictures, and a prolonged return to baseline for the overall blood oxygen level-dependent response averaged across all pictures. Despite amygdala overactivation, BPD patients showed blunted self-report ratings of emotional but not neutral pictures. Fewer dissociative symptoms in both patient groups were associated with greater amygdala activation to repeated unpleasant pictures.
Conclusions: The increased amygdala response to the repeated emotional pictures observed in BPD was not observed in schizotypal patients, suggesting diagnostic specificity. This BPD-related abnormality is consistent with the well-documented clinical feature of high sensitivity to emotional stimuli with unusually strong and long-lasting reactions. The finding of a mismatch between physiological and self-report measures of emotion reactivity in BPD patients suggests they may benefit from treatments targeting emotion recognition.
C1 [Hazlett, Erin A.; New, Antonia S.; Goodman, Marianne; Siever, Larry J.; Chu, King-Wai] James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network VISN 3, Bronx, NY 10468 USA.
[Haznedar, M. Mehmet; Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY 10468 USA.
[Hazlett, Erin A.; Zhang, Jing; New, Antonia S.; Zelmanova, Yuliya; Goldstein, Kim E.; Haznedar, M. Mehmet; Meyerson, David; Goodman, Marianne; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
RP Hazlett, EA (reprint author), James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network VISN 3, 130 W Kingsbridge Rd,Room 6A-45, Bronx, NY 10468 USA.
EM erin.hazlett@mssm.edu
FU National Institute of Mental Health Grant [R01MH073911]; National Center
for Research Resources, National Institutes of Health [UL1RR029887]
FX This research was supported by National Institute of Mental Health Grant
R01MH073911 to EAH and Grant UL1RR029887 from the National Center for
Research Resources, National Institutes of Health.
NR 75
TC 57
Z9 57
U1 4
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD SEP 15
PY 2012
VL 72
IS 6
BP 448
EP 456
DI 10.1016/j.biopsych.2012.03.027
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 996IC
UT WOS:000308077100005
PM 22560044
ER
PT J
AU Gault, CR
Eblen, ST
Neumann, CA
Hannun, YA
Obeid, LM
AF Gault, Christopher R.
Eblen, Scott T.
Neumann, Carola A.
Hannun, Yusuf A.
Obeid, Lina M.
TI Oncogenic K-Ras Regulates Bioactive Sphingolipids in a Sphingosine
Kinase 1-dependent Manner
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TANDEM MASS-SPECTROMETRY; BREAST-CANCER CELLS; QUANTITATIVE-ANALYSIS;
PLASMA-MEMBRANE; POOR SURVIVAL; SPHINGOSINE-1-PHOSPHATE; EXPRESSION;
GROWTH; PHOSPHORYLATION; TRANSLOCATION
AB Sphingosine kinase 1 (SK1) is an important enzyme involved in the production of the bioactive lipid sphingosine 1-phosphate (S1P). SK1 is overexpressed in many forms of cancer, however, the contribution of SK1 to cancer progression is still unclear. One of the best characterized mutations found in several forms of human cancer is an activating point mutation in the Ras oncogene, which disrupts its GTPase activity and leads to stimulation of the MEK/ERK pathway. Because SK1 activity and subcellular localization have been shown to be regulated by ERK, we wished to investigate the effect of oncogenic Ras, a potent activator of the Raf/MEK/ERK pathway, on the activity of SK1 and sphingolipid metabolism. Using HEK293T cells transiently transfected with the K-RasG12V oncogene and both wild type and Sphk1(-/-) mouse embryonic fibroblasts stably infected with retroviral K-RasG12V, we found that K-RasG12V increases the production of S1P and decreases the production of ceramide in a SK1-dependent manner. In addition, we found that expression of the K-RasG12V oncogene leads to plasma membrane localization of SK1 and a reduction in cytosolic levels of SK1. This effect is likely mediated by the Raf/MEK/ERK pathway as constitutively active B-Raf or MEK1 are able to activate SK1, but constitutively active Akt1 is not. We believe this research has important implications for how sphingolipids may be contributing to oncogenic transformation and provide some of the first evidence for oncogenes inducing specific changes in sphingolipid metabolism through SK1 regulation.
C1 [Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Gault, Christopher R.; Hannun, Yusuf A.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA.
[Eblen, Scott T.; Neumann, Carola A.] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA.
RP Obeid, LM (reprint author), SUNY Stony Brook, Hlth Sci Ctr, L-4,179, Stony Brook, NY 11794 USA.
EM lina.obeid@stonybrookmedicine.edu
OI obeid, lina/0000-0002-0734-0847
FU National Institutes of Health from the Extramural Research Facilities
Program of the National Center for Research Resources [C06 RR018823];
NCI [IPO1CA097132, P30 CA 138313, R01CA131-200, P01 CA0971321]; National
Institutes of Health NCRR SC COBRE [P20 RR017677]; National Institutes
of Health [NHLBI NRSA 5F30 HL093991, NIGMS R01 GM062887, NCI
P01CA097132]; NIEHS [K22 ES012985-01]; MERIT Award from the Office of
Research and Development, Department of Veterans Affairs, Ralph H.
Johnson Veterans Medical Center, Charleston, SC [1I0 BX000156 01A1]
FX We thank Marianne Dubard-Gault for help in generating the SK1 mutants
and Kathy Wiita-Fisk for administrative assistance in preparing this
manuscript. Measurement of sphingolipids was conducted by the Lipidomics
Core of Medical University of South Carolina (MUSC) in a facility
constructed with support from National Institutes of Health Grant C06
RR018823 from the Extramural Research Facilities Program of the National
Center for Research Resources. LC-MS/MS analysis of sphingolipids was
performed by Lipidomics Shared Resource, MUSC(25) supported by NCI
Grants IPO1CA097132 and P30 CA 138313 and National Institutes of Health
NCRR SC COBRE Grant P20 RR017677. Laboratory space in the CRI building
of MUSC was supported by National Institutes of Health Grant C06
RR018823 from the Extramural Research Facilities Program of the National
Center for Research Resources.; This work was supported, in whole or in
part, by National Institutes of Health Grants NHLBI NRSA 5F30 HL093991
(to C. R. G.), NIGMS R01 GM062887 and NCI P01CA097132 (to Y. A. H.),
R01CA131-200 from the NCI (to S. E.), K22 ES012985-01 from the NIEHS (to
C. N.), P01 CA0971321 from the NCI (to L. M. O.), and by MERIT Award 1I0
BX000156 01A1) (to L. M. O.) from the Office of Research and
Development, Department of Veterans Affairs, Ralph H. Johnson Veterans
Medical Center, Charleston, SC.
NR 43
TC 10
Z9 11
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 14
PY 2012
VL 287
IS 38
BP 31794
EP 31803
DI 10.1074/jbc.M112.385765
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 009XT
UT WOS:000309059400020
PM 22833671
ER
PT J
AU Zhu, L
Su, M
Lucast, L
Liu, LJ
Netzer, WJ
Gandy, SE
Cai, DM
AF Zhu, Li
Su, Meng
Lucast, Louise
Liu, Lijuan
Netzer, William J.
Gandy, Samuel E.
Cai, Dongming
TI Dynamin 1 Regulates Amyloid Generation through Modulation of BACE-1
SO PLOS ONE
LA English
DT Article
ID ONSET ALZHEIMERS-DISEASE; PRECURSOR-PROTEIN; BETA-SECRETASE;
CELL-SURFACE; IN-VIVO; ENDOCYTOSIS; PRESENILIN-1; INHIBITION; PATHWAYS;
PHOSPHORYLATION
AB Background: Several lines of investigation support the notion that endocytosis is crucial for Alzheimer's disease (AD) pathogenesis. Substantial evidence have already been reported regarding the mechanisms underlying amyloid precursor protein (APP) traffic, but the regulation of beta-site APP-Cleaving Enzyme 1 (BACE-1) distribution among endosomes, TGN and plasma membrane remains unclear. Dynamin, an important adaptor protein that controls sorting of many molecules, has recently been associated with AD but its functions remain controversial. Here we studied possible roles for dynamin 1 (dyn1) in A beta biogenesis.
Principal Findings: We found that genetic perturbation of dyn1 reduces both secreted and intracellular A beta levels in cell culture. There is a dramatic reduction in BACE-1 cleavage products of APP (sAPP beta and beta CTF). Moreover, dyn1 knockdown (KD) leads to BACE-1 redistribution from the Golgi-TGN/endosome to the cell surface. There is an increase in the amount of surface holoAPP upon dyn1 KD, with resultant elevation of alpha-secretase cleavage products sAPP alpha and alpha CTF. But no changes are seen in the amount of nicastrin (NCT) or PS1 N-terminal fragment (NTF) at cell surface with dyn1 KD. Furthermore, treatment with a selective dynamin inhibitor Dynasore leads to similar reduction in beta CTF and A beta levels, comparable to changes with BACE inhibitor treatment. But combined inhibition of BACE-1 and dyn1 does not lead to further reduction in A beta, suggesting that the A beta-lowering effects of dynamin inhibition are mainly mediated through regulation of BACE-1 internalization. A beta levels in dyn1(-/-) primary neurons, as well as in 3-month old dyn1 haploinsufficient animals with AD transgenic background are consistently reduced when compared to their wildtype counterparts.
Conclusions: In summary, these data suggest a previously unknown mechanism by which dyn1 affects amyloid generation through regulation of BACE-1 subcellular localization and therefore its enzymatic activities.
C1 [Zhu, Li; Su, Meng; Gandy, Samuel E.; Cai, Dongming] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Zhu, Li; Su, Meng; Gandy, Samuel E.; Cai, Dongming] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY USA.
[Zhu, Li; Gandy, Samuel E.; Cai, Dongming] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Lucast, Louise; Liu, Lijuan] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA.
[Lucast, Louise; Liu, Lijuan] Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT USA.
[Netzer, William J.] Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA.
[Su, Meng] John Hopkins Med Ctr, Dept Pathol, Baltimore, MD USA.
RP Zhu, L (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
EM dongming.cai@mssm.edu
OI Cai, Dongming/0000-0002-0601-6826
FU Department of Veteran Affairs Career Development Award; Mount Sinai
School of Medicine Friedman Brain Institute Seeding Fund
FX The authors' studies are supported by Department of Veteran Affairs
Career Development Award (to D.C.) and Mount Sinai School of Medicine
Friedman Brain Institute Seeding Fund (to D.C.). The funders provide
financial support to our studies. They had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 35
TC 6
Z9 6
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 14
PY 2012
VL 7
IS 9
AR e45033
DI 10.1371/journal.pone.0045033
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 007AD
UT WOS:000308860100045
PM 23024787
ER
PT J
AU Esquivel, A
Sittig, DF
Murphy, DR
Singh, H
AF Esquivel, Adol
Sittig, Dean F.
Murphy, Daniel R.
Singh, Hardeep
TI Improving the Effectiveness of Electronic Health Record-Based Referral
Processes
SO BMC MEDICAL INFORMATICS AND DECISION MAKING
LA English
DT Article
ID CENTERED MEDICAL HOME; PRIMARY-CARE; INFORMATION-TECHNOLOGY;
GENERAL-PRACTITIONERS; SPECIALTY CARE; SAFETY-NET; PHYSICIAN REFERRALS;
CANCER DIAGNOSIS; UNITED-KINGDOM; COMMUNICATION
AB Electronic health records are increasingly being used to facilitate referral communication in the outpatient setting. However, despite support by technology, referral communication between primary care providers and specialists is often unsatisfactory and is unable to eliminate care delays. This may be in part due to lack of attention to how information and communication technology fits within the social environment of health care. Making electronic referral communication effective requires a multifaceted "socio-technical" approach. Using an 8-dimensional socio-technical model for health information technology as a framework, we describe ten recommendations that represent good clinical practices to design, develop, implement, improve, and monitor electronic referral communication in the outpatient setting. These recommendations were developed on the basis of our previous work, current literature, sound clinical practice, and a systems-based approach to understanding and implementing health information technology solutions. Recommendations are relevant to system designers, practicing clinicians, and other stakeholders considering use of electronic health records to support referral communication.
C1 [Murphy, Daniel R.; Singh, Hardeep] Michael E DeBakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA.
[Murphy, Daniel R.; Singh, Hardeep] Baylor Coll Med, VA Med Ctr 152, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Murphy, Daniel R.; Singh, Hardeep] Michael E DeBakey VA Med Ctr, Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX 77030 USA.
[Esquivel, Adol] St Lukes Episcopal Hlth Syst, Dept Clin Effectiveness & Performance Measurement, Houston, TX USA.
[Sittig, Dean F.] Univ Texas Houston, Sch Biomed Informat, Houston, TX USA.
[Sittig, Dean F.] Univ Texas Houston, UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA.
RP Singh, H (reprint author), Michael E DeBakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
FU NIH [K23CA125585]; VA National Center of Patient Safety; Houston VA
HSR&D Center for Excellence [HFP90-020]; Office of the National
Coordinator for Health Information Technology (ONC) [10510592]
FX Dr. Singh is supported by an NIH K23 career development award
(K23CA125585), the VA National Center of Patient Safety, and in part by
the Houston VA HSR&D Center for Excellence (HFP90-020). Dr. Sittig is
supported in part by a SHARP contract from the Office of the National
Coordinator for Health Information Technology (ONC #10510592).
NR 99
TC 5
Z9 5
U1 4
U2 25
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6947
J9 BMC MED INFORM DECIS
JI BMC Med. Inform. Decis. Mak.
PD SEP 13
PY 2012
VL 12
AR 107
DI 10.1186/1472-6947-12-107
PG 8
WC Medical Informatics
SC Medical Informatics
GA 034FH
UT WOS:000310855300001
PM 22973874
ER
PT J
AU Bedolla, RG
Gong, JJ
Prihoda, TJ
Yeh, IT
Thompson, IM
Ghosh, R
Kumar, AP
AF Bedolla, Roble G.
Gong, Jingjing
Prihoda, Thomas J.
Yeh, I-Tien
Thompson, Ian M.
Ghosh, Rita
Kumar, Addanki P.
TI Predictive Value of Sp1/Sp3/FLIP Signature for Prostate Cancer
Recurrence
SO PLOS ONE
LA English
DT Article
ID RECEPTOR-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; C-FLIP EXPRESSION;
TRANSGENIC ADENOCARCINOMA; RADICAL PROSTATECTOMY; MOUSE PROSTATE;
STERNBERG CELLS; BIOMARKERS; DIAGNOSIS; SP3
AB Prediction of prostate cancer prognosis is challenging and predictive biomarkers of recurrence remain elusive. Although prostate specific antigen (PSA) has high sensitivity (90%) at a PSA level of 4.0 ng/mL, its low specificity leads to many false positive results and considerable overtreatment of patients and its performance at lower ranges is poor. Given the histopathological and molecular heterogeneity of prostate cancer, we propose that a panel of markers will be a better tool than a single marker. We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years. Immunohistochemical staining for Sp1, Sp3, and FLIP was performed on these tissues and scored based on the proportion and intensity of staining. The predictive value of the FLIP/Sp1/Sp3 signature for clinical outcome (recurrence vs. non-recurrence) was explored with logistic regression, and combinations of FLIP/Sp1/Sp3 and Gleason score were analyzed with a stepwise (backward and forward) logistic model. The discrimination of the markers was identified by sensitivity-specificity analysis and the diagnostic value of FLIP/Sp1/Sp3 was determined using area under the curve (AUC) for receiver operator characteristic curves. The AUCs for FLIP, Sp1, Sp3, and Gleason score for predicting PSA failure and non-failure were 0.71, 0.66, 0.68, and 0.76, respectively. However, this increased to 0.93 when combined. Thus, the "biomarker signature'' of FLIP/Sp1/Sp3 combined with Gleason score predicted disease recurrence and stratified patients who are likely to benefit from more aggressive treatment.
C1 [Bedolla, Roble G.; Gong, Jingjing; Thompson, Ian M.; Ghosh, Rita; Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
[Prihoda, Thomas J.; Yeh, I-Tien] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Ghosh, Rita; Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Thompson, Ian M.; Ghosh, Rita; Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
[Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Bedolla, RG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
EM kumara3@uthscsa.edu
FU Clinical Translational Science Award (CTSA) [UL1RR025767]; National
Cancer Institute [R01 CA 135451]; Veterans Affairs-Merit Award [1 I01 BX
000766-01, R01 CA 149516]; EDRN [UO1 054174]; Cancer Therapy and
Research Center at University of Texas Health Science Center San Antonio
through the National Cancer Institute [2P30 CA 054174-7]
FX This work was supported in part by funds from Clinical Translational
Science Award (CTSA) grant (UL1RR025767); National Cancer Institute R01
CA 135451 and Veterans Affairs-Merit Award 1 I01 BX 000766-01(APK); R01
CA 149516 (RG); and EDRN (UO1 054174; IT). The authors acknowledge
support provided by Cancer Therapy and Research Center at University of
Texas Health Science Center San Antonio through the National Cancer
Institute support grant #2P30 CA 054174-7 (APK, IMT, and RG). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 39
TC 10
Z9 11
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 13
PY 2012
VL 7
IS 9
AR e44917
DI 10.1371/journal.pone.0044917
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 005ZK
UT WOS:000308788700056
PM 23028678
ER
PT J
AU Zhang, JH
Xi, MC
Fung, SJ
Sampogna, S
Chase, MH
AF Zhang, Jianhua
Xi, Mingchu
Fung, Simon J.
Sampogna, Sharon
Chase, Michael H.
TI Projections from the central nucleus of the amygdala to the nucleus
pontis oralis in the rat: An anterograde labeling study
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Phaseolus vulgaris-leucoagglutinin; VGluT2; Brainstem; Active sleep
ID PARADOXICAL REM-SLEEP; BRAIN-STEM; RETICULAR-FORMATION;
MEDULLA-OBLONGATA; NEURONS; PONS; CAT; STIMULATION; MODULATION
AB The present study was designed to elucidate the neuronal projections from the amygdala to the nucleus pontis oralis (NPO). We propose that glutamatergic cells in the central nucleus of the amygdala (CNA) activate neurons in the NPO, which is the critical brainstem site that is responsible for the generation and maintenance of active (REM) sleep. Phaseolus vulgaris-leucoagglutinin (PHA-L), an anterograde transported neuronal tracer, was iontophoresed into the CNA of adult male Sprague-Dawley rats. After a survival time of 7-8 days, the animals were perfused with a fixative and brain tissue was prepared for histological analysis. Sections of the NPO and CNA, which were immunostained with an antibody against PHA-L, were examined with light microscopy. In addition, in order to identify the phenotype of PHA-L-labeled fibers and terminals in the NPO, a double immunohistochemical technique was employed with antibodies against PHA-L and the vesicular glutamate transporter type 2 (VGluT2). Numerous PHA-L-labeled axons and terminals were found in the NPO ipsilateral to the injection site in the CNA. Within the NPO, the majority of labeled fibers were located in the dorsolateral portion of the caudal part of the nucleus. Double-labeling immunostaining studies revealed that PHA-L-labeled axons and terminals in the NPO were glutamatergic. The present demonstration of direct, excitatory (glutamatergic) projections from the CNA to the NPO provide an anatomical basis for the amygdalar control of active sleep. Published by Elsevier Ireland Ltd.
C1 [Zhang, Jianhua; Xi, Mingchu; Fung, Simon J.; Sampogna, Sharon; Chase, Michael H.] WebSci Int, Los Angeles, CA 90024 USA.
[Zhang, Jianhua; Xi, Mingchu; Fung, Simon J.; Chase, Michael H.] VA Greater LA Healthcare Syst, Los Angeles, CA USA.
[Chase, Michael H.] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA.
RP Zhang, JH (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA.
EM jzhang@websciences.org
FU NIH [NS 60917]
FX This research was supported by NIH grant NS 60917. We are grateful to
Mr. Vincent Lim for his excellent technical assistance.
NR 30
TC 6
Z9 6
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD SEP 13
PY 2012
VL 525
IS 2
BP 157
EP 162
DI 10.1016/j.neulet.2012.07.059
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 009HA
UT WOS:000309015600014
PM 22884644
ER
PT J
AU Balasubramanian, S
Quinones, L
Kasiganesan, H
Zhang, YH
Pleasant, DL
Sundararaj, KP
Zile, MR
Bradshaw, AD
Kuppuswamy, D
AF Balasubramanian, Sundaravadivel
Quinones, Lakeya
Kasiganesan, Harinath
Zhang, Yuhua
Pleasant, Dorea L.
Sundararaj, Kamala P.
Zile, Michael R.
Bradshaw, Amy D.
Kuppuswamy, Dhandapani
TI beta 3 Integrin in Cardiac Fibroblast Is Critical for Extracellular
Matrix Accumulation during Pressure Overload Hypertrophy in Mouse
SO PLOS ONE
LA English
DT Article
ID FOCAL ADHESION KINASE; BETA(3) INTEGRIN; TYROSINE KINASE;
ALPHA(V)BETA(3) INTEGRIN; CELL-ADHESION; MUSCLE-CELLS; C-SRC;
ACTIVATION; SURVIVAL; MICE
AB The adhesion receptor beta 3 integrin regulates diverse cellular functions in various tissues. As beta 3 integrin has been implicated in extracellular matrix (ECM) remodeling, we sought to explore the role of beta 3 integrin in cardiac fibrosis by using wild type (WT) and b3 integrin null (beta 3-/-) mice for in vivo pressure overload (PO) and in vitro primary cardiac fibroblast phenotypic studies. Compared to WT mice, beta 3-/- mice upon pressure overload hypertrophy for 4 wk by transverse aortic constriction (TAC) showed a substantially reduced accumulation of interstitial fibronectin and collagen. Moreover, pressure overloaded LV from beta 3-/- mice exhibited reduced levels of both fibroblast proliferation and fibroblast-specific protein-1 (FSP1) expression in early time points of PO. To test if the observed impairment of ECM accumulation in beta 3-/- mice was due to compromised cardiac fibroblast function, we analyzed primary cardiac fibroblasts from WT and beta 3-/- mice for adhesion to ECM proteins, cell spreading, proliferation, and migration in response to platelet derived growth factor-BB (PDGF, a growth factor known to promote fibrosis) stimulation. Our results showed that beta 3-/- cardiac fibroblasts exhibited a significant reduction in cell-matrix adhesion, cell spreading, proliferation and migration. In addition, the activation of PDGF receptor associated tyrosine kinase and non-receptor tyrosine kinase Pyk2, upon PDGF stimulation were impaired in beta 3-/- cells. Adenoviral expression of a dominant negative form of Pyk2 (Y402F) resulted in reduced accumulation of fibronectin. These results indicate that beta 3 integrin-mediated Pyk2 signaling in cardiac fibroblasts plays a critical role in PO-induced cardiac fibrosis.
C1 [Balasubramanian, Sundaravadivel; Quinones, Lakeya; Kasiganesan, Harinath; Zhang, Yuhua; Pleasant, Dorea L.; Sundararaj, Kamala P.; Zile, Michael R.; Bradshaw, Amy D.; Kuppuswamy, Dhandapani] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA.
[Zile, Michael R.; Bradshaw, Amy D.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA.
RP Balasubramanian, S (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA.
EM kuppusd@musc.edu
FU National Institutes of Health [R01 RHL092124A]
FX This study was funded by National Institutes of Health R01 RHL092124A.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 49
TC 16
Z9 20
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 12
PY 2012
VL 7
IS 9
AR e45076
DI 10.1371/journal.pone.0045076
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 005GJ
UT WOS:000308738500114
PM 22984613
ER
PT J
AU Reyes, RC
Brennan, AM
Shen, YG
Baldwin, Y
Swanson, RA
AF Reyes, Reno C.
Brennan, Angela M.
Shen, Yiguo
Baldwin, Ylva
Swanson, Raymond A.
TI Activation of Neuronal NMDA Receptors Induces Superoxide-Mediated
Oxidative Stress in Neighboring Neurons and Astrocytes
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID NITRIC-OXIDE; NADPH OXIDASE; GLUTAMATE NEUROTOXICITY; PROTEIN;
EXCITOTOXICITY; PEROXYNITRITE; RADICALS; EPILEPSY; EFFICACY; GLUCOSE
AB Excitotoxic neuronal death is mediated in part by NMDA receptor-induced activation of NOX2, an enzyme that produces superoxide and resultant oxidative stress. It is not known, however, whether the superoxide is generated in the intracellular space, producing oxidative stress in the neurons responding to NMDA receptor activation, or in the extracellular space, producing oxidative stress in neighboring cells. We evaluated these alternatives by preparing cortical neuron cultures from p47(phox-/-) mice, which are unable to form a functional NOX2 complex, and transfecting the cultures at low density with GFP-tagged p47(phox) to reconstitute NOX2 activity in widely scattered neurons. NMDA exposure did not induce oxidative stress or cell death in the nontransfected, p47-phox(-/-) cultures, but did produce oxidative stress and neuronal death in neurons surrounding the transfected, NOX2-competent neurons. This cell-to-cell spread of NMDA-induced oxidative injury was blocked by coincubation with either superoxide dismutase or the anion channel blocker 4'-diisothiocyanostilbene-2,2'-disulphonate, confirming superoxide anion as the mediating oxidant. In neurons plated on a preexisting astrocyte layer, NMDA induced oxidative stress in both the neurons and the astrocytes, and this was also prevented by superoxide dismutase. These findings show that activation of NMDA receptors on one neuron can lead to oxidative stress and cell death in neighboring neurons and astrocytes by a process involving the extracellular release of superoxide by NOX2.
C1 [Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, VAMC, San Francisco, CA 94121 USA.
San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA USA.
RP Swanson, RA (reprint author), Univ Calif San Francisco, Dept Neurol, VAMC, 4150 Clement St, San Francisco, CA 94121 USA.
EM raymond.swanson@ucsf.edu
OI Swanson, Raymond/0000-0002-3664-5359
FU NIH [2 RO1 NS041421]; U.S. Department of Veterans Affairs
FX This work was supported by NIH Grant 2 RO1 NS041421 (R.A.S.) and the
U.S. Department of Veterans Affairs. We thank Colleen Hefner for expert
technical assistance.
NR 37
TC 33
Z9 33
U1 0
U2 6
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD SEP 12
PY 2012
VL 32
IS 37
BP 12973
EP 12978
DI 10.1523/JNEUROSCI.1597-12.2012
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 006FV
UT WOS:000308805800033
PM 22973021
ER
PT J
AU Wallace, AW
AF Wallace, Arthur W.
TI Risk of Acute Myocardial Infarction in Patients With Total Hip or Knee
Replacement
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID NONCARDIAC SURGERY; CARDIOVASCULAR MORBIDITY; MORTALITY; ASSOCIATION;
ATENOLOL; ISCHEMIA
C1 [Wallace, Arthur W.] San Francisco VA Med Ctr, Dept Anesthesiol, San Francisco, CA 94121 USA.
[Wallace, Arthur W.] Univ Calif San Francisco, Dept Anesthesiol, San Francisco, CA 94143 USA.
RP Wallace, AW (reprint author), San Francisco VA Med Ctr, Dept Anesthesiol, 4150 Clement St, San Francisco, CA 94121 USA.
EM art.wallace@va.gov
NR 9
TC 4
Z9 4
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD SEP 10
PY 2012
VL 172
IS 16
BP 1235
EP 1236
DI 10.1001/archinternmed.2012.3776
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 003MV
UT WOS:000308616800009
PM 22825029
ER
PT J
AU Giordano, S
Lee, J
Darley-Usmar, VM
Zhang, JH
AF Giordano, Samantha
Lee, Jisun
Darley-Usmar, Victor M.
Zhang, Jianhua
TI Distinct Effects of Rotenone, 1-methyl-4-phenylpyridinium and
6-hydroxydopamine on Cellular Bioenergetics and Cell Death
SO PLOS ONE
LA English
DT Article
ID ELECTRON-TRANSPORT CHAIN; MITOCHONDRIAL COMPLEX-I; NEUROBLASTOMA SH-SY5Y
CELLS; PARKINSONS-DISEASE; DOPAMINE TRANSPORTER; HYDROGEN-PEROXIDE;
CYTOTOXIC AGENTS; VITRO MODEL; NDI1 GENE; WILD-TYPE
AB Parkinson's disease is characterized by dopaminergic neurodegeneration and is associated with mitochondrial dysfunction. The bioenergetic susceptibility of dopaminergic neurons to toxins which induce Parkinson's like syndromes in animal models is then of particular interest. For example, rotenone, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its active metabolite 1-methyl-4-phenylpyridinium (MPP+), and 6-hydroxydopamine (6-OHDA), have been shown to induce dopaminergic cell death in vivo and in vitro. Exposure of animals to these compounds induce a range of responses characteristics of Parkinson's disease, including dopaminergic cell death, and Reactive Oxygen Species (ROS) production. Here we test the hypothesis that cellular bioenergetic dysfunction caused by these compounds correlates with induction of cell death in differentiated dopaminergic neuroblastoma SH-SY5Y cells. At increasing doses, rotenone induced significant cell death accompanied with caspase 3 activation. At these concentrations, rotenone had an immediate inhibition of mitochondrial basal oxygen consumption rate (OCR) concomitant with a decrease of ATP-linked OCR and reserve capacity, as well as a stimulation of glycolysis. MPP+ exhibited a different behavior with less pronounced cell death at doses that nearly eliminated basal and ATP-linked OCR. Interestingly, MPP+, unlike rotenone, stimulated bioenergetic reserve capacity. The effects of 6-OHDA on bioenergetic function was markedly less than the effects of rotenone or MPP+ at cytotoxic doses, suggesting a mechanism largely independent of bioenergetic dysfunction. These studies suggest that these dopaminergic neurotoxins induce cell death through distinct mechanisms and differential effects on cellular bioenergetics.
C1 [Giordano, Samantha; Lee, Jisun; Darley-Usmar, Victor M.; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
[Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL USA.
RP Giordano, S (reprint author), Univ Alabama Birmingham, Dept Pathol, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
EM zhanja@uab.edu
FU United States National Institutes of Health [NIH-ES/HL10167,
NIH-DK75865]; VA merit award; [NIH-NS064090]; [P30 DK079337]; [P30
AR50948]; [S10 RR19231]
FX This work was supported by United States National Institutes of Health
NIH-ES/HL10167, and NIH-DK75865 (to VM DU); NIH-NS064090 and a VA merit
award (to JZ). MPP+ mass spectrometry was supported by P30 DK079337, P30
AR50948 and S10 RR19231. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 90
TC 34
Z9 34
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 6
PY 2012
VL 7
IS 9
AR e44610
DI 10.1371/journal.pone.0044610
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 001KC
UT WOS:000308458400093
PM 22970265
ER
PT J
AU Asch, DA
Volpp, KG
AF Asch, David A.
Volpp, Kevin G.
TI What Business Are We In? The Emergence of Health as the Business of
Health Care
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Asch, David A.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
Univ Penn, Penn Med Ctr Innovat, Philadelphia, PA 19104 USA.
Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
RP Asch, DA (reprint author), Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
OI Asch, David/0000-0002-7970-286X
NR 5
TC 15
Z9 15
U1 1
U2 9
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 6
PY 2012
VL 367
IS 10
BP 888
EP 889
DI 10.1056/NEJMp1206862
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 999VO
UT WOS:000308343300003
PM 22931228
ER
PT J
AU Wells, JM
Washko, GR
Han, MK
Abbas, N
Nath, H
Mamary, AJ
Regan, E
Bailey, WC
Martinez, FJ
Westfall, E
Beaty, TH
Curran-Everett, D
Curtis, JL
Hokanson, JE
Lynch, DA
Make, BJ
Crapo, JD
Silverman, EK
Bowler, RP
Dransfield, MT
AF Wells, J. Michael
Washko, George R.
Han, MeiLan K.
Abbas, Naseer
Nath, Hrudaya
Mamary, A. James
Regan, Elizabeth
Bailey, William C.
Martinez, Fernando J.
Westfall, Elizabeth
Beaty, Terri H.
Curran-Everett, Douglas
Curtis, Jeffrey L.
Hokanson, John E.
Lynch, David A.
Make, Barry J.
Crapo, James D.
Silverman, Edwin K.
Bowler, Russell P.
Dransfield, Mark T.
CA COPDGene & ECLIPSE Study Invest
TI Pulmonary Arterial Enlargement and Acute Exacerbations of COPD
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID DISEASE; HYPERTENSION; EMPHYSEMA; EPIDEMIOLOGY; PREVALENCE; PREVENTION;
PHENOTYPE; PERFUSION; SMOKERS; DEATH
AB BACKGROUND
Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with accelerated loss of lung function and death. Identification of patients at risk for these events, particularly those requiring hospitalization, is of major importance. Severe pulmonary hypertension is an important complication of advanced COPD and predicts acute exacerbations, though pulmonary vascular abnormalities also occur early in the course of the disease. We hypothesized that a computed tomographic (CT) metric of pulmonary vascular disease (pulmonary artery enlargement, as determined by a ratio of the diameter of the pulmonary artery to the diameter of the aorta [PA:A ratio] of >1) would be associated with severe COPD exacerbations.
METHODS We conducted a multicenter, observational trial that enrolled current and former smokers with COPD. We determined the association between a PA: A ratio of more than 1 and a history at enrollment of severe exacerbations requiring hospitalization and then examined the usefulness of the ratio as a predictor of these events in a longitudinal follow-up of this cohort, as well as in an external validation cohort. We used logistic-regression and zero-inflated negative binomial regression analyses and adjusted for known risk factors for exacerbation.
RESULTS
Multivariate logistic-regression analysis showed a significant association between a PA: A ratio of more than 1 and a history of severe exacerbations at the time of enrollment in the trial (odds ratio, 4.78; 95% confidence interval [CI], 3.43 to 6.65; P<0.001). A PA: A ratio of more than 1 was also independently associated with an increased risk of future severe exacerbations in both the trial cohort (odds ratio, 3.44; 95% CI, 2.78 to 4.25; P<0.001) and the external validation cohort (odds ratio, 2.80; 95% CI, 2.11 to 3.71; P<0.001). In both cohorts, among all the variables analyzed, a PA: A ratio of more than 1 had the strongest association with severe exacerbations.
CONCLUSIONS
Pulmonary artery enlargement (a PA: A ratio of > 1), as detected by CT, was associated with severe exacerbations of COPD. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov numbers, NCT00608764 and NCT00292552.)
C1 [Wells, J. Michael; Abbas, Naseer; Bailey, William C.; Westfall, Elizabeth; Dransfield, Mark T.] Univ Alabama Birmingham, Lung Hlth Ctr, Div Pulm Allergy & Crit Care, Birmingham, AL 35294 USA.
[Nath, Hrudaya] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL 35294 USA.
[Dransfield, Mark T.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Washko, George R.; Silverman, Edwin K.] Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA.
[Silverman, Edwin K.] Brigham & Womens Hosp, Channing Lab, Div Network Med, Boston, MA 02115 USA.
[Han, MeiLan K.; Martinez, Fernando J.; Curtis, Jeffrey L.] Univ Michigan Hlth Syst, Div Pulm & Crit Care Med, Ann Arbor, MI USA.
[Curtis, Jeffrey L.] Vet Affairs Hlth Syst, Med Serv, Pulm & Crit Care Med Sect, Ann Arbor, MI USA.
[Mamary, A. James] Temple Univ, Sch Med, Div Pulm & Crit Care, Philadelphia, PA 19122 USA.
[Regan, Elizabeth; Lynch, David A.; Make, Barry J.; Crapo, James D.; Bowler, Russell P.] Natl Jewish Hlth, Div Pulm & Crit Care, Denver, CO USA.
[Curran-Everett, Douglas] Natl Jewish Hlth, Div Biostat & Bioinformat, Denver, CO USA.
[Hokanson, John E.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA.
[Beaty, Terri H.] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
RP Wells, JM (reprint author), Univ Alabama Birmingham, Lung Hlth Ctr, Div Pulm Allergy & Crit Care, 422 THT,1900 Univ Blvd, Birmingham, AL 35294 USA.
EM jmwells@uab.edu
RI Reilly, John/H-8755-2012; Coxson, Harvey/A-9861-2017
OI Coxson, Harvey/0000-0001-5750-9711; MacNee, William/0000-0002-3692-1448;
Curtis, Jeffrey/0000-0001-5191-4847
FU National Heart, Lung, and Blood Institute [U01 HL089856, U01 HL089897,
1T32HL105346-1]
FX Supported by grants (U01 HL089856, U01 HL089897, and 1T32HL105346-1)
from the National Heart, Lung, and Blood Institute.
NR 33
TC 126
Z9 131
U1 3
U2 25
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 6
PY 2012
VL 367
IS 10
BP 913
EP 921
DI 10.1056/NEJMoa1203830
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 999VO
UT WOS:000308343300008
PM 22938715
ER
PT J
AU Anderson, RM
AF Anderson, Rozalyn M.
TI A Role for Dicer in Aging and Stress Survival
SO CELL METABOLISM
LA English
DT Editorial Material
ID ADIPOSE-TISSUE
AB The link between aging and stress resistance is well established, but the nature of this relationship and which mechanisms are shared is still unknown. Mori et al. (2012) demonstrate that microRNA processing, specifically in adipose tissues, is a major component in aging and stress survival.
C1 [Anderson, Rozalyn M.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA.
RP Anderson, RM (reprint author), Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53706 USA.
EM rmanderson@medicine.wisc.edu
FU NIA NIH HHS [R01 AG037000]
NR 8
TC 2
Z9 2
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
J9 CELL METAB
JI Cell Metab.
PD SEP 5
PY 2012
VL 16
IS 3
BP 285
EP 286
DI 10.1016/j.cmet.2012.08.006
PG 2
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 018DU
UT WOS:000309641100001
PM 22958915
ER
PT J
AU Latif, R
Teixeira, A
Michalek, K
Ali, MR
Schlesinger, M
Baliram, R
Morshed, SA
Davies, TF
AF Latif, Rauf
Teixeira, Avelino
Michalek, Krzysztof
Ali, M. Rejwan
Schlesinger, Max
Baliram, Ramkumarie
Morshed, Syed A.
Davies, Terry F.
TI Antibody Protection Reveals Extended Epitopes on the Human TSH Receptor
SO PLOS ONE
LA English
DT Article
ID THYROID-STIMULATING AUTOANTIBODY; HUMAN THYROTROPIN RECEPTOR;
LEUCINE-RICH DOMAIN; HORMONE-RECEPTOR; CRYSTAL-STRUCTURE; HINGE REGION;
MONOCLONAL-ANTIBODY; MASS-SPECTROMETRY; GRAVES-DISEASE; BINDING
AB Stimulating, and some blocking, antibodies to the TSH receptor (TSHR) have conformation-dependent epitopes reported to involve primarily the leucine rich repeat region of the ectodomain (LRD). However, successful crystallization of TSHR residues 22-260 has omitted important extracellular non-LRD residues including the hinge region which connects the TSHR ectodomain to the transmembrane domain and which is involved in ligand induced signal transduction. The aim of the present study, therefore, was to determine if TSHR antibodies (TSHR-Abs) have non-LRD binding sites outside the LRD. To obtain this information we employed the method of epitope protection in which we first protected TSHR residues 1-412 with intact TSHR antibodies and then enzymatically digested the unprotected residues. Those peptides remaining were subsequently delineated by mass spectrometry. Fourteen out of 23 of the reported stimulating monoclonal TSHR-Ab crystal contact residues were protected by this technique which may reflect the higher binding energies of certain residues detected in this approach. Comparing the protected epitopes of two stimulating TSHR-Abs we found both similarities and differences but both antibodies also contacted the hinge region and the amino terminus of the TSHR following the signal peptide and encompassing cysteine box 1 which has previously been shown to be important for TSH binding and activation. A monoclonal blocking TSHR antibody revealed a similar pattern of binding regions but the residues that it contacted on the LRD were again distinct. These data demonstrated that conformationally dependent TSHR-Abs had epitopes not confined to the LRDs but also incorporated epitopes not revealed in the available crystal structure. Furthermore, the data also indicated that in addition to overlapping contact regions within the LRD, there are unique epitope patterns for each of the antibodies which may contribute to their functional heterogeneity.
C1 [Latif, Rauf; Teixeira, Avelino] Mt Sinai Sch Med, Dept Med, Prote Lab, New York, NY 10029 USA.
[Latif, Rauf; Ali, M. Rejwan; Schlesinger, Max; Baliram, Ramkumarie; Morshed, Syed A.; Davies, Terry F.] James J Peters VA Med Ctr, Thyroid Res Unit, New York, NY USA.
[Michalek, Krzysztof] Poznan Univ Med Sci, Dept Endocrinol Metab & Internal Dis, Poznan, Poland.
RP Latif, R (reprint author), Mt Sinai Sch Med, Dept Med, Prote Lab, New York, NY 10029 USA.
EM rauf.latif@mssm.edu
FU NIH [DK069713, DK052464]; Veterans Administration Merit Award program
FX Funding was provided by NIH grants DK069713 and DK052464 and the
Veterans Administration Merit Award program. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 41
TC 4
Z9 4
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 5
PY 2012
VL 7
IS 9
AR e44669
DI 10.1371/journal.pone.0044669
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 001MC
UT WOS:000308463800090
PM 22957097
ER
PT J
AU Keith, DJ
Wolfrum, K
Eshleman, AJ
Janowsky, A
AF Keith, Dove J.
Wolfrum, Katherine
Eshleman, Amy J.
Janowsky, Aaron
TI Melittin initiates dopamine transporter internalization and recycling in
transfected HEK-293 cells
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Dopamine transporter; Melittin; Trafficking; Protein kinase
ID PROTEIN-KINASE-C; PHOSPHOLIPASE A(2); ARACHIDONIC-ACID; FUNCTIONAL
REGULATION; NEUROTRANSMITTER TRANSPORTERS; INDUCED TRAFFICKING;
DOWN-REGULATION; RECEPTOR; PHOSPHORYLATION; VESICLES
AB The dopamine transporter removes the neurotransmitter from the synapse, regulating dopamine availability. The transporter can be internalized and its function is blocked by cocaine and other ligands. Melittin inhibits dopamine transporter function and causes internalization of the recombinant transporter in stably transfected HEK-293 cells, but the specific pathways for internalization and disposition of the transporter are unknown. Here we report that melittin treatment increased both transporter internalization and colocalization with clathrin, effects that were blocked by pretreatment with cocaine. Density gradient centrifugation revealed that melittin treatment caused the dopamine transporter to associate with a density fraction containing the early endosome marker Rab 5A. Confocal microscopy revealed that melittin treatment also increased transporter colocalization with Rab 5A and decreased colocalization with the late endosome marker Rab 7 and the recycling endosome marker Rab 11. Following 60 min of melittin treatment, the transporter was trafficked back to the membrane. By comparison, phorbol ester treatment increased transporter colocalization with early endosome antigen 1 and Rab 7 in a time-dependent manner. Cocaine treatment alone does not affect transporter trafficking in these cells. Results indicate multiple dopamine transporter internalization and recycling pathways that depend on transporter-ligand interactions and post-translational modifications. Published by Elsevier B.V.
C1 [Janowsky, Aaron] VA Med Ctr, Res Serv R&D 22, Grad Program Neurosci, Portland, OR 97239 USA.
[Wolfrum, Katherine; Eshleman, Amy J.; Janowsky, Aaron] Portland VA Med Ctr, Res Serv, Portland, OR USA.
[Eshleman, Amy J.; Janowsky, Aaron] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Eshleman, Amy J.; Janowsky, Aaron] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA.
[Janowsky, Aaron] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97201 USA.
RP Janowsky, A (reprint author), VA Med Ctr, Res Serv R&D 22, Grad Program Neurosci, 3710 SW,US Vet Hosp Rd, Portland, OR 97239 USA.
EM janowsky@ohsu.edu
FU NINDS [T32NS007466]; NIDA [F31DA016499]; NCCAM [T32AT002688]; Tartar
Trust Fellowship; NIH/VA Interagency agreement [Y1 -DA5007]; VA Merit
Review and Research Career Scientist Programs
FX We thank Dr. Kim Neve for providing the cDNA for the D2L
receptor and David Buck for his assistance with confocal imaging. This
project was supported by a NINDS T32NS007466, NIDA F31DA016499, NCCAM
T32AT002688, and a Tartar Trust Fellowship to DJK, the NIH/VA
Interagency agreement Y1 -DA5007, and VA Merit Review and Research
Career Scientist Programs (AJ).
NR 48
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 5
PY 2012
VL 690
IS 1-3
BP 13
EP 21
DI 10.1016/j.ejphar.2012.05.020
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 981KA
UT WOS:000306965200003
PM 22683840
ER
PT J
AU Henry, SR
Goetz, MB
Asch, SM
AF Henry, Stephen Randal
Goetz, Matthew B.
Asch, Steven M.
TI The Effect of Automated Telephone Appointment Reminders on HIV Primary
Care No-Shows by Veterans
SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
LA English
DT Article
DE appointment reminders; HIV primary care; no-shows
ID ACTIVE ANTIRETROVIRAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; OUTREACH
PROGRAM; INFECTION; ATTENDANCE; RETENTION; SYSTEMS; HEALTH; RATES
AB Appointment attendance for follow-up care and laboratory monitoring are central components of HIV treatment. In general, appointment reminders are an effective method of reducing outpatient no-shows; however, no single strategy has proven superior. This study tested the effectiveness of adding an automated telephone reminder for laboratory monitoring to the standard set of three appointment reminders to reduce subsequent HIV primary care no-shows. We conducted a quasi-experimental design study in three geographically and administratively affiliated Veterans Administration HIV clinics with one clinic serving as the intervention facility and two others as control facilities. The intervention lasted 6 months. The data show that patients who were not homeless, who were not diagnosed with depression, and who had five or more appointments scheduled in 6 months had significantly fewer no-shows after intervention. The intervention was not effective in reducing no-shows among homeless patients, racial/ethnic minorities, and patients with mental health disorders. (Journal of the Association of Nurses in AIDS Care, 23, 409-418) Published by Elsevier Inc. on behalf of Association of Nurses in AIDS Care
C1 [Henry, Stephen Randal; Goetz, Matthew B.; Asch, Steven M.] VA Greater Los Angeles Hlth Care Syst, Qual Enhancement Res Initiat HIV AIDS Hepatitis C, Los Angeles, CA USA.
RP Henry, SR (reprint author), VA Greater Los Angeles Hlth Care Syst, Qual Enhancement Res Initiat HIV AIDS Hepatitis C, Los Angeles, CA USA.
OI Goetz, Matthew/0000-0003-4542-992X
FU Department of Veterans Affairs, Health Services Research and
Development, Quality Enhancement Research Initiative [RRP 07-282]
FX Financial support for this project was provided by the Department of
Veterans Affairs, Health Services Research and Development, Quality
Enhancement Research Initiative, RRP 07-282.
NR 24
TC 7
Z9 7
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-3290
J9 J ASSOC NURSE AIDS C
JI J. Assoc. Nurses Aids Care
PD SEP-OCT
PY 2012
VL 23
IS 5
BP 409
EP 418
DI 10.1016/j.jana.2011.11.001
PG 10
WC Nursing
SC Nursing
GA 183NO
UT WOS:000321823200005
PM 22424961
ER
PT J
AU Stewart, JM
Dancy, BL
AF Stewart, Jennifer M.
Dancy, Barbara L.
TI Factors Contributing to the Development of an HIV Ministry Within an
African American Church
SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
LA English
DT Article
DE African American; faith; HIV; HIV ministry; religious culture
ID FAITH COMMUNITIES; PREVENTION; RISK; EDUCATION; HIV/AIDS; CONTEXT; WOMEN
AB Having an HIV ministry within a church depends on the religious culture of that church. However, little is known about how a church's religious culture influences an HIV ministry. This study's purpose was to examine how an African American church's religious culture supported the development, implementation, and maintenance of an HIV ministry within the church. An ethnographic case study research design was used. Data were collected through interviews, nonparticipant and participant observations, review of pertinent documents, and survey of congregants. Results revealed the following as important for an HIV ministry: (a) a belief in helping others and treating everyone with respect and dignity, (b) feelings of compassion toward individuals infected with HIV, and (c) HIV education. This information can assist in developing interventions to enhance the African American church movement toward HIV ministries. Copyright (C) 2012 Association of Nurses in AIDS Care
C1 [Stewart, Jennifer M.] Univ Penn, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
[Dancy, Barbara L.] Univ Illinois, Hlth Syst Sci Dept, Chicago, IL USA.
RP Stewart, JM (reprint author), Univ Penn, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
FU National Institutes of Health/National Institute of Nursing Research
(NIH/NINR) [5T32NR007964]
FX This study was funded in part by Health Disparities in Underserved
Populations Training grant 5T32NR007964 from the National Institutes of
Health/National Institute of Nursing Research (NIH/NINR). Its contents
are solely the responsibility of the authors and do not necessarily
represent the official views of NIH/NINR.
NR 29
TC 14
Z9 14
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-3290
J9 J ASSOC NURSE AIDS C
JI J. Assoc. Nurses Aids Care
PD SEP-OCT
PY 2012
VL 23
IS 5
BP 419
EP 430
DI 10.1016/j.jana.2011.09.008
PG 12
WC Nursing
SC Nursing
GA 183NO
UT WOS:000321823200006
PM 22212914
ER
PT J
AU Paucar, M
Winnberg, E
Walker, RH
Svenningsson, P
AF Paucar, M.
Winnberg, E.
Walker, R. H.
Svenningsson, P.
TI A CASE OF HUNTINGTON DISEASE-LIKE 1 (HDL1) WITH LONG DISEASE DURATION
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Meeting Abstract
CT Plenary Meeting of the European-Huntington's-Disease-Network (EHDN)
CY SEP 14-16, 2012
CL Stockholm, SWEDEN
SP European Huntingtons Dis Network (EHDN)
C1 [Paucar, M.; Svenningsson, P.] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden.
[Paucar, M.; Svenningsson, P.] Karolinska Hosp, Neurol Clin, S-10401 Stockholm, Sweden.
[Winnberg, E.] Ersta Skondal Univ Coll, Dept Caring Sci, Stockholm, Sweden.
[Walker, R. H.] James Peters Vet Med Affair Ctr, Movement Disorders Clin, Bronx, NY USA.
[Walker, R. H.] Mt Sinai Sch Med, New York, NY USA.
NR 2
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD SEP
PY 2012
VL 83
SU 1
BP A19
EP A19
DI 10.1136/jnnp-2012-303524.59
PG 1
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 170QQ
UT WOS:000320868800060
ER
PT J
AU Walker, R
AF Walker, R.
TI THE DIFFERENTIAL DIAGNOSIS OF CHOREA
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Meeting Abstract
CT Plenary Meeting of the European-Huntington's-Disease-Network (EHDN)
CY SEP 14-16, 2012
CL Stockholm, SWEDEN
SP European Huntingtons Dis Network (EHDN)
C1 [Walker, R.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Walker, R.] Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD SEP
PY 2012
VL 83
SU 1
BP A3
EP A3
DI 10.1136/jnnp-2012-303524.9
PG 1
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 170QQ
UT WOS:000320868800010
ER
PT J
AU Mehta, RS
Liman, AD
Passero, VA
Liman, AK
AF Mehta, R. S.
Liman, A. D.
Passero, V. A.
Liman, A. K.
TI Lung Squamous Cell Carcinoma Metastatic To The Gastrointestinal Tract:
Report Of Three Cases.
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article; Proceedings Paper
CT Chicago Multidisciplinary Symposium in Thoracic Oncology
CY SEP 06-08, 2012
CL Chicago, IL
C1 [Mehta, R. S.; Passero, V. A.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Liman, A. D.; Liman, A. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD SEP
PY 2012
VL 7
IS 9
SU 4
BP S311
EP S311
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 118OO
UT WOS:000317035000286
ER
PT J
AU Serrano, NA
Xu, C
Liu, Y
Wang, P
Fan, WH
Upton, MP
Houck, JR
Lohavanichbutr, P
Kao, M
Zhao, LP
Schwartz, SM
Chen, C
Mendez, E
AF Serrano, Nicholas A.
Xu, Chang
Liu, Yan
Wang, Pei
Fan, Wenhong
Upton, Melissa P.
Houck, John R.
Lohavanichbutr, Pawadee
Kao, Michael
Zhao, Lue Ping
Schwartz, Stephen M.
Chen, Chu
Mendez, Eduardo
TI Integrative Analysis in Oral Squamous Cell Carcinoma Reveals DNA Copy
Number-Associated miRNAs Dysregulating Target Genes
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE oral squamous cell carcinoma; microRNA; head and neck cancer;
miRNA-140-3p; miRNA-29a; miRNA-29c; metastases; oral cancer metastases;
DNA copy number; miRNA profiling; integrative analysis
ID BREAST-CANCER; MICRORNA; EXPRESSION; HEAD; METASTASIS; MIR-21; RNA;
MIRBASE; PROFILE; PCR
AB Objective. To better understand possible mechanisms involved in the dysregulation of gene expression unique to oral squamous cell carcinoma (OSCC) metastasis, the investigators examined the differential expression of microRNAs (miRNAs) in OSCC metastasis and their functional impact on target gene expression.
Study Design. Observational assessment of DNA copy number, miRNA, and RNA expression in primary and metastatic OSCC.
Setting. University of Washington Medical Center and affiliated hospitals.
Subjects. Tumor samples were taken from patients with primary incident OSCC; cells were laser-capture microdissected from 17 nonmetastatic primary tumors and 20 metastatic lymph nodes.
Methods. DNA copy number aberrations and gene expression profiles were previously determined using Affymetrix 250K Nsp I SNP arrays and HU133 plus 2.0 expression arrays. miRNAs were interrogated with Exiqon's Ready-to-Use PCR Panels assessing the expression of 368 human miRNAs.
Results. Investigators found 31 miRNAs differentially expressed between metastatic and nonmetastatic samples (false discovery rate <0.4; 26 overexpressed and 5 underexpressed in metastatic samples). Expression of 7 of these miRNAs was significantly associated with their DNA copy numbers, and expressions of 8 of these miRNAs were significantly associated with their target genes. Among these unique miRNAs, miR-140-3p, miR-29c, and miR-29a were differentially expressed in metastasis versus nonmetastatic samples and had a strong positive correlation with their DNA copy numbers and a negative correlation with the expression of their target genes.
Conclusion. Results suggest that DNA copy number aberration may play a role in the dysregulation of some differentially expressed miRNAs in OSCC metastasis, warranting further investigation.
C1 [Serrano, Nicholas A.; Xu, Chang; Kao, Michael; Chen, Chu; Mendez, Eduardo] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98115 USA.
[Serrano, Nicholas A.] Univ Washington, Sch Med, Seattle, WA 98115 USA.
[Xu, Chang; Mendez, Eduardo] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Liu, Yan; Wang, Pei; Fan, Wenhong; Zhao, Lue Ping] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Biostat & Biomath, Seattle, WA 98104 USA.
[Upton, Melissa P.] Univ Washington, Dept Pathol, Seattle, WA 98115 USA.
[Houck, John R.; Lohavanichbutr, Pawadee; Schwartz, Stephen M.; Chen, Chu] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98104 USA.
[Zhao, Lue Ping] Univ Washington, Dept Biostat, Seattle, WA 98115 USA.
[Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98115 USA.
[Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA.
RP Mendez, E (reprint author), Univ Washington, Dept Otolaryngol Head & Neck Surg, Fred Hutchinson Canc Res Ctr,Surg & Perioperat Ca, VA Puget Sound Hlth Care Syst,Clin Res Div, 6507,52nd Ave NE, Seattle, WA 98115 USA.
EM edmendez@u.washington.edu
OI Schwartz, Stephen/0000-0001-7499-8502
FU National Center for Research Resources, National Institutes of Health
(NIH) [5KL2RR025015-03]; Amos Medical Faculty Development Program Award
from the Robert Wood Johnson Foundation; Early Physician-Scientist
Career Development Award from the Howard Hughes Medical Institute; NIH,
Department of Health and Human Services Public Health Service Ruth L.
Kirschstein National Research Service Award [5T32DC000018-27]; NIH
[RO1CA095419]; Fred Hutchinson Cancer Research center; Department of
Otolaryngology-Head and Neck Surgery, University of Washington
FX This work was supported in part by grants 5KL2RR025015-03 from National
Center for Research Resources, National Institutes of Health (NIH); Amos
Medical Faculty Development Program Award from the Robert Wood Johnson
Foundation; Early Physician-Scientist Career Development Award from the
Howard Hughes Medical Institute; 5T32DC000018-27 from the NIH,
Department of Health and Human Services Public Health Service Ruth L.
Kirschstein National Research Service Award; NIH RO1CA095419; funds from
the Fred Hutchinson Cancer Research center; and center funds from the
Department of Otolaryngology-Head and Neck Surgery, University of
Washington; and by resources from and use of facilities at the VA Puget
Sound Health Care System, Fred Hutchinson Cancer Research Center,
University of Washington Medical Center and Harborview Medical Center,
Seattle, Washington.
NR 35
TC 8
Z9 10
U1 2
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD SEP
PY 2012
VL 147
IS 3
BP 501
EP 508
DI 10.1177/0194599812442490
PG 8
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 080YT
UT WOS:000314281300017
PM 22470160
ER
PT J
AU Lam, CSP
Carson, PE
Anand, IS
Rector, TS
Kuskowski, M
Komajda, M
McKelvie, RS
McMurray, JJ
Zile, MR
Massie, BM
Kitzman, DW
AF Lam, Carolyn S. P.
Carson, Peter E.
Anand, Inder S.
Rector, Thomas S.
Kuskowski, Michael
Komajda, Michel
McKelvie, Robert S.
McMurray, John J.
Zile, Michael R.
Massie, Barry M.
Kitzman, Dalane W.
TI Sex Differences in Clinical Characteristics and Outcomes in Elderly
Patients With Heart Failure and Preserved Ejection Fraction The
Irbesartan in Heart Failure With Preserved Ejection Fraction
(I-PRESERVE) Trial
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE aging; heart failure; sex; prognosis; preserved left ventricular
function
ID VENTRICULAR SYSTOLIC FUNCTION; LONG-TERM; ATRIAL-FIBRILLATION;
GENDER-DIFFERENCES; MORTALITY; POPULATION; MORBIDITY; SURVIVAL; DEATH;
WOMEN
AB Background-There are few sex-specific outcome data in heart failure with preserved ejection fraction.
Methods and Results-We assessed sex differences in baseline characteristics and outcomes among 4128 patients with heart failure with preserved ejection fraction in the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Women (n=2491) with heart failure with preserved ejection fraction were approximate to 1 year older (72 +/- 7 years versus 71 +/- 7 years) and more likely to be obese (46% versus 35%) and have chronic kidney disease (34% versus 26%) and hypertension (91% versus 85%) than men but less likely to have an ischemic cause (19% versus 34%), atrial fibrillation (27% versus 33%), or chronic obstructive pulmonary disease (8% versus 13%) (all P<0.001). During a mean of 49.5 months, there were 881 deaths (447 in women, 434 in men; risk ratio, 0.64; 95% CI, 0.56-0.74) and 5776 hospitalizations (3239 in women, 2537 in men; risk ratio, 0.80; 95% CI, 0.76-0.84). Women had lower risk of all-cause events (deaths and hospitalizations), even after adjusting for baseline characteristics (adjusted hazards ratio, 0.81; 95% CI, 0.73-0.89). However, the sex-related difference in risk of all-cause events was modified in the presence or absence of atrial fibrillation, renal dysfunction, stable angina pectoris, or advanced New York Heart Association class symptoms.
Conclusions-In patients with typical heart failure with preserved ejection fraction, there were prominent sex differences in baseline characteristics and outcomes. Women had better overall prognosis, although the presence of 4 common baseline characteristics seemed to moderate this finding.
C1 [Lam, Carolyn S. P.] Natl Univ Hlth Syst, Singapore, Singapore.
[Carson, Peter E.] Georgetown Univ, Washington, DC USA.
[Carson, Peter E.] Washington DC Vet Affairs Med Ctr, Washington, DC USA.
[Anand, Inder S.; Rector, Thomas S.; Kuskowski, Michael] Univ Minnesota, Dept Vet Affairs Hlth Care Syst, Minneapolis, MN USA.
[Anand, Inder S.; Rector, Thomas S.; Kuskowski, Michael] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Kuskowski, Michael] Univ Paris 06, Paris, France.
[Kuskowski, Michael] Hosp Pitie Salpetriere, Paris, France.
[McMurray, John J.] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.
[McKelvie, Robert S.] McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada.
[Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Kitzman, Dalane W.] Wake Forest Sch Med, Dept Internal Med, Cardiol Sect, Winston Salem, NC 27157 USA.
RP Kitzman, DW (reprint author), Wake Forest Sch Med, Dept Internal Med, Cardiol Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM dkitzman@wfubmc.edu
OI mcmurray, john/0000-0002-6317-3975
FU Bristol-Myers Squibb; Sanofi-Aventis; National Institutes of Health
[37AG18915, P30AG21222]
FX The I-PRESERVE trial was funded by Bristol-Myers Squibb and
Sanofi-Aventis, as was the present subanalysis. Also, it was supported,
in part, by National Institutes of Health grants 37AG18915 and
P30AG21222 (Dalane W. Kitzman).
NR 33
TC 27
Z9 28
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3289
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD SEP
PY 2012
VL 5
IS 5
BP 571
EP 578
DI 10.1161/CIRCHEARTFAILURE.112.970061
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 071GV
UT WOS:000313579500008
PM 22887722
ER
PT J
AU Koszdin, K
Pekow, C
Carey, SL
Varnam, S
Davis, P
Hamilton, K
Porter, A
Dang, H
Domingo, C
Villanueva, B
Tran, T
Shaffer, J
AF Koszdin, K.
Pekow, C.
Carey, S. L.
Varnam, S.
Davis, P.
Hamilton, K.
Porter, A.
Dang, H.
Domingo, C.
Villanueva, B.
Tran, T.
Shaffer, J.
TI Staff-Directed Environmental Enrichment Program
SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE
LA English
DT Meeting Abstract
C1 [Koszdin, K.; Pekow, C.; Carey, S. L.; Varnam, S.; Davis, P.; Hamilton, K.; Porter, A.; Dang, H.; Domingo, C.; Villanueva, B.; Tran, T.; Shaffer, J.] Vet Affairs Puget Sound Hlth Care Syst, Anim Res Facil, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC LABORATORY ANIMAL SCIENCE
PI MEMPHIS
PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA
SN 1559-6109
J9 J AM ASSOC LAB ANIM
JI J. Amer. Assoc. Lab. Anim. Sci.
PD SEP
PY 2012
VL 51
IS 5
BP 675
EP 676
PG 2
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA 067NV
UT WOS:000313303300193
ER
PT J
AU Matarazzo, BB
AF Matarazzo, Bridget B.
TI Adaptive institutional transference in the treatment of individuals with
borderline personality disorder
SO BULLETIN OF THE MENNINGER CLINIC
LA English
DT Article
ID ENVIRONMENT; ISSUES
AB The author introduces "adaptive institutional transference" (AIT) and describes how it develops in some patients in response to psychotherapist transfer in psychology training clinics. Individuals with borderline personality disorder are especially likely to develop AIT because of difficulties related to abandonment depression. Directors, supervisors, and student psychotherapists in a variety of training settings should be aware of these dynamics because of their important treatment implications, which are described. Limitations and ideas for future exploratory and qualitative research are also discussed. (Bulletin of the Menninger Clinic, 76[4], 297-313)
C1 [Matarazzo, Bridget B.] Denver Vet Affairs Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 19, Denver, CO USA.
[Matarazzo, Bridget B.] Univ Colorado Denver, Sch Med, Dept Psychiat, Denver, CO USA.
RP Matarazzo, BB (reprint author), Denver VAMC, VA VISN 19 MIRECC,1055 Clermont St, Denver, CO 80220 USA.
EM Bridget.Matarazzo@va.gov
NR 23
TC 0
Z9 0
U1 2
U2 5
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0025-9284
J9 B MENNINGER CLIN
JI Bull. Menninger Clin.
PD FAL
PY 2012
VL 76
IS 4
BP 297
EP 313
PG 17
WC Psychiatry; Psychology, Psychoanalysis
SC Psychiatry; Psychology
GA 066HJ
UT WOS:000313211100001
PM 23244524
ER
PT J
AU Fischer, CA
Licht, EA
Mendez, MF
AF Fischer, Christopher A.
Licht, Eliot A.
Mendez, Mario F.
TI The Neuropsychiatric Manifestations of Huntington's Disease-Like 2
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article
ID REPEAT EXPANSION; HUNTINGTON-DISEASE-LIKE-2; PHENOTYPE; ANCESTRY;
FEATURES
AB Huntington's disease-like 2 (HDL2) is a rare neuropsychiatric disorder that resembles HD but results from a distinct mutation. The authors present a patient with HDL2, hospitalized for psychiatric management, and they review the neuropsychiatric manifestations of this disorder. Depression, irritability/aggression, and frontal lobe personality changes are common presentations of HDL2 and are comparable to classic HD. Patients with HDL2 may differ from those with HD in having a lower incidence of obsessive-compulsive acts, known suicides, antisocial acts, and changes in sexuality. Clinicians should be aware of the psychiatric presentations of this disorder, when to obtain genetic testing, and how to manage problematic behaviors. (The Journal of Neuropsychiatry and Clinical Neurosciences 2012; 24:489-492)
C1 [Fischer, Christopher A.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA.
[Licht, Eliot A.; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Dept Neurobehav, Los Angeles, CA USA.
RP Fischer, CA (reprint author), Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA.
EM Cfischer@mednet.ucla.edu; mmendez@UCLA.edu
FU NIMH Grant [R01AG034499-03]
FX This work was supported by NIMH Grant #R01AG034499-03.
NR 15
TC 2
Z9 2
U1 0
U2 2
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD FAL
PY 2012
VL 24
IS 4
BP 489
EP 492
PG 4
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 057WK
UT WOS:000312594700047
PM 23224457
ER
PT J
AU Mendez, MF
AF Mendez, Mario F.
TI Loss of Meaning for "Marriage" in Semantic Dementia
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Letter
ID KNOWLEDGE
C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF,Dept Neurol & Psychiat, Los Angeles, CA 90095 USA.
RP Mendez, MF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF,Dept Neurol & Psychiat, Los Angeles, CA 90095 USA.
EM mmendez@UCLA.edu
FU NIA NIH HHS [01AG034499-03]
NR 5
TC 0
Z9 0
U1 0
U2 2
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD FAL
PY 2012
VL 24
IS 4
BP E56
EP E57
PG 2
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 057WK
UT WOS:000312594700033
PM 23224492
ER
PT J
AU Baker, JF
Baker, DG
Toedter, G
Shults, J
Von Feldt, JM
Leonard, MB
AF Baker, J. F.
Baker, D. G.
Toedter, G.
Shults, J.
Von Feldt, J. M.
Leonard, M. B.
TI Associations between vitamin D, disease activity, and clinical response
to therapy in rheumatoid arthritis
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE vitamin D; rheumatoid arthritis; disease activity; erosion; response to
therapy
ID D DEFICIENCY; HEALTH
AB Objective
Vitamin D deficiency is a potential risk factor for autoimmunity. Prior studies of the association between vitamin D levels and rheumatoid arthritis (RA) disease activity have yielded conflicting results.
Methods
Serum 25(OH)vitamin D levels were measured at baseline in 499 participants with active RA, ages 18-85 years, enrolled in a randomised clinical trial of golimumab (Go-Before Trial). Subjects were methotrexate and biologic therapy naive. Multivariable linear regression was used to assess associations between vitamin D levels and disease activity scores (DAS28), van der Heijde-Sharp (vdHS) erosion scores, and serum inflammatory markers. Generalised estimating equations were used to evaluate the associations between vitamin D status and the response to therapy over 52 weeks, using the DAS28 and ACR response.
Results
Forty-eight percent of participants were vitamin D deficient, defined as serum 25(OH)vitamin D <20 ng/mL. Deficiency was not associated with greater DAS28 (beta-0.021 [95% CI -0.22, 0.18]), adjusted for age, race, sex, BMI, disease duration and glomerular filtration rate. Vitamin D deficiency was not associated with baseline vdHS scores or inflammatory markers in adjusted or unadjusted models. There was no association between baseline vitamin D deficiency and change in DAS28 (beta = -0.024 [-0.30, 0.25]), proportion meeting ACR response (OR 0.82 [0.56, 1.20]), or radiographic progression at 52 weeks (OR 0.91 [0.59-1.40]).
Conclusions
Vitamin D levels were not associated with RA disease activity, inflammatory markers, or vdHS scores at baseline. Furthermore, there was no association between baseline vitamin D level and response to therapy or radiographic progression.
C1 [Baker, J. F.] Univ Penn, Div Rheumatol, Dept Med, Philadelphia, PA 19104 USA.
[Baker, D. G.] Centocor Res & Dev, Clin Immunol, Malvern, PA USA.
[Shults, J.; Leonard, M. B.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Von Feldt, J. M.] Vet Affairs Med Ctr, Div Rheumatol, Dept Med, Philadelphia, PA USA.
[Leonard, M. B.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA.
[Toedter, G.] Centocor Res & Dev, Biomarker, Malvern, PA USA.
RP Baker, JF (reprint author), Hosp Univ Penn, Dept Med, Div Rheumatol, 8 Penn Tower Bldg,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM bakerjo@uphs.upenn.edu
NR 23
TC 32
Z9 33
U1 1
U2 6
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392-856X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD SEP-OCT
PY 2012
VL 30
IS 5
BP 658
EP 664
PG 7
WC Rheumatology
SC Rheumatology
GA 033VG
UT WOS:000310828600003
PM 22776409
ER
PT J
AU Dhital, SM
Shenker, Y
Meredith, M
Davis, DB
AF Dhital, Subarna M.
Shenker, Yoram
Meredith, Melissa
Davis, Dawn Belt
TI A RETROSPECTIVE STUDY COMPARING NEUTRAL PROTAMINE HAGEDORN INSULIN WITH
GLARGINE AS BASAL THERAPY IN PREDNISONE-ASSOCIATED DIABETES MELLITUS IN
HOSPITALIZED PATIENTS
SO ENDOCRINE PRACTICE
LA English
DT Article
ID HYPERGLYCEMIA; MANAGEMENT; NPH; PHARMACOKINETICS; METAANALYSIS;
MORTALITY; EFFICACY; MARKER; TYPE-1; RISK
AB Objective: To compare glycemic outcomes in hospitalized patients with or without type 2 diabetes mellitus receiving neutral protamine Hagedorn insulin (NPH) vs glargine as basal insulin for management of glucocorticoid-associated hyperglycemia.
Methods: We conducted a retrospective review of electronic medical records in prednisone-treated adult patients with hyperglycemia in a university hospital. Consecutive patients were selected in both the NPH and glargine cohorts using inclusion and exclusion criteria. Baseline characteristics were assessed in each cohort. Glycemic outcomes were analyzed by comparing fasting blood glucose, mean daily blood glucose concentration, median daily blood glucose concentration, and the number of hypoglycemic episodes on a prespecified index day.
Results: One hundred twenty patients were included: 60 patients in the NPH cohort and 60 patients in the glargine cohort. The weight-based insulin requirement was lower in the NPH cohort than in the glargine cohort (0.27 +/- 0.2 units/kg vs 0.34 +/- 0.2 units/kg [P = .04] for basal insulin and 0.26 +/- 0.2 units/kg vs 0.36 +/- 0.2 units/kg [P = .03] for bolus insulin). NPH and glargine cohorts were similar regarding age, sex, race, body mass index, hemoglobin A(1c), serum creatinine, and prednisone dosage. Glycemic outcomes in the NPH cohort compared with outcomes in the glargine cohort were similar regarding mean fasting blood glucose concentration (134 +/- 49 mg/dL vs 139 +/- 54 mg/dL [P = .63]), mean daily blood glucose (167 +/- 46 mg/dL vs 165 +/- 52 mg/dL [P = .79]), median blood glucose (160 +/- 49 mg/dL vs 159 +/- 57 mg/dL [P = .90]), and number of hypoglycemic episodes per day (0.12 +/- 0.3 vs 0.10 +/- 0.3 [P = .77]).
Conclusions: NPH and glargine appear to be equally effective as basal insulin in the management of hyperglycemia in hospitalized patients receiving prednisone. However, the total daily insulin doses used were lower in the NPH cohort. (Endocr Pract. 2012;18:712-719)
C1 [Dhital, Subarna M.; Shenker, Yoram; Meredith, Melissa; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Endocrinol Diabet & Metab, Madison, WI USA.
[Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Davis, DB (reprint author), 1685 Highland Ave,MC 5148, Madison, WI 53705 USA.
EM dbd@medicine.wisc.edu
RI Davis, Dawn/B-1624-2013
FU NIDDK [DK083442]; University of Wisconsin; Novo-Nordisk; Medtronic
FX The authors would like to thank Zhanhai Li, PhD, for assistance with
statistical issues. Dr. Davis has received support from NIDDK (DK083442)
and the University of Wisconsin. The contents of this manuscript do not
represent the views of the Department of Veterans Affairs or the United
States government.; Drs. Dhital, Shenker, and Davis have no multiplicity
of interest to disclose. Dr. Meredith has received research support from
Novo-Nordisk and Medtronic for separate projects.
NR 22
TC 14
Z9 14
U1 0
U2 1
PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS
PI JACKSONVILLE
PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA
SN 1530-891X
J9 ENDOCR PRACT
JI Endocr. Pract.
PD SEP-OCT
PY 2012
VL 18
IS 5
BP 712
EP 719
DI 10.4158/EP11371.OR
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 031PH
UT WOS:000310653900011
PM 22784834
ER
PT J
AU Marinelli, LJ
Fitz-Gibbon, S
Hayes, C
Bowman, C
Inkeles, M
Loncaric, A
Russell, DA
Jacobs-Sera, D
Cokus, S
Pellegrini, M
Kim, J
Miller, JF
Hatfull, GF
Modlin, RL
AF Marinelli, Laura J.
Fitz-Gibbon, Sorel
Hayes, Clarmyra
Bowman, Charles
Inkeles, Megan
Loncaric, Anya
Russell, Daniel A.
Jacobs-Sera, Deborah
Cokus, Shawn
Pellegrini, Matteo
Kim, Jenny
Miller, Jeff F.
Hatfull, Graham F.
Modlin, Robert L.
TI Propionibacterium acnes Bacteriophages Display Limited Genetic Diversity
and Broad Killing Activity against Bacterial Skin Isolates
SO MBIO
LA English
DT Article
ID COMPARATIVE GENOMIC ANALYSIS; CRISPR-CAS SYSTEMS; TRANSFER-RNA GENES;
RESISTANT PROPIONIBACTERIA; PSEUDOMONAS; SEQUENCE; MICE; ANTIBIOTICS;
MICROBIOME; PROTECTION
AB Investigation of the human microbiome has revealed diverse and complex microbial communities at distinct anatomic sites. The microbiome of the human sebaceous follicle provides a tractable model in which to study its dominant bacterial inhabitant, Propionibacterium acnes, which is thought to contribute to the pathogenesis of the human disease acne. To explore the diversity of the bacteriophages that infect P. acnes, 11 P. acnes phages were isolated from the sebaceous follicles of donors with healthy skin or acne and their genomes were sequenced. Comparative genomic analysis of the P. acnes phage population, which spans a 30-year temporal period and a broad geographic range, reveals striking similarity in terms of genome length, percent GC content, nucleotide identity (>85%), and gene content. This was unexpected, given the far-ranging diversity observed in virtually all other phage populations. Although the P. acnes phages display a broad host range against clinical isolates of P. acnes, two bacterial isolates were resistant to many of these phages. Moreover, the patterns of phage resistance correlate closely with the presence of clustered regularly interspaced short palindromic repeat elements in the bacteria that target a specific subset of phages, conferring a system of prokaryotic innate immunity. The limited diversity of the P. acnes bacteriophages, which may relate to the unique evolutionary constraints imposed by the lipid-rich anaerobic environment in which their bacterial hosts reside, points to the potential utility of phage-based antimicrobial therapy for acne.
IMPORTANCE Propionibacterium acnes is a dominant member of the skin microflora and has also been implicated in the pathogenesis of acne; however, little is known about the bacteriophages that coexist with and infect this bacterium. Here we present the novel genome sequences of 11 P. acnes phages, thereby substantially increasing the amount of available genomic information for this phage population. Surprisingly, we find that, unlike other well-studied bacteriophages, P. acnes phages are highly homogeneous and show a striking lack of genetic diversity, which is perhaps related to their unique and restricted habitat. They also share a broad ability to kill clinical isolates of P. acnes; phage resistance is not prevalent, but when detected, it appears to be conferred by chromosomally encoded immunity elements within the host genome. We believe that these phages display numerous features that would make them ideal candidates for the development of a phage-based therapy for acne.
C1 [Bowman, Charles; Russell, Daniel A.; Jacobs-Sera, Deborah; Hatfull, Graham F.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.
[Bowman, Charles; Russell, Daniel A.; Jacobs-Sera, Deborah; Hatfull, Graham F.] Univ Pittsburgh, Pittsburgh Bacteriophage Inst, Pittsburgh, PA 15260 USA.
[Kim, Jenny] VA Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA.
[Marinelli, Laura J.; Miller, Jeff F.; Modlin, Robert L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
[Marinelli, Laura J.; Hayes, Clarmyra; Loncaric, Anya; Kim, Jenny; Modlin, Robert L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA.
[Fitz-Gibbon, Sorel; Inkeles, Megan; Cokus, Shawn; Pellegrini, Matteo] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA USA.
RP Hatfull, GF (reprint author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.
EM gfh@pitt.edu
OI Modlin, Robert/0000-0003-4720-031X
FU National Institute of Arthritis and Musculo-skeletal and Skin Diseases
of the National Institutes of Health [R21AR060382, R01AR053542,
F32AR060655]; American Acne and Rosacea Society
FX This work was supported by grants R21AR060382, R01AR053542, and
F32AR060655 (L.J.M) from the National Institute of Arthritis and
Musculo-skeletal and Skin Diseases of the National Institutes of Health
and by a clinical research grant from the American Acne and Rosacea
Society (L.J.M.).
NR 52
TC 15
Z9 15
U1 3
U2 38
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2012
VL 3
IS 5
AR e00279-12
DI 10.1128/mBio.00279-12
PG 13
WC Microbiology
SC Microbiology
GA 030QK
UT WOS:000310585000019
ER
PT J
AU Donohue, JM
Marcum, ZA
Gellad, WF
Lave, JR
Men, A
Hanlon, JT
AF Donohue, Julie M.
Marcum, Zachary A.
Gellad, Walid F.
Lave, Judith R.
Men, Aiju
Hanlon, Joseph T.
TI Systemic Lupus Erythematosus Disease Overview Access this educational
presentation that addresses different aspects of the SLE disease state.
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID MEDICARE-PART-D; OLDER-ADULTS; ELDERLY-PATIENTS; BEERS CRITERIA; DRUG;
BENEFIT; RISK; IMPLEMENTATION; PREVALENCE; VETERANS
AB Objectives: Inappropriate medication use, which is common in older adults, may be responsive to out-of-pocket costs. We examined the impact of Medicare Part D on inappropriate medication use among Medicare beneficiaries.
Study Design: Pre-post with comparison group.
Methods: Using data from 34,679 elderly beneficiaries in Medicare plans from 2004 to 2007, we used Healthcare Effectiveness Data and Information Set measures of prescribing quality: (1) any use of Drugs to Avoid in the Elderly (DAE), (2) a proportion of total medication use attributable to DAEs, and (3) any Potentially Harmful Drug-Disease Interactions in the Elderly (DDE). Rates of inappropriate use among 3 groups transitioning from no drug coverage or limited coverage ($150 or $350 quarterly caps) to Part D in 2006 were compared with those with constant drug coverage.
Results: DAE use increased slightly among those moving from no coverage to Part D (from 15.72%-17.61%) whereas the comparison group's use decreased (20.97%-18.32%) [relative odds ratio (ROR) = 1.34, 95% confidence interval [CI] 1.22-1.48, P <.0001]. However, the proportion of total drug use attributable to DAEs declined among the no coverage group after Part D (3.01%-1.98%), a significant difference relative to the comparison group (ROR = 0.84, 95% CI 0.72-0.98, P =.03). Rates of DDE were low (1%) both before and after Part D.
Conclusions: While use of high-risk drugs increased slightly among those gaining Part D drug coverage, high-risk drug use actually declined as a proportion of total drug use, and the prevalence of drug-disease interactions remained stable.
C1 [Donohue, Julie M.; Hanlon, Joseph T.] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Marcum, Zachary A.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RAND Corp, Pittsburgh, PA USA.
Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA.
Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Donohue, JM (reprint author), Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, 130 DeSoto St,Crabtree Hall A613, Pittsburgh, PA 15261 USA.
EM jdonohue@pitt.edu
FU National Institute of Health [KL2 RR024154, P30AG024827, T32 AG021885,
K07AG033174, R01 AG034056, 3U01 AGO 12553, R34 MH082682, R01 NR010135,
2R56AG027017]; Agency for Healthcare Research and Quality [R01 HS017695,
R01 HS018721, K12 HS019461]; VA Health Services [IIR-06-062]; VA HSR&D
Career Development Award [CDA 09-207-1]
FX This study was supported by National Institute of Health grants (KL2
RR024154, P30AG024827, T32 AG021885, K07AG033174, R01 AG034056, 3U01 AGO
12553, R34 MH082682, R01 NR010135,2R56AG027017), grants from the Agency
for Healthcare Research and Quality grants (R01 HS017695, R01 HS018721,
K12 HS019461), and a VA Health Services Research grant (IIR-06-062) and
VA HSR&D Career Development Award (CDA 09-207-1).
NR 32
TC 0
Z9 0
U1 1
U2 1
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD SEP
PY 2012
VL 18
IS 9
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 020XV
UT WOS:000309850800010
ER
PT J
AU McCauley, JL
Killeen, T
Gros, DF
Brady, KT
Back, SE
AF McCauley, Jenna L.
Killeen, Therese
Gros, Daniel F.
Brady, Kathleen T.
Back, Sudie E.
TI Posttraumatic Stress Disorder and Co-Occurring Substance Use Disorders:
Advances in Assessment and Treatment
SO CLINICAL PSYCHOLOGY-SCIENCE AND PRACTICE
LA English
DT Review
DE addiction; integrated treatment; posttraumatic stress disorder;
substance use disorders; trauma
ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL;
CARBOHYDRATE-DEFICIENT TRANSFERRIN; COCAINE-DEPENDENT INDIVIDUALS;
NATIONAL COMORBIDITY SURVEY; SELF-MEDICATION HYPOTHESIS; SEEKING-SAFETY
THERAPY; MENTAL-HEALTH PROBLEMS; DRUG-USE DISORDERS; GULF-WAR VETERANS
AB Posttraumatic stress disorder (PTSD) and substance use disorders (SUDs) are prevalent and frequently co-occur. Comorbid PTSD/SUD is associated with a more complex and costly clinical course when compared with either disorder alone, including increased chronic physical health problems, poorer social functioning, higher rates of suicide attempts, more legal problems, increased risk of violence, worse treatment adherence, and less improvement during treatment. In response, psychosocial treatment options have increased substantially over the past decade and integrated approachestreatments that address symptoms of both PTSD and SUD concurrentlyare fast becoming the preferred model for treatment. This article reviews the prevalence, etiology, and assessment practices as well as advances in the behavioral and pharmacologic treatment of comorbid PTSD and SUDs.
C1 [Back, Sudie E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA.
RP Back, SE (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Ralph H Johnson Vet Affairs Med Ctr, 67 President St, Charleston, SC 29425 USA.
EM backs@musc.edu
NR 159
TC 45
Z9 45
U1 8
U2 46
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0969-5893
J9 CLIN PSYCHOL-SCI PR
JI Clin. Psychol.-Sci. Pract.
PD SEP
PY 2012
VL 19
IS 3
BP 283
EP 304
DI 10.1111/cpsp.12006
PG 22
WC Psychology, Clinical
SC Psychology
GA 029HW
UT WOS:000310486500008
ER
PT J
AU Thienelt, CD
Green, K
Bowles, DW
AF Thienelt, C. D.
Green, K.
Bowles, D. W.
TI NEW AND ESTABLISHED TYROSINE KINASE INHIBITORS FOR CHRONIC MYELOID
LEUKEMIA
SO DRUGS OF TODAY
LA English
DT Review
DE Tyrosine kinase inhibitors; Chronic myeloid leukemia; Philadelphia
chromosome; BCR-ABL fusion protein
ID CHRONIC MYELOGENOUS LEUKEMIA; DIAGNOSED CHRONIC-PHASE; PATIENTS
RECEIVING IMATINIB; NILOTINIB FORMERLY AMN107; BCR-ABL;
ACCELERATED-PHASE; CYTOGENETIC RESPONSES; FOLLOW-UP;
EUROPEAN-LEUKEMIANET; MESYLATE THERAPY
AB Chronic myeloid leukemia (CML) is an uncommon malignancy, the treatment and prognosis of which have dramatically shifted over the last decade. Characterized by a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, small-molecule tyrosine kinase inhibitors (TKIs) targeted against the oncogenic BCR-ABL fusion protein have changed this once fatal disease into the model of targeted therapy. This article will review the pharmacological and clinical data supporting the use of imatinib and the second-generation TKIs dasatinib and nilotinib, and the novel TKIs bosutinib and ponatinib.
C1 [Thienelt, C. D.; Bowles, D. W.] Eastern Colorado Hlth Care Syst, Denver Vet Affairs Med Ctr, Sect Hematol Oncol, Denver, CO 80220 USA.
[Thienelt, C. D.; Green, K.] Univ Colorado, Sch Med, Div BMT Hematol, Denver, CO USA.
[Green, K.; Bowles, D. W.] Univ Colorado, Sch Med, Div Med Oncol, Denver, CO USA.
RP Bowles, DW (reprint author), Eastern Colorado Hlth Care Syst, Denver Vet Affairs Med Ctr, Sect Hematol Oncol, 1055 Clermont Ave,111F, Denver, CO 80220 USA.
EM daniel.bowles@ucdenver.edu
NR 68
TC 6
Z9 6
U1 0
U2 10
PU PROUS SCIENCE, SA-THOMSON REUTERS
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 1699-3993
J9 DRUG TODAY
JI Drugs Today
PD SEP
PY 2012
VL 48
IS 9
BP 601
EP 613
DI 10.1358/dot.2012.48.9.1869590
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 022SL
UT WOS:000309983700004
PM 23032801
ER
PT J
AU Rapuano, BE
Hackshaw, KM
Schniepp, HC
MacDonald, DE
AF Rapuano, Bruce E.
Hackshaw, Kyle M.
Schniepp, Hannes C.
MacDonald, Daniel E.
TI Effects of Coating a Titanium Alloy with Fibronectin on the Expression
of Osteoblast Gene Markers in the MC3T3 Osteoprogenitor Cell Line
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE coatings; differentiation; fibronectin; metal oxides; osteoblast;
real-time polymerase chain reaction
ID HUMAN PLASMA FIBRONECTIN; OXIDE NET CHARGE; IN-VITRO; SURFACE
CHARACTERISTICS; TRANSCRIPTION FACTORS; DISSOLUTION BEHAVIOR; BONE
SIALOPROTEIN; DENTAL IMPLANTS; DIFFERENTIATION; PROLIFERATION
AB Purpose: A number of environmental and patient-related factors contribute to implant failure. A significant fraction of these failures can be attributed to limited osseointegration resulting from poor bone healing responses. The overall goal of this study was to determine whether surface treatment of a titanium-aluminum-vanadium alloy (Ti-6Al-4V) implant material in combination with a biomimetic protein coating could promote the differentiation of attached osteoblastic cells. The specific aims of the study were to investigate whether osteo progenitor cells cultured on a rigorously cleaned implant specimen showed a normal pattern of differentiation and whether preadsorbed fibronectin accelerated or enhanced osteoblast differentiation. Materials and Methods: Ti-6Al-4V disks were rigorously cleaned, passivated in nitric acid, and dry heat-sterilized; some of the disks were then coated with 1 nmol/L fibronectin. MC3T3 osteo progenitor cells were then cultured on the pretreated disks for several weeks. Quantitative real-time polymerase chain reaction was performed to measure changes over time in the mRNA levels of osteoblast genes. Results: Fibronectin increased the peak expression of all analyzed osteoblast gene markers. "Early" genes that normally mark the proliferative phase (0 to 10 days) of osteoblastic development showed peak expression within the first 10 days after cell attachment to the titanium alloy. In contrast, "late" genes that normally mark the differentiation (10 to 20 days) and mineralization (20 to 36 days) phases of osteoblastogenesis achieved peak expression only after approximately 3 to 4 weeks of culture. Conclusions: Osteo progenitors cultured on a rigorously cleaned Ti-6Al-4V alloy were found to demonstrate a normal pattern of osteoblast differentiation. Preadsorbed fibronectin was observed to stimulate osteoblast differentiation during the mineralization phase of osteoblastogenesis. INT J ORAL MAXILLOFAC IMPLANTS 2012;27:1081-1090
C1 [MacDonald, Daniel E.] Columbia Univ, Langmuir Ctr Colloids & Interfaces, New York, NY 10027 USA.
[Rapuano, Bruce E.; Hackshaw, Kyle M.; MacDonald, Daniel E.] Cornell Univ, Hosp Special Surg, Weill Med Coll, New York, NY 10021 USA.
[Schniepp, Hannes C.] Coll William & Mary, Dept Appl Sci, Williamsburg, VA USA.
[MacDonald, Daniel E.] James J Peters VA Med Ctr, Bronx, NY USA.
RP MacDonald, DE (reprint author), Columbia Univ, Langmuir Ctr Colloids & Interfaces, 911 SW Mudd Bldg,Mail Code 4711,500 W 120th St, New York, NY 10027 USA.
EM dem14@columbia.edu
RI Schniepp, Hannes/B-8368-2008
OI Schniepp, Hannes/0000-0003-4645-9469
FU US National Institutes of Health [R01 DE017695]; National Center for
Research Resources, National Institutes of Health [C06-RR12538-01]
FX The project described was supported by a grant from the US National
Institutes of Health (#R01 DE017695, awarded to DEM). The sponsor did
not have any role in the study design; the collection, analysis, and
interpretation of data; the writing of the report; or the decision to
submit the paper for publication. This material is also the result of
work supported with resources and the use of facilities at the James J.
Peters VA Medical Center, Bronx, New York. This investigation was also
conducted at the Hospital for Special Services research facility
constructed with support of Grant C06-RR12538-01 from the National
Center for Research Resources, National Institutes of Health. The
authors would like to acknowledge Dr Xiaoyu Hu for technical advice with
the qRT-PCR analyses. Special thanks goes to Christine Marsh for her
technical assistance with cell culture and analysis of gene expression
using qRT-PCR.
NR 62
TC 11
Z9 13
U1 0
U2 10
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0882-2786
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PD SEP-OCT
PY 2012
VL 27
IS 5
BP 1081
EP 1090
PG 10
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 028AT
UT WOS:000310395900012
PM 23057020
ER
PT J
AU Dixon, LB
Cohen, AN
Drapalski, A
Glynn, SM
Medoff, D
Fang, LJ
AF Dixon, Lisa B.
Cohen, Amy N.
Drapalski, Amy
Glynn, Shirley M.
Medoff, Deborah
Fang, Li Juan
TI Effectiveness of a Patient-Centered Strategy to Increasing Use of
Evidenced-Based Interventions that Involve Families in the Care of
Persons with SMI
SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS
LA English
DT Meeting Abstract
C1 [Dixon, Lisa B.; Medoff, Deborah; Fang, Li Juan] Univ Maryland, Sch Med, Dept Psychiat, VA Capitol Network MIRECC, Baltimore, MD 21201 USA.
[Cohen, Amy N.] Greater Los Angeles VA Healthcare Ctr, Desert Pacific VA Mental Illness Res Educ & Clin, Los Angeles, CA USA.
[Glynn, Shirley M.] Univ Calif Los Angeles, Gteater Los Angeles VA Healthcare Ctr, Dept Biobehav Sci, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE
PI MILANO
PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY
SN 1091-4358
J9 J MENT HEALTH POLICY
JI J. Ment. Health Policy Econ.
PD SEP
PY 2012
VL 15
SU 1
BP S8
EP S8
PG 1
WC Health Policy & Services; Psychiatry
SC Health Care Sciences & Services; Psychiatry
GA 025LF
UT WOS:000310190000019
ER
PT J
AU Ritchie, C
Richman, J
Farmer, L
Bodner, E
Houston, T
AF Ritchie, Christine
Richman, Joshua
Farmer, Luke
Bodner, Eric
Houston, Thomas
TI How Much is Symptom Burden in Heart Failure Associated with Low
Self-Efficacy?
SO JOURNAL OF PALLIATIVE CARE
LA English
DT Meeting Abstract
C1 [Ritchie, Christine] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Ritchie, Christine] Jewish Home San Francisco, San Francisco, CA USA.
[Richman, Joshua] Birmingham VA Med Ctr, Birmingham, AL USA.
[Richman, Joshua; Farmer, Luke; Bodner, Eric] Univ Alabama Birmingham, Birmingham, AL USA.
[Houston, Thomas] Univ Massachusetts, Worcester, MA 01605 USA.
RI Houston, Thomas/F-2469-2013
NR 0
TC 0
Z9 0
U1 1
U2 1
PU CENTRE RECHERCHE INSTITUT UNIV GERIATRIE MONTREAL
PI MONTREAL
PA 4565 CHEMIN QUEEN MARY, MONTREAL, QUEBEC H3W 1W5, CANADA
SN 0825-8597
J9 J PALLIAT CARE
JI J. Palliative Care
PD FAL
PY 2012
VL 28
IS 3
BP 201
EP 201
PG 1
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 017EK
UT WOS:000309572700069
ER
PT J
AU Ramaswamy, R
Williams, A
Clark, E
Kelley, A
AF Ramaswamy, Ravishankar
Williams, Alicia
Clark, Elizabeth
Kelley, Amy
TI Fulfilling an ACGME Competency: Development and Impact of a
Communication Skills Curriculum in Internal Medicine Internship
SO JOURNAL OF PALLIATIVE CARE
LA English
DT Meeting Abstract
C1 [Ramaswamy, Ravishankar; Williams, Alicia; Clark, Elizabeth; Kelley, Amy] James J Peters VA Med Ctr, Bronx, NY USA.
[Ramaswamy, Ravishankar; Williams, Alicia; Clark, Elizabeth] Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CENTRE RECHERCHE INSTITUT UNIV GERIATRIE MONTREAL
PI MONTREAL
PA 4565 CHEMIN QUEEN MARY, MONTREAL, QUEBEC H3W 1W5, CANADA
SN 0825-8597
J9 J PALLIAT CARE
JI J. Palliative Care
PD FAL
PY 2012
VL 28
IS 3
BP 207
EP 207
PG 1
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 017EK
UT WOS:000309572700091
ER
PT J
AU Tonks, SA
Makwana, S
Salanitro, AH
Safford, MM
Houston, TK
Allison, JJ
Curry, W
Estrada, CA
AF Tonks, Stephen A.
Makwana, Sohil
Salanitro, Amanda H.
Safford, Monika M.
Houston, Thomas K.
Allison, Jeroan J.
Curry, William
Estrada, Carlos A.
TI Quality of Diabetes Mellitus Care by Rural Primary Care Physicians
SO JOURNAL OF RURAL HEALTH
LA English
DT Article
DE family medicine; health disparities; internal medicine; medical care;
quality
ID HEALTH-CARE; MEDICARE BENEFICIARIES; GEOGRAPHIC ACCESS; CLINICAL
INERTIA; OF-LIFE; DISPARITIES; MANAGEMENT; RESIDENCE; ADULTS;
INTERVENTION
AB Purpose: To explore the relationship between degree of rurality and glucose (hemoglobin A1c), blood pressure (BP), and lipid (LDL) control among patients with diabetes. Methods: Descriptive study; 1,649 patients in 205 rural practices in the United States. Patients residence ZIP codes defined degree of rurality (Rural-Urban Commuting Areas codes). Outcomes were measures of acceptable control (A1c < = 9%, BP < 140/90 mmHg, LDL < 130 mg/dL) and optimal control (A1c < 7%, BP < 130/80 mmHg, LDL < 100 mg/dL). Statistical significance was set at P < .008 (Bonferroni's correction). Findings: Although the proportion of patients with reasonable A1c control worsened by increasing degree of rurality, the differences were not statistically significant (urban 90%, large rural 88%, small rural 85%, isolated rural 83%; P= .10); mean A1c values also increased by degree of rurality, although not statistically significant (urban 7.2 [SD 1.6], large rural 7.3 [SD 1.7], small rural 7.5 [SD 1.8], isolated rural 7.5 [SD 1.9]; P= .16). We observed no differences between degree of rural and reasonable BP or LDL control (P= .42, P= .23, respectively) or optimal A1c or BP control (P= .52, P= .65, respectively). Optimal and mean LDL values worsened as rurality increased (P= .08, P= .029, respectively). Conclusions: In patients with diabetes who seek care in the rural Southern United States, we observed no relationship between degree of rurality of patients residence and traditional measures of quality of care. Further examination of the trends and explanatory factors for relative worsening of metabolic control by increasing degree of rurality is warranted.
C1 [Tonks, Stephen A.; Safford, Monika M.; Curry, William; Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Makwana, Sohil] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Salanitro, Amanda H.] Vanderbilt Univ, Nashville, TN USA.
[Salanitro, Amanda H.] VA Tennessee Valley Healthcare Geriatr Res Educ C, Nashville, TN USA.
[Houston, Thomas K.] Bedford Vet Affairs Med Ctr, Bedford, MA USA.
[Houston, Thomas K.; Allison, Jeroan J.] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA.
RP Estrada, CA (reprint author), Univ Alabama Birmingham, 720 Fac Off Tower,510 20th St S, Birmingham, AL 35294 USA.
EM cestrada@uab.edu
RI Houston, Thomas/F-2469-2013
OI Allison, Jeroan/0000-0003-4472-2112
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[5R18DK065001]; Veterans Affairs National Quality Scholars Program
FX This work was supported by the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) 5R18DK065001 to Dr. Allison. Drs.
Salanitro and Estrada were supported by the Veterans Affairs National
Quality Scholars Program. The sponsors had no role in the design and
conduct of the study; collection, management, analysis, and
interpretation of the data; and preparation, review, or approval of the
manuscript.
NR 45
TC 2
Z9 2
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0890-765X
J9 J RURAL HEALTH
JI J. Rural Health
PD FAL
PY 2012
VL 28
IS 4
BP 364
EP 371
DI 10.1111/j.1748-0361.2012.00410.x
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 027IT
UT WOS:000310346400005
PM 23083082
ER
PT J
AU Ross, GW
Duda, JE
Abbott, RD
Pellizzari, E
Petrovitch, H
Miller, DB
O'Callaghan, JP
Tanner, CM
Noorigian, JV
Masaki, K
Launer, L
White, LR
AF Ross, G. Webster
Duda, John E.
Abbott, Robert D.
Pellizzari, Edo
Petrovitch, Helen
Miller, Diane B.
O'Callaghan, James P.
Tanner, Caroline M.
Noorigian, Joseph V.
Masaki, Kamal
Launer, Lenore
White, Lon R.
TI Brain organochlorines and Lewy pathology: The Honolulu-Asia aging study
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; Lewy body; organochlorines; pesticides
ID PARKINSONS-DISEASE; PESTICIDE EXPOSURE; SUBSTANTIA-NIGRA; BREAST-CANCER;
RISK; SERUM; DIELDRIN; PARAQUAT; MIDLIFE; HAWAII
AB Although organochlorines have been reported more frequently in Parkinson's disease (PD) brains than in controls, the association with brain Lewy pathology is unknown. Honolulu-Asia Aging Study (HAAS) participants, exposed to organochlorines from a variety of sources during midlife, represent a population well suited to determining the relationship of brain organochlorines with Lewy pathology in decedents from the longitudinal HAAS. The study design included the measurement of 21 organochlorine levels in frozen occipital lobe samples from HAAS decedents. Alpha-synuclein immunostaining performed on 225 brains was used to identify Lewy bodies and Lewy neurites. With the potential for spurious associations to appear between Lewy pathology and 17 organochlorine compounds found in at least 1 brain, initial assessments identified heptachlor epoxide isomer b, methoxychlor, and benzene hexachloride b as being most important. The prevalence of Lewy pathology was 75% (6 of 8) among brains with any 2 of the 3 compounds, 48.8% (79 of 162) among those with 1, and 32.7% (18 of 55) for those with neither (P = .007 test for trend). Although findings persisted after removing cases with PD and dementia with Lewy bodies and after adjustment for age at death, body mass index, pack-years of cigarette smoking, and coffee intake (P = .013), the results were insignificant when correcting for multiple testing. Although consistent with earlier accounts of an association between organochlorines and clinical PD, associations with Lewy pathology warrant further study. (c) 2012 Movement Disorder Society
C1 [Ross, G. Webster; Petrovitch, Helen] VA Pacific Isl Hlth Care Syst, Honolulu, HI 96819 USA.
[Ross, G. Webster; Petrovitch, Helen; Masaki, Kamal; White, Lon R.] Honolulu Asia Aging Study, Kuakini Med Ctr, Honolulu, HI USA.
[Ross, G. Webster; Abbott, Robert D.; Petrovitch, Helen] Pacific Hlth Res & Educ Inst, Honolulu, HI USA.
[Ross, G. Webster; Petrovitch, Helen; Masaki, Kamal; White, Lon R.] Univ Hawai, John A Burns Sch Med, Dept Med, Honolulu, HI USA.
[Ross, G. Webster; Petrovitch, Helen; Masaki, Kamal; White, Lon R.] Univ Hawai, John A Burns Sch Med, Dept Geriatr, Honolulu, HI USA.
[Duda, John E.; Noorigian, Joseph V.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Duda, John E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Abbott, Robert D.] Univ Virginia, Sch Med, Div Biostat, Charlottesville, VA 22908 USA.
[Pellizzari, Edo] Res Triangle Inst, Res Triangle Pk, NC 27709 USA.
[Miller, Diane B.; O'Callaghan, James P.] NIOSH, Ctr Dis Control, Morgantown, WV USA.
[Tanner, Caroline M.] Parkinsons Inst, Sunnyvale, CA USA.
[Launer, Lenore] NIA, NIH, Bethesda, MD 20892 USA.
RP Ross, GW (reprint author), VA Pacific Isl Hlth Care Syst, 459 Patterson Rd, Honolulu, HI 96819 USA.
EM george.ross@va.gov
RI O'Callaghan, James/O-2958-2013
FU United States Department of the Army [DAMD17-98-1-8621]; National
Institutes of Health, National Institute of Neurological Disorders and
Stroke [5 R01 NS041265]; National Institute on Aging [1 U01 AG19349, 5
R01 AG017155]; Office of Research and Development, Medical Research
Service Department of Veterans Affairs; NIH, National Institute on
Aging; Department of Defense; Department of Veterans Affairs; NIH
FX This work was supported by United States Department of the Army, Grant
DAMD17-98-1-8621; National Institutes of Health, National Institute of
Neurological Disorders and Stroke, Grant 5 R01 NS041265; National
Institute on Aging Grants 1 U01 AG19349 and 5 R01 AG017155; and the
Office of Research and Development, Medical Research Service Department
of Veterans Affairs and was also supported in part by the Intramural
Research Program of the NIH, National Institute on Aging.; G. Webster
Ross received research support from the Department of Defense; NIA, NIH;
NINDS, NIH; and the Department of Veterans Affairs. John E. Duda and
Joseph V. Noorigian received research support from NINDS, NIH. Robert D.
Abbott received research support from the Department of Defense; NIA,
NIH; and NINDS, NIH. Edo Pellizzari received research support from the
Department of Defense. Helen Petrovitch received research support from
the Department of Defense; NIA, NIH; and NINDS, NIH. Diane B. Miller and
James P. O'Callaghan received research support from NIH. Caroline M.
Tanner received research support from the Department of Defense; NIA,
NIH; and NINDS, NIH. Kamal Masaki received research support from the
NIA, NIH. Lenore Launer has nothing to disclose. Lon R. White received
research support from the Department of Defense; NIA, NIH; and NINDS,
NIH.
NR 38
TC 4
Z9 4
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP
PY 2012
VL 27
IS 11
BP 1418
EP 1424
DI 10.1002/mds.25144
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 021WG
UT WOS:000309915500017
PM 22976848
ER
PT J
AU Demirjian, M
Rumbyrt, JS
Gowda, VC
Klaustermeyer, WB
AF Demirjian, M.
Rumbyrt, J. S.
Gowda, V. C.
Klaustermeyer, W. B.
TI Serum IgE and eosinophil count in allergic rhinitis-Analysis using a
modified Bayes' theorem
SO ALLERGOLOGIA ET IMMUNOPATHOLOGIA
LA English
DT Article
DE Rhinitis; IgE level; Eosinophil count; Bayes' theorem; Atopy
ID SKIN-TEST REACTIVITY; IMMUNOGLOBULIN-E LEVELS; COMMUNITY-BASED
POPULATION; RESPIRATORY ALLERGY; EPIDEMIOLOGIC SURVEY; VETERAN
POPULATION; PASSIVE SMOKING; ASTHMA; OMALIZUMAB; ADULTS
AB Background: To use probability theory to establish threshold values for total serum IgE and eosinophil counts that support a diagnosis of allergic rhinitis and to compare our results with previously published data.
Methods: Prospective study of rhinitis patients using a modified version of Bayes' theorem. Study included 125 patients at the West Los Angeles VA Medical Center diagnosed with rhinitis who completed allergy consultation and immediate hypersensitivity skin testing.
Results: Eighty-nine of 125 patients were atopic by prick and/or intradermal skin testing. Using a modified version of Bayes' theorem and positive and negative probability weights, calculations for different thresholds of serum IgE and eosinophil counts were summated and a posttest probability for atopy was calculated. Calculated posttest probabilities varied according to the threshold used to determine a positive or negative test; however, IgE thresholds greater than 140 IU/ml and eosinophil counts greater that 80 cells/ml were found to have a high probability of predicting atopy in patients with rhinitis. Moreover, had a greater influence than eosinophil count in determining posttest probability of allergy in this population. Considerable differences were noted in the IgE levels of atopic and non-atopic patients, including those with asthma or a history of smoking. However, these differences were not observed with eosinophil levels.
Conclusions: Using a modified version of Bayes' theorem to determine posttest probability, IgE threshold levels greater than 140 IU/ml and eosinophil counts greater than 80 cells/ml in an individual with clinical signs and symptoms of rhinitis are likely to correlate with an atopic aetiology. This model of probability may be helpful in evaluating individuals for diagnostic skin testing and certain types of allergy-modifying treatment. (c) 2011 SEICAP. Published by Elsevier Espana, S.L. All rights reserved.
C1 [Demirjian, M.; Gowda, V. C.; Klaustermeyer, W. B.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Div Allergy & Immunol,Dept Med, Los Angeles, CA 90095 USA.
[Rumbyrt, J. S.] Denver Allergy & Asthma Associates PC, Golden, CO 80401 USA.
RP Demirjian, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Div Allergy & Immunol,Dept Med, Los Angeles, CA 90095 USA.
EM mdemirjian@mednet.ucla.edu; william.klaustermeyer@va.gov
FU GlaxoSmithKline; Schering AG; Novartis
FX Dr. Rumbyrt is currently on the speaker's bureau for GlaxoSmithKline,
Merck, Astra Zeneca and has received research support from
GlaxoSmithKline and Schering AG. Dr. Gowda is on the speaker's bureau
for GlaxoSmithKline and Meda Pharmaceuticals and has received clinical
research support from Novartis.
NR 49
TC 3
Z9 3
U1 1
U2 5
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0301-0546
J9 ALLERGOL IMMUNOPATH
JI Allergol. Immunopath.
PD SEP-OCT
PY 2012
VL 40
IS 5
BP 281
EP 287
DI 10.1016/j.aller.2011.05.016
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA 020DN
UT WOS:000309789000004
PM 21978887
ER
PT J
AU Vina, ER
Masi, CM
Green, SL
Utset, TO
AF Vina, Ernest R.
Masi, Christopher M.
Green, Stephanie L.
Utset, Tammy O.
TI A study of racial/ethnic differences in treatment preferences among
lupus patients
SO RHEUMATOLOGY
LA English
DT Article
DE systemic lupus erythematosus; racial inequities; patient
decision-making; patient preferences; cyclophosphamide
ID 3 ETHNIC-GROUPS; RACIAL-DIFFERENCES; REPLACEMENT SURGERY; JOINT
REPLACEMENT; KNEE REPLACEMENT; AFRICAN-AMERICAN; DISEASE-ACTIVITY;
ERYTHEMATOSUS; NEPHRITIS; OUTCOMES
AB Objectives. To determine whether there are racial/ethnic differences in the willingness of SLE patients to receive CYC or participate in clinical trials, and whether demographic, psychosocial and clinical characteristics contribute to these differences.
Methods. Data from 120 African-American and 62 white lupus patients were evaluated. Structured telephone interviews were conducted to determine treatment preferences, as well as to study characteristics and beliefs that may affect these preferences. Data were analysed using serial hierarchical multivariate logistic regression and deviances were calculated from a saturated model.
Results. Compared with their white counterparts, African-American SLE patients expressed less willingness to receive CYC (67.0% vs 84.9%, P = 0.02) if their lupus worsened. This racial/ethnic difference remained significant after adjusting for socioeconomic and psychosocial variables. Logistic regression analysis showed that African-American race [odds ratio (OR) 0.29, 95% CI 0.10, 0.80], physician trust (OR 1.05, 95% CI 1.00, 1.12) and perception of treatment effectiveness (OR 1.40, 95% CI 1.22, 1.61) were the most significant determinants of willingness to receive CYC. A trend in difference by race/ethnicity was also observed in willingness to participate in a clinical trial, but this difference was not significant.
Conclusion. This study demonstrated reduced likelihood of accepting CYC in African-American lupus patients compared with white lupus patients. This racial/ethnic variation was associated with belief in medication effectiveness and trust in the medical provider, suggesting that education about therapy and improved trust can influence decision-making among SLE patients.
C1 [Vina, Ernest R.] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15260 USA.
[Vina, Ernest R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
[Masi, Christopher M.] N Shore Univ Hlth Syst, Internal Med Practice Based Improvement Res Netwo, Evanston, IL USA.
[Green, Stephanie L.; Utset, Tammy O.] Univ Chicago, Rheumatol Sect, Chicago, IL 60637 USA.
RP Vina, ER (reprint author), Arthrit Res Ctr, 3347 Forbes Ave,Ste 220, Pittsburgh, PA 15213 USA.
EM evina1@pitt.edu
OI Vina, Ernest/0000-0001-8135-1731
FU ACR/Research and Education Foundation Rheumatology Scientist Development
Award
FX ACR/Research and Education Foundation Rheumatology Scientist Development
Award.
NR 40
TC 6
Z9 6
U1 1
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD SEP
PY 2012
VL 51
IS 9
BP 1697
EP 1706
DI 10.1093/rheumatology/kes128
PG 10
WC Rheumatology
SC Rheumatology
GA 992ME
UT WOS:000307779700026
PM 22653381
ER
PT J
AU Muir, ER
Renteria, RC
Duong, TQ
AF Muir, Eric R.
Renteria, Rene C.
Duong, Timothy Q.
TI Reduced Ocular Blood Flow as an Early Indicator of Diabetic Retinopathy
in a Mouse Model of Diabetes
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID STREPTOZOTOCIN-INDUCED CONSTRICTION; RETINAL HEMODYNAMICS; CONTRAST
SENSITIVITY; INS2(AKITA) MOUSE; FUNCTIONAL MRI; RAT RETINA; MICE;
DYSFUNCTION; THRESHOLD; MELLITUS
AB PURPOSE. To investigate ocular blood flow and visual function in the Ins2(Akita) diabetic retinopathy mouse model at early and late time points after onset of hyperglycemia.
METHODS. Mice heterozygous for the Ins2(Akita) mutation, which become hyperglycemic at approximately 4 weeks old, were studied at 2.5 and 7.5 months of age, with age-matched wild-type littermates used as controls. Retinal and choroidal blood flows were noninvasively imaged at 42 X 42 X 400 mu m using magnetic resonance imaging. Visual function was measured using optokinetic tracking to determine spatial frequency and contrast thresholds from the same mice.
RESULTS. At 2.5 months, choroidal blood flow was significantly reduced (P < 0.01) by 20% in Ins2(Akita) mice (n = 13) compared with age-matched controls (n = 16), whereas retinal blood flow and visual function were not significantly affected (P > 0.05). At 7.5 months, both choroidal and retinal blood flow were significantly reduced (P < 0.05) by 27% and 28%, respectively, in Ins2(Akita) mice (n = 11) compared with age-matched controls (n = 15). Visual functions were also significantly worse (P < 0.05) in Ins2(Akita) mice at 7.5 months, as indicated by a 19% decreased spatial frequency threshold and 135% increased contrast threshold compared with age-matched controls. The magnitudes of the blood flow and vision deficits, however, were not correlated.
CONCLUSIONS. Although both choroidal and retinal blood flow and vision were altered after prolonged diabetes in the Ins2(Akita) mouse, choroidal blood flow was reduced even in young diabetic animals, suggesting ocular blood flow deficit could be an early pathological change in diabetic retinopathy. (Invest Ophthalmol Vis Sci. 2012;53:6488-6494) DOI:10.1167/iovs.12-9758
C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Res Imaging Inst, San Antonio, TX 78229 USA.
[Renteria, Rene C.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Renteria, Rene C.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Muir, Eric/H-8830-2013
OI Renteria, Rene/0000-0002-4490-0735
FU National Institutes of Health/National Eye Institute [R01 EY014211,
EY018855]; MERIT Award from the Department of Veterans Affairs;
Translational Technology Resources and Pilot Grant programs of the
Clinical Translational Science Award Parent [8UL1TR000149]; National
Institutes of Health [5T32HL007446-29]
FX Supported in part by National Institutes of Health/National Eye
Institute Grants R01 EY014211 and EY018855, a MERIT Award from the
Department of Veterans Affairs (TQD), Translational Technology Resources
and Pilot Grant programs of the Clinical Translational Science Award
Parent Grant 8UL1TR000149 (RCR and TQD), and partially supported by
National Institutes of Health Grant 5T32HL007446-29 (ERM).
NR 50
TC 35
Z9 35
U1 1
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2012
VL 53
IS 10
BP 6488
EP 6494
DI 10.1167/iovs.12-9758
PG 7
WC Ophthalmology
SC Ophthalmology
GA 016NQ
UT WOS:000309526200065
PM 22915034
ER
PT J
AU Tang, LL
Zhou, XH
AF Tang, Liansheng Larry
Zhou, Xiao-Hua
TI A Semiparametric Separation Curve Approach for Comparing Correlated ROC
Data From Multiple Markers
SO JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS
LA English
DT Article
DE Confidence band; Empirical distribution function; Least squares
ID OPERATING CHARACTERISTIC CURVES
AB In this article, we propose a separation curve method to identify the range of false positive rates for which two receiver operating characteristic (ROC) curves differ or one ROC curve is superior to the other. Our method is based on a general multivariate ROC curve model, including interaction terms between discrete covariates and false positive rates. It is applicable with most existing ROC curve models. Furthermore, we introduce a semiparametric least squares ROC estimator and apply the estimator to the separation curve method. We derive a sandwich estimator for the covariance matrix of the semiparametric estimator. We illustrate the application of our separation curve method through two real life examples. The technical proofs, a dataset, and the computer code are available in the online supplementary materials.
C1 [Tang, Liansheng Larry] George Mason Univ, Dept Stat, Fairfax, VA 22030 USA.
[Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, NW HSR & D Ctr Excellence, Seattle, WA 98101 USA.
[Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Zhou, Xiao-Hua] Harbin Med Univ, Dept Biostat, Harbin 150081, Heilongjiang, Peoples R China.
RP Tang, LL (reprint author), George Mason Univ, Dept Stat, Fairfax, VA 22030 USA.
EM ltang1@gmu.edu; azhou@u.washington.edu
FU National Cancer Institute under the American Recovery and Reinvestment
Act [R15CA150698]; National Security Agency [H98230-11-1-0196];
Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service [XVA 61-036]
FX The authors thank two anonymous referees, the associate editor, and the
editor for their constructive comments and useful suggestions. The
project described here was supported by Award Number R15CA150698 from
the National Cancer Institute under the American Recovery and
Reinvestment Act of 2009; by Award Number H98230-11-1-0196 from the
National Security Agency; and by Department of Veterans Affairs,
Veterans Health Administration, Health Services Research and Development
Service, project grant XVA 61-036. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Cancer Institute, the National Institutes
of Health, or the Department Of Veterans Affairs.
NR 9
TC 3
Z9 3
U1 0
U2 0
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA
SN 1061-8600
J9 J COMPUT GRAPH STAT
JI J. Comput. Graph. Stat.
PD SEP
PY 2012
VL 21
IS 3
BP 662
EP 676
DI 10.1080/10618600.2012.663303
PG 15
WC Statistics & Probability
SC Mathematics
GA 999AR
UT WOS:000308282000006
PM 23074360
ER
PT J
AU Carmel, L
Koonin, EV
Dracheva, S
AF Carmel, Liran
Koonin, Eugene V.
Dracheva, Stella
TI Dependencies among Editing Sites in Serotonin 2C Receptor mRNA
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID 5-HT2C RECEPTORS; CONSTITUTIVE ACTIVITY; HUMAN BRAIN; ADAR2; SUICIDE;
GENE; IDENTIFICATION; TRANSCRIPTOME; PHARMACOLOGY; SELECTIVITY
AB The serotonin 2C receptor (5-HT2CR)-a key regulator of diverse neurological processes-exhibits functional variability derived from editing of its pre-mRNA by site-specific adenosine deamination (A-to-I pre-mRNA editing) in five distinct sites. Here we describe a statistical technique that was developed for analysis of the dependencies among the editing states of the five sites. The statistical significance of the observed correlations was estimated by comparing editing patterns in multiple individuals. For both human and rat 5-HT2CR, the editing states of the physically proximal sites A and B were found to be strongly dependent. In contrast, the editing states of sites C and D, which are also physically close, seem not to be directly dependent but instead are linked through the dependencies on sites A and B, respectively. We observed pronounced differences between the editing patterns in humans and rats: in humans site A is the key determinant of the editing state of the other sites, whereas in rats this role belongs to site B. The structure of the dependencies among the editing sites is notably simpler in rats than it is in humans implying more complex regulation of 5-HT2CR editing and, by inference, function in the human brain. Thus, exhaustive statistical analysis of the 5-HT2CR editing patterns indicates that the editing state of sites A and B is the primary determinant of the editing states of the other three sites, and hence the overall editing pattern. Taken together, these findings allow us to propose a mechanistic model of concerted action of ADAR1 and ADAR2 in 5-HT2CR editing. Statistical approach developed here can be applied to other cases of interdependencies among modification sites in RNA and proteins.
C1 [Carmel, Liran] Hebrew Univ Jerusalem, Dept Genet, Alexander Silberman Inst Life Sci, Fac Sci, IL-91904 Jerusalem, Israel.
[Koonin, Eugene V.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA.
[Dracheva, Stella] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Dracheva, Stella] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
RP Carmel, L (reprint author), Hebrew Univ Jerusalem, Dept Genet, Alexander Silberman Inst Life Sci, Fac Sci, J Safra Campus, IL-91904 Jerusalem, Israel.
EM Stella.Dracheva@mssm.edu
FU European Union Marie Curie International Reintegration Grant
[PIRG05-GA-2009-248639]; Lohenstein August and Elza Foundation;
Intramural Program of the US Department of Health and Human Services
(National Library of Medicine, NIH); VA Merit award; NIMH grant
[MH090352]; Hope for Depression Foundation grant; VISN3 Mental Illness
Research and Education Clinical Center (MIRECC)
FX LC was supported by the European Union Marie Curie International
Reintegration Grant (PIRG05-GA-2009-248639), and by the Lohenstein
August and Elza Foundation. EVK is supported by the Intramural Program
of the US Department of Health and Human Services (National Library of
Medicine, NIH). SD is supported by VA Merit award, NIMH MH090352 grant,
the Hope for Depression Foundation grant, and by the VISN3 Mental
Illness Research and Education Clinical Center (MIRECC). The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 43
TC 3
Z9 4
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD SEP
PY 2012
VL 8
IS 9
AR e1002663
DI 10.1371/journal.pcbi.1002663
PG 13
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 016IJ
UT WOS:000309510900008
PM 22969417
ER
PT J
AU Cohen, SP
Gallagher, RM
Davis, SA
Griffith, SR
Carragee, EJ
AF Cohen, Steven P.
Gallagher, Rollin M.
Davis, Shelton A.
Griffith, Scott R.
Carragee, Eugene J.
TI Spine-area pain in military personnel: a review of epidemiology,
etiology, diagnosis, and treatment
SO SPINE JOURNAL
LA English
DT Review
DE Back pain; Neck pain; Nonbattle injury; Soldier; War
ID LOW-BACK-PAIN; EPIDURAL STEROID INJECTIONS;
POSTTRAUMATIC-STRESS-DISORDER; OPERATION IRAQI FREEDOM; NECK PAIN;
MUSCULOSKELETAL DISORDERS; SACROILIAC JOINT; RADIOFREQUENCY DENERVATION;
WORKING POPULATION; ENDURING FREEDOM
AB BACKGROUND CONTEXT: Nonbattle illnesses and injuries are the major causes of unit attrition in modern warfare. Spine-area pain is a common disabling injury in service members associated with a very low return-to-duty (RTD) rate.
PURPOSE: To provide an overview of the current understanding of epidemiology, possible causes, and relative prognosis of spine-area pain syndromes in military personnel, including a discussion of various treatment options available in theaters of operation.
STUDY DESIGN: Literature review.
METHODS: Search focusing on epidemiology, etiology and associative factors, and treatment of spinal pain using electronic databases, textbooks, bibliographic references, and personal accounts.
RESULTS: Spine-area pain is the most common injury or complaint "in garrison" and appears to increase during training and combat deployments. Approximately three-quarters involve low back pain, followed by cervical and midback pain syndromes. Some predictive factors associated with spine-area pain are similar to those observed in civilian cohorts, such as psychosocial distress, heavy physical activity, and more sedentary lifestyle. Risk factors specific to military personnel include concomitant psychological trauma, g-force exposure in pilots and airmen, extreme shock and vibration exposure, heavy combat load requirements, and falls incurred during airborne, air assault, and urban dismounted ground operations. Effective forward-deployed treatment has been difficult to implement, but newer strategies may improve RTD rates.
CONCLUSIONS: Spine-area pain syndromes comprise a major source of unit attrition and are often the result of duty-related burdens incurred during combat operations. Current strategies in theaters of operation that may improve the low RTD rates include individual and unit level psychological support, early resumption of at least some forward-area duties, multimodal treatments, and ergonomic modifications. Published by Elsevier Inc.
C1 [Cohen, Steven P.] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Pain Management Div, Baltimore, MD 21205 USA.
[Cohen, Steven P.] Walter Reed Natl Mil Med Ctr, Dept Anesthesiol, Bethesda, MD 20889 USA.
[Gallagher, Rollin M.] Philadelphia VA Med Ctr, Dept Psychiat, Philadelphia, PA 19104 USA.
[Gallagher, Rollin M.] Philadelphia VA Med Ctr, Dept Anesthesiol, Philadelphia, PA 19104 USA.
[Davis, Shelton A.] Walter Reed Natl Mil Med Ctr, Dept Orthoped Surg, Phys Med & Rehabil Serv, Bethesda, MD 20889 USA.
[Griffith, Scott R.] Walter Reed Natl Mil Med Ctr, Dept Surg, Anesthesia Serv, Bethesda, MD 20889 USA.
[Carragee, Eugene J.] Stanford Univ, Sch Med, Dept Orthoped Surg, Stanford, CA 94305 USA.
RP Cohen, SP (reprint author), Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Pain Management Div, 550 N Broadway,Suite 301, Baltimore, MD 21205 USA.
EM scohen40@jhmi.edu
FU NIH; OREF; AO Foundation; John P. Murtha Neuroscience and Pain
Institute, Johnstown, PA, USA; Defense and Veterans Pain Management
Initiative, Washington, DC, USA
FX SPC: Nothing to disclose. RMG: Nothing to disclose. SAD: Nothing to
disclose. SRG: Nothing to disclose. EJC: Stock Ownership: Intrinsic
Spine (B), Bioassetts (B); Private Investments: Simpirica (D); Research
Support (Investigator Salary): NIH (C, Paid directly to
institution/employer); Trips/Travel: The Spine Journal (A); Other
Office: NASS/The Spine Journal (E, Editor in Chief); Fellowship Support:
OREF (E, Paid directly to institution/employer), AO Foundation (E, Paid
directly to institution/employer).; Funded in part by a congressional
grant from the John P. Murtha Neuroscience and Pain Institute,
Johnstown, PA, USA, and the Defense and Veterans Pain Management
Initiative, Washington, DC, USA.
NR 83
TC 17
Z9 20
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1529-9430
J9 SPINE J
JI Spine Journal
PD SEP
PY 2012
VL 12
IS 9
SI SI
BP 833
EP 842
DI 10.1016/j.spinee.2011.10.010
PG 10
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 016OF
UT WOS:000309527900019
PM 22100208
ER
PT J
AU Paintlia, AS
Paintlia, MK
Hollis, BW
Singh, AK
Singh, I
AF Paintlia, Ajaib S.
Paintlia, Manjeet K.
Hollis, Bruce W.
Singh, Avtar K.
Singh, Inderjit
TI Interference with RhoA-ROCK Signaling Mechanism in Autoreactive CD4(+) T
Cells Enhances the Bioavailability of 1,25-Dihydroxyvitamin D-3 in
Experimental Autoimmune Encephalomyelitis
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID REMITTING MULTIPLE-SCLEROSIS; VITAMIN-D-RECEPTOR; COA REDUCTASE
INHIBITOR; ADD-ON THERAPY; COMBINATION THERAPY; SUPPRESSES SEVERITY;
SEASONAL-VARIATION; GENE POLYMORPHISM; HEALTHY-SUBJECTS;
CONTROLLED-TRIAL
AB Vitamin D deficiency is a major risk factor for central nervous system (CNS) demyelinating diseases including multiple sclerosis (MS) and its animal model, that of experimental autoimmune encephalomyelitis (EAE). Both vitamin D-3 and 1, 25-dihydroxyviatmin-D-3 (calcitriol) had beneficial effects in EAE/MS. However, the exact cause of vitamin D deficiency in EAE/MS is not clear. Previously, we documented that lovastatin (LOV) provides protection in EAE animals via inhibition of RhoA-ROCK signaling. Herein, we demonstrate that LOV prevents the lowering of circulating 25-hydroxyvitamin-D-3 and 1,25-dihydroxyviatmin-D-3 levels including 1,25-dihydroxyviatmin-D-3 levels in the peripheral lymphoid organs and CNS of treated EAE animals. These effects of LOV were attributed to enhanced expression of vitamin D synthesizing enzyme (la-hydroxylase) in kidney and the CNS, with corresponding reduction of vitamin D catabolizing enzyme (24-hydorxylase) expression in the CNS of EAE animals via inhibition of RhoA-ROCK signaling. Ex vivo and in vitro studies established that autoreactive Th1/Th17 cells had higher expression of 24-hydroxylase than Th2/T regulatory cells, that was reverted by LOV or ROCK inhibitor. Interestingly, LOV-mediated regulation of vitamin D metabolism had improved vitamin D-3 efficacy to confer protection in EAE animals and that was ascribed to the LOV- and calcitriol-induced immunomodulatory synergy. Together, these data provide evidence that interfering with RhoA-ROCK signaling in autoreactive Th1/Th17 cells can improve vitamin D-3 efficacy in clinical trials of MS and related neurodegenerative disorders. (Am J Pathol 2012,181:993-1006 http://dx.doi.org/10.1016/j.ajpath.2012.05.028)
C1 [Paintlia, Ajaib S.; Paintlia, Manjeet K.; Hollis, Bruce W.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA.
RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, 173 Ashley Ave, Charleston, SC 29425 USA.
EM singhi@musc.edu
OI Paintlia, Ajaib/0000-0003-4525-5333
FU NIH [NS-22576, NS-37766, 1BX001072, C06-RR015455, C06-RR018823]
FX Supported by grants from the NIH (NS-22576, NS-37766, 1BX001072,
C06-RR015455, and C06-RR018823).
NR 64
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD SEP
PY 2012
VL 181
IS 3
BP 993
EP 1006
DI 10.1016/j.ajpath.2012.05.028
PG 14
WC Pathology
SC Pathology
GA 012QH
UT WOS:000309251100027
PM 22796435
ER
PT J
AU Seshasai, RK
Katz, R
de Boer, IH
Siscovick, D
Shlipak, MG
Rifkin, DE
Sarnak, MJ
AF Seshasai, Rebecca Kurnik
Katz, Ronit
de Boer, Ian H.
Siscovick, David
Shlipak, Michael G.
Rifkin, Dena E.
Sarnak, Mark J.
TI Apolipoprotein E and kidney function in older adults
SO CLINICAL NEPHROLOGY
LA English
DT Article
DE apolipoprotein E; chronic kidney disease; kidney function; elderly
ID GLOMERULAR-FILTRATION-RATE; SERUM CYSTATIN-C; RENAL-DISEASE; RISK;
POLYMORPHISM; NEPHROPATHY; ASSOCIATION; PROGRESSION; CREATININE; DECLINE
AB Background: Previous studies suggest that the epsilon 4 and epsilon 2 alleles of apolipoprotein E (APOE) may be associated with decreased and increased risks of CKD, respectively, but there are limited data in older adults. We evaluated the associations of apolipoprotein E alleles with kidney function among older adults in the cardiovascular health study (CHS). Methods: Caucasian participants had APOE allelic analysis and serum creatinine and cystatin C measured at baseline (n = 3,844 for cross sectional analysis) and in follow up (n = 3,226 for longitudinal analysis). APOE variation was evaluated as an additive model with number of epsilon 2, epsilon 3 and epsilon 4 alleles. GFR was estimated using the CKD epidemiology equation (eGFRcreat) and the cystatin C demographic equation (eGFRcys). The primary outcome was CKD defined by eGFR < 60 ml/min/1.73 m(2). The secondary outcome was rapid progression defined by annual loss of eGFR > 3 ml/min/1.73 m(2). Results: Mean eGFRcreat was 72 ml/min/1.73 m(2) (25% CKD). Compared with the epsilon 3 allele, the APOE epsilon 4 allele was associated with reduced risk of CKD by eGFRcreat: unadjusted odds ratio (OR) and 95% confidence interval (CI) 0.79 (0.67-0.93) per allele, fully adjusted OR (95% CI) 0.80 (0.68-0.96) per allele. Results were consistent using eGFRcys. There was no association of the epsilon 2 allele with CKD or between the apolipoprotein E gene with rapid progression. Conclusions: The apolipoprotein epsilon 4 allele was associated with lower odds of CKD in elderly Caucasian individuals. Future research should confirm these findings in other races and explore mechanisms to explain these results.
C1 [Seshasai, Rebecca Kurnik; Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Dept Med, Boston, MA 02111 USA.
[Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA.
[de Boer, Ian H.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA.
[Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Gen Internal Med Sect, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Rifkin, Dena E.] Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92103 USA.
RP Sarnak, MJ (reprint author), Tufts Med Ctr, Div Nephrol, Dept Med, Box 391,800 Washington St, Boston, MA 02111 USA.
EM msarnak@tuftsmedicalcenter.org
FU National Heart, Lung, and Blood Institute [HL080295, HL-075366];
National Institute on Aging [AG-023269, AG-15928, AG-20098, AG-027058];
University of Pittsburgh Claude D. Pepper Older Americans Independence
Center [P30-AG-024827]; [R01-AG-027002]; [K24DK078204];
[N01-HC-85239]; [N01-HC-85079]; [N01-HC-85086]; [N01-HC-35129]; [N01
HC-15103]; [N01 HC-55222]; [N01-HC-75150]; [N01-HC-45133]
FX The research reported in this article was supported by grants
R01-AG-027002, K24DK078204 and contract numbers N01-HC-85239,
N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01
HC-55222, N01-HC-75150, N01-HC-45133, grant number HL080295 from the
National Heart, Lung, and Blood Institute and grant number AG-023269
from the National Institute on Aging, with additional contribution from
the National Institute of Neurological Disorders and Stroke. Additional
support was provided through AG-15928, AG-20098, and AG-027058 from the
National Institute on Aging, HL-075366 from the National Heart, Lung and
Blood Institute, and the University of Pittsburgh Claude D. Pepper Older
Americans Independence Center P30-AG-024827. A full list of principal
CHS investigators and institutions can be found at
http://www.chs-nhlbi.org/pi.htm. Dr. Katz had full access to all of the
data in the study and takes responsibility for the integrity of the data
and the accuracy of the data analysis. An abstract representing this
work was presented at the American Society of Nephrology Annual Meeting
in Denver, Colorado in 2010.
NR 25
TC 6
Z9 6
U1 0
U2 0
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0301-0430
J9 CLIN NEPHROL
JI Clin. Nephrol.
PD SEP
PY 2012
VL 78
IS 3
BP 174
EP 180
DI 10.5414/CN107427
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 014MC
UT WOS:000309378900002
PM 22874105
ER
PT J
AU Rao, SV
Dai, D
Subherwal, S
Weintraub, WS
Brindis, RS
Messenger, JC
Lopes, RD
Peterson, ED
AF Rao, Sunil V.
Dai, David
Subherwal, Sumeet
Weintraub, William S.
Brindis, Ralph S.
Messenger, John C.
Lopes, Renato D.
Peterson, Eric D.
TI Association Between Periprocedural Bleeding and Long-Term Outcomes
Following Percutaneous Coronary Intervention in Older Patients
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE elderly patients; percutaneous coronary intervention; periprocedural
bleeding
ID CARDIOVASCULAR DATA REGISTRY; ACUTE MYOCARDIAL-INFARCTION;
BLOOD-TRANSFUSION; CLINICAL-OUTCOMES; MORTALITY; RISK; CLOPIDOGREL;
IMPACT; THERAPY; ASPIRIN
AB Objectives The authors sought to describe the association between post-procedural bleeding and long-term recurrent bleeding, major adverse cardiac events (MACE), and mortality among older patients undergoing percutaneous coronary intervention (PCI).
Background Bleeding complications after PCI are associated with an increased risk for acute morbidity and long-term mortality, but the association of these bleeding complications with other events is unknown.
Methods Patients entered into the National Cardiovascular Data Registry (NCDR) CathPCI Registry (n = 461,311; 946 sites) from January 2004 to December 2008 were linked with claims from the Centers for Medicare & Medicaid Services and grouped according to in-hospital post-PCI bleeding. The association between post-PCI bleeding and 1-, 12-, and 30-month readmission for bleeding, MACE, and all-cause mortality was examined with Cox regression that included patient and procedural characteristics using no bleeding as the reference.
Results Overall, 3.1% (n = 14,107) of patients experienced post-PCI bleeding. Patients who bled were older, more often female, had more medical comorbidities, less often received bivalirudin, and more often underwent PCI via the femoral approach. After adjustment, bleeding after the index procedure was significantly associated with readmission for bleeding (adjusted hazard ratios [95% confidence interval]: 1 month, 1.54 [1.42 to 1.67]; 12 months, 1.52 [1.40 to 1.66]; 30 months, 1.29 [1.11 to 1.50]), MACE (1 month, 1.11 [1.07 to 1.15]; 12 months, 1.17 [1.13 to 1.21]; 30 months, 1.12 [1.06 to 1.19]) and all-cause mortality (1 month, 1.32 [1.26 to 1.38]; 12 months, 1.33 [1.27 to 1.40]); 30 months, 1.22 [1.15 to 1.30]).
Conclusions Post-PCI bleeding complications are associated with an increased risk for short-and long-term recurrent bleeding, MACE, and all-cause mortality. These data underscore the prognostic importance of periprocedural bleeding and the need for identifying strategies to reduce long-term bleeding risk among patients undergoing PCI. (J Am Coll Cardiol Intv 2012;5:958-65) (C) 2012 by the American College of Cardiology Foundation
C1 [Rao, Sunil V.; Dai, David; Subherwal, Sumeet; Lopes, Renato D.; Peterson, Eric D.] Durham Vet Affairs Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA.
[Brindis, Ralph S.] San Francisco Kaiser Permanente Hosp, San Francisco, CA USA.
[Messenger, John C.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Rao, SV (reprint author), Durham Vet Affairs Med Ctr, Duke Clin Res Inst, 508 Fulton St 111A, Durham, NC 27705 USA.
EM sunil.rao@duke.edu
FU American College of Cardiology; Medicines Company, Parsippany, New
Jersey; Ikaria and Sanofi-Aventis; Medicines Company, Terumo, Zoll;
Bristol-Myers Squibb; Eli Lilly; Johnson Johnson
FX This analysis was supported by the American College of Cardiology and
The Medicines Company, Parsippany, New Jersey. The Medicines Company did
not have input into the design of the study nor in the preparation of
the paper. Dr. Rao has received research funding from Ikaria and
Sanofi-Aventis (<$ 10,000), and consulting fees from The Medicines
Company, Terumo, and Zoll (<$ 10,000). Dr. Lopes has received research
grant support from Bristol-Myers Squibb (<$ 10,000). Dr. Peterson has
received research grant support from Eli Lilly and Johnson & Johnson (<$
10,000). All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.
NR 29
TC 31
Z9 34
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD SEP
PY 2012
VL 5
IS 9
BP 958
EP 965
DI 10.1016/j.jcin.2012.05.010
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 014CB
UT WOS:000309351600010
PM 22995883
ER
PT J
AU Patrician, PA
Dolansky, M
Estrada, C
Brennan, C
Miltner, R
Newsom, J
Olds, D
Splaine, M
Moore, S
AF Patrician, Patricia A.
Dolansky, Mary
Estrada, Carlos
Brennan, Caitlin
Miltner, Rebecca
Newsom, Jeremiah
Olds, Danielle
Splaine, Mark
Moore, Shirley
TI Interprofessional Education in Action: The VA Quality Scholars
Fellowship Program
SO NURSING CLINICS OF NORTH AMERICA
LA English
DT Article
DE Quality improvement; Interprofessional education; Patient safety; VA
Quality Scholars Fellowship Program
ID IMPROVEMENT; SAFETY; CARE
AB Although there are many examples of interprofessional education activities that focus on quality and safety, few include longitudinal experiences of teams working together over time. One exception is the Veterans Affairs Quality Scholars (VAQS) fellowship program. This article describes the integration of interprofessional education into the VAQS fellowship program, offers 2 examples of interprofessional projects conducted by the fellows, and discusses the VAQS program as a model for others to consider in developing interprofessional training programs in safety and quality improvement.
C1 [Patrician, Patricia A.; Miltner, Rebecca] Univ Alabama Birmingham, Sch Nursing, Dept Community Hlth Outcomes & Syst, Birmingham, AL 35294 USA.
[Patrician, Patricia A.; Estrada, Carlos; Miltner, Rebecca; Newsom, Jeremiah] Birmingham VA Med Ctr, Vet Affairs VA Natl Qual Scholars Program, Birmingham, AL 35233 USA.
[Dolansky, Mary; Brennan, Caitlin; Olds, Danielle] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
[Dolansky, Mary] Cleveland VA Med Ctr, VA Natl Qual Scholars Program, Cleveland, OH 44106 USA.
[Estrada, Carlos; Miltner, Rebecca; Newsom, Jeremiah] Univ Alabama Birmingham, Div Gen Internal Med, Birmingham, AL 35294 USA.
[Brennan, Caitlin; Olds, Danielle] Case Western Reserve Univ, VA Natl Qual Scholar Program, Louis Stokes Cleveland VA Med Ctr, Cleveland, OH 44106 USA.
[Splaine, Mark] Dartmouth Inst Hlth Policy & Clin Practice, VA Natl Qual Scholars Fellowship Program, Ctr Leadership & Improvement, Lebanon, NH 03766 USA.
[Splaine, Mark] Dartmouth Med Sch, Geisel Sch Med, Hanover, NH 03766 USA.
RP Patrician, PA (reprint author), Birmingham VA Med Ctr, Vet Affairs VA Natl Qual Scholars Program, Birmingham, AL 35233 USA.
EM ppatrici@uab.edu
OI Miltner, Rebecca/0000-0002-4653-0328
NR 25
TC 5
Z9 5
U1 1
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0029-6465
J9 NURS CLIN N AM
JI Nurs. Clin. North Am.
PD SEP
PY 2012
VL 47
IS 3
BP 347
EP +
DI 10.1016/j.cnur.2012.05.006
PG 9
WC Nursing
SC Nursing
GA 013PJ
UT WOS:000309317000004
PM 22920425
ER
PT J
AU Kobayashi, K
Bhargava, P
Raja, S
Nasseri, F
Al-Balas, HA
Smith, DD
George, SP
Vij, MS
AF Kobayashi, Katsuhiro
Bhargava, Peeyush
Raja, Shanker
Nasseri, Farbod
Al-Balas, Hassan A.
Smith, Darryl D.
George, Sharad P.
Vij, Meena S.
TI Image-guided Biopsy: What the Interventional Radiologist Needs to Know
about PET/CT
SO RADIOGRAPHICS
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; FDG UPTAKE; INTRATUMORAL DISTRIBUTION;
CANCER-CELLS; ELECTROMAGNETIC TRACKING; INDETERMINATE BIOPSY; METABOLIC
BIOPSY; LESIONS; SPECTRUM; FLUORINE-18-FLUORODEOXYGLUCOSE
AB Positron emission tomography (PET)/computed tomography (CT) with fluorine 18 fluorodeoxyglucose (FDG) is increasingly used in evaluation of oncology patients. Because PET/CT can demonstrate malignancy before morphologic changes are evident, application of PET/CT information to image-guided biopsy can facilitate early histologic diagnosis and staging. However, because FDG uptake is not specific to cancer, PET/CT findings may raise questions about whether uptake in a lesion is an indication for biopsy. To properly select patients for image-guided biopsy, interventional radiologists should be familiar with the biologic significance of FDG uptake and various causes of false-positive uptake. PET/CT images may also become a source of confusion in the interpretation of biopsy results. Various causes of false-positive and false-negative FDG uptake need to be considered, especially when there is a discrepancy between biopsy results and PET/CT findings. False-negative FDG uptake can result from cancers that are too small to be observed or not FDG avid. False-positive FDG uptake can be due to underlying inflammation from recent treatment. Conversely, complete resolution of FDG uptake in a treated lesion does not necessarily indicate absence of viable cells. When questions about PET/CT findings arise in the context of image-guided biopsy, discussion with experienced nuclear imaging physicians is essential. (C)RSNA, 2012 . radiographics.rsna.org
C1 [Kobayashi, Katsuhiro; Al-Balas, Hassan A.; Smith, Darryl D.; Vij, Meena S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Radiol, Unit 114, Houston, TX 77030 USA.
[Nasseri, Farbod] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA.
RP Kobayashi, K (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Radiol, Unit 114, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM Katsuhiro.Kobayashi@va.gov
NR 34
TC 22
Z9 22
U1 0
U2 1
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD SEP-OCT
PY 2012
VL 32
IS 5
BP 1483
EP 1501
DI 10.1148/rg.325115159
PG 19
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 003SZ
UT WOS:000308632900023
PM 22977031
ER
PT J
AU Tracy, JJ
Lombardo, TW
Bentley, JP
AF Tracy, Josie J.
Lombardo, Thomas W.
Bentley, John P.
TI A Smoker Identity Measure for Experimental, Intermittent, and Daily
College Student Smokers
SO AMERICAN JOURNAL OF HEALTH PROMOTION
LA English
DT Article
DE College Students; Smoker Identity; Cigarette Smoking; Light and
Intermittent Smokers; Experimental Smokers; Scale Development;
Psychometrics; Prevention Research
ID BEHAVIOR SURVEY QUESTIONNAIRE; SMOKING-CESSATION; PLANNED BEHAVIOR;
EXTENDED VERSION; SOCIAL-INFLUENCE; RISK BEHAVIOR; UNITED-STATES;
SELF-IDENTITY; QUIT SMOKING; NICOTINE DEPENDENCE
AB Purpose. To provide initial tests of internal consistency reliability, and both structural and concurrent validity of a smoker identity (SI) scale for college student populations.
Design. Cross-sectional design.
Setting. Midsouth university.
Participants. Undergraduates in a random sample of university classes completed surveys (92.3% response rate).
Method. items derived from a literature review and clinical expertise, lifetime and current tobacco use, cigarette purchasing patterns, and quitting variables.
Analysis. Current (some days or eve?), day) cigarette users (n = 362) were divided into daily, intermittent, and experimental smoker groups. After principal components analysis was conducted on the SI items, analysis of variance (ANOVA) was used to assess SI differentiation of smoker groups, and correlational analysis or ANOVA was used to assess SI relationships with smoking and quitting variables.
Results. Eight SI items produced a high-internal-consistency, single-factor structure (alpha = .93) and clearly differentiated the three smoker groups. Higher SI scores indicated greater smoking rate, smoking within 30 minutes of awakening, larger purchased quantities, and both greater interest and lower confidence in quitting.
Conclusions. The scale demonstrated good reliability and validity. Other SI measures exist, but this is the first scale to establish utility with experimental and intermittent smokers-substantial groups among college students. The extent to which cigarette users identify as smokers may provide useful information beyond behavioral measures, especially among college students. (Am J Health Promot 2012;27[1]:55-62.)
C1 [Tracy, Josie J.] Dept Vet Affairs Med Ctr, Portland, OR USA.
[Tracy, Josie J.; Lombardo, Thomas W.] Univ Mississippi, Dept Psychol, University, MS 38677 USA.
[Bentley, John P.] Univ Mississippi, Dept Pharm Adm, University, MS 38677 USA.
RP Tracy, JJ (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,POB 1035,V3SATP, Portland, OR 97207 USA.
EM josie.tracy@va.gov
NR 52
TC 3
Z9 3
U1 1
U2 26
PU AMER JOURNAL HEALTH PROMOTION INC
PI TROY
PA PO BOX 1254, TROY, MI 48099-1254 USA
SN 0890-1171
J9 AM J HEALTH PROMOT
JI Am. J. Health Promot.
PD SEP-OCT
PY 2012
VL 27
IS 1
BP 55
EP 62
DI 10.4278/ajhp.110401-QUAN-146
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 004MI
UT WOS:000308685400010
PM 22950927
ER
PT J
AU Wu, X
Yu, T
Bullard, DC
Kucik, DF
AF Wu, Xing
Yu, Tao
Bullard, Daniel C.
Kucik, Dennis F.
TI SDF-1 alpha (CXCL12) regulation of lateral mobility contributes to
activation of LFA-1 adhesion
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE chemokines; integrins; avidity; lateral mobility; single particle
tracking
ID INTEGRIN AFFINITY; AVIDITY REGULATION; FLOW; CELLS; CHEMOKINES;
MOVEMENTS; MIGRATION; ICAM-1
AB Wu X, Yu T, Bullard DC, Kucik DF. SDF-1 alpha (CXCL12) regulation of lateral mobility contributes to activation of LFA-1 adhesion. Am J Physiol Cell Physiol 303: C666-C672, 2012. First published August 8, 2012; doi:10.1152/ajpcell.00190.2012.-Regulation of integrin activity enables leukocytes to circulate freely, avoiding inappropriate adhesion while maintaining the ability to adhere quickly at sites of infection or inflammation. This regulation involves at least two components: affinity for ligand and affinity-independent avidity effects such as lateral mobility. Using lymphocyte function associated antigen-1 (LFA-1) as a model, we investigated the role of integrin release from cytoskeletal motion constraints in response to the chemokine stromal cell-derived factor-1 (SDF-1 alpha) in this process. All experiments were done in primary T cells to avoid nonphysiological activation processes often seen with the use of cell lines. We found that SDF-1 alpha releases LFA-1 from cytoskeletal constraints as effectively as does cytochalasin D. The resultant increased diffusion is correlated with a robust increase in LFA-1-mediated adhesion under physiological shear stress. We further investigated the role of the highly conserved GFFKR sequence in the LFA-1 cytoplasmic domain. We report that the GFFKR sequence is both necessary and sufficient for regulation of the SDF-1 alpha-triggered proadhesive release from cytoskeleton interactions. While this does not address the role of transient SDF-1 alpha-induced conformational changes in the activation process, these results strongly suggest that any model of chemokine-induced LFA-1 activation must take into account chemokine-induced integrin lateral mobility. In addition, these results have ramifications for models of differential binding of LFA-1 to surface-bound vs. soluble intercellular adhesion molecule-1.
C1 [Wu, Xing; Yu, Tao; Kucik, Dennis F.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Bullard, Daniel C.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
[Kucik, Dennis F.] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA.
[Kucik, Dennis F.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Kucik, DF (reprint author), Univ Alabama Birmingham, Dept Pathol, Kaul Bldg,Rm 640A,619 S 19th St, Birmingham, AL 35294 USA.
EM kucik@uab.edu
FU Department of Veterans Affairs Merit Award
FX This work was supported by a Department of Veterans Affairs Merit Award.
NR 22
TC 4
Z9 4
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD SEP
PY 2012
VL 303
IS 6
BP C666
EP C672
DI 10.1152/ajpcell.00190.2012
PG 7
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 012RU
UT WOS:000309255000010
PM 22875786
ER
PT J
AU Stubbs, ND
Geraci, SA
Stephenson, PL
Jones, DB
Sanders, S
AF Stubbs, Nancy D.
Geraci, Stephen A.
Stephenson, Priscilla L.
Jones, Dianne B.
Sanders, Suzanne
TI Methods to Reduce Outpatient Non-attendance
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Review
DE Mail reminders; Telephone reminders; Text message reminders; Short
message service reminders; Non-attendance
ID RANDOMIZED CONTROLLED-TRIAL; TEXTING APPOINTMENT REMINDERS; ACCESS
SCHEDULING SYSTEM; PRIMARY-CARE; TELEPHONE REMINDERS; INCREASE
ATTENDANCE; IMPROVE ATTENDANCE; SMS REMINDERS; HEALTH-CARE; SHOW RATES
AB Non-attendance reduces clinic and provider productivity and efficiency, compromises access and increases cost of health care. This systematic review of the English language literature (November 1999-November 2009) compares telephone, mail, text/short message service, electronic mail and open-access scheduling to determine which is best at reducing outpatient non-attendance and providing net financial benefit. Telephone, mail and text/short message service interventions all improved attendance modestly but at varying costs. Text messaging was the most cost-effective of the 3, but its applicability may be limited. Few data are available regarding electronic mail reminders, whereas open-access scheduling is an area of active research.
C1 [Sanders, Suzanne] GV Sonny Montgomery Vet Affairs Med Ctr, Med Serv, Jackson, MS USA.
[Jones, Dianne B.] GV Sonny Montgomery Vet Affairs Med Ctr, Lib Serv, Jackson, MS USA.
[Geraci, Stephen A.; Sanders, Suzanne] Univ Mississippi, Div Rheumatol, Dept Med, Sch Med, Jackson, MS 39216 USA.
[Stephenson, Priscilla L.] Philadelphia Vet Affairs Med Ctr, Lib Serv, Philadelphia, PA USA.
RP Sanders, S (reprint author), Med Serv 111, 1500 E Woodrow Wilson Dr, Jackson, MS 39216 USA.
EM Suzanne.Sanders@va.gov
NR 57
TC 17
Z9 19
U1 0
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD SEP
PY 2012
VL 344
IS 3
BP 211
EP 219
DI 10.1097/MAJ.0b013e31824997c6
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 003LQ
UT WOS:000308613400009
PM 22475731
ER
PT J
AU Badrane, H
Nguyen, MH
Blankenship, JR
Cheng, SJ
Hao, BH
Mitchell, AP
Clancy, CJ
AF Badrane, Hassan
Nguyen, M. Hong
Blankenship, Jill R.
Cheng, Shaoji
Hao, Binghua
Mitchell, Aaron P.
Clancy, Cornelius J.
TI Rapid Redistribution of Phosphatidylinositol-(4,5)-Bisphosphate and
Septins during the Candida albicans Response to Caspofungin
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID WALL DAMAGE RESPONSE; CELL-WALL; SACCHAROMYCES-CEREVISIAE; HYPHAL
FORMATION; BUDDING YEAST; INVASIVE GROWTH; GENE DISRUPTION; VIRULENCE;
PROTEINS; KINASE
AB We previously showed that phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] and septin regulation play major roles in maintaining Candida albicans cell wall integrity in response to caspofungin and other stressors. Here, we establish a link between P1(4,5)P2 signaling and septin localization and demonstrate that rapid redistribution of PI(4,5)P2 and septins is part of the natural response of C. albicans to caspofungin. First, we studied caspofungin-hypersusceptible C. albicans irs4 and inp51 mutants, which have elevated PI(4,5)P2 levels due to loss of PI(4,5)P2-specific 5'-phosphatase activity. PI(4,5)P2 accumulated in discrete patches, rather than uniformly, along surfaces of mutants in yeast and filamentous morphologies, as visualized with a green fluorescent protein (GFP)-pleckstrin homology domain. The patches also contained chitin (calcofluor white staining) and cell wall protein Rbt5 (Rbt5-GFP). By transmission electron microscopy, patches corresponded to plasma membrane invaginations that incorporated cell wall material. Fluorescently tagged septins Cdc10 and Sep7 colocalized to these sites, consistent with well-described PI(4,5)P2-septin physical interactions. Based on expression patterns of cell wall damage response genes, irs4 and inp51 mutants were firmly positioned within a group of caspofungin-hypersusceptible, septin-regulatory protein kinase mutants. irs4 and inp51 were linked most closely to the gin4 mutant by expression profiling, PI(4,5)P2-septin-chitin redistribution and other phenotypes. Finally, sublethal 5-min exposure of wild-type C. albicans to caspofungin resulted in redistribution of P1(4,5)P2 and septins in a manner similar to those of irs4, inp51, and gin4 mutants. Taken together, our data suggest that the C. albicans Irs4-Inp51 5'-phosphatase complex and Gin4 function upstream of PI(4,5)P2 and septins in a pathway that helps govern responses to caspofungin.
C1 [Badrane, Hassan; Nguyen, M. Hong; Cheng, Shaoji; Hao, Binghua; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA 15260 USA.
[Blankenship, Jill R.; Mitchell, Aaron P.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA.
[Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA 15260 USA.
EM cjc76@pitt.edu
OI Mitchell, Aaron/0000-0002-0868-4000
FU US Department of Veterans Affairs; National Institutes of Health
[R56DE020831]
FX This project was funded in part by grant support from the US Department
of Veterans Affairs (Merit Review to C. J. Clancy) and the National
Institutes of Health (R56DE020831 to C. J. Clancy).
NR 61
TC 14
Z9 23
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 2012
VL 56
IS 9
BP 4614
EP 4624
DI 10.1128/AAC.00112-12
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 994CN
UT WOS:000307908600006
PM 22687514
ER
PT J
AU Kabir, A
Hegde, M
Santos-Sanchez, C
Hess, C
Garcia, P
AF Kabir, A.
Hegde, M.
Santos-Sanchez, C.
Hess, C.
Garcia, P.
TI WORSENING OF SEIZURES FOLLOWING ABRUPT DISCONTINUATION OF MARIJUANA IN
AN EPILEPSY MONITORING UNIT
SO EPILEPSIA
LA English
DT Meeting Abstract
CT 10th European Congress on Epileptology
CY SEP 30-OCT 04, 2012
CL London, ENGLAND
C1 [Kabir, A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Hegde, M.; Santos-Sanchez, C.; Hess, C.; Garcia, P.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD SEP
PY 2012
VL 53
SU 5
SI SI
BP 156
EP 156
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 007GD
UT WOS:000308875900536
ER
PT J
AU Brown, AD
Kuznetsova, MS
Spain, WJ
Stecker, GC
AF Brown, Andrew D.
Kuznetsova, Marina S.
Spain, William J.
Stecker, G. Christopher
TI Frequency-specific, location-nonspecific adaptation of interaural time
difference sensitivity
SO HEARING RESEARCH
LA English
DT Article
ID SOUND LOCALIZATION; POTASSIUM CURRENTS; COCHLEAR NUCLEUS; LEVEL;
LATERALIZATION; INHIBITION; CUES
AB Human listeners' sensitivity to interaural time differences (ITD) was assessed for 1000 Hz tone bursts (500 ms duration) preceded by trains of 500-ms "adapter" tone bursts (7 s total adapter duration, frequencies of 200, 665, 1000, or 1400 Hz) carrying random ITD, or by an equal-duration period of silence. Presentation of the adapter burst train reduced ITD sensitivity in a frequency-specific manner. The observed effect differs from previously described forms of location-specific psychophysical adaptation, as it was produced using a binaurally diffuse sequence of tone bursts (i.e., a location-nonspecific adapter stimulus). Results are discussed in the context of pre-binaural adaptation. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Brown, Andrew D.; Stecker, G. Christopher] Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98105 USA.
[Kuznetsova, Marina S.] Univ Washington, Interdisciplinary Grad Program Neurobiol & Behav, Seattle, WA 98105 USA.
[Spain, William J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Brown, AD (reprint author), Univ Washington, Dept Speech & Hearing Sci, 1417 NE 42nd St, Seattle, WA 98105 USA.
EM andrewdb@uw.edu; msk@uw.edu; spain@uw.edu; cstecker@uw.edu
FU National Institute on Deafness and Other Communication Disorders [NIH]
[T32-DC000033, F31-DC010543, F31-DC091763, R03-DC009482]; VA Merit
Review
FX The authors thank Anna Mamiya and Shiboney Dumo for help with data
collection. This work was supported by the National Institute on
Deafness and Other Communication Disorders [NIH Grant Nos. T32-DC000033,
F31-DC010543 (ADB), F31-DC091763 (MSK), R03-DC009482 (GCS)] and a VA
Merit Review (WJS).
NR 27
TC 1
Z9 1
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5955
J9 HEARING RES
JI Hear. Res.
PD SEP
PY 2012
VL 291
IS 1-2
BP 52
EP 56
DI 10.1016/j.heares.2012.06.002
PG 5
WC Audiology & Speech-Language Pathology; Neurosciences;
Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Neurosciences & Neurology;
Otorhinolaryngology
GA 004MA
UT WOS:000308684600006
PM 22732693
ER
PT J
AU Jones, J
McDermott, CM
Nowels, CT
Matlock, DD
Bekelman, DB
AF Jones, Jacqueline
McDermott, Carrie M.
Nowels, Carolyn T.
Matlock, Daniel D.
Bekelman, David B.
TI The experience of fatigue as a distressing symptom of heart failure
SO HEART & LUNG
LA English
DT Article
DE Fatigue; Heart failure; Patient experiences; Qualitative research;
Patient-centered care
ID QUALITY-OF-LIFE; PALLIATIVE CARE; PREDICTORS; BURDEN
AB OBJECTIVE: We explored the perceptions, experience, and meaning of fatigue as a distressing symptom of chronic heart failure (HP).
BACKGROUND: Fatigue, a common symptom of HF, may indicate worsening condition. Patients interpret their symptoms to determine the need for assistance. The meaning of fatigue in everyday life for HF patients in the United States is not well understood. METHODS: We performed an interpretive study of in-depth interviews with HF patients (n = 26) who reported fatigue as a symptom, using a thematic analysis of transcripts within an iterative group framework.
RESULTS: Fatigue is characterized by patient values related to their self-identity, their body, their experience of time, their environment, and their relationships with others, including the healthcare system.
CONCLUSIONS: Fatigue influences perceived proximity to death and how patients try to preserve what they can do. A patient's HF management plan should be tailored and responsive to that patient's experience of fatigue as communicated by the patient.
C1 [Jones, Jacqueline; McDermott, Carrie M.] Univ Colorado, Coll Nursing, Aurora, CO 80045 USA.
[Nowels, Carolyn T.; Matlock, Daniel D.] Univ Colorado, Sch Med, Aurora, CO 80045 USA.
[Nowels, Carolyn T.; Bekelman, David B.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Jones, J (reprint author), Univ Colorado, Coll Nursing, Anchutz Med Campus,13120 E 19th Ave,Campus Box C-, Aurora, CO 80045 USA.
EM jacqueline.jones@ucdenver.edu
OI Jones, Jacqueline/0000-0001-9714-995X
FU University of Colorado Hartford/Jahnigen Center for Excellence in
Geriatric Medicine; Department of Veterans Affairs Career Development
Award (Health Services Research & Development Service Career Development
Award [HSRD CDA] [08-022]; Mordecai Palliative Care Grants Fund
FX This research was funded by the University of Colorado Hartford/Jahnigen
Center for Excellence in Geriatric Medicine and the Mordecai Palliative
Care Grants Fund. D.B.B. is funded by a Department of Veterans Affairs
Career Development Award (Health Services Research & Development Service
Career Development Award [HSR&D CDA] 08-022). The funding organizations
had no role in any part of the study. The views expressed in this paper
are those of the authors, and do not necessarily reflect the views of
the Department of Veterans Affairs. The authors thank Jessica Haxton
Retrum, PhD, LCSW, for her contributions to early analytic discussions.
NR 43
TC 8
Z9 8
U1 2
U2 9
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0147-9563
J9 HEART LUNG
JI Heart Lung
PD SEP-OCT
PY 2012
VL 41
IS 5
BP 484
EP 491
DI 10.1016/j.hrtlng.2012.04.004
PG 8
WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System
SC Cardiovascular System & Cardiology; Nursing; Respiratory System
GA 011DP
UT WOS:000309145200008
PM 22652166
ER
PT J
AU Singh, JA
Jensen, MR
Lewallen, DG
AF Singh, Jasvinder A.
Jensen, Matthew R.
Lewallen, David G.
TI Patient Factors Predict Periprosthetic Fractures After Revision Total
Hip Arthroplasty
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article
DE total hip arthroplasty; periprosthetic fracture; predictors; risk
factors; comorbidity; primary THA
ID PERI-PROSTHETIC FRACTURE; KNEE ARTHROPLASTY; FEMORAL FRACTURES; FEMUR;
FALLS; RISK; REPLACEMENT; MORBIDITY; MORTALITY; OUTCOMES
AB We assessed important patient risk factors for postoperative periprosthetic fractures after revision total hip arthroplasty (THA) using prospectively collected Institutional Joint Registry data. We used univariate and multivariable-adjusted Cox regression analyses. There were 330 postoperative periprosthetic fractures after 6281 revision THAs. In multivariable-adjusted analyses, hazard ratio (95% confidence interval) of periprosthetic fracture was higher for women (1.66 [1.32-2.080], P < .001), a higher Deyo-Charlson comorbidity index of 2 (1.46 [1.03-2.07]) and index of 3+ (2.01 [1.48-2.73]; overall, P < .001), and operative diagnosis, especially previous nonunion (5.76 [2.55-13.02]; overall, P < .001). Hazard ratio was lower in patients 61 to 70 years old (0.64 [0.49-0.84]) and 71 to 80 years old (0.57 [0.43-0.76]) compared with those younger than 60 years (overall, P < .0001). Our study identified important modifiable and unmodifiable risk factors for fractures after revision THA.
C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.; Lewallen, David G.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
[Jensen, Matthew R.] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
OI singh, jasvinder/0000-0003-3485-0006
FU National Institutes of Health Clinical Translational Science Award [1
KL2 RR024151-01]
FX This material is the result of work supported with the National
Institutes of Health Clinical Translational Science Award 1 KL2
RR024151-01 (Mayo Clinic Center for Clinical and Translational Research)
and the resources and the use of facilities at the Birmingham VA Medical
Center, Birmingham, Ala.
NR 30
TC 10
Z9 11
U1 0
U2 4
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD SEP
PY 2012
VL 27
IS 8
BP 1507
EP 1512
DI 10.1016/j.arth.2011.12.010
PG 6
WC Orthopedics
SC Orthopedics
GA 003NH
UT WOS:000308618100015
PM 22342128
ER
PT J
AU Salanitro, AH
Hovater, M
Hearld, KR
Roth, DL
Sawyer, P
Locher, JL
Bodner, E
Brown, CJ
Allman, RM
Ritchie, CS
AF Salanitro, Amanda H.
Hovater, Martha
Hearld, Kristine R.
Roth, David L.
Sawyer, Patricia
Locher, Julie L.
Bodner, Eric
Brown, Cynthia J.
Allman, Richard M.
Ritchie, Christine S.
TI Symptom Burden Predicts Hospitalization Independent of Comorbidity in
Community-Dwelling Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE healthcare utilization; symptom; older adults; comorbidity
ID MEDICAL CONDITIONS; HEALTH; PREVALENCE; DISTRESS; PROFILE; ELDERS
AB Objectives To determine whether cumulative symptom burden predicts hospitalization or emergency department (ED) visits in a cohort of older adults. Design Prospective, observational study with a baseline in-home assessment of symptom burden. Setting Central Alabama. Participants Nine hundred eighty community-dwelling adults aged 65 and older (mean 75.3 +/- 6.7) recruited from a random sample of Medicare beneficiaries stratified according to sex, race, and urban/rural residence. Measurements Symptom burden score (range 010). One point was given for each symptom reported: shortness of breath, tiredness or fatigue, problems with balance or dizziness, leg weakness, poor appetite, pain, stiffness, constipation, anxiety, and loss of interest in activities. Dependent variables were hospitalizations and ED visits, assessed every 6 months during the 8.5-year follow-up period. Using Cox proportional hazards models, time from the baseline in-home assessment to the first hospitalization and first hospitalization or ED visit was determined. Results During the 8.5-year follow-up period, 545 (55.6%) participants were hospitalized or had an ED visit. Participants with greater symptom burden had higher risk of hospitalization (hazard ratio (HR) = 1.09, 95% confidence interval (CI) = 1.051.14) and hospitalization or ED visit (HR = 1.10, 95% CI = 1.061.14) than those with lower scores. Participants living in rural areas had significantly lower risk of hospitalization (HR = 0.83, 95% CI = 0.690.99) and hospitalization or ED visit (HR = 0.80, 95% CI = 0.700.95) than individuals in urban areas, independent of symptom burden and comorbidity. Conclusion Greater symptom burden was associated with higher risk of hospitalization and ED visits in community-dwelling older adults. Healthcare providers treating older adults should consider symptom burden to be an additional risk factor for subsequent hospital utilization.
C1 [Salanitro, Amanda H.] Vet Affairs Tennessee Valley Healthcare, Geriatr Res Educ & Clin Ctr, Nashville, TN USA.
[Salanitro, Amanda H.] Vanderbilt Univ, Sect Hosp Med, Nashville, TN USA.
[Hovater, Martha; Hearld, Kristine R.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
[Roth, David L.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD USA.
[Sawyer, Patricia; Locher, Julie L.; Bodner, Eric; Brown, Cynthia J.; Allman, Richard M.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA.
[Brown, Cynthia J.; Allman, Richard M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Brown, Cynthia J.; Allman, Richard M.] Atlanta Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA.
[Ritchie, Christine S.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Ritchie, Christine S.] Jewish Home San Francisco, Ctr Res Aging, San Francisco, CA USA.
RP Salanitro, AH (reprint author), Room A-414,1310 24th Ave S, Nashville, TN 37212 USA.
EM Amanda.Salanitro@Vanderbilt.Edu
FU National Institutes of Health [R01-AG015062, P30AG031054, 1UL
1RR025777]; National Institute on Aging K07 award
FX This study was funded in part by Grants R01-AG015062, P30AG031054, and
1UL 1RR025777 from the National Institutes of Health. Dr. Ritchie is
supported by a National Institute on Aging K07 award. The content is
solely the responsibility of the authors and does not necessarily
reflect the policy of the National Institute on Aging or the National
Institutes of Health.
NR 21
TC 9
Z9 9
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD SEP
PY 2012
VL 60
IS 9
BP 1632
EP 1637
DI 10.1111/j.1532-5415.2012.04121.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 008ER
UT WOS:000308940700005
PM 22985139
ER
PT J
AU Adams, SG
Pitts, J
Wynne, J
Yawn, BP
Diamond, EJ
Lee, S
Dellert, E
Hanania, NA
AF Adams, Sandra G.
Pitts, Jennifer
Wynne, JoEllen
Yawn, Barbara P.
Diamond, Edward J.
Lee, Shuko
Dellert, Ed
Hanania, Nicola A.
TI Effect of a Primary Care Continuing Education Program on Clinical
Practice of Chronic Obstructive Pulmonary Disease: Translating Theory
Into Practice
SO MAYO CLINIC PROCEEDINGS
LA English
DT Article
ID MEDICAL-EDUCATION; AMERICAN-COLLEGE; GUIDELINES; COMMITMENT; MODEL
AB Objectives: To describe the development and implementation process and assess the effect on self-reported clinical practice changes of a multidisciplinary, collaborative, interactive continuing medical education (CME)/continuing education (CE) program on chronic obstructive pulmonary disease (CORD).
Methods: Multidisciplinary subject matter experts and education specialists used a systematic instructional design approach and collaborated with the American College of Chest Physicians and American Academy of Nurse Practitioners to develop, deliver, and reproduce a 1-day interactive COPD CME/CE program for 351 primary care clinicians in 20 US cities from September 23, 2009, through November 13, 2010.
Results: We recorded responses to demographic, self-confidence, and knowledge/comprehension questions by using an audience response system. Before the program, 173 of 320 participants (54.1%) had never used the Global Initiative for Chronic Obstructive Lung Disease recommendations for COPD. After the program, clinician self-confidence improved in all areas measured. In addition, participant knowledge and comprehension significantly improved (mean score, 77.1%-94.7%; P<.001). We implemented the commitment-to-change strategy in courses 6 through 20. A total of 271 of 313 participants (86.6%) completed 971 commitment-to-change statements, and 132 of 271 (48.7%) completed the follow-up survey. Of the follow-up survey respondents, 92 of 132 (69.7%) reported completely implementing at least one clinical practice change, and only 8 of 132 (6.1%) reported inability to make any clinical practice change after the program.
Conclusion: A carefully designed, interactive, flexible, dynamic, and reproducible COPD CME/CE program tailored to clinicians' needs that involves diverse instructional strategies and media can have short-term and long-term improvements in clinician self-confidence, knowledge/comprehension, and clinical practice. (C) 2012 Mayo Foundation for Medical Education and Research rectangle Mayo Clin Proc. 2012;87:(9),862-870
C1 [Adams, Sandra G.; Lee, Shuko] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Adams, Sandra G.; Lee, Shuko] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA.
[Pitts, Jennifer; Dellert, Ed] Amer Coll Chest Phys, Northbrook, IL USA.
[Wynne, JoEllen] Amer Acad Nurse Practitioners, Austin, TX USA.
[Yawn, Barbara P.] Univ Minnesota, Dept Family & Community Hlth, Minneapolis, MN USA.
[Diamond, Edward J.] Suburban Lung Associates, Elk Grove Village, IL USA.
[Hanania, Nicola A.] Baylor Coll Med, Dept Med, Pulm Crit Care Div, Houston, TX 77030 USA.
RP Adams, SG (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, Pulm Dis Sect 111E, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM adamssg@uthscsa.edu
FU National Institute of Health; Veterans Affairs Cooperative Studies
Program; Bayer Pharmaceuticals Corp; Boehringer Ingelheim
Pharmaceuticals Inc; Centocor Inc; GlaxoSmithKline; Novartis
Pharmaceuticals AG; Pfizer Inc; Schering-Plough Corp; Aerocrine;
Boehringer Ingelheim; Forrest GlaxoSmithKline; Novartis; Astra Zeneca;
MedImmune; Pfizer; Sunovion; Pearl; ACCP; AANP; Wilmington, DE;
Ridgefield, CT; Philadelphia, PA
FX Dr Adams discloses the following: investigator/grant research: National
Institute of Health, Veterans Affairs Cooperative Studies Program, Bayer
Pharmaceuticals Corp, Boehringer Ingelheim Pharmaceuticals Inc, Centocor
Inc, GlaxoSmithKline, Novartis Pharmaceuticals AG, Pfizer Inc, and
Schering-Plough Corp; honoraria for speaking at CE programs
(unrestricted grants for CE): AstraZeneca Pharmaceuticals LP, Bayer
Pharmaceuticals Corp, Boehringer Ingelheim Pharmaceuticals Inc,
GlaxoSmithKline, Novartis Pharmaceuticals AG, Pfizer Inc, and
Schering-Plough Corp. Ms Pitts and Mr Dellert are both employees of the
ACCP. Ms Wynn is employed by the AANP. Dr Yawn discloses the following:
research support from Aerocrine, Boehringer Ingelheim, Forrest
GlaxoSmithKline, and Novartis. Dr Hanania discloses the following:
investigator/research support from Astra Zeneca, Boehringer Ingelheim,
GlaxoSmitfiKline, MedImmune, Novartis, Pfizer, and Sunovion; speaker
bureau of Boehringer Ingelheim, GlaxoSmithKline, and Pfizer; advisory
board/consultancy for Dey Inc, GlaxoSmithKline, Navartis, Pearl, and
Pfizer. The programs described were conducted and sponsored by the ACCP
and the AANP, Which received unrestricted grants from AstraZeneca
Pharmaceuticals LP, Wilmington, DE, Boehringer Ingelheim Pharmaceuticals
Inc, Ridgefield, CT, and GlaxoSmithKline Pharmaceuticals Ltd,
Philadelphia, PA. The funders of the unrestricted grants were not
involved in the development or implementation of these programs, in the
interpretation of the data, or in the preparation, review, or any part
of the manuscript.
NR 28
TC 4
Z9 4
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0025-6196
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD SEP
PY 2012
VL 87
IS 9
BP 862
EP 870
DI 10.1016/j.mayocp.2012.02.028
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 009MT
UT WOS:000309030600008
PM 22958990
ER
PT J
AU Lovera, JF
Kim, E
Heriza, E
Fitzpatrick, M
Hunziker, J
Turner, AP
Adams, J
Stover, T
Sangeorzan, A
Sloan, A
Howieson, D
Wild, K
Haselkorn, J
Bourdette, D
AF Lovera, Jesus F.
Kim, Edward
Heriza, Elizabeth
Fitzpatrick, Mary
Hunziker, James
Turner, Aaron P.
Adams, Joshua
Stover, Thomas
Sangeorzan, Adam
Sloan, Alicia
Howieson, Diane
Wild, Katherine
Haselkorn, Jodie
Bourdette, Dennis
TI Ginkgo biloba does not improve cognitive function in MS A randomized
placebo-controlled trial
SO NEUROLOGY
LA English
DT Article
ID MULTIPLE-SCLEROSIS PATIENTS; L-AMPHETAMINE SULFATE; MEMORY IMPAIRMENT;
DYSFUNCTION; PERFORMANCE; EXPRESSION; MEMANTINE; GLUTAMATE
AB Objective: To determine whether Ginkgo biloba extract (ginkgo) improves cognitive function in persons with multiple sclerosis (MS).
Methods: Persons with MS from the Seattle and Portland VA clinics and adjacent communities who scored 1 SD or more below the mean on one of 4 neuropsychological tests (Stroop Test, California Verbal Learning Test II [CVLT-II], Controlled Oral Word Association Test [COWAT], and Paced Auditory Serial Addition Task [PASAT]) were randomly assigned to receive either one 120-mg tablet of ginkgo (EGb-761; Willmar Schwabe GmbH & Co, Germany) or one placebo tablet twice a day for 12 weeks. As the primary outcome, we compared the performance of the 2 groups on the 4 tests at exit after adjusting for baseline performance.
Results: Fifty-nine subjects received placebo and 61 received ginkgo; 1 participant receiving placebo and 3 receiving ginkgo were lost to follow-up. Two serious adverse events (AEs) (myocardial infarction and severe depression) believed to be unrelated to the treatment occurred in the ginkgo group; otherwise, there were no significant differences in AEs. The differences (ginkgo - placebo) at exit in the z scores for the cognitive tests were as follows: PASAT -0.2 (95% confidence interval [CI] -0.5 to 0.1); Stroop Test -0.5 (95% CI -0.9 to -0.1); COWAT 0.0 (95% CI -0.2 to 0.3); and CVLT-II 0.0 (95% CI -0.3 to 0.3); none was statistically significant.
Conclusions: Treatment with ginkgo 120 mg twice a day did not improve cognitive performance in persons with MS. Classification of evidence: This study provides Class I evidence that treatment with ginkgo 120 mg twice a day for 12 weeks does not improve cognitive performance in people with MS. Neurology (R) 2012; 79: 1278-1284
C1 [Lovera, Jesus F.] Louisiana State Univ, Dept Neurol, Hlth Sci Ctr New Orleans, New Orleans, LA USA.
[Kim, Edward; Heriza, Elizabeth; Fitzpatrick, Mary; Hunziker, James; Bourdette, Dennis] Portland VA Med Ctr, MS Ctr Excellence W & Neurol Serv, Portland, OR USA.
[Hunziker, James; Turner, Aaron P.; Stover, Thomas; Sangeorzan, Adam; Sloan, Alicia; Haselkorn, Jodie] Puget Sound Hlth Care Syst, MS Ctr Excellence W, Seattle, WA USA.
[Turner, Aaron P.; Haselkorn, Jodie] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Haselkorn, Jodie] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Kim, Edward; Howieson, Diane; Wild, Katherine; Bourdette, Dennis] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
RP Lovera, JF (reprint author), Louisiana State Univ, Dept Neurol, Hlth Sci Ctr New Orleans, New Orleans, LA USA.
EM jlover@lsuhsc.edu
OI sloan, alicia/0000-0003-4891-3266; Turner, Aaron/0000-0001-6897-8003
FU Department of Veterans Affair, Office of Research and Development,
Rehabilitation Research and Development; NIH NCCAM [K23AT004433];
Rehabilitation Research and Development Service Career Development Award
[B4927W]; VA RRD [I01 RX000223-01A1]; NSF BCS [0826654]; NIH/NIA [P30
AG008017]; VA Merit Review Grants [112705, 05-2706, B4368R, RDIS 01104];
VA Cooperative Studies [558]; Biogen Idec; Serono; Teva Neurosciences;
Department of Veterans Affairs/BLRD Merit Review; Department of Veterans
Affairs/RRD [B4368R]; National MS Society [CA 1055-A-3]; [NIH/NINDS
1P30 NS069346-01]; [NIH/NINDS 1R01 NS057433]
FX Supported by the Department of Veterans Affair, Office of Research and
Development, Rehabilitation Research and Development. The contents of
this manuscript do not represent the views of the Department of Veterans
Affairs or the US government.; J. Lovera is funded by NIH NCCAM
K23AT004433 and has received compensation from EMD Serono and TEVA
Pharmaceuticals for conducting educational activities for physicians. He
is on the speakers' bureau for Biogen Idec and EMD Serono. E. Kim has
received honoraria from Biogen Idec for conducting educational
activities for physicians. E. Heriza, M. Fitzpatrick, and J. Hunziker
report no disclosures. A. Turner is funded by a Rehabilitation Research
and Development Service Career Development Award (B4927W) and by VA RR&D
I01 RX000223-01A1. J. Adams, T. Stover, and A. Sangeorzan report no
disclosures. A. Sloan received travel expenses from Paralyzed Veterans
of America and Consortium of MS Centers for serving as faculty in
conferences. D. Howieson is funded by NSF BCS 0826654 and NIH/NIA P30
AG008017 grants. K. Wild is funded by NIH/NIA grants P30 AG008017 and
R01 AG024059. J. Haselkorn received compensation from Paralyzed Veterans
of America for travel to their Education Planning Committee and to the
MS Summit conference; she is funded by VA Merit Review Grants 112705,
05-2706, B4368R, and RDIS 01104 and VA Cooperative Studies 558. D.
Bourdette has received honoraria and travel expenses for speaking and
serving as faculty at company sponsored meetings from Biogen Idec,
Serono, and Teva Neurosciences. He is funded by the following grants:
NIH/NINDS 1P30 NS069346-01, NIH/NINDS 1R01 NS057433, Department of
Veterans Affairs/BLR&D Merit Review, Department of Veterans Affairs/RR&D
B4368R; and National MS Society, CA 1055-A-3. Go to Neurology.org for
full disclosures.
NR 28
TC 14
Z9 14
U1 1
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD SEP
PY 2012
VL 79
IS 12
BP 1278
EP 1284
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 009WK
UT WOS:000309055900020
PM 22955125
ER
PT J
AU Kofonow, JM
Adappa, ND
AF Kofonow, Jennifer M.
Adappa, Nithin D.
TI In vitro Antimicrobial Activity of SinuSurf (TM)
SO ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY
LA English
DT Article
DE Sinusitis; Biofilm; Mupirocin; Gentamicin; Irrigations; Surfactants;
Staphylococcus; Pseudomonas
ID ENDOSCOPIC SINUS SURGERY; IRRIGATION BOTTLE CONTAMINATION; CHRONIC
RHINOSINUSITIS; STAPHYLOCOCCUS-AUREUS; BACTERIAL BIOFILMS;
CLINICAL-OUTCOMES; SHEEP MODEL; BIOTECHNOLOGY; MICROBIOLOGY; SURFACTANTS
AB Background: Topical surfactant therapy has been found to be effective in the management of recalcitrant chronic rhinosinusitis. Objective: To determine in vitro the antibacterial potential of SinuSurf (TM), a previously commercially available sinonasal surfactant. Methods: Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (PA) cultures were grown in the presence or absence of serial dilutions of mupirocin or gentamicin with and without SinuSurf and quantified by colony-forming units (CFUs). Biofilm formation was also assessed. Finally, bacterial growth was evaluated in sinus irrigation bottles inoculated with MRSA or PA and rinsed daily with SinuSurf. Results: SinuSurf alone evinced a 3-log (1,000-fold) and 6-log (10(6)-fold) reduction in CFUs for MRSA and PA, respectively. The combination of SinuSurf with a 1:10 dilution mupirocin and 1:100 dilution gentamicin demonstrated complete bacterial eradication. Similar concentrations of antibiotic dilutions alone demonstrated bacterial growth. SinuSurf averaged an 83% MRSA and 76% PA reduction in biofilm formation. Bottle contamination evaluation demonstrated reduction of MRSA and PA (p < 0.05) with SinuSurf. Conclusion: Biofilms have been demonstrated in chronic rhinosinusitis patients and implicated in recalcitrant disease. Our in vitro data demonstrates the addition of SinuSurf improved the effectiveness of a lower concentration of topical antibiotics in biofilm mass and viability. Copyright (C) 2012 S. Karger AG, Basel
C1 [Kofonow, Jennifer M.; Adappa, Nithin D.] Univ Penn, Dept Otorhinolaryngol, Div Rhinol, Philadelphia, PA 19104 USA.
[Kofonow, Jennifer M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Adappa, ND (reprint author), Hosp Univ Penn, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA.
EM Nithin.Adappa@uphs.upenn.edu
NR 23
TC 7
Z9 7
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0301-1569
J9 ORL J OTO-RHINO-LARY
JI ORL-J. Oto-Rhino-Laryngol. Head Neck Surg.
PD SEP
PY 2012
VL 74
IS 4
BP 179
EP 184
DI 10.1159/000339585
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 011DI
UT WOS:000309143800001
PM 22814356
ER
PT J
AU Stalvey, MS
Clines, KL
Chung, WJ
Clines, GA
AF Stalvey, M. S.
Clines, K. L.
Chung, W. J.
Clines, G. A.
TI CYSTIC FIBROSIS BONE DISEASE: INTERACTIONS BETWEEN OSTEOBLASTS AND
OSTEOCLASTS MAY BE THE KEY TO INCREASED BONE LOSS
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
C1 [Stalvey, M. S.; Clines, K. L.; Chung, W. J.] Univ Alabama Birmingham, Birmingham, AL USA.
[Clines, G. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD SEP
PY 2012
VL 47
SU 35
SI SI
BP 422
EP 422
PG 1
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA 007IM
UT WOS:000308882000626
ER
PT J
AU Katiyar, SK
Singh, T
Prasad, R
Sun, Q
Vaid, M
AF Katiyar, Santosh K.
Singh, Tripti
Prasad, Ram
Sun, Qian
Vaid, Mudit
TI Epigenetic Alterations in Ultraviolet Radiation-Induced Skin
Carcinogenesis: Interaction of Bioactive Dietary Components on
Epigenetic Targets
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Review
ID TUMOR-SUPPRESSOR GENES; GREEN TEA POLYPHENOLS; PROSTATE-CANCER CELLS;
CPG BINDING-PROTEIN; SKH-1 HAIRLESS MICE; DNA METHYLATION; HISTONE
ACETYLATION; ANTICANCER AGENTS; HYDROPHILIC CREAM; HUMAN-DISEASE
AB The importance of epigenetic alterations in the development of various diseases including the cancers has been realized. As epigenetic changes are reversible heritable changes, these can be utilized as an effective strategy for the prevention of cancers. DNA methylation is the most characterized epigenetic mechanism that can be inherited without changing the DNA sequence. Although limited available data suggest that silencing of tumor suppressor genes in ultraviolet (UV) radiation-exposed epidermis leads to photocarcinogenesis and is associated with a network of epigenetic modifications including alterations in DNA methylation, DNA methyltransferases and histone acetylations. Various bioactive dietary components have been shown to protect skin from UV radiation-induced skin tumors in animal models. The role of bioactive dietary components, such as, (-)-epicatechins from green tea and proanthocyanidins from grape seeds has been assessed in chemoprevention of UV-induced skin carcinogenesis and underlying epigenetic mechanism in vitro and in vivo animal models. These bioactive components have the ability to block UV-induced DNA hypermethylation and histone modifications in the skin required for the silencing of tumor suppressor genes (e.g. Cip1/p21, p16INK4a). This information is of importance for understanding the role of epigenetic modulation in UV-induced skin tumor and the chemopreventive mechanism of bioactive dietary components.
C1 [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Katiyar, Santosh K.; Singh, Tripti; Prasad, Ram; Sun, Qian; Vaid, Mudit] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Obes Res Ctr, Dept Nutr, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Comprehens Canc Ctr, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
EM skatiyar@uab.edu
FU National Cancer Institute/NCCAM/NIH [CA140197, AT2536, CA140832];
Veterans Affairs Merit Review Award
FX The work reported from Dr. Katiyar's laboratory was supported by funds
from National Cancer Institute/NCCAM/NIH (CA140197, AT2536, CA140832,)
and Veterans Affairs Merit Review Award (S. K. K.). The content of this
article does not necessarily reflect the views or policies of the
funding sources.
NR 69
TC 22
Z9 22
U1 1
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD SEP-OCT
PY 2012
VL 88
IS 5
BP 1066
EP 1074
DI 10.1111/j.1751-1097.2011.01020.x
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 000OM
UT WOS:000308396000004
PM 22017262
ER
PT J
AU Hansen, RA
Maciejewski, M
Yu-Isenberg, K
Farley, JF
AF Hansen, Richard A.
Maciejewski, Matthew
Yu-Isenberg, Kristina
Farley, Joel F.
TI Adherence to Antipsychotics and Cardiometabolic Medication: Association
With Health Care Utilization and Costs
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID ADMINISTRATIVE CLAIMS DATA; PSYCHOTIC DISORDERS; RISK-FACTORS; EXCESS
MORTALITY; OLDER PATIENTS; UNITED-STATES; SCHIZOPHRENIA; NONADHERENCE;
HOSPITALIZATION; HYPERTENSION
AB Objective: This study examined the association between adherence to antipsychotic and cardiometabolic medication and annual use of health care services and expenditures. Methods: MarketScan Medicaid files from 2004 to 2008 were used to evaluate annual cross-sections of patients with schizophrenia and diabetes, hypertension, or hyperlipidemia. Annual adherence to antipsychotic and cardiometabolic medication was defined as a score of at least 80% on proportion of days covered. Logistic regression was used to examine the association between antipsychotic adherence and adherence to cardiometabolic medications. Count data models and generalized linear models estimated health care utilization and health care expenditures, respectively, for outpatient, emergency, inpatient, and overall health services. Results: A total of 87,015 unique patients with schizophrenia received at least one antipsychotic medication. The overall prevalence of any comorbid cardiometabolic condition was 42.9% in 2004 and increased to 52.5% in 2008. Adherence to cardiometabolic medications was significantly greater among patients who were adherent to antipsychotic medications (adjusted odds ratio=6.9). Adjusted annual expenditures for emergency and inpatient care were higher for patients who were nonadherent to either antipsychotics or cardiometabolic medications than for patients who were adherent to antipsychotic and cardiometabolic medications. They were highest for patients who were nonadherent to both groups of medications. Outpatient, medication, and overall expenditures were lower for patients who were nonadherent to antipsychotic medications, regardless of cardiometabolic medication adherence. Conclusions: Among Medicaid patients with schizophrenia, cardiometabolic conditions are common, and adherence to antipsychotics and adherence to cardiometabolic medications are strongly related. Interventions that can improve medication adherence to treatment of both schizophrenia and comorbid cardiometabolic conditions may reduce emergency visits and hospitalizations. (Psychiatric Services 63:920-928, 2012; doi: 10.1176/appi.ps.201100328)
C1 [Hansen, Richard A.] Auburn Univ, Dept Pharm Care Syst, Auburn, AL 36849 USA.
[Maciejewski, Matthew] Duke Univ, Div Gen Internal Med, Durham, NC 27706 USA.
[Maciejewski, Matthew] US Dept Vet Affairs, Med Ctr, Durham, NC USA.
[Yu-Isenberg, Kristina] Novartis Pharmaceut, E Hanover, NJ USA.
[Farley, Joel F.] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC USA.
RP Hansen, RA (reprint author), Auburn Univ, Dept Pharm Care Syst, 207 Dunstan Hall, Auburn, AL 36849 USA.
EM rah0019@auburn.edu
OI Hansen, Richard/0000-0002-4578-6698
FU Novartis Pharmaceuticals Corporation; U.S. Department of Veterans
Affairs [RCS 10-391]; Pfizer; Robert Wood Johnson Foundation
FX This study was funded by Novartis Pharmaceuticals Corporation. Dr.
Maciejewski is a recipient of Research Career Scientist award RCS 10-391
from the U.S. Department of Veterans Affairs. The authors acknowledge
the helpful comments of Christopher Zacker, Ph.D., during the early
stages of manuscript preparation.; Dr. Hansen, Dr. Maciejewski, and Dr.
Farley have served as consultants to Takeda Pharmaceuticals, Inc., and
Novartis. Dr. Maciejewski owns stock in Amgen. Dr. Farley has received
unrestricted grant support from Pfizer and the Robert Wood Johnson
Foundation. At the time of this research, Dr. Yu-Isenberg was with
Novartis Pharmaceutical Corporation and is now with GlaxoSmithKline.
NR 43
TC 10
Z9 10
U1 3
U2 10
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD SEP
PY 2012
VL 63
IS 9
BP 920
EP 928
DI 10.1176/appi.ps.201100328
PG 9
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 006TK
UT WOS:000308841700013
PM 22706887
ER
PT J
AU Naragon-Gainey, K
Hoerster, KD
Malte, CA
Jakupcak, M
AF Naragon-Gainey, Kristin
Hoerster, Katherine D.
Malte, Carol A.
Jakupcak, Matthew
TI Distress Symptoms and High-Risk Behaviors Prospectively Associated With
Treatment Use Among Returning Veterans
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH DIAGNOSES; AFGHANISTAN
VETERANS; PRIMARY-CARE; IRAQ; SERVICES
AB Objective: Distress symptoms and high-risk behaviors among Iraq and Afghanistan veterans were examined as predictors of treatment utilization. Methods: Veterans (N=618) completed self-report measures upon treatment enrollment (2005-2008). Two-year utilization data were obtained for five settings: primary care, mental health within primary care, outpatient mental health, emergency room, and inpatient psychiatric. Results: Pain was associated with primary care use; depression, panic, post-traumatic stress disorder (PTSD), alcohol misuse, and aggression were associated with use of other settings. After adjustment for comorbidity, veterans with high levels of PTSD and depression symptoms had more treatment visits across several settings than veterans with lower levels. Specialty mental health utilization was low among those reporting elevated psychiatric symptoms (for example, a mean of 8.8 outpatient visits over two years). Conclusions: Symptoms and high-risk behaviors were differentially associated with treatment settings; PTSD and depression predicted greater treatment use. Veterans may have overutilized emergency care while underutilizing specialty mental health services. (Psychiatric Services 63:942-944, 2012; doi: 10.1176/appi.ps.201100349)
C1 [Naragon-Gainey, Kristin; Hoerster, Katherine D.; Malte, Carol A.; Jakupcak, Matthew] US Dept Vet Affairs VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA.
[Hoerster, Katherine D.; Jakupcak, Matthew] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Malte, Carol A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
RP Naragon-Gainey, K (reprint author), US Dept Vet Affairs VA Puget Sound Hlth Care Syst, Seattle Div, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM kristin.piney@gmail.com
FU VA Puget Sound Health Care System, Seattle
FX This report is the result of work supported by the VA Puget Sound Health
Care System, Seattle.
NR 12
TC 9
Z9 9
U1 1
U2 3
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD SEP
PY 2012
VL 63
IS 9
BP 942
EP 944
DI 10.1176/appi.ps.201100349
PG 3
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 006TK
UT WOS:000308841700017
PM 22810211
ER
PT J
AU Anzueto, A
Miravitlles, M
Ewig, S
Legnani, D
Heldner, S
Stauch, K
AF Anzueto, Antonio
Miravitlles, Marc
Ewig, Santiago
Legnani, Delfino
Heldner, Stephanie
Stauch, Kathrin
TI Identifying patients at risk of late recovery (>= 8 days) from acute
exacerbation of chronic bronchitis and COPD
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Exacerbation; AECOPD; AECB; Moxifloxacin; Observational;
Non-interventional
ID OBSTRUCTIVE PULMONARY-DISEASE; PRIMARY-CARE; ANTIBIOTIC-TREATMENT;
SPIROMETRY; DIAGNOSIS; OUTCOMES
AB Objectives: To identify factors associated with late recovery (>= 8 days from exacerbation start) in patients with acute exacerbations of chronic bronchitis/COPD (AECB/AECOPD).
Methods: An international, observational, non-interventional study in outpatients with AECB/AECOPD who received treatment for their exacerbation with the antibiotic moxifioxacin. Factors analyzed for late recovery included patient demographic characteristics, geographic region and disease severity. Additionally, logistic regression analysis was undertaken to identify factors associated with late recovery.
Results: The analysis population was 40,435 patients aged >= 35 years, from Asia-Pacific, Europe, the Americas and Middle East/Africa. Most were male (63.1%), mean age 60.4 years and current or ex-smokers (60.6%) with history of >= 2 exacerbations in the previous year. Patients who underwent spirometry (n = 6408, 19.7%) had moderate airflow obstruction (mean FEV1 1.7 L). Both clinicians and patients reported that moxifloxacin provided clinical improvement in a mean of 3 days and recovery in 6 days. Clinical factors significantly associated with late recovery were: age >= 65 years, duration of chronic bronchitis >10 years, cardiac comorbidity, >3 exacerbations in the previous 12 months, current exacerbation type (Anthonisen I/II) and hospitalization in the last 12 months.
Conclusions: In a large cohort of patients, all treated with the same antibiotic for an exacerbation of chronic bronchitis or COPD, the main factors associated with late recovery (>= 8 days) were: older age, history of frequent exacerbations, current exacerbation type of Anthonisen I/II, history of prior hospitalizations and cardiac comorbid conditions. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Anzueto, Antonio] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Miravitlles, Marc] Hosp Clin Barcelona, Ciber Enfermedades Resp CIBERES, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Barcelona, Spain.
[Ewig, Santiago] EVK Herne & Augusta Kranken Anstalt Bochum, Kliniken Pneumol & Infektiol, Thoraxzentrum Ruhrgebiet, Bochum, Germany.
[Legnani, Delfino] Osped L Sacco, I-20157 Milan, Italy.
[Heldner, Stephanie] Bayer HealthCare, D-13342 Berlin, Germany.
[Stauch, Kathrin] Bayer HealthCare Germany GmbH, D-51368 Leverkusen, Germany.
RP Anzueto, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 111E,7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM anzueto@uthscsa.edu
OI Miravitlles, Marc/0000-0002-9850-9520
FU Bayer Schering Pharma (BSP); Bayer Schering Pharma; Boehringer
Ingelheim; Pfizer; GlaxoSmithKline; Schering Plough Corporation;
University of Texas Health Science Center at San Antonio; C R Bard;
Lilly; GSK; National Institutes of Health, National Heart, Lung and
Blood Institute; Novartis; AstraZeneca; Wyeth; MSD; Sanofi Aventis
FX This study was supported by a research grant from Bayer Schering Pharma
(BSP). Project Management including the set-up and conduct of the study
was supervised by Kathrin Stauch and Stephanie Heldner from Global
Non-Interventional Studies at BSP. The contract research organisation
(CRO) Institute Dr. Schauerte (Oberhaching, Germany) was responsible for
data capture and data management. The CRO Kantar Health (Munich,
Germany) was responsible for statistical analysis and reporting of study
results. Highfield Communication Consultancy (funded by Bayer Schering
Pharma) provided editorial assistance in the preparation of this
manuscript.; Antonio Anzueto has participated as a speaker in scientific
meetings or courses organized and financed by pharmaceutical companies
including: Boehringer Ingelheim, Bayer Schering Pharma, Pfizer,
GlaxoSmithKline, and the Schering Plough Corporation. He has also
provided consultancy services to Boehringer Ingelheim, Bayer Schering
Pharma, Pfizer, GlaxoSmithKline and the Schering Plough Corporation. He
has been the principal investigator for research grants and the
University of Texas Health Science Center at San Antonio was paid for
participating in multicenter clinical trials sponsored by: C R Bard,
Lilly, GSK, Pfizer, and the National Institutes of Health, National
Heart, Lung and Blood Institute.; Marc Miravitlles has participated as a
speaker in scientific meetings or courses organized and financed by
pharmaceutical companies including: Boehringer Ingelheim, Bayer Schering
Pharma, Pfizer, Novartis, and AstraZeneca. He has been a consultant for
Boehringer Ingelheim, Bayer Schering Pharma, Pfizer, AstraZeneca and
Novartis.; Santiago Ewig has participated as a speaker in scientific
meetings or courses organized and financed by pharmaceutical companies
including: GlaxoSmithKline, Boehringer Ingelheim, Bayer Schering Pharma,
Pfizer, Wyeth, Novartis, AstraZeneca and MSD.; Delfino Legnani has
participated as a speaker in scientific meetings or courses organized
and financed by pharmaceutical companies including Bayer Schering
Pharma, Sanofi Aventis and GSK.
NR 31
TC 5
Z9 6
U1 0
U2 8
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2012
VL 106
IS 9
BP 1258
EP 1267
DI 10.1016/j.rmed.2012.06.002
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA 005RT
UT WOS:000308768300007
PM 22749710
ER
PT J
AU Bromley, E
Mikesell, L
Mates, A
Smith, M
Brekke, JS
AF Bromley, Elizabeth
Mikesell, Lisa
Mates, Andrea
Smith, Michael
Brekke, John S.
TI A Video Ethnography Approach to Assessing The Ecological Validity of
Neurocognitive and Functional Measures in Severe Mental Illness: Results
From A Feasibility Study
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE schizophrenia; neurocognition; functional performance
ID NEUROPSYCHOLOGICAL ASSESSMENT; PSYCHOSOCIAL REHABILITATION; PART 1;
SCHIZOPHRENIA; COMMUNITY; SKILLS; INDIVIDUALS; PERFORMANCE; PREDICTORS;
DEMENTIA
AB Background. The ecological validity of neurocognitive and functional measures in severe mental illness is poorly understood because of a lack of validated research methods to study community life-as-lived. We describe the development of a video ethnography method that measures naturalistic behaviors with codes called community performance indicators (CPIs). The method could provide a strategy to test the ecological validity of neurocognitive and functional assessments. Methods. We gathered up to 18.5 hours of video ethnography data on each of 9 subjects with schizophrenia selected for high or low composite scores on the MATRICS Consensus Cognitive Battery (MCCB). We used video ethnography to capture subjects' everyday behaviors in their usual environments. We established 4 CPIs that showed excellent inter-rater and promising test-retest reliability: (1) behavioral activity level, (2) goal pursuit, (3) social interaction, and (4) problem solving. Results. (1) High and low MCCB subjects showed statistically significantly differences on all 4 CPIs. (2) MCCB composite scores were correlated with all 4 CPIs (r = .54 to -.77, P < .01 to .07). (3) The MCCB domain scores demonstrated some specificity in their correlations with the CPIs; eg, verbal learning, reasoning/problem solving, and social cognition were correlated with CPI domains of social interaction and problem solving. Conclusions. We present a method for reliably measuring everyday functional performance in schizophrenia. Results from a small select sample suggest that CPIs capture skills associated with neurocognition, supporting their use in a larger study of ecological validity.
C1 [Bromley, Elizabeth; Mikesell, Lisa] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst, Ctr Hlth Serv & Soc, Los Angeles, CA 90024 USA.
[Bromley, Elizabeth; Mikesell, Lisa] W Los Angeles VA Healthcare Ctr, Desert Pacific Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
[Mates, Andrea; Smith, Michael] Univ Calif Los Angeles, Dept Appl Linguist, Neurobiol Language Res Grp, Los Angeles, CA USA.
[Brekke, John S.] Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA.
RP Bromley, E (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst, Ctr Hlth Serv & Soc, Los Angeles, CA 90024 USA.
EM ebromley@ucla.edu
FU VA Desert Pacific Mental Illness Research, Education and Clinical
Center; University of California, Los Angeles Faculty Senate Council on
Research; University of Southern California Clinical and Translational
Science Institute
FX VA Desert Pacific Mental Illness Research, Education and Clinical Center
to E.B; University of California, Los Angeles Faculty Senate Council on
Research to E.B.; University of Southern California Clinical and
Translational Science Institute to J.S.B.
NR 51
TC 6
Z9 6
U1 1
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD SEP
PY 2012
VL 38
IS 5
BP 981
EP 991
DI 10.1093/schbul/sbr002
PG 11
WC Psychiatry
SC Psychiatry
GA 009LS
UT WOS:000309027900016
PM 21402723
ER
PT J
AU Lunardon, L
Tsai, KJ
Propert, KJ
Fett, N
Stanley, JR
Werth, VP
Tsai, DE
Payne, AS
AF Lunardon, Luisa
Tsai, Kathleen J.
Propert, Kathleen J.
Fett, Nicole
Stanley, John R.
Werth, Victoria P.
Tsai, Donald E.
Payne, Aimee S.
TI Adjuvant Rituximab Therapy of Pemphigus A Single-Center Experience With
31 Patients
SO ARCHIVES OF DERMATOLOGY
LA English
DT Article
ID MYCOPHENOLATE-MOFETIL; VULGARIS; RESPONSES; DISEASE; TRIAL
AB Background: We conducted a retrospective study of patients with pemphigus vulgaris (n = 24) and foliaceus (n = 7) treated with adjuvant rituximab to determine efficacy and adverse events. The end point for efficacy was complete remission of disease taking no or minimal therapy.
Observations: Eighteen patients (58%) achieved the study end point. Of these, 13 patients achieved complete remission off systemic therapy. Patients achieving the study end point had a median disease duration before rituximab therapy of 19 months vs 86 months in those not achieving the end point (P =. 01). For the 18 patients achieving the end point, the median (SD) duration of remission was 19 (2) months. Eight of these 18 patients (44%) relapsed from 6 to 17 months after treatment. Serious adverse events attributed to rituximab treatment (osteomyelitis or phlegmon) occurred in 2 patients (6%). In paired serum samples from 10 patients before and after rituximab treatment, the percent change in serum desmoglein index value (median, -80%) was unrelated to the percent change in pneumococcal antibodies (median, +8%) (Spearman rank correlation coefficient r =-0.2).
Conclusions: Patients treated with rituximab earlier in the course of disease may have better outcomes. A discussion of rituximab's mechanism of action supports the rationale for early therapy. Prospective clinical studies are necessary to substantiate this observation.
C1 [Lunardon, Luisa; Fett, Nicole; Stanley, John R.; Werth, Victoria P.; Payne, Aimee S.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
[Tsai, Kathleen J.; Tsai, Donald E.] Univ Penn, Dept Hematol Oncol, Philadelphia, PA 19104 USA.
[Propert, Kathleen J.] Univ Penn, Dept Biostat, Philadelphia, PA 19104 USA.
[Fett, Nicole; Werth, Victoria P.] Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Payne, AS (reprint author), Univ Penn, Dept Dermatol, 217A Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.
EM paynea@mail.med.upenn.edu
FU Department of Dermatology, University of Milan, Milan, Italy; CTSA
[UL1-RR-024134]; Skin Disease Research Center grant from the National
Institutes of Health, Bethesda, Maryland [AR057217]; [AR052672];
[AR002207]; [AR053505]; [AR057001]
FX This work was supported by the Department of Dermatology, University of
Milan, Milan, Italy (Dr Lunardon), and grants AR052672 (Dr Stanley),
AR002207 (Dr Werth), AR053505 and AR057001 (Dr Payne), CTSA
UL1-RR-024134 (Dr Propert), and Skin Disease Research Center grant
AR057217 (Drs Stanley and Payne) from the National Institutes of Health,
Bethesda, Maryland.
NR 17
TC 37
Z9 39
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-987X
J9 ARCH DERMATOL
JI Arch. Dermatol.
PD SEP
PY 2012
VL 148
IS 9
BP 1031
EP 1036
PG 6
WC Dermatology
SC Dermatology
GA 007JB
UT WOS:000308883500010
PM 22710375
ER
PT J
AU Danczyk, RC
Mitchell, EL
Petersen, BD
Edwards, J
Liem, TK
Landry, GJ
Moneta, GL
AF Danczyk, Rachel C.
Mitchell, Erica L.
Petersen, Bryan D.
Edwards, James
Liem, Timothy K.
Landry, Gregory J.
Moneta, Gregory L.
TI Outcomes of Open Operation for Aortoiliac Occlusive Disease After Failed
Endovascular Therapy
SO ARCHIVES OF SURGERY
LA English
DT Article
ID CRITICAL LIMB ISCHEMIA; CONSENSUS-CLASS-C; RANDOMIZED-TRIALS; EVENTS;
ANGIOPLASTY; ASPIRIN; LESIONS; INTERVENTION; METAANALYSIS; CLOPIDOGREL
AB Objectives: To compare patient outcomes of primary open operation for aortoiliac occlusive disease (AIOD) with those of secondary open operations for failed endovascular therapy (ET) of AIOD.
Design: A retrospective cohort study was performed analyzing demographic characteristics, comorbidities, and outcomes.
Setting: Affiliated Veterans Affairs Hospital from January 1, 1998, through March 31, 2010.
Patients: Patients who underwent primary open operation for AIOD or secondary open operation for failed ET of AIOD.
Main Outcome Measures: Overall survival and limb salvage.
Results: Primary open operations (n=153) were 67 aortobifemoral grafts (43.8%), 38 axillobifemoral grafts (24.8%), and 48 femoral-femoral grafts (31.4%). Secondary open operations (n=35) were 28 aortobifemoral grafts (80.0%), 5 axillobifemoral grafts (14.3%), and 2 femoral-femoral grafts (5.7%). Mean (SD) 5-year survival was 48.2%(5.6%) and 66.8%(10.0%), respectively, for patients undergoing primary vs secondary open surgery for AIOD (P=.01). There were 7 amputations during a mean follow-up of 3 years, all in the primary open surgery group.
Conclusions: Despite a higher proportion of coronary artery disease and a 20% conversion of claudication to critical limb ischemia after failed ET for AIOD, survival was longer in patients undergoing secondary vs primary open surgery. Patients who underwent open surgery after failed ET for AIOD did not require amputation. Failed ET for AIOD does not lead to worse outcomes for patients undergoing open surgery for AIOD.
C1 [Danczyk, Rachel C.; Mitchell, Erica L.; Liem, Timothy K.; Landry, Gregory J.; Moneta, Gregory L.] Oregon Hlth & Sci Univ, Div Vasc Surg, Portland, OR 97239 USA.
[Petersen, Bryan D.] Oregon Hlth & Sci Univ, Dotter Inst, Portland, OR 97239 USA.
[Petersen, Bryan D.; Edwards, James] Portland VA Med Ctr, Portland, OR USA.
RP Mitchell, EL (reprint author), Oregon Hlth & Sci Univ, Div Vasc Surg, 3181 Sam Jackson Pk Rd SW,Mail Stop OP 11, Portland, OR 97239 USA.
EM mitcheer@ohsu.edu
NR 17
TC 5
Z9 8
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0004-0010
J9 ARCH SURG-CHICAGO
JI Arch. Surg.
PD SEP
PY 2012
VL 147
IS 9
BP 841
EP 845
PG 5
WC Surgery
SC Surgery
GA 007JD
UT WOS:000308883700017
PM 22987177
ER
PT J
AU Franklin, TR
Shin, J
Jagannathan, K
Suh, JJ
Detre, JA
O'Brien, CP
Childress, AR
AF Franklin, Teresa R.
Shin, Joshua
Jagannathan, Kanchana
Suh, Jesse J.
Detre, John A.
O'Brien, Charles P.
Childress, Anna Rose
TI Acute baclofen diminishes resting baseline blood flow to limbic
structures: A perfusion fMRI study
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Addiction; fMRI; GABA B agonist; Cerebral blood flow; Smoking cessation;
Treatment; Baclofen
ID PLACEBO-CONTROLLED TRIAL; SMOKING-CESSATION; ALCOHOL INTAKE;
DOUBLE-BLIND; ORBITOFRONTAL CORTEX; NICOTINE REPLACEMENT; TARGETED
NALTREXONE; CIGARETTE-SMOKING; NUCLEUS-ACCUMBENS; PROBLEM DRINKERS
AB Background: Preclinical and clinical evidence show that the GABA B agonist, baclofen is a promising treatment for addictive disorders; however, until recently its mechanism of action in the human brain was unknown. In previous work we utilized a laboratory model that included a medication versus placebo regimen to examine baclofen's actions on brain circuitry. Perfusion fMRI [measure of cerebral blood flow (CBF)] data acquired 'at rest' before and on the last day of the 21-day medication regimen showed that baclofen diminished CBF bilaterally in the VS, insula and medial orbitofrontal cortex (mOFC). In the present study, we hypothesized that a single dose of baclofen would have effects similar to repeated dosing.
Methods: To test our hypothesis, in a crossover design, CBF data were acquired using pseudo continuous arterial spin labeled (pCASL) perfusion fMRI. Subjects were either un-medicated or were administered a 20 mg dose of baclofen approximately 110 min prior to scanning.
Results: Acute baclofen diminished mOFC, amygdala, and ventral anterior insula CBF without causing sedation (family-wise error corrected at p = 0.001).
Conclusions: Results demonstrate that similar to repeated dosing, an acute dose of baclofen blunts the 'limbic' substrate that is hyper-responsive to drugs and drug cues. Smokers often manage their craving and can remain abstinent for extended periods after quitting, however the risk of eventual relapse approaches 90%. Given that chronic medication may not be a practical solution to the long-term risk of relapse, acute baclofen may be useful on an 'as-needed' basis to block craving during 'at risk' situations. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Franklin, Teresa R.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Detre, John A.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
[Detre, John A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Suh, Jesse J.; O'Brien, Charles P.; Childress, Anna Rose] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP Franklin, TR (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA.
EM franklin_t@mail.trc.upenn.edu
FU NIH [5-P60-DA-005186-18, 1R21DA025882 - 01A1, MH080729, EB015893]
FX Work supported by NIH grants 5-P60-DA-005186-18, 1R21DA025882 - 01A1,
MH080729 and EB015893.
NR 73
TC 10
Z9 10
U1 0
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD SEP 1
PY 2012
VL 125
IS 1-2
BP 60
EP 66
DI 10.1016/j.drugalcdep.2012.03.016
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 004ZS
UT WOS:000308720700008
PM 22513380
ER
PT J
AU Hsia, E
Seggelke, S
Gibbs, J
Hawkins, RM
Cohlmia, E
Rasouli, N
Wang, C
Kam, I
Draznin, B
AF Hsia, Elisa
Seggelke, Stacey
Gibbs, Joanna
Hawkins, R. Matthew
Cohlmia, Elizabeth
Rasouli, Neda
Wang, Cecilia
Kam, Igal
Draznin, Boris
TI Subcutaneous Administration of Glargine to Diabetic Patients Receiving
Insulin Infusion Prevents Rebound Hyperglycemia
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID GLYCEMIC CONTROL; INTRAVENOUS INSULIN; BASAL INSULIN; MANAGEMENT;
PROTOCOL; TRANSITION; SURGERY; ORDERS; US
AB Context: Transition of diabetic patients from iv insulin infusion to sc insulin frequently results in rebound hyperglycemia.
Objectives: We hypothesized that initiation of a long-acting insulin therapy concurrently with iv insulin infusion would decrease the rate of rebound hyperglycemia after discontinuation of the insulin infusion.
Design and Intervention: Sixty-one diabetic patients receiving iv insulin therapy participated in this prospective randomized study. Subjects in the intervention group received daily injections of glargine sc (0.25 U/kg body weight) starting within 12 h of initiation of iv insulin infusion. Capillary blood glucose measurements were obtained up to 12 h after discontinuation of insulin infusion. Rebound hyperglycemia was defined as a blood glucose level greater than 180 mg/dl.
Setting: The study was conducted at the University of Colorado Hospital.
Patients: Sixty-one hospitalized patients with known type 1 or type 2 diabetes receiving iv insulin infusion participated in the study.
Main Outcome: The primary outcome of this study was to compare the rates of rebound hyperglycemia between the control and the intervention groups after iv insulin infusion is discontinued.
Results: Overall, 29 subjects in the control group (93.5%) had at least one glucose value above 180 mg/dl during the 12-h follow-up period. This was significantly greater than the rate of rebound hyperglycemia in the intervention group (10 subjects or 33.3%, P < 0.001). The effect of the intervention was apparent in subjects who presented with diabetic ketoacidosis, after solid organ transplantation, and in patients with other surgical and medical diagnoses. There were three hypoglycemic measurements in two control subjects (68, 62, and 58 mg/dl) and none in the intervention group.
Conclusions: Once-daily sc insulin glargine administered during iv insulin infusion is a safe method for preventing future rebound hyperglycemia, without increased risk of hypoglycemia. (J Clin Endocrinol Metab 97: 3132-3137, 2012)
C1 [Hsia, Elisa; Seggelke, Stacey; Gibbs, Joanna; Hawkins, R. Matthew; Cohlmia, Elizabeth; Rasouli, Neda; Wang, Cecilia; Draznin, Boris] Univ Colorado, Sch Med, Div Endocrinol, Dept Med,Div Transplant Surg, Denver, CO 80045 USA.
[Kam, Igal] Univ Colorado, Sch Med, Dept Surg, Denver, CO 80045 USA.
[Rasouli, Neda; Wang, Cecilia] Denver Vet Affairs Med Ctr, Denver, CO 80045 USA.
RP Draznin, B (reprint author), Univ Colorado, Sch Med, Div Endocrinol Metab & Diabet, MS 8106,12801 E 17th Ave,RC1 S RM 7103, Aurora, CO 80045 USA.
EM boris.draznin@ucdenver.edu
FU Sanofi-Aventis; Veterans Affairs Career Development Award
FX This work was supported by a grant from Sanofi-Aventis. C.W. is a
recipient of the Veterans Affairs Career Development Award.
NR 26
TC 17
Z9 17
U1 0
U2 5
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2012
VL 97
IS 9
BP 3132
EP 3137
DI 10.1210/jc.2012-1244
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 004PF
UT WOS:000308692900050
PM 22685233
ER
PT J
AU Brent, GA
AF Brent, Gregory A.
TI Mechanisms of thyroid hormone action
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID RECEPTOR-ALPHA GENE; MONOCARBOXYLATE TRANSPORTER 8; RETINOIC ACID
RECEPTORS; CELL-SURFACE RECEPTOR; EMBRYONIC STEM-CELLS; V-ERBA ONCOGENE;
ACTION IN-VIVO; TYPE-3 DEIODINASE; RESPONSE ELEMENT; PROTEIN-KINASE
AB Our understanding of thyroid hormone action has been substantially altered by recent clinical observations of thyroid signaling defects in syndromes of hormone resistance and in a broad range of conditions, including profound mental retardation, obesity, metabolic disorders, and a number of cancers. The mechanism of thyroid hormone action has been informed by these clinical observations as well as by animal models and has influenced the way we view the role of local ligand availability; tissue and cell-specific thyroid hormone transporters, corepressors, and coactivators; thyroid hormone receptor (TR) isoform-specific action; and cross-talk in metabolic regulation and neural development. In some cases, our new understanding has already been translated into therapeutic strategies, especially for treating hyperlipidemia and obesity, and other drugs are in development to treat cardiac disease and cancer and to improve cognitive function.
C1 [Brent, Gregory A.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
[Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
RP Brent, GA (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM gbrent@ucla.edu
FU Veterans Affairs Merit Review Funds; NIH [R01 CA89364]
FX This work was supported by Veterans Affairs Merit Review Funds and NIH
grant R01 CA89364.
NR 135
TC 132
Z9 140
U1 10
U2 56
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD SEP
PY 2012
VL 122
IS 9
BP 3035
EP 3043
DI 10.1172/JCI60047
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 002EC
UT WOS:000308513100003
PM 22945636
ER
PT J
AU Lui, N
Chitsaz, S
Wisneski, AD
Takabe, K
Azadani, A
Tseng, EE
AF Lui, Natalie
Chitsaz, Sam
Wisneski, Andrew D.
Takabe, Kiyoaki
Azadani, Ali
Tseng, Elaine E.
TI Successful use of an eptifibatide bridge for patients taking clopidogrel
before cardiac surgery
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Meeting Abstract
CT 98th Annual Clinical Congress of the American-College-of-Surgeons/67th
Annual Sessions of the Owen H Wangensteen Forum on Fundamental Surgical
Problems
CY SEP 30-OCT 04, 2012
CL Chicago, IL
SP Amer Coll Surg
C1 San Francisco VA Med Ctr, San Francisco, CA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
RI Chitsaz, Sam/C-4586-2008
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD SEP
PY 2012
VL 215
IS 3
SU S
BP S34
EP S35
PG 2
WC Surgery
SC Surgery
GA 007SX
UT WOS:000308909600059
ER
PT J
AU Richman, JS
Henderson, WG
Itani, KMF
Vick, C
Hawn, MT
AF Richman, Joshua S.
Henderson, William G.
Itani, Kamal M. F.
Vick, Catherine
Hawn, Mary T.
TI Associations between perioperative beta-blocker use and surgical
outcomes
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Meeting Abstract
CT 98th Annual Clinical Congress of the American-College-of-Surgeons/67th
Annual Sessions of the Owen H Wangensteen Forum on Fundamental Surgical
Problems
CY SEP 30-OCT 04, 2012
CL Chicago, IL
SP Amer Coll Surg
C1 [Richman, Joshua S.; Henderson, William G.; Itani, Kamal M. F.; Vick, Catherine; Hawn, Mary T.] Birmingham VAMC, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD SEP
PY 2012
VL 215
IS 3
SU S
BP S102
EP S103
PG 2
WC Surgery
SC Surgery
GA 007SX
UT WOS:000308909600220
ER
PT J
AU Wisneski, AD
Matthews, PB
Azadani, AN
Chitsaz, S
Lui, N
Takabe, K
Ge, L
Tseng, EE
AF Wisneski, Andrew D.
Matthews, Peter B.
Azadani, Ali N.
Chitsaz, Sam
Lui, Natalie
Takabe, Kiyoaki
Ge, Liang
Tseng, Elaine E.
TI Finite element modeling of the human pulmonary autograft: A quantitative
analysis of wall stress after the Ross procedure
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Meeting Abstract
CT 98th Annual Clinical Congress of the American-College-of-Surgeons/67th
Annual Sessions of the Owen H Wangensteen Forum on Fundamental Surgical
Problems
CY SEP 30-OCT 04, 2012
CL Chicago, IL
SP Amer Coll Surg
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
RI Chitsaz, Sam/C-4586-2008
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD SEP
PY 2012
VL 215
IS 3
SU S
BP S46
EP S46
PG 1
WC Surgery
SC Surgery
GA 007SX
UT WOS:000308909600088
ER
PT J
AU Hsu, I
Saha, S
Korthuis, PT
Sharp, V
Cohn, J
Moore, RD
Beach, MC
AF Hsu, Ian
Saha, Somnath
Korthuis, Phillip Todd
Sharp, Victoria
Cohn, Jonathon
Moore, Richard D.
Beach, Mary Catherine
TI Providing support to patients in emotional encounters: A new perspective
on missed empathic opportunities
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Empathy; Patient-physician communication; Emotion; Physician-patient
relations
ID COMMUNICATION; CARE; REASSURANCE; CANCER; DOCTOR
AB Objective: Studies have repeatedly found that providers miss 70-90% of opportunities to express empathy. Our study sought to characterize provider responses to patients' emotions, with the overall goal of better understanding reasons for lack of empathic response.
Methods: We analyzed 47 visits between patients and their providers. We defined empathic opportunities as instances where patients expressed a strong negative emotion. We then developed thematic categories to describe provider response.
Results: We found a total of 29 empathic opportunities within 21 visits. Provider responses were categorized as ignore, dismiss, elicit information, problem-solve, or empathize. An empathic statement occurred at some point in the response sequence in 13/29 opportunities (45%). When problem-solving was the initial response, empathic statements rarely occurred in subsequent dialogue. Among the 16 instances with no empathic statements, providers engaged in problem-solving in 8 (50%).
Conclusion: Similar to other studies, we found providers missed most opportunities to respond empathically to patient emotion. Yet contrary to common understanding, providers often addressed the problem underlying the emotion, especially when the problem involved logistical or biomedical issues, as opposed to grief. Practice implications: With enhanced awareness, providers may better recognize situations where they cans offer empathy in addition to problem-solving. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Hsu, Ian; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD 21287 USA.
[Saha, Somnath; Korthuis, Phillip Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
[Sharp, Victoria] St Lukes Roosevelt Hosp, New York, NY USA.
[Cohn, Jonathon] Wayne State Univ, Detroit, MI USA.
RP Beach, MC (reprint author), Johns Hopkins Univ, 2024 E Monument St,Room 2-511, Baltimore, MD 21287 USA.
EM mcbeach@jhmi.edu
FU Health Resources Service Administration; Agency for Healthcare Research
and Quality [AHRQ 290-01-0012, K08 HS013903-05]; National Institute of
Drug Abuse [K23 DA019809]; Department of Veterans Affairs; Robert Wood
Johnson Generalist Physician Faculty Scholars Awards
FX This research was supported by a contract from the Health Resources
Service Administration and the Agency for Healthcare Research and
Quality (AHRQ 290-01-0012). In addition, Dr. Korthuis was supported by
the National Institute of Drug Abuse (K23 DA019809), Dr. Saha was
supported by the Department of Veterans Affairs, Dr. Beach was supported
by the Agency for Healthcare Research and Quality (K08 HS013903-05) and
both Drs. Beach and Saha were supported by Robert Wood Johnson
Generalist Physician Faculty Scholars Awards.
NR 26
TC 10
Z9 10
U1 4
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD SEP
PY 2012
VL 88
IS 3
SI SI
BP 436
EP 442
DI 10.1016/j.pec.2012.06.015
PG 7
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA 005SD
UT WOS:000308769300013
PM 22818767
ER
PT J
AU Burguete, SR
Levine, SM
Restrepo, MI
Angel, LF
Levine, DJ
Coalson, JJ
Peters, JI
AF Burguete, S. Rodrigo
Levine, Stephanie M.
Restrepo, Marcos I.
Angel, Luis F.
Levine, Deborah J.
Coalson, Jacqueline J.
Peters, Jay I.
TI Lung Transplantation for Williams-Campbell Syndrome With a Probable
Familial Association
SO RESPIRATORY CARE
LA English
DT Article
DE Williams-Campbell syndrome; bronchiectasis; lung transplantation;
bronchial cartilage deficiency
ID CONGENITAL BRONCHIECTASIS; CARTILAGE DEFICIENCY; COMPUTED-TOMOGRAPHY; CT
AB Williams-Campbell syndrome is a rare disorder characterized by deficiency of subsegmental bronchial cartilage and development of airway collapse and bronchiectasis that may subsequently progress to respiratory failure and death. There are only 2 published reports suggesting a familial association, and only one report of lung transplantation being used as a therapeutic modality. Due to postoperative airway complications, transplantation has not been recommended for this disease. We report the first lung transplant with prolonged survival, approaching 10 years, in a patient with Williams-Campbell syndrome, and provide further evidence to support a familial association.
C1 [Burguete, S. Rodrigo; Levine, Stephanie M.; Restrepo, Marcos I.; Angel, Luis F.; Levine, Deborah J.; Coalson, Jacqueline J.; Peters, Jay I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA.
[Burguete, S. Rodrigo; Levine, Stephanie M.; Restrepo, Marcos I.; Angel, Luis F.; Levine, Deborah J.; Coalson, Jacqueline J.; Peters, Jay I.] S Texas Vet Hlth Care Syst, Vet Evidence Res Disseminat & Implementat Ctr, San Antonio, TX USA.
RP Burguete, SR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm & Crit Care Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM burguete@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
FU National Heart, Lung, and Blood Institute [K23HL096054]
FX The authors have disclosed no conflicts of interest. Dr Restrepo was
partly supported by grant K23HL096054 from the National Heart, Lung, and
Blood Institute.
NR 20
TC 2
Z9 3
U1 0
U2 1
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD SEP
PY 2012
VL 57
IS 9
BP 1505
EP 1508
DI 10.4187/respcare.01484
PG 4
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 007PX
UT WOS:000308901700018
PM 22348466
ER
PT J
AU Mallipattu, SK
He, JC
Uribarri, J
AF Mallipattu, Sandeep K.
He, John C.
Uribarri, Jaime
TI Role of Advanced Glycation Endproducts and Potential Therapeutic
Interventions in Dialysis Patients
SO SEMINARS IN DIALYSIS
LA English
DT Review
ID GLYCOSYLATION END-PRODUCTS; HEMODIALYSIS-ASSOCIATED AMYLOIDOSIS;
AMBULATORY PERITONEAL-DIALYSIS; OXIDATION PROTEIN PRODUCTS; RENAL
REPLACEMENT THERAPY; CHRONIC KIDNEY-DISEASE; DIABETIC-NEPHROPATHY;
CARBONYL STRESS; IN-VIVO; VASCULAR-DISEASE
AB It has been nearly 100 years since the first published report of advanced glycation end products (AGEs) by the French chemist Maillard. Since then, our understanding of AGEs in diseased states has dramatically changed. Especially in the last 25 years, AGEs have been implicated in complications related to aging, neurodegenerative diseases, diabetes, and chronic kidney disease. Although AGE formation has been well characterized by both in vitro and in vivo studies, few prospective human studies exist demonstrating the role of AGEs in patients on chronic renal replacement therapy. As the prevalence of end-stage renal disease (ESRD) in the United States rises, it is essential to identify therapeutic strategies that either delay progression to ESRD or improve morbidity and mortality in this population. This article reviews the role of AGEs, especially those of dietary origin, in ESRD patients as well as potential therapeutic anti-AGE strategies in this population.
C1 [Mallipattu, Sandeep K.; He, John C.; Uribarri, Jaime] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA.
[He, John C.] James J Peters VA Med Ctr, Dept Med, Renal Sect, New York, NY USA.
RP Uribarri, J (reprint author), Mt Sinai Sch Med, Dept Med Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA.
EM jaime.uribarri@mssm.edu
RI Mallipattu , Sandeep/M-7009-2014
NR 146
TC 7
Z9 7
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-0959
EI 1525-139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD SEP-OCT
PY 2012
VL 25
IS 5
BP 529
EP 538
DI 10.1111/j.1525-139X.2012.01081.x
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 008OQ
UT WOS:000308966800011
PM 22548330
ER
PT J
AU Yaffe, K
Falvey, C
Hamilton, N
Schwartz, AV
Simonsick, EM
Satterfield, S
Cauley, JA
Rosano, C
Launer, LJ
Strotmeyer, ES
Harris, TB
AF Yaffe, Kristine
Falvey, Cherie
Hamilton, Nathan
Schwartz, Ann V.
Simonsick, Eleanor M.
Satterfield, Suzanne
Cauley, Jane A.
Rosano, Caterina
Launer, Lenore J.
Strotmeyer, Elsa S.
Harris, Tamara B.
TI Diabetes, Glucose Control, and 9-Year Cognitive Decline Among Older
Adults Without Dementia
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID MIDDLE-AGED ADULTS; MELLITUS; RISK; IMPAIRMENT; COHORT; ASSOCIATION;
DISEASE; WOMEN
AB Objectives: To determine if prevalent and incident diabetes mellitus (DM) increase risk of cognitive decline and if, among elderly adults with DM, poor glucose control is related to worse cognitive performance.
Design: Prospective cohort study.
Setting: Health, Aging, and Body Composition Study at 2 community clinics.
Participants: A total of 3069 elderly adults (mean age, 74.2 years; 42% black; 52% female).
Main Outcome Measures: Participants completed the Modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST) at baseline and selected intervals over 10 years. Diabetes mellitus status was determined at baseline and during follow-up visits. Glycosylated hemoglobin A(1c) level was measured at years 1 (baseline), 4, 6, and 10 from fasting whole blood.
Results: At baseline, 717 participants (23.4%) had prevalent DM and 2352 (76.6%) were without DM, 159 of whom developed incidentDMduring follow-up. Participants with prevalent DM had lower baseline test scores than participants without DM(3MS: 88.8 vs 90.9; DSST: 32.5 vs 36.3, respectively; t = 6.09; P =. 001 for both tests). Results from mixed-effects models showed a similar pattern for 9-year decline (3MS: -6.0-vs -4.5-point decline; t = 2.66; P =. 008; DSST: -7.9-vs -5.7-point decline; t = 3.69; P =. 001, respectively). Participants with incident DM tended to have baseline and 9-year decline scores between the other 2 groups but were not statistically different from the group without DM. Multivariate adjustment for demographics and medical comorbidities produced similar results. Among participants with prevalent DM, glycosylated hemoglobin A1c level was associated with lower average mean cognitive scores (3MS: F = 8.2; P for overall =. 003; DSST: F = 3.4; P for overall =. 04), even after multivariate adjustment.
Conclusion: Among well-functioning older adults, DM and poor glucose control among those with DM are associated with worse cognitive function and greater decline. This suggests that severity of DM may contribute to accelerated cognitive aging. Arch Neurol. 2012; 69(9): 1170-1175. Published online June 18, 2012. doi: 10.1001/archneurol.2012.1117
C1 [Yaffe, Kristine; Falvey, Cherie] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Yaffe, Kristine; Schwartz, Ann V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA.
[Yaffe, Kristine; Falvey, Cherie; Hamilton, Nathan] San Francisco VA Med Ctr, San Francisco, CA USA.
[Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA.
[Simonsick, Eleanor M.] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[Launer, Lenore J.; Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA.
[Cauley, Jane A.; Rosano, Caterina; Strotmeyer, Elsa S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, Box 181,4150 Clement St, San Francisco, CA 94121 USA.
EM kristine.yaffe@ucsf.edu
RI Strotmeyer, Elsa/F-3015-2014
OI Rosano, Caterina/0000-0002-0909-1506; Strotmeyer,
Elsa/0000-0002-4093-6036; Rosano, Caterina/0000-0002-4271-6010; Cauley,
Jane A/0000-0003-0752-4408
FU NIH (NIA, National Institute of Diabetes and Digestive and Kidney
Diseases, and National Institute of Mental Health); Department of
Defense; American Health Assistance Foundation; Anonymous Foundation;
Alzheimer's Association; Amgen; Merck Serono; GlaxoSmithKline; NIH
(National Institute of Diabetes and Digestive and Kidney Diseases and
NIA); NIH/NIA; NIH/NIA Intramural Research Program; NIH; NIA
[N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; National
Institute of Nursing Research [R01-NR012459]; Intramural Research
Program of the NIH, NIA; American Health Assistance Foundation
[A201-0029]
FX Dr Yaffe has served on data safety monitoring boards for Pfizer Inc,
Medivation Inc, and the National Institutes of Health (NIH) (National
Institute of Mental Health and National Institute on Aging [NIA] trials)
and has received research support from the NIH (NIA, National Institute
of Diabetes and Digestive and Kidney Diseases, and National Institute of
Mental Health), the Department of Defense, American Health Assistance
Foundation, Anonymous Foundation, and the Alzheimer's Association. Dr
Schwartz serves on a scientific advisory board for GlaxoSmithKline; has
received speaker honoraria from Amgen and Merck Serono; has received
funding for travel from Amgen; and receives research support from Merck
Serono, GlaxoSmithKline, and the NIH (National Institute of Diabetes and
Digestive and Kidney Diseases and NIA). Dr Simonsick serves as an
associate editor for the Journal of Gerontology Medical Sciences. Dr
Satterfield receives research support from the NIH/NIA. Dr Cauley
receives research support from Novartis. Dr Launer receives research
support from the NIH/NIA Intramural Research Program. Dr Harris receives
research support from the NIH.; This work was supported by NIA contracts
N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106; NIA grant R01-AG028050;
and National Institute of Nursing Research grant R01-NR012459. This
research was supported in part by the Intramural Research Program of the
NIH, NIA, and grant A201-0029 from the American Health Assistance
Foundation. Dr Yaffe is supported in part by NIA grant K24AG031155.
NR 32
TC 90
Z9 94
U1 2
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD SEP
PY 2012
VL 69
IS 9
BP 1170
EP 1175
DI 10.1001/archneurol.2012.1117
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 002UB
UT WOS:000308560600011
PM 22710333
ER
PT J
AU Falade-Nwulia, OO
Dhaliwal, G
Schreiber, MP
Saint, S
Shorr, AF
AF Falade-Nwulia, Oluwaseun O.
Dhaliwal, Gurpreet
Schreiber, Matthew P.
Saint, Sanjay
Shorr, Andrew F.
TI A 36-Year-Old Haitian Man With Coma, Acute Kidney Injury, Lactic
Acidosis, and Respiratory Failure
SO CHEST
LA English
DT Editorial Material
ID FALCIPARUM-MALARIA; UNITED-STATES
C1 [Falade-Nwulia, Oluwaseun O.] NIH, Dept Crit Care Med, Bethesda, MD 20892 USA.
Johns Hopkins Sch Med, Div Infect Dis, Baltimore, MD USA.
Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
[Schreiber, Matthew P.; Shorr, Andrew F.] Washington Hosp Ctr, Div Pulm & Crit Care Med, Washington, DC 20010 USA.
Georgetown Univ, Washington, DC USA.
[Saint, Sanjay] Univ Michigan, Ann Arbor VA Med Ctr, Ann Arbor, MI 48109 USA.
[Saint, Sanjay] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
RP Falade-Nwulia, OO (reprint author), NIH, Dept Crit Care Med, 10 Ctr Dr,Rm 2C145, Bethesda, MD 20892 USA.
EM ofalade1@jhmi.edu
NR 10
TC 1
Z9 2
U1 1
U2 1
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD SEP
PY 2012
VL 142
IS 3
BP 798
EP 801
DI 10.1378/chest.11-3209
PG 4
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 003PE
UT WOS:000308623000037
PM 22948586
ER
PT J
AU Thomas, RM
Gerstel, PAF
Williams, EC
Sun, HL
Bryson, CL
Au, DH
Bradley, KA
AF Thomas, Rachel M.
Gerstel, Patricia A. Francis
Williams, Emily C.
Sun, Haili
Bryson, Chris L.
Au, David H.
Bradley, Katharine A.
TI Association Between Alcohol Screening Scores and Diabetic Self-care
Behaviors
SO FAMILY MEDICINE
LA English
DT Article
ID NATIONAL EPIDEMIOLOGIC SURVEY; IDENTIFICATION TEST AUDIT; AT-RISK
DRINKING; USE DISORDERS; MEDICATION ADHERENCE; GENERAL-POPULATION;
GLYCEMIC CONTROL; GLUCOSE CONTROL; BLOOD-GLUCOSE; MALE VETERANS
AB BACKGROUND AND OBJECTIVES: Alcohol misuse is associated with poor adherence to recommended self-care behaviors, which are critical for diabetes management. This study investigated whether scores on a validated brief alcohol misuse screen are associated with diabetes self-care.
METHODS: Male outpatients (n=3,930) from seven Veterans Affairs sites returned the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) alcohol screen on mailed surveys and indicated they had diabetes. Patients were divided into five alcohol screening groups: no past year alcohol use (AUDIT-C 0), low-level alcohol use (AUDIT-C 1-3); and mild (AUDIT-C 4-5), moderate (AUDIT-C 6-7), and severe (AUDIT-C 8-12) misuse. Outcomes included self-report of monitoring blood glucose, maintaining normal blood glucose levels, inspecting feet, following a meal plan, not smoking, and laboratory data indicating that glycosylated hemoglobin A1c (HbA1c) had been tested in the past year. For each group, the proportion of patients adherent to each behavior were estimated from logistic regression models adjusted for demographics, comorbidity, and depressive symptoms.
RESULTS: Patients who did not drink were most likely to report adherence to self-care behaviors, except for past-year HbA1c testing. Compared to patients who did not drink, patients with AUDIT-C scores were significantly less likely to report maintaining normal blood glucose levels (eg, AUDIT-C 6-7 44% versus AUDIT-C 0 59%) or following a meal plan (48% versus 58%), and were more likely to smoke (71% abstained versus 85%) in adjusted analyses.
CONCLUSIONS: Results of this study indicate that higher alcohol screening scores are associated with poorer diabetes self-care.
C1 [Thomas, Rachel M.; Williams, Emily C.; Sun, Haili; Bryson, Chris L.; Au, David H.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev NW Ctr Excellence, Seattle, WA 98101 USA.
[Bryson, Chris L.; Au, David H.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA 98101 USA.
[Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98101 USA.
[Bryson, Chris L.; Au, David H.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Gerstel, Patricia A. Francis] Univ Hosp Geneva, Qual Care Unit, Geneva, Switzerland.
[Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA.
RP Thomas, RM (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev NW Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM rachel.thomas3@va.gov
FU Veterans Affairs (VA) Health Services Research & Development (HSRD) IIR
Grant [IAC 05-206-1]; VA [RCD 03-177, RCD 00-018]; VA Ambulatory Care
Quality Improvement Project (ACQUIP); VA HSRD [SDR 96-002, BR 99-376]
FX This project was funded by Veterans Affairs (VA) Health Services
Research & Development (HSR&D) IIR Grant IAC 05-206-1, VA Career
Development Awards RCD 03-177 (to Dr Bryson) and RCD 00-018 (to Dr Au),
and the VA Ambulatory Care Quality Improvement Project (ACQUIP) was
funded by VA HSR&D Grants SDR 96-002 and BR 99-376. The views expressed
in this article are those of the authors and do not necessarily reflect
the position or policy of the Department of Veterans Affairs or the US
government. A portion of this work was presented at the 2009 Addiction
Health Services Research Conference in San Francisco as a poster.
NR 57
TC 8
Z9 8
U1 6
U2 12
PU SOC TEACHERS FAMILY MEDICINE
PI LEAWOOD
PA 11400 TOMAHAWK CREEK PARKWAY, STE 540, LEAWOOD, KS 66207 USA
SN 0742-3225
J9 FAM MED
JI Fam. Med.
PD SEP
PY 2012
VL 44
IS 8
BP 555
EP 563
PG 9
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 002HS
UT WOS:000308523300005
PM 22930120
ER
PT J
AU Werner, RM
Dudley, RA
AF Werner, Rachel M.
Dudley, R. Adams
TI Medicare's New Hospital Value-Based Purchasing Program Is Likely To Have
Only A Small Impact On Hospital Payments
SO HEALTH AFFAIRS
LA English
DT Article
ID PAY-FOR-PERFORMANCE; QUALITY IMPROVEMENT; INCENTIVES; MORTALITY; CARE
AB Medicare's new hospital pay-for-performance program for all acute care hospitals will begin in October 2012. It will be the largest Medicare quality improvement initiative for hospitals to date. Using 2009 data on hospital performance, we calculated hospital performance scores and projected payments under the new program for all eligible hospitals. Despite differences across hospitals in terms of performance, expected changes in payments were small, even for hospitals with the best and worst performance scores. Almost two-thirds of hospitals would experience changes of just a fraction of 1 percent. Although the program will in effect redistribute resources among hospitals, our data suggest that the redistribution is not likely to cause major problems because the amount being redistributed is also small. These results raise questions about whether the new pay-for-performance program will substantially alter the quality of hospital care, and they highlight the challenges of designing effective quality improvement incentives.
C1 [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Werner, Rachel M.] Univ Penn, Philadelphia, PA 19104 USA.
[Dudley, R. Adams] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA.
RP Werner, RM (reprint author), Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
EM rwerner@upenn.edu
FU Agency for Healthcare Research and Quality [R01 HS018409]; Veterans
Affairs Health Services Research and Development Career Development
Award
FX This project was supported by a grant from the Agency for Healthcare
Research and Quality (R01 HS018409). Rachel Werner was supported in part
by a Veterans Affairs Health Services Research and Development Career
Development Award.
NR 18
TC 29
Z9 29
U1 5
U2 15
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD SEP
PY 2012
VL 31
IS 9
BP 1932
EP 1940
DI 10.1377/hlthaff.2011.0990
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 002NU
UT WOS:000308539700005
PM 22949441
ER
PT J
AU Wortzel, HS
Arciniegas, DB
Anderson, CA
Vanderploeg, RD
Brenner, LA
AF Wortzel, Hal S.
Arciniegas, David B.
Anderson, C. Alan
Vanderploeg, Rodney D.
Brenner, Lisa A.
TI A Phase I Study of Low-Pressure Hyperbaric Oxygen Therapy for
Blast-Induced Post-Concussion Syndrome and Post-Traumatic Stress
Disorder: A Neuropsychiatric Perspective
SO JOURNAL OF NEUROTRAUMA
LA English
DT Letter
ID TRAUMATIC BRAIN-INJURY; METAANALYSIS; ANTIDEPRESSANT; DEPRESSION;
VETERANS; IMPACT
C1 [Wortzel, Hal S.; Brenner, Lisa A.] Denver Vet Affairs Med Ctr, VISN MIRECC 19, VA Rocky Mt Network, Mental Illness Res Educ & Clin Ctr, Denver, CO 80220 USA.
[Arciniegas, David B.; Anderson, C. Alan; Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA.
[Wortzel, Hal S.; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA.
[Anderson, C. Alan] Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO 80220 USA.
[Vanderploeg, Rodney D.] James A Haley Vet Hosp, Tampa, FL 33612 USA.
RP Wortzel, HS (reprint author), Denver Vet Affairs Med Ctr, VISN MIRECC 19, VA Rocky Mt Network, Mental Illness Res Educ & Clin Ctr, 1055 Clermont St, Denver, CO 80220 USA.
EM hal.wortzel@ucdenver.edu
NR 24
TC 1
Z9 1
U1 1
U2 9
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD SEP
PY 2012
VL 29
IS 14
BP 2421
EP 2424
DI 10.1089/neu.2012.2426
PG 4
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 004SM
UT WOS:000308701400006
PM 22519979
ER
PT J
AU Bosworth, CR
Levin, G
Robinson-Cohen, C
Hoofnagle, AN
Ruzinski, J
Young, B
Schwartz, SM
Himmelfarb, J
Kestenbaum, B
de Boer, IH
AF Bosworth, Cortney R.
Levin, Gregory
Robinson-Cohen, Cassianne
Hoofnagle, Andrew N.
Ruzinski, John
Young, Bessie
Schwartz, Stephen M.
Himmelfarb, Jonathan
Kestenbaum, Bryan
de Boer, Ian H.
TI The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D
catabolism, is reduced in chronic kidney disease
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE chronic kidney disease; mineral metabolism; vitamin D
ID CHRONIC-RENAL-FAILURE; D METABOLISM; BIOLOGICAL ACTIVITY; MINERAL
METABOLISM; EXPRESSION; RAT; 1,25-DIHYDROXYCHOLECALCIFEROL;
1,25-DIHYDROXYVITAMIN-D; 25-HYDROXYVITAMIN-D3; DYSREGULATION
AB Chronic kidney disease is characterized, in part, as a state of decreased production of 1,25-dihydroxyvitamin D (1,25(OH)(2)D); however, this paradigm overlooks the role of vitamin D catabolism. We developed a mass spectrometric assay to quantify serum concentration of 24,25-dihydroxyvitamin D (24,25(OH)(2)D), the first metabolic product of 25-hydroxyvitamin D (25(OH)D) by CYP24A1, and determined its clinical correlates and associated outcomes among 278 participants with chronic kidney disease in the Seattle Kidney Study. For eGFRs of 60 or more, 45-59, 30-44, 15-29, and under 15 ml/min per 1.73m(2), the mean serum 24,25(OH)(2)D concentrations significantly trended lower from 3.6, 3.2, 2.6, 2.6, to 1.7 ng/ml, respectively. Non-Hispanic black race, diabetes, albuminuria, and lower serum bicarbonate were also independently and significantly associated with lower 24,25(OH)(2)D concentrations. The 24,25(OH)(2)D concentration was more strongly correlated with that of parathyroid hormone than was 25(OH)D or 1,25(OH)(2)D. A 24,25(OH)(2)D concentration below the median was associated with increased risk of mortality in unadjusted analysis, but this was attenuated with adjustment for potential confounding variables. Thus, chronic kidney disease is a state of stagnant vitamin D metabolism characterized by decreases in both 1,25(OH)(2)D production and vitamin D catabolism.
C1 [Bosworth, Cortney R.; Ruzinski, John; Young, Bessie; Himmelfarb, Jonathan; Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Div Nephrol, Dept Med, Seattle, WA 98104 USA.
[Bosworth, Cortney R.; Ruzinski, John; Young, Bessie; Himmelfarb, Jonathan; Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Seattle, WA 98104 USA.
[Levin, Gregory] Univ Washington, Dept Biostat, Seattle, WA 98104 USA.
[de Boer, Ian H.] Univ Washington, Dept Epidemiol, Div Nephrol, Seattle, WA 98104 USA.
[Hoofnagle, Andrew N.] Univ Washington, Dept Lab Med, Seattle, WA 98104 USA.
[Young, Bessie] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP de Boer, IH (reprint author), Univ Washington, Div Nephrol, Dept Med, Box 359606,325 9th Ave, Seattle, WA 98104 USA.
EM deboer@u.washington.edu
OI Robinson-Cohen, Cassianne/0000-0003-4783-7046; Schwartz,
Stephen/0000-0001-7499-8502
FU Abbott Laboratories; Amgen; National Institutes of Health [R01HL096875,
R01HL070938, R01DK087726]; Northwest Kidney Center Foundation; NIH grant
[R01DK079745]; Veterans Affairs Puget Sound Health Care System
FX IHdB has received research funding from Abbott Laboratories. BK has
received research funding from Amgen. JH has consulting and advisory
roles for Ardea Biosciences, Cytopheryx, and Thrasos Innovation.; This
work was supported by the National Institutes of Health (R01HL096875,
R01HL070938, and R01DK087726) and an unrestricted grant from the
Northwest Kidney Center Foundation. BY was supported by NIH grant
R01DK079745 and the Veterans Affairs Puget Sound Health Care System. We
would like to thank study coordinators Noah Citron and Georgia Galvin,
and study manager Ernie Ayers for their contributions to the study.
NR 42
TC 52
Z9 52
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD SEP
PY 2012
VL 82
IS 6
BP 693
EP 700
DI 10.1038/ki.2012.193
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 004FF
UT WOS:000308665200012
PM 22648296
ER
PT J
AU Pol, S
Ghalib, RH
Rustgi, VK
Martorell, C
Everson, GT
Tatum, HA
Hezode, C
Lim, JK
Bronowicki, JP
Abrams, GA
Brau, N
Morris, DW
Thuluvath, PJ
Reindollar, RW
Yin, PD
Diva, U
Hindes, R
McPhee, F
Hernandez, D
Wind-Rotolo, M
Hughes, EA
Schnittman, S
AF Pol, Stanislas
Ghalib, Reem H.
Rustgi, Vinod K.
Martorell, Claudia
Everson, Greg T.
Tatum, Harvey A.
Hezode, Christophe
Lim, Joseph K.
Bronowicki, Jean-Pierre
Abrams, Gary A.
Braeu, Norbert
Morris, David W.
Thuluvath, Paul J.
Reindollar, Robert W.
Yin, Philip D.
Diva, Ulysses
Hindes, Robert
McPhee, Fiona
Hernandez, Dennis
Wind-Rotolo, Megan
Hughes, Eric A.
Schnittman, Steven
TI Daclatasvir for previously untreated chronic hepatitis C genotype-1
infection: a randomised, parallel-group, double-blind,
placebo-controlled, dose-finding, phase 2a trial
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID SUSTAINED VIROLOGICAL RESPONSE; REPLICATION COMPLEX INHIBITOR;
1B-INFECTED NULL RESPONDERS; VIRUS-INFECTION; NS5A INHIBITOR;
PEGINTERFERON ALPHA-2A; COMBINATION THERAPY; PROTEASE INHIBITOR;
IN-VITRO; BMS-790052
AB Background Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules. Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was generally well tolerated in phase 1 studies. We assessed daclatasvir in combination with pegylated interferon (peginterferon) and ribavirin for chronic HCV.
Methods In this double-blind, parallel-group, dose-finding, phase 2a study, treatment-naive patients with HCV genotype-1 infection (without cirrhosis) from 14 centres in the USA and France were randomly assigned (1:1:1:1) to receive peginterferon alfa-2a (180 mu g per week) and ribavirin (1000-1200 mg daily) plus placebo or 3 mg, 10 mg, or 60 mg of daclatasvir taken once daily, for 48 weeks. The primary efficacy endpoint was undetectable HCV RNA at 4 weeks and 12 weeks after start of treatment (extended rapid virological response, eRVR). Analysis was of all participants who received one dose of study drug. We used descriptive analyses to compare results. This study is registered with ClinicalTrials.gov, number NCT00874770.
Findings 48 patients were randomly assigned (12 per group); all received at least one dose of study drug. 15 patients discontinued treatment before week 48. Five of 12 patients (42%, 80% CI 22-64%) who received 3 mg daclatasvir achieved eRVR, compared with ten of 12 (83%, 61-96%) who received 10 mg daclatasvir, nine of 12 (75%, 53-90%) who received 60 mg daclatasvir, and one of 12 (8%, 1-29%) who received placebo. Adverse events and discontinuations as a result of adverse events occurred with similar frequency across groups.
Interpretation Daclatasvir seems to be a potent NS5A replication complex inhibitor that increases the antiviral potency of peginterferon and ribavirin. Our findings support the further development of regimens containing 60 mg daclatasvir for the treatment of chronic genotype-1 HCV infection.
C1 [Pol, Stanislas] Hop Cochin, F-75679 Paris 14, France.
[Ghalib, Reem H.] Texas Clin Res Inst, Arlington, TX USA.
[Rustgi, Vinod K.] Metropolitan Res, Fairfax, VA USA.
[Martorell, Claudia] Res Inst, Springfield, MA USA.
[Everson, Greg T.] Univ Colorado Denver, Aurora, CO USA.
[Tatum, Harvey A.] Opt Hlth Res, Tulsa, OK USA.
[Hezode, Christophe] Hop Henri Mondor, F-94010 Creteil, France.
[Lim, Joseph K.] Yale Univ, Sch Med, New Haven, CT USA.
[Bronowicki, Jean-Pierre] Univ Lorraine, INSERM 954, Ctr Hosp Univ Nancy, Vandoeuvre Les Nancy, France.
[Abrams, Gary A.] Alabama Liver & Digest Specialists, Montgomery, AL USA.
[Braeu, Norbert] James J Peters VA Med Ctr, Bronx, NY USA.
[Morris, David W.] Healthcare Res Consultants, Tulsa, OK USA.
[Thuluvath, Paul J.] St Johns Mercy Med Ctr, Baltimore, MD USA.
[Reindollar, Robert W.] Carolinas Ctr Liver Dis, Statesville, NC USA.
[Yin, Philip D.; Diva, Ulysses; McPhee, Fiona; Hernandez, Dennis; Schnittman, Steven] Bristol Myers Squibb Co, Res & Dev, Wallingford, CT 06492 USA.
[Hindes, Robert] Gilead Sci Inc, Foster City, CA 94404 USA.
[Wind-Rotolo, Megan; Hughes, Eric A.] Bristol Myers Squibb Co, Res & Dev, Princeton, NJ USA.
RP Pol, S (reprint author), Hop Cochin, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France.
EM stanislas.pol@cch.aphp.fr
FU Bristol-Myers Squibb; Gilead; Merck/Schering-Plough; Roche; Abbott;
Boehringer Ingelheim; GlaxoSmithKline; Novartis; Tibotec; Achillion;
Debio; Genentech; Inhibitex; Pharmasset; Vertex; Zymogenetics
(Bristol-Myers Squibb); Globe Immune; Roche/Genentech; Merck; Janssen
FX SP has received research grants from Bristol-Myers Squibb, Gilead,
Merck/Schering-Plough, and Roche; and consulting or lecture fees from
Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead,
GlaxoSmithKline, Merck/Schering-Plough, Novartis, Roche, and Tibotec.
RHG has received research grants from Abbott, Achillion, Boehringer
Ingelheim, Bristol-Myers Squibb, Debio, Genentech, Gilead, Inhibitex,
Pharmasset, Tibotec, Vertex, and Zymogenetics (Bristol-Myers Squibb).
VKR received research grants from Bristol-Myers Squibb for this study.
CM has received research grants from Abbott, Bristol-Myers Squibb,
Gilead, and Novartis; and lecture fees from Abbott, Bristol-Myers
Squibb, and Gilead. GTE received a research grant from Bristol-Myers
Squibb (administered by the University of Colorado Denver) for this
study; and has served on advisory boards for Bristol-Myers Squibb. JKL
has received research grants from Bristol-Myers Squibb, Gilead, Globe
Immune, Roche/Genentech, Tibotec, and Vertex; and consulting fees from
Bristol-Myers Squibb, Gilead, Merck, and Vertex. J-PB has received
consulting fees from Bristol-Myers Squibb, Merck, Boehringer Ingelheim,
Novartis, Roche, Gilead, and Janssen. PIT received research grants from
Bristol-Myers Squibb for this study. RWR has received research grants
from Abbott, Bristol-Myers Squibb, Merck, Novartis, Pharmasset, and
Tibotec; and lecture fees from Merck and Vertex. PDY, UD, FM, DH, MW-R,
EAH, and SS are employees of Bristol-Myers Squibb. HAT, CH, GAA, NB,
DWM, and RH declare that they have no conflicts of interest.
NR 30
TC 105
Z9 108
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD SEP
PY 2012
VL 12
IS 9
BP 671
EP 677
DI 10.1016/S1473-3099(12)70138-X
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 994FM
UT WOS:000307916300022
PM 22714001
ER
PT J
AU Block, K
Gorin, Y
AF Block, Karen
Gorin, Yves
TI Aiding and abetting roles of NOX oxidases in cellular transformation
SO NATURE REVIEWS CANCER
LA English
DT Review
ID GENERATING NADPH OXIDASE; ADENINE-DINUCLEOTIDE PHOSPHATE;
EPIDERMAL-GROWTH-FACTOR; PROSTATE-CANCER CELLS; SMOOTH-MUSCLE-CELLS;
MEDIATED TYROSINE PHOSPHORYLATION; ACTIVATE SUPEROXIDE GENERATION;
TUMOR-SUPPRESSOR PROTEIN; NON-HODGKIN-LYMPHOMA; REACTIVE OXYGEN
AB NADPH oxidases of the NADPH oxidase (NOX) family are dedicated reactive oxygen species-generating enzymes that broadly and specifically regulate redox-sensitive signalling pathways that are involved in cancer development and progression. They act at specific cellular membranes and microdomains through the activation of oncogenes and the inactivation of tumour suppressor proteins. In this Review, we discuss primary targets and redox-linked signalling systems that are influenced by NOX-derived ROS, and the biological role of NOX oxidases in the aetiology of cancer.
C1 [Block, Karen] S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, Dept Med MC 7882, San Antonio, TX 78229 USA.
[Block, Karen; Gorin, Yves] Univ Texas Hlth Sci Ctr San Antonio, Dept Med MC 7882, San Antonio, TX 78229 USA.
RP Block, K (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, Dept Med MC 7882, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM block@uthscsa.edu
OI Gorin, Yves/0000-0003-4048-6925
FU Veterans Administration Career Development Award, NIH [R01 NCI CA131272]
FX The authors acknowledge H. E. Abboud, R. A. Clark and R. Li for critical
reading of the Review and F. Wauquier for unconditional assistance.
Supported by Veterans Administration Career Development Award, NIH R01
NCI CA131272 (K.B.).
NR 187
TC 86
Z9 89
U1 1
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-175X
J9 NAT REV CANCER
JI Nat. Rev. Cancer
PD SEP
PY 2012
VL 12
IS 9
BP 627
EP 637
DI 10.1038/nrc3339
PG 11
WC Oncology
SC Oncology
GA 998OI
UT WOS:000308249400015
PM 22918415
ER
PT J
AU Silverman, JM
Schmeidler, J
Beeri, MS
Rosendorff, C
Sano, M
Grossman, HT
Carrion-Baralt, JR
Bespalova, IN
West, R
Haroutunian, V
AF Silverman, Jeremy M.
Schmeidler, James
Beeri, Michal S.
Rosendorff, Clive
Sano, Mary
Grossman, Hillel T.
Carrion-Baralt, Jose R.
Bespalova, Irina N.
West, Rebecca
Haroutunian, Vahram
TI C-reactive protein and familial risk for dementia A phenotype for
successful cognitive aging
SO NEUROLOGY
LA English
DT Article
ID MINI-MENTAL-STATE; OLDEST-OLD; ALZHEIMER-DISEASE; INFLAMMATORY MARKERS;
METABOLIC SYNDROME; HISTORY METHOD; AGE; POPULATION; DECLINE; PLASMA
AB Objectives: Identifying phenotypes for successful cognitive aging, intact cognition into late-old age (>age 75), can help identify genes and neurobiological systems that may lead to interventions against and prevention of late-life cognitive impairment. The association of C-reactive protein (CRP) with cognitive impairment and dementia, observed primarily in young-elderly samples, appears diminished or reversed in late-old age (75+ years). A family history study determined if high CRP levels in late-old aged cognitively intact probands are associated with a reduced risk of dementia in their first-degree family members, suggesting a familial successful cognitive aging phenotype.
Methods: The primary sample was 1,329 parents and siblings of 277 cognitively intact male veteran probands at least 75 years old. The replication sample was 202 relatives of 51 cognitively intact community-ascertained probands at least 85 years old. Relatives were assessed for dementia by proband informant interview. Their hazard ratio (HR) for dementia as a function of the proband's log-transformed CRP was calculated using the proportional hazards model.
Results: Covarying for key demographics, higher CRP in probands was strongly associated with lower risk of dementia in relatives (HR = 0.55 [95% confidence interval (CI) 0.41, 0.74], p < 0.02). The replication sample relationship was in the same direction, stronger in magnitude, and also significant (HR = 0.15 [95% CI 0.06, 0.37], p < 0.0001).
Conclusions: Relatives of successful cognitive aging individuals with high levels of CRP are relatively likely to remain free of dementia. High CRP in successful cognitive aging individuals may constitute a phenotype for familial-and thus possibly genetic-successful cognitive aging. Neurology (R) 2012;79:1116-1123
C1 [Silverman, Jeremy M.; Schmeidler, James; Beeri, Michal S.; Sano, Mary; Grossman, Hillel T.; Bespalova, Irina N.; West, Rebecca; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Silverman, Jeremy M.; Beeri, Michal S.; Sano, Mary; Haroutunian, Vahram] Mt Sinai Sch Med, Friedman Brain Inst, New York, NY USA.
[Rosendorff, Clive] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Silverman, Jeremy M.; Beeri, Michal S.; Rosendorff, Clive; Sano, Mary; Grossman, Hillel T.; Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Carrion-Baralt, Jose R.] Univ Puerto Rico, Grad Sch Publ Hlth, Gerontol Program, San Juan, PR 00936 USA.
RP Silverman, JM (reprint author), Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
EM jeremy.silverman@mssm.edu
FU National Institute of Aging [P01-AG02219, K01-AG023515, K01-AG025203,
P50-AG05138]; United States Department of Veterans Affairs; Berkman
Charitable Trust; Alzheimer's Association
FX National Institute of Aging grants: P01-AG02219, K01-AG023515,
K01-AG025203, P50-AG05138; United States Department of Veterans Affairs;
Berkman Charitable Trust; and Alzheimer's Association.
NR 40
TC 10
Z9 10
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD SEP
PY 2012
VL 79
IS 11
BP 1116
EP 1123
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 005JE
UT WOS:000308745900029
PM 22895578
ER
PT J
AU Typpo, KV
Tcharmtchi, MH
Thomas, EJ
Kelly, PA
Castillo, LD
Singh, H
AF Typpo, Katri V.
Tcharmtchi, M. Hossein
Thomas, Eric J.
Kelly, P. Adam
Castillo, Leticia D.
Singh, Hardeep
TI Impact of resident duty hour limits on safety in the intensive care
unit: A national survey of pediatric and neonatal intensivists
SO PEDIATRIC CRITICAL CARE MEDICINE
LA English
DT Article
DE graduate medical education; intensive care; medical errors; patient
safety; pediatrics; resident duty-hours
ID EXTENDED WORK SHIFTS; ACCREDITATION-COUNCIL; ATTENDING PHYSICIANS;
MEDICAL ERRORS; PATIENT SAFETY; EDUCATION; INTERNS; FACULTY; RISK;
PRODUCTIVITY
AB Objective: Resident duty-hour regulations potentially shift the workload from resident to attending physicians. We sought to understand how current or future regulatory changes might impact safety in academic pediatric and neonatal intensive care units.
Design: Web-based survey.
Setting: U.S. academic pediatric and neonatal intensive care units.
Subjects: Attending pediatric and neonatal intensivists.
Interventions: We evaluated perceptions on four intensive care unit safety-related risk measures potentially affected by current duty-hour regulations: 1) attending physician and resident fatigue; 2) attending physician workload; 3) errors (self-reported rates by attending physicians or perceived resident error rates); and 4) safety culture. We also evaluated perceptions of how these risks would change with further duty-hour restrictions.
Measurements and Main Results: We administered our survey between February and April 2010 to 688 eligible physicians, of whom 360 (52.3%) responded. Most believed that resident error rates were unchanged or worse (91.9%) and safety culture was unchanged or worse (84.4%) with current duty-hour regulations. Of respondents, 61.9% believed their own work-hours providing direct patient care increased and 55.8% believed they were more fatigued while providing direct patient care. Most (85.3%) perceived no increase in their own error rates currently, but in the scenario of further reduction in resident duty-hours, over half (53.3%) believed that safety culture would worsen and a significant proportion (40.3%) believed that their own error rates would increase.
Conclusions: Pediatric intensivists do not perceive improved patient safety from current resident duty-hour restrictions. Policies to further restrict resident duty-hours should consider unintended consequences of worsening certain aspects of intensive care unit safety. (Pediatr Crit Care Med 2012; 13:578-582)
C1 [Typpo, Katri V.; Singh, Hardeep] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Typpo, Katri V.] Univ Arizona, Hlth Sci Ctr, Dept Pediat, Sect Crit Care Med, Tucson, AZ 85721 USA.
[Typpo, Katri V.] Univ Arizona, Dept Pediat, Sect Crit Care Med, Steele Childrens Res Ctr, Tucson, AZ 85721 USA.
[Tcharmtchi, M. Hossein] Baylor Coll Med, Dept Pediat, Sect Crit Care Med, Houston, TX 77030 USA.
[Thomas, Eric J.] Univ Texas Houston, Mem Herman Ctr Healthcare Qual & Safety, Houston, TX USA.
[Thomas, Eric J.] Univ Texas Med Sch Houston, Dept Med, Div Gen Med, Houston, TX USA.
[Kelly, P. Adam] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA.
[Castillo, Leticia D.] Univ Texas Dallas, Dept Pediat, Sect Pediat Crit Care Med, Dallas, TX 75230 USA.
RP Typpo, KV (reprint author), Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
EM ktyppo@email.arizona.edu
FU National Institutes of Health K23 career development award
[K23CA125585]; Houston VA HSR&D Center of Excellence [HFP90[hyphen]020];
Eunice Kennedy Shriver National Institute of Child Health and Human
Development, Improving the Safety and Quality of Pediatric Health Care
[1K24HD053771]
FX This work was partially supported by a National Institutes of Health K23
career development award (K23CA125585) and in part by the Houston VA
HSR&D Center of Excellence (HFP90[hyphen]020) and the Eunice Kennedy
Shriver National Institute of Child Health and Human Development,
Improving the Safety and Quality of Pediatric Health Care
(1K24HD053771).
NR 36
TC 9
Z9 9
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1529-7535
J9 PEDIATR CRIT CARE ME
JI Pediatr. Crit. Care Med.
PD SEP
PY 2012
VL 13
IS 5
BP 578
EP 582
DI 10.1097/PCC.0b013e318241785c
PG 5
WC Critical Care Medicine; Pediatrics
SC General & Internal Medicine; Pediatrics
GA 002NB
UT WOS:000308537800022
PM 22614570
ER
PT J
AU LaVela, SL
Burns, SP
Goldstein, B
Miskevics, S
Smith, B
Weaver, FM
AF LaVela, S. L.
Burns, S. P.
Goldstein, B.
Miskevics, S.
Smith, B.
Weaver, F. M.
TI Dysfunctional sleep in persons with spinal cord injuries and disorders
SO SPINAL CORD
LA English
DT Article
DE sleep dysfunction; spinal cord injury; prevalence; health behaviors;
comorbidities
ID APNEA-HYPOPNEA; DURATION; POPULATION; PREVALENCE; QUALITY; WEIGHT
AB Study design: Cross-sectional survey of veterans with spinal cord injuries and disorders (SCI/D).
Objectives: To describe sleep dysfunction (independent of sleep apnea) in persons with traumatic and non-traumatic SCI/D, and to examine characteristics and health outcomes independently associated with sleep dysfunction unrelated to sleep apnea.
Setting: Seven Veterans Affairs SCI care facilities in the United States.
Methods: Mailed cross-sectional survey with follow-up calls completed by end of 2008. Bivariate analyses to compare measures outcomes in persons with SCI/D who were dysfunctional sleepers vs those who were not. Multivariate logistic regression used to identify variables independently associated with dysfunctional sleep in veterans with SCI/D.
Results: Overall, 49% of the sample had sleep dysfunction unrelated to sleep apnea. In this subgroup, bivariate analyses showed that a greater proportion of dysfunctional sleepers than non-dysfunctional sleepers were current smokers, had problems with drinking alcohol, hypertension, asthma, chronic obstructive pulmonary disease (COPD) and problematic weight gain. Variables independently associated with higher odds of dysfunctional sleep included white race, being a current smoker, problems with drinking alcohol, asthma, COPD and problematic weight gain.
Conclusion: Consistent with epidemiological evidence for the general population, we found significant associations of sleep dysfunction with weight gain, smoking, alcohol misuse and select chronic conditions (COPD, asthma). Sustained sleep dysfunction may contribute to health deterioration and mortality, highlighting the need to address the high prevalence of sleep dysfunction (independent of sleep apnea) in persons with SCI/D. In particular, efforts aimed at modifying problematic weight gain, alcohol misuse and smoking are warranted in this cohort to improve sleep. Spinal Cord (2012) 50, 682-685; doi:10.1038/sc.2012.31; published online 17 April 2012
C1 [LaVela, S. L.; Smith, B.; Weaver, F. M.] Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA.
[LaVela, S. L.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA.
[Burns, S. P.; Goldstein, B.] Spinal Cord Injury Qual Enhancement Improvement I, VA Puget Sound, Seattle, WA USA.
[Smith, B.; Weaver, F. M.] Loyola Univ, Stritch Sch Med, Program Hlth Serv Res, Maywood, IL 60153 USA.
RP LaVela, SL (reprint author), Hines VA Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave,151-H, Hines, IL 60141 USA.
EM Sherri.LaVela@va.gov
FU Office of Research and Development, Health Services Research and
Development Service of the Department of Veterans Affairs
FX This material is based on work supported by the Office of Research and
Development, Health Services Research and Development Service of the
Department of Veterans Affairs. This paper reflects only the authors'
opinions and does not necessarily reflect the official position of the
Department of Veterans Affairs.
NR 25
TC 6
Z9 6
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD SEP
PY 2012
VL 50
IS 9
BP 682
EP 685
DI 10.1038/sc.2012.31
PG 4
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 004UC
UT WOS:000308705600007
PM 22508535
ER
PT J
AU Williams, EC
Lapham, GT
Hawkins, EJ
Rubinsky, AD
Morales, LS
Young, BA
Bradley, KA
AF Williams, Emily C.
Lapham, Gwen T.
Hawkins, Eric J.
Rubinsky, Anna D.
Morales, Leo S.
Young, Bessie A.
Bradley, Katharine A.
TI Variation in Documented Care for Unhealthy Alcohol Consumption Across
Race/Ethnicity in the Department of Veterans Affairs Healthcare System
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Race; Ethnicity; Alcohol; Alcohol Misuse; Healthcare Disparities
ID BEHAVIORAL-COUNSELING INTERVENTIONS; ETHNIC DISPARITIES; AUDIT-C;
PREVENTIVE-SERVICES; SCREENING-TEST; UNITED-STATES; USE DISORDERS;
SUBSTANCE USE; MISUSE; RISK
AB Background The VA Healthcare System has made progress implementing evidence-based care for unhealthy alcohol use, but whether there are differences in care across race/ethnicity is unclear. We describe alcohol-related care for 3 racial/ethnic groups among VA outpatients with unhealthy alcohol use. Methods This cross-sectional study utilized secondary quality improvement data collected for the VA Office of Quality and Performance (July 2006 to June 2007) to identify a sample of 9,194 black (n=1,436), Hispanic (n=500), and white (n=7,258) VA outpatients who screened positive for unhealthy alcohol use (AUDIT-C score=4 men; =3 women). Alcohol-related care was defined as medical record documentation of brief intervention (advice or feedback) and/or referral (discussion of or scheduled). Logistic regression models estimated the prevalence of alcohol-related care among black, Hispanic, and white patients after adjustment for sociodemographic characteristics, alcohol use severity, other substance use, and mental health comorbidity. Results Among all eligible patients, 2,903 (32%) had documented alcohol-related care. Adjusted prevalences were 35.3% (95% CI 30.0 to 40.5) for black, 27.3% (95% CI 21.1 to 33.5) for Hispanic, and 28.9% (95% CI 25.5 to 32.3) for white patients. Differences in documented alcohol-related care between all racial/ethnic groups were significant (p-values all<0.05). Conclusions Among VA patients with unhealthy alcohol use, black patients had the highest, and Hispanic the lowest, prevalence of documented alcohol-related care. Future research should evaluate contextual and system-, provider-, or patient-level factors that may attenuate racial/ethnic differences in documented alcohol-related care, as well as whether differences in documented care are associated with differences in outcomes.
C1 [Williams, Emily C.; Lapham, Gwen T.; Hawkins, Eric J.; Rubinsky, Anna D.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA.
[Williams, Emily C.; Lapham, Gwen T.; Hawkins, Eric J.; Rubinsky, Anna D.; Young, Bessie A.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, NW Ctr Excellence Hlth Serv Res & Dev, Seattle, WA USA.
[Williams, Emily C.; Lapham, Gwen T.; Hawkins, Eric J.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98101 USA.
[Williams, Emily C.; Lapham, Gwen T.; Rubinsky, Anna D.; Morales, Leo S.; Young, Bessie A.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Hawkins, Eric J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Young, Bessie A.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA 98101 USA.
[Young, Bessie A.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98101 USA.
[Young, Bessie A.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA.
[Bradley, Katharine A.] Res Inst, Grp Hlth, Seattle, WA USA.
RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM emily.williams3@va.gov
FU VA Substance Use Disorders Quality Enhancement Research Initiative (SUD
QuERI); VA's Northwest Center of Excellence for Health Services Research
Development
FX The authors gratefully acknowledge India J. Ornelas, PhD, MPH, and David
Grembowski, PhD, MA, for critical review of the conceptual framework
presented, as well as Stacey Rittmueller, MPH, and Rachel M. Thomas,
MPH, for help with manuscript preparation and revision. This study was
supported by the VA Substance Use Disorders Quality Enhancement Research
Initiative (SUD QuERI) and the VA's Northwest Center of Excellence for
Health Services Research & Development. Data for this study came from
the VA Office of Quality and Performance.
NR 55
TC 15
Z9 15
U1 2
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD SEP
PY 2012
VL 36
IS 9
BP 1614
EP 1622
DI 10.1111/j.1530-0277.2012.01761.x
PG 9
WC Substance Abuse
SC Substance Abuse
GA 001BQ
UT WOS:000308435200018
PM 22404130
ER
PT J
AU Rodriguez, HP
Chen, J
Owusu-Edusei, K
Suh, A
Bekemeier, B
AF Rodriguez, Hector P.
Chen, Jie
Owusu-Edusei, Kwame
Suh, Allen
Bekemeier, Betty
TI Local Public Health Systems and the Incidence of Sexually Transmitted
Diseases
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID US LATINO ADULTS; UNITED-STATES; RACIAL/ETHNIC DISPARITIES;
INSURANCE-COVERAGE; CARE ACCESS; PARTNERSHIPS; RATES; INFECTIONS;
BEHAVIORS; CHLAMYDIA
AB Objectives. We examined the associations of local public health system organization and local health department resources with county-level sexually transmitted disease (STD) incidence rates in large US health jurisdictions.
Methods. We linked annual county STD incidence data (2005-2008) to local health department director responses (n = 211) to the 2006 wave of the National Longitudinal Study of Local Public Health Systems, the 2005 national Local Health Department Profile Survey, and the Area Resource File. We used nested mixed effects regression models to assess the relative contribution of local public health system organization, local health department financial and resource factors, and sociodemographic factors known to be associated with STD incidence to county-level (n = 307) STD incidence.
Results. Jurisdictions with local governing boards had significantly lower county-level STD incidence. Local public health systems with comprehensive services where local health departments shoulder much of the effort had higher county-level STD rates than did conventional systems.
Conclusions. More integration of system partners in local public health system activities, through governance and interorganizational arrangements, may reduce the incidence and burden of STDs. (Am J Public Health. 2012;102: 1773-1781. doi:10.2105/AJPH.2011.300497)
C1 [Rodriguez, Hector P.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90095 USA.
[Chen, Jie] CUNY Coll Staten Isl, Dept Polit Sci Econ & Philosophy, Staten Isl, NY USA.
[Owusu-Edusei, Kwame] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
[Suh, Allen] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
[Bekemeier, Betty] Univ Washington, Sch Nursing, Div Psychosocial & Community Hlth, Seattle, WA 98195 USA.
RP Rodriguez, HP (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, 650 Charles E Young Dr S, Los Angeles, CA 90095 USA.
EM hrod@ucla.edu
FU Center for Public Health Systems and Services Research at the University
of Kentucky; Robert Wood Johnson Foundation
FX The Center for Public Health Systems and Services Research at the
University of Kentucky and the Robert Wood Johnson Foundation funded
this research project.
NR 64
TC 5
Z9 5
U1 3
U2 10
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD SEP
PY 2012
VL 102
IS 9
BP 1773
EP 1781
DI 10.2105/AJPH.2011.300497
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 994EJ
UT WOS:000307913400024
PM 22813090
ER
PT J
AU Stineman, MG
Xie, DW
Streim, JE
Pan, Q
Kurichi, JE
Henry-Sanchez, JT
Zhang, Z
Saliba, D
AF Stineman, Margaret G.
Xie, Dawei
Streim, Joel E.
Pan, Qiang
Kurichi, Jibby E.
Henry-Sanchez, John T.
Zhang, Zi
Saliba, Debra
TI Home Accessibility, Living Circumstances, Stage of Activity Limitation,
and Nursing Home Use
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Activities of daily living; Nursing homes; Rehabilitation
ID DWELLING OLDER-ADULTS; FUNCTIONAL STATUS; CHRONIC DISEASE; INDEPENDENCE;
COMMUNITY; HEALTH; ADMISSION; RISK; INSTITUTIONALIZATION; INTERVENTION
AB Stineman MG, Xie D, Streim JE, Pan Q, Kurichi JE, Henry-Sanchez JT, Zhang Z, Saliba D. Home accessibility, living circumstances, stage of activity limitation, and nursing home use. Arch Phys Med Rehabil 2012;93: 1609-16.
Objective: To explore the influence of physical home and social environments and disability patterns on nursing home (NH) use.
Design: Longitudinal cohort study. Self- or proxy-reported perception of home environmental barriers accessibility, 5 stages expressing the severity and pattern of activities of daily living (ADLs) limitations, and other characteristics at baseline were applied to predict NH use within 2 years or prior to death through logistic regression.
Setting: General community.
Participants: Population-based, community-dwelling individuals (N=7836; >= 70y) from the Second Longitudinal Study of Aging interviewed in 1994 with 2-year follow-up that was prospectively collected.
Interventions: Not applicable.
Main Outcome Measure: NH use within 2 years.
Results: Perceptions of home environmental barriers and living alone were both associated with approximately 40% increased odds of NH use after adjustment for other factors. Compared with those with no limitations at ADL stage 0, the odds of NH use peaked for those with severe limitations at ADL stage III (odds ratio [OR]=3.12; 95% confidence interval [CI] 2.20-4.41), then declined sharply for those with total limitations at ADL stage IV (OR=.96; 95% CI,.33-2.81). Sensitivity analyses for missing NH use showed similar results.
Conclusions: Accessibility of home environment, living circumstance, and ADL stage represent potentially modifiable targets for rehabilitation interventions for decreasing NH use in the aging U.S. population.
C1 [Stineman, Margaret G.; Xie, Dawei; Kurichi, Jibby E.; Zhang, Zi] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Stineman, Margaret G.; Henry-Sanchez, John T.] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Streim, Joel E.] Univ Penn, Geriatr Psychiat Sect, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Streim, Joel E.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Philadelphia, PA USA.
[Saliba, Debra] Greater Los Angeles Vet Affairs Geriatr Res Educ, Los Angeles, CA USA.
Univ Calif Los Angeles, JH Bonin Ctr Gerontol Res, Los Angeles, CA USA.
[Saliba, Debra] RAND Hlth, Santa Monica, CA USA.
RP Stineman, MG (reprint author), Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, 904 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM mstinema@exchange.upenn.edu
FU National Institutes of Health [AG032420-01A1]; National Institute of
Child Health and Human Development National Center for Medical
Rehabilitation Research [T32-HD-007425]
FX Supported by the National Institutes of Health (grant no. AG032420-01A1)
and by a postdoctoral fellowship (no. T32-HD-007425) awarded to the
University of Pennsylvania from the National Institute of Child Health
and Human Development National Center for Medical Rehabilitation
Research.
NR 37
TC 8
Z9 8
U1 4
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD SEP
PY 2012
VL 93
IS 9
BP 1609
EP 1616
DI 10.1016/j.apmr.2012.03.027
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 001IL
UT WOS:000308453800014
PM 22484216
ER
PT J
AU Tuomela, J
Sandholm, J
Karihtala, P
Ilvesaro, J
Vuopala, KS
Kauppila, JH
Kauppila, S
Chen, DQ
Pressey, C
Harkonen, P
Harris, KW
Graves, D
Auvinen, PK
Soini, Y
Jukkola-Vuorinen, A
Selander, KS
AF Tuomela, Johanna
Sandholm, Jouko
Karihtala, Peeter
Ilvesaro, Joanna
Vuopala, Katri S.
Kauppila, Joonas H.
Kauppila, Saila
Chen, Dongquan
Pressey, Christine
Harkonen, Pirkko
Harris, Kevin W.
Graves, David
Auvinen, Paivi K.
Soini, Ylermi
Jukkola-Vuorinen, Arja
Selander, Katri S.
TI Low TLR9 expression defines an aggressive subtype of triple-negative
breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Toll-like receptor-9; Triple negative; Hypoxia; Invasion; Breast cancer
ID TOLL-LIKE RECEPTOR-9; HELICOBACTER-PYLORI; CELLULAR INVASION;
PROSTATE-CANCER; POOR-PROGNOSIS; IN-VITRO; HYPOXIA; TUMORS; CELLS;
CARCINOMA
AB Toll-like receptor-9 (TLR9) is a DNA receptor widely expressed in cancers. Although synthetic TLR9 ligands induce cancer cell invasion in vitro, the role of TLR9 in cancer pathophysiology is unclear. We discovered that low tumor TLR9 expression is associated with significantly shortened disease-specific survival in patients with triple negative but not with ER+ breast cancers. A likely mechanism of this clinical finding involves differential responses to hypoxia. Our pre-clinical studies indicate that while TLR9 expression is hypoxia-regulated, low TLR9 expression has different effects on triple negative and ER+ breast cancer invasion in hypoxia. Hypoxia-induced invasion is augmented by TLR9 siRNA in triple negative, but not in ER+ breast cancer cells. This is possibly due to differential TLR9-regulated TIMP-3 expression, which remains detectable in ER+ cells but disappears from triple-negative TLR9 siRNA cells in hypoxia. Our results demonstrate a novel role for this innate immunity receptor in cancer biology and suggest that TLR9 expression may be a novel marker for triple-negative breast cancer patients who are at a high risk of relapse. Furthermore, these results suggest that interventions or events, which induce hypoxia or down-regulate TLR9 expression in triple-negative breast cancer cells may actually induce their spread.
C1 [Tuomela, Johanna; Sandholm, Jouko; Ilvesaro, Joanna; Chen, Dongquan; Pressey, Christine; Harris, Kevin W.; Selander, Katri S.] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA.
[Tuomela, Johanna; Sandholm, Jouko; Ilvesaro, Joanna; Chen, Dongquan; Pressey, Christine; Harris, Kevin W.; Graves, David; Selander, Katri S.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
[Karihtala, Peeter; Jukkola-Vuorinen, Arja] Oulu Univ Hosp, Dept Radiotherapy & Oncol, Oulu, Finland.
[Vuopala, Katri S.] Lapland Cent Hosp, Dept Pathol, Rovaniemi, Finland.
[Kauppila, Joonas H.; Kauppila, Saila] Oulu Univ Hosp, Dept Pathol, Oulu, Finland.
[Kauppila, Joonas H.] Oulu Univ Hosp, Dept Surg, Oulu, Finland.
[Kauppila, Joonas H.] Univ Oulu, Dept Anat & Cell Biol, Oulu, Finland.
[Harkonen, Pirkko] Univ Turku, Dept Cell Biol & Anat, Turku, Finland.
[Harris, Kevin W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Graves, David] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA.
[Auvinen, Paivi K.] Kuopio Univ Hosp, Canc Ctr Eastern Finland, Dept Oncol, SF-70210 Kuopio, Finland.
[Soini, Ylermi] Univ Eastern Finland, Dept Pathol & Forens Med, Kuopio, Finland.
RP Selander, KS (reprint author), Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, SHEL 514,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM Katri.Selander@ccc.uab.edu
RI Kauppila, Joonas/P-1363-2015
OI Kauppila, Joonas/0000-0001-6740-3726; Tuomela,
Johanna/0000-0003-4390-4563
FU Lapland Cultural Foundation; Northern Finnish Duodecim Foundation;
Finnish Medical Foundation; Oulu University Scholarship Foundation;
Cancer Foundation of Northern Finland; Elsa U. Pardee Foundation;
Department of Defense
FX This work was funded by grants from the Lapland Cultural Foundation (K.
S. V., A.J-V., K.S.S.), Northern Finnish Duodecim Foundation (A.J-V),
the Finnish Medical Foundation (P.K.), Oulu University Scholarship
Foundation (J.H.K.), Cancer Foundation of Northern Finland (J.H.K.),
Elsa U. Pardee Foundation (K.S.S) and Department of Defense (K.S.S.,
D.G.).
NR 41
TC 18
Z9 19
U1 3
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD SEP
PY 2012
VL 135
IS 2
BP 481
EP 493
DI 10.1007/s10549-012-2181-7
PG 13
WC Oncology
SC Oncology
GA 996QU
UT WOS:000308108700014
PM 22847512
ER
PT J
AU Johansen, KL
Zhang, R
Huang, YJ
Patzer, RE
Kutner, NC
AF Johansen, Kirsten L.
Zhang, Rebecca
Huang, Yijian
Patzer, Rachel E.
Kutner, Nancy C.
TI Association of Race and Insurance Type with Delayed Assessment for
Kidney Transplantation among Patients Initiating Dialysis in the United
States
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CADAVERIC RENAL-TRANSPLANTATION; RACIAL-DIFFERENCES; DISPARITIES;
ACCESS; PREFERENCES; RATES
AB Background and objectives The extent to which racial and socioeconomic disparities in access to kidney transplantation are related to not being assessed for transplant suitability before or shortly after the time of initiation of dialysis is not known. The aims of this study were to determine whether there were disparities based on race, ethnicity, or type of insurance in delayed assessment for transplantation and whether delayed assessment was associated with lower likelihood of waitlisting and kidney transplantation.
Design, setting, participants, & measurements This retrospective cohort study used data from the US Renal Data System and included 426,489 adult patients beginning dialysis in the United States between January 1, 2005 and September 30, 2009 without prior kidney transplant.
Results Overall, 12.5% of patients had reportedly not been assessed for transplantation. Patients without private insurance were more likely to be reported as not assessed (multivariable adjusted odds ratio=1.33, 95% confidence interval=1.28-1.40 for Medicaid), with a pronounced racial disparity but no ethnic disparity among patients aged 18 to <35 years (odds ratio=1.27, 95% confidence interval=1.13-1.43; P<0.001 for interaction with age). Not being assessed for transplant around the time of dialysis initiation was associated with lower likelihood of waitlisting in multivariable analysis (hazard ratio=0.59, 95% confidence interval=0.57-0.62 in the first year) and transplantation (hazard ratio=0.46, 95% confidence interval=0.41-0.51 in the first year), especially within the first 2 years.
Conclusions Racial and insurance-related disparities in transplant assessment potentially delay transplantation, particularly among younger patients. Clin J Am Soc Nephrol 7: 1490-1497, 2012. doi: 10.2215/CJN.13151211
C1 [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA.
[Johansen, Kirsten L.; Zhang, Rebecca; Huang, Yijian; Kutner, Nancy C.] Emory Univ, US Renal Data Syst Rehabil Qual Life Special Stud, Atlanta, GA 30322 USA.
[Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Patzer, Rachel E.] Emory Univ, Sch Med, Dept Surg, Div Transplantat, Atlanta, GA 30322 USA.
RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA.
EM kirsten.johansen@ucsf.edu
FU National Institutes of Health Contract [HHSN267200715004C]; NIH
Administrative Database Contract [N01-DK-7-5004]
FX Sources of support were National Institutes of Health Contract
HHSN267200715004C and NIH Administrative Database Contract
N01-DK-7-5004.
NR 16
TC 31
Z9 31
U1 0
U2 2
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD SEP
PY 2012
VL 7
IS 9
BP 1490
EP 1497
DI 10.2215/CJN.13151211
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 002DG
UT WOS:000308510600016
PM 22837273
ER
PT J
AU Cadena, J
Sreeramoju, P
Nair, S
Henao-Martinez, A
Jorgensen, J
Patterson, JE
AF Cadena, Jose
Sreeramoju, Pranavi
Nair, Shalini
Henao-Martinez, Andres
Jorgensen, James
Patterson, Jan E.
TI Clindamycin-resistant methicillin-resistant Staphylococcus aureus:
epidemiologic and molecular characteristics and associated clinical
factors
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE Methicillin-resistant Staphylococcus aureus; Clindamycin resistance;
Epidemiology; Skin and soft tissue infection; Adults
ID SOFT-TISSUE INFECTIONS; EMERGENCY-DEPARTMENT; USA-300 CLONE;
UNITED-STATES; SKIN; CARE; SURVEILLANCE; CHILDREN; DISEASE; USA300
AB In this prospective, observational study of 618 consecutive adult patients with skin and soft tissue infections (SSTI) caused by methicillin-resistant Staphylococcus aureus (MRSA), the clinical characteristics, molecular epidemiology, and outcome of patients with clindamycin-resistant MRSA (n = 64) and clindamycin-susceptible MRSA (n = 554) were compared (including factors predictive of clindamycin-resistant MRSA SSTI). Patients with clindamycin-resistant MRSA were more likely to have had antibiotic exposure within 3 months (37.5% versus 17%, P < 0.01), surgery (25% versus 8%, P < 0.01), MRSA infection/colonization within 12 months (23% versus 7%, P < 0.01), or intravascular catheters (5% versus 0.5%, P = 0.02). On multivariate analysis, previous surgery (adjusted odds ratio [AOR] 2.97; 95% confidence interval [C] 1.5-6.0), history of MRSA (AOR 3.4:95% CI 1.7-7.1), and exposure to clindamycin (AOR 8.5:95% CI 2.3-32) and to macrolides (AOR 7.2, 95% CI 1.6-31.8) were independently associated with presence of clindamycin-resistant MRSA. Clinical resolution was similar between groups (77% versus 68%; P = 0.26). Clindamycin-resistant MRSA was less often USA-300 (82% versus 98%, P = 0.004). Clindamycin resistance did not affect MRSA-SSTI clinical outcomes. Published by Elsevier Inc.
C1 [Cadena, Jose; Patterson, Jan E.] S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA.
[Cadena, Jose; Nair, Shalini; Henao-Martinez, Andres; Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Cadena, Jose; Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, San Antonio, TX 78229 USA.
[Jorgensen, James; Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Sreeramoju, Pranavi] Univ Texas SW Med Ctr Dallas, Div Infect Dis, Dept Med, Dallas, TX 75390 USA.
RP Cadena, J (reprint author), S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA.
EM cadenazuluag@uthscsa.edu
OI Henao-Martinez, Andres/0000-0001-7363-8652
FU BD diagnostics; bioMerieux; Pfizer; Merck; Schering Plough;
Basilea/Astellas
FX James Jorgensen, PhD, has served on the advisory boards of BD
Diagnostics and RibX Pharmaceuticals, and has received research support
from BD diagnostics, bioMerieux, and Pfizer. Dr. Patterson's spouse has
been on the advisory boards for Pfizer and Basilea, and has received
research support from Merck, Schering Plough, Pfizer, and
Basilea/Astellas. Other authors did not report any conflicts of
interest.
NR 34
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD SEP
PY 2012
VL 74
IS 1
BP 16
EP 21
DI 10.1016/j.diagmicrobio.2012.05.010
PG 6
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 996TE
UT WOS:000308116900004
PM 22795962
ER
PT J
AU Banks, WA
AF Banks, William A.
TI Brain Meets Body: The Blood-Brain Barrier as an Endocrine Interface
SO ENDOCRINOLOGY
LA English
DT Review
ID SLEEP-INDUCING PEPTIDE; NECROSIS-FACTOR-ALPHA; APOLIPOPROTEIN-E
GENOTYPE; ENDOTHELIAL-CELLS; CEREBROSPINAL-FLUID;
INTRACEREBROVENTRICULAR INJECTION; ALZHEIMERS-DISEASE; P-GLYCOPROTEIN;
DELTA-SLEEP; LEPTIN RESISTANCE
AB The blood-brain barrier (BBB) separates the central nervous system (CNS) from the peripheral tissues. However, this does not prevent hormones from entering the brain, but shifts the main control of entry to the BBB. In general, steroid hormones cross the BBB by transmembrane diffusion, a nonsaturable process resulting in brain levels that reflect blood levels, whereas thyroid hormones and many peptides and regulatory proteins cross using transporters, a saturable process resulting in brain levels that reflect blood levels and transporter characteristics. Protein binding, brain-to-blood transport, and pharmacokinetics modulate BBB penetration. Some hormones have the opposite effect within the CNS than they do in the periphery, suggesting that these hormones cross the BBB to act as their own counterregulators. The cells making up the BBB are also endocrine like, both responding to circulating substances and secreting substances into the circulation and CNS. By dividing a hormone's receptors into central and peripheral pools, the former of which may not be part of the hormone's negative feed back loop, the BBB fosters the development of variable hormone resistance syndromes, as exemplified by evidence that altered insulin action in the CNS can contribute to Alzheimer's disease. In summary, the BBB acts as a regulatory interface in an endocrine-like, humoral-based communication between the CNS and peripheral tissues. (Endocrinology 153: 4111-4119, 2012)
C1 [Banks, William A.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98195 USA.
[Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
RP Banks, WA (reprint author), 1660 S Columbian Way, Seattle, WA 98108 USA.
EM wabanks1@uw.edu
FU National Institutes of Health [RO1 DK083485, R01 AG029839, R01
NS051134]; Veterans Affairs Merit Review
FX This work was supported by National Institutes of Health grants RO1
DK083485, R01 AG029839, R01 NS051134, and Veterans Affairs Merit Review.
NR 131
TC 32
Z9 32
U1 3
U2 25
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD SEP
PY 2012
VL 153
IS 9
BP 4111
EP 4119
DI 10.1210/en.2012-1435
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 997VH
UT WOS:000308194900002
PM 22778219
ER
PT J
AU Seal, KH
Abadjian, L
McCamish, N
Shi, Y
Tarasovsky, G
Weingardt, K
AF Seal, Karen H.
Abadjian, Linda
McCamish, Nicole
Shi, Ying
Tarasovsky, Gary
Weingardt, Kenneth
TI A randomized controlled trial of telephone motivational interviewing to
enhance mental health treatment engagement in Iraq and Afghanistan
veterans
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE War veterans; Treatment engagement; Trial; Posttraumatic stress
disorder; Motivational interviewing
ID POSTTRAUMATIC-STRESS-DISORDER; REFERRAL-CARE MANAGEMENT; SUBSTANCE USE
DISORDERS; WAR VETERANS; INTERVENTION; SOLDIERS; PTSD; DEPRESSION;
ATTITUDES; SERVICES
AB Objective: To test the efficacy of telephone-administered motivational interviewing (MI) to enhance treatment engagement in Iraq and Afghanistan veterans with mental health (MH) problems.
Method: Between April 23, 2008, and February 25, 2011, 73 Iraq and Afghanistan veterans who screened positive for >= 1 MH problem(s) on telephone-administered psychometric assessment, but were not engaged in treatment, were randomized to either personalized referral for MH services and four sessions of telephone MI or standard referral and four neutral telephone check-in sessions (control) at baseline, 2, 4 and 8 weeks. Blinded assessment occurred at 8 and 16
Results: In intent-to-treat analyses, 62% assigned to telephone MI engaged in MH treatment compared to 26% of controls [relative risk (RR)=2.41, 95% confidence interval (CI)=1.33-4.37, P=.004], which represented a large effect size (Cohen's h=0.74). Participants in the MI group also demonstrated significantly greater retention in MH treatment than controls [MI mean visits (S.D.)=1.68 (2.73) and control mean visits (S.D.)=0.38 (0.81), incidence rate ratio (IRR)=4.36, 95% CI=1.96-9.68, P<.001], as well as significant reductions in stigma and marijuana use at 8 weeks (P<.05).
Conclusions: Telephone MI enhances MH treatment engagement in Iraq and Afghanistan veterans with MH problems. Published by Elsevier Inc.
C1 [Seal, Karen H.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA.
[Weingardt, Kenneth] Palo Alto VA Hlth Care Syst, Palo Alto, CA USA.
[Weingardt, Kenneth] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
RP Seal, KH (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, 4150 Clement St,Box 111A-1, San Francisco, CA 94121 USA.
EM Karen.Seal@va.gov
FU Department of Veterans Affairs (VA), Clinical Sciences Research and
Development [MN078889-01]; VA Health Services Research and Development
(HSR&D) Research Enhancement Award Program at the San Francisco VA
Medical Center
FX This work was funded by a grant from the Department of Veterans Affairs
(VA), Clinical Sciences Research and Development (award no. MN078889-01)
and by the VA Health Services Research and Development (HSR&D) Research
Enhancement Award Program at the San Francisco VA Medical Center.
NR 42
TC 21
Z9 21
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD SEP-OCT
PY 2012
VL 34
IS 5
BP 450
EP 459
DI 10.1016/j.genhosppsych.2012.04.007
PG 10
WC Psychiatry
SC Psychiatry
GA 002DP
UT WOS:000308511500002
PM 22632925
ER
PT J
AU Zivin, K
Campbell, DG
Lanto, AB
Chaney, EF
Bolkan, C
Bonner, LM
Miller, EM
Valenstein, M
Waltz, TJ
Rubenstein, LV
AF Zivin, Kara
Campbell, Duncan G.
Lanto, Andrew B.
Chaney, Edmund F.
Bolkan, Cory
Bonner, Laura M.
Miller, Erin M.
Valenstein, Marcia
Waltz, Thomas J.
Rubenstein, Lisa V.
TI Relationships between mood and employment over time among depressed VA
primary care patients
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Employment; Veterans; Depression
ID MENTAL-HEALTH; PSYCHIATRIC-DISORDERS; WORK PRODUCTIVITY; UNEMPLOYMENT;
UNDEREMPLOYMENT; VETERANS; IMPACT; POPULATION; ADJUSTMENT; INSURANCE
AB Objective: Associations between depression, productivity and work loss have been reported, yet few studies have examined relationships between longitudinal depression status and employment continuity. We assessed these relationships among Veterans of conventional working ages.
Methods: We used longitudinal survey data from Veterans receiving primary care in 1 of 10 Veterans Health Administration primary care practices in five states. Our sample included 516 participants with nine-item Patient Health Questionnaire (PHQ-9) scores indicating probable major depression (PHQ-9 >= 10) at baseline and who completed either the 7-month follow-up survey or follow-up surveys at both 7 and 18 months postbaseline. We examined relationships between depression persistence and employment status using multinomial logistic regression models.
Results: Although general employment rates remained stable (21%-23%), improved depression status was associated with an increased likelihood of becoming employed over 7 months among those who were both depressed and nonemployed at baseline. Improvements in depression status starting at 7 months and continuing through 18 months were associated with remaining employed over the 18-month period, relative to those who were depressed throughout the same time frame.
Conclusions: Given the pressing need to prevent socioeconomic deterioration in the increasing population of conventional working-aged Operation Enduring Freedom and Operation Iraqi Freedom Veterans, further attention to the depression/employment relationship is urgently needed. Published by Elsevier Inc.
C1 [Zivin, Kara; Miller, Erin M.; Valenstein, Marcia] Vet Affairs Ann Arbor, Natl Serious Mental Illness Treatment Resource &, HSR&D, Ann Arbor, MI USA.
[Zivin, Kara; Miller, Erin M.; Valenstein, Marcia] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA.
[Campbell, Duncan G.] Univ Montana, Dept Psychol, Missoula, MT 59812 USA.
[Lanto, Andrew B.] Vet Affairs Greater Los Angeles, HSR&D, Los Angeles, CA USA.
[Chaney, Edmund F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Chaney, Edmund F.] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA.
[Bonner, Laura M.] VA Puget Sound, HSR&D, Washington, DC USA.
[Bolkan, Cory] Washington State Univ, Dept Human Dev, Vancouver, WA USA.
[Waltz, Thomas J.] Little Rock Dept Vet Affairs, HSR&D, Little Rock, AR USA.
[Waltz, Thomas J.] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA.
[Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA.
RP Zivin, K (reprint author), Vet Affairs Ann Arbor, Natl Serious Mental Illness Treatment Resource &, HSR&D, Ann Arbor, MI USA.
EM kzivin@umich.edu
OI Waltz, Thomas/0000-0001-7976-430X
FU Department of Veterans Affairs (VA) Health Services Research and
Development (HSRD) Service; VA Quality Enhancement Research Initiative
(QUERI) [MHI 99-375, MNT 01-027, MHQ 10-06, RRP 12-175]; Department of
Veterans Affairs [CD2 07-206-1]
FX This project was funded by the Department of Veterans Affairs (VA)
Health Services Research and Development (HSR&D) Service and the VA
Quality Enhancement Research Initiative (QUERI) (Project nos. MHI
99-375, MNT 01-027, MHQ 10-06, RRP 12-175) and Department of Veterans
Affairs CD2 07-206-1 and IIR #10-176-3. The views expressed in this
article are those of the authors and do not necessarily represent the
views of the Department of Veterans Affairs.
NR 41
TC 8
Z9 8
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD SEP-OCT
PY 2012
VL 34
IS 5
BP 468
EP 477
DI 10.1016/j.genhosppsych.2012.05.008
PG 10
WC Psychiatry
SC Psychiatry
GA 002DP
UT WOS:000308511500004
PM 22771108
ER
PT J
AU Ganzini, L
Mansoor, D
Socherman, R
Duckart, J
AF Ganzini, Linda
Mansoor, David
Socherman, Robert
Duckart, Jonathan
TI Delirium and decisional incapacity in veterans with schizophrenia and
medical illness
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Delirium; Schizophrenia; Decision-making capacity; Veterans
ID CONSULTATION; MANAGEMENT; CARE; ILL
AB Objective: The objective was to examine the characteristics of Veterans with schizophrenia admitted for nonpsychiatric hospitalizations.
Method: We conducted a review of the electronic medical record and data warehouse downloads of Veterans with schizophrenia admitted to nonpsychiatric services of a large, academic Veterans Affairs hospital between 2004 and 2009 on whom psychiatry was consulted.
Results: Seventy-four veterans were admitted 89 times. Their mean age was 62 years. Among these veterans, the most common reasons for nonpsychiatric admission were infection, cardiac disease or altered mental status. Thirty-three percent of consultations were for patients who required intensive care. Consultation was requested most frequently for assessing psychotropic medication, decision-making capacity or altered mental status, or for assistance with behavioral problems. Thirty-seven percent of patients were diagnosed with delirium, and 42% lacked decision-making capacity, mostly secondary to delirium. Twenty-seven percent of patients died during the study period.
Conclusion: In an aging cohort of Veterans with schizophrenia, a substantial proportion of patients developed delirium, lost decision-making capacity and required intensive care during nonpsychiatric hospital admission. Published by Elsevier Inc.
C1 [Ganzini, Linda; Mansoor, David; Socherman, Robert; Duckart, Jonathan] Portland VA Med Ctr, Div Mental Hlth, Portland, OR 97207 USA.
[Ganzini, Linda; Mansoor, David; Socherman, Robert] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA.
RP Ganzini, L (reprint author), Portland VA Med Ctr, Div Mental Hlth, POB 1034, Portland, OR 97207 USA.
EM Linda.Ganzini@va.gov
NR 13
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD SEP-OCT
PY 2012
VL 34
IS 5
BP 506
EP 509
DI 10.1016/j.genhosppsych.2012.04.003
PG 4
WC Psychiatry
SC Psychiatry
GA 002DP
UT WOS:000308511500008
PM 22632926
ER
PT J
AU Pompili, M
Innamorati, M
Serafini, G
Gonda, X
Campi, S
Rapinesi, C
Giordano, G
Montebovi, F
Palermo, M
Giupponi, G
Tatarelli, R
Biondi, M
Amore, M
Sher, L
Rihmer, Z
Girardi, P
AF Pompili, Maurizio
Innamorati, Marco
Serafini, Gianluca
Gonda, Xenia
Campi, Sandra
Rapinesi, Chiara
Giordano, Gloria
Montebovi, Franco
Palermo, Mario
Giupponi, Giancarlo
Tatarelli, Roberto
Biondi, Massimo
Amore, Mario
Sher, Leo
Rihmer, Zoltan
Girardi, Paolo
TI How does subjective experience of pain relate to psychopathology among
psychiatric patients?
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Anxiety disorder; Depressive disorder; Pain severity; Psychopathology
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PRIMARY-CARE; DEPRESSIVE
SYMPTOMS; ANXIETY DISORDERS; PHYSICAL SYMPTOMS; SOMATIC SYMPTOMS;
DSM-IV; GENDER; MINI; SOMATIZATION
AB Objective: The study aimed to investigate to what extent general psychopathology is associated with subjective experience of pain in psychiatric outpatients without comorbidity with severe physical diagnosis and whether there are any differences in the experience of pain between genders or diagnoses.
Method: Participants were 575 consecutive outpatients affected by mood disorder or anxiety disorder. Patients completed the West Haven-Yale Multidimensional Pain Inventory (WHYMPI) and the Symptom Checklist 90-Revised.
Results: Women had higher mean scores on the Global Severity Index (1.52 +/- 0.76 vs. 1.33 +/- 0.79), higher perception of negative responses from others (1.84 +/- 1.59 vs. 1.46 +/- 1.35) and higher perception of pain severity (3.31 +/- 1.73 vs. 2.88 +/- 1.63) than men. They also reported higher mean scores on the WHYMPI's General Activity (2.14 +/- 0.98 vs. 1.93 +/- 0.95) and Household Chores (3.64 +/- 1.75 vs. 2.27 +/- 1.58) and lower mean scores on the Outdoor Work (1.24 +/- 1.26 vs. 1.87 +/- 1.51) dimension than men. Higher pain severity, more negative responses from others and higher household chores are predictors of higher psychopathology, while the general level of activity may be considered as a protective factor.
Conclusions: Pain and its subjective experience play a central role in psychiatric disorders, and it is a great burden for patients and caregivers. Clinicians should pay more attention to recognize and adequately treat painful symptoms in patients with anxiety and depressive disorder. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Pompili, Maurizio; Innamorati, Marco; Serafini, Gianluca; Campi, Sandra; Rapinesi, Chiara; Giordano, Gloria; Montebovi, Franco; Palermo, Mario; Tatarelli, Roberto; Girardi, Paolo] Univ Roma La Sapienza, St Andrea Hosp, Suicide Prevent Ctr, Dept Neurosci Mental Hlth & Sensory Organs, I-00189 Rome, Italy.
[Pompili, Maurizio] Harvard Univ, McLean Hosp, Sch Med, Belmont, MA USA.
[Gonda, Xenia] Semmelweis Univ, Kutvolgyi Clin Ctr, Dept Clin & Theoret Mental Hlth, H-1125 Budapest, Hungary.
[Campi, Sandra; Biondi, Massimo; Rihmer, Zoltan] Univ Roma La Sapienza, Dept Psychiat & Psychol Med, I-00189 Rome, Italy.
[Giupponi, Giancarlo] Dept Psychiat, Bolzano, Italy.
[Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Sher, Leo] James J Peters Vet Adm Med Ctr, Dept Psychiat, New York, NY USA.
[Amore, Mario] Univ Parma, Dept Neurosci, Div Psychiat, I-43100 Parma, Italy.
RP Pompili, M (reprint author), Univ Roma La Sapienza, St Andrea Hosp, Dept Psychiat, 1035-1039 Via Grottarossa, I-00189 Rome, Italy.
EM maurizio.pompili@uniroma1.it
RI Innamorati, Marco/H-8877-2013; Giupponi, Giancarlo/J-9824-2016
OI Innamorati, Marco/0000-0003-1389-2290; Giupponi,
Giancarlo/0000-0001-6430-0000; biondi, massimo/0000-0001-8777-5498;
Pompili, Maurizio/0000-0003-1886-4977; Tatarelli,
Roberto/0000-0003-4396-2632
NR 52
TC 6
Z9 6
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD SEP-OCT
PY 2012
VL 34
IS 5
BP 534
EP 540
DI 10.1016/j.genhosppsych.2012.03.022
PG 7
WC Psychiatry
SC Psychiatry
GA 002DP
UT WOS:000308511500013
PM 22595339
ER
PT J
AU Farnan, JM
Burger, A
Boonayasai, RT
Leykum, L
Harrison, R
Machulsky, J
Parekh, V
Sharpe, BA
Schleyer, AM
Arora, VM
AF Farnan, Jeanne M.
Burger, Alfred
Boonayasai, Romsai T.
Leykum, Luci
Harrison, Rebecca
Machulsky, Julie
Parekh, Vikas
Sharpe, Bradley A.
Schleyer, Anneliese M.
Arora, Vineet M.
CA SGIM Housestaff Oversight Subcomm
TI Survey of overnight academic hospitalist supervision of trainees
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID SAFETY
AB In 2003, Accreditation Council for Graduate Medical Education (ACGME) announced the first in a series of guidelines related to the residency training. The most recent recommendations include explicit recommendations regarding the provision of on-site clinical supervision for trainees of internal medicine. To meet these standards, many internal medicine residency programs turned to hospitalist programs to fill that need. However, much is unknown about the current relationships between hospitalist and residency programs, specifically with regard to supervisory roles and supervision policies. We aimed to describe how academic hospitalists currently supervise housestaff during the on-call, or overnight, period and hospitalist program leader their perceptions of how these new policies would impact trainee-hospitalist interactions. Journal of Hospital Medicine 2012;(C) 2012 Society of Hospital Medicine
C1 [Farnan, Jeanne M.] Univ Chicago, Dept Med, Sect Hosp Med, Chicago, IL 60637 USA.
[Burger, Alfred] Albert Einstein Coll Med, Dept Med, Gen Internal Med Sect, Beth Israel Med Ctr, New York, NY USA.
[Boonayasai, Romsai T.] Johns Hopkins Univ, Sch Med, Dept Med, Gen Internal Med Sect, Baltimore, MD 21205 USA.
[Leykum, Luci] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Harrison, Rebecca] Oregon Hlth & Sci Univ, Dept Med, Div Hosp Med, Portland, OR 97201 USA.
[Machulsky, Julie] Soc Gen Internal Med, Alexandria, VA USA.
[Parekh, Vikas] Univ Michigan, Sch Med, Dept Med, Div Gen Med, Ann Arbor, MI 48104 USA.
[Sharpe, Bradley A.] Univ Calif San Francisco, Dept Med, Div Hosp Med, San Francisco, CA USA.
[Schleyer, Anneliese M.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA.
[Arora, Vineet M.] Gen Internal Med Sect, Dept Med, New Haven, CT USA.
RP Farnan, JM (reprint author), Univ Chicago, Dept Med, Sect Hosp Med, 5841 S Maryland Ave,MC 2007,AMB W216, Chicago, IL 60637 USA.
EM jfarnan@medicine.bsd.uchicago.edu
OI Arora, Vineet/0000-0002-4745-7599
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service [REA 05-129, CDA 07-022]
FX The research reported here was supported by the Department of Veterans
Affairs, Veterans Health Administration, Health Services Research and
Development Service (REA 05-129, CDA 07-022). The views expressed in
this article are those of the authors and do not necessarily reflect the
position or policy of the Department of Veterans Affairs.
NR 8
TC 8
Z9 8
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
EI 1553-5606
J9 J HOSP MED
JI J. Hosp. Med.
PD SEP
PY 2012
VL 7
IS 7
BP 521
EP 523
DI 10.1002/jhm.1961
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 000YQ
UT WOS:000308427400002
PM 22956452
ER
PT J
AU Englander, H
Kansagara, D
AF Englander, Honora
Kansagara, Devan
TI Planning and designing the care transitions innovation (C-Train) for
uninsured and Medicaid patients
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID CONTROLLED-TRIAL; HOSPITALIZATION; INTERVENTION; QUALITY
AB BACKGROUND: Uninsured and Medicaid patients are particularly vulnerable as they transition from hospital to home. Transitional care improvement programs require time and capital, incentives for which may be unclear for those lacking a third-party payor. This article describes our experience developing a hospital-funded transitional care program for uninsured and Medicaid patients. METHODS: We performed an inpatient needs assessment, convened multi-stakeholder work groups, and engaged institutional change-agents to inform program development and a business case. RESULTS: We mapped needs to specific program elements, including a transitional care nurse, pharmacy consult and provision of medications for uninsured patients, medical home linkages including community payment for medical homes, and monthly quality improvement meetings. A business case was informed by local needs and utilization data, and compelled the hospital to invest in up-front resources for this population. DISCUSSION: We are studying our program's impact on 30-day readmission and emergency department rates through a clustered, randomized controlled trial. Lessons from our experience may be useful to others aiming to improve care for socioeconomically disadvantaged patients. Journal of Hospital Medicine 2012; (C) 2012 Society of Hospital Medicine
C1 [Englander, Honora; Kansagara, Devan] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
[Kansagara, Devan] Portland VA Med Ctr, Portland, OR USA.
RP Englander, H (reprint author), Oregon Hlth & Sci Univ, Dept Med, Mail Code BTE 119,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM englandh@ohsu.edu
NR 16
TC 11
Z9 11
U1 3
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD SEP
PY 2012
VL 7
IS 7
BP 524
EP 529
DI 10.1002/jhm.1926
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 000YQ
UT WOS:000308427400003
PM 22411913
ER
PT J
AU Saliba, D
Jones, M
Streim, J
Ouslander, J
Berlowitz, D
Buchanan, J
AF Saliba, Debra
Jones, Malia
Streim, Joel
Ouslander, Joseph
Berlowitz, Dan
Buchanan, Joan
TI Overview of Significant Changes in the Minimum Data Set for Nursing
Homes Version 3.0
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Nursing home; assessment; pain; mood; preferences; Minimum Data Set 3.0;
pressure ulcers; delirium; behavior; falls; continence
ID CONFUSION ASSESSMENT METHOD; PAIN INTENSITY; COGNITIVE IMPAIRMENT;
DEPRESSIVE SYMPTOMS; RESIDENTS; CARE; DELIRIUM; RECOGNITION;
PERFORMANCE; OUTCOMES
AB The Minimum Data Set (MDS) is a standardized assessment that is completed on all residents admitted to Medicare certified nursing homes in the US. It is also completed on all residents admitted to Veteran Health Administration Community Living Centers. Its content addresses multiple domains of resident health and function and is intended to facilitate better recognition of each resident's needs. A new version of the MDS, MDS 3.0, was implemented in October, 2010. This article highlights significant clinical changes found in the MDS 3.0, including new structured resident interviews to assess mood, preferences, pain and cognition; inclusion of the Confusion Assessment Method to screen for delirium; revised psychosis and behavior items; revised balance and falls sections; revised bladder and bowel assessment items; revised pressure ulcer assessment items; revisions to the nutrition items; items reporting on resident expectations for return to the community; and changes to race/ethnicity item and language report. These changes aim to improve the clinical utility of these assessment items. Published by Elsevier Inc. on behalf of the American Medical Directors Association, Inc.
C1 [Saliba, Debra] UCLA JH Borun Ctr Gerontol Res, Los Angeles, CA 90095 USA.
[Saliba, Debra] RAND Corp, Greater Los Angeles VA GRECC, Santa Monica, CA USA.
[Jones, Malia] RAND Corp, UCLA Sch Publ Hlth, Dept Community Hlth Sci, Santa Monica, CA USA.
[Streim, Joel] Univ Penn, Perelman Sch Med, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA.
[Ouslander, Joseph] Florida Atlantic Univ, Charles E Schmidt Coll Med, Geriatr Programs, Boca Raton, FL 33431 USA.
[Berlowitz, Dan] Bedford VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Berlowitz, Dan] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Berlowitz, Dan] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Buchanan, Joan] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Saliba, Debra] RAND Corp, HSR&D Ctr Excellence, Santa Monica, CA USA.
[Streim, Joel] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA.
[Ouslander, Joseph] Florida Atlantic Univ, Christine E Lynn Coll Nursing, Boca Raton, FL 33431 USA.
RP Saliba, D (reprint author), UCLA JH Borun Ctr Gerontol Res, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA.
EM saliba@rand.org
OI Jones, Malia/0000-0002-8198-0826
FU U.S. Department of Veterans Affairs, Veterans Health Administration,
Health Services Research and Development (HSRD) Service [SDR 03-217];
Centers for Medicare & Medicaid Services; UCLA/JH Borun Center
FX Parts of this work were funded by the U.S. Department of Veterans
Affairs, Veterans Health Administration, Health Services Research and
Development (HSR&D) Service (Project SDR 03-217), the Centers for
Medicare & Medicaid Services, and the UCLA/JH Borun Center. The views
expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the U.S. Department of
Veterans Affairs or the Centers for Medicare and Medicaid Services.
NR 43
TC 37
Z9 38
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
EI 1538-9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD SEP
PY 2012
VL 13
IS 7
BP 595
EP 601
DI 10.1016/j.jamda.2012.06.001
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 002IX
UT WOS:000308526400006
PM 22784698
ER
PT J
AU Saliba, D
Buchanan, J
Edelen, MO
Streim, J
Ouslander, J
Berlowitz, D
Chodosh, J
AF Saliba, Debra
Buchanan, Joan
Edelen, Maria Orlando
Streim, Joel
Ouslander, Joseph
Berlowitz, Dan
Chodosh, Joshua
TI MDS 3.0: Brief Interview for Mental Status
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Cognition; nursing home; assessment; Minimum Data Set; screening;
interview; procedural memory
ID NURSING-HOME RESIDENTS; MINIMUM DATA SET; CONFUSION ASSESSMENT METHOD;
INTENSIVE-CARE-UNIT; COGNITIVE IMPAIRMENT; DEMENTIA; VALIDITY;
RECOGNITION; DELIRIUM; 3MS
AB Objectives: To test the feasibility and validity of the Brief Interview for Mental Status (BIMS) as a performance-based cognitive screener that could be easily completed by nursing home staff. The current study examines the performance of the BIMS as part of the national testing of the Minimum Data Set 3.0 (MDS 3.0) for Nursing Homes.
Methods: The BIMS was tested as part of the national MDS 3.0 evaluation study among 3822 residents scheduled for MDS 2.0 assessments. Residents were from 71 community nursing homes (NHs) in eight states. Residents were randomly included in a feasibility sample (n = 3258) and a validation sample (n = 418). Cognition was assessed with three instruments: the Brief Interview for Mental Status (BIMS), the MDS 2.0 Cognitive Performance Scale (CPS), and the Modified Mini-Mental State Examination (3MS). Trained research nurses administered the 3MS and BIMS to all subjects in the validation study. The CPS score was determined based on the MDS 2.0 completed by nursing home staff who had undergone additional training on cognitive testing. Standard cutoff scores on the 100-point 3MS were used as the gold standard for any cognitive impairment (<78) and for severe impairment (<48). Staff impressions were obtained from anonymous surveys.
Results: The BIMS was attempted and completed in 90% of the 3258 residents in the feasiblity sample. BIMS scores covered the full instrument range (0-15). In the validation sample, correlation with the criterion measure (3MS) was higher for BIMS (0.906, P<.0001) than for CPS (-0.739, P<.0001); P<.01 for difference. For identifying any impairment, a BIMS score of 12 had sensitivity = 0.83 and specificity = 0.91; for severe impairment, a BIMS score of 7 had sensitivity = 0.83 and specificity = 0.92. The area under the receiver operator characteristics curve, a measure of test accuracy, was higher for BIMS than for CPS for identifying any impairment (AUC = 0.930 and 0.824, respectively) and for identifying severe impairment (AUC = 0.960 and 0.857, respectively). Eighty-eight percent of survey respondents reported that the BIMS provided new insight into residents' cognitive abilities. The average time for completing the BIMS was 3.2 minutes.
Discussion: The BIMS, a short performance-based cognitive screener expressly designed to facilitate cognitive screening in MDS assessments, was completed in the majority of NH residents scheduled for MDS assessments in a large sample of NHs, demonstrating its feasibility. Compared with MDS 2.0 observational items, the BIMS performance-based assessment approach was more highly correlated with a criterion cognitive screening test and demonstrated greater accuracy. The majority of surveyed staff reported improved assessments with the new approach. Published by Elsevier Inc. on behalf of the American Medical Directors Association, Inc.
C1 [Saliba, Debra] UCLA Jewish Home Borun Ctr Gerontol Res, Los Angeles, CA USA.
[Saliba, Debra] RAND Corp, Greater Los Angeles VA GRECC, Santa Monica, CA USA.
[Saliba, Debra] RAND Corp, HSR&D Ctr Excellence, Santa Monica, CA USA.
[Buchanan, Joan] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Edelen, Maria Orlando] RAND Corp, Boston, MA USA.
[Streim, Joel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network 4, Philadelphia, PA USA.
[Streim, Joel] Univ Penn, Dept Psychiat, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA.
[Ouslander, Joseph] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA.
[Ouslander, Joseph] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
[Berlowitz, Dan] Bedford VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Berlowitz, Dan] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Chodosh, Joshua] UCLA Dept Med, Greater Los Angeles VA GRECC, Los Angeles, CA USA.
[Chodosh, Joshua] UCLA Dept Med, HSR&D Ctr Excellence, Los Angeles, CA USA.
RP Saliba, D (reprint author), UCLA Borun Ctr Gerontol Res, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA.
EM saliba@rand.org
OI Chodosh, Joshua/0000-0001-7784-4306
FU U.S. Department of Veterans Affairs, Veterans Health Administration,
Health Services Research and Development (HSRD) Service [SDR 03-217];
Centers for Medicare & Medicaid Services; UCLA/JH Borun Center
FX This work was funded by the U.S. Department of Veterans Affairs,
Veterans Health Administration, Health Services Research and Development
(HSR&D) Service (Project SDR 03-217), the Centers for Medicare &
Medicaid Services, and the UCLA/JH Borun Center. The views expressed in
this article are those of the authors and do not necessarily reflect the
position or policy of the U.S. Department of Veterans Affairs or the
Centers for Medicare and Medicaid Services.
NR 30
TC 37
Z9 37
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
EI 1538-9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD SEP
PY 2012
VL 13
IS 7
BP 611
EP 617
DI 10.1016/j.jamda.2012.06.004
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 002IX
UT WOS:000308526400008
PM 22796362
ER
PT J
AU Saliba, D
DiFilippo, S
Edelen, MO
Kroenke, K
Buchanan, J
Streim, J
AF Saliba, Debra
DiFilippo, Suzanne
Edelen, Maria Orlando
Kroenke, Kurt
Buchanan, Joan
Streim, Joel
TI Testing the PHQ-9 Interview and Observational Versions (PHQ-9 OV) for
MDS 3.0
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Mood; nursing home; assessment; Minimum Data Set; depression;
observation; interview; PHQ-9
ID NURSING-HOME RESIDENTS; QUALITY-OF-LIFE; LONG-TERM-CARE; PATIENT HEALTH
QUESTIONNAIRE; SEROTONIN REUPTAKE INHIBITORS; OLDER-ADULTS;
MYOCARDIAL-INFARCTION; DEPRESSIVE SYMPTOMS; ELDERLY-PATIENTS; PRIME-MD
AB Objectives: To test the feasibility and validity of the Patient Health Questionnaire-9 item interview (PHQ-9) and the newly developed Patient Health Questionnaire Observational Version (PHQ-9 OV) for screening for mood disorder in nursing home populations.
Methods: The PHQ-9 was tested as part of the national Minimum Data Set 3.0 (MDS 3.0) evaluation study among 3822 residents scheduled for MDS 2.0 assessments. Residents from 71 community nursing homes (NHs) in eight states were randomly included in a feasibility sample (n = 3258) and a validation sample (n = 418). Each resident's ability to communicate determined whether the PHQ-9 interview or the PHQ-9 OV was initially attempted. In the validation sample, trained research nurses administered the instruments. For residents in the validation sample without severe cognitive impairment (3 MS >= 30) agreement between PHQ-9 and the modified Schedule for Affective Disorders and Schizophrenia (m-SADS) was measured with weighted kappas (kappa). For residents with severe cognitive impairment (3MS < 30), agreement between PHQ-9 interview or PHQ-9 OV and the Cornell Scale for Depression in Dementia (Cornell Scale) was measured using correlation coefficients. Staff impressions were obtained from an anonymous survey mailed to all MDS assessors.
Results: The PHQ-9 was completed in 86% of the 3258 residents in the feasibility sample. In the validation sample, the agreement between PHQ-9 and m-SADS was very good (weighted kappa = 0.69, 95% CI = 0.61-0.76), whereas agreement between MDS 2.0 and m-SADS was poor (weighted kappa = 0.15, 95% CI = 0.06-0.25). Likewise, in residents with severe cognitive impairment, PHQ correlations with the criterion standard Cornell Scale were superior to the MDS 2.0 for both the PHQ-9 (0.63 vs 0.34) and the PHQ-9 OV (0.84 vs 0.28). Eighty-six percent of survey respondents reported that the PHQ-9 provided new insight into residents' mood. The average time for completing the PHQ-9 interview was 4 minutes.
Discussion: Compared with the MDS 2.0 observational items, the PHQ-9 interview had greater agreement with criterion standard diagnostic assessments. For residents who could not complete the interview, the PHQ-9 OV also had greater agreement with a criterion measure for depression than did the MDS 2.0 observational items. Moreover, the majority of NH residents were able to complete the PHQ-9, and most surveyed staff reported improved assessments with the new approach. Published by Elsevier Inc. on behalf of the American Medical Directors Association, Inc.
C1 [Saliba, Debra] UCLA Jewish Home Borun Ctr Gerontol Res, Los Angeles, CA USA.
[Saliba, Debra] RAND Corp, Greater Los Angeles VA GRECC, Santa Monica, CA USA.
[Saliba, Debra] RAND Corp, HSR&D Ctr Excellence, Santa Monica, CA USA.
[DiFilippo, Suzanne] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network 4, Philadelphia, PA USA.
[DiFilippo, Suzanne] Univ Penn, Dept Psychiat, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA.
[Edelen, Maria Orlando] RAND Corp, Boston, MA USA.
[Kroenke, Kurt] Richard Roudebush VA Med Ctr, Ctr Implementing Evidence Based Practice, Indianapolis, IN USA.
[Buchanan, Joan] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Streim, Joel] Univ Penn, Perelman Sch Med, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA.
[Streim, Joel] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA.
RP Saliba, D (reprint author), UCLA Borun Ctr Gerontol Res, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA.
EM saliba@rand.org
FU U.S. Department of Veterans Affairs, Veterans Health Administration,
Health Services Research and Development (HSRD) Service [SDR 03-217];
Centers for Medicare & Medicaid Services; UCLA/JH Borun Center
FX This work was funded by the U.S. Department of Veterans Affairs,
Veterans Health Administration, Health Services Research and Development
(HSR&D) Service (Project SDR 03-217), the Centers for Medicare &
Medicaid Services and the UCLA/JH Borun Center. The views expressed in
this article are those of the authors and do not necessarily reflect the
position or policy of the U. S. Department of Veterans Affairs or the
Centers for Medicare and Medicaid Services.
NR 91
TC 32
Z9 32
U1 4
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
EI 1538-9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD SEP
PY 2012
VL 13
IS 7
BP 618
EP 625
DI 10.1016/j.jamda.2012.06.003
PG 8
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 002IX
UT WOS:000308526400009
PM 22796361
ER
PT J
AU Tena-Nelson, R
Santos, K
Weingast, E
Amrhein, S
Ouslander, J
Boockvar, K
AF Tena-Nelson, Roxanne
Santos, Kathryn
Weingast, Elizabeth
Amrhein, Scott
Ouslander, Joseph
Boockvar, Kenneth
TI Reducing Potentially Preventable Hospital Transfers: Results from a
Thirty Nursing Home Collaborative
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Nursing homes; hospitalization; quality improvement
ID RESIDENTS; INFECTION; ILLNESS
AB Background: Nursing home (NH) residents experience frequent hospital transfers, some potentially avoidable. The objective of this report is to describe a replication of the Interventions to Reduce Acute Care Transfers program among member facilities of a New York City area NH provider association (INTERACT NY) and estimate its effect on hospital transfers.
Methods: INTERACT is a program that provides tools and strategies to assist NH staff in early identification, communication, and documentation of changes in resident status. Funding was obtained from a New York State health workforce training grant to conduct 13 INTERACT education and training sessions in 2010-2011. INTERACT NY session topics included the implementation process; use of its simple standardized communication tools, advance care planning tools, care paths, and change in condition support tools; quality review of hospital transfers; exercises for refining clinical skills; teamwork; and lessons learned. Sessions engaged NH executives, department heads, front-line nursing staff and their labor union, and staff from NHs' partner hospitals. Pre-/post-INTERACT NY hospitalization rates per 1000-resident days were compared using paired t-tests, stratified by level of facility engagement with the program and by baseline hospitalization rates.
Results: All 100% of participating NHs were non-profit or public. Those with complete evaluation data had 377 beds on average. There were a total of 333 attendees of the program (mean 25.6 per session; mean 11.1 per facility over the course of the program; range 1e44 per facility). The most common attendees in order of frequency were (1) nurse administrators, (2) unit-based nurses, (3) medical directors and attending physicians, (4) nursing home administrators, (5) certified nursing assistants, and (6) case managers and social workers. Sixteen nursing homes implemented at least one INTERACT tool. Overall, there was a nonsignificant 10.6% reduction in hospital admissions from 4.07 to 3.64 per 1000 resident-days from pre-to post-INTERACT NY (P=.332). Among nursing homes with high engagement there was a nonsignificant 14.3% reduction in hospital admissions from 4.19 to 3.59 per 1000 resident-days (P=0.213). Finally, among nursing homes in the highest tertile of baseline (pre-INTERACT NY) hospital admission rate, there was a nonsignificant 27.2% reduction in hospital admissions from 7.32 to 5.33 per 1000 resident-days (P=.102). Planning and implementation lessons from INTERACT NY leaders and participants are reported.
Conclusions: INTERACT NY, a novel collaborative training program, resulted in good uptake of the INTERACT tools and processes among its member nursing homes. Changes in hospitalization rates associated with INTERACT NY were similar to those observed in previous implementations of INTERACT. The program addresses a growing interest in reducing potentially preventable hospital admissions among nursing home residents and providing alternatives to hospital care through standardized approaches to communication, early identification of clinical issues, decision-support, and support for partnerships between acute and post-acute care providers. Copyright (C) 2012 - American Medical Directors Association, Inc.
C1 [Weingast, Elizabeth; Boockvar, Kenneth] Jewish Home Lifecare, New York, NY 10025 USA.
[Tena-Nelson, Roxanne; Santos, Kathryn; Amrhein, Scott] Continuing Care Leadership Coalit, New York, NY 10019 USA.
[Ouslander, Joseph] Florida Atlantic Univ, Boca Raton, FL 33431 USA.
[Boockvar, Kenneth] Mt Sinai Sch Med, New York, NY USA.
[Boockvar, Kenneth] James J Peters VA Med Ctr, Bronx, NY USA.
RP Boockvar, K (reprint author), Jewish Home Lifecare, 120 W 106th St, New York, NY 10025 USA.
EM tena-nelson@gnyha.org; kenneth.boockvar@mssm.edu
OI Boockvar, Kenneth/0000-0003-1165-5558
FU New York State Workforce Training grant; Greenwall Foundation
FX This project was supported by a New York State Workforce Training grant.
One author was supported by the Greenwall Foundation.
NR 10
TC 21
Z9 21
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD SEP
PY 2012
VL 13
IS 7
BP 651
EP 656
DI 10.1016/j.jamda.2012.06.011
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 002IX
UT WOS:000308526400015
PM 22835484
ER
PT J
AU Sauna, ZE
Ameri, A
Kim, B
Yanover, C
Viel, KR
Rajalingam, R
Cole, SA
Howard, TE
AF Sauna, Z. E.
Ameri, A.
Kim, B.
Yanover, C.
Viel, K. R.
Rajalingam, R.
Cole, S. A.
Howard, T. E.
TI Observations regarding the immunogenicity of BDD-rFVIII derived from a
mechanistic personalized medicine perspective
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Letter
ID RECOMBINANT FACTOR-VIII; HEMOPHILIA-A; INHIBITORS; PROTEIN
C1 [Howard, T. E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA 90073 USA.
[Sauna, Z. E.] US FDA, Lab Hemostasis, Div Hematol, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA.
[Ameri, A.] Georgia Hlth Sci Univ, Div Hematol & Oncol, Dept Pediat, Augusta, GA USA.
[Kim, B.] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA.
[Yanover, C.] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98104 USA.
[Viel, K. R.] Histonis Inc, Atlanta, GA USA.
[Rajalingam, R.] Univ Calif Los Angeles, Dept Pathol & Lab Med, David Geen Sch Med, Immunogenet Ctr, Los Angeles, CA USA.
[Cole, S. A.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA.
[Howard, T. E.] Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90033 USA.
[Howard, T. E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
RP Howard, TE (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Bldg 500,Room 1258, Los Angeles, CA 90073 USA.
EM tom.howard@va.gov
RI Yanover, Chen/A-3754-2012
OI Yanover, Chen/0000-0003-3663-4286
FU NHLBI NIH HHS [HL-71130, 1RC2-HL101851, HL-72533]
NR 17
TC 6
Z9 6
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD SEP
PY 2012
VL 10
IS 9
BP 1961
EP 1965
DI 10.1111/j.1538-7836.2012.04830.x
PG 5
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 999FI
UT WOS:000308294400032
PM 22734827
ER
PT J
AU Goebel-Stengel, M
Stengel, A
Lambrecht, N
Sachs, G
AF Goebel-Stengel, M.
Stengel, A.
Lambrecht, N.
Sachs, G.
TI Selective gene expression by rat small and large bowel epithelia
SO NEUROGASTROENTEROLOGY AND MOTILITY
LA English
DT Meeting Abstract
C1 [Goebel-Stengel, M.] Martin Luther Krankenhaus Berlin, Innere Med Abt, Berlin, Germany.
[Stengel, A.] Charite, Innere Med Abt, Berlin, Germany.
[Lambrecht, N.] VA Long Beach, Long Beach, CA USA.
[Sachs, G.] VA Greater Los Angeles, Los Angeles, CA USA.
[Sachs, G.] Univ Calif Los Angeles, Membrane Biol Lab, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1350-1925
J9 NEUROGASTROENT MOTIL
JI Neurogastroenterol. Motil.
PD SEP
PY 2012
VL 24
SU 2
BP 153
EP 153
PG 1
WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences
SC Gastroenterology & Hepatology; Neurosciences & Neurology
GA 001BS
UT WOS:000308435400500
ER
PT J
AU Wang, L
Magen, I
Yuan, PQ
Subramaniam, SR
Richter, F
Chesselet, MF
Tache, Y
AF Wang, L.
Magen, I.
Yuan, P. -Q.
Subramaniam, S. R.
Richter, F.
Chesselet, M. -F
Tache, Y.
TI Mice overexpressing wild-type human alpha-synuclein display alterations
in colonic myenteric ganglia and defecation
SO NEUROGASTROENTEROLOGY AND MOTILITY
LA English
DT Article
DE colon; defecation; gastric emptying; mice; myenteric neurons; peripheral
choline acetyltransferase; a-synuclein
ID CORTICOTROPIN-RELEASING-FACTOR; ENTERIC DOPAMINERGIC-NEURONS;
PARKINSONS-DISEASE; NERVOUS-SYSTEM; CHOLINE-ACETYLTRANSFERASE; MOTOR
FUNCTION; FACTOR CRF; MOUSE; RATS; DYSFUNCTION
AB Background Prevalent non-motor symptoms of Parkinsons disease (PD) include gastrointestinal motor impairments and advanced stage PD displays pathological aggregates of a-synuclein in colonic enteric neurons. We previously showed that 12 months old mice overexpressing human wild type (WT) a-synuclein under the Thy1 promoter (Thy1-aSyn) displayed colonic motor dysfunction. We investigated functional gut alterations at earlier ages and histological correlates. Methods Defecation, gastric emptying (GE), and immunostaining for a-synuclein, peripheral choline acetyltransferase (pChAT), tyrosine hydroxylase (TH), neuronal nitric oxide synthase (nNOS), and vasoactive intestinal peptide (VIP) in distal colon myenteric plexuses were assessed in male Thy1-aSyn compared to littermate WT mice. Key Results Thy1-aSyn mice aged 2.53 or 78 months old had 81% and 55% reduction in fecal pellet output, respectively, in the first 15 min of exposure to a novel environment. The reduction remained significant in the older group for 2-h, and subsequent refeeding resulted also in a 60% and 69% reduction of defecation in the first hour, respectively. Thy1-aSyn mice (810 months) displayed increased a-synuclein in the myenteric plexuses with abundant varicose terminals surrounding pChAT-immunoreactive (ir) neurons, and only a few, nNOS-ir neurons. There were no conspicuous changes in pChAT- and nNOS-ir neurons, or TH- and VIP-ir nerve fibers. Thy1-aSyn mice aged 418 months had normal GE. Conclusions & Inferences The occurrence of over-production of pre-synaptic a-synuclein in colonic myenteric ganglia several months before the loss of striatal dopamine may provide an anatomical basis for interference with cholinergic neuronal activation, causing an early impairment in defecation to stimuli.
C1 [Wang, L.; Yuan, P. -Q.; Tache, Y.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Dept Med,CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
[Wang, L.; Yuan, P. -Q.; Tache, Y.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Dept Med,Ctr Neurobiol Stress, Los Angeles, CA 90095 USA.
[Wang, L.; Yuan, P. -Q.; Tache, Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Magen, I.; Subramaniam, S. R.; Richter, F.; Chesselet, M. -F] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
RP Wang, L (reprint author), 11301 Wilshire Blvd,Bldg 115, Los Angeles, CA 90073 USA.
EM lixinw@ucla.edu
RI Richter, Franziska/N-8009-2014
OI Richter, Franziska/0000-0003-0803-4398
FU Michael Fox Foundation; Morris K. Udall Parkinson's Disease Research
Center of Excellence at UCLA [P50NS38367]; Center grant NIHDDK [41301,
RO1 DK 57238]; VA Career Scientist Award
FX The authors thank Dr. G. Ohning (CURE: Digestive Diseases Research
Center, Bldg 115, VA Greater Los Angeles Health Care System, Los
Angeles) for the generous supply of the VIP antibody CURE ab 7913 and
Dr. Hiroshi Kimura (Molecular Neuroscience Research Center, Shiga
University of Medical Science, Otsu, Japan) for the generous donation of
pChAT antibody, Mrs. Honghui Liang for her technical support, and Ms.
Eugenia Hu for her review of the manuscript. This work was supported by
the (Target validation grant, Michael Fox Foundation), the Morris K.
Udall Parkinson's Disease Research Center of Excellence at UCLA
(P50NS38367), Center grant NIHDDK 41301 (Animal Core), RO1 DK 57238 and
a VA Career Scientist Award.
NR 55
TC 20
Z9 21
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1350-1925
J9 NEUROGASTROENT MOTIL
JI Neurogastroenterol. Motil.
PD SEP
PY 2012
VL 24
IS 9
BP e425
EP e436
DI 10.1111/j.1365-2982.2012.01974.x
PG 12
WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences
SC Gastroenterology & Hepatology; Neurosciences & Neurology
GA 996LK
UT WOS:000308089000003
PM 22779732
ER
PT J
AU Price, M
Gros, DF
McCauley, JL
Gros, KS
Ruggiero, KJ
AF Price, Matthew
Gros, Daniel F.
McCauley, Jenna L.
Gros, Kirstin Stauffacher
Ruggiero, Kenneth J.
TI Nonuse and Dropout Attrition for a Web-Based Mental Health Intervention
Delivered in a Post-Disaster Context
SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; 2004 FLORIDA HURRICANES; INTERNET
INTERVENTIONS; TERRORIST ATTACKS; RANDOMIZED-TRIAL; CLINICAL-TRIALS;
NEW-YORK; DEPRESSION; DISASTER; ADULTS
AB Web-based mental health interventions are an excellent means to provide low cost, easily accessible care to disaster-affected populations shortly after exposure to an event. However, the extent that individuals will access and use such interventions is largely unknown. We examined predictors of nonuse and dropout attrition for a web-based mental health intervention in 1,249 randomly selected adults in two Texas counties-Galveston and Chambers-that were hardest hit by Hurricane Ike in 2008. Participants completed a structured telephone interview to assess demographics, impact of disaster exposure, history of traumatic events, mental health symptoms, and service utilization. Following the interview, participants were oriented and invited to access a web-based intervention and then contacted four months later to evaluate their use of the website and mental health functioning. Separate logistic and Poisson regressions were used to determine baseline predictors of nonuse attrition, predictors of dropout attrition, and predictors of completing intervention modules. Results suggested that the strongest buffer against nonuse attrition and dropout attrition was having considered seeking formal mental health treatment. Results of this study inform the development and dissemination of web-based interventions in future disaster affected areas.
C1 [Price, Matthew] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA.
[Price, Matthew; Gros, Daniel F.; Gros, Kirstin Stauffacher; Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Price, M (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, 67 President St,2 S MSC 861, Charleston, SC 29425 USA.
EM prima@musc.edu
FU National Institute of Mental Health [R34 MH77149]; NIMH [R01 MH081056];
[T32 MH018869]; [P60 MH082598]
FX This study is supported by National Institute of Mental Health Grant R34
MH77149 (PI: Ruggiero). Dr. Price is supported by T32 MH018869. Dr.
Ruggiero is also supported by P60 MH082598 (PI: Norris); and Drs.
Ruggiero, McCauley, and K. S. Gros are supported by NIMH Grant R01
MH081056 (PI: Ruggiero).
NR 57
TC 15
Z9 16
U1 2
U2 7
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0033-2747
J9 PSYCHIATRY
JI Psychiatry-Interpers. Biol. Process.
PD FAL
PY 2012
VL 75
IS 3
BP 267
EP 284
PG 18
WC Psychiatry
SC Psychiatry
GA 001GO
UT WOS:000308448800007
PM 22913502
ER
PT J
AU Bartzokis, G
Lu, PH
Raven, EP
Amar, CP
Detore, NR
Couvrette, AJ
Mintz, J
Ventura, J
Casaus, LR
Luo, JS
Subotnik, KL
Nuechterlein, KH
AF Bartzokis, George
Lu, Po H.
Raven, Erika P.
Amar, Chetan P.
Detore, Nicole R.
Couvrette, Alexander J.
Mintz, Jim
Ventura, Joseph
Casaus, Laurie R.
Luo, John S.
Subotnik, Kenneth L.
Nuechterlein, Keith H.
TI Impact on intracortical myelination trajectory of long acting injection
versus oral risperidone in first-episode schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Antipsychotic; Medication; Dopamine; Second generation; Atypical;
Myelin; White matter; Gray matter; Oligodendrocyte; Development; Aging
ID WHITE-MATTER; SCHIZOAFFECTIVE DISORDER; PREFRONTAL CORTEX; ATYPICAL
ANTIPSYCHOTICS; DIFFERENTIAL IMPACT; TREATMENT RESPONSE; NEURONAL
DENSITY; BIPOLAR DISORDER; MOOD DISORDERS; 1ST EPISODE
AB Context: Imaging and post-mortem studies suggest that frontal lobe intracortical myelination is dysregulated in schizophrenia (SZ). Prior MRI studies suggested that early in the treatment of SZ, antipsychotic medications initially increase frontal lobe intracortical myelin (ICM) volume, which subsequently declines prematurely in chronic stages of the disease. Insofar as the trajectory of ICM decline in chronic SZ is due to medication non-adherence or pharmacokinetics, it may be modifiable by long acting injection (LAI) formulations.
Objectives: Assess the effect of risperidone formulation on the ICM trajectory during a six-month randomized trial of LAI (RLAI) versus oral (RisO) in first-episode SZ subjects.
Design: Two groups of SZ subjects (RLAI, N=9; and RisO, N=13) matched on pre-randomization oral medication exposure were prospectively examined at baseline and 6 months later, along with 12 healthy controls (HCs). Frontal lobe ICM volume was assessed using inversion recovery (IR) and proton density (PD) MRI images. Medication adherence was tracked.
Main outcome measure: ICM volume change scores were adjusted for the change in the HCs.
Results: ICM volume increased significantly (p=.005) in RLAI and non-significantly (p=.39) in the RisO groups compared with that of the healthy controls. A differential between-group treatment effect was at a trend level (p=.093). SZ subjects receiving RLAI had better medication adherence and more ICM increases (chi-square p<.05).
Conclusions: The results suggest that RLAI may promote ICM development in first-episode SZ patients. Better adherence and/or pharmacokinetics provided by LAI may modify the ICM trajectory. In vivo MRI myelination measures can help clarify pharmacotherapeutic mechanisms of action. (C) 2012 Elsevier B. V. All rights reserved.
C1 [Bartzokis, George; Raven, Erika P.; Amar, Chetan P.; Detore, Nicole R.; Couvrette, Alexander J.; Ventura, Joseph; Casaus, Laurie R.; Luo, John S.; Subotnik, Kenneth L.; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Div Brain Mapping, Dept Neurol,Lab Neuroimaging, Los Angeles, CA 90095 USA.
[Bartzokis, George; Raven, Erika P.; Amar, Chetan P.; Couvrette, Alexander J.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
[Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
RP Bartzokis, G (reprint author), 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA.
EM gbar@ucla.edu
RI Bartzokis, George/K-2409-2013
FU NIH [MH 0266029, AG027342, MH51928, MH6357, MH037705, P50 MH066286];
Ortho-McNeil Janssen Scientific Affairs, LLC.; Department of Veterans
Affairs; Janssen Pharmaceutical Inc.
FX Funding for this study was supported in part by NIH grants (MH 0266029;
AG027342; MH51928; MH6357; MH037705; P50 MH066286), and by two
investigator-initiated grants from Ortho-McNeil Janssen Scientific
Affairs, LLC., and the Department of Veterans Affairs. The NIH, Janssen
Pharmaceutical Inc., and the Department of Veterans Affairs had no
further role in the study design; in the collection, analysis and
interpretation of data; in the writing of the report; and in the
decision to submit the paper for publication.; George Bartzokis and
Keith Nuechterlein have received funding from Janssen Pharmaceutical
Inc. George Bartzokis has consulted for Janssen Pharmaceutical Inc. All
other authors declare that they have no conflicts of interest.
NR 78
TC 17
Z9 17
U1 3
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD SEP
PY 2012
VL 140
IS 1-3
BP 122
EP 128
DI 10.1016/j.schres.2012.06.036
PG 7
WC Psychiatry
SC Psychiatry
GA 996FK
UT WOS:000308070000022
PM 22809684
ER
PT J
AU Tsukamoto, H
Zhu, NL
Asahina, K
Machida, K
AF Tsukamoto, H.
Zhu, N-L.
Asahina, K.
Machida, K.
TI DLK1 IN ALCOHOLIC LIVER FIBROSIS, REGENERATION, AND CANCER
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 16th World Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY SEP 09-12, 2012
CL Sapporo, JAPAN
SP Int Soc Biomed Res Alcoholism (ISBRA), Japanese Med Soc Alcohol & Drug Studies (JMSAS), Sci Council Japan
C1 Univ So Calif, So Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA USA.
Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD SEP
PY 2012
VL 36
SU 2
SI SI
BP 21A
EP 21A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 000OS
UT WOS:000308396700037
ER
PT J
AU Mendez, MF
Lee, AS
Joshi, A
Shapira, JS
AF Mendez, Mario F.
Lee, Albert S.
Joshi, Aditi
Shapira, Jill S.
TI Nonamnestic Presentations of Early-Onset Alzheimer's Disease
SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
LA English
DT Article
DE Alzheimer's disease; early-onset; aphasia; posterior cortical atrophy;
apraxia
ID POSTERIOR CORTICAL ATROPHY; CLINICAL CHARACTERISTICS; PROGRESSIVE
APHASIA; GREY-MATTER; DEMENTIA; AGE; DIAGNOSIS; FEATURES; BATTERY;
ASSOCIATION
AB Early-onset Alzheimer's disease (EOAD) beginning before the age of 65 may differ from late-onset AD (LOAD) in clinical course and frequency of nonamnestic presentations. In a 10-year retrospective review, 125 patients with EOAD, diagnosed clinically and verified by functional neuroimaging, were compared with 56 patients with LOAD and further classified depending on predominant cognitive difficulty on presentation. Eighty (64%) of the patients with EOAD had a nonamnestic presentation, compared with only 7 (12.5%) of the patients with LOAD. Compared with LOAD, the patients with EOAD had a shorter duration with lower Mini-Mental State Examination scores. The neuroimaging reports among the patients with EOAD showed more hippocampal atrophy with an amnestic presentation, more left parietal changes with impaired language presentations, and more right parietal and occipital changes with impaired visuospatial presentations. These findings indicate that EOAD differs from LOAD in a more aggressive course and in having predominantly nonamnestic presentations that vary in neuropathological location.
C1 [Mendez, Mario F.; Joshi, Aditi; Shapira, Jill S.] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Mendez, Mario F.] VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, Neurol Sect, Los Angeles, CA 90073 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Dis Res, Los Angeles, CA USA.
[Lee, Albert S.] Western Univ Hlth Sci, Pomona, CA USA.
RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, Neurol Sect, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mmendez@ucla.edu
FU VA Merit Review; Alzheimer's Disease Research Center [NIA P50 AG-16570];
[R01AG034499-03]
FX The authors disclosed receipt of the following financial support for the
research, authorship and/or publication of this article: grant
#R01AG034499-03 and a VA Merit Review (A. Joshi, A. Lee, M. F. Mendez)
and Alzheimer's Disease Research Center Grant NIA P50 AG-16570 (M.F.
Mendez).
NR 44
TC 26
Z9 26
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-3175
J9 AM J ALZHEIMERS DIS
JI Am. J. Alzheimers Dis. Other Dement.
PD SEP
PY 2012
VL 27
IS 6
BP 413
EP 420
DI 10.1177/1533317512454711
PG 8
WC Geriatrics & Gerontology; Clinical Neurology
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 995PA
UT WOS:000308021300007
PM 22871906
ER
PT J
AU Salloway, S
Mintzer, J
Cummings, JL
Geldmacher, D
Sun, YJ
Yardley, J
Mackell, J
AF Salloway, Stephen
Mintzer, Jacobo
Cummings, Jeffrey L.
Geldmacher, David
Sun, Yijun
Yardley, Jane
Mackell, Joan
TI Subgroup Analysis of US and Non-US Patients in a Global Study of
High-Dose Donepezil (23 mg) in Moderate and Severe Alzheimer's Disease
SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
LA English
DT Article
DE Alzheimer's disease; donepezil; efficacy; tolerability; clinical trial;
United States
ID MILD COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E EPSILON-4; DOUBLE-BLIND;
DECLINE; TOLERABILITY; EDUCATION; EFFICACY; 24-WEEK; SAFETY; RATES
AB To better understand responses in the large number of US-based patients included in a global trial of donepezil 23 mg/d versus 10 mg/d for moderate-to-severe Alzheimer's disease (AD), post hoc exploratory analyses were performed to assess the efficacy and safety in US and non-US (rest of the world [RoW]) patient subgroups. In both subgroups, donepezil 23 mg/d was associated with significantly greater cognitive benefits than donepezil 10 mg/d. Significant global function benefits of donepezil 23 mg/d over 10 mg/d were also observed in the US subgroup only. Compared with RoW patients, US patients had relatively more severe AD, had been treated with donepezil 10 mg/d for longer periods prior to the start of the study, and a higher proportion took concomitant memantine. In both subgroups, donepezil had acceptable tolerability; overall incidence of treatment-emergent adverse events was higher in patients receiving donepezil 23 mg/d compared with donepezil 10 mg/d.
C1 [Salloway, Stephen] Brown Alpert Med Sch, Providence, RI 02906 USA.
[Mintzer, Jacobo] Med Univ S Carolina, Alzheimers Res Program, Charleston, SC 29425 USA.
[Mintzer, Jacobo] Med Univ S Carolina, Clin Program, Charleston, SC 29425 USA.
[Mintzer, Jacobo] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Cummings, Jeffrey L.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA.
[Geldmacher, David] Univ Alabama Birmingham, Div Memory Disorders & Behav Neurol, Birmingham, AL USA.
[Sun, Yijun] Eisai Inc, Dept Biometr, Woodcliff Lake, NJ USA.
[Yardley, Jane] Eisai Ltd, Neurosci Prod Creat Unit, European Knowledge Ctr, Hatfield, Herts, England.
[Mackell, Joan] Pfizer Inc, New York, NY USA.
RP Salloway, S (reprint author), Brown Alpert Med Sch, 345 Blackstone Blvd, Providence, RI 02906 USA.
EM ssalloway@butler.org
FU Eisai Inc.; Pfizer Inc.; Pfizer; Eisai
FX The authors declared the following potential conflicts of interest with
respect to the research, authorship, and/or publication of this article:
Stephen Salloway has received consultation fees from the Eisai Inc.
Jacobo Mintzer has no relevant conflicts of interest to disclose.
Jeffrey L. Cummings has provided consultation to Eisai Inc. David
Geldmacher has received both research support related to the conduct of
the reported study and consulting honoraria in relation to donepezil
from Eisai Inc. Yijun Sun is a ex-employee of Eisai Inc. Jane Yardley is
a current employee of Eisai Ltd. Joan Mackell is a current employee of
Pfizer Inc and holds stock in Pfizer Inc.; The authors disclosed receipt
of the following financial support for the research, authorship and/or
publication of this article: The described analyses derive from a phase
3 clinical study (ClinicalTrials.gov identifier: NCT00478205) is
sponsored by Eisai Inc. Editorial support in the development of this
manuscript was provided by Richard Daniel, PhD, of PAREXEL, and was
funded by Eisai Inc. and Pfizer Inc. Jacobo Mintzer has received grant
research support from Pfizer and Eisai, but not for the specific
activities reported in this study.
NR 19
TC 6
Z9 6
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-3175
J9 AM J ALZHEIMERS DIS
JI Am. J. Alzheimers Dis. Other Dement.
PD SEP
PY 2012
VL 27
IS 6
BP 421
EP 432
DI 10.1177/1533317512454708
PG 12
WC Geriatrics & Gerontology; Clinical Neurology
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 995PA
UT WOS:000308021300008
PM 22930699
ER
PT J
AU Sweet, RA
Seltman, H
Emanuel, JE
Lopez, OL
Becker, JT
Bis, JC
Weamer, EA
DeMichele-Sweet, MAA
Kuller, LH
AF Sweet, Robert A.
Seltman, Howard
Emanuel, James E.
Lopez, Oscar L.
Becker, James T.
Bis, Joshua C.
Weamer, Elise A.
DeMichele-Sweet, Mary Ann A.
Kuller, Lewis H.
TI Effect of Alzheimer's Disease Risk Genes on Trajectories of Cognitive
Function in the Cardiovascular Health Study
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMPLEMENT RECEPTOR 1; IDENTIFIES VARIANTS;
SYNAPSE LOSS; FLIP-FLOP; DECLINE; BINDING; EPIDEMIOLOGY; METAANALYSIS;
BIOMARKERS
AB Objective: The trajectory of cognitive decline in patients with late-onset Alzheimer's disease varies widely. Genetic variations in CLU, PICALM, and CR1 are associated with Alzheimer's disease, but it is unknown whether they exert their effects by altering cognitive trajectory in elderly individuals at risk for the disease.
Method: The authors developed a Bayesian model to fit cognitive trajectories in a cohort of elderly subjects and test for genetic effects. They first validated the model's ability to detect the previously established effects of APOE epsilon 4 alleles on age at cognitive decline and of psychosis on the rate of cognitive decline in 802 subjects from the Cardiovascular Health Cognition Study who did not have dementia at study entry and developed incident dementia during follow-up. The authors then evaluated the effects of CLU, PICALM, and CR1 on age and rate of decline in 1,831 subjects who did not have dementia at study entry and then did or did not develop incident dementia by study's end.
Results: The model generated robust fits to the observed cognitive trajectory data, and validation analysis supported the model's utility. CLU and CR1 were associated with more rapid cognitive decline. PICALM was associated with an earlier age at midpoint of cognitive decline. Associations remained after accounting for the effects of APOE and demographic factors.
Conclusions: Evaluation of cognitive trajectories provides a powerful approach to dissecting genetic effects on the processes leading to cognitive deterioration and Alzheimer's disease.
C1 [Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA.
Univ Pittsburgh, Dept Neurol, Pittsburgh, PA USA.
Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA.
Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
Univ Washington, Dept Med, Seattle, WA 98195 USA.
VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA.
Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA.
EM sweetra@upmc.edu
OI Seltman, Howard/0000-0002-7543-3578; Becker, James/0000-0003-4425-4726
FU National Institute on Aging (NIA) [AG05133, AG027224, AG20098]; National
Heart, Lung, and Blood Institute [N0-1-HC-85239, N01-HC-85079,
N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084,
N01-HC-85085, N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222,
N01-HC-75150, N01-HC-45133, U01 HL080295, HL087251]; NIA [AG15928]
FX Supported in part by National Institute on Aging (NIA) grants AG05133,
AG027224, and AG20098. The research reported in this article was also
supported by National Heart, Lung, and Blood Institute contracts
N0-1-HC-85239, N01-HC-85079 through N01-HC-85086, N01-HC-35129,
N01-HC-15103, N01-HC-55222, N01-HC-75150, and N01-HC-45133 and grants
U01 HL080295 and HL087251, with additional contributions from the
National Institute of Neurological Disorders and Stroke and from NIA
grant AG15928. A full list of Cardiovascular Health Study principal
investigators and institutions can be found at
http://www.chs-nhlbi.org/pi.htm.
NR 38
TC 31
Z9 32
U1 1
U2 7
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD SEP
PY 2012
VL 169
IS 9
BP 954
EP 962
DI 10.1176/appi.ajp.2012.11121815
PG 9
WC Psychiatry
SC Psychiatry
GA 998ZE
UT WOS:000308278100012
PM 22952074
ER
PT J
AU Schumacher, HR
Chen, LX
Mandell, BF
AF Schumacher, H. Ralph
Chen, Lan X.
Mandell, Brian F.
TI The time has come to incorporate more teaching and formalized assessment
of skills in synovial fluid analysis into rheumatology training programs
SO ARTHRITIS CARE & RESEARCH
LA English
DT Editorial Material
ID ARTHRITIS CLASSIFICATION CRITERIA; AMERICAN-COLLEGE; CRYSTAL
IDENTIFICATION; QUALITY-CONTROL; REPRODUCIBILITY; LABORATORIES; LEAGUE
C1 [Schumacher, H. Ralph] Univ Penn, Philadelphia, PA 19104 USA.
[Schumacher, H. Ralph] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Chen, Lan X.] Penn Presbyterian Med Ctr, Philadelphia, PA USA.
[Mandell, Brian F.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
RP Mandell, BF (reprint author), Cleveland Clin, A50,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM mandelb@ccf.org
NR 18
TC 5
Z9 5
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
EI 2151-4658
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD SEP
PY 2012
VL 64
IS 9
BP 1271
EP 1273
DI 10.1002/acr.21714
PG 3
WC Rheumatology
SC Rheumatology
GA 995ST
UT WOS:000308033800001
PM 22555864
ER
PT J
AU Piper, SL
Kim, HT
AF Piper, Samantha L.
Kim, Hubert T.
TI Thermal Stress Potentiates Bupivacaine Chondrotoxicity
SO ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY
LA English
DT Article
ID GLENOHUMERAL FLUID TEMPERATURE; BOVINE ARTICULAR CHONDROCYTES; SHOULDER
ARTHROSCOPY; IN-VITRO; 0.5-PERCENT BUPIVACAINE; RADIOFREQUENCY ENERGY;
RAPID CHONDROLYSIS; PAIN PUMP; CARTILAGE; CAPSULORRHAPHY
AB Purpose: The primary objective of this study was to determine whether thermal stress potentiates the chondrotoxic effect of bupivacaine, resulting in decreased articular chondrocyte viability compared with exposure to bupivacaine alone. Methods: Bovine articular cartilage explants and cultured chondrocytes were treated with a range of thermal exposures (10 to 20 minutes at 37 degrees C to 65 degrees C) to create time/temperature viability curves and to determine threshold conditions for cell death. A second set of experiments was performed to determine whether subthreshold thermal stress potentiates bupivacaine toxicity. Explants were exposed to 37 degrees C or 55 degrees C for 10 or 20 minutes, and cultured chondrocytes were exposed to 37 degrees C or 45 degrees C for 10 or 20 minutes. Thirty minutes later, the explants and chondrocytes were treated with either 0.9% normal saline solution or 0.5% bupivacaine for 30 minutes. Chondrocyte viability was quantified 24 hours after treatment. Results: There was a temperature-and time-dependent decrease in chondrocyte viability above the thermo-toxicity threshold in both intact cartilage explants and cultured chondrocytes (55 degrees C and 45 degrees C, respectively; P < .05). Chondrocyte viability in cartilage explants was significantly lower after treatment with thermal stress for 10 or 20 minutes followed by bupivacaine for 30 minutes compared with treatment with bupivacaine at 37 degrees C (bupivacaine and 55 degrees C for 10 minutes, 0.09% +/- 0%; bupivacaine and 55 degrees C for 20 minutes, 0.08% +/- 0%; bupivacaine and 37 degrees C for 10 minutes, 37.4% +/- 1.2% [P < .001]; and bupivacaine and 37 degrees C for 20 minutes, 47.1% +/- 0.8% [P < .001]). A similar trend was seen in cultured chondrocytes, although it was not statistically significant (P > .05). Conclusions: Thermal stress potentiates the chondrotoxic effects of bupivacaine in intact cartilage, leading to decreased chondrocyte viability compared with exposure to bupivacaine alone. Clinical Relevance: Intra-articular injection of bupivacaine after arthroscopic procedures during which cartilage is exposed to elevated temperatures, such as with prolonged use of radiofrequency probes, may increase the risk of chondrocyte toxicity.
C1 [Piper, Samantha L.; Kim, Hubert T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA.
[Kim, Hubert T.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Kim, HT (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 500 Parnassus Ave,MUW 320, San Francisco, CA 94143 USA.
EM KimH@orthosurg.ucsf.edu
FU Orthopaedic Research and Education Foundation (OREF)/DePuy Resident
Research Project Grant
FX The authors report the following source of funding in relation to this
article: Orthopaedic Research and Education Foundation (OREF)/DePuy
Resident Research Project Grant.
NR 38
TC 4
Z9 4
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-8063
J9 ARTHROSCOPY
JI Arthroscopy
PD SEP
PY 2012
VL 28
IS 9
BP 1246
EP U296
DI 10.1016/j.arthro.2012.02.012
PG 10
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 996DW
UT WOS:000308065500012
PM 22579775
ER
PT J
AU Cooke, CR
Kennedy, EH
Wiitala, WL
Almenoff, PL
Sales, AE
Iwashyna, TJ
AF Cooke, Colin R.
Kennedy, Edward H.
Wiitala, Wyndy L.
Almenoff, Peter L.
Sales, Anne E.
Iwashyna, Theodore J.
TI Despite variation in volume, Veterans Affairs hospitals show consistent
outcomes among patients with non-postoperative mechanical ventilation
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE critical care; delivery of health care; health services research;
intensive care units/organization and administration; respiratory
insufficiency; risk adjustment
ID UNIT RISK ADJUSTMENT; HEALTH-CARE-SYSTEM; QUALITY-OF-CARE;
INTENSIVE-CARE; LONGITUDINAL DATA; PROPENSITY SCORE; MORTALITY;
TRANSFORMATION; ORGANIZATION; REGRESSION
AB Objective: To assess the relationship between volume of non-operative mechanically ventilated patients receiving care in a specific Veterans Health Administration hospital and their mortality.
Design: Retrospective cohort study.
Setting: One-hundred nineteen Veterans Health Administration medical centers.
Patients: We identified 5,131 hospitalizations involving mechanically ventilated patients in an intensive care unit during 2009, who did not receive surgery.
Interventions: None.
Measurements and Main Results: We extracted demographic and clinical data from the VA Inpatient Evaluation Center. For each hospital, we defined volume as the total number of nonsurgical admissions receiving mechanical ventilation in an intensive care unit during 2009. We examined the hospital contribution to 30-day mortality using multilevel logistic regression models with a random intercept for each hospital. We quantified the extent of interhospital variation in 30-day mortality using the intraclass correlation coefficient and median odds ratio. We used generalized estimating equations to examine the relationship between volume and 30-day mortality and risk-adjusted all models using a patient-level prognostic score derived from clinical data representing the risk of death conditional on treatment at a high-volume hospital. Mean age for the sample was 65 (so 11) yrs, 97% were men, and 60% were white. The median VA hospital cared for 40 (interquartile range 19-62) mechanically ventilated patients in 2009. Crude 30-day mortality for these patients was 36.9%. After reliability and risk adjustment to the median patient, adjusted hospital-level mortality varied from 33.5% to 40.6%. The intraclass correlation coefficient for the hospital-level variation was 0.6% (95% confidence interval 0.1, 3.4%), with a median odds ratio of 1.15 (95% confidence interval 1.06, 1.38). The relationship between hospital volume of mechanically ventilated and 30-day mortality was not statistically significant: each 50-patient increase in volume was associated with a nonsignificant 2% decrease in the odds of death within 30 days (odds ratio 0.98, 95% confidence interval 0.87-1.10).
Conclusions: Veterans Health Administration hospitals caring for lower volumes of mechanically ventilated patients do not have worse mortality. Mechanisms underlying this finding are unclear, but, if elucidated, may offer other integrated health systems ways to overcome the disadvantages of small-volume centers in achieving good outcomes. (Crit Care Med 2012; 40:2569-2575)
C1 Univ Michigan, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA.
[Kennedy, Edward H.; Wiitala, Wyndy L.; Sales, Anne E.; Iwashyna, Theodore J.] Ann Arbor VA Hlth Serv Res & Dev Ctr Excellence, VA Ctr Clin Management Res, Ann Arbor, MI USA.
[Almenoff, Peter L.] Univ Kansas, Div Pulm Crit Care Med, Kansas City, KS USA.
[Almenoff, Peter L.; Sales, Anne E.] US Dept Vet Affairs, Vet Hlth Adm, Off Informat & Analyt, Washington, DC USA.
Univ Michigan, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.
EM cookecr@umich.edu
OI Sales, Anne/0000-0001-9360-3334; Iwashyna, Theodore/0000-0002-4226-9310;
Cooke, Colin/0000-0001-9713-5371
FU U.S. Department of Veterans Affairs Health Services Research &
Development Services [IIR 11-109]
FX Supported, in part, by U.S. Department of Veterans Affairs Health
Services Research & Development Services IIR 11-109 (TJI).
NR 44
TC 20
Z9 20
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD SEP
PY 2012
VL 40
IS 9
BP 2569
EP 2575
DI 10.1097/CCM.0b013e3182591eee
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA 992RP
UT WOS:000307797700004
PM 22732289
ER
PT J
AU Paski, SC
Dominitz, JA
AF Paski, Shirley C.
Dominitz, Jason A.
TI Endoscopic solutions to challenging enteral feeding problems
SO CURRENT OPINION IN GASTROENTEROLOGY
LA English
DT Review
DE enteral feeding; feeding tube; gastrostomy; jejunostomy
ID GASTROSTOMY TUBE PLACEMENT; DOUBLE-BALLOON ENTEROSCOPY; Y GASTRIC
BYPASS; JEJUNOSTOMY PLACEMENT; ACCESS; COMPLICATIONS; INSERTION;
CHILDREN; STOMACH; PREVENT
AB Purpose of review
Enteral nutrition support is often required in patients who are unable to meet their own nutritional requirements. Endoscopists play a key role in the placement of enteral feeding catheters. This review focuses on the recently published solutions to common problems encountered during endoscopic placement of enteral feeding devices.
Recent findings
Case reports and case series describe solutions for overcoming common problems encountered during the placement of enteral feeding devices. Transnasal techniques can simplify nasojejunal tube placement, whereas deep enteroscopy techniques provide more reliable jejunostomy placement. Endoscopic ultrasound can help when transillumination is not possible or in the setting of postsurgical anatomy like Roux-en-Y. Laparoscopic-assisted procedures are useful when endoscopic techniques have failed in adults or in select high-risk pediatric patients. The American Society for Gastrointestinal Endoscopy and the American Gastroenterology Association both published comprehensive guidelines that outline the indications, contraindications, technical aspects of feeding catheter placement, and complications.
Summary
Advances in endoscopic techniques, including deep enteroscopy, endoscopic ultrasound, ultra-slim transnasal endoscopes and laparoscopic-assisted procedures, have enabled endoscopists to successfully place enteral feeding tubes in patients who previously required open procedures.
C1 VA Puget Sound Healthcare Syst, Seattle, WA USA.
Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA.
RP Paski, SC (reprint author), VAPSHCS S111GI, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM shirley.paski@va.gov
OI Dominitz, Jason/0000-0002-8070-7086
FU American Society for Gastrointestinal Endoscopy Endoscopic Research
Career Development Award (JAD); VA Puget Sound Healthcare System,
Department of Veterans Affairs
FX Grant Support: American Society for Gastrointestinal Endoscopy
Endoscopic Research Career Development Award (JAD).; This material is
based upon work supported by the VA Puget Sound Healthcare System,
Department of Veterans Affairs. The views expressed in this article are
those of the authors and do not necessarily reflect the position or
policy of the Department of Veterans Affairs.
NR 32
TC 3
Z9 4
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0267-1379
EI 1531-7056
J9 CURR OPIN GASTROEN
JI Curr. Opin. Gastroenterol.
PD SEP
PY 2012
VL 28
IS 5
BP 427
EP 431
DI 10.1097/MOG.0b013e328355ecc9
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 991DI
UT WOS:000307681300003
PM 22885942
ER
PT J
AU Thameem, F
Puppala, S
Schneider, J
Bhandari, B
Arya, R
Arar, NH
Vasylyeva, TL
Farook, VS
Fowler, S
Almasy, L
Blangero, J
Duggirala, R
Abboud, HE
AF Thameem, Farook
Puppala, Sobha
Schneider, Jennifer
Bhandari, Basant
Arya, Rector
Arar, Nedal H.
Vasylyeva, Tetyana L.
Farook, Vidya S.
Fowler, Sharon
Almasy, Laura
Blangero, John
Duggirala, Ravindranath
Abboud, Hanna E.
TI The Gly(972)Arrg Variant of Human IRS1 Gene Is Associated with Variation
in Glomerular Filtration Rate Likely Through Impaired Insulin Receptor
Signaling
SO DIABETES
LA English
DT Article
ID DEPENDENT DIABETES-MELLITUS; AMINO-ACID POLYMORPHISM; CHRONIC
KIDNEY-DISEASE; WIDE LINKAGE SCANS; SERUM CREATININE; MEXICAN-AMERICANS;
SUBSTRATE-1 GENE; RENAL-FUNCTION; MEASURED GENOTYPE; G972R VARIANT
AB The objective of this study is to identify and characterize the genetic variants related to the glomerular filtration rate (GFR) linkage on 2q37. Of the positional candidate genes, we selected IRS1 and resequenced its 2-kb promoter region and exons for sequence variants in 32 subjects. A total of 11 single nucleotide polymorphisms (SNPs) were identified. To comprehensively cover the 59-kb-long intron-1, eight additional tagging SNPs were selected from the HapMap. All the 19 SNPs were genotyped by TaqMan Assay in the entire data set (N = 670; 39 families). Association analyses between the SNPs and GFR and type 2 diabetes-related traits were performed using the measured genotype approach. Of the SNPs examined for association, only the Gly(972) Arg variant of IRS1 exhibited a significant association with GFR (P = 0.0006) and serum triglycerides levels (P = 0.003), after accounting for trait-specific covariate effects. Carriers of Arg972 had significantly decreased GFR values. Gly(972)Arg contributed to 26% of the linkage signal on 2q. Expression of IRS1 mutant Arg972 in human mesangial cells significantly reduced the insulin-stimulated phosphorylation of IRS1 and Akt kinase. Taken together, the data provide the first evidence that genetic variation in IRS1 may influence variation in GFR probably through impaired insulin receptor signaling. Diabetes 61:2385-2393,2012
C1 [Thameem, Farook; Bhandari, Basant; Arar, Nedal H.; Vasylyeva, Tetyana L.; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, San Antonio, TX 78229 USA.
[Puppala, Sobha; Schneider, Jennifer; Farook, Vidya S.; Almasy, Laura; Blangero, John; Duggirala, Ravindranath] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA.
[Arya, Rector] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA.
[Arar, Nedal H.; Abboud, Hanna E.] S Texas Vet Healthcare Syst, San Antonio, TX USA.
[Fowler, Sharon] Univ Texas Hlth Sci Ctr San Antonio, Div Clin Epidemiol, Dept Med, San Antonio, TX 78229 USA.
RP Thameem, F (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, San Antonio, TX 78229 USA.
EM thameem@uthscsa.edu
RI Abu Laban , Dr. Nidal /E-5809-2011
FU American Heart Association [0855175F]; American Society of Nephrology;
Satellite Healthcare; Diabetes Action Research and Education Foundation;
National Institute of Diabetes and Digestive and Kidney Diseases
[DK-42273, DK-47482, DK-53889]; VA-Merit Review; National Center for
Research Resources [RR025767, KL2 RR025766]
FX This study was supported by a grant-in-aid award (0855175F) (F.T.) from
the American Heart Association, the Carl W. Gottschalk Research Scholar
Award from the American Society of Nephrology (F.T.), the Norman S.
Coplon Award from Satellite Healthcare (F.T.), and the Diabetes Action
Research and Education Foundation (F.T.). This work was also supported
by grants from the National Institute of Diabetes and Digestive and
Kidney Diseases (DK-42273, DK-47482, and DK-53889 [to R.D.]) and
VA-Merit Review and the National Center for Research Resources Contracts
UL1 RR025767 and KL2 RR025766 for the Institute for Integration of
Medicine and Science.
NR 52
TC 18
Z9 19
U1 0
U2 0
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD SEP
PY 2012
VL 61
IS 9
BP 2385
EP 2393
DI 10.2337/db11-1078
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 998PY
UT WOS:000308254100027
PM 22617042
ER
PT J
AU Sauna, ZE
Ameri, A
Kim, B
Yanover, C
Viel, KR
Rajalingam, R
Cole, SA
Howard, TE
AF Sauna, Z. E.
Ameri, A.
Kim, B.
Yanover, C.
Viel, K. R.
Rajalingam, R.
Cole, S. A.
Howard, T. E.
TI A view of the Aledort-Iorio Debate concerning the immunogenicity of
B-Domain-deleted and full-length recombinant FVIII products from a
mechanistic personalized medicine perspective
SO HAEMOPHILIA
LA English
DT Meeting Abstract
C1 [Sauna, Z. E.] US FDA, Lab Hemostasis, Div Hematol, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA.
[Ameri, A.] Georgia Hlth Sci Univ, Div Hematol & Oncol, Dept Pediat, Augusta, GA USA.
[Kim, B.; Howard, T. E.] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA.
[Kim, B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Dept Med, Los Angeles, CA 90095 USA.
[Yanover, C.] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98104 USA.
[Viel, K. R.] Histonis Inc, Atlanta, GA USA.
[Rajalingam, R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, UCLA Immunogenet Ctr, Los Angeles, CA 90095 USA.
[Cole, S. A.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA.
[Howard, T. E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA.
[Howard, T. E.] Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90033 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-8216
J9 HAEMOPHILIA
JI Haemophilia
PD SEP
PY 2012
VL 18
IS 5
BP 830
EP 830
PG 1
WC Hematology
SC Hematology
GA 993ZT
UT WOS:000307900700054
ER
PT J
AU Cordasco, KM
Homeier, DC
Franco, I
Wang, PC
Sarkisian, CA
AF Cordasco, Kristina M.
Homeier, Diana C.
Franco, Idalid
Wang, Pin-Chieh
Sarkisian, Catherine A.
TI Health literacy screening of geriatric monolingual Spanish-speaking
patients using single-item literacy screening questions and education
SO HEALTH EDUCATION JOURNAL
LA English
DT Article
DE aged; educational achievement; health literacy; Latinos;
receiving-operator characteristic curve
ID IDENTIFY PATIENTS
AB Objective: We describe the performance of Single Item Literacy Screener (SILS) questions, and educational attainment, as screening for inadequate health literacy (IHL) in older monolingual Spanish speakers.
Design: We used a cross-sectional design, interviewing participants once at the time of their arrival for a clinic appointment.
Setting: We conducted this study in primary care and geriatrics clinics in an urban US safety-net hospital.
Method: We conducted in-person interviews with older monolingual Spanish-speaking diabetes patients, comparing responses to three SILS questions, and education, to shortened Test of Functional Health Literacy in Adults (sTOFHLA) scores. We calculated sensitivities, specificities and areas under the receiving-operator characteristic (AUROC) curve.
Results: We interviewed 160 patients -134 (84%) had IHL by sTOFHLA scores. The best performing SILS question, 'How confident are you filling out medical forms by yourself?' had an AUROC curve of 0.82 (95% CI 0.75-0.89). Using this question's most stringent cut-off, sensitivity was 0.93 (95% CI 0.89-0.97); specificity was 0.27 (95% CI 0.20-0.34). The other two SILS questions had AUROC curves less than 0.50. The educational achievement AUROC curve was 0.88 (95% CI 0.78-0.97); using an education cut-off of six years or less had a specificity to 0.81 (95% CI 0.75-0.87) and sensitivity of 0.83 (95% CI 0.77-0.89).
Conclusion: Clinicians and investigators considering using single items as screeners for IHL in older US monolingual Spanish speakers should either use the ` confidence with forms' SILS, being aware of its specificity limitations, or a single question assessing educational achievement.
C1 [Cordasco, Kristina M.; Franco, Idalid; Sarkisian, Catherine A.] RAND Corp, Santa Monica, CA 90407 USA.
[Cordasco, Kristina M.; Sarkisian, Catherine A.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA.
[Cordasco, Kristina M.; Wang, Pin-Chieh; Sarkisian, Catherine A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA.
[Homeier, Diana C.] Univ So Calif, Dept Family Med, Los Angeles, CA 90089 USA.
RP Cordasco, KM (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA.
EM kcordasc@rand.org
FU NINR NIH HHS [R21 NR011309, R21 NR011309-01, R21 NR011309-02]
NR 13
TC 4
Z9 4
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0017-8969
EI 1748-8176
J9 HEALTH EDUC J
JI Health Educ. J.
PD SEP
PY 2012
VL 71
IS 5
BP 597
EP 605
DI 10.1177/0017896911411764
PG 9
WC Education & Educational Research; Public, Environmental & Occupational
Health
SC Education & Educational Research; Public, Environmental & Occupational
Health
GA 995CK
UT WOS:000307984400007
PM 23788818
ER
PT J
AU Ioannou, GN
AF Ioannou, George N.
TI Beyond obesity: Is cholesterol-induced liver injury the cause of
non-alcoholic steatohepatitis?
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Editorial Material
ID DIETARY-CHOLESTEROL; MICE; INFLAMMATION; STEATOSIS; FIBROSIS
AB See article in J. Gastroenterol. Hepatol. 2012; 27: 15201527.
C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA 98108 USA.
[Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, S-111-GI,1660 S Columbian Way, Seattle, WA 98108 USA.
EM georgei@medicine.washington.edu
FU NIDDK NIH HHS [P30 DK017047]
NR 11
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD SEP
PY 2012
VL 27
IS 9
BP 1412
EP 1414
DI 10.1111/j.1440-1746.2012.07196.x
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 994WN
UT WOS:000307965100002
PM 22908868
ER
PT J
AU Roullet, JB
Merkens, LS
Pappu, AS
Jacobs, MD
Winter, R
Connor, WE
Steiner, RD
AF Roullet, Jean-Baptiste
Merkens, Louise S.
Pappu, Anuradha S.
Jacobs, Megan D.
Winter, Rolf
Connor, William E.
Steiner, Robert D.
TI No evidence for mevalonate shunting in moderately affected children with
Smith-Lemli-Opitz syndrome
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID CHOLESTEROL-SYNTHESIS; DIETARY-CHOLESTEROL; LIPOPROTEIN CHOLESTEROL;
REDUCTASE GENE; PLASMA; URINARY; ACID; 7-DEHYDROCHOLESTEROL; MUTATIONS;
BIOSYNTHESIS
AB Smith-Lemli-Opitz syndrome (SLOS) is caused by a genetic deficiency in 7-dehydrocholesterol (7-DHC) reductase (EC 1.3.1.21), the last enzyme of the cholesterol synthetic pathway. In SLOS, plasma cholesterol concentration is reduced and immediate precursor concentration (7-DHC) is elevated. Surprisingly, total sterol synthesis is reduced but HMG-CoA reductase activity, a rate-limiting enzyme in cholesterol synthesis is unaltered as judged by normal urinary excretion of mevalonic acid (MVA) (Pappu et al. J Lipid Res 43:1661-1669, 2002). These findings raise the possibility of increased diversion of MVA into the MVA shunt pathway away from sterol synthesis, by activation of the shunt pathway enzymes. To test this hypothesis, we measured the urinary excretion of 3-methylglutaconic acid (U-3MGC), a by-product of the shunt pathway, in 19 mildly to moderately severely affected SLOS subjects (ten males, nine females) receiving either a cholesterol-free or a high cholesterol diet, and in 20 age- and sex-matched controls. U-3MGC was similar in SLOS and controls, and was unaffected by dietary cholesterol intake. Further, no change in U-3MGC was observed in a subset of SLOS subjects (n = 9) receiving simvastatin. In contrast, U-MVA was reduced by cholesterol supplementation (54%, p < 0.05) and by simvastatin (50%, p < 0.04). There was no correlation between U-3MGC and either plasma sterol concentrations, urinary isoprenoids, or the subjects' clinical severity score. However U-3MGC was inversely correlated with age (p < 0.04) and body weight (p < 0.02), and higher in females than in males (65%, p < 0.025). The data show that DHCR7 deficiency does not result in 3MGC accumulation in SLOS and suggest that the MVA shunt pathway is not activated in patients with the condition.
C1 [Roullet, Jean-Baptiste] Oregon Hlth & Sci Univ, Dept Pediat, CDRC P, Div Res, Portland, OR 97239 USA.
[Pappu, Anuradha S.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA.
[Winter, Rolf] Portland VA Med Ctr, Antimalarial Drug Discovery Lab, Portland, OR USA.
[Connor, William E.] Oregon Hlth & Sci Univ, Dept Med, Div Endocrinol Diabet & Clin Nutr, Portland, OR 97239 USA.
[Steiner, Robert D.] Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Oregon Clin & Translat Res Inst, Dept Pediat,Child Dev & Rehabil Ctr, Portland, OR 97239 USA.
[Steiner, Robert D.] Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Oregon Clin & Translat Res Inst, Dept Mol & Med Genet,Child Dev & Rehabil Ctr, Portland, OR 97239 USA.
RP Roullet, JB (reprint author), Oregon Hlth & Sci Univ, Dept Pediat, CDRC P, Div Res, 707 SW Gaines St, Portland, OR 97239 USA.
EM roulletj@ohsu.edu
OI Steiner, Robert/0000-0003-4177-4590
FU NIH [R01 HL073980]; Oregon Clinical and Translational Research Institute
(OCTRI) from National Center for Research Resources (NCRR), National
Institutes of Health (NIH) [UL1 RR024140]; NIH Roadmap for Medical
Research
FX This work was supported by a grant from NIH (R01 HL073980). This
publication was made possible with support from the Oregon Clinical and
Translational Research Institute (OCTRI), grant number UL1 RR024140 from
the National Center for Research Resources (NCRR), a component of the
National Institutes of Health (NIH), and NIH Roadmap for Medical
Research. The authors confirm independence from the sponsors; the
content of the article has not been influenced by the sponsors.
NR 36
TC 8
Z9 8
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD SEP
PY 2012
VL 35
IS 5
BP 859
EP 869
DI 10.1007/s10545-012-9453-6
PG 11
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
Medicine
GA 998NO
UT WOS:000308247000013
PM 22391996
ER
PT J
AU Kothari, CL
Rhodes, KV
Wiley, JA
Fink, J
Overholt, S
Dichter, ME
Marcus, SC
Cerulli, C
AF Kothari, Catherine L.
Rhodes, Karin V.
Wiley, James A.
Fink, Jeffrey
Overholt, Scott
Dichter, Melissa E.
Marcus, Steven C.
Cerulli, Catherine
TI Protection Orders Protect Against Assault and Injury: A Longitudinal
Study of Police-Involved Women Victims of Intimate Partner Violence
SO JOURNAL OF INTERPERSONAL VIOLENCE
LA English
DT Article
DE battered women; legal intervention; domestic violence
ID DOMESTIC VIOLENCE; HELP-SEEKING; ABUSE; SYSTEM; STATES
AB The objective of this study was to measure the efficacy of protection orders (POs) in reducing assault and injury-related outcomes using a matched comparison group and tracking outcomes over time. This study was a retrospective review of police, emergency department, family court, and prosecutor administrative records for a cohort of police-involved female IPV victims; all events over a 4-year study period were abstracted. Victims who obtained POs were compared with a propensity-score-based match group without POs over three time periods: Before, During, and After the issuance of a PO. Having a PO in place was associated with significantly more calls to police for nonassaultive incidents and more police charging requests that were of multiple-count and felony-level. Comparing outcomes, PO victims had police incident rates that were more than double the matched group prior to the PO but dropped to the level of the matched group during and after the order. ED visits dropped over time for both groups. This study confirmed the protective effect of POs, which are associated with reduced police incidents and emergency department visits both during and after the order and reduced police incidents compared with a matched comparison group.
C1 [Kothari, Catherine L.] Michigan State Univ, Kalamazoo Ctr Med Studies, Kalamazoo, MI 49008 USA.
[Rhodes, Karin V.] Univ Penn, Sch Med, Dept Emergency Med, Div Emergency Care Policy Res, Philadelphia, PA 19104 USA.
[Wiley, James A.] San Francisco State Univ, Hlth Dispar Program, San Francisco, CA 94132 USA.
[Fink, Jeffrey] Kalamazoo Cty, Kalamazoo, MI USA.
[Overholt, Scott] State Michigan, Judicial Circuit Court 9, Kalamazoo, MI USA.
[Dichter, Melissa E.; Marcus, Steven C.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA.
[Cerulli, Catherine] Univ Rochester, Med Ctr, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA.
RP Kothari, CL (reprint author), Michigan State Univ, Kalamazoo Ctr Med Studies, 1000 Oakland Dr, Kalamazoo, MI 49008 USA.
EM kothari@kcms.msu.edu
OI Kothari, Catherine/0000-0001-8072-8920
FU NIMH NIH HHS [K11MH75965, K23MH64572, K01 MH075965]
NR 43
TC 9
Z9 9
U1 0
U2 18
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0886-2605
J9 J INTERPERS VIOLENCE
JI J. Interpers. Violence
PD SEP
PY 2012
VL 27
IS 14
BP 2845
EP 2868
DI 10.1177/0886260512438284
PG 24
WC Criminology & Penology; Family Studies; Psychology, Applied
SC Criminology & Penology; Family Studies; Psychology
GA 995RZ
UT WOS:000308031300006
PM 22491224
ER
PT J
AU Sham, CW
Chan, AM
Kwong, JMK
Caprioli, J
Nusinowitz, S
Chen, B
Lee, JG
Gandhi, NM
Francisco, LM
Sharpe, AH
Chen, L
Braun, J
Gordon, LK
AF Sham, Caroline W.
Chan, Ann M.
Kwong, Jacky M. K.
Caprioli, Joseph
Nusinowitz, Steven
Chen, Bryan
Lee, Janice G.
Gandhi, Nishant M.
Francisco, Loise M.
Sharpe, Arlene H.
Chen, Ling
Braun, Jonathan
Gordon, Lynn K.
TI Neuronal Programmed Cell Death-1 Ligand Expression Regulates Retinal
Ganglion Cell Number in Neonatal and Adult Mice
SO JOURNAL OF NEURO-OPHTHALMOLOGY
LA English
DT Article
ID NERVE GROWTH-FACTOR; MOUSE RETINA; VERTEBRATE RETINA; IN-VIVO; RECEPTOR;
PD-1; RESPONSES; SURVIVAL; DIFFERENTIATION; AP-2-ALPHA
AB Objectives: During mouse retina maturation, the final number of retinal ganglion cells (RGCs) is determined by highly regulated programmed cell death. Previous studies demonstrated that the immunoregulatory receptor programmed cell death-1 (PD-1) promotes developmental RGC death. To identify the functional signaling partner(s) for PD-1, we identified retinal expression of PD-1 ligands and examined the effect of PD-1 ligand expression on RGC number. We also explored the hypothesis that PD-1 signaling promotes the development of functional visual circuitry.
Methods: Characterization of retinal and brain programmed cell death-1 ligand 1 (PD-L1) expression were examined by immunofluorescence on tissue sections. The contribution of PD-ligands, PD-L1, and programmed cell death-1 ligand 2 (PD-L2) to RGC number was examined in PD-ligand knockout mice lacking 1 or both ligands. Retinal architecture was assessed by spectral-domain optical coherence tomography, and retinal function was analyzed by electroretinography in wild-type and PD-L1/L2 double-deficient mice.
Results: PD-L1 expression is found throughout the neonatal retina and persists in adult RGCs, bipolar interneurons, and Muller glia. In the absence of both PD-ligands, there is a significant numerical increase in RGCs (34% at postnatal day 2 [P2] and 18% in adult), as compared to wild type, and PD-ligands have redundant function in this process. Despite the increased RGC number, adult PD-L1/L2 double-knockout mice have normal retinal architecture and outer retina function.
Conclusion: This study demonstrates that PD-L1 and PD-L2 together impact the final number of RGCs in adult mice and supports a novel role for active promotion of neuronal cell death through PD- 1 receptor-ligand engagement.
C1 [Chan, Ann M.; Kwong, Jacky M. K.; Caprioli, Joseph; Nusinowitz, Steven; Chen, Bryan; Lee, Janice G.; Gandhi, Nishant M.; Gordon, Lynn K.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
[Sham, Caroline W.; Braun, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Francisco, Loise M.; Sharpe, Arlene H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Francisco, Loise M.; Sharpe, Arlene H.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Chen, Ling] Fudan Univ, Shanghai Med Sch, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200433, Peoples R China.
[Gordon, Lynn K.] Greater Los Angeles Vet Affairs Healthcare Syst, Ophthalmol Sect, Los Angeles, CA USA.
RP Gordon, LK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM lgordon@mednet.ucla.edu
OI Caprioli, Joseph/0000-0002-2383-7263
FU UCLA Medical Scientist Training Program NIH [T32 GM08042]; National
Institutes of Health/National Institute of Allergy and Infectious
Diseases Grant [RO1 AI021256]; JSEI Vision Science Training Grant
NIH/NEI [T32 EY007026, P01AI56299]; Pujiang Talent Foundation
[10PJ1401900]; National Science Foundation of China [81000381]
FX This work was supported by the UCLA Medical Scientist Training Program
NIH T32 GM08042 (CWS), National Institutes of Health/National Institute
of Allergy and Infectious Diseases Grant RO1 AI021256 (CWS), JSEI Vision
Science Training Grant NIH/NEI T32 EY007026 (CWS), P01AI56299 (AHS),
Pujiang Talent Foundation 10PJ1401900 (LC), and National Science
Foundation of China 81000381 (LC).
NR 44
TC 1
Z9 2
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1070-8022
J9 J NEURO-OPHTHALMOL
JI J. Neuro-Ophthal.
PD SEP
PY 2012
VL 32
IS 3
BP 227
EP 237
DI 10.1097/WNO.0b013e3182589589
PG 11
WC Clinical Neurology; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA 997SY
UT WOS:000308187800010
PM 22635166
ER
PT J
AU Gros, DF
Price, M
Gros, KS
Paul, LA
McCauley, JL
Ruggiero, KJ
AF Gros, Daniel F.
Price, Matthew
Gros, Kirstin Stauffacher
Paul, Lisa A.
McCauley, Jenna L.
Ruggiero, Kenneth J.
TI Relations between Loss of Services and Psychiatric Symptoms in Urban and
Non-Urban Settings following a Natural Disaster
SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT
LA English
DT Article
DE PTSD; Depression; Worry; Preparedness; Disaster; Urban; Non-urban
ID MENTAL-HEALTH PROBLEMS; PSYCHOMETRIC PROPERTIES; PTSD CHECKLIST; VICTIMS
SPEAK; PREPAREDNESS; CONTEXT; IMPACT; MODEL
AB Disasters have been associated with both acute and prolonged distress and significant post-disaster psychiatric symptoms. These outcomes may be further complicated by extended periods without vital services and supplies, such as electricity and drinking water. The present study investigated the relations between post-disaster loss of services and psychiatric symptoms in urban/non-urban disaster victims. Random-digit-dial methodology was used to interview 1,249 victims of Hurricane Ike, a strong storm that hit Galveston, TX in 2008. Findings demonstrated significant relations between loss of services and post-disaster symptoms of posttraumatic stress disorder (PTSD), depression, and worry. These relations varied by urban/non-urban settings; there were significant positive relations between loss of services and symptoms of depression in non-urban settings, but not in urban settings. Similarly, a stronger relation between loss of services and symptoms of PTSD also was demonstrated in non-urban compared to urban settings. Findings highlight the potential importance of pre-disaster preparation, post-disaster restoration of services, and post-disaster community support in post-disaster psychiatric outcomes, with a particular emphasis in non-urban settings.
C1 [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Serv 116, Charleston, SC 29401 USA.
[Gros, Daniel F.; Price, Matthew; Gros, Kirstin Stauffacher; Paul, Lisa A.; McCauley, Jenna L.; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA.
RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM grosd@musc.edu
FU NIMH NIH HHS [R01 MH081056, T32 MH018869, R34 MH077149]
NR 29
TC 2
Z9 2
U1 3
U2 13
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0882-2689
J9 J PSYCHOPATHOL BEHAV
JI J. Psychopathol. Behav. Assess.
PD SEP
PY 2012
VL 34
IS 3
BP 343
EP 350
DI 10.1007/s10862-012-9290-9
PG 8
WC Psychology, Clinical
SC Psychology
GA 995GW
UT WOS:000307997200005
PM 23105170
ER
PT J
AU Gutierrez, OM
Katz, R
Peralta, CA
de Boer, IH
Siscovick, D
Wolf, M
Roux, AD
Kestenbaum, B
Nettleton, JA
Ix, JH
AF Gutierrez, Orlando M.
Katz, Ronit
Peralta, Carmen A.
de Boer, Ian H.
Siscovick, David
Wolf, Myles
Roux, Ana Diez
Kestenbaum, Bryan
Nettleton, Jennifer A.
Ix, Joachim H.
TI Associations of Socioeconomic Status and Processed Food Intake With
Serum Phosphorus Concentration in Community-Living Adults: The
Multi-Ethnic Study of Atherosclerosis (MESA)
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; CHRONIC KIDNEY-DISEASE; 3RD
NATIONAL-HEALTH; GROWTH-FACTOR 23; DIETARY PHOSPHATE; MORTALITY; MEN;
HEMODIALYSIS; CALCIUM; QUESTIONNAIRE
AB Objective: Higher serum phosphorus concentrations are associated with cardiovascular disease events and mortality. Low socioeconomic status is linked with higher serum phosphorus concentration, but the reasons are unclear. Poor individuals disproportionately consume inexpensive processed foods commonly enriched with phosphorus-based food preservatives. Accordingly, we hypothesized that excess intake of these foods accounts for a relationship between lower socioeconomic status and higher serum phosphorus concentration.
Design: Cross-sectional analysis.
Setting and Participants: We examined a random cohort of 2,664 participants with available phosphorus measurements in the Multi-Ethnic Study of Atherosclerosis, a community-based sample of individuals free of clinically apparent cardiovascular disease from across the United States.
Predictor Variables: Socioeconomic status, the intake of foods commonly enriched with phosphorus-based food additives (processed meats, sodas), and frequency of fast-food consumption.
Outcomes: Fasting morning serum phosphorus concentrations.
C1 [Gutierrez, Orlando M.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Gutierrez, Orlando M.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
[Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[de Boer, Ian H.; Siscovick, David; Kestenbaum, Bryan] Univ Washington, Dept Med, Seattle, WA USA.
[de Boer, Ian H.; Siscovick, David; Kestenbaum, Bryan] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Wolf, Myles] Univ Miami, Dept Med, Miami, FL USA.
[Roux, Ana Diez] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Nettleton, Jennifer A.] Univ Texas Hlth Sci Ctr, Div Epidemiol Human Genet & Environm Sci, Houston, TX USA.
[Ix, Joachim H.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
[Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA.
RP Gutierrez, OM (reprint author), Univ Alabama Birmingham, Dept Med, ZRB 614,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM ogutierr@uab.edu
FU associated ARRA supplement [R21HL091217-01A2S1]; National Institutes of
Health [N01-HC-95169]; [K23DK081673]; [R21HL091217]; [N01-HC95159];
[N01-HC95160]; [N01-HC95161]; [N01-HC95162]; [N01-HC95163];
[N01-HC95164]; [N01-HC-95165]
FX This study was supported by grants K23DK081673 (O.M.G.), R21HL091217 and
an associated ARRA supplement R21HL091217-01A2S1 (JHI), and contracts
N01-HC95159 through N01-HC-95165 and N01-HC-95169 from the National
Institutes of Health. A full list of participating MESA investigators
and institutions can be found at http://www.mesa-nhlbi.org.
NR 43
TC 9
Z9 9
U1 0
U2 30
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
J9 J RENAL NUTR
JI J. Renal Nutr.
PD SEP
PY 2012
VL 22
IS 5
BP 480
EP 489
DI 10.1053/j.jrn.2011.08.008
PG 10
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA 997YB
UT WOS:000308202800006
PM 22217539
ER
PT J
AU McCoy, AB
Wright, A
Laxmisan, A
Ottosen, MJ
McCoy, JA
Butten, D
Sittig, DF
AF McCoy, Allison B.
Wright, Adam
Laxmisan, Archana
Ottosen, Madelene J.
McCoy, Jacob A.
Butten, David
Sittig, Dean F.
TI Development and evaluation of a crowdsourcing methodology for knowledge
base construction: identifying relationships between clinical problems
and medications
SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
LA English
DT Article
ID ELECTRONIC HEALTH RECORDS; PROVIDER ORDER ENTRY; UNINTENDED
CONSEQUENCES; DRUG KNOWLEDGE; SYSTEM; INFORMATION; INTERNET; QUALITY;
ERRORS
AB Objective We describe a novel, crowdsourcing method for generating a knowledge base of problem-medication pairs that takes advantage of manually asserted links between medications and problems.
Methods Through iterative review, we developed metrics to estimate the appropriateness of manually entered problem-medication links for inclusion in a knowledge base that can be used to infer previously unasserted links between problems and medications.
Results Clinicians manually linked 231 223 medications (55.30% of prescribed medications) to problems within the electronic health record, generating 41 203 distinct problem-medication pairs, although not all were accurate. We developed methods to evaluate the accuracy of the pairs, and after limiting the pairs to those meeting an estimated 95% appropriateness threshold, 11 166 pairs remained. The pairs in the knowledge base accounted for 183 127 total links asserted (76.47% of all links). Retrospective application of the knowledge base linked 68 316 medications not previously linked by a clinician to an indicated problem (36.53% of unlinked medications). Expert review of the combined knowledge base, including inferred and manually linked problem-medication pairs, found a sensitivity of 65.8% and a specificity of 97.9%.
Conclusion Crowdsourcing is an effective, inexpensive method for generating a knowledge base of problememedication pairs that is automatically mapped to local terminologies, up-to-date, and reflective of local prescribing practices and trends.
C1 [McCoy, Allison B.; Sittig, Dean F.] Univ Texas Hlth Sci Ctr Houston UTHealth, Sch Biomed Informat, Houston, TX 77030 USA.
[McCoy, Allison B.; Ottosen, Madelene J.; Sittig, Dean F.] Univ Texas Houston, Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA.
[Wright, Adam] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Laxmisan, Archana; Butten, David] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA.
[Laxmisan, Archana; Butten, David] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[McCoy, Jacob A.] Univ Texas Med Sch Houston, Houston, TX USA.
RP McCoy, AB (reprint author), Univ Texas Hlth Sci Ctr Houston UTHealth, Sch Biomed Informat, 6410 Fannin St,UTPB 1100, Houston, TX 77030 USA.
EM allison.b.mccoy@uth.tmc.edu
RI McCoy, Allison/I-1951-2013
OI McCoy, Allison/0000-0003-2292-9147
FU Office of the National Coordinator for Health Information Technology
[10510592]; NCRR [3UL1RR024148]
FX This project was supported in part by Grant No. 10510592 for
Patient-Centered Cognitive Support under the Strategic Health IT
Advanced Research Projects Program (SHARP) from the Office of the
National Coordinator for Health Information Technology. The UTHealth
Clinical Data Warehouse is supported by NCRR Grant 3UL1RR024148.
NR 32
TC 18
Z9 18
U1 2
U2 30
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1067-5027
J9 J AM MED INFORM ASSN
JI J. Am. Med. Inf. Assoc.
PD SEP
PY 2012
VL 19
IS 5
BP 713
EP 718
DI 10.1136/amiajnl-2012-000852
PG 6
WC Computer Science, Information Systems; Computer Science,
Interdisciplinary Applications; Health Care Sciences & Services;
Information Science & Library Science; Medical Informatics
SC Computer Science; Health Care Sciences & Services; Information Science &
Library Science; Medical Informatics
GA 994MJ
UT WOS:000307934600005
PM 22582202
ER
PT J
AU Emile, JF
Brahimi, S
Coindre, JM
Bringuier, PP
Monges, G
Samb, P
Doucet, L
Hostein, I
Landi, B
Buisine, MP
Neuville, A
Bouche, O
Cervera, P
Pretet, JL
Tisserand, J
Gauthier, A
Le Cesne, A
Sabourin, JC
Scoazec, JY
Bonvalot, S
Corless, CL
Heinrich, MC
Blay, JY
Aegerter, P
AF Emile, J. F.
Brahimi, S.
Coindre, J. M.
Bringuier, P. P.
Monges, G.
Samb, P.
Doucet, L.
Hostein, I.
Landi, B.
Buisine, M. P.
Neuville, A.
Bouche, O.
Cervera, P.
Pretet, J. L.
Tisserand, J.
Gauthier, A.
Le Cesne, A.
Sabourin, J. C.
Scoazec, J. Y.
Bonvalot, S.
Corless, C. L.
Heinrich, M. C.
Blay, J. Y.
Aegerter, P.
TI Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective
population-based study differ from those of advanced GISTs
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Epidemiology; Sarcoma; Gastrointestinal tumor; Tyrosine kinase receptor
ID GASTROINTESTINAL STROMAL TUMORS; C-KIT; PROGNOSIS; IMATINIB; SURVIVAL;
TRIAL
AB Gastrointestinal stromal tumors (GISTs) are the most common human sarcoma. Most of the data available on GISTs derive from retrospective studies of patients referred to oncology centers. The MolecGIST study sought to determine and correlate clinicopathological and molecular characteristics of GISTs. Tumor samples and clinical records were prospectively obtained and reviewed for patients diagnosed in France during a 24-month period. Five hundred and ninety-six patients were included, of whom 10% had synchronous metastases. GISTs originated from the stomach, small bowel or other site in 56.4, 30.2 and 13.4% of cases, respectively. The main prognostic markers, tumor localization, size and mitotic index were not independent variables (P<0.0001). Mutational status was determined in 492 (83%) patients, and 138 different mutations were identified. KIT and PDGFRA mutations were detected in 348 (71%) and 74 (15%) patients, respectively, contrasting with 82.8 and 2.1% in patients with advanced GIST (MetaGIST) (P<0.0001). Further comparison of localized GISTs in the MolecGIST cohort with advanced GISTs from previous clinical trials showed that the mutations of PDGFRA exon18 (D842V and others) as well as KIT exon11 substitutions (W557R and V559D) were more likely to be seen in patients with localized GISTs (odds ratio 7.9, 3.1, 2.7 and 2.5, respectively), while KIT exon 9 502_503dup and KIT exon 11 557_559del were more frequent in metastatic GISTs (odds ratio of 0.3 and 0.5, respectively). These data suggest that KIT and PDGFRA mutations and standardized mitotic count deserve to be investigated to evaluate the relapse risk of GISTs.
C1 [Emile, J. F.] Ambroise Pare Hosp, APHP, Dept Pathol, Boulogne, France.
[Emile, J. F.; Brahimi, S.; Tisserand, J.; Gauthier, A.] Versailles SQY Univ, Hop Ambroise Pare, Serv Pathol, EA4340, F-92104 Boulogne, France.
[Coindre, J. M.; Hostein, I.] Bergonie Inst, Dept Pathol, Bordeaux, France.
[Bringuier, P. P.; Scoazec, J. Y.] E Herriot Hosp, HCL, Lyon, France.
[Monges, G.] Inst J Paoli I Calmettes, Dept Pathol, F-13009 Marseille, France.
[Samb, P.; Aegerter, P.] Versailles SQY Univ, Ambroise Pare Hosp, APHP, EA2506,Publ Hlth Dept, Boulogne, France.
[Doucet, L.] CHU Brest, Dept Pathol, F-29285 Brest, France.
[Landi, B.] Gorges Pompidou European Hosp, APHP, Paris, France.
[Buisine, M. P.] CHU Lille, Biochem & Mol Biol Dept, F-59037 Lille, France.
[Neuville, A.] CHU Strasbourg, Dept Pathol, F-67000 Strasbourg, France.
[Bouche, O.] CHU Reims, Reims, France.
[Cervera, P.] St Antoine Hosp, APHP, Dept Pathol, Paris, France.
[Pretet, J. L.] Univ Franche Comte, CHU Besancon, F-25030 Besancon, France.
[Le Cesne, A.; Bonvalot, S.] Inst Gustave Roussy, Villejuif, France.
[Sabourin, J. C.] CHU Rouen, Dept Pathol, Rouen, France.
[Corless, C. L.; Heinrich, M. C.] Portland VA Med Ctr, OHSU Knight Canc Inst, Portland, OR USA.
[Blay, J. Y.] Ctr Leon Berard, F-69373 Lyon, France.
RP Emile, JF (reprint author), Ambroise Pare Hosp, APHP, Dept Pathol, Boulogne, France.
EM Jean-francois.emile@apr.aphp.fr
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
FU Ligue contre le Cancer, Institut National du Cancer (INCa); Novartis
Pharma
FX MolecGIST study was supported by grants from Ligue contre le Cancer,
Institut National du Cancer (INCa) and unrestricted grants from Novartis
Pharma. The authors would like to thank patients who participated to
MolecGIST study and their families, as well as all the pathologists,
oncologists, surgeons, gastroenterologists, physicians and clinical
research assistants who participated to the collection of the data. The
list is available on http://www.gist-france.org/remerciements.html.
NR 30
TC 32
Z9 33
U1 0
U2 3
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
J9 MED ONCOL
JI Med. Oncol.
PD SEP
PY 2012
VL 29
IS 3
BP 1765
EP 1772
DI 10.1007/s12032-011-0074-y
PG 8
WC Oncology
SC Oncology
GA 994WE
UT WOS:000307964100053
PM 21953054
ER
PT J
AU Kuna, ST
Maislin, G
Pack, FM
Staley, B
Hachadoorian, R
Coccaro, EF
Pack, AI
AF Kuna, Samuel T.
Maislin, Greg
Pack, Frances M.
Staley, Bethany
Hachadoorian, Robert
Coccaro, Emil F.
Pack, Allan I.
TI Heritability of Performance Deficit Accumulation During Acute Sleep
Deprivation in Twins
SO SLEEP
LA English
DT Article
DE Sleep homeostasis; sleep deprivation; twins
ID NUMBER TANDEM REPEAT; CLOCK GENE PERIOD3; HUMAN PER3 GENE; LENGTH
POLYMORPHISM; DIURNAL PREFERENCE; COLLABORATIVE CROSS; CAGE
QUESTIONNAIRE; VIGILANT ATTENTION; CIRCADIAN PHASE; EEG SLEEP
AB Study Objectives: To determine if the large and highly reproducible interindividual differences in rates of performance deficit accumulation during sleep deprivation, as determined by the number of lapses on a sustained reaction time test, the Psychomotor Vigilance Task (PVT), arise from a heritable trait.
Design: Prospective, observational cohort study.
Setting: Academic medical center.
Participants: There were 59 monozygotic (mean age 29.2 +/- 6.8 [SD] yr; 15 male and 44 female pairs) and 41 dizygotic (mean age 26.6 +/- 7.6 yr; 15 male and 26 female pairs) same-sex twin pairs with a normal polysomnogram.
Interventions: Thirty-eight hr of monitored, continuous sleep deprivation.
Measurements and Results: Patients performed the 10-min PVT every 2 hr during the sleep deprivation protocol. The primary outcome was change from baseline in square root transformed total lapses (response time >= 500 ms) per trial. Patient-specific linear rates of performance deficit accumulation were separated from circadian effects using multiple linear regression. Using the classic approach to assess heritability, the intraclass correlation coefficients for accumulating deficits resulted in a broad sense heritability (h(2)) estimate of 0.834. The mean within-pair and among-pair heritability estimates determined by analysis of variance-based methods was 0.715. When variance components of mixed-effect multilevel models were estimated by maximum likelihood estimation and used to determine the proportions of phenotypic variance explained by genetic and non-genetic factors, 51.1% (standard error = 8.4%, P < 0.0001) of twin variance was attributed to combined additive and dominance genetic effects.
Conclusion: Genetic factors explain a large fraction of interindividual variance among rates of performance deficit accumulations on PVT during sleep deprivation.
C1 [Kuna, Samuel T.] Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA 19104 USA.
[Kuna, Samuel T.; Maislin, Greg; Pack, Frances M.; Staley, Bethany; Hachadoorian, Robert; Pack, Allan I.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Kuna, Samuel T.; Maislin, Greg; Pack, Frances M.; Staley, Bethany; Hachadoorian, Robert; Pack, Allan I.] Univ Penn, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA.
[Coccaro, Emil F.] Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA.
RP Kuna, ST (reprint author), Philadelphia VA Med Ctr, Dept Med, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM skuna@mail.med.upenn.edu
FU NIH from National Center for Research Resources [P50 HL060287, P01
HL094307, UL1RR024134]; Philips-Respironics; Philips-Respironics
Foundation; Azevan Pharmaceuticals, Inc.
FX This study was supported by NIH P50 HL060287, P01 HL094307 and
UL1RR024134 from the National Center for Research Resources. The content
is solely the responsibility of the authors and does not necessarily
represent the official views of the National Center for Research
Resources or the National Institutes of Health. The Penn Twins Cohort
and the MidAtlantic Twins Registry assisted in recruitment of the twin
pairs. The contributions of Melissa Fernando, Michele Pliner, Marian
Whitlock, and Colleen Crowley to the study are gratefully acknowledged
and to Daniel Barrett for assistance in manuscript preparation.; Dr.
Kuna receives grant support from Philips-Respironics. Mr. Maislin is the
owner of Biomedical Statistical Consulting Services. Dr. Coccaro is a
member of the Scientific Advisory Board of Azevan Pharmaceuticals, Inc.
and receives grant support from that company. Dr. Pack is The John L.
Miclot Professor of Medicine at the University of Pennsylvania. Funds
for this endowment were provided by the Philips-Respironics Foundation.
The other authors have indicated no financial conflicts of interest.
NR 64
TC 31
Z9 32
U1 0
U2 10
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD SEP 1
PY 2012
VL 35
IS 9
BP 1223
EP 1233
DI 10.5665/sleep.2074
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 000AY
UT WOS:000308360100009
PM 22942500
ER
PT J
AU Szabo, S
Tache, Y
Somogyi, A
AF Szabo, Sandor
Tache, Yvette
Somogyi, Arpad
TI The legacy of Hans Selye and the origins of stress research: A
retrospective 75 years after his landmark brief "Letter" to the Editor
of Nature
SO STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS
LA English
DT Article
DE Anti-inflammatory drugs; corticosteroids; distress; eustress; Hans
Selye; stress
ID STEROIDS; SPIRONOLACTONE; CLASSIFICATION; CYSTEAMINE; HORMONES; ULCERS;
MODEL; RAT
AB Hans Selye's single author short letter to Nature (1936, 138(3479): 32) inspired a huge and still growing wave of medical research. His experiments with rats led to recognition of the "general adaptation syndrome", later renamed by Selye "stress response": the triad of enlarged adrenal glands, lymph node and thymic atrophy, and gastric erosions/ulcers. Because of the major role of glucocorticoids (named by Selye), he performed extensive structure-activity studies in the 1930s-1940s, resulting in the first rational classification of steroid hormones, e. g. corticoids, testoids/androgens, and folliculoids/estrogens. During those years, he recognized the respective anti-and pro-inflammatory actions of gluco- and mineralocorticoids in animal models, several years before demonstration of anti-rheumatic actions of cortisone and adrenocorticotrophic hormones in patients. Nevertheless, Selye did not receive a Nobel Prize, which was awarded in 1950 to the clinician Hench and the two chemists who isolated and synthesized some of the glucocorticoids. Nonetheless, Selye was internationally recognized as a world authority in endocrinology, steroid chemistry, experimental surgery, and pathology. He wrote over 1500 original and review articles, singly authored 32 books, and trained 40 PhD students, one of whom (Roger Guillemin) won a Nobel Prize for isolating the hypothalamic releasing factors/hormones. Here, we consider the main implications of his first article launching the biological stress concept and the key ideas and problems that occupied him. Selye considered "Stress in heath and disease is medically, sociologically, and philosophically the most meaningful subject for humanity that I can think of".
C1 [Szabo, Sandor] Univ Calif Irvine, VA Med Ctr, VA Long Beach Healthcare Syst, Long Beach, CA 90822 USA.
[Szabo, Sandor] Univ Calif Irvine, Dept Pathol, Long Beach, CA 90822 USA.
[Szabo, Sandor] Univ Calif Irvine, Dept Pharmacol, Long Beach, CA 90822 USA.
[Tache, Yvette] Univ Calif Los Angeles, Dept Med, Oppenheimer Family Ctr Ctr Neurobiol Stress, Digest Dis Div,CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA.
[Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Somogyi, Arpad] EU Select Inc, Brussels, Belgium.
RP Szabo, S (reprint author), Univ Calif Irvine, VA Med Ctr, VA Long Beach Healthcare Syst, 5901 E 7th St, Long Beach, CA 90822 USA.
EM sandor.szabo@va.gov
NR 49
TC 44
Z9 47
U1 9
U2 51
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1025-3890
J9 STRESS
JI Stress
PD SEP
PY 2012
VL 15
IS 5
BP 472
EP 478
DI 10.3109/10253890.2012.710919
PG 7
WC Behavioral Sciences; Endocrinology & Metabolism; Neurosciences
SC Behavioral Sciences; Endocrinology & Metabolism; Neurosciences &
Neurology
GA 994AW
UT WOS:000307904200002
PM 22845714
ER
PT J
AU Aspinall, SL
Cunningham, FE
Zhao, XH
Boresi, JS
Tonnu-Mihara, IQ
Smith, KJ
Stone, RA
Good, CB
AF Aspinall, Sherrie L.
Cunningham, Francesca E.
Zhao, Xinhua
Boresi, Joy S.
Tonnu-Mihara, Ivy Q.
Smith, Kenneth J.
Stone, Roslyn A.
Good, Chester B.
CA ESA Clinic Study Grp
TI Impact of Pharmacist-Managed Erythropoiesis-Stimulating Agents Clinics
for Patients With Non-Dialysis-Dependent CKD
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Chronic kidney disease; anemia; erythropoietin
ID CHRONIC KIDNEY-DISEASE; IMPLEMENTED ANEMIA MANAGEMENT; STAGE
RENAL-DISEASE; ECONOMIC-BENEFITS; HEMOGLOBIN LEVEL; VARIABILITY;
MORTALITY; PROTOCOL; PROGRAM; TARGET
AB Background: Erythropoiesis-stimulating agents (ESAs) are associated with serious adverse events, and maintaining hemoglobin levels within a narrow range can be difficult. We examined the quality of ESA prescribing and monitoring in pharmacist-managed ESA clinics versus usual care in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD).
Study Design: Historical cohort.
Setting & Participants: Outpatients receiving ESAs for NDD-CKD at 10 Veterans Affairs Medical Centers with both pharmacist-managed ESA clinics (n = 314) and physician-based care (ie, usual care; n = 91) and 6 sites with usual care only (n = 167) on January 1, 2009, were followed up for 6 months.
Predictor: Type/site of care (ie, pharmacist-managed ESA clinic, usual care at ESA clinic site, usual-care site).
Outcomes: Primary outcomes were proportion of hemoglobin values in the target range of 10-12 g/dL, ESA dose, and frequency of hemoglobin monitoring. Factors associated with hemoglobin values out of target range were identified using multinomial logistic regression.
Results: More hemoglobin values were in the target range in pharmacist-managed ESA clinics (71.1% vs 56.9% for usual-care sites; P < 0.001). The average 30-day dose of darbepoetin was 163 mu g in pharmacist-managed ESA clinic patients versus 240 mu g in usual-care site patients and 258 mu g in usual-care patients at ESA clinic sites. For epoetin, corresponding average 30-day doses were 44,890 versus 47,141 and 57,436 IU. Veterans in pharmacist-managed ESA clinics had more hemoglobin measurements on average (5.8 vs 3.6 in usual-care sites and 3.8 in usual care at ESAclinic sites; P = 0.007). In the multinomial model, usual care was associated with hemoglobin levels out of target range, whereas heart failure and diabetes were associated with values in range.
Limitations: We could not assess whether different hemoglobin targets were used by usual-care providers.
Conclusions: Relative to usual care, pharmacist-managed clinics provided improved quality of ESA dosing and monitoring for patients with NDD-CKD. Am J Kidney Dis. 60(3): 371-379. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
C1 [Aspinall, Sherrie L.; Cunningham, Francesca E.; Good, Chester B.] Vet Affairs Ctr Medicat Safety, Hines, IL USA.
[Aspinall, Sherrie L.; Zhao, Xinhua; Stone, Roslyn A.; Good, Chester B.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Aspinall, Sherrie L.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA.
[Good, Chester B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
[Smith, Kenneth J.] Univ Pittsburgh, Div Clin Modeling & Decis Sci, Pittsburgh, PA USA.
[Boresi, Joy S.] St Louis Vet Affairs Med Ctr, St Louis, MO USA.
[Tonnu-Mihara, Ivy Q.] Vet Affairs Long Beach Healthcare Syst, Long Beach, CA USA.
RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA.
EM sherrie.aspinall@va.gov
OI Smith, Kenneth J/0000-0001-8088-566X
FU VA Center for Medication Safety/VA Pharmacy Benefits Management
Services, Hines, IL; VA Pittsburgh Healthcare System, Pittsburgh, PA; VA
medical centers
FX There was no specific funding support for the work. However, these
findings are the result of work supported in kind by the VA Center for
Medication Safety/VA Pharmacy Benefits Management Services, Hines, IL;
VA Pittsburgh Healthcare System, Pittsburgh, PA; and the other VA
medical centers that participated in the study. The views expressed in
this report are those of the authors, and no official endorsement by the
Department of Veteran Affairs or the United States Government is
intended or should be inferred.
NR 25
TC 8
Z9 8
U1 1
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD SEP
PY 2012
VL 60
IS 3
BP 371
EP 379
DI 10.1053/j.ajkd.2012.04.013
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 994OT
UT WOS:000307941200011
PM 22633556
ER
PT J
AU Jutras-Aswad, D
Widlitz, M
Scimeca, MM
AF Jutras-Aswad, Didier
Widlitz, Michelle
Scimeca, Michael M.
TI Treatment of Buprenorphine Precipitated Withdrawal: A Case Report
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID METHADONE
C1 [Jutras-Aswad, Didier; Widlitz, Michelle; Scimeca, Michael M.] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY 10468 USA.
[Jutras-Aswad, Didier; Widlitz, Michelle; Scimeca, Michael M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Jutras-Aswad, Didier] Univ Montreal, Dept Psychiat, Quebec City, PQ, Canada.
[Jutras-Aswad, Didier] Ctr Hosp Univ Montreal, CRCHUM, Quebec City, PQ, Canada.
RP Scimeca, MM (reprint author), James J Peters Vet Affairs Med Ctr, Dept Psychiat, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM scimecas@aol.com
NR 5
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD SEP-OCT
PY 2012
VL 21
IS 5
BP 492
EP 493
DI 10.1111/j.1521-0391.2012.00262.x
PG 2
WC Substance Abuse
SC Substance Abuse
GA 986WT
UT WOS:000307377400016
PM 22882402
ER
PT J
AU Horibe, M
Nair, BG
Yurina, G
Neradilek, MB
Rozet, I
AF Horibe, Mayumi
Nair, Bala G.
Yurina, Gary
Neradilek, Moni B.
Rozet, Irene
TI A Novel Computerized Fading Memory Algorithm for Glycemic Control in
Postoperative Surgical Patients
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID CRITICALLY-ILL PATIENTS; INTENSIVE INSULIN THERAPY; GLUCOSE CONTROL;
DELIVERY; VARIABILITY; MORTALITY; INFUSION; RELEASE; TRIAL
AB BACKGROUND: Hyperglycemia is commonly encountered in critically ill patients and is associated with increased mortality and morbidity. To better control blood glucose levels, we previously developed a new computerized fading memory (FM) algorithm.(1) In this study we evaluated the safety and efficacy of this algorithm in surgical intensive care unit (SICU) patients and compared its performance against the existing insulin-infusion algorithm (named VA algorithm) used in our institution.
METHODS: A computer program was developed to run the FM and VA algorithms. Forty eight patients, who were scheduled to have elective surgery, were randomly assigned to receive insulin infusion on the basis of either the FM or VA algorithm. On SICU admission, an insulin infusion was either continued from the operating room or initiated when the glucose level exceeded the target level of 140 mg/dL. Hourly blood glucose measurements were performed and entered into the computer program, which then prescribed the next insulin dose. The randomly assigned algorithm was applied for the first 8 hours of SICU stay, after which the VA algorithm was used. The number of episodes of hypoglycemia (glucose <60 mg/dL) and excessive hyperglycemia (>300 mg/dL) were noted. Additionally, the time required to bring the glucose level within target range (140 +/- 20 mg/dL), the number of glucose measurements within the target range, glycemic variability, and insulin usage were analyzed and compared between the 2 algorithms.
RESULTS: Patient demographics and starting glucose levels were similar between the groups. With the existing VA algorithm, 1 episode of severe hypoglycemia was observed. Three patients did not reach the target range within 8 hours. With the FM algorithm no hypoglycemia occurred, and all patients achieved the target range within 8 hours. Glycemic variability measured by the SD of mean glucose levels was 28% (95% confidence interval, 14% to 39%) lower for the FM algorithm (P < 0.001). The FM algorithm used 1.1 U/h less insulin than did the VA algorithm (P = 0.043).
CONCLUSION: The novel computerized FM algorithm for glycemic control, which emulates physiologic biphasic insulin secretion, managed glucose better than the existing algorithm without any episodes of hypoglycemia. The FM algorithm had less glycemic variability and used less insulin when compared to the conventional clinical algorithm. (Anesth Analg 2012;115:580-7)
C1 [Horibe, Mayumi; Yurina, Gary; Rozet, Irene] VA Puget Sound Hlth Care Syst, Dept Anesthesiol, Seattle, WA 98108 USA.
[Horibe, Mayumi; Nair, Bala G.; Rozet, Irene] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.
[Neradilek, Moni B.] Mt Whisper Light Stat, Seattle, WA USA.
RP Horibe, M (reprint author), VA Puget Sound Hlth Care Syst, Dept Anesthesiol, Mail Stop S-112-ANES,1660 S Columbian Way, Seattle, WA 98108 USA.
EM Mayumi.Horibe@va.gov
FU Anesthesiology and Pain Medicine Department of the University of
Washington; Washington State Society of Anesthesiologists
FX This study was funded by a new investigator seed fund provided by the
Anesthesiology and Pain Medicine Department of the University of
Washington as well as a Seafair Education and Research Grant by the
Washington State Society of Anesthesiologists.
NR 32
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD SEP
PY 2012
VL 115
IS 3
BP 580
EP 587
DI 10.1213/ANE.0b013e318259ee31
PG 8
WC Anesthesiology
SC Anesthesiology
GA 994PI
UT WOS:000307942900015
PM 22669346
ER
PT J
AU Skwara, AJ
Karwoski, TE
Czambel, RK
Rubin, RT
Rhodes, ME
AF Skwara, Amanda J.
Karwoski, Tracy E.
Czambel, R. Kenneth
Rubin, Robert T.
Rhodes, Michael E.
TI Influence of environmental enrichment on hypothalamic-pituitary-adrenal
(HPA) responses to single-dose nicotine, continuous nicotine by osmotic
mini-pumps, and nicotine withdrawal by mecamylamine in male and female
rats
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE Environmental enrichment; HPA axis; Mecamylamine; Nicotine; Sexual
diergism; Withdrawal
ID CENTRAL-NERVOUS-SYSTEM; SEXUAL DIERGISM; AXIS RESPONSES; CHOLINERGIC
STIMULATION; PSYCHOLOGICAL STRESS; MESOLIMBIC DOPAMINE; ADRENOCORTICAL
AXIS; ABSTINENCE SYNDROME; COCAINE ADDICTION; LABORATORY RATS
AB In the present study, we determined the effects of environmental enrichment (EE; Kong Toys (R) and Nestlets (R)) on sexually diergic HPA axis responses to single-dose nicotine (NIC), single-dose NIC following continuous NIC administration for two weeks, and NIC withdrawal by single-dose mecamylamine (MEC) in male and female rats. Blood sampling occurred before and after MEC and NIC administrations for the determination of adrenocorticotropic hormone (ACTH) and corticosterone (CORT).
Supporting and extending our previous findings, EE appeared to produce anxiolytic effects by reducing hormone responses: Male and female rats housed with EE had lower baseline ACTH and significantly lower HPA axis responses to the mild stress of saline (SAL) injection than did those housed without EE. The sexually diergic responses to single dose NIC, continuous NIC, and MEC-induced NIC withdrawal were reduced by EE in many male and female groups. ACTH responses to continuous NIC and MEC-induced NIC withdrawal were blunted to a greater extent in female EE groups than in male EE groups, suggesting that females are more sensitive to the anxiolytic effects of EE. Because EE lowered stress-responsive hormones of the HPA axis in most groups, EE may be a useful intervention for stress reduction in animal models of NIC addiction. As well, the effectiveness of EE in animal studies of NIC withdrawal may enlighten human studies addressing coping styles and tobacco cessation in men and women. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Skwara, Amanda J.; Rhodes, Michael E.] St Vincent Coll, Dept Biol, Latrobe, PA 15650 USA.
[Karwoski, Tracy E.; Czambel, R. Kenneth] Allegheny Gen Hosp, Neurosci Res Ctr, Pittsburgh, PA 15212 USA.
[Rubin, Robert T.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
[Rubin, Robert T.] Univ Calif Los Angeles, Dept Psychiat, Pittsburgh, PA USA.
RP Rhodes, ME (reprint author), St Vincent Coll, Dept Biol, 300 Fraser Purchase Rd, Latrobe, PA 15650 USA.
EM michael.rhodes@email.stvincent.edu
FU Department of Health Tobacco Settlement Funds; NIH [MH28380]
FX The technical assistance of Natalie E. Gentile and Julie D. Andrekanic
is gratefully acknowledged. Supported by 2004 Department of Health
Tobacco Settlement Funds to MER and by NIH grant MH28380 to RTR.
NR 82
TC 19
Z9 19
U1 2
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD SEP 1
PY 2012
VL 234
IS 1
BP 1
EP 10
DI 10.1016/j.bbr.2012.06.003
PG 10
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 991HV
UT WOS:000307693000001
PM 22705101
ER
PT J
AU Zappaterra, MW
Lehtinen, MK
AF Zappaterra, Mauro W.
Lehtinen, Maria K.
TI The cerebrospinal fluid: regulator of neurogenesis, behavior, and beyond
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Cerebrospinal fluid; Choroid plexus; Neurogenesis; Traumatic brain
injury
ID TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM;
FIBROBLAST-GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; REDUCES INFARCT
VOLUME; TUMOR-NECROSIS-FACTOR; HINDBRAIN CHOROID-PLEXUS;
BINDING-PROTEINS IGFBPS; CORTICAL IMPACT INJURY; FACTOR-II GENE
AB The cerebrospinal fluid (CSF) has attracted renewed interest as an active signaling milieu that regulates brain development, homeostasis, and disease. Advances in proteomics research have enabled an improved characterization of the CSF from development through adulthood, and key neurogenic signaling pathways that are transmitted via the CSF are now being elucidated. Due to its immediate contact with neural stem cells in the developing and adult brain, the CSF's ability to swiftly distribute signals across vast distances in the central nervous system is opening avenues to novel and exciting therapeutic approaches. In this review, we will discuss the development of the choroid plexus-CSF system, and review the current literature on how the CSF actively regulates mammalian brain development, behavior, and responses to traumatic brain injury.
C1 [Lehtinen, Maria K.] Harvard Univ, Childrens Hosp Boston, Dept Pathol, Sch Med, Boston, MA 02115 USA.
[Zappaterra, Mauro W.] VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA 90073 USA.
RP Lehtinen, MK (reprint author), Harvard Univ, Childrens Hosp Boston, Dept Pathol, Sch Med, 300 Longwood Ave, Boston, MA 02115 USA.
EM mauro.zappaterra@ucla.edu; maria.lehtinen@childrens.harvard.edu
FU Eleanor and Miles Shore Fellowship Program for Scholars in
Medicine/Children's Hospital Boston Career Development Award; NIH [R00
NS072192]
FX We thank V. Ho and A. Malesz for critical reading of this manuscript. We
are grateful for support from the Eleanor and Miles Shore Fellowship
Program for Scholars in Medicine/Children's Hospital Boston Career
Development Award, and the NIH (Award number R00 NS072192). M.K.L. is an
Alfred P. Sloan Research Fellow.
NR 183
TC 44
Z9 46
U1 1
U2 14
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD SEP
PY 2012
VL 69
IS 17
BP 2863
EP 2878
DI 10.1007/s00018-012-0957-x
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 988UQ
UT WOS:000307516600005
PM 22415326
ER
PT J
AU Tsao, CK
Small, AC
Moshier, EL
Gartrell, BA
Wisnivesky, JP
Sonpavde, G
Godbold, JH
Palese, MA
Hall, SJ
Oh, WK
Galsky, MD
AF Tsao, Che-Kai
Small, Alexander C.
Moshier, Erin L.
Gartrell, Benjamin A.
Wisnivesky, Juan P.
Sonpavde, Guru
Godbold, James H.
Palese, Michael A.
Hall, Simon J.
Oh, William K.
Galsky, Matthew D.
TI Trends in the Use of Cytoreductive Nephrectomy in the United States
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE Kidney cancer; Renal cell carcinoma; Socioeconomic differences; Tyrosine
kinase inhibitor
ID RENAL-CELL CARCINOMA; TARGETED THERAPY; SURVIVAL; CANCER; IMPACT;
DISEASE
AB Cytoreductive nephrectomy had been considered a standard in the treatment of metastatic renal cell carcinoma in the cytokine era, but with the introduction of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) an 'evidence void' for this approach has been created. In this study, we found that the use of cytoreductive nephrectomy (CyNx) has declined in the VEGFR TKI era, and in addition, potential racial and socioeconomic disparities exist.
Background: Two randomized trials published in 2001 established CyNx for patients with metastatic renal carcinoma (mRCC) as a treatment standard in the cytokine era. However, first-line systemic therapy for mRCC changed in 2005 with FDA approval of VEGFR TKIs. We evaluated the patterns of use of CyNx from 2000 to 2008. Materials and Methods: The National Cancer Database was queried for patients diagnosed with mRCC. Patients who underwent CyNx were identified and were further categorized by pre-VEGFR versus VEGFR TKI era, race, insurance status, and hospital. For these subcategories, prevalence ratios (PRs) were generated using the proportion of patients with mRCC undergoing CyNx versus those not undergoing CyNx. Results: Of the 47,417 patients (pts) identified with mRCC, the prevalence of cytoreductive nephrectomy increased 3% each year from 2000 to 2005 (P < .0001), then decreased 3% each year from 2005 to 2008 (P = .0048), with a significant difference between the eras (0.97 vs. 1.025; P < .0001). Black and Hispanic pts were less likely than Caucasian pts to undergo CyNx. Pts with Medicaid, Medicare, and no insurance were less likely than pts with private insurance to undergo CyNx. Pts diagnosed at community hospitals were significantly less likely than pts at teaching hospitals to undergo CyNx. Conclusion: The use of CyNx has declined in the VEGFR-TKI era. In addition, racial and socioeconomic disparities exist in the use of CyNx. The results of pending randomized trials evaluating the role of CyNx in the VEGFR-TKI era are awaited to optimize use of this modality and address potential disparities.
C1 [Tsao, Che-Kai; Small, Alexander C.; Moshier, Erin L.; Gartrell, Benjamin A.; Godbold, James H.; Oh, William K.; Galsky, Matthew D.] Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA.
[Sonpavde, Guru] Texas Oncol, Houston, TX USA.
[Sonpavde, Guru] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Med Oncol, Houston, TX 77030 USA.
[Palese, Michael A.; Hall, Simon J.] Mt Sinai Sch Med, Dept Urol, New York, NY USA.
RP Galsky, MD (reprint author), Tisch Canc Inst, Div Hematol & Med Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM matthew.galsky@mssm.edu
RI Oh, William/B-9163-2012
OI Oh, William/0000-0001-5113-8147
FU NCI NIH HHS [R21 CA176551]
NR 24
TC 13
Z9 13
U1 0
U2 2
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1558-7673
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD SEP
PY 2012
VL 10
IS 3
BP 159
EP 163
DI 10.1016/j.clgc.2012.03.008
PG 5
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 992ZJ
UT WOS:000307820600004
PM 22651971
ER
PT J
AU Justice, AC
Tate, JP
Freiberg, MS
Rodriguez-Barradas, MC
Tracy, R
AF Justice, Amy C.
Tate, Janet P.
Freiberg, Matthew S.
Rodriguez-Barradas, Maria C.
Tracy, Russ
TI Role of the Veterans Aging Cohort Study Index in Assessing Total
Atherosclerotic Burden Reply
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
ID CARDIOVASCULAR-DISEASE; CALCIFICATION; ASSOCIATION; HIV
C1 [Justice, Amy C.; Tate, Janet P.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT 06516 USA.
[Justice, Amy C.; Tate, Janet P.] Yale Univ, Dept Med, Gen Internal Med Sect, New Haven, CT 06520 USA.
[Freiberg, Matthew S.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Infect Dis Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Tracy, Russ] Univ Vermont, Coll Med, Burlington, VT 05405 USA.
RP Justice, AC (reprint author), Vet Affairs Connecticut Healthcare Syst, 950 Campbell Ave,11 ACSLG, West Haven, CT 06516 USA.
EM amy.justice2@va.gov
NR 11
TC 8
Z9 8
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2012
VL 55
IS 5
BP 751
EP 752
DI 10.1093/cid/cis539
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 988NR
UT WOS:000307498300024
ER
PT J
AU Dransfield, MT
Harnden, S
Burton, RL
Albert, RK
Bailey, WC
Casaburi, R
Connett, J
Cooper, JAD
Criner, GJ
Curtis, JL
Han, MK
Make, B
Marchetti, N
Martinez, FJ
McEvoy, C
Nahm, MH
Niewoehner, DE
Porszasz, J
Reilly, J
Scanlon, PD
Scharf, SM
Sciurba, FC
Washko, GR
Woodruff, PG
Lazarus, SC
AF Dransfield, Mark T.
Harnden, Sarah
Burton, Robert L.
Albert, Richard K.
Bailey, William C.
Casaburi, Richard
Connett, John
Cooper, J. Allen D., Jr.
Criner, Gerard J.
Curtis, Jeffrey L.
Han, MeiLan K.
Make, Barry
Marchetti, Nathaniel
Martinez, Fernando J.
McEvoy, Charlene
Nahm, Moon H.
Niewoehner, Dennis E.
Porszasz, Janos
Reilly, John
Scanlon, Paul D.
Scharf, Steven M.
Sciurba, Frank C.
Washko, George R.
Woodruff, Prescott G.
Lazarus, Stephen C.
CA NIH COPD Clinical Res Network
TI Long-term Comparative Immunogenicity of Protein Conjugate and Free
Polysaccharide Pneumococcal Vaccines in Chronic Obstructive Pulmonary
Disease
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID OLDER-ADULTS; STREPTOCOCCUS-PNEUMONIAE; ELDERLY ADULTS; VACCINATION;
EFFICACY; ANTIBODY; RESPONSES; PROTECTION; INFLUENZA; SAFETY
AB Background. Although the 23-valent pneumococcal polysaccharide vaccine (PPSV23) protects against invasive disease in young healthy persons, randomized controlled trials in chronic obstructive pulmonary disease (COPD) have demonstrated no benefit in the intention-to-treat population. We previously reported that the 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV7) is safe and induced greater serotype-specific immunoglobulin G (IgG) and functional antibody than did PPSV23 1 month after vaccination. We hypothesized that these advantages would persist at 1 and 2 years.
Methods. One hundred eighty-one patients with moderate to severe COPD were randomized to receive PPSV23 (n = 90) or PCV7 (1.0 mL; n = 91). We measured IgG by enzyme-linked immunosorbent assay and assessed functional antibody activity by a standardized opsonophagocytosis assay, reported as a killing index (OPK). We determined differences in IgG and OPK between vaccine groups at 1 and 2 years.
Results. Relative to PPSV23, PCV7 induced greater OPK at both 1 and 2 years for 6 of 7 serotypes (not 19F). This response was statistically greater for 5 of 7 serotypes at 1 year and 4 of 7 at 2 years. Comparable differences in IgG were observed but were less often statistically significant. Despite meeting Centers for Disease Control and Prevention criteria for PPSV23 administration, almost 50% of individuals had never been vaccinated. No differences in the frequency of acute exacerbations, pneumonia, or hospitalization were observed.
Conclusions. PCV7 induces a greater functional antibody response than PPSV23 in patients with COPD that persists for 2 years after vaccination. This superior functional response supports testing of conjugate vaccination in studies examining clinical end points.
C1 [Dransfield, Mark T.; Bailey, William C.; Cooper, J. Allen D., Jr.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
[Dransfield, Mark T.; Cooper, J. Allen D., Jr.] Birmingham VA Med Ctr, Pulm Sect, Birmingham, AL USA.
[Harnden, Sarah; Connett, John] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA.
[Burton, Robert L.; Nahm, Moon H.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Burton, Robert L.; Nahm, Moon H.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
[Albert, Richard K.] Denver Hlth Med Ctr, Dept Med, Denver, CO USA.
[Casaburi, Richard; Porszasz, Janos] Harbor UCLA Med Ctr, Div Resp & Crit Care Physiol & Med, Torrance, CA 90509 USA.
[Criner, Gerard J.; Marchetti, Nathaniel] Temple Univ, Div Pulm & Crit Care Med, Philadelphia, PA 19122 USA.
[Curtis, Jeffrey L.; Han, MeiLan K.; Martinez, Fernando J.] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.
[Make, Barry] Univ Colorado, Natl Jewish Hlth, Denver, CO 80202 USA.
[McEvoy, Charlene; Niewoehner, Dennis E.] Univ Minnesota, VA Med Ctr, Pulm Sect, Minneapolis, MN USA.
[Reilly, John; Sciurba, Frank C.] Univ Pittsburgh, Div Pulm & Crit Care Med, Pittsburgh, PA 15260 USA.
[Scanlon, Paul D.] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA.
[Scharf, Steven M.] Univ Maryland, Div Pulm & Crit Care Med, Baltimore, MD 21201 USA.
[Washko, George R.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Woodruff, Prescott G.; Lazarus, Stephen C.] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA.
[Woodruff, Prescott G.; Lazarus, Stephen C.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.
RP Dransfield, MT (reprint author), Univ Alabama Birmingham, Div Pulm & Crit Care, 422 THT 1900 Univ Blvd, Birmingham, AL 35294 USA.
EM mdransfield99@msn.com
RI Reilly, John/H-8755-2012
OI Nahm, Moon/0000-0002-6922-1042; Porszasz, Janos/0000-0002-5823-0031;
Curtis, Jeffrey/0000-0001-5191-4847
FU Division of Lung Diseases of the National Heart, Lung, and Blood
Institute; GCRC [RR02635, RR00051, RR16500, RR00056]; UpToDate;
ePocrates; Pfizer; Actelion; GSK; Forest; MPex; Nycomed; American Lung
Association; Almirall; Altana/Nycomed; Astra Zeneca; Boehringer
Ingelheim; CME Incite; France Foundation; MedEd; NACE; Potomac;
Prescott; Sanofi Aventis; Vox Medic; WebMD; Associates in Medical
Marketing; Castle Connolly; Merck; Genentech; [HL074428]; [HL074409];
[1U10-HL074416]; [HL074408]; [HL074418]; [1U10-HL074431];
[HL074441]; [HL074422]; [HL074439]; [1U10-HL074424]
FX The COPD Clinical Research Network is supported by a Cooperative
Agreement from the Division of Lung Diseases of the National Heart,
Lung, and Blood Institute.; Brigham and Women's Hospital: J. J. Reilly,
Jr, G. Washko (PIs), S. Peterson (Coordinator). Grant HL074428, GCRC
Grant RR02635.; Denver Health Medical Center: R. K. Albert (PI), B. Make
(Co-PI), M. Schwarz, C. Welsh (Investigators), C. Verano, J. Binford, J.
Herrell (Coordinators). Grant HL074409, GCRC Grant RR00051.; Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center: R.
Casaburi, (PI), G. Mason, J. Porszasz, (Investigators), K. Norulak, R.
Kiledjian, L. Diaz, R. Love, P. Walker (Coordinators). Grant HL074407,
GCRC Grant RR00425.; Minnesota Veterans Research Institute, Minneapolis
(Affiliated Sites: HealthPartners Research Foundation, Mayo Clinic): D.
E. Niewoehner (PI), C. McEvoy, K. R. Rice, P. D. Scanlon (Co-PIs). C.
Andrist, J. Hart, K. Timm (Coordinators). Grant 1U10-HL074416.; Temple
University: G. J. Criner (PI), W. Chatila, N. Marchetti, V. Kim, G.
D'Alonzo, S. Krachman, F. Cordova, K. Brennan, N. Patel, J. Mamary
(Investigators), C. Grabianowski, G. Jones, N. Krayger, A. M. Kuzma, H.
Smith (Coordinators). Grant HL074408.; University of Alabama at
Birmingham: M. T. Dransfield (PI), J. A. D. Cooper (Co-PI), W. C.
Bailey, L. B. Gerald, P. O'Reilly (Investigators), S. Tidwell
(Coordinator). Grant HL074418.; University of California, San Francisco:
S. C. Lazarus (PI), H. A. Boushey, J. V. Fahy, P. G. Woodruff
(Investigators), K. Schardein, C. Nguyen, R. Sakurai, M. Dyjak
(Coordinators). 1U10-HL074431.; University of Maryland, Baltimore: S. M.
Scharf (PI), M. Alattar, P. Amelung, M. Cowan, J. Hanson, J. Hasday, A.
Iacono, C. Shanholtz, N. Todd, A. Verceles (Investigators), W.
Bell-Farrell, T. Fitzgerald, P. Wood(Coordinators). Grant HL074441, GCRC
Grant RR16500.; University of Michigan, Ann Arbor: F. J. Martinez (PI),
J. L. Curtis, M. K. Han, S. E. Gay, T. H. Sisson, P. J. Christensen, M.
Mendez (Investigators), D. Thompson (Project Manager), C. Flaherty, T.
Felt, S. Smith, L. Husselman, D. White (Coordinators at UM), C. Getty,
C. Jett, L. McCloskey, M. Christensen (Coordinators at VA). Grant
HL074422.; University of Pittsburgh: F. Sciurba (PI), L. Kniolek, L.
Lane, M. Pitaro (Coordinators). Grant HL074439, GCRC Grant RR00056.;
University of Minnesota (Data Coordinating Center): J. E. Connett (PI),
N. R. Anthonisen (Steering Committee Chair), C. Wendt (Co-PI), S.
Harnden, W. Patrek, H. Voelker (Coordinators). Grant 1U10-HL074424.; M.
T. D. has served as an advisory board member for GlaxoSmithKline and
Boehringer Ingelheim and has received industry contracts for clinical
trials from GlaxoSmithKline, Boehringer Ingelheim, Otsuka, Boston
Scientific and Centocor. R. C. has served in the speakers' bureau for
Pfizer Pharmaceuticals. M. K. H. has participated in advisory boards for
Boehringer Ingelheim GmbH, Pfizer, GlaxoSmithKline, Genentech, Novartis,
and Medimmune; has participated on speaker's bureaus for Boehringer
Ingelheim GmbH, Pfizer, GlaxoSmithKline, the National Association for
Continuing Education, and WebMD; has consulted for Novartis and Nycomed;
and has received royalties from UpToDate and ePocrates. B. M. has served
on an advisory boards for Merck and Pfizer and has been the local
principal investigator for multicenter trials sponsored by Pfizer. F. J.
M. has participated in Advisory Boards in COPD development for Actelion,
Astra Zeneca, Bayer, Boom-Comm, fbCommunications, Forest/Almirall, GSK,
Ikaria, MedImmune, Merck, Novartis, Nycomed, Pearl, Pfizer, Roche,
Schering, and Talecris; has been a member of Steering Committee for COPD
studies sponsored by Actelion, GSK, Forest, MPex, and Nycomed; has
participated in FDA Mock panels for Boehringer Ingelheim and Forest; has
served on speaker's bureaus or in CME activities sponsored by American
Lung Association, Almirall, Altana/Nycomed, Astra Zeneca, Boehringer
Ingelheim, CME Incite, ePocrates, Forest, France Foundation, GSK, MedEd,
NACE, Pfizer, Potomac, Prescott, Sanofi Aventis, Vox Medic, WebMD, and
UpToDate; and has received royalties from Associates in Medical
Marketing, Castle Connolly. D. E. N has received advisory fees from
Merck and Pfizer. P. D, S. has participated in clinical trials funded by
Pfizer and Boehringer Ingelheim, and his wife works for Merck Research
Laboratories. P. G. W. has had a recent research grant with Genentech,
recent consulting for Medimmune, and is co-inventor on a patent pending
for asthma diagnostics. The University of Alabama at Birmingham owns the
intellectual property rights to some of the reagents described in this
work. M. H. N., R. L. B., W. C. B., J. A. D. C. and M. T. D. are
employees of the University of Alabama at Birmingham, and M. H. N. has
been a consultant to Merck regarding the diagnosis of pneumonia. All
other authors report no potential conflicts.
NR 32
TC 21
Z9 22
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2012
VL 55
IS 5
BP E35
EP E44
DI 10.1093/cid/cis513
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 988NR
UT WOS:000307498300001
PM 22652582
ER
PT J
AU Krishna, V
Lazaridis, C
Ellegala, D
Glazier, S
Kindy, M
Spampinato, M
Chalela, JA
AF Krishna, Vibhor
Lazaridis, Christos
Ellegala, Dilantha
Glazier, Steven
Kindy, Mark
Spampinato, Maria
Chalela, Julio A.
TI Spinal cord infarction associated with subarachnoid hemorrhage
SO CLINICAL NEUROLOGY AND NEUROSURGERY
LA English
DT Article
DE Delayed ischemia; Subarachnoid hemorrhage; Spinal cord stroke
C1 [Krishna, Vibhor; Lazaridis, Christos; Ellegala, Dilantha; Glazier, Steven; Chalela, Julio A.] Med Univ S Carolina, Div Neurosurg, Dept Neurosci, Charleston, SC 29407 USA.
[Kindy, Mark] Med Univ S Carolina, Div Res, Dept Neurosci, Charleston, SC 29407 USA.
[Kindy, Mark] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Spampinato, Maria] Med Univ S Carolina, Dept Radiol, Charleston, SC 29407 USA.
[Lazaridis, Christos; Chalela, Julio A.] Med Univ S Carolina, Div Neurol, Dept Neurosci, Charleston, SC 29407 USA.
RP Krishna, V (reprint author), Med Univ S Carolina, Div Neurosurg, Dept Neurosci, 96 Jonathan Lucas St, Charleston, SC 29407 USA.
EM Krishna@musc.edu
FU NCRR NIH HHS [P20 RR021949]; NIEHS NIH HHS [R01 ES016774]; NIGMS NIH HHS
[P20 GM103444]
NR 6
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0303-8467
J9 CLIN NEUROL NEUROSUR
JI Clin. Neurol. Neurosurg.
PD SEP
PY 2012
VL 114
IS 7
BP 1030
EP 1032
DI 10.1016/j.clineuro.2012.01.037
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 993JU
UT WOS:000307855800042
PM 22386902
ER
PT J
AU Cheng, G
Alavi, A
Lim, E
Akers, SR
AF Cheng, Gang
Alavi, Abass
Lim, Esther
Akers, Scott R.
TI Superscan-like Hypermetabolic Lesions on Delayed FDG PET/CT Imaging in a
Patient With Lung Cancer
SO CLINICAL NUCLEAR MEDICINE
LA English
DT Editorial Material
DE FDG PET/CT; superscan; bone marrow metastasis; lung cancer
ID BONE-SCINTIGRAPHY; PULMONARY NODULES; F-18-FDG PET; POINT
AB A 69-year-oldman with a lung mass underwent multiple-time-point FDG PET/CT imaging for diagnostic evaluation. The initial PET imaging (performed at 1 hour after tracer injection) revealed equivocal bone marrow uptake in the right iliac bone and proximal femurs in addition to lung and mediastinal lesions. The 3-hour delayed PET imaging, however, demonstrated widespread bone marrow metastases. Biopsies of the right lung mass and right iliac bone marrow were later performed and revealed a poorly differentiated squamous cell carcinoma in both sites. This case indicates the value of delayed FDG PET in detecting superscan-like hypermetabolic bone marrow lesions in patients with lung cancer.
C1 [Cheng, Gang; Lim, Esther; Akers, Scott R.] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA.
[Alavi, Abass] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
RP Akers, SR (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM Scott.Akers@va.gov
NR 9
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0363-9762
J9 CLIN NUCL MED
JI Clin. Nucl. Med.
PD SEP
PY 2012
VL 37
IS 9
BP 912
EP 913
DI 10.1097/RLU.0b013e31825b23d5
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 992VL
UT WOS:000307808000034
PM 22889790
ER
PT J
AU Brodsky, MB
Abbott, KV
McNeil, MR
Palmer, CV
Grayhack, JP
Martin-Harris, B
AF Brodsky, Martin B.
Abbott, Katherine Verdolini
McNeil, Malcolm R.
Palmer, Catherine V.
Grayhack, Judith P.
Martin-Harris, Bonnie
TI Effects of Divided Attention on Swallowing in Persons with Idiopathic
Parkinson's Disease
SO DYSPHAGIA
LA English
DT Article
DE Deglutition; Deglutition disorders; Attention; Reaction time; Cognition;
Parkinson's disease
ID COGNITIVE STATUS EXAMINATION; DUAL-TASK; CORTICAL REPRESENTATION; MOTOR;
ACTIVATION; GAIT; DYSPHAGIA; VALIDITY; HUMANS; BOTTLENECK
AB The purpose of this study was to determine whether attentional resources are involved in swallowing in persons with idiopathic Parkinson's disease, and if so, in which phase(s) of swallowing. The approach involved a dual-task, reaction time (RT) paradigm using ten participants with Parkinson's disease. Single-task baseline measures were obtained for durations of the anticipatory phase and oropharyngeal phase of swallowing and RTs were obtained for nonword auditory stimuli. A dual-task then required participants to swallow 5 ml of water from an 8-oz. cup while listening for a target nonword presented auditorily during the anticipatory or oropharyngeal phase. Target stimuli were randomized across baseline and dual-task trials. Durations of the anticipatory and oropharyngeal phases of swallowing and RTs during baseline and dual-task trials were determined. Results showed a nonsignificant change in speed of completion for both the anticipatory phase and the oropharyngeal phase of swallowing during dual-task trials. However, there was a statistically significant increase in RT during the anticipatory phase during the dual-task condition. RT during the oropharyngeal phase remained unaffected. Given a need for additional research using more complex competing tasks, these data on attention are consistent with earlier claims of an automatic, nonresource-demanding, oropharyngeal swallowing mechanism that is preserved for persons with early-to-mid-stage Parkinson's disease. Clinical implications of these data suggest that disruptive environmental stimuli to individuals with early-to-mid-stage Parkinson's disease may alter feeding but have little effect on the oropharyngeal swallow.
C1 [Brodsky, Martin B.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD 21231 USA.
[Abbott, Katherine Verdolini; McNeil, Malcolm R.; Palmer, Catherine V.; Grayhack, Judith P.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA.
[McNeil, Malcolm R.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Washington, DC USA.
[Martin-Harris, Bonnie] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
RP Brodsky, MB (reprint author), Johns Hopkins Univ, Dept Phys Med & Rehabil, 98 N Broadway,Suite 403, Baltimore, MD 21231 USA.
EM brodsky@jhmi.edu
FU Mark and Evelyn Trammell Trust, Atlanta, Georgia; Evelyn Trammell
Institute for Voice and Swallowing in the Department of
Otolaryngology-Head and Neck Surgery, Medical University of South
Carolina, Charleston, South Carolina; Trident Parkinson's Support Group
FX The authors thank the Mark and Evelyn Trammell Trust, Atlanta, Georgia;
the Evelyn Trammell Institute for Voice and Swallowing in the Department
of Otolaryngology-Head and Neck Surgery, Medical University of South
Carolina, Charleston, South Carolina; and the Trident Parkinson's
Support Group for their support. The authors also thank Neil Szuminsky
and Pete Arvenitis for their dedication, ingenuity, and technical
expertise that lead to the design and creation of the hardware and
programming necessary for this research.
NR 50
TC 5
Z9 8
U1 2
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0179-051X
J9 DYSPHAGIA
JI Dysphagia
PD SEP
PY 2012
VL 27
IS 3
BP 390
EP 400
DI 10.1007/s00455-011-9381-x
PG 11
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 988VF
UT WOS:000307518100011
PM 22197910
ER
PT J
AU Bandelow, B
Sher, L
Bunevicius, R
Hollander, E
Kasper, S
Zohar, J
Moller, HJ
AF Bandelow, Borwin
Sher, Leo
Bunevicius, Robertas
Hollander, Eric
Kasper, Siegfried
Zohar, Joseph
Moeller, Hans-Juergen
TI Guidelines for the pharmacological treatment of anxiety disorders,
obsessive compulsive disorder and post-traumatic stress disorder in
primary care (vol 16, pg 77, 2012)
SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
LA English
DT Correction
C1 [Sher, Leo] Mt Sinai Sch Med, New York, NY USA.
[Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA.
RI Bandelow, Borwin/E-7295-2011
OI Bandelow, Borwin/0000-0003-2511-3768
NR 1
TC 0
Z9 0
U1 0
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1365-1501
J9 INT J PSYCHIAT CLIN
JI Int. J. Psychiat. Clin.
PD SEP
PY 2012
VL 16
IS 3
BP 242
EP 242
DI 10.3109/13651501.2012.700008
PG 1
WC Psychiatry
SC Psychiatry
GA 985WF
UT WOS:000307300500013
ER
PT J
AU Zickmund, SL
Campbell, SA
Tirado, CF
Zook, CL
Weinrieb, RM
AF Zickmund, Susan L.
Campbell, Scott A.
Tirado, Carlos F.
Zook, Carolyn L.
Weinrieb, Robert M.
TI Perceived Barriers to Hepatitis C Therapy for Patients Receiving Opioid
Agonist Treatment
SO JOURNAL OF ADDICTION MEDICINE
LA English
DT Article
DE barriers to antiviral therapy; hepatitis C; opioid agonist treatment;
provider communication; stigmatization
ID METHADONE-MAINTENANCE PATIENTS; VIRUS-INFECTION; DRUG-USERS; ANTIVIRAL
TREATMENT; TREATMENT SERVICES; UNITED-STATES; KNOWLEDGE; EXPERIENCES;
CLIENTS; MANAGEMENT
AB Objectives: To explore attitudes toward hepatitis C antiviral therapy in a real-world setting, we asked patients in opioid agonist treatment who were offered antiviral therapy about perceived barriers to initiating therapy.
Methods: We recruited patients in opioid agonist treatment who had previously been offered cost-free hepatitis C antiviral therapy in a clinical trial. We collected demographic and open-ended interview data. The semistructured interview guide included questions about attitudes toward hepatitis C therapy and barriers to initiating treatment. Each interview was audio recorded and transcribed verbatim. We used the qualitative editing method to analyze the interview transcripts.
Results: We enrolled 19 patients who had been approached to initiate hepatitis C therapy in a clinical trial. All participants were low-income men, with one third self-identifying as racial minorities. When asked about possible barriers to treatment, multiple problems emerged, including the fear of treatment side effects, difficulties with health care providers, limited access to medical care and health information, and misperceptions about antiviral therapy.
Conclusions: Despite intense educational efforts, concerns over antiviral therapy, relations with providers, and access to the health care system remain critical barriers. These factors should be addressed to improve antiviral therapy rates for patients receiving opioid agonist treatment.
C1 [Zickmund, Susan L.; Zook, Carolyn L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Zickmund, Susan L.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA.
[Campbell, Scott A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Tirado, Carlos F.] Univ Texas SW Med Ctr, Dept Psychiat, Austin, TX USA.
[Zook, Carolyn L.] Univ Pittsburgh, Dept Sociol, Pittsburgh, PA USA.
[Weinrieb, Robert M.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
RP Zickmund, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA.
EM Susan.Zickmund@va.gov
FU Veterans Administration (VA) Health Services Research & Development
(HSR&D) Merit Review Entry Program Career Development Award and Merit
Review; VA VISN 4 Mental Illness Research, Education, and Clinical
Center; VA HSRD; National Institutes of Health (NIH)
FX Supported in part by the Veterans Administration (VA) Health Services
Research & Development (HSR&D) Merit Review Entry Program Career
Development Award and Merit Review and was also supported by pilot funds
from the VA VISN 4 Mental Illness Research, Education, and Clinical
Center. Dr Zickmund is currently receiving research support from the VA
HSR&D. Dr Tirado has received honoraria from Rickett-Benckiser,
Alkermes, and has received payments for educational presentations from
the Texas Department of State Health Services. Dr Weinrieb is currently
receiving research support from National Institutes of Health (NIH), has
given legal testimony, and has given lectures to the University of
Pennsylvania and received payment. The remaining authors have no
conflicts of interest to declare.
NR 39
TC 6
Z9 6
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1932-0620
J9 J ADDICT MED
JI J. Addict. Med.
PD SEP
PY 2012
VL 6
IS 3
BP 233
EP 239
DI 10.1097/ADM.0b013e31825f491b
PG 7
WC Substance Abuse
SC Substance Abuse
GA 993CS
UT WOS:000307833400009
PM 22790464
ER
PT J
AU Spelman, JF
Hunt, SC
Seal, KH
Burgo-Black, AL
AF Spelman, Juliette F.
Hunt, Stephen C.
Seal, Karen H.
Burgo-Black, A. Lucile
TI Post Deployment Care for Returning Combat Veterans
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Review
DE combat; post-deployment; OEF/OIF; veteran; Iraq; Afghanistan
ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH
DIAGNOSES; PERSISTENT POSTCONCUSSIVE SYMPTOMS; CHRONIC PAIN; AFGHANISTAN
VETERANS; WAR VETERANS; GULF-WAR; LONGITUDINAL ASSESSMENT; MILITARY
COHORT
AB Since September 11, 2001, 2.4 million military personnel have deployed to Iraq and Afghanistan. To date, roughly 1.44 million have separated from the military and approximately 772,000 of these veterans have used VA health care. Combat deployments impact the physical, psychological, and social health of veterans. Given that many veterans are receiving care from non-VA providers, it is important that all community health care workers be familiar with the unique health care needs of this patient population, which include injuries associated with blast exposures (including mild traumatic brain injury), as well as a variety of mental health conditions, such as post-traumatic stress disorder. Other important health concerns are chronic musculoskeletal pain, medically unexplained symptoms, sequelae of environmental exposures, depression, suicide, substance abuse, sleep disturbances, and impairments in family, occupational and social functioning. Elevated rates of hypertension and tobacco use remind us that deployment may result not only in immediate impacts on health, but also increase risk for chronic disease, contributing to a growing public health burden. This paper provides a comprehensive review of these health concerns and offers practical management guidelines for primary care providers. In light of relationships between physical, psychological and psychosocial concerns in this population, we recommend an interdisciplinary approach to care directed toward mitigating the long-term health impacts of combat.
C1 [Spelman, Juliette F.; Burgo-Black, A. Lucile] VA Connecticut Hlth Care Syst, West Haven, CT 06511 USA.
[Spelman, Juliette F.; Burgo-Black, A. Lucile] Yale Univ, Sch Med, West Haven, CT USA.
[Hunt, Stephen C.] Puget Sound VA Med Ctr, Seattle, WA USA.
[Hunt, Stephen C.] Univ Washington, Sch Med, Seattle, WA USA.
[Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Seal, Karen H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Seal, Karen H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Spelman, JF (reprint author), VA Connecticut Hlth Care Syst, 950 Campbell Ave,11 ACSL, West Haven, CT 06511 USA.
EM Juliette.spelman@va.gov
FU Department of Veterans Affairs, (VA) Health Services Research and
Development (HSR&D) Research Enhancement Award Program at the San
Francisco VA Medical Center
FX Dr. Seal was financially supported by the Department of Veterans
Affairs, (VA) Health Services Research and Development (HSR&D) Research
Enhancement Award Program at the San Francisco VA Medical Center.
NR 53
TC 46
Z9 46
U1 5
U2 30
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD SEP
PY 2012
VL 27
IS 9
BP 1200
EP 1209
DI 10.1007/s11606-012-2061-1
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 988SP
UT WOS:000307511300021
PM 22648608
ER
PT J
AU Ahluwalia, SC
Gross, CP
Chaudhry, SI
Ning, YMM
Leo-Summers, L
Van Ness, PH
Fried, TR
AF Ahluwalia, Sangeeta C.
Gross, Cary P.
Chaudhry, Sarwat I.
Ning, Yuming M.
Leo-Summers, Linda
Van Ness, Peter H.
Fried, Terri R.
TI Impact of Comorbidity on Mortality Among Older Persons with Advanced
Heart Failure (vol 27, pg 513, 2012)
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Correction
C1 [Ahluwalia, Sangeeta C.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA 90064 USA.
[Gross, Cary P.; Chaudhry, Sarwat I.] Yale Univ, Sch Med, Dept Med, Sect Gen Internal Med, New Haven, CT 06510 USA.
[Ning, Yuming M.; Leo-Summers, Linda; Van Ness, Peter H.] Yale Univ, Sch Med, Program Aging, New Haven, CT USA.
[Van Ness, Peter H.; Fried, Terri R.] Yale Univ, Sch Med, Dept Internal Med, Sect Geriatr, New Haven, CT 06510 USA.
[Fried, Terri R.] VA Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA.
RP Ahluwalia, SC (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, 11301 Wilshire Blvd,111-G, Los Angeles, CA 90064 USA.
EM sangeeta.ahluwalia@va.gov
NR 1
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD SEP
PY 2012
VL 27
IS 9
BP 1228
EP 1230
DI 10.1007/s11606-012-2127-0
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 988SP
UT WOS:000307511300029
ER
PT J
AU Huang, JV
Greyson, CR
Schwartz, GG
AF Huang, Janice V.
Greyson, Clifford R.
Schwartz, Gregory G.
TI PPAR-gamma as a therapeutic target in cardiovascular disease: evidence
and uncertainty
SO JOURNAL OF LIPID RESEARCH
LA English
DT Review
DE peroxisome proliferator-activated receptor gamma; diabetes; insulin
resistance; fatty acids; atherosclerosis; randomized clinical trials
ID ACTIVATED-RECEPTOR-GAMMA; TYPE-2 DIABETES-MELLITUS; IMPAIRED
GLUCOSE-TOLERANCE; ENDOTHELIAL PROGENITOR CELLS;
RANDOMIZED-CONTROLLED-TRIAL; DENSITY-LIPOPROTEIN-CHOLESTEROL;
CORONARY-ARTERY-DISEASE; INTIMA-MEDIA THICKNESS; K-ATP CHANNEL;
ALL-CAUSE MORTALITY
AB Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a key regulator of fatty acid metabolism, promoting its storage in adipose tissue and reducing circulating concentrations of free fatty acids. Activation of PPAR-gamma has favorable effects on measures of adipocyte function, insulin sensitivity, lipoprotein metabolism, and vascular structure and function. Despite these effects, clinical trials of thiazolidinedione PPAR-gamma activators have not provided conclusive evidence that they reduce cardiovascular morbidity and mortality. The apparent disparity between effects on laboratory measurements and clinical outcomes may be related to limitations of clinical trials, adverse effects of PPAR-gamma activation, or off-target effects of thiazolidinedione agents.(jlr) This review addresses these issues from a clinician's perspective and highlights several ongoing clinical trials that may help to clarify the therapeutic role of PPAR-gamma activators in cardiovascular disease.-Huang, J. V., C. R. Greyson, and G. G. Schwartz. PPAR-gamma as a therapeutic target in cardiovascular disease: evidence and uncertainty. J. Lipid Res. 2012. 53: 1738-1754.
C1 [Schwartz, Gregory G.] US Dept Vet Affairs, Denver VA Med Ctr, Cardiol Sect, Denver, CO USA.
Univ Colorado, Sch Med, Denver, CO USA.
RP Schwartz, GG (reprint author), US Dept Vet Affairs, Denver VA Med Ctr, Cardiol Sect, Denver, CO USA.
EM Gregory.Schwartz@va.gov
FU Medical Research Service, US Department of Veterans Affairs; National
Institutes of Health Grant [5-R01-HL-049944]; Roche Laboratories
FX This work was supported by the Medical Research Service, US Department
of Veterans Affairs and by National Institutes of Health Grant
5-R01-HL-049944 (to G.G.S.). Its contents are solely the responsibility
of the authors and do not necessarily represent the official views of
the National Institutes of Health. G. G. Schwartz received research
grant support from Roche Laboratories.
NR 217
TC 31
Z9 32
U1 0
U2 19
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
J9 J LIPID RES
JI J. Lipid Res.
PD SEP
PY 2012
VL 53
IS 9
BP 1738
EP 1754
DI 10.1194/jlr.R024505
PG 17
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 991ZN
UT WOS:000307743500003
PM 22685322
ER
PT J
AU Aversa, LH
Stoddard, JA
Doran, NM
Au, S
Chow, B
McFall, M
Saxon, A
Baker, DG
AF Aversa, Laura H.
Stoddard, Jill A.
Doran, Neal M.
Au, Selwyn
Chow, Bruce
McFall, Miles
Saxon, Andrew
Baker, Dewleen G.
TI PTSD and depression as predictors of physical health-related quality of
life in tobacco-dependent veterans
SO JOURNAL OF PSYCHOSOMATIC RESEARCH
LA English
DT Article
DE Health-related quality of life; PTSD; Depression; Smoking; Tobacco;
SF-36
ID POSTTRAUMATIC-STRESS-DISORDER; COMORBID ANXIETY DISORDERS; EXPOSURE
THERAPY; PSYCHIATRIC-DISORDERS; SMOKING-CESSATION; PRIMARY-CARE;
PSYCHOMETRIC PROPERTIES; RISK-FACTOR; PRIME-MD; MORTALITY
AB Objective: Smoking, depression and PTSD are related to poor physical health outcomes and health-related quality of life (HRQoL). Previous studies examining the effects of quitting smoking on HRQoL have been mixed. This study aimed to examine the effects of PTSD, depressive symptoms and smoking cessation on HRQoL in a sample receiving treatment for PTSD.
Method: This study utilized archival interview and self-report data from a clinical trial (VA Cooperative Study 519) that recruited tobacco dependent veterans with chronic FTSD (N=943).
Results: Analyses were conducted using hierarchical linear modeling and indicated that PTSD and depressive symptoms differentially affected the various physical health status domains. Additionally, quitting smoking was associated with better self-perceived health status and social functioning.
Conclusion: Our findings further explain the interrelationships of PTSD, depression, and smoking in the prediction of physical HRQoL and advocate the importance of integrated care. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Aversa, Laura H.; Baker, Dewleen G.] VA San Diego Healthcare Syst, San Diego, CA 92161 USA.
[Aversa, Laura H.; Stoddard, Jill A.] Alliant Int Univ, Calif Sch Profess Psychol, San Diego, CA USA.
[Doran, Neal M.; Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Au, Selwyn; Chow, Bruce] Vet Affairs Palo Alto Hlth Care Syst, Cooperat Studies Program, Mountain View, CA USA.
[McFall, Miles; Saxon, Andrew] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[McFall, Miles; Saxon, Andrew] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Baker, Dewleen G.] Vet Affairs Ctr Excellence Stress & Mental Hlth, San Diego, CA USA.
RP Aversa, LH (reprint author), VA San Diego Healthcare Syst, 3350 La Jolla Village Dr 151, San Diego, CA 92161 USA.
EM laura.harder@gmail.com
RI Doran, Neal/E-5653-2013
FU Cooperative Studies Program of the Clinical Science Research and
Development Service, U.S. Department of Veterans Affairs (DVA) (CSP)
[519, NCT00118534]; Tobacco-Related Disease Research Program
[19DT-0003]; Department of Defense [PTO 090738]; DVA HSRD [SDR09-128];
VA Center of Excellence for Stress and Mental Health; VA Merit [821];
DVA; NIAAA [1 P20 AA017839-01]; NIDA [5 U10 DA013714-08]; VA HSRD [1 101
HX000616-01]
FX Funding was provided by the Cooperative Studies Program of the Clinical
Science Research and Development Service, U.S. Department of Veterans
Affairs (DVA) (CSP #519, NCT00118534) and the Tobacco-Related Disease
Research Program 19DT-0003. Dr. Baker receives research support from the
Department of Defense (Navy BUMED and CDMRP) (PTO 090738) and the DVA
HSR&D (SDR09-128) and is supported in part by the VA Center of
Excellence for Stress and Mental Health. Dr. McFall receives research
support from VA Merit #821 and DVA. Dr. Saxon receives research support
from NIAAA (1 P20 AA017839-01), NIDA (5 U10 DA013714-08), and from VA
HSR&D (1 101 HX000616-01). The views expressed herein are those of the
authors and not necessarily those of the U.S. Department of Veterans
Affairs. The authors have no competing interests to report.
NR 82
TC 13
Z9 13
U1 7
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3999
J9 J PSYCHOSOM RES
JI J. Psychosomat. Res.
PD SEP
PY 2012
VL 73
IS 3
BP 185
EP 190
DI 10.1016/j.jpsychores.2012.06.010
PG 6
WC Psychiatry
SC Psychiatry
GA 986UW
UT WOS:000307372100006
PM 22850258
ER
PT J
AU Bonawitz, SC
Duvvuri, U
AF Bonawitz, Steven C.
Duvvuri, Umamaheswar
TI Robot-Assisted Oropharyngeal Reconstruction with Free Tissue Transfer
SO JOURNAL OF RECONSTRUCTIVE MICROSURGERY
LA English
DT Article
DE robotic; TORS; free tissue transfer
ID NECK-CANCER; SURGERY TORS; HEAD; CARCINOMA
AB The surgical robot has been demonstrated to have useful applications in urologic, gynecologic, cardiac, general, and endocrine surgery. The development of robotic surgery has enhanced the precision and control of the surgeon in minimally invasive surgical situations specific to these specialties and, more recently, has been applied to the treatment of oropharyngeal tumors in the form of transoral robotic surgery (TORS). The elimination of the need for lip- and mandible-splitting approaches has allowed a reassessment of surgical options for the treatment of tumors that have until recently been primarily addressed nonoperatively with chemoradiation. The TORS approach has created the need to adapt current reconstructive options to robotic technology to manage the resultant tissue defects and to assess and compare the effectiveness of these procedures. This report details our early experience with the use of robot-assisted free tissue transfer for management of soft tissue defects of the oropharynx.
C1 [Duvvuri, Umamaheswar] Univ Pittsburgh, Dept Otolaryngol, VA Pittsburgh Hlth Syst, Med Ctr,Eye & Ear Inst, Pittsburgh, PA 15213 USA.
[Bonawitz, Steven C.] Johns Hopkins Univ, Sch Med, Dept Plast & Reconstruct Surg, Baltimore, MD USA.
RP Duvvuri, U (reprint author), Univ Pittsburgh, Dept Otolaryngol, VA Pittsburgh Hlth Syst, Med Ctr,Eye & Ear Inst, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM duvvuriu@upmc.edu
NR 12
TC 5
Z9 5
U1 0
U2 6
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0743-684X
J9 J RECONSTR MICROSURG
JI J. Reconstr. Microsurg.
PD SEP
PY 2012
VL 28
IS 7
BP 485
EP 490
DI 10.1055/s-0032-1313758
PG 6
WC Surgery
SC Surgery
GA 990KR
UT WOS:000307630200010
PM 22638875
ER
PT J
AU Baibergenova, AT
Weinstock, MA
AF Baibergenova, A. T.
Weinstock, M. A.
CA VATTC Trial Grp
TI Oral prednisone use and risk of keratinocyte carcinoma in non-transplant
population. The VATTC trial
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Article
ID TRETINOIN CHEMOPREVENTION TRIAL; SKIN-CANCER; TOPICAL TRETINOIN;
IMMUNOSUPPRESSIVE THERAPY; GLUCOCORTICOID-RECEPTOR; TRANSPLANT
RECIPIENTS; LYMPHOMA; CYCLOSPORINE; INFLAMMATION; ASSOCIATION
AB Background Glucorticosteroids (GC) are potent anti-inflammatory medications with immunosuppressive property. Few retrospective studies have reported the increased risk of development of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) associated with GC use. Objective We aimed to assess the effect of oral GC use on the risk of BCC and SCC using prospective data. Methods We analysed data from the Veterans Affairs Topical Tretinoin Chemoprevention Trial, which followed up patients from 1998 to 2004. Exposure to oral GCs was defined as (1) use of any oral GCs at any point during follow-up and (2) use of GCs for a month or longer. Outcome was occurrence of new BCC or SCC. Cox proportional hazard models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results Among the 1051 study participants, 148 patients (14%) had prednisone prescription filled during study period, and 63 (6%) used prednisone for over a month. A total of 472 patients (45%) developed at least one BCC during study: 394 (44%) among non-users of prednisone and 78 (53%) among any time users. The total number of new SCC was 309 (29%): 258 (29%) among non-users of prednisone and 51 (34%) among users. Among any time prednisone users, the adjusted HR was 1.11 (95% CI, 0.871.42) for BCC, and 1.05 (95% CI, 0.761.45) for SCC. Among those who used prednisone for 30 or more days, the HR was 1.26 (95% CI, 0.901.78) for BCC, and 1.03 (95% CI, 0.661.60) for SCC. Conclusion This study does not support the existence of association between use of oral GCs and risk of BCC or SCC.
C1 [Baibergenova, A. T.] Univ Toronto, Fac Med, Div Dermatol, Toronto, ON, Canada.
[Weinstock, M. A.] Rhode Isl Hosp, Dept Dermatol, Providence, RI USA.
[Weinstock, M. A.] Brown Univ, Dept Community Hlth, Providence, RI 02912 USA.
[VATTC Trial Grp] US Dept Vet Affairs, Cooperat Studies Program, Washington, DC USA.
[Weinstock, M. A.] VA Med Ctr Providence, Dermatoepidemiol Unit, Providence, RI USA.
RP Baibergenova, AT (reprint author), Univ Toronto, Fac Med, Div Dermatol, Toronto, ON, Canada.
EM akerke_b@yahoo.com
FU Medical Dermatology Society
FX We thank the Medical Dermatology Society for their mentorship program
grant that allowed Dr A. Baibergenova to conduct this research under the
mentorship of Dr M. Weinstock.
NR 29
TC 7
Z9 7
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
PD SEP
PY 2012
VL 26
IS 9
BP 1109
EP 1115
DI 10.1111/j.1468-3083.2011.04226.x
PG 7
WC Dermatology
SC Dermatology
GA 989JF
UT WOS:000307555400008
PM 21923839
ER
PT J
AU Kogai, T
Brent, GA
AF Kogai, Takahiko
Brent, Gregory A.
TI The sodium iodide symporter (NIS): Regulation and approaches to
targeting for cancer therapeutics
SO PHARMACOLOGY & THERAPEUTICS
LA English
DT Review
DE Sodium iodide symporter; Thyroid cancer; Breast cancer; Transcriptional
regulation; Posttranslational regulation
ID MCF-7 BREAST-CANCER; RAT-THYROID CELLS; TRANS-RETINOIC ACID;
GROWTH-FACTOR-BETA; RECOMBINANT HUMAN THYROTROPIN; PAIRED-DOMAIN
TRANSCRIPTION; PROTEIN-KINASE-A; ADENOSINE-3',5'-MONOPHOSPHATE SIGNAL
ACTION; ACUTE PROMYELOCYTIC LEUKEMIA; SYSTEMIC NONVIRAL DELIVERY
AB Expression of the sodium iodide symporter (NIS) is required for efficient iodide uptake in thyroid and lactating breast. Since most differentiated thyroid cancer expresses NIS, beta-emitting radioactive iodide is routinely utilized to target remnant thyroid cancer and metastasis after total thyroidectomy. Stimulation of NIS expression by high levels of thyroid-stimulating hormone is necessary to achieve radioiodide uptake into thyroid cancer that is sufficient for therapy. The majority of breast cancer also expresses NIS, but at a low level insufficient for radioiodine therapy. Retinoic acid is a potent NIS inducer in some breast cancer cells. NIS is also modestly expressed in some non-thyroidal tissues, including salivary glands, lacrimal glands and stomach. Selective induction of iodide uptake is required to target tumors with radioiodide. Iodide uptake in mammalian cells is dependent on the level of NIS gene expression, but also successful translocation of NIS to the cell membrane and correct insertion. The regulatory mechanisms of NIS expression and membrane insertion are regulated by signal transduction pathways that differ by tissue. Differential regulation of NIS confers selective induction of functional NIS in thyroid cancer cells, as well as some breast cancer cells, leading to more efficient radioiodide therapy for thyroid cancer and a new strategy for breast cancer therapy. The potential for systemic radioiodide treatment of a range of other cancers, that do not express endogenous NIS, has been demonstrated in models with tumor-selective introduction of exogenous NIS. Published by Elsevier Inc.
C1 [Kogai, Takahiko] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, David Geffen Sch Med,Dept Med, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, David Geffen Sch Med,Dept Physiol, Los Angeles, CA 90073 USA.
RP Kogai, T (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, David Geffen Sch Med,Dept Med, Bldg 114,Room 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM tkogai@ucla.edu; gbrent@ucla.edu
FU NIH [R01 CA089364]
FX We would like to thank Drs. Jerome Hershman, Masahiro Sugawara, and
Yan-Yun Liu for helpful discussions. This study was supported by NIH R01
CA089364 and VA merit review funds.
NR 208
TC 47
Z9 51
U1 0
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0163-7258
J9 PHARMACOL THERAPEUT
JI Pharmacol. Ther.
PD SEP
PY 2012
VL 135
IS 3
BP 355
EP 370
DI 10.1016/j.pharmthera.2012.06.007
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 988ZD
UT WOS:000307529100007
PM 22750642
ER
PT J
AU Kraft, S
Mackler, E
Schlickman, P
Welch, K
DePestel, DD
AF Kraft, Shawna
Mackler, Emily
Schlickman, Peter
Welch, Kathy
DePestel, Daryl D.
TI Outcomes of therapy vancomycin-resistant enterococcal bacteremia in
hematology and bone marrow transplant patients
SO SUPPORTIVE CARE IN CANCER
LA English
DT Letter
C1 [Kraft, Shawna; DePestel, Daryl D.] Univ Michigan Hlth Syst, Ann Arbor, MI 48109 USA.
[Mackler, Emily] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA.
[DePestel, Daryl D.] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA.
[Schlickman, Peter] Denver VA Med Ctr, Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA.
[Welch, Kathy] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA.
RP Kraft, S (reprint author), Univ Michigan Hlth Syst, 1500 E Med Ctr Dr,UH B2D301,Box 0008, Ann Arbor, MI 48109 USA.
EM svandeko@umich.edu
NR 1
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD SEP
PY 2012
VL 20
IS 9
BP 1935
EP 1936
DI 10.1007/s00520-012-1440-9
PG 2
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 985RE
UT WOS:000307285800002
PM 22447367
ER
PT J
AU Walling, AM
Asch, SM
Lorenz, KA
Malin, J
Roth, CP
Barry, T
Wenger, NS
AF Walling, Anne M.
Asch, Steven M.
Lorenz, Karl A.
Malin, Jennifer
Roth, Carol P.
Barry, Tod
Wenger, Neil S.
TI The quality of supportive care among inpatients dying with advanced
cancer
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Quality of care; Supportive care; Advanced cancer
ID PALLIATIVE CARE; LIFE; END; DEATH; PHYSICIANS; PROVIDERS; FAMILIES
AB Managing symptoms and communicating effectively are essential aspects of providing high-quality cancer care, especially among patients with advanced cancer. The purpose of this study is to apply novel quality indicators to measure the quality of supportive care provided to patients with advanced cancer who died in a large university medical center.
Cancer quality ASSIST is a comprehensive quality indicator (QI) set that includes 92 symptom and care planning indicators, of which we piloted 15 applicable to persons with advanced cancer who died in the hospital setting. We evaluated medical records of all adult terminal hospitalizations with lengths of stay a parts per thousand yen3 days at one university medical center between April 2005 and April 2006.
Of 496 decedents, 118 had advanced cancer (mean age 60, 54 % male). Forty-five percent received chemotherapy or radiation in the month prior to or during admission. During the hospitalization, 56 % of the patients spent time in the ICU (median length of stay 8 days), one in five received first-time hemodialysis, and 23 % had a ventilator withdrawn anticipating death. The 118 patients triggered 596 quality indicators of which 476 passed (QI level pass rate 80 %, range 50-100 %). Pain assessment and management were consistently performed; however, other cancer supportive care needed improvement: 26 % of patients not receiving cancer therapy who had nausea and vomiting received inadequate follow-up, more than one quarter of patients with dyspnea had this symptom inadequately addressed, and 29 % of patients taking long-acting opioids were not prescribed a bowel regimen. Timely discussion of patient preferences upon admission to the ICU or initiation of mechanical ventilation occurred in 64 and 69 % of cases, respectively.
This set of quality indicators can evaluate the quality of supportive and end-of-life care provided to inpatients dying with advanced cancer and identify aspects of care that need improvement.
C1 [Walling, Anne M.; Wenger, Neil S.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Wenger, Neil S.] UCLA Hlth Syst Eth Ctr, Los Angeles, CA USA.
[Walling, Anne M.; Lorenz, Karl A.; Malin, Jennifer] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
[Lorenz, Karl A.; Roth, Carol P.; Wenger, Neil S.] RAND Hlth, Santa Monica, CA USA.
[Barry, Tod] UCLA Ctr Patient Safety & Qual, Los Angeles, CA USA.
[Asch, Steven M.] VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA.
[Asch, Steven M.] Stanford Sch Med, Stanford, CA 94305 USA.
RP Walling, AM (reprint author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, 911 Broxton Plaza, Los Angeles, CA 90024 USA.
EM awalling@mednet.ucla.edu
FU National Research Service Award Training Grant [T32 PE19001]; UCLA; NIH;
National Palliative Care Research Center
FX This project was supported by a donation from Mary Kay Farley to RAND
Health. Dr. Walling was supported by National Research Service Award
Training Grant T32 PE19001, the UCLA Specialty Training & Advanced
Research Program, the NIH Loan Repayment Program, and a National
Palliative Care Research Center Career Development Award.
NR 21
TC 11
Z9 11
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD SEP
PY 2012
VL 20
IS 9
BP 2189
EP 2194
DI 10.1007/s00520-012-1462-3
PG 6
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 985RE
UT WOS:000307285800032
PM 22544290
ER
PT J
AU Offner, H
Hurn, PD
AF Offner, Halina
Hurn, Patricia D.
TI A Novel Hypothesis: Regulatory B Lymphocytes Shape Outcome from
Experimental Stroke
SO TRANSLATIONAL STROKE RESEARCH
LA English
DT Article
DE Experimental stroke; Bregs; IL-10; PD-1; Immunotherapy
ID ACUTE ISCHEMIC-STROKE; MURINE EXPERIMENTAL STROKE; T-CELLS; INDUCED
IMMUNODEPRESSION; NEUROLOGIC DEFICITS; IMMUNE PATHOLOGY; BRAIN ISCHEMIA;
PD-1; AUTOIMMUNITY; INFLAMMATION
AB Although inflammatory immune cells clearly contribute to the development of middle cerebral artery occlusion (MCAO) in mice, the failure to block neutrophil-associated injury in clinical stroke trials has discouraged further development of immunotherapeutic approaches. However, there is renewed interest in a possible protective role for regulatory T and B cells that can suppress inflammation and limit central nervous system damage induced by infiltrating pro-inflammatory cells. Our failure to implicate CD4(+)FoxP3(+) T cells in limiting brain lesion volume after MCAO turned our focus towards regulatory B cells known to mediate protection against other inflammatory CNS conditions. Our results clearly demonstrated that B cell-deficient mice developed larger infarct volumes, higher mortality, and more severe functional deficits compared to wild-type mice and had increased numbers of activated T cells, macrophages, microglial cells, and neutrophils in the affected brain hemisphere. These MCAO-induced changes were completely prevented in B cell-restored mice after transfer of highly purified WT B cells but not IL-10-deficient B cells. Our novel observations are the first to implicate IL-10-secreting B cells as a major regulatory cell type in stroke and suggest that enhancement of regulatory B cells might have application as a novel therapy for this devastating neurologic condition.
C1 [Offner, Halina] Portland VA Med Ctr, Neuroimmunol Res R&D 31, Portland, OR 97239 USA.
[Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
[Hurn, Patricia D.] Univ Texas Syst, Off Hlth Affairs, Austin, TX USA.
RP Offner, H (reprint author), Portland VA Med Ctr, Neuroimmunol Res R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM offnerva@ohsu.edu
FU NIH [NS075887, NR003521]
FX The authors wish to thank Ms. Eva Niehaus for assistance with manuscript
preparation. This work was supported by NIH grants NS075887 (HO) and
NR003521 (PDH). This material is the result of work supported with
resources and the use of facilities at the Portland VA Medical Center,
Portland, OR. The contents do not represent the views of the Department
of Veterans Affairs or the US government.
NR 48
TC 23
Z9 23
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1868-4483
J9 TRANSL STROKE RES
JI Transl. Stroke Res.
PD SEP
PY 2012
VL 3
IS 3
SI SI
BP 324
EP 330
DI 10.1007/s12975-012-0187-4
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 992FK
UT WOS:000307760800005
PM 23175646
ER
PT J
AU Tang, XN
Zheng, Z
Yenari, MA
AF Tang, Xian Nan
Zheng, Zhen
Yenari, Midori A.
TI Bone Marrow Chimeras in the Study of Experimental Stroke
SO TRANSLATIONAL STROKE RESEARCH
LA English
DT Article
DE Bone marrow; Chimera; Inflammation; Stroke
ID FOCAL CEREBRAL-ISCHEMIA; BLOOD-BRAIN-BARRIER; PROTEIN-KINASE-C; NADPH
OXIDASE; IN-VIVO; REPERFUSION INJURY; REACTIVE OXYGEN; ACTIVATION;
MATRIX-METALLOPROTEINASE-9; CELLS
AB Inflammation is known to contribute to stroke evolution, and poststroke immune responses have been documented to emanate from the brain via microglia. However, circulating immune cells are increasingly recognized to play a significant role as well. Recent work has demonstrated the importance of the peripheral circulation and stroke pathogenesis. Understanding how the peripheral circulation contributes to ischemic brain injury may reveal important therapeutic targets and strategies. The use of bone marrow chimeras can be a useful tool in understanding the relative contributions of brain resident and peripheral inflammatory responses.
C1 [Zheng, Zhen; Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Tang, Xian Nan; Zheng, Zhen; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Tang, Xian Nan] Stanford Univ, Dept Anesthesia, Sch Med, Stanford, CA 94305 USA.
RP Yenari, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM yenari@alum.mit.edu
FU NIH [R01 NS40516, P50 NS014543]; VA Merit Award; Veterans Affairs
Medical Center, San Francisco, California
FX This work was supported by NIH grants R01 NS40516 (MAY), P50 NS014543
(MAY) and a VA Merit Award (MAY). Grants to MAY were administered by the
Northern California Institute for Research and Education and supported
by resources of the Veterans Affairs Medical Center, San Francisco,
California.
NR 58
TC 4
Z9 4
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1868-4483
J9 TRANSL STROKE RES
JI Transl. Stroke Res.
PD SEP
PY 2012
VL 3
IS 3
SI SI
BP 341
EP 347
DI 10.1007/s12975-012-0169-6
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 992FK
UT WOS:000307760800007
PM 24323809
ER
PT J
AU Hawkins, EJ
Malte, CA
Baer, JS
Kivlahan, DR
AF Hawkins, Eric J.
Malte, Carol A.
Baer, John S.
Kivlahan, Daniel R.
TI Prevalence, predictors, and service utilization of patients with
recurrent use of Veterans Affairs substance use disorder specialty care
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Chronic; Recurrent; Prevalence; Predictors; Utilization
ID ABUSE TREATMENT; ADDICTION TREATMENT; FOLLOW-UP; MANAGEMENT CHECKUPS;
ALCOHOL DEPENDENCE; COLLABORATIVE CARE; TREATMENT REENTRY;
MENTAL-HEALTH; DRUG; RECOVERY
AB Although substance use disorders (SUDs) are chronic conditions for many patients, the prevalence, predictors, and health care utilization patterns of those who reenter SUD specialty care are understudied. We identified 1,640 patients who initiated SUD specialty care at 1 Veterans Affairs (VA) medical center and categorized them, using their subsequent 24 and prior 60 months receipt of VA SUD care, as index episode only (35.7%, 33.5-38.1), index and prior episode(s) (24.6%, 22.5-22.7), and index and postindex episodes (39.6%, 37.3-42.0). Compared with the index episode-only group, the postindex episode(s) group had modestly higher percentages of men, divorced/separated, and alcohol use, cocaine use, bipolar disorder, and psychotic disorders. Patients with postindex episodes averaged 2 times more postindex emergency visits and mental health hospitalizations than patients with an index only episode. Results document the prevalence, overall health care utilization, and limited predictability of SUD treatment reentry and support development of new models of care for these complex patients. Published by Elsevier Inc.
C1 [Hawkins, Eric J.; Malte, Carol A.; Kivlahan, Daniel R.] VA Puget Sound Hlth Care Syst, Seattle Div S116ATC, Hlth Serv Res & Dev, Seattle, WA 98108 USA.
[Hawkins, Eric J.; Malte, Carol A.; Baer, John S.; Kivlahan, Daniel R.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA.
[Baer, John S.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
[Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Hawkins, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div S116ATC, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM Eric.Hawkins@va.gov
NR 41
TC 7
Z9 7
U1 3
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD SEP
PY 2012
VL 43
IS 2
BP 221
EP 230
DI 10.1016/j.jsat.2011.11.002
PG 10
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 984QV
UT WOS:000307207100009
PM 22197302
ER
PT J
AU Santa-Maria, I
Diaz-Ruiz, C
Ksiezak-Reding, H
Chen, A
Ho, L
Wang, J
Pasinetti, GM
AF Santa-Maria, Ismael
Diaz-Ruiz, Carmen
Ksiezak-Reding, Hanna
Chen, Alice
Ho, Lap
Wang, Jun
Pasinetti, Giulio Maria
TI GSPE interferes with tau aggregation in vivo: implication for treating
tauopathy
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE GSPE; JNPL3 mouse model; tauopathy; hyperphosphorylation
ID NANOELECTROSPRAY MASS-SPECTROMETRY; P301L HUMAN-TAU; ALZHEIMERS-DISEASE;
FILAMENT FORMATION; TRANSGENIC MICE; NEURODEGENERATIVE DISEASES;
PHOSPHORYLATION SITES; MOUSE MODEL; INHIBITION; PROTEIN
AB Tauopathies are characterized by progressive neurodegeneration caused by intracellular accumulation of hyperphosphorylated tau protein aggregates in the brain. The present study was designed to test whether a grape seed polyphenolic extract (GSPE) previously shown to inhibit tau protein aggregation in vitro could benefit tau-mediated neuropathology and behavior deficits in JNPL3 transgenic mice expressing a human tau protein containing the P301L mutation. Nine-month-old JNPL3 mice were treated with GSPE delivered through their drinking water for 6 months. We found that GSPE treatment significantly reduced the number of motor neurons immunoreactive for hyperphosphorylated and conformationally-modified tau in the ventral horns of the spinal cord identified using AT100, PHF-1, AT8, and Alz50 tau antibodies. This coincided with a drastically reduced level of hyperphosphorylated and sarcosyl-insoluble tau in spinal cord fractions. Furthermore, the reduction of tau pathology was accompanied by an improvement in the motor function assessed by a wire hang test. Collectively, our results suggest that GSPE can interfere with tau-mediated neurodegenerative mechanisms and ameliorate neurodegenerative phenotype in an animal model of tauopathy. Our studies support further evaluation of GSPE for preventing and/or treating of tauopathies in humans. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Santa-Maria, Ismael; Diaz-Ruiz, Carmen; Ksiezak-Reding, Hanna; Chen, Alice; Ho, Lap; Wang, Jun; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Santa-Maria, Ismael] Queen Sofia Fdn, CIEN Fdn, Alzheimer Dis Res Unit, Madrid, Spain.
[Ksiezak-Reding, Hanna; Chen, Alice; Ho, Lap; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
OI Diaz-Ruiz, Carmen/0000-0002-0112-0595
FU Polyphenolics Inc.; Division of Constellation Wine U.S. Inc.; Society
for Progressive Supranuclear Palsy; NIH [PO1 AT004511]; Veterans
Administration
FX This work is supported by Polyphenolics Inc., Division of Constellation
Wine U.S. Inc., the Society for Progressive Supranuclear Palsy, NIH PO1
AT004511, and in part from a MERIT Review grant from Veterans
Administration to G.M.P.
NR 36
TC 11
Z9 11
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD SEP
PY 2012
VL 33
IS 9
BP 2072
EP 2081
DI 10.1016/j.neurobiolaging.2011.09.027
PG 10
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 981TW
UT WOS:000306994600020
PM 22054871
ER
PT J
AU Bekris, LM
Lutz, F
Li, G
Galasko, DR
Farlow, MR
Quinn, JF
Kaye, JA
Leverenz, JB
Tsuang, DW
Montine, TJ
Peskind, ER
Yu, CE
AF Bekris, Lynn M.
Lutz, Franziska
Li, Gail
Galasko, Douglas R.
Farlow, Martin R.
Quinn, Joseph F.
Kaye, Jeffrey A.
Leverenz, James B.
Tsuang, Debby W.
Montine, Thomas J.
Peskind, Elaine R.
Yu, Chang-En
TI ADAM10 expression and promoter haplotype in Alzheimer's disease
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE ADAM10; Haplotype; sAPP alpha; Alzheimer's disease; Reporter assay;
Neuritic plaques; Brain; Hippocampus; Cerebrospinal fluid
ID AMYLOID PRECURSOR PROTEIN; ALPHA-SECRETASE ADAM10; UP-REGULATION; MOUSE
MODEL; ADAM-10; MUTATIONS; BACE
AB Alzheimer's disease is confirmed at autopsy according to the accumulation of brain neuritic plaques and neurofibrillary tangles in the brain. Neuritic plaques contain amyloid-beta (A beta) and lower levels of A beta correspond to an increase in ADAM10 alpha-secretase activity. ADAM10 alpha-secretase activity produces a soluble amyloid precursor protein (APP) alpha (sAPP alpha) product and negates the pathological production of A beta. In this investigation, it was hypothesized that genetic variation with the ADAM10 promoter is associated with ADAM10 expression levels as well as cerebrospinal fluid sAPP alpha levels. Results from this investigation suggest that the ADAM10 rs514049-rs653765 C-A promoter haplotype is associated with: (1) higher CSF sAPP alpha levels in cognitively normal controls compared with Alzheimer's disease (AD) patients, (2) higher postmortem brain hippocampus, but not cerebellum, ADAM10 protein levels in subjects with low plaque scores compared with those with high plaque scores, and (3) higher promoter activity for promoter-only reporter constructs compared with promoter 3' untranslated region (3' UTR) constructs in the human neuroblastoma SHSY5Y cell line, but not in HepG2 or U118 cell lines. Taken together, these findings suggest that ADAM10 expression is modulated according to a promoter haplotype that is influenced in a brain region-and cell type-specific manner. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Bekris, Lynn M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA.
[Bekris, Lynn M.; Lutz, Franziska; Tsuang, Debby W.; Yu, Chang-En] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
[Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
[Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Galasko, Douglas R.] VA Med Ctr San Diego, San Diego, CA USA.
[Farlow, Martin R.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA.
[Quinn, Joseph F.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Quinn, Joseph F.; Kaye, Jeffrey A.] Portland VA Med Ctr, Portland, OR USA.
[Leverenz, James B.] VA Puget Sound Hlth Care Syst, MIRECC, NW Network VISN 20, Seattle, WA USA.
[Leverenz, James B.] Parkinsons Dis Res Educ & Clin Ctr PADRECC, NW Network VISN 20, Philadelphia, PA USA.
[Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
RP Bekris, LM (reprint author), Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Box 358280,VAPSHCS GRECC S182,1660 S Columbian Wa, Seattle, WA 98108 USA.
EM lbekris@u.washington.edu
RI Tsuang, Debby/L-7234-2016
OI Tsuang, Debby/0000-0002-4716-1894; Kaye, Jeffrey/0000-0002-9971-3478
FU U.S. Department of Veterans Affairs, Office of Research and Development;
Biomedical Laboratory; NIH [2P50AG005136-27, 1P50NS062684-01A1,
K99AG034214-02]
FX This work is supported in part by the U.S. Department of Veterans
Affairs, Office of Research and Development Clinical Research and
Development Program, the Biomedical Laboratory Research Program, and NIH
Grants 2P50AG005136-27, 1P50NS062684-01A1, and K99AG034214-02.
Additional support includes University of Washington Alzheimer's Disease
Research Center NIH P50-AB005136 and University of California San Diego
Alzheimer's Disease Research Center AGO 5131.
NR 32
TC 4
Z9 4
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD SEP
PY 2012
VL 33
IS 9
AR 2229.e1
DI 10.1016/j.neurobiolaging.2012.03.013
PG 9
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 981TW
UT WOS:000306994600036
PM 22572541
ER
PT J
AU Aparici, CM
Seo, Y
AF Aparici, Carina Mari
Seo, Youngho
TI Functional Imaging for Prostate Cancer: Therapeutic Implications
SO SEMINARS IN NUCLEAR MEDICINE
LA English
DT Review
ID POSITRON-EMISSION-TOMOGRAPHY; LYMPH-NODE DISSECTION;
ANDROGEN-DEPRIVATION THERAPY; MODULATED RADIATION-THERAPY; MEMBRANE
ANTIGEN-EXPRESSION; RADICAL RETROPUBIC PROSTATECTOMY; DOMINANT
INTRAPROSTATIC LESIONS; EXTERNAL-BEAM RADIOTHERAPY; MONOCLONAL-ANTIBODY
J591; WHOLE-PELVIC IRRADIATION
AB Functional radionuclide imaging modalities, now commonly combined with anatomical imaging modalities computed tomography (CT) or magnetic resonance imaging (single photon emission computed tomography [SPECT]/CT, positron emission tomography [PET]/CT, and PET/magnetic resonance imaging), are promising tools for the management of prostate cancer, particularly for therapeutic implications. Sensitive detection capability of prostate cancer using these imaging modalities is one issue; however, the treatment of prostate cancer using the information that can be obtained from functional radionuclide imaging techniques is another challenging area. There are not many SPECT or PET radiotracers that can cover the full spectrum of the management of prostate cancer from initial detection to staging, prognosis predictor, and all the way to treatment response assessment. However, when used appropriately, the information from functional radionuclide imaging improves, and sometimes significantly changes, the whole course of the cancer management. The limitations of using SPECT and PET radiotracers with regard to therapeutic implications are not so much different from their limitations solely for the task of detecting prostate cancer; however, the specific imaging target and how this target is reliably imaged by SPECT and PET can potentially make significant impact in the treatment of prostate cancer. Finally, although the localized prostate cancer is considered manageable, there is still significant need for improvement in noninvasive imaging of metastatic prostate cancer, in treatment guidance, and in response assessment from functional imaging, including radionuclide-based techniques. In this review article, we present the rationale of using functional radionuclide imaging and the therapeutic implications for each of radionuclide imaging agent that have been studied in human subjects. Semin Nucl Med 42:328-342 (c) 2012 Elsevier Inc. All rights reserved.
C1 [Seo, Youngho] UCSF, Phys Res Lab, Dept Radiol & Biomed Imaging, San Francisco, CA 94107 USA.
[Aparici, Carina Mari] San Francisco VA Med Ctr, Nucl Med Serv, San Francisco, CA USA.
[Seo, Youngho] Univ Calif San Francisco, Dept Radiat Oncol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94107 USA.
[Seo, Youngho] Univ Calif San Francisco, UCSF Grad Program Bioengn, UC Berkeley, San Francisco, CA 94107 USA.
RP Seo, Y (reprint author), UCSF, Phys Res Lab, Dept Radiol & Biomed Imaging, 185 Berry St,Suite 350, San Francisco, CA 94107 USA.
EM youngho.seo@ucsf.edu
FU National Institutes of Health (NIH) [K25 CA114254]; American Recovery
and Reinvestment Act (ARRA) through NIH [K25 CA114254-04S1]; UCSF
Research Evaluation and Allocation Committee; UCSF Department of
Radiation Oncology
FX This work was supported by grants K25 CA114254 from the National
Institutes of Health (NIH); K25 CA114254-04S1 American Recovery and
Reinvestment Act (ARRA) of 2009 through NIH; and from UCSF Research
Evaluation and Allocation Committee and UCSF Department of Radiation
Oncology.
NR 214
TC 13
Z9 13
U1 1
U2 15
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0001-2998
EI 1558-4623
J9 SEMIN NUCL MED
JI Semin. Nucl. Med.
PD SEP
PY 2012
VL 42
IS 5
BP 328
EP 342
DI 10.1053/j.semnuclmed.2012.04.004
PG 15
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 986TO
UT WOS:000307368700006
ER
PT J
AU Lehavot, K
Molina, Y
Simoni, JM
AF Lehavot, Keren
Molina, Yamile
Simoni, Jane M.
TI Childhood Trauma, Adult Sexual Assault, and Adult Gender Expression
among Lesbian and Bisexual Women
SO SEX ROLES
LA English
DT Article
DE Childhood abuse; Sexual assault; Lesbian; Bisexual; Gender expression;
Gender identity; Butch/femme
ID PHYSICAL ABUSE; SUBSTANCE USE; BUTCH/FEMME DIFFERENCES; IDENTITY
DEVELOPMENT; INITIAL RELIABILITY; ATYPICAL BEHAVIOR; EATING-DISORDER;
MENTAL-HEALTH; UNITED-STATES; VICTIMIZATION
AB Several studies have demonstrated that lesbian and bisexual women are more likely than heterosexual women to report childhood abuse and adult sexual assault. It is unknown, however, which sexual minority women are most likely to experience such abuse. We recruited adult sexual minority women living in the US through electronic fliers sent to listservs and website groups inviting them to complete an online survey (N = 1,243). We examined differences in both childhood abuse and adult sexual assault by women's current gender identity (i.e., butch, femme, androgynous, or other) and a continuous measure of gender expression (from butch/masculine to femme/feminine), adjusting for sexual orientation identity, age, education, and income. Results indicated that a more butch/masculine current self-assessment of gender expression, but not gender identity, was associated with more overall reported childhood trauma. Although one aspect of gender expression, a more butch/masculine gender role, was associated with adult sexual assault, feminine appearance and a femme gender identity also significantly predicted adult sexual assault. These findings highlight the significance of gender identity and expression in identifying women at greater risk for various abuse experiences.
C1 [Lehavot, Keren] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Lehavot, Keren] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Molina, Yamile] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Simoni, Jane M.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
RP Lehavot, K (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM klehavot@u.washington.edu
OI Simoni, Jane/0000-0002-8711-1576
FU NCI NIH HHS [P50 CA148143]; NIMH NIH HHS [K24 MH093243]; ODCDC CDC HHS
[R36 CD000996]
NR 58
TC 10
Z9 10
U1 3
U2 21
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-0025
J9 SEX ROLES
JI Sex Roles
PD SEP
PY 2012
VL 67
IS 5-6
BP 272
EP 284
DI 10.1007/s11199-012-0171-1
PG 13
WC Psychology, Developmental; Psychology, Social; Women's Studies
SC Psychology; Women's Studies
GA 985LU
UT WOS:000307268800002
PM 24003263
ER
PT J
AU Novara, G
Ficarra, V
Mocellin, S
Ahlering, TE
Carroll, PR
Graefen, M
Guazzoni, G
Menon, M
Patel, VR
Shariat, SF
Tewari, AK
Van Poppel, H
Zattoni, F
Montorsi, F
Mottrie, A
Rosen, RC
Wilson, TG
AF Novara, Giacomo
Ficarra, Vincenzo
Mocellin, Simone
Ahlering, Thomas E.
Carroll, Peter R.
Graefen, Markus
Guazzoni, Giorgio
Menon, Mani
Patel, Vipul R.
Shariat, Shahrokh F.
Tewari, Ashutosh K.
Van Poppel, Hendrik
Zattoni, Filiberto
Montorsi, Francesco
Mottrie, Alexandre
Rosen, Raymond C.
Wilson, Timothy G.
TI Systematic Review and Meta-analysis of Studies Reporting Oncologic
Outcome After Robot-assisted Radical Prostatectomy
SO EUROPEAN UROLOGY
LA English
DT Review
DE Prostatic neoplasms; Prostatectomy; Laparoscopy; Robotics
ID POSITIVE SURGICAL MARGINS; LEARNING-CURVE; LAPAROSCOPIC PROSTATECTOMY;
FUNCTIONAL OUTCOMES; PERIOPERATIVE OUTCOMES; CANCER CONTROL; RETROPUBIC
PROSTATECTOMY; SINGLE-SURGEON; CONTINENCE OUTCOMES; FOLLOW-UP
AB Context: Despite the large diffusion of robot-assisted radical prostatectomy (RARP), literature and data on the oncologic outcome of RARP are limited.
Objective: Evaluate lymph node yield, positive surgical margins (PSMs), use of adjuvant therapy, and biochemical recurrence (BCR)-free survival following RARP and perform a cumulative analysis of all studies comparing the oncologic outcomes of RARP and retropubic radical prostatectomy (RRP) or laparoscopic radical prostatectomy (LRP).
Evidence acquisition: A systematic review of the literature was performed in August 2011, searching Medline, Embase, and Web of Science databases. A free-text protocol using the term radical prostatectomy was applied. The following limits were used: humans; gender (male); and publications dating from January 1, 2008. A cumulative analysis was conducted using Review Manager software v. 4.2 (Cochrane Collaboration, Oxford, UK) and Stata 11.0 SE software (StataCorp, College Station, TX, USA).
Evidence synthesis: We retrieved 79 papers evaluating oncologic outcomes following RARP. The mean PSM rate was 15% in all comers and 9% in pathologically localized cancers, with some tumor characteristics being the most relevant predictors of PSMs. Several surgeon-related characteristics or procedure-related issues may play a major role in PSM rates. With regard to BCR, the very few papers with a follow-up duration >5 yr demonstrated 7-yr BCR-free survival estimates of approximately 80%. Finally, all the cumulative analyses comparing RARP with RRP and comparing RARP with LRP demonstrated similar overall PSM rates (RARP vs RRP: odds ratio [OR]: 1.21; p = 0.19; RARP vs LRP: OR: 1.12; p = 0.47), pT2 PSM rates (RARP vs RRP: OR: 1.25; p = 0.31; RARP vs LRP: OR: 0.99; p = 0.97), and BCR-free survival estimates (RARP vs RRP: hazard ratio [ HR]: 0.9; p = 0.526; RARP vs LRP: HR: 0.5; p = 0.141), regardless of the surgical approach.
Conclusions: PSM rates are similar following RARP, RRP, and LRP. The few data available on BCR from high-volume centers are promising, but definitive comparisons with RRP or LRP are not currently possible. Finally, significant data on cancer-specific mortality are not currently available. (C) 2012 Published by Elsevier B.V. on behalf of European Association of Urology.
C1 [Novara, Giacomo] Univ Padua, Dept Surg & Oncol Sci, Urol Unit, I-35100 Padua, Italy.
[Ficarra, Vincenzo; Mottrie, Alexandre] OLV Robot Surg Inst, Aalst, Belgium.
[Ahlering, Thomas E.] Univ Calif Irvine, Orange, CA 92668 USA.
[Carroll, Peter R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA.
[Graefen, Markus] Univ Hamburg Eppendorf, Prostate Canc Ctr, Martini Clin, Hamburg, Germany.
[Guazzoni, Giorgio; Montorsi, Francesco] Univ Vita Salute San Raffaele, Milan, Italy.
[Menon, Mani] Henry Ford Hosp, Vattikuti Urol Inst, Detroit, MI 48202 USA.
[Patel, Vipul R.] Florida Hosp Celebrat Hlth, Global Robot Inst, Celebration, FL USA.
[Shariat, Shahrokh F.; Tewari, Ashutosh K.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
[Van Poppel, Hendrik] Katholieke Univ Leuven, Univ Hosp, Louvain, Belgium.
[Rosen, Raymond C.] New England Res Inst Inc, Watertown, MA USA.
[Wilson, Timothy G.] City Hope Natl Canc Ctr, Duarte, CA USA.
RP Novara, G (reprint author), Univ Padua, Dept Surg & Oncol Sci, Urol Unit, Via Giustiniani 2, I-35100 Padua, Italy.
EM giacomonovara@gmail.com
OI Ahlering, Thomas/0000-0002-6492-4910; Guazzoni, Giorgio
Ferruccio/0000-0002-5713-8313
FU Astellas; Eli Lilly; Pierre Fabre; Provenge; Recordati Int.; Takeda;
Intuitive Surgical, Sunnyvale, CA, USA
FX Giacomo Novara certifies that all conflicts of interest, including
specific financial interests and relationships and affiliations relevant
to the subject matter or materials discussed in the manuscript (eg,
employment/affiliation, grants or funding, consultancies, honoraria,
stock ownership or options, expert testimony, royalties, or patents
filed, received, or pending), are the following: Giacomo Novara was
lecturer/advisory board member for Astellas, Eli Lilly, Pierre Fabre,
Provenge, Recordati Int., Takeda. Vincenzo Ficarra was speaker for
Intuitive Surgical, Sunnyvale, CA, USA. Giorgio Guazzoni, Francesco
Montorsi, and Alexandre Mottrie acknowledge receiving research grants
from Intuitive Surgical, Sunnyvale, CA, USA.
NR 104
TC 160
Z9 166
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
J9 EUR UROL
JI Eur. Urol.
PD SEP
PY 2012
VL 62
IS 3
BP 382
EP 404
DI 10.1016/j.eururo.2012.05.047
PG 23
WC Urology & Nephrology
SC Urology & Nephrology
GA 981VM
UT WOS:000306999400013
PM 22749851
ER
PT J
AU McMillan, GP
Konrad-Martin, D
Dille, MF
AF McMillan, Garnett P.
Konrad-Martin, Dawn
Dille, Marilyn F.
TI Accuracy of distortion-product otoacoustic emissions-based ototoxicity
monitoring using various primary frequency step-sizes
SO INTERNATIONAL JOURNAL OF AUDIOLOGY
LA English
DT Article
DE Distortion-product otoacoustic emissions; ototoxicity monitoring;
cisplatin; fine structure
ID FINE-STRUCTURE; MODEL
AB Objective: A cisplatin ototoxicity monitoring protocol was recently proposed using distortion-product otoacoustic emissions (DPOAEs) measured in 1/48th octave steps over the highest obtainable quarter octave (Dille et al, 2010). This protocol can take up to 40 minutes to complete in both ears among seriously ill patients in a potentially noisy test environment. The goal of the current study was to contrast the diagnostic accuracy of ototoxicity monitoring protocols based on changes in DPOAE levels at wider, more rapidly tested, primary frequency step sizes. Design: Measure DPOAE levels in 1/48th octave steps over the highest half-octave of obtainable DPOAEs prior to treatment and at each ototoxicity monitoring session during the course of treatment with cisplatin. Study sample: Nineteen cancer patients being treated with cisplatin at the Portland Veterans Affairs Medical Center were observed over 56 monitoring appointments. Hearing thresholds in the sensitive region for ototoxicity (SRO) were measured concurrently with DPOAE levels. Results: DPOAE levels measured in 1/24th octave steps provided comparable accuracy, and half the testing time, to the 1/48th octave step protocol previously described. Conclusions: DPOAE level shifts measured in 1/24th octave steps may provide a basis for rapid ototoxicity monitoring among adult cancer patients treated with cisplatin.
C1 [McMillan, Garnett P.; Konrad-Martin, Dawn; Dille, Marilyn F.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA.
[Konrad-Martin, Dawn; Dille, Marilyn F.] Oregon Hlth & Sci Univ, Dept Otolaryngol HNS, Portland, OR 97201 USA.
RP McMillan, GP (reprint author), Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM garnett.mcmillan@va.gov
FU Department of Veterans Affairs RRD Service [C4183R, C7113N]; VA RR&D
National Center for Rehabilitative Auditory Research, Portland, Oregon,
USA
FX Work supported by the Department of Veterans Affairs RR&D Service
(grants C4183R and C7113N) and the VA RR&D National Center for
Rehabilitative Auditory Research, Portland, Oregon, USA. Helpful
comments were provided by an anonymous reviewer to an early draft of
this paper.
NR 15
TC 3
Z9 3
U1 1
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1499-2027
J9 INT J AUDIOL
JI Int. J. Audiol.
PD SEP
PY 2012
VL 51
IS 9
BP 689
EP 696
DI 10.3109/14992027.2012.688143
PG 8
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 986QY
UT WOS:000307360500006
PM 22676700
ER
PT J
AU Anaya, HD
Bokhour, B
Feld, J
Golden, JF
Asch, SM
Knapp, H
AF Anaya, Henry D.
Bokhour, Barbara
Feld, Jamie
Golden, Joya F.
Asch, Steven M.
Knapp, Herschel
TI Implementation of Routine Rapid HIV Testing Within the US Department of
Veterans Affairs Healthcare System
SO JOURNAL FOR HEALTHCARE QUALITY
LA English
DT Article
DE rapid HIV testing; nurse-initiated health interventions; implementation;
evaluation
AB Current HIV testing methods can be ineffective; patients often do not return for results. HIV rapid testing (RT) provides accurate results in 20 min. Patients find nurse-initiated HIV rapid testing (NRT) more acceptable than current testing methods and increases receipt of test results. Translating research findings into sustainable practice poses widely recognized implementation challenges. To ascertain effectiveness of NRT implementation, formative and process evaluations were conducted within the U. S. Department of Veterans Affairs Healthcare System (VA). Nurses and physicians at 2 VA medical centers were trained to administer RT. A preimplementation formative evaluation was conducted at Site 1. Process evaluations of ongoing RT activities were conducted at Site 2. Interviews were conducted with key informants. Content and thematic analysis was conducted on the field notes. A variety of barriers and facilitators were discovered that impacted the implementation of NRT. Findings indicate concerns regarding training and incorporating NRT into workflow. Process interviews indicated that training concerns could be alleviated through various means. Finally, interviewees highlighted that other clinic settings might be a more preferred setting for NRT than primary care. Findings are currently being used for the implementation of additional NRT interventions, and can also guide NRT adoption in other facilities.
C1 [Anaya, Henry D.] US Dept Vet Affairs VA, West Los Angeles, CA USA.
[Anaya, Henry D.] Univ Calif Los Angeles, Dept Biobehav Sci, Neuropsychiat Inst, Los Angeles, CA 90024 USA.
Univ Calif Los Angeles, Ctr HIV Prevent & Treatment Serv, Los Angeles, CA 90024 USA.
[Anaya, Henry D.; Golden, Joya F.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Bokhour, Barbara] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA.
[Bokhour, Barbara] US Dept Vet Affairs, Ctr Hlth Qual, Bedford, MA USA.
[Feld, Jamie; Golden, Joya F.; Asch, Steven M.] US Dept Vet Affairs, West Los Angeles, CA USA.
[Feld, Jamie] United Nations Observ Urbano, Cordoba, Argentina.
[Asch, Steven M.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Asch, Steven M.] Robert Wood Johnson Clin Scholars Program, Chapel Hill, NC USA.
RP Anaya, HD (reprint author), US Dept Vet Affairs VA, West Los Angeles, CA USA.
EM henry.anaya@va.gov
OI Bokhour, Barbara/0000-0001-8238-0745
FU VHA
FX The authors would like to thank B. Lane Turzan, Brenda Rue, Rebecca
Jones, and Alicia Alcantara for their assistance on this project. We
would also like to acknowledge Jaimi Butler for her substantive review
and editorial suggestions and comments. The views and opinions expressed
in this article are those of the author(s) and do not necessarily
represent the views of the U.S. Department of Veterans Affairs. The VHA
supported this study but had no input in the design or reporting, or
decision to submit this paper for publication. This study was reviewed
and sanctioned by a U.S. Department of Veterans Affairs Internal Review
Board (IRB) process.
NR 18
TC 11
Z9 11
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1062-2551
EI 1945-1474
J9 J HEALTHC QUAL
JI J. Healthc. Qual.
PD SEP-OCT
PY 2012
VL 34
IS 5
BP 7
EP 14
DI 10.1111/j.1945-1474.2011.00151.x
PG 8
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA V36OP
UT WOS:000209221300001
PM 22060061
ER
PT J
AU Burney, BO
Garcia, JM
AF Burney, Basil O.
Garcia, Jose M.
TI Hypogonadism in male cancer patients
SO JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
LA English
DT Review
DE Inflammation; Leptin; Ghrelin; Cachexia; Sarcopenia
ID GONADOTROPIN-RELEASING-HORMONE; ANDROGEN REPLACEMENT THERAPY;
QUALITY-OF-LIFE; LUTEINIZING-HORMONE; SEXUAL FUNCTION; TESTOSTERONE
LEVELS; BODY-COMPOSITION; ORAL OPIOIDS; AGING MALES; HEALTHY-MEN
AB Prevalence of hypogonadism in men with cancer has been reported between 40% and 90%, which is significantly higher than in the general population. Hypogonadism is likely to affect the quality of life in these patients by contributing to non-specific symptoms, including decreased energy, anorexia, sarcopenia, weight loss, depression, insomnia, fatigue, weakness, and sexual dysfunction. Pathogenesis of hypogonadism in cancer patients is thought to be multi-factorial. Inflammation may play an important role, but leptin, opioids, ghrelin, and high-dose chemotherapy through different mechanisms have all been implicated as the cause. Hypogonadism is also associated with poor survival in cancer patients. Data looking into the treatment of hypogonadal male cancer patients with testosterone are limited. However, improvements in body weight, muscle strength, lean body mass, and quality of life have been shown in hypogonadal men with other chronic diseases on testosterone replacement therapy. Prospective and interventional trials are needed to test the efficacy and safety of testosterone treatment in improving quality of life of these patients.
C1 [Burney, Basil O.; Garcia, Jose M.] Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Garcia, JM (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,Bldg 109,Rm 210, Houston, TX 77030 USA.
EM jgarcia1@bcm.edu
FU Abbott
FX JMG receives research support from and is a consultant with Abbott.
NR 60
TC 12
Z9 12
U1 0
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-5991
J9 J CACHEXIA SARCOPENI
JI J. Caxhexia Sarcopenia Muscle
PD SEP
PY 2012
VL 3
IS 3
BP 149
EP 155
DI 10.1007/s13539-012-0065-7
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 218WO
UT WOS:000324463400002
PM 22528986
ER
PT J
AU Cohen, BE
Maguen, S
Bertenthal, D
Shi, Y
Jacoby, V
Seal, KH
AF Cohen, Beth E.
Maguen, Shira
Bertenthal, Daniel
Shi, Ying
Jacoby, Vanessa
Seal, Karen H.
TI Reproductive and Other Health Outcomes in Iraq and Afghanistan Women
Veterans Using VA Health Care: Association with Mental Health Diagnoses
SO WOMENS HEALTH ISSUES
LA English
DT Article
AB Background: An increasing number of women serve in the military and are exposed to trauma during service that can lead to mental health problems. Understanding how these mental health problems affect reproductive and physical health outcomes will inform interventions to improve care for women veterans.
Methods: We analyzed national Department of Veterans Affairs (VA) data from women Iraq and Afghanistan veterans who were new users of VA healthcare from October 7, 2001, through December 31, 2010 (n = 71,504). We used ICD-9 codes to categorize veterans into five groups by mental health diagnoses (MH Dx): Those with no MH Dx, posttraumatic stress disorder (PTSD), depression, comorbid PTSD and depression, and a MH Dx other than PTSD and depression. We determined the association between mental health category and reproductive and other physical health outcomes defined by ICD-9 codes. Categories included sexually transmitted infections, other infections (e. g., urinary tract infections), pain-related conditions (e. g., dysmenorrhea and dsypareunia), and other conditions (e. g., polycystic ovarian syndrome, infertility, sexual dysfunction). Models were adjusted for sociodemographic and military service factors.
Results: There were 31,481 patients (44%) who received at least one mental health diagnosis. Women veterans with any mental health diagnosis had significantly higher prevalences of nearly all categories of reproductive and physical disease diagnoses (p < .0001 for adjusted prevalences). There was a trend of increasing prevalence of disease outcomes in women with PTSD, depression, and comorbid PTSD and depression (p for trend <.0001 for all outcomes).
Conclusions: Iraq and Afghanistan women veterans with mental health diagnoses had significantly greater prevalences of several important reproductive and physical health diagnoses. These results provide support for VA initiatives to address mental and physical health concerns and improve comprehensive care for women veterans. Published by Elsevier Inc.
C1 [Cohen, Beth E.; Maguen, Shira; Bertenthal, Daniel; Shi, Ying; Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Cohen, Beth E.; Maguen, Shira; Bertenthal, Daniel; Jacoby, Vanessa; Seal, Karen H.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Jacoby, Vanessa] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Bertenthal, Daniel; Seal, Karen H.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA USA.
RP Cohen, BE (reprint author), 4150 Clement St, San Francisco, CA 94121 USA.
EM beth.cohen@va.gov
FU NHLBI NIH HHS [K23 HL 094765-01, K23 HL094765]
NR 63
TC 18
Z9 18
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD SEP-OCT
PY 2012
VL 22
IS 5
BP E461
EP E471
DI 10.1016/j.whi.2012.06.005
PG 11
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA V33ST
UT WOS:000209039200007
PM 22944901
ER
PT J
AU Katon, J
Maynard, C
Reiber, G
AF Katon, Jodie
Maynard, Charles
Reiber, Gayle
TI Attempts at Weight Loss in US Women with and without a History of
Gestational Diabetes Mellitus
SO WOMENS HEALTH ISSUES
LA English
DT Article
AB Background and Objective: Gestational diabetes mellitus (GDM) is a risk factor for type 2 diabetes. Relatively modest weight loss can delay or prevent the onset of type 2 diabetes. The objective of this study was to determine, using a nationally representative survey, whether among women without diabetes, those with a history of GDM (hGDM) were more likely than those without hGDM to be currently attempting weight loss.
Methods: This study used data from the 2003 Behavioral Risk Factor Surveillance System, a national, population-based, random-sample telephone survey. Women aged 18 to 44 years without diabetes who answered questions related to current weight loss activity were included in the analysis. The primary outcome was currently attempting weight loss. Logistic regression was used to analyze the association between hGDM and currently attempting weight loss.
Results: We included 53,608 women without diabetes: 1,260 (2%) with hGDM, and 52,348 (98%) without hGDM. Among women with hGDM, 53% were currently attempting weight loss compared with 47% of women without hGDM. Overall, after adjusting for age, race/ethnicity, education, marital status, and medical insurance, compared with women without hGDM, those with hGDM had 20% higher odds of currently attempting weight loss (95% confidence interval [CI], 0.97-1.49); however, among obese women (body mass index >= 30 kg/m(2)), compared with women without hGDM, those with hGDM had 46% lower odds of currently attempting weight loss (95% CI, 0.35-0.82).
Conclusions: Obese women with hGDM are less likely to be currently attempting weight loss compared with those without hGDM. Effective interventions for obese women with hGDM are needed. Published by Elsevier Inc.
C1 [Katon, Jodie; Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Maynard, Charles; Reiber, Gayle] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA USA.
[Maynard, Charles; Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
RP Katon, J (reprint author), Univ Washington, Sch Publ Hlth, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA.
EM jkaton@u.washington.edu
RI Maynard, Charles/N-3906-2015
OI Maynard, Charles/0000-0002-1644-7814
FU NICHD NIH HHS [T32 HD052462]
NR 23
TC 2
Z9 2
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD SEP-OCT
PY 2012
VL 22
IS 5
BP E447
EP E453
DI 10.1016/j.whi.2012.07.004
PG 7
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA V33ST
UT WOS:000209039200005
PM 22944900
ER
PT J
AU Bromley, E
AF Bromley, Elizabeth
TI Building patient-centeredness: Hospital design as an interpretive act
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE Patient-centeredness; Hospital design; USA; Medical professionalism;
Consumerism; Patienthood
ID HEALTH-CARE; MEDICAL PROFESSIONALISM; THERAPEUTIC LANDSCAPES;
SATISFACTION; TECHNOLOGY; COMMUNICATION; PHYSICIAN; ENCOUNTER; ILLNESS;
ISSUES
AB Hospital designs reflect the sociocultural, economic, professional, and aesthetic priorities prevalent at a given time. As such, hospital buildings concretize assumptions about illness, care and healing, patienthood, and medical providers' roles. Trends in hospital design have been attributed to the increasing influence of consumerism on healthcare, the influx of business-oriented managers, and technological changes. This paper describes the impact of the concept of patient-centeredness on the design of a new hospital in the USA. Data come from 35 interviews with planners, administrators, and designers of the new hospital, as well as from public documents about the hospital design. Thematic content analysis was used to identify salient design principles and intents. For these designers, administrators, and planners, an interpretation of patient-centeredness served as a heuristic, guiding the most basic decisions about space, people, and processes in the hospital. 1 detail the particular interpretation of patient-centeredness used to build and manage the new hospital space and the roles and responsibilities of providers working within it. Three strategies were central to the implementation of patient-centeredness: an onstage/offstage layout; a concierge approach to patients; and the scripting of communication. I discuss that this interpretation of patient-centeredness may challenge medical professionals' roles, may construct medical care as a product that should sate the patient's desire, and may distance patients from the realities of medical care. By describing the ways in which hospital designs reflect and reinforce contemporary concepts of patienthood and caring, this paper raises questions about the implementation of patient-centeredness that deserve further empirical study by medical social scientists. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Bromley, Elizabeth] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Ctr Hlth Serv & Soc, Los Angeles, CA 90024 USA.
[Bromley, Elizabeth] W Los Angeles VA Healthcare Ctr, VA Desert Pacific Mental Illness Res Educ & Clin, Los Angeles, CA USA.
RP Bromley, E (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Ctr Hlth Serv & Soc, Los Angeles, CA 90024 USA.
EM ebromley@ucla.edu
FU UniHealth Foundation
FX This study was funded by the UniHealth Foundation. An earlier version of
this paper was presented to the American Anthropological Association
annual meeting November 2010 in New Orleans, LA. The author wishes to
thank Lisa Mikesell, Marian Katz, Susan Stockdale, Joseph Mango,
Elizabeth O'Toole, Stefan Timmermans, Kenneth B. Wells, Peter Whybrow,
Joel T. Braslow, Neil Wenger, and James B. Atkinson for invaluable
contributions to this research. The author also gratefully acknowledges
anonymous reviewers for their insightful comments.
NR 101
TC 16
Z9 16
U1 3
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD SEP
PY 2012
VL 75
IS 6
BP 1057
EP 1066
DI 10.1016/j.socscimed.2012.04.037
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 979LQ
UT WOS:000306821900013
PM 22703887
ER
PT J
AU Liu, XH
Joshi, SK
Samagh, SP
Dang, YX
Laron, D
Lovett, DH
Bodine, SC
Kim, HT
Feeley, BT
AF Liu, Xuhui
Joshi, Sunil K.
Samagh, Sanjum P.
Dang, Yu-Xuan
Laron, Dominique
Lovett, David H.
Bodine, Sue C.
Kim, Hubert T.
Feeley, Brian T.
TI Evaluation of Akt/mTOR activity in muscle atrophy after rotator cuff
tears in a rat model
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE muscle atrophy; rotator cuff tear; Akt; mTOR; denervation
ID FOXO TRANSCRIPTION FACTORS; SKELETAL-MUSCLE; UBIQUITIN LIGASES; FATTY
INFILTRATION; EXPRESSION; PATHWAY; SUPRASPINATUS; HYPERTROPHY;
ATROGIN-1; REVEALS
AB Atrophy of the rotator cuff muscles is a factor that complicates the treatment of a massive rotator cuff tear (RCT). However, the molecular mechanisms that govern the development of muscle atrophy after RCTs have not been well defined. The Akt/mammalian target of rapamycin (mTOR) signaling pathway plays a central role in maintaining muscle mass in response to mechanical loading. The role of this pathway in the development of muscle atrophy after a massive RCT remains unknown. The purpose of this study was to investigate the regulation of the Akt/mTOR pathway in the development of muscle atrophy after a RCT and suprascapular nerve (SSN) injury. We evaluated the activity of the Akt/mTOR signaling pathway and how this pathway interacts with two atrophy-related genes, MuRF-1 and MAFbx, in supraspinatus muscles of rats that underwent unilateral complete rotator cuff tendon transection or SSN transection. Akt/mTOR activity was significantly reduced after tendon rupture, but increased after nerve injury. MuRF-1 and MAFbx were only up-regulated following denervation. These results suggest that tendon transection leads to a decrease in protein synthesis with down-regulation of the Akt/mTOR signaling pathway, whereas denervation leads to an increase in protein degradation via up-regulation of expression of MuRF-1 and MAFbx. (C) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:14401446, 2012
C1 [Liu, Xuhui; Joshi, Sunil K.; Dang, Yu-Xuan; Lovett, David H.; Kim, Hubert T.; Feeley, Brian T.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA.
[Liu, Xuhui; Samagh, Sanjum P.; Laron, Dominique; Kim, Hubert T.; Feeley, Brian T.] Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA 94143 USA.
[Lovett, David H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Bodine, Sue C.] Univ Calif Davis, Dept Physiol & Membrane Biol, Davis, CA 95616 USA.
RP Feeley, BT (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA.
EM feeleyb@orthosurg.ucsf.edu
FU Orthopaedic Research & Education Foundation (OREF); VA RRD [RX000195]
FX This work was supported by the Orthopaedic Research & Education
Foundation (OREF) and VA RR&D (grant #: RX000195).
NR 24
TC 15
Z9 15
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD SEP
PY 2012
VL 30
IS 9
BP 1440
EP 1446
DI 10.1002/jor.22096
PG 7
WC Orthopedics
SC Orthopedics
GA 972WH
UT WOS:000306311400013
PM 22378614
ER
PT J
AU Gan, Y
Ji, XM
Hu, XM
Luo, YM
Zhang, LL
Li, PY
Liu, XR
Yan, F
Vosler, P
Gao, YQ
Stetler, RA
Chen, J
AF Gan, Yu
Ji, Xunming
Hu, Xiaoming
Luo, Yumin
Zhang, Lili
Li, Peiying
Liu, Xiangrong
Yan, Feng
Vosler, Peter
Gao, Yanqin
Stetler, R. Anne
Chen, Jun
TI Transgenic Overexpression of Peroxiredoxin-2 Attenuates Ischemic
Neuronal Injury Via Suppression of a Redox-Sensitive Pro-Death Signaling
Pathway
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article
ID FOCAL CEREBRAL-ISCHEMIA; CYSTEINE SULFINIC ACID; CENTRAL-NERVOUS-SYSTEM;
OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION; BRAIN-INJURY; CELL-DEATH;
APOPTOSIS; THIOREDOXIN; STROKE
AB Aims: Peroxiredoxins (PRXs) are a newly characterized family of peroxide scavenging enzymes that not only help maintain cellular redox homeostasis but also may directly engage in a variety of intracellular signaling pathways. PRX2 is a neuronal-specific PRX believed to participate in cerebral antioxidant responses in several neurodegenerative diseases. This study investigates the potential neuroprotective effect and the underlying mechanism of PRX2 in models of ischemic neuronal injury. Results: Transgenic mice overexpressing PRX2 showed reduced brain injury and improved neurological recovery up to 3 weeks after transient focal cerebral ischemia compared to wild-type littermates. In primary cultures of cortical neurons, transfection of PRX2 but not the loss-of-catalytic-site PRX2 mutant conferred neuroprotection against cell death induced by oxygen glucose deprivation. PRX2 exhibited potent pro-survival effects in ischemic neurons by maintaining thioredoxin (Trx) in its reduced state, thereby preventing oxidative stress-mediated activation of apoptosis signal-regulating kinase 1 (ASK1) and the downstream MKK/JNK pro-death signaling pathway. PRX2 failed to provide additional neuroprotection against ischemic injury in Trx- or ASK1-knockdown neuron cultures and in mice treated with a JNK inhibitor. Innovation: This study provides evidence that neuronal overexpression of PRX2 confers prolonged neuroprotection against ischemic/reperfusion brain injury. Moreover, the results suggest a signaling pathway by which PRX2 suppresses ischemia-induced neuronal apoptosis. Conclusions: Enhanced neuronal expression and activity of PRX2 protect against ischemic neuronal injury by directly modulating the redox-sensitive Trx-ASK1 signaling complex. Antioxid. Redox Signal. 17, 719-732.
C1 [Gan, Yu; Ji, Xunming; Luo, Yumin; Liu, Xiangrong; Yan, Feng] Capital Med Univ, Dept Neurosurg, Xuanwu Hosp, Beijing 100053, Peoples R China.
[Gan, Yu; Ji, Xunming; Luo, Yumin; Liu, Xiangrong; Yan, Feng] Capital Med Univ, Cerebrovasc Dis Res Inst, Xuanwu Hosp, Beijing 100053, Peoples R China.
[Gan, Yu; Hu, Xiaoming; Zhang, Lili; Li, Peiying; Vosler, Peter; Gao, Yanqin; Stetler, R. Anne; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA.
[Hu, Xiaoming; Zhang, Lili; Stetler, R. Anne; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Ji, XM (reprint author), Capital Med Univ, Dept Neurosurg, Cerebrovasc Dis Res Inst, Beijing 100053, Peoples R China.
EM Jixm70@hotmail.com
RI Gao, Yanqin/I-6790-2016
OI Gao, Yanqin/0000-0002-4915-9819
FU Chinese Natural Science Foundation [30870854]; Chinese Ministry of
Education [NCET-08-0625]; NIH [NS036736, NS043802, NS045048]; AHA
[10POST4150028]
FX This work was supported by Chinese Natural Science Foundation Grant
#30870854 (to X.J.), Chinese Ministry of Education Grant NCET-08-0625
(to XJ), and NIH Grants NS036736, NS043802, and NS045048 (to JC).
Xiaoming Hu is supported by AHA grant 10POST4150028. We thank Carol
Culver and Susan Giegel for their excellent editorial assistance.
NR 43
TC 29
Z9 29
U1 3
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD SEP
PY 2012
VL 17
IS 5
BP 719
EP 732
DI 10.1089/ars.2011.4298
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 969TQ
UT WOS:000306082000001
PM 22356734
ER
PT J
AU Strachan, M
Gros, DF
Ruggiero, KJ
Lejuez, CW
Acierno, R
AF Strachan, Martha
Gros, Daniel F.
Ruggiero, Kenneth J.
Lejuez, Carl W.
Acierno, Ron
TI An Integrated Approach to Delivering Exposure-Based Treatment for
Symptoms of PTSD and Depression in OIF/OEF Veterans: Preliminary
Findings
SO BEHAVIOR THERAPY
LA English
DT Article
DE PTSD; Behavioral Activation Exposure; telehealth; OEF/OIF
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS;
COGNITIVE-BEHAVIORAL THERAPY; PROLONGED EXPOSURE; PSYCHOMETRIC
PROPERTIES; MAJOR DEPRESSION; RANDOMIZED-TRIAL; COMBAT; ACTIVATION; IRAQ
AB Combat-exposed military personnel from the wars in Iraq and Afghanistan report high rates of PTSD and associated psychiatric problems. A formidable body of research supports exposure therapy as a front-line intervention for PTSD; however, relative to studies of civilians, fewer investigations have evaluated the effectiveness of exposure therapy using military samples. Specifically, barriers to care (e.g., stigma associated with receiving mental health services) may compromise utilization of evidence-based psychotherapy. As such, researchers have argued that veterans with PTSD may require an integrated and innovative approach to the delivery of exposure techniques. This paper presents the rationale for and preliminary data from an ongoing clinical trial that compares the home-based telehealth (HET) application of a brief, behavioral treatment (Behavioral Activation and Therapeutic Exposure; BA-TE) for veterans with PTSD to the standard, in-person application of the same treatment. Forty OIF/OEF veterans with PTSD and MDD were consented, enrolled, and randomized to condition (BA-TE in-person, or BA-TE HBT) and symptoms of anxiety and depression were assessed at pre- and posttreatment. Participants in both conditions experienced reductions in depression, anxiety, and PTSD symptoms between pre- and posttreatment, suggesting that HBT application of an integrated PTSD treatment may be feasible and effective.
C1 [Strachan, Martha] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Strachan, Martha; Gros, Daniel F.; Ruggiero, Kenneth J.; Acierno, Ron] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
[Lejuez, Carl W.] Univ Maryland, College Pk, MD 20742 USA.
RP Strachan, M (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,2-S, Charleston, SC 29425 USA.
EM stracham@musc.edu
NR 58
TC 36
Z9 36
U1 7
U2 32
PU ASSOC ADV BEHAVIOR THERAPY
PI NEW YORK
PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA
SN 0005-7894
J9 BEHAV THER
JI Behav. Therapy
PD SEP
PY 2012
VL 43
IS 3
BP 560
EP 569
PG 10
WC Psychology, Clinical
SC Psychology
GA 964BB
UT WOS:000305667600009
PM 22697444
ER
PT J
AU Le, HQ
Batterman, SA
Wirth, JJ
Wahl, RL
Hoggatt, KJ
Sadeghnejad, A
Hultin, ML
Depa, M
AF Le, Hien Q.
Batterman, Stuart A.
Wirth, Julia J.
Wahl, Robert L.
Hoggatt, Katherine J.
Sadeghnejad, Alireza
Hultin, Mary Lee
Depa, Michael
TI Air pollutant exposure and preterm and term small-for-gestational-age
births in Detroit, Michigan: Long-term trends and associations
SO ENVIRONMENT INTERNATIONAL
LA English
DT Article
DE Ambient air pollution; Term low birth weight; Term
small-for-gestational-age; Preterm birth
ID OF-THE-LITERATURE; CARBON-MONOXIDE; PARTICULATE MATTER; PREGNANCY
OUTCOMES; FETAL-GROWTH; LOS-ANGELES; DEVELOPMENTAL TOXICITY; SOUTHERN
CALIFORNIA; MATERNAL EXPOSURE; CHILDREN BORN
AB Studies in a number of countries have reported associations between exposure to ambient air pollutants and adverse birth outcomes, including low birth weight, preterm birth (PTB) and, less commonly, small for gestational age (SGA). Despite their growing number, the available studies have significant limitations, e.g., incomplete control of temporal trends in exposure, modest sample sizes, and a lack of information regarding individual risk factors such as smoking. No study has yet examined large numbers of susceptible individuals. We investigated the association between ambient air pollutant concentrations and term SGA and PTB outcomes among 164,905 singleton births in Detroit, Michigan occurring between 1990 and 2001. SO2, CO, NO2, O-3 and PM10 exposures were used in single and multiple pollutant logistic regression models to estimate odds ratios (OR) for these outcomes, adjusted for the infant's sex and gestational age, the mother's race, age group, education level, smoking status and prenatal care, birth season, site of residence, and long-term exposure trends.
Term SGA was associated with CO levels exceeding 0.75 ppm (OR = 1.14, 95% confidence interval = 1.02-1.27) and NO2 exceeding 6.8 ppb (1.11, 1.03-1.21) exposures in the first month, and with PM10 exceeding 35 mu g/m(3) (1.22, 1.03-1.46) and O-3 (1.11, 1.02-1.20) exposure in the third trimester. PTB was associated with SO2 (1.07, 1.01-1.14) exposure in the last month, and with (hourly) O-3 exceeding 92 ppb (1.08, 1.02-1.14) exposure in the first month.
Exposure to several air pollutants at modest concentrations was associated with adverse birth outcomes. This study, which included a large Black population, suggests the importance of the early period of pregnancy for associations between term SGA with CO and NO2, and between O-3 with PTB; and the late pregnancy period for associations between term SGA and O-3 and PM10, and between SO2 with PTB. It also highlights the importance of accounting for individual risk factors such as maternal smoking, maternal race, and long-term trends in air pollutant levels and adverse birth outcomes in evaluating relationships between pollutant exposures and adverse birth outcomes. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Le, Hien Q.; Batterman, Stuart A.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Wirth, Julia J.; Sadeghnejad, Alireza] Michigan State Univ, E Lansing, MI 48824 USA.
[Wirth, Julia J.; Wahl, Robert L.] Michigan Dept Community Hlth, Lansing, MI USA.
[Hoggatt, Katherine J.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Hoggatt, Katherine J.] VA Greater Los Angeles, Los Angeles, CA USA.
[Hultin, Mary Lee; Depa, Michael] Michigan Dept Environm Qual, Lansing, MI USA.
RP Batterman, SA (reprint author), Univ Michigan, Ann Arbor, MI 48109 USA.
EM stuartb@umich.edu
OI Batterman, Stuart/0000-0001-9894-5325
FU Agency for Toxic Substances and Disease Registry [572305]
FX This study was in part supported by Cooperative Agreement Number 572305
from the Agency for Toxic Substances and Disease Registry.
NR 62
TC 20
Z9 22
U1 1
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0160-4120
J9 ENVIRON INT
JI Environ. Int.
PD SEP 1
PY 2012
VL 44
BP 7
EP 17
DI 10.1016/j.envint.2012.01.003
PG 11
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 951UQ
UT WOS:000304745900002
PM 22314199
ER
PT J
AU Bush, AL
Armento, MEA
Weiss, BJ
Rhoades, HM
Novy, DM
Wilson, NL
Kunik, ME
Stanley, MA
AF Bush, Amber L.
Armento, Maria E. A.
Weiss, Brandon J.
Rhoades, Howard M.
Novy, Diane M.
Wilson, Nancy L.
Kunik, Mark E.
Stanley, Melinda A.
TI The Pittsburgh Sleep Quality Index in older primary care patients with
generalized anxiety disorder: Psychometrics and outcomes following
cognitive behavioral therapy
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Pittsburgh Sleep Quality Index; Psychometrics; Generalized anxiety
disorder; Elderly; Cognitive behavioral therapy
ID PERCEIVED SOCIAL SUPPORT; MULTIDIMENSIONAL SCALE; ADULTS; INSOMNIA;
DEPRESSION; COMPLAINTS; SYMPTOMS; EFFICACY; OPTIMISM; HEALTH
AB The Pittsburgh Sleep Quality Index (PSQI) is a widely used, comprehensive self-report measure of sleep quality and impairment, which has demonstrated good psychometric properties within various populations, including older adults. However, the psychometric properties of the PSQI and its component scores have not been evaluated for older adults with generalized anxiety disorder (GAD). Additionally, changes in PSQI global or component scores have not been reported following cognitive-behavioral treatment (CBT) of late-life GAD. This study examined (1) the psychometric properties of the PSQI within a sample of 216 elderly primary care patients age 60 or older with GAD who were referred for treatment of worry and/or anxiety; as well as (2) response to CBT, relative to usual care, for 134 patients with principal or coprincipal GAD. The PSQI demonstrated good internal consistency reliability and adequate evidence of construct validity. Those receiving CBT experienced greater reductions in PSQI global scores at post-treatment, relative to those receiving usual care. Further, PSQI global and component scores pertaining to sleep quality and difficulties falling asleep (i.e., sleep latency and sleep disturbances) demonstrated response to treatment over a 12-month follow-up period. Overall, results highlight the usefulness of the PSQI global and component scores for use in older adults with GAD. Published by Elsevier Ireland Ltd.
C1 [Bush, Amber L.; Armento, Maria E. A.; Wilson, Nancy L.; Kunik, Mark E.; Stanley, Melinda A.] Houston VA Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Bush, Amber L.; Armento, Maria E. A.; Kunik, Mark E.; Stanley, Melinda A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Weiss, Brandon J.] Univ Nebraska Lincoln, Dept Psychol, Lincoln, NE USA.
[Rhoades, Howard M.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, DC USA.
[Novy, Diane M.] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Pain Med, Houston, TX 77030 USA.
[Wilson, Nancy L.] Baylor Coll Med, Dept Internal Med, Sect Geriatr, Houston, TX 77030 USA.
RP Bush, AL (reprint author), Hlth Serv Res & Dev Ctr Excellence, 2002 Holcombe Blvd,MEDVAMC 152, Houston, TX 77030 USA.
EM amspoker@bcm.tmc.edu
FU National Institute of Mental Health [53932]; Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development; Houston VA Health Services Research and Development Center
of Excellence [HFP90-020]
FX This research was supported by Grant 53932 from the National Institute
of Mental Health to the last author and was party supported by The
Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, and the Houston VA Health Services Research
and Development Center of Excellence (HFP90-020). The content is solely
the responsibility of the authors and does not necessarily represent the
official views of the NIMH, the National Institutes of health, the
Department of Veterans Affairs, the US Government, or Baylor College of
Medicine. The NIMH had no role in the design and conduct of the study;
the collection, management, analysis, and interpretation of the data; or
the preparation, review or approval of the manuscript. We thank Anthony
Greisinger and the staff of the Kelsey Research Foundation and
Kelsey-Seybold Clinic, who provided consultation and assisted with
recruitment. Portions of this work were presented at the 2008 convention
for the Association for Behavioral and Cognitive Therapies, November,
Orlando, FL.
NR 47
TC 16
Z9 16
U1 2
U2 20
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD AUG 30
PY 2012
VL 199
IS 1
BP 24
EP 30
DI 10.1016/j.psychres.2012.03.045
PG 7
WC Psychiatry
SC Psychiatry
GA 050HS
UT WOS:000312045000005
PM 22503380
ER
PT J
AU Goldstein, G
Luther, JF
Haas, GL
AF Goldstein, Gerald
Luther, James Francis
Haas, Gretchen Louise
TI Medical, psychiatric and demographic factors associated with suicidal
behavior in homeless veterans
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Suicide; Homelessness; Logistic regression
ID MENTAL-ILLNESS; AMERICAN VETERANS; SUBSTANCE-ABUSE; IDEATION; RISK;
DISORDERS; MODEL; PEOPLE; ILL
AB This study assessed potential for suicidal behaviors associated with sociodemographic, predisposing physical and mental health factors and self-reported psychological problems among homeless veterans in a large northeastern region. Data were obtained from a demographic and clinical history interview conducted with 3595 homeless veterans. Odds-ratio (OR) statistics were used to assess potential for suicidal behavior. Statistically significant ratios were similar for ideation and attempts. The highest ratios were for self-report of depression and difficulty controlling violence, but statistically significant ratios were found for reporting sleeping in a treatment facility the night before the interview, receiving VA support for a psychiatric condition, and the diagnoses of Alcoholism, Mood Disorder and Post Traumatic Stress Disorder (PTSD). Low but statistically significant odds-ratios were obtained for most of the physical health items. A negative odds-ratio was obtained for African-American ethnicity. Logistic regression results indicated that for ideation and attempts items entered first involved subjective report of trouble controlling violent behavior and experiencing depression. High odds ratios for the interview items concerning experiencing serious depression and having difficulties controlling violence may have strong implications for treatment and management of homeless veterans. There may be up to 14-1 odds that an individual who reports being seriously depressed or having difficulty inhibiting aggression may have a serious potential for suicidal behaviors. Published by Elsevier Ireland Ltd.
C1 [Goldstein, Gerald; Luther, James Francis; Haas, Gretchen Louise] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA.
[Goldstein, Gerald; Luther, James Francis; Haas, Gretchen Louise] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, 7180 Highland Dr,151R, Pittsburgh, PA 15206 USA.
EM ggold@nb.net
FU Mental Illness Research, Educational and Clinical Center, VA Pittsburgh
Healthcare System, Pittsburgh, PA; Medical Research Service, Department
of Veterans Affairs
FX This research was supported by the Mental Illness Research, Educational
and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA,
and the Medical Research Service, Department of Veterans Affairs.
NR 23
TC 7
Z9 7
U1 1
U2 17
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD AUG 30
PY 2012
VL 199
IS 1
BP 37
EP 43
DI 10.1016/j.psychres.2012.03.029
PG 7
WC Psychiatry
SC Psychiatry
GA 050HS
UT WOS:000312045000007
PM 22521899
ER
PT J
AU Baker, BM
Shah, RP
Silverstein, AM
Esterhai, JL
Burdick, JA
Mauck, RL
AF Baker, Brendon M.
Shah, Roshan P.
Silverstein, Amy M.
Esterhai, John L.
Burdick, Jason A.
Mauck, Robert L.
TI Sacrificial nanofibrous composites provide instruction without
impediment and enable functional tissue formation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE anisotropy; electrospinning; nanofiber; tissue engineering; meniscus
fibrocartilage
ID ENGINEERING SCAFFOLDS; ELECTROSPUN SCAFFOLDS; CELLULAR INFILTRATION;
MENISCUS; ANISOTROPY; CELLS; ALIGNMENT; FIBERS; MATRIX; REPAIR
AB The fibrous tissues prevalent throughout the body possess an ordered structure that underlies their refined and robust mechanical properties. Engineered replacements will require recapitulation of this exquisite architecture in three dimensions. Aligned nanofibrous scaffolds can dictate cell and matrix organization; however, their widespread application has been hindered by poor cell infiltration due to the tight packing of fibers during fabrication. Here, we develop and validate an enabling technology in which tunable composite nanofibrous scaffolds are produced to provide instruction without impediment. Composites were formed containing two distinct fiber fractions: slow-degrading poly(e-caprolactone) and water-soluble, sacrificial poly(ethylene oxide), which can be selectively removed to increase pore size. Increasing the initial fraction of sacrificial poly(ethylene oxide) fibers enhanced cell infiltration and improved matrix distribution. Despite the removal of >50% of the initial fibers, the remaining scaffold provided sufficient instruction to align cells and direct the formation of a highly organized ECM across multiple length scales, which in turn led to pronounced increases in the tensile properties of the engineered constructs (nearly matching native tissue). This approach transforms what is an interesting surface phenomenon (cells on top of nanofibrous mats) into a method by which functional, 3D tissues (>1 mm thick) can be formed, both in vitro and in vivo. As such, this work represents a marked advance in the engineering of load-bearing fibrous tissues, and will find widespread applications in regenerative medicine.
C1 [Baker, Brendon M.; Shah, Roshan P.; Silverstein, Amy M.; Esterhai, John L.; Mauck, Robert L.] Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Baker, Brendon M.; Silverstein, Amy M.; Burdick, Jason A.; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.
[Esterhai, John L.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP Mauck, RL (reprint author), Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM lemauck@mail.med.upenn.edu
FU National Institutes of Health [R01 AR056624]; Department of Veterans
Affairs [I01 RX000174]; National Science Foundation
FX This work was supported by National Institutes of Health Grant R01
AR056624 and Department of Veterans Affairs Grant I01 RX000174. The
views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States government. Additional support was provided
by the Penn Center for Musculoskeletal Disorders and a National Science
Foundation Graduate Research Fellowship (to B.M.B.).
NR 33
TC 56
Z9 56
U1 2
U2 57
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 28
PY 2012
VL 109
IS 35
BP 14176
EP 14181
DI 10.1073/pnas.1206962109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 002VP
UT WOS:000308565300062
PM 22872864
ER
PT J
AU Ahmed, MI
Aban, I
Lloyd, SG
Gupta, H
Howard, G
Inusah, S
Peri, K
Robinson, J
Smith, P
McGiffin, DC
Schiros, CG
Denney, T
Dell'Italia, LJ
AF Ahmed, Mustafa I.
Aban, Inmaculada
Lloyd, Steven G.
Gupta, Himanshu
Howard, George
Inusah, Seidu
Peri, Kalyani
Robinson, Jessica
Smith, Patty
McGiffin, David C.
Schiros, Chun G.
Denney, Thomas, Jr.
Dell'Italia, Louis J.
TI A Randomized Controlled Phase IIb Trial of Beta(1)-Receptor Blockade for
Chronic Degenerative Mitral Regurgitation
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE beta blockade; medical therapy; mitral regurgitation; mitral valve
disease
ID CARDIAC-HYPERTROPHY; VOLUME-OVERLOAD; CARDIOCYTE; FRACTION; EJECTION;
DOG
AB Objectives The purpose of the study was to evaluate the effect of long-term beta(1)-aderergic receptor (AR) blockade on left ventricular (LV) remodeling and function in patients with chronic, isolated, degenerative mitral regurgitation (MR).
Background Isolated MR currently has no proven therapy that attenuates LV remodeling or preserves systolic function.
Methods Thirty-eight asymptomatic subjects with moderate to severe, isolated MR were randomized either to placebo or beta(1)-AR blockade (Toprol-XL, AstraZeneca, London, United Kingdom) for 2 years. Magnetic resonance imaging with tissue tagging and 3-dimensional analysis was performed at baseline and at 6-month intervals for 2 years. Rate of progression analysis was performed for endpoint variables for primary outcomes: LV end-diastolic volume/body surface area, LV ejection fraction, LV end-diastolic (ED) mass/ED volume ratio, LV ED 3-dimensional radius/wall thickness; LV end-systolic volume/body surface area, LV longitudinal strain rate, and LV early diastolic filling rate.
Results Baseline LV magnetic resonance imaging or demographic variables did not differ between the 2 groups. Significant treatment effects were found on LV ejection fraction (p = 0.006) and LV early diastolic filling rate (p = 0.001), which decreased over time in untreated patients on an intention-to-treat analysis and remained significant after sensitivity analysis. There were no significant treatment effects found on LV ED or LV end-systolic volumes, LV ED mass/LV ED volume or LV ED 3-dimensional radius/wall thickness, or LV longitudinal strain rate. Over 2 years, 6 patients treated in the placebo group and 2 patients in the beta(1)-AR blockade group required mitral valve surgery (p = 0.23).
Conclusions beta(1)-AR blockade improves LV function over a 2-year follow-up in isolated MR and provides the impetus for a large-scale clinical trial with clinical outcomes. (Molecular Mechanisms of Volume Overload-Aim 1 [SCCOR in Cardiac Dysfunction and Disease]; NCT01052428) (J Am Coll Cardiol 2012;60:833-8) (C) 2012 by the American College of Cardiology Foundation
C1 [Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med & Cardiovasc Dis, Div Cardiol, Birmingham, AL 35294 USA.
[Aban, Inmaculada; Howard, George; Inusah, Seidu; Peri, Kalyani] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
[Lloyd, Steven G.; Gupta, Himanshu; Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[McGiffin, David C.] Univ Alabama Birmingham, Dept Cardiovasc Surg, Birmingham, AL 35294 USA.
[Schiros, Chun G.; Denney, Thomas, Jr.] Auburn Univ, Samuel Ginn Coll Engn, Auburn, AL 36849 USA.
RP Dell'Italia, LJ (reprint author), Univ Alabama Birmingham, Dept Med & Cardiovasc Dis, Div Cardiol, 901 19th St S,434 BMR2, Birmingham, AL 35294 USA.
EM loudell@uab.edu
FU National Heart, Lung and Blood Institute Specialized Center for
Clinically Oriented Research (SCCOR) in Cardiac Dysfunction; National
Institutes of Health, Bethesda, Maryland [P50HL077100]
FX From the Department of Medicine and Cardiovascular Disease, University
of Alabama at Birmingham, Birmingham, Alabama; Department of
Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama;
Birmingham Veteran Affairs Medical Center, Birmingham, Alabama;
Department of Cardiovascular Surgery, University of Alabama at
Birmingham, Birmingham, Alabama; and the Samuel Ginn College of
Engineering, Auburn University, Auburn, Alabama. This study was funded
by the National Heart, Lung and Blood Institute Specialized Center for
Clinically Oriented Research (SCCOR) in Cardiac Dysfunction, National
Institutes of Health, Bethesda, Maryland (grant no.: P50HL077100). Drugs
and placebos were supplied by AstraZeneca. The authors have reported
that they have no relationships relevant to the contents of this paper
to disclose.
NR 19
TC 28
Z9 28
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD AUG 28
PY 2012
VL 60
IS 9
BP 833
EP 838
DI 10.1016/j.jacc.2012.04.029
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 997AY
UT WOS:000308137600008
PM 22818065
ER
PT J
AU Steffan, JJ
Koul, S
Meacham, RB
Koul, HK
AF Steffan, Joshua J.
Koul, Sweaty
Meacham, Randall B.
Koul, Hari K.
TI The Transcription Factor SPDEF Suppresses Prostate Tumor Metastasis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID GELATINASE B EXPRESSION; ETS FACTOR; CANCER-CELLS; BREAST-CANCER; MATRIX
METALLOPROTEINASES; AGGRESSIVE PHENOTYPE; PROGNOSTIC MARKER;
GENE-EXPRESSION; CARCINOMA CELLS; FACTOR PDEF
AB Emerging evidence suggests that the SAM pointed domain containing ETS transcription factor (SPDEF) plays a significant role in tumorigenesis in prostate, breast, colon, and ovarian cancer. However, there are no in vivo studies with respect to the role of SPDEF in tumor metastasis. The present study examined the effects of SPDEF on tumor cell metastasis using prostate tumor cells as a model. Utilizing two experimental metastasis models, we demonstrate that SPDEF inhibits cell migration and invasion in vitro and acts a tumor metastasis suppressor in vivo. Using stable expression of SPDEF in PC3-Luc cells and shRNA-mediated knockdown of SPDEF in LNCaP-Luc cells, we demonstrate for the first time that SPDEF diminished the ability of disseminated tumors cells to survive at secondary sites and establish micrometastases. These effects on tumor metastasis were not a result of the effect of SPDEF on cell growth as SPDEF expression had no effect on cell growth in vitro or subcutaneous tumor xenograft-growth in vivo. Transcriptional analysis of several genes associated with tumor metastasis, invasion, and the epithelial-mesenchymal transition demonstrated that SPDEF expression selectively down-regulated MMP9 and MMP13 in prostate cancer cells. Further analysis indicated that forced MMP9 or MMP13 expression rescued the invasive phenotype in SPDEF expressing PC3 cells in vitro, suggesting that the effects of SPDEF on tumor invasion are mediated, in part, through the suppression of MMP9 and MMP13 expression. These results demonstrate for the first time, in any system, that SPDEF functions as a tumor metastasis suppressor in vivo.
C1 [Steffan, Joshua J.; Koul, Sweaty; Meacham, Randall B.; Koul, Hari K.] Univ Colorado, Sch Med, Dept Surg, Program Urosci,Div Urol, Aurora, CO 80045 USA.
[Steffan, Joshua J.; Koul, Sweaty; Koul, Hari K.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
[Koul, Hari K.] Univ Colorado, Ctr Comprehens Canc, Aurora, CO 80045 USA.
RP Koul, HK (reprint author), 12700 E 19th Ave,RC2-6001,MS-C317, Aurora, CO 80045 USA.
EM hari.koul@ucdenver.edu
FU Department of Surgery (School of Medicine Academic Enrichment Funds);
Veterans Affairs Merit Award [01BX001258]; National Institutes of Health
[DK54084]; National Institutes of Health/NCI [R01CA161880]
FX This work was supported in part by chair commitment (to H. K. K.) and
Department of Surgery (School of Medicine Academic Enrichment Funds) (to
H. K. K.).; Supported in part by Veterans Affairs Merit Award
01BX001258, National Institutes of Health Grant DK54084, and National
Institutes of Health/NCI Grant R01CA161880. To whom correspondence
should be addressed: 12700 E. 19th Ave, RC2-6001; MS-C317, Aurora, CO
80045. Tel.: 303-724-6300; Fax: 303-724-6330; E-mail:
hari.koul@ucdenver.edu.
NR 44
TC 20
Z9 20
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 24
PY 2012
VL 287
IS 35
BP 29968
EP 29978
DI 10.1074/jbc.M112.379396
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 999CO
UT WOS:000308286900070
PM 22761428
ER
PT J
AU Chiyomaru, T
Yamamura, S
Zaman, MS
Majid, S
Deng, GR
Shahryari, V
Saini, S
Hirata, H
Ueno, K
Chang, I
Tanaka, Y
Tabatabai, ZL
Enokida, H
Nakagawa, M
Dahiya, R
AF Chiyomaru, Takeshi
Yamamura, Soichiro
Zaman, Mohd Saif
Majid, Shahana
Deng, Guoren
Shahryari, Varahram
Saini, Sharanjot
Hirata, Hiroshi
Ueno, Koji
Chang, Inik
Tanaka, Yuichiro
Tabatabai, Z. Laura
Enokida, Hideki
Nakagawa, Masayuki
Dahiya, Rajvir
TI Genistein Suppresses Prostate Cancer Growth through Inhibition of
Oncogenic MicroRNA-151
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION; JAPANESE MEN; CHROMOSOMAL-ABERRATIONS; RISK;
ISOFLAVONES; CARCINOMA; FAMILY; CELLS; CONSUMPTION; INVASION
AB Genistein has been shown to suppress the growth of several cancers through modulation of various pathways. However, the effects of genistein on the regulation of oncogenic microRNA-151 (miR-151) have not been reported. In this study, we investigated whether genistein could alter the expression of oncogenic miR-151 and its target genes that are involved in the progression and metastasis of prostate cancer (PCa). Real-time RT-PCR showed that the expression of miR-151 was higher in PC3 and DU145 cells compared with RWPE-1 cells. Treatment of PC3 and DU145 cells with 25 mu M genistein down-regulated the expression of miR-151 compared with vehicle control. Inhibition of miR-151 in PCa cells by genistein significantly inhibited cell migration and invasion. In-silico analysis showed that several genes (CASZ1, IL1RAPL1, SOX17, N4BP1 and ARHGDIA) suggested to have tumor suppressive functions were target genes of miR-151. Luciferase reporter assays indicated that miR-151 directly binds to specific sites on the 3'UTR of target genes. Quantitative real-time PCR analysis showed that the mRNA expression levels of the five target genes in PC3 and DU145 were markedly changed with miR-151 mimics and inhibitor. Kaplan-Meier curves and log-rank tests revealed that high expression levels of miR-151 had an adverse effect on survival rate. This study suggests that genistein mediated suppression of oncogenic miRNAs can be an important dietary therapeutic strategy for the treatment of PCa.
C1 [Chiyomaru, Takeshi; Yamamura, Soichiro; Zaman, Mohd Saif; Majid, Shahana; Deng, Guoren; Shahryari, Varahram; Saini, Sharanjot; Hirata, Hiroshi; Ueno, Koji; Chang, Inik; Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA.
[Chiyomaru, Takeshi; Yamamura, Soichiro; Zaman, Mohd Saif; Majid, Shahana; Deng, Guoren; Shahryari, Varahram; Saini, Sharanjot; Hirata, Hiroshi; Ueno, Koji; Chang, Inik; Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA.
[Chiyomaru, Takeshi; Yamamura, Soichiro; Zaman, Mohd Saif; Majid, Shahana; Deng, Guoren; Shahryari, Varahram; Saini, Sharanjot; Hirata, Hiroshi; Ueno, Koji; Chang, Inik; Tanaka, Yuichiro; Tabatabai, Z. Laura; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Enokida, Hideki; Nakagawa, Masayuki] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Urol, Kagoshima 890, Japan.
RP Chiyomaru, T (reprint author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA.
EM rdahiya@urology.ucsf.edu
RI Jackson, Benjamin/C-4297-2012
FU National Center for Research Resources of the National Institutes of
Health [R01CA160079, R01CA138642, T32DK007790]; VA Merit Review and VA
Program Project
FX This research was supported by the National Center for Research
Resources of the National Institutes of Health through Grant Numbers
R01CA160079, R01CA138642, T32DK007790 and VA Merit Review and VA Program
Project. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 43
TC 40
Z9 43
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 23
PY 2012
VL 7
IS 8
AR e43812
DI 10.1371/journal.pone.0043812
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 998GE
UT WOS:000308224700028
PM 22928040
ER
PT J
AU Kastman, EK
Willette, AA
Coe, CL
Bendlin, BB
Kosmatka, KJ
McLaren, DG
Xu, GF
Canu, E
Field, AS
Alexander, AL
Voytko, ML
Beasley, TM
Colman, RJ
Weindruch, RH
Johnson, SC
AF Kastman, Erik K.
Willette, Auriel A.
Coe, Christopher L.
Bendlin, Barbara B.
Kosmatka, Kris J.
McLaren, Donald G.
Xu, Guofan
Canu, Elisa
Field, Aaron S.
Alexander, Andrew L.
Voytko, Mary Lou
Beasley, T. Mark
Colman, Ricki J.
Weindruch, Richard H.
Johnson, Sterling C.
TI A Calorie-Restricted Diet Decreases Brain Iron Accumulation and
Preserves Motor Performance in Old Rhesus Monkeys (vol 30, pg 7940,
2010)
SO JOURNAL OF NEUROSCIENCE
LA English
DT Correction
ID TRANSVERSE RELAXATION RATES; VOXEL-BASED MORPHOMETRY;
ALZHEIMERS-DISEASE; SUBSTANTIA-NIGRA; PARKINSONS-DISEASE;
CEREBROSPINAL-FLUID; NONHUMAN-PRIMATES; OXIDATIVE DAMAGE; HEME
OXYGENASE-1; SKELETAL-MUSCLE
AB Caloric restriction (CR) reduces the pathological effects of aging and extends the lifespan inmanyspecies, including nonhuman primates, although the effect on the brain is less well characterized. We used two common indicators of aging, motor performance speed and brain iron deposition measured in vivo using magnetic resonance imaging, to determine the potential effect of CR on elderly rhesus macaques eating restricted (n = 24, 13 males, 11 females) and standard (n = 17, 8 males, 9 females) diets. Both the CR and control monkeys showed age-related increases in iron concentrations in globus pallidus (GP) and substantia nigra (SN), although the CR group had significantly less iron deposition in the GP, SN, red nucleus, and temporal cortex. ADiet x Age interaction revealed that CR modified age-related brain changes, evidenced as attenuation in the rate of iron accumulation in basal ganglia and parietal, temporal, and perirhinal cortex. Additionally, control monkeys had significantly slower fine motor performance on the Movement Assessment Panel, which was negatively correlated with iron accumulation in left SN and parietal lobe, although CR animals did not show this relationship. Our observations suggest that the CR-induced benefit of reduced iron deposition and preserved motor function may indicate neural protection similar to effects described previously in aging rodent and primate species.
C1 [Kastman, Erik K.; Bendlin, Barbara B.; Kosmatka, Kris J.; McLaren, Donald G.; Xu, Guofan; Canu, Elisa; Weindruch, Richard H.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA.
[Kastman, Erik K.; Willette, Auriel A.; Bendlin, Barbara B.; Kosmatka, Kris J.; McLaren, Donald G.; Xu, Guofan; Canu, Elisa; Weindruch, Richard H.; Johnson, Sterling C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53705 USA.
[Willette, Auriel A.; Coe, Christopher L.] Univ Wisconsin, Dept Psychol, Harlow Primate Lab, Madison, WI 53715 USA.
[Willette, Auriel A.; Coe, Christopher L.; Alexander, Andrew L.; Johnson, Sterling C.] Univ Wisconsin, Waisman Imaging Ctr, Madison, WI 53705 USA.
[McLaren, Donald G.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA.
[Field, Aaron S.] Univ Wisconsin, Dept Radiol, Madison, WI 53792 USA.
[Voytko, Mary Lou] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurobiol & Anat, Winston Salem, NC 27157 USA.
[Voytko, Mary Lou] Wake Forest Univ, Bowman Gray Sch Med, Interdisciplinary Neurosci Program, Winston Salem, NC 27157 USA.
[Beasley, T. Mark; Colman, Ricki J.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
[Weindruch, Richard H.; Johnson, Sterling C.] Wisconsin Natl Primate Res Ctr, Madison, WI 53792 USA.
RP Johnson, SC (reprint author), D4225 Vet Adm Hosp, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM scj@medicine.wisc.edu
RI Kastman, Erik/N-6645-2016
OI Kastman, Erik/0000-0001-7221-9042
FU NCRR NIH HHS [P51 RR000167, RR020141-01, RR15459-01]; NIA NIH HHS [P01
AG11915, AG000213, P01 AG011915, R01 AG040178, R01 AG043125]; NIH HHS
[P51 OD011106]
NR 82
TC 14
Z9 14
U1 1
U2 4
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD AUG 22
PY 2012
VL 32
IS 34
BP 11897
EP 11904
DI 10.1523/JNEUROSCI.2553-12.2012
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 997BZ
UT WOS:000308140500034
PM 23082321
ER
PT J
AU Uccellini, L
De Giorgi, V
Zhao, YD
Tumaini, B
Erdenebileg, N
Dudley, ME
Tomei, S
Bedognetti, D
Ascierto, ML
Liu, QZ
Simon, R
Kottyan, L
Kaufman, KM
Harley, JB
Wang, E
Rosenberg, SA
Marincola, FM
AF Uccellini, Lorenzo
De Giorgi, Valeria
Zhao, Yingdong
Tumaini, Barbara
Erdenebileg, Narnygerel
Dudley, Mark E.
Tomei, Sara
Bedognetti, Davide
Ascierto, Maria Libera
Liu, Qiuzhen
Simon, Richard
Kottyan, Leah
Kaufman, Kenneth M.
Harley, John B.
Wang, Ena
Rosenberg, Steven A.
Marincola, Francesco M.
TI IRF5 gene polymorphisms in melanoma
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; INTERFERON REGULATORY FACTOR; METASTATIC
MELANOMA; IMMUNOLOGICAL CONSTANT; MULTIPLE-SCLEROSIS; CELL-LINES; RISK;
INTERFERON-REGULATORY-FACTOR-5; VARIANTS; THERAPY
AB Background: Interferon regulatory factor (IRF)-5 is a transcription factor involved in type I interferon signaling whose germ line variants have been associated with autoimmune pathogenesis. Since relationships have been observed between development of autoimmunity and responsiveness of melanoma to several types of immunotherapy, we tested whether polymorphisms of IRF5 are associated with responsiveness of melanoma to adoptive therapy with tumor infiltrating lymphocytes (TILs).
Methods: 140 TILs were genotyped for four single nucleotide polymorphisms (rs10954213, rs11770589, rs6953165, rs2004640) and one insertion-deletion in the IRF5 gene by sequencing. Gene-expression profile of the TILs, 112 parental melanoma metastases (MM) and 9 cell lines derived from some metastases were assessed by Affymetrix Human Gene ST 1.0 array.
Results: Lack of A allele in rs10954213 (G > A) was associated with non-response (p < 0.005). Other polymorphisms in strong linkage disequilibrium with rs10954213 demonstrated similar trends. Genes differentially expressed in vitro between cell lines carrying or not the A allele could be applied to the transcriptional profile of 112 melanoma metastases to predict their responsiveness to therapy, suggesting that IRF5 genotype may influence immune responsiveness by affecting the intrinsic biology of melanoma.
Conclusions: This study is the first to analyze associations between melanoma immune responsiveness and IRF5 polymorphism. The results support a common genetic basis which may underline the development of autoimmunity and melanoma immune responsiveness.
C1 [Uccellini, Lorenzo; De Giorgi, Valeria; Erdenebileg, Narnygerel; Tomei, Sara; Bedognetti, Davide; Ascierto, Maria Libera; Liu, Qiuzhen; Wang, Ena; Rosenberg, Steven A.] NIH, IDIS, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.
[Uccellini, Lorenzo; De Giorgi, Valeria; Erdenebileg, Narnygerel; Tomei, Sara; Bedognetti, Davide; Ascierto, Maria Libera; Liu, Qiuzhen; Wang, Ena; Rosenberg, Steven A.] NIH, Trans NIH Ctr Human Immunol, Bethesda, MD 20892 USA.
[Uccellini, Lorenzo] Univ Milan, Inst Infect Dis, L Sacco Hosp, Milan, Italy.
[Uccellini, Lorenzo] Univ Milan, Inst Trop Dis, L Sacco Hosp, Milan, Italy.
[Zhao, Yingdong] NCI, Biometr Res Branch, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA.
[Tumaini, Barbara] NIH, Cell Proc Sect, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.
[Bedognetti, Davide; Ascierto, Maria Libera] Univ Genoa, Dept Internal Med DiMI, I-16132 Genoa, Italy.
[Dudley, Mark E.; Kottyan, Leah; Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol CAGE, Cincinnati, OH 45229 USA.
[Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH 45229 USA.
[Marincola, Francesco M.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA.
RP Uccellini, L (reprint author), NIH, IDIS, Dept Transfus Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
EM uccellinilorenzo@gmail.com; fmarincola@mail.cc.nih.gov
RI De Giorgi, Valeria/D-4582-2017
OI Bedognetti, Davide/0000-0002-5857-773X; Kottyan,
Leah/0000-0003-3979-2220
FU Conquer Cancer Foundation of the American Society of Clinical Oncology
FX DB's fellowship was supported by the Conquer Cancer Foundation of the
American Society of Clinical Oncology.
NR 33
TC 18
Z9 18
U1 2
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD AUG 21
PY 2012
VL 10
AR 170
DI 10.1186/1479-5876-10-170
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 033LJ
UT WOS:000310797500001
PM 22909381
ER
PT J
AU Roseman, M
Turner, EH
Lexchin, J
Coyne, JC
Bero, LA
Thombs, BD
AF Roseman, Michelle
Turner, Erick H.
Lexchin, Joel
Coyne, James C.
Bero, Lisa A.
Thombs, Brett D.
TI Reporting of conflicts of interest from drug trials in Cochrane reviews:
cross sectional study
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID SYSTEMATIC REVIEWS; PHARMACEUTICAL-INDUSTRY; RANDOMIZED-TRIALS; PRISMA
STATEMENT; FINANCIAL TIES; METAANALYSES; QUALITY; IMPACT; CONCLUSIONS;
PUBLICATION
AB Objectives To investigate the degree to which Cochrane reviews of drug interventions published in 2010 reported conflicts of interest from included trials and, among reviews that reported this information, where it was located in the review documents.
Design Cross sectional study.
Data sources Cochrane Database of Systematic Reviews.
Selection criteria Systematic reviews of drug interventions published in 2010 in the Cochrane Database of Systematic Reviews, with review content classified as up to date in 2008 or later and with results from one or more randomised controlled trials.
Results Of 151 included Cochrane reviews, 46 (30%, 95% confidence interval 24% to 38%) reported information on the funding sources of included trials, including 30 (20%, 14% to 27%) that reported information on trial funding for all included trials and 16 (11%, 7% to 17%) that reported for some, but not all, trials. Only 16 of the 151 Cochrane reviews (11%, 7% to 17%) provided any information on trial author-industry financial ties or trial author-industry employment. Information on trial funding and trial author-industry ties was reported in one to seven locations within each review, with no consistent reporting location observed.
Conclusions Most Cochrane reviews of drug trials published in 2010 did not provide information on trial funding sources or trial author-industry financial ties or employment. When this information was reported, location of reporting was inconsistent across reviews.
C1 [Roseman, Michelle; Thombs, Brett D.] Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E4, Canada.
[Roseman, Michelle; Thombs, Brett D.] McGill Univ, Montreal, PQ H3T 1E4, Canada.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Turner, Erick H.] Portland VA Med Ctr, Portland, OR USA.
[Lexchin, Joel] York Univ, Sch Hlth Policy & Management, Toronto, ON M3J 2R7, Canada.
[Coyne, James C.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Hlth Psychol Sect, NL-9700 AB Groningen, Netherlands.
[Bero, Lisa A.] Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA.
[Bero, Lisa A.] Univ Calif San Francisco, Sch Med, Inst Hlth Policy Studies, San Francisco, CA 94143 USA.
RP Thombs, BD (reprint author), Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E4, Canada.
EM brett.thombs@mcgill.ca
OI Turner, Erick/0000-0002-3522-3357; Thombs, Brett/0000-0002-5644-8432
FU Canadian Institutes of Health Research; Fonds de la Recherche en Sante
Quebec; McGill University provost's graduate fellowship; McGill
University principal's graduate fellowship; Etablissement de Jeunes
Chercheurs award from the Fonds de la Recherche en Sante Quebec;
Cochrane Collaboration Methodological Fund
FX MR was supported by a Frederick Banting and Charles Best Canadian
graduate scholarship-master's award from the Canadian Institutes of
Health Research, a master's training award from the Fonds de la
Recherche en Sante Quebec, a McGill University provost's graduate
fellowship, and a McGill University principal's graduate fellowship. BDT
was supported by a new investigator award from the Canadian Institutes
of Health Research and an Etablissement de Jeunes Chercheurs award from
the Fonds de la Recherche en Sante Quebec. This study received no
funding, and no funding body had any input into any aspect of the
study.; All authors have completed the ICMJE uniform disclosure form at
www.icmje.org/coi_disclosure.pdf (available on request from the
corresponding author) and declare that: no authors had any financial
support for the submitted work; JL was a consultant to a law firm
representing Apotex in 2007, a consultant to the Canadian federal
government in a lawsuit challenging the Canadian ban on direct to
consumer advertising of prescription drugs in 2007-08, and a consultant
to a law firm representing a plaintiff in a case against Allergan in
2010; LAB has received a grant from the Cochrane Collaboration
Methodological Fund to examine how systematic reviewers identify
unpublished drug trial data, and is an active member of the Cochrane
Collaboration.
NR 44
TC 18
Z9 18
U1 1
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD AUG 21
PY 2012
VL 345
AR e5155
DI 10.1136/bmj.e5155
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 996GP
UT WOS:000308073200004
PM 22906823
ER
PT J
AU McElligott, S
Field, RI
Bristol-Demeter, M
Domchek, SM
Asch, DA
AF McElligott, Sean
Field, Robert I.
Bristol-Demeter, Mirar
Domchek, Susan M.
Asch, David A.
TI How Genetic Variant Libraries Effectively Extend Gene Testing Patents:
Implications for Intellectual Property and Good Clinical Care
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID UNCERTAIN SIGNIFICANCE; SEQUENCE VARIATION; BRCA2 VARIANTS; RISK
C1 [McElligott, Sean; Bristol-Demeter, Mirar; Asch, David A.] Univ Penn, Philadelphia, PA 19104 USA.
[Field, Robert I.] Drexel Univ, Philadelphia, PA 19104 USA.
[Domchek, Susan M.] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP McElligott, S (reprint author), Univ Penn, Philadelphia, PA 19104 USA.
OI Asch, David/0000-0002-7970-286X
FU NCI NIH HHS [UC2 CA148310]
NR 10
TC 1
Z9 2
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD AUG 20
PY 2012
VL 30
IS 24
BP 2943
EP 2945
DI 10.1200/JCO.2012.42.7757
PG 3
WC Oncology
SC Oncology
GA 996JR
UT WOS:000308082300007
PM 22802312
ER
PT J
AU Zhang, GT
Liu, RJ
Zhong, YF
Plotnikov, AN
Zhang, WJ
Zeng, L
Rusinova, E
Gerona-Nevarro, G
Moshkina, N
Joshua, J
Chuang, PY
Ohlmeyer, M
He, JC
Zhou, MM
AF Zhang, Guangtao
Liu, Ruijie
Zhong, Yifei
Plotnikov, Alexander N.
Zhang, Weijia
Zeng, Lei
Rusinova, Elena
Gerona-Nevarro, Guillermo
Moshkina, Natasha
Joshua, Jennifer
Chuang, Peter Y.
Ohlmeyer, Michael
He, John Cijiang
Zhou, Ming-Ming
TI Down-regulation of NF-kappa B Transcriptional Activity in HIV-associated
Kidney Disease by BRD4 Inhibition
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TUBULAR EPITHELIAL-CELLS; PROBE LEVEL DATA; DIABETIC-NEPHROPATHY;
TRANSGENIC MICE; APOPTOSIS; ACTIVATION; INFECTION; THERAPY; NMR;
GLOMERULOSCLEROSIS
AB NF-kappa B-mediated inflammation is the major pathology in chronic kidney diseases, including HIV-associated nephropathy (HIVAN) that ultimately progresses to end stage renal disease. HIV infection in the kidney induces NF-kappa B activation, leading to the production of proinflammatory chemokines, cytokines, and adhesion molecules. In this study, we explored selective inhibition of NF-kappa B transcriptional activity by small molecule blocking NF-kappa B binding to the transcriptional cofactor BRD4, which is required for the assembly of the productive transcriptional complex comprising positive transcription elongation factor b and RNA polymerase II. We showed that our BET (Bromodomain and Extra-Terminal domain)-specific bromodomain inhibitor MS417, designed to block BRD4 binding to the acetylated NF-kappa B, effectively attenuates NF-kappa B transcriptional activation of proinflammatory genes in kidney cells treated with TNF alpha or infected by HIV. MS417 ameliorates inflammation and kidney injury in HIV-1 transgenic mice, an animal model for HIVAN. Our study suggests that BET bromodomain inhibition, targeting at the proinflammatory activity of NF-kappa B, represents a new therapeutic approach for treating NF-kappa B-mediated inflammation and kidney injury in HIVAN.
C1 [Zhang, Guangtao; Plotnikov, Alexander N.; Zeng, Lei; Rusinova, Elena; Gerona-Nevarro, Guillermo; Moshkina, Natasha; Joshua, Jennifer; Ohlmeyer, Michael; Zhou, Ming-Ming] Mt Sinai Sch Med, Dept Struct & Chem Biol, New York, NY 10029 USA.
[Liu, Ruijie; Zhang, Weijia; Chuang, Peter Y.; He, John Cijiang] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
[Liu, Ruijie; He, John Cijiang] James J Peters Vet Affairs Med Ctr, Dept Med, Bronx, NY 10486 USA.
[Zhong, Yifei] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Nephrol, Shanghai 201203, Peoples R China.
RP He, JC (reprint author), 1425 Madison Ave,Box 1677, New York, NY 10029 USA.
EM cijiang.he@mssm.edu; ming-ming.zhou@mssm.edu
RI Zhang, Guangtao/C-7341-2011
FU National Institutes of Health [HG004508, DK088541]; Veterans Affairs
Merit Award [1I01BX000345]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants HG004508 (to M.-M. Z.) and DK088541 (to J. C. H.). This
work was also supported by Veterans Affairs Merit Award 1I01BX000345 (to
J. C. H.).
NR 53
TC 84
Z9 91
U1 2
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 17
PY 2012
VL 287
IS 34
BP 28840
EP 28851
DI 10.1074/jbc.M112.359505
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 996HD
UT WOS:000308074600056
PM 22645123
ER
PT J
AU Smith, LR
Chambers, HG
Subramaniam, S
Lieber, RL
AF Smith, Lucas R.
Chambers, Henry G.
Subramaniam, Shankar
Lieber, Richard L.
TI Transcriptional Abnormalities of Hamstring Muscle Contractures in
Children with Cerebral Palsy
SO PLOS ONE
LA English
DT Article
ID GROSS MOTOR FUNCTION; SKELETAL-MUSCLE; EXTRACELLULAR-MATRIX; MEDIAL
GASTROCNEMIUS; SPASTIC DIPLEGIA; GENE ONTOLOGY; STIFFNESS;
HYPOEXTENSIBILITY; DIFFERENTIATION; ARCHITECTURE
AB Cerebral palsy (CP) is an upper motor neuron disease that results in a spectrum of movement disorders. Secondary to the neurological lesion, muscles from patients with CP are often spastic and form debilitating contractures that limit range of motion and joint function. With no genetic component, the pathology of skeletal muscle in CP is a response to aberrant complex neurological input in ways that are not fully understood. This study was designed to gain further understanding of the skeletal muscle response in CP using transcriptional profiling correlated with functional measures to broadly investigate muscle adaptations leading to mechanical deficits. Biospsies were obtained from both the gracilis and semitendinosus muscles from a cohort of patients with CP (n = 10) and typically developing patients (n = 10) undergoing surgery. Biopsies were obtained to define the unique expression profile of the contractures and passive mechanical testing was conducted to determine stiffness values in previously published work. Affymetrix HG-U133A 2.0 chips (n = 40) generated expression data, which was validated for selected transcripts using quantitative real-time PCR. Chips were clustered based on their expression and those from patients with CP clustered separately. Significant genes were determined conservatively based on the overlap of three summarization algorithms (n = 1,398). Significantly altered genes were analyzed for over-representation among gene ontologies and muscle specific networks. The majority of altered transcripts were related to increased extracellular matrix expression in CP and a decrease in metabolism and ubiquitin ligase activity. The increase in extracellular matrix products was correlated with mechanical measures demonstrating the importance in disability. These data lay a framework for further studies and development of novel therapies.
C1 [Smith, Lucas R.; Subramaniam, Shankar; Lieber, Richard L.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
[Chambers, Henry G.] Rady Childrens Hosp, Dept Orthoped Surg, San Diego, CA USA.
[Chambers, Henry G.; Lieber, Richard L.] Univ Calif San Diego, Dept Orthoped Surg, La Jolla, CA 92093 USA.
[Lieber, Richard L.] US Dept Vet Affairs, Med Ctr, San Diego, CA USA.
RP Smith, LR (reprint author), Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
EM rlieber@ucsd.edu
FU National Institutes of Health [AR057393]
FX This work was supported by the National Institutes of Health [grant
number AR057393]. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 64
TC 8
Z9 8
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 16
PY 2012
VL 7
IS 8
AR e40686
DI 10.1371/journal.pone.0040686
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 993AN
UT WOS:000307824300004
PM 22956992
ER
PT J
AU Kaddurah-Daouk, R
McEvoy, J
Baillie, R
Zhu, HJ
Yao, JK
Nimgaonkar, VL
Buckley, PF
Keshavan, MS
Georgiades, A
Nasrallah, HA
AF Kaddurah-Daouk, Rima
McEvoy, Joseph
Baillie, Rebecca
Zhu, Hongjie
Yao, Jeffrey K.
Nimgaonkar, Vishwajit L.
Buckley, Peter F.
Keshavan, Matcheri S.
Georgiades, Anastasia
Nasrallah, Henry A.
TI Impaired plasmalogens in patients with schizophrenia
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Schizophrenia; Drug-naive; Metabolomics; Lipidomics; Plasmalogen;
Phospholipids
ID POLYUNSATURATED FATTY-ACIDS; GLOBAL BIOCHEMICAL APPROACH; BLOOD-CELL
MEMBRANE; ETHANOLAMINE PLASMALOGEN; ALZHEIMERS-DISEASE; OXIDATIVE
STRESS; ENDOTHELIAL-CELLS; ARACHIDONIC-ACID; SURROGATE MARKER;
ION-TRANSPORT
AB Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naive patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects.
Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Kaddurah-Daouk, Rima; McEvoy, Joseph; Georgiades, Anastasia] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA.
[Baillie, Rebecca] Rosa & Co LLC, San Carlos, CA 94070 USA.
[Zhu, Hongjie] N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA.
[Zhu, Hongjie] N Carolina State Univ, Bioinformat Res Ctr, Raleigh, NC 27695 USA.
[Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA.
[Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
[Yao, Jeffrey K.; Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Nimgaonkar, Vishwajit L.] Western Psychiat Inst & Clin, Dept Human Genet, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Buckley, Peter F.] Med Coll Georgia, Dept Psychiat, Augusta, GA 30912 USA.
[Keshavan, Matcheri S.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Nasrallah, Henry A.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45219 USA.
RP Kaddurah-Daouk, R (reprint author), Duke Univ, Med Ctr, Dept Psychiat, Box 3950, Durham, NC 27710 USA.
EM kaddu001@mc.duke.edu
NR 67
TC 23
Z9 23
U1 3
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD AUG 15
PY 2012
VL 198
IS 3
BP 347
EP 352
DI 10.1016/j.psychres.2012.02.019
PG 6
WC Psychiatry
SC Psychiatry
GA 050HQ
UT WOS:000312044800002
PM 22513041
ER
PT J
AU Vaid, M
Prasad, R
Singh, T
Jones, V
Katiyar, SK
AF Vaid, Mudit
Prasad, Ram
Singh, Tripti
Jones, Virginia
Katiyar, Santosh K.
TI Grape seed proanthocyanidins reactivate silenced tumor suppressor genes
in human skin cancer cells by targeting epigenetic regulators
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Grape seed proanthocyanidins; DNA methylation; Skin cancer cells;
Histone acetylation; Tumor suppressor genes and proteins
ID SKH-1 HAIRLESS MICE; DNA METHYLATION; HISTONE ACETYLATION; OXIDATIVE
STRESS; MECHANISMS; PREVENTION; REPAIR; PHOTOCARCINOGENESIS;
HYPERMETHYLATION; INACTIVATION
AB Grape seed proanthocyanidins (GSPs) have been shown to have anti-skin carcinogenic effects in in vitro and in vivo models. However, the precise epigenetic molecular mechanisms remain unexplored. This study was designed to investigate whether GSPs reactivate silenced tumor suppressor genes following epigenetic modifications in skin cancer cells. For this purpose, A431 and SCC13 human squamous cell carcinoma cell lines were used as in vitro models. The effects of GSPs on DNA methylation, histone modifications and tumor suppressor gene expressions were studied in these cell lines using enzyme activity assays, western blotting, dot-blot analysis and real-time polymerase chain reaction (RT-PCR). We found that treatment of A431 and SCC13 cells with GSPs decreased the levels of: ( i) global DNA methylation, (ii) 5-methylcytosine, (iii) DNA methyltransferase (DNMT) activity and (iv) messenger RNA (mRNA) and protein levels of DNMT1, DNMT3a and DNMT3b in these cells. Similar effects were noted when these cancer cells were treated identically with 5-aza-2'-deoxycytidine, an inhibitor of DNA methylation. GSPs decreased histone deacetylase activity, increased levels of acetylated lysines 9 and 14 on histone H3 (H3-Lys 9 and 14) and acetylated lysines 5, 12 and 16 on histone H4, and reduced the levels of methylated H3-Lys 9. Further, GSP treatment resulted in re-expression of the mRNA and proteins of silenced tumor suppressor genes, RASSF1A, p16(INK4a) and Cip1/p21. Together, this study provides a new insight into the epigenetic mechanisms of GSPs and may have significant implications for epigenetic therapy in the treatment/prevention of skin cancers in humans. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Vaid, Mudit; Prasad, Ram; Singh, Tripti; Jones, Virginia; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU Veterans Administration Merit Review Award [ONCA-029-11S]; National
Institutes of Health [CA140832]
FX This work was supported by funds from the Veterans Administration Merit
Review Award (ONCA-029-11S, S.K.K.) and the National Institutes of
Health (CA140832, S.K.K.). The human keratinocytes were obtained from
the UAB Skin Diseases Research Center (AR050948). Editorial assistance
from Dr. Fiona Hunter is gratefully acknowledged. The content of this
manuscript does not necessarily reflect the views or policies of the
funding sources.
NR 33
TC 18
Z9 19
U1 1
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD AUG 15
PY 2012
VL 263
IS 1
BP 122
EP 130
DI 10.1016/j.taap.2012.06.013
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 984RK
UT WOS:000307208900015
PM 22749965
ER
PT J
AU Heinrich, MC
Griffith, D
McKinley, A
Patterson, J
Presnell, A
Ramachandran, A
Debiec-Rychter, M
AF Heinrich, Michael C.
Griffith, Diana
McKinley, Arin
Patterson, Janice
Presnell, Ajia
Ramachandran, Abhijit
Debiec-Rychter, Maria
TI Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated
with Imatinib-Resistant Gastrointestinal Stromal Tumors
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; KINASE INHIBITORS; PHASE-II; KIT; MUTANT;
CANCER; MECHANISMS; SORAFENIB; ONCOLOGY; MESYLATE
AB Purpose: To determine the potential of crenolanib, a potent inhibitor of PDGFRA, to treat malignancies driven by mutant PDGFRA.
Experimental Design: The biochemical activity of crenolanib was compared with imatinib using a panel of PDGFRA-mutant kinases expressed in several different cell line models, including primary gastrointestinal stromal tumors (GIST) cells. The antiproliferative activity of crenolanib was also studied in several cell lines with PDGFRA-dependent growth.
Results: Crenolanib was significantly more potent than imatinib in inhibiting the kinase activity of imatinib-resistant PDGFRA kinases (D842I, D842V, D842Y, DI842-843IM, and deletion I843). For example, crenolanib was 135-fold more potent than imatinib against D842V in our isogenic model system, with an IC50 of approximately 10 nmol/L. The relative potency of crenolanib was further confirmed in BaF3 and primary GIST cells expressing PDGFRA D842V. In contrast, imatinib was at least 10-fold more potent than crenolanib in inhibiting the V561D mutation. For all other tested PDGFRA mutations, crenolanib and imatinib had comparable potency.
Conclusions: Crenolanib is a potent inhibitor of imatinib-resistant PDGFRA kinases associated with GIST, including the PDGFRA D842V mutation found in approximately 5% of GISTs. The spectrum of activity of crenolanib suggests that this drug is a type I inhibitor (inhibitor of activated conformation of kinase). Based in part on these results, a phase II clinical study of this agent to treat GIST with the PDGFRA D842V mutation has been initiated. Clin Cancer Res; 18(16); 4375-84. (C) 2012 AACR.
C1 [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Med, Div Hematol Oncol, Portland, OR 97239 USA.
[Heinrich, Michael C.; Griffith, Diana; McKinley, Arin; Patterson, Janice; Presnell, Ajia] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Portland, OR 97239 USA.
[Ramachandran, Abhijit] AROG Pharmaceut LLC, Dallas, TX USA.
[Debiec-Rychter, Maria] Katholieke Univ Leuven, Dept Human Genet, Louvain, Belgium.
Univ Hosp, Louvain, Belgium.
RP Heinrich, MC (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Med, Div Hematol Oncol, R&D-19 3710 US Vet Hosp Rd, Portland, OR 97239 USA.
EM Heinrich@ohsu.edu
OI Patterson, Janice/0000-0002-8969-2933
FU AROG; Novartis; Imclone; Ariad; Veterans Affairs Merit Review Grant;
AROG Pharmaceuticals LLC; Life Raft Group; GIST Cancer Research Fund
FX M.C. Heinrich has received commercial research grants from AROG,
Novartis, Imclone, and Ariad, and honoraria from speakers bureau of
Novartis. He also has ownership interest (including patents) from
MolecularMD and is a consultant and an advisory board member of
Novartis, Pfizer, and MolecularMD. No potential conflicts of interest
were disclosed by the other authors.; The work was supported in part
from funding from a Veterans Affairs Merit Review Grant (M. C.
Heinrich), AROG Pharmaceuticals LLC, the Life Raft Group (M. C.
Heinrich, M. Debiec-Rychter), and the GIST Cancer Research Fund (M.C.
Heinrich).
NR 34
TC 57
Z9 58
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 15
PY 2012
VL 18
IS 16
BP 4375
EP 4384
DI 10.1158/1078-0432.CCR-12-0625
PG 10
WC Oncology
SC Oncology
GA 988PY
UT WOS:000307504200020
PM 22745105
ER
PT J
AU Bouldin, SD
Darch, MA
Hart, PJ
Outten, CE
AF Bouldin, Samantha D.
Darch, Maxwell A.
Hart, P. John
Outten, Caryn E.
TI Redox properties of the disulfide bond of human Cu,Zn superoxide
dismutase and the effects of human glutaredoxin 1
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE Cu,Zn superoxide dismutase (SOD); disulfide; glutaredoxin; monothiol;
redox potential; yeast
ID AMYOTROPHIC-LATERAL-SCLEROSIS; COPPER CHAPERONE CCS; MUTANT
CU,ZN-SUPEROXIDE DISMUTASE; INTERMEMBRANE SPACE; FAMILIAL ALS;
BINDING-SITE; REDUCED FORM; MOUSE MODEL; WILD-TYPE; SOD1
AB The intramolecular disulfide bond in hSOD1 [human SOD1 (Cu,Zn superoxide dismutase 1)] plays a key role in maintaining the protein's stability and quaternary structure. In mutant forms of SOD1 that cause familial ALS (amyotrophic lateral sclerosis), this disulfide bond is more susceptible to chemical reduction, which may lead to destabilization of the dimer and aggregation. During hSOD1 maturation, disulfide formation is catalysed by CCS1 (copper chaperone for SOD1). Previous studies in yeast demonstrate that the yeast GSH/Grx (glutaredoxin) redox system promotes reduction of the hSOD1 disulfide in the absence of CCS1. In the present study, we probe further the interaction between hSOD1, GSH and Grxs to provide mechanistic insight into the redox kinetics and thermodynamics of the hSOD1 disulfide. We demonstrate that hGrx1 (human Grx1) uses a monothiol mechanism to reduce the hSOD1 disulfide, and the GSH/hGrx1 system reduces ALS mutant SOD1 at a faster rate than WT (wild-type) hSOD1. However, redox potential measurements demonstrate that the thermodynamic stability of the disulfide is not consistently lower in ALS mutants compared with WT hSOD1. Furthermore, the presence of metal cofactors does not influence the disulfide redox potential. Overall, these studies suggest that differences in the GSH/hGrx1 reaction rate with WT compared with ALS mutant hSOD1 and not the inherent thermodynamic stability of the hSOD1 disulfide bond may contribute to the greater pathogenicity of ALS mutant hSOD1.
C1 [Bouldin, Samantha D.; Darch, Maxwell A.; Outten, Caryn E.] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.
[Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA.
[Hart, P. John] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, San Antonio, TX 78229 USA.
RP Outten, CE (reprint author), Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.
EM outten@mailbox.sc.edu
OI Outten, Caryn/0000-0003-0335-6531
FU National Institutes of Health [K22 ES013780, R01 GM086619, R01
NS039112]; Judith and Jean Pape Adams Charitable Foundation
FX This work was supported by the National Institutes of Health [grant
numbers K22 ES013780 and R01 GM086619 (to C.E.O.), and R01 NS039112 (to
P.J.H.)] and the Judith and Jean Pape Adams Charitable Foundation (to
P.J.H.).
NR 65
TC 14
Z9 14
U1 0
U2 9
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD AUG 15
PY 2012
VL 446
BP 59
EP 67
DI 10.1042/BJ20120075
PN 1
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 990JH
UT WOS:000307626300006
PM 22651090
ER
PT J
AU O'Horo, JC
Thompson, D
Safdar, N
AF O'Horo, John C.
Thompson, Deb
Safdar, Nasia
TI Is the Gram Stain Useful in the Microbiologic Diagnosis of VAP? A
Meta-analysis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Review
ID VENTILATOR-ASSOCIATED PNEUMONIA; BRONCHOALVEOLAR LAVAGE FLUID;
APPROPRIATE ANTIBIOTIC-THERAPY; PROTECTED SPECIMEN BRUSH; INTRACELLULAR
ORGANISMS; RANDOMIZED-TRIAL; PREDICTIVE-VALUE; MICROSCOPIC EXAMINATION;
NOSOCOMIAL PNEUMONIA; INJURED PATIENTS
AB In a meta-analysis examining respiratory specimen Gram stain for diagnosis of ventilator-associated pneumonia, absence of bacteria on Gram stain had a high negative predictive value, but a positive Gram stain correlated poorly with organisms recovered in culture.
Rapid and accurate diagnosis of ventilator-associated pneumonia (VAP) is a major challenge and no generally accepted gold standard exists for VAP diagnosis. We conducted a meta-analysis to examine the role of respiratory specimen Gram stain to diagnose VAP, and the correlation with final culture results. In 21 studies, pooled sensitivity of Gram stain for VAP was 0.79 (95% confidence interval [CI],.77-0.81; P < .0001) and specificity was 0.75 (95% CI,.73-.78; P < .0001). Negative predictive value of Gram stain for a VAP prevalence of 20%-30% was 91%, suggesting that VAP is unlikely with a negative Gram stain but the positive predictive value of Gram stain was only 40%. Pooled kappa was 0.42 for gram-positive organisms and 0.34 for gram-negative organisms, suggesting fair concordance between organisms on Gram stain and recovery by culture. Therefore, a positive Gram stain should not be used to narrow anti-infective therapy until culture results become available.
C1 [O'Horo, John C.] Aurora Healthcare Metro, Dept Grad Med Educ, Milwaukee, WI USA.
[Thompson, Deb] Infect Dis Associates, Milwaukee, WI USA.
[Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA.
[Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA.
RP Safdar, N (reprint author), Hlth Sci Learning Ctr, Sect Infect Dis, MFCB 5221,1685 Highland Ave, Madison, WI 53705 USA.
EM ns2@medicine.wisc.edu
RI O'Horo, John/A-8787-2013; O'Horo, John/N-8681-2013
OI O'Horo, John/0000-0002-0880-4498; O'Horo, John/0000-0002-0880-4498
NR 52
TC 20
Z9 24
U1 1
U2 27
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2012
VL 55
IS 4
BP 551
EP 561
DI 10.1093/cid/cis512
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 977RQ
UT WOS:000306682500014
PM 22677711
ER
PT J
AU Hempel, S
Miles, JNV
Shekelle, PG
AF Hempel, Susanne
Miles, Jeremy N. V.
Shekelle, Paul G.
TI Probiotics for Antibiotic-Associated Diarrhea Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID THERAPY; BLIND
C1 [Hempel, Susanne] RAND Hlth, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA.
[Miles, Jeremy N. V.] RAND Corp, Santa Monica, CA USA.
[Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
RP Hempel, S (reprint author), RAND Hlth, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA.
EM Susanne_hempel@rand.org
NR 3
TC 0
Z9 0
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 15
PY 2012
VL 308
IS 7
BP 665
EP 666
DI 10.1001/jama.2012.8738
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 988NC
UT WOS:000307496700013
ER
PT J
AU Westreich, D
Cole, SR
Young, JG
Palella, F
Tien, PC
Kingsley, L
Gange, SJ
Hernan, MA
AF Westreich, Daniel
Cole, Stephen R.
Young, Jessica G.
Palella, Frank
Tien, Phyllis C.
Kingsley, Lawrence
Gange, Stephen J.
Hernan, Miguel A.
TI The parametric g-formula to estimate the effect of highly active
antiretroviral therapy on incident AIDS or death
SO STATISTICS IN MEDICINE
LA English
DT Article
DE cohort study; confounding; g-formula; HIV; AIDS; Monte Carlo methods
ID MARGINAL STRUCTURAL MODELS; CAUSAL INFERENCE; CONTROLLED-TRIAL;
G-COMPUTATION; TIME; DISEASE; EPIDEMIOLOGY; MORTALITY; SURVIVAL; FAILURE
AB The parametric g-formula can be used to contrast the distribution of potential outcomes under arbitrary treatment regimes. Like g-estimation of structural nested models and inverse probability weighting of marginal structural models, the parametric g-formula can appropriately adjust for measured time-varying confounders that are affected by prior treatment. However, there have been few implementations of the parametric g-formula to date. Here, we apply the parametric g-formula to assess the impact of highly active antiretroviral therapy on time to acquired immune deficiency syndrome (AIDS) or death in two US-based human immunodeficiency virus cohorts including 1498 participants. These participants contributed approximately 7300 person-years of follow-up (49% exposed to highly active antiretroviral therapy) during which 382 events occurred and 259 participants were censored because of dropout. Using the parametric g-formula, we estimated that antiretroviral therapy substantially reduces the hazard of AIDS or death (hazard ratio?=?0.55; 95% confidence limits [CL]: 0.42, 0.71). This estimate was similar to one previously reported using a marginal structural model, 0.54 (95% CL: 0.38, 0.78). The 6.5-year difference in risk of AIDS or death was 13% (95% CL: 8%, 18%). Results were robust to assumptions about temporal ordering, and extent of history modeled, for time-varying covariates. The parametric g-formula is a viable alternative to inverse probability weighting of marginal structural models and g-estimation of structural nested models for the analysis of complex longitudinal data. Copyright (c) 2012 John Wiley & Sons, Ltd.
C1 [Westreich, Daniel] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Sch Med, Durham, NC 27710 USA.
[Westreich, Daniel] Duke Univ, Duke Global Hlth Inst, Durham, NC 27710 USA.
[Cole, Stephen R.] Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA.
[Young, Jessica G.; Hernan, Miguel A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Hernan, Miguel A.] Harvard Mit Div Hlth Sci & Technol, Boston, MA USA.
[Palella, Frank] Northwestern Univ, Div Infect Dis, Feinberg Sch Med, Chicago, IL 60611 USA.
[Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Kingsley, Lawrence] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
[Gange, Stephen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
RP Westreich, D (reprint author), Duke Univ, Med Ctr, Dept Obstet & Gynecol, Sch Med, Box 3084 Med Ctr, Durham, NC 27710 USA.
EM daniel.westreich@duke.edu
OI Gange, Stephen/0000-0001-7842-512X
FU NIH [K99-HD-063961, 5 T32 AI 07001-32, R01-AA-017594, P30-AI-50410,
R01-AI-073127-01A2]; National Institute of Allergy and Infectious
Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989,
UO1-AI-34993, UO1-AI-42590]; National Institute of Child Health and
Human Development [UO1-HD-32632]; National Cancer Institute
[UO1-AI-35042, 5-MO1-RR-00052, UO1-AI-35043, UO1-AI-35039, UO1-AI-35040,
UO1-AI-35041]; National Institute on Drug Abuse; National Institute on
Deafness and Other Communication Disorders; National Center for Research
Resources (UCSF-CTSI) [UL1 RR024131]
FX Dr. Daniel Westreich was supported by NIH grants K99-HD-063961 and 5 T32
AI 07001-32. Dr. Stephen R. Cole was partially supported by NIH grants
R01-AA-017594 and P30-AI-50410. Drs. Jessica Young and Miguel A. Hernan
were supported by NIH grant R01-AI-073127-01A2. The authors would like
to thank Dr. James Robins for expert advice.; Data in this manuscript
were collected by the WIHS Collaborative Study Group with centers
(principal investigators) at New York City/Bronx Consortium (Kathryn
Anastos); Brooklyn, NY (Howard Minkoff); Washington, DC, Metropolitan
Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern
California (Ruth Greenblatt); Los Angeles County/Southern California
Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); and
Data Coordinating Center (Stephen Gange). The WIHS is funded by the
National Institute of Allergy and Infectious Diseases (UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and
UO1-AI-42590) and by the National Institute of Child Health and Human
Development (UO1-HD-32632). The study is co-funded by the National
Cancer Institute, the National Institute on Drug Abuse, and the National
Institute on Deafness and Other Communication Disorders. Funding is also
provided by the National Center for Research Resources (UCSF-CTSI grant
number UL1 RR024131). The contents of this publication are solely the
responsibility of the authors and do not necessarily represent the
official views of the National Institutes of Health.; Data in this
manuscript were collected by the MACS with centers (principal
investigators) at The Johns Hopkins Bloomberg School of Public Health
(Joseph B. Margolick, Lisa P. Jacobson); Howard Brown Health Center,
Feinberg School of Medicine, Northwestern University, and Cook County
Bureau of Health Services (John P. Phair, Steven M. Wolinsky);
University of California, Los Angeles (Roger Detels); and University of
Pittsburgh (Charles R. Rinaldo). The MACS is funded by the National
Institute of Allergy and Infectious Diseases, with additional
supplemental funding from the National Cancer Institute (UO1-AI-35042,
5-MO1-RR-00052 (GCRC), UO1-AI-35043, UO1-AI-35039, UO1-AI-35040,
UO1-AI-35041; website located at
http://www.statepi.jhsph.edu/macs/macs.html).
NR 35
TC 27
Z9 27
U1 1
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
J9 STAT MED
JI Stat. Med.
PD AUG 15
PY 2012
VL 31
IS 18
BP 2000
EP 2009
DI 10.1002/sim.5316
PG 10
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA 974XO
UT WOS:000306471100008
PM 22495733
ER
PT J
AU Yao, JK
Condray, R
Dougherty, GG
Keshavan, MS
Montrose, DM
Matson, WR
McEvoy, J
Kaddurah-Daouk, R
Reddy, RD
AF Yao, Jeffrey K.
Condray, Ruth
Dougherty, George G., Jr.
Keshavan, Matcheri S.
Montrose, Debra M.
Matson, Wayne R.
McEvoy, Joseph
Kaddurah-Daouk, Rima
Reddy, Ravinder D.
TI Associations between Purine Metabolites and Clinical Symptoms in
Schizophrenia
SO PLOS ONE
LA English
DT Article
ID SERUM URIC-ACID; NEUROLOGIC EXAMINATION ABNORMALITIES;
NEUROLEPTIC-NAIVE; NEUROPSYCHOLOGICAL PERFORMANCE; ACHIEVEMENT BEHAVIOR;
PARKINSONS-DISEASE; SOFT SIGNS; ARRAY; CHOLESTEROL; CATABOLISM
AB Background: The antioxidant defense system, which is known to be dysregulated in schizophrenia, is closely linked to the dynamics of purine pathway. Thus, alterations in the homeostatic balance in the purine pathway may be involved in the pathophysiology of schizophrenia.
Methodology/Principal Findings: Breakdown products in purine pathway were measured using high-pressure liquid chromatography coupled with a coulometric multi-electrode array system for 25 first-episode neuroleptic-naive patients with schizophrenia at baseline and at 4-weeks following initiation of treatment with antipsychotic medication. Associations between these metabolites and clinical and neurological symptoms were examined at both time points. The ratio of uric acid and guanine measured at baseline predicted clinical improvement following four weeks of treatment with antipsychotic medication. Baseline levels of purine metabolites also predicted clinical and neurological symtpoms recorded at baseline; level of guanosine was associated with degree of clinical thought disturbance, and the ratio of xanthosine to guanosine at baseline predicted degree of impairment in the repetition and sequencing of actions.
Conclusions/Significance: Findings suggest an association between optimal levels of purine byproducts and dynamics in clinical symptoms and adjustment, as well as in the integrity of sensory and motor processing. Taken together, alterations in purine catabolism may have clinical relevance in schizophrenia pathology.
C1 [Yao, Jeffrey K.; Condray, Ruth; Dougherty, George G., Jr.; Reddy, Ravinder D.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA.
[Yao, Jeffrey K.; Condray, Ruth; Dougherty, George G., Jr.; Keshavan, Matcheri S.; Montrose, Debra M.; Reddy, Ravinder D.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Med Ctr, Pittsburgh, PA 15213 USA.
[Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
[Keshavan, Matcheri S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Keshavan, Matcheri S.] Harvard Univ, Boston, MA 02115 USA.
[Matson, Wayne R.] Bedford Vet Affairs Med Ctr, Bedford, MA USA.
[McEvoy, Joseph; Kaddurah-Daouk, Rima] Duke Univ, Med Ctr, Durham, NC USA.
RP Yao, JK (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA.
EM jkyao@pitt.edu
FU Department of Veterans Affairs (VA); Veterans Health Administration;
Office of Research and Development; Biomedical Laboratory Research
Development; Senior Research Career Scientist Award; VA Pittsburgh
Healthcare System; National Institutes of Health [MH58141, MH64118,
MH45203, MH84941, R24 GM078233, c UL1 RR024153, M01 RR00056];
Metabolomics Research Network; Stanley Medical Research Institute;
National Alliance for Research on Schizophrenia and Affective Disorders;
Merck; Psychogenics; Roche; Sunovion
FX This material is based on work supported in part by the grants from the
Department of Veterans Affairs (VA), Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research &
Development [Merit Reviews (JKY) and Senior Research Career Scientist
Award (JKY)], VA Pittsburgh Healthcare System (JKY, GGD), National
Institutes of Health [MH58141 (JKY), MH64118 (RDR), MH45203 (MSK),
MH84941 (RKD), R24 GM078233 (RKD), c UL1 RR024153 and NIH/NCRR/GCRC
Grant M01 RR00056], Metabolomics Research Network (RKD); Stanley Medical
Research Institute (RKD), and National Alliance for Research on
Schizophrenia and Affective Disorders (RKD). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript. The contents of this article do not
represent the views of the Department of Veterans Affairs or the United
States Government.; Dr. McEvoy received honoraria from Lilly, Merck, and
Sunovion, and grant supports from Merck, Psychogenics, Roche, and
Sunovion. Dr. Kaddurah-Daouk is a co-inventor on a series of patents in
the metabolomics field. (1. One patent Issued (3/20/12) "Lipidomic
approaches to determine drug response - Phenotypes in cardiovascular
disease" Patent # 8137977, expires 12/10/27. 2. One patent pending:
"Lipidomic approaches for central nervous system disorders" Application
# 12/091,213 filed 12/10/08, Publication # US 2009/0305323 12/10/09.)
All other authors declare no conflict of interest. This does not alter
the authors' adherence to all the PLoS ONE policies on sharing data and
materials.
NR 44
TC 10
Z9 10
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 14
PY 2012
VL 7
IS 8
AR e42165
DI 10.1371/journal.pone.0042165
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 988OQ
UT WOS:000307500800009
PM 22916123
ER
PT J
AU Biris, N
Yang, Y
Taylor, AB
Tomashevski, A
Guo, M
Hart, PJ
Diaz-Griffero, F
Ivanov, DN
AF Biris, Nikolaos
Yang, Yang
Taylor, Alexander B.
Tomashevski, Andrei
Guo, Miao
Hart, P. John
Diaz-Griffero, Felipe
Ivanov, Dmitri N.
TI Structure of the rhesus monkey TRIM5 alpha PRYSPRY domain, the HIV
capsid recognition module
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID MURINE LEUKEMIA-VIRUS; RETROVIRAL RESTRICTION; B30.2(SPRY) DOMAIN;
B30.2/SPRY DOMAIN; COMBINING SITE; SPRY DOMAIN; PROTEIN; DETERMINANTS;
SPECIFICITY; INFECTION
AB Tripartite motif protein TRIM5 alpha blocks retroviral replication after cell entry, and species-specific differences in its activity are determined by sequence variations within the C-terminal B30.2/PRYSPRY domain. Here we report a high-resolution structure of a TRIM5 alpha PRYSPRY domain, the PRYSPRY of the rhesus monkey TRIM5 alpha that potently restricts HIV infection, and identify features involved in its interaction with the HIV capsid. The extensive capsid-binding interface maps on the structurally divergent face of the protein formed by hypervariable loop segments, confirming that TRIM5 alpha evolution is largely determined by its binding specificity. Interactions with the capsid are mediated by flexible variable loops via a mechanism that parallels antigen recognition by IgM antibodies, a similarity that may help explain some of the unusual functional properties of TRIM5 alpha. Distinctive features of this pathogen-recognition interface, such as structural plasticity conferred by the mobile v1 segment and interaction with multiple epitopes, may allow restriction of divergent retroviruses and increase resistance to capsid mutations.
C1 [Biris, Nikolaos; Taylor, Alexander B.; Tomashevski, Andrei; Guo, Miao; Hart, P. John; Ivanov, Dmitri N.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Ivanov, Dmitri N.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
[Yang, Yang; Diaz-Griffero, Felipe] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA.
[Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Ivanov, DN (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
EM ivanov@uthscsa.edu
OI Biris, Nikolaos/0000-0003-4055-5521
FU University of Texas Health Science Center Executive Research Committee;
Cancer Therapy Research Center (P30 Cancer Center Support Grant from the
National Cancer Institute) [CA054174]; National Institutes of Health
(NIH) [R21 AI068548, R21 AI084612, R01 AI087390]; Robert A. Welch
Foundation [AQ-1399]; Cancer Prevention and Research Institute of Texas
(CPRIT); NIH [K99/R00]
FX We thank Dr. Oleg Tsodikov and the staff of Life Sciences Collaborative
Access Team (LS-CAT) sector at the Advanced Photon Source at the Argonne
National Laboratory for assistance with collection of the X-ray
diffraction data. Support for the NMR Core Facility and the X-ray
Crystallography Core Laboratory is provided by University of Texas
Health Science Center Executive Research Committee and the Cancer
Therapy Research Center (P30 Cancer Center Support Grant from the
National Cancer Institute CA054174). This research was supported in part
by National Institutes of Health (NIH) Grants R21 AI068548 (to D. I.),
R21 AI084612 (to D. I.), R01 AI087390 (to F. D.-G.), and the Robert A.
Welch Foundation grant AQ-1399 (to P.J.H.). The Scholar Award from the
Cancer Prevention and Research Institute of Texas (CPRIT) (D. I.) and
the NIH K99/R00 Pathway to Independence Award (F. D.-G.) are gratefully
acknowledged.
NR 48
TC 38
Z9 39
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 14
PY 2012
VL 109
IS 33
BP 13278
EP 13283
DI 10.1073/pnas.1203536109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 992VC
UT WOS:000307807000036
PM 22847415
ER
PT J
AU Graham, SM
Holte, SE
Dragavon, JA
Ramko, KM
Mandaliya, KN
McClelland, RS
Peshu, NM
Sanders, EJ
Krieger, JN
Coombs, RW
AF Graham, Susan M.
Holte, Sarah E.
Dragavon, Joan A.
Ramko, Kelly M.
Mandaliya, Kishor N.
McClelland, R. Scott
Peshu, Norbert M.
Sanders, Eduard J.
Krieger, John N.
Coombs, Robert W.
TI HIV-1 RNA May Decline More Slowly in Semen than in Blood following
Initiation of Efavirenz-Based Antiretroviral Therapy
SO PLOS ONE
LA English
DT Article
ID HIV-1-INFECTED MEN; DRUG CONCENTRATIONS; GENITAL-TRACT; COMPARTMENTS;
PLASMA; TRANSMISSION; METAANALYSIS; PENETRATION; LAMIVUDINE; INFECTION
AB Objectives: Antiretroviral therapy (ART) decreases HIV-1 RNA levels in semen and reduces sexual transmission from HIV-1-infected men. Our objective was to study the time course and magnitude of seminal HIV-1 RNA decay after initiation of efavirenz-based ART among 13 antiretroviral-naive Kenyan men.
Methods: HIV-1 RNA was quantified (lower limit of detection, 120 copies/mL) in blood and semen at baseline and over the first month of ART. Median log(10) HIV-1 RNA was compared at each time-point using Wilcoxon Signed Rank tests. Perelson's two-phase viral decay model and nonlinear random effects were used to compare decay rates in blood and semen.
Results: Median baseline HIV-1 RNA was 4.40 log(10) copies/mL in blood (range, 3.20-5.08 log(10) copies/mL) and 3.69 log(10) copies/mL in semen (range, <2.08-4.90 log(10) copies/mL). The median reduction in HIV-1 RNA by day 28 was 1.90 log(10) copies/mL in blood (range, 0.56-2.68 log(10) copies/mL) and 1.36 log(10) copies/mL in semen (range, 0-2.66 log(10) copies/mL). ART led to a decrease from baseline by day 7 in blood and day 14 in semen (p = 0.005 and p = 0.006, respectively). The initial modeled decay rate was slower in semen than in blood (p = 0.06). There was no difference in second-phase decay rates between blood and semen.
Conclusions: Efavirenz-based ART reduced HIV-1 RNA levels more slowly in semen than in blood. Although this difference was of borderline significance in this small study, our observations suggest that there is suboptimal suppression of seminal HIV-1 RNA for some men in the early weeks of treatment.
C1 [Graham, Susan M.; McClelland, R. Scott; Coombs, Robert W.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Graham, Susan M.; McClelland, R. Scott; Krieger, John N.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
[Graham, Susan M.; McClelland, R. Scott] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya.
[Graham, Susan M.; Ramko, Kelly M.; Peshu, Norbert M.; Sanders, Eduard J.] Kenya Govt Med Res Ctr, Ctr Geog Med & Res Coast, Kilifi, Kenya.
[Holte, Sarah E.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Holte, Sarah E.] Fred Hutchinson Canc Res Ctr, Dept Biostat & Biomath, Seattle, WA 98104 USA.
[Dragavon, Joan A.; Coombs, Robert W.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
[Mandaliya, Kishor N.] PathCare Kenya, Mombasa, Kenya.
[McClelland, R. Scott] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Sanders, Eduard J.] Univ Oxford, Nuffield Dept Clin Med, Headington, England.
[Krieger, John N.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
[Krieger, John N.] VA Puget Sound Hlth Care Syst, Dept Urol, Seattle, WA USA.
RP Graham, SM (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA.
EM grahamsm@u.washington.edu
OI Graham, Susan/0000-0001-7847-8686
FU National Institutes of Health (NIH) [R21 HD-055864, K23 AI-069990, R01
AI-055343, P30 AI027757]; University of Washington Center for AIDS
Research (CFAR); NIH (NIAID); NIH (NCI); NIH (NIMH); NIH (NIDA); NIH
(NICHD); NIH (NHLBI); NIH (NCCAM); Kenya Medical Research Institute
(KEMRI); International AIDS Vaccine Initiative (IAVI)
FX This study was supported by National Institutes of Health (NIH) grant
R21 HD-055864. Dr. Graham was supported by NIH grant K23 AI-069990, and
Dr. Holte was supported by NIH grant R01 AI-055343. Additional funding
was provided by the University of Washington Center for AIDS Research
(CFAR), an NIH funded program (P30 AI027757), which is supported by the
following NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD,
NHLBI, NCCAM). The funders had no role in study design, data collection
and analysis, decision to publish, or prepartion of the manuscript.; We
would like to thank the research staff who helped make this project a
success, the Kenya Medical Research Institute (KEMRI) and the
International AIDS Vaccine Initiative (IAVI) for support of E. Sanders
and use of clinical space, the Coast Provincial General Hospital for
provision of laboratory space, and the KEMRI Director for permission to
publish. Special thanks go to the men who participated in this study.
NR 30
TC 8
Z9 9
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 13
PY 2012
VL 7
IS 8
AR e43086
DI 10.1371/journal.pone.0043086
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 988OJ
UT WOS:000307500100060
PM 22912795
ER
PT J
AU Groeneveld, PW
AF Groeneveld, Peter W.
TI How Drug-Eluting Stents Illustrate Our Health System's Flawed
Relationship With Technology Value Lost
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Groeneveld, Peter W.] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
RP Groeneveld, PW (reprint author), Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, 1229 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM petergro@upenn.edu
NR 8
TC 2
Z9 2
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD AUG 13
PY 2012
VL 172
IS 15
BP 1152
EP 1153
DI 10.1001/archinternmed.2012.2724
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 986TT
UT WOS:000307369200011
PM 22777509
ER
PT J
AU Odden, MC
Peralta, CA
Haan, MN
Covinsky, KE
AF Odden, Michelle C.
Peralta, Carmen A.
Haan, Mary N.
Covinsky, Kenneth E.
TI Rethinking the Association of High Blood Pressure With Mortality in
Elderly Adults The Impact of Frailty
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID OLDER-ADULTS; GAIT SPEED; TASK-FORCE; HYPERTENSION; AGE; PREVENTION;
SURVIVAL; PROGRAM; DISEASE
AB Background: The association of hypertension and mortality is attenuated in elderly adults. Walking speed, as a measure of frailty, may identify which elderly adults are most at risk for the adverse effects of hypertension. We hypothesized that elevated blood pressure (BP) would be associated with a greater risk of mortality in faster-, but not slower-, walking older adults.
Methods: Participants included 2340 persons 65 years and older in the National Health and Nutrition Examination Survey, 1999-2000 and 2001-2002. Mortality data were linked to death certificates in the National Death Index. Walking speed was measured over a 20-ft (6 m) walk and classified as faster (>= 0.8 m/s [n=1307]), slower (n = 790), or incomplete (n = 243). Potential confounders included age, sex, race, survey year, lifestyle and physiologic variables, health conditions, and antihypertensive medication use.
Results: Among the participants, there were 589 deaths through December 31, 2006. The association between BP and mortality varied by walking speed. Among faster walkers, those with elevated systolic BP (>= 140 mm Hg) had a greater adjusted risk of mortality compared with those without (hazard ratio [HR], 1.35; 95% CI, 1.03-1.77). Among slower walkers, neither elevated systolic nor diastolic BP (>= 90 mm Hg) was associated with mortality. In participants who did not complete the walk test, elevated BP was strongly and independently associated with a lower risk of death: HR, 0.38; 95% CI, 0.23-0.62 (systolic); and HR, 0.10; 95% CI, 0.01-0.81 (diastolic).
Conclusions: Walking speed could be a simple measure to identify elderly adults who are most at risk for adverse outcomes related to high BP.
C1 [Odden, Michelle C.] Oregon State Univ, Coll Publ Hlth & Human Sci, Corvallis, OR 97331 USA.
[Peralta, Carmen A.; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Haan, Mary N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Peralta, Carmen A.; Covinsky, Kenneth E.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA.
RP Odden, MC (reprint author), Oregon State Univ, Coll Publ Hlth & Human Sci, 401 Waldo Hall, Corvallis, OR 97331 USA.
EM Michelle.Odden@oregonstate.edu
FU American Heart Association Western States Affiliate Clinical Research
Program; National Institute on Aging [K01AG039387]
FX Dr Odden is supported by the American Heart Association Western States
Affiliate Clinical Research Program and the National Institute on Aging
(grant K01AG039387).
NR 23
TC 98
Z9 100
U1 2
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD AUG 13
PY 2012
VL 172
IS 15
BP 1162
EP 1168
DI 10.1001/archinternmed.2012.2555
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 986TT
UT WOS:000307369200014
PM 22801930
ER
PT J
AU Cudaback, E
Li, XW
Yang, Y
Yoo, T
Montine, KS
Craft, S
Montine, TJ
Keene, CD
AF Cudaback, Eiron
Li, Xianwu
Yang, Yue
Yoo, Thomas
Montine, Kathleen S.
Craft, Suzanne
Montine, Thomas J.
Keene, Christopher Dirk
TI Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial
activation
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE ApoE; ApoC-I; Alzheimer's disease; Cerebrospinal fluid; Targeted
replacement mice
ID INNATE IMMUNE-RESPONSE; ONSET ALZHEIMERS-DISEASE;
CENTRAL-NERVOUS-SYSTEM; TOLL-LIKE RECEPTORS; TARGETED REPLACEMENT;
AMYLOID-BETA; GENE-CLUSTER; MEMORY FUNCTIONS; KNOCKOUT MICE; A-BETA
AB Background: Inheritance of the human epsilon 4 allele of the apolipoprotein (apo) E gene (APOE) significantly increases the risk of developing Alzheimer's disease (AD), in addition to adversely influencing clinical outcomes of other neurologic diseases. While apoE isoforms differentially interact with amyloid beta (A beta), a pleiotropic neurotoxin key to AD etiology, more recent work has focused on immune regulation in AD pathogenesis and on the mechanisms of innate immunomodulatory effects associated with inheritance of different APOE alleles. APOE genotype modulates expression of proximal genes including APOC1, which encodes a small apolipoprotein that is associated with A beta plaques. Here we tested the hypothesis that APOE-genotype dependent innate immunomodulation may be mediated in part by apoC-I.
Methods: ApoC-I concentration in cerebrospinal fluid from control subjects of differing APOE genotypes was quantified by ELISA. Real-time PCR and ELISA were used to analyze apoC-I mRNA and protein expression, respectively, in liver, serum, cerebral cortex, and cultured primary astrocytes derived from mice with targeted replacement of murine APOE for human APOE epsilon 3 or epsilon 4. ApoC-I direct modulation of innate immune activity was investigated in cultured murine primary microglia and astrocytes, as well as human differentiated macrophages, using specific toll-like receptor agonists LPS and PIC as well as A beta.
Results: ApoC-I levels varied with APOE genotype in humans and in APOE targeted replacement mice, with epsilon 4 carriers showing significantly less apoC-I in both species. ApoC-I potently reduced pro-inflammatory cytokine secretion from primary murine microglia and astrocytes, and human macrophages, stimulated with LPS, PIC, or A beta.
Conclusions: ApoC-I is immunosuppressive. Our results illuminate a novel potential mechanism for APOE genotype risk for AD; one in which patients with an epsilon 4 allele have decreased expression of apoC-I resulting in increased innate immune activity.
C1 [Cudaback, Eiron; Li, Xianwu; Yang, Yue; Yoo, Thomas; Montine, Kathleen S.; Montine, Thomas J.; Keene, Christopher Dirk] Univ Washington, Dept Pathol, Seattle, WA 98104 USA.
[Craft, Suzanne] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
RP Keene, CD (reprint author), Univ Washington, Dept Pathol, Seattle, WA 98104 USA.
EM cdkeene@uw.edu
RI Keene, Christopher/N-1806-2015
FU NIH [AG05136, ES16754, AG10880, T32AG00258]
FX The authors wish to thank Meilany Wijaya and Amy Look for technical
assistance, and Carol Arnold for managerial support. We also thank Dr.
Nobuyo Maeda for the generous gift of apoE2-, apoE3-, and apoE4-targeted
replacement mice, and Dr. Cecilia Giachelli for providing the human
THP-1 cell line. This work was supported by NIH grants AG05136, ES16754,
AG10880, and T32AG00258 (EC).
NR 60
TC 11
Z9 11
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD AUG 10
PY 2012
VL 9
AR 192
DI 10.1186/1742-2094-9-192
PG 13
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 033NA
UT WOS:000310802900001
PM 22883744
ER
PT J
AU Dufresne, SF
Datta, K
Li, XM
Dadachova, E
Staab, JF
Patterson, TF
Feldmesser, M
Marr, KA
AF Dufresne, Simon F.
Datta, Kausik
Li, Xinming
Dadachova, Ekaterina
Staab, Janet F.
Patterson, Thomas F.
Feldmesser, Marta
Marr, Kieren A.
TI Detection of Urinary Excreted Fungal Galactomannan-like Antigens for
Diagnosis of Invasive Aspergillosis
SO PLOS ONE
LA English
DT Article
ID LINKED-IMMUNOSORBENT-ASSAY; LATEX AGGLUTINATION-TEST;
ENZYME-IMMUNOASSAY; PULMONARY ASPERGILLOSIS; NEUTROPENIC PATIENTS;
INFECTED-RABBITS; FUMIGATUS; SERUM; PCR; SAMPLES
AB Mortality associated with invasive aspergillosis (IA) remains high, partly because of delayed diagnosis. Detection of microbial exoantigens, released in serum and other body fluids during infection, may help timely diagnosis. In course of IA, Aspergillus galactomannan (GM), a well established polysaccharide biomarker, is released in body fluids including urine. Urine is an abundant, safely collected specimen, well-suited for point-of-care (POC) testing, which could play an increasing role in screening for early disease. Our main objective was to demonstrate GM antigenuria as a clinically relevant biological phenomenon in IA and establish proof-of-concept that it could be translated to POC diagnosis. Utilizing a novel IgM monoclonal antibody (MAb476) that recognizes GM-like antigens from Aspergillus and other molds, we demonstrated antigenuria in an experimental animal IA model (guinea pig), as well as in human patients. In addition, we investigated the chemical nature of the urinary excreted antigen in human samples, characterized antigen detection in urine by immunoassays, described a putative assay inhibitor in urine, and indicated means of alleviation of the inhibition. We also designed and used a lateral flow immunochromatographic assay to detect urinary excreted antigen in a limited number of IA patient urine samples. In this study, we establish that POC diagnosis of IA based on urinary GM detection is feasible. Prospective studies will be necessary to establish the performance characteristics of an optimized device and define its optimal clinical use.
C1 [Dufresne, Simon F.; Datta, Kausik; Staab, Janet F.; Marr, Kieren A.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
[Marr, Kieren A.] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.
[Li, Xinming; Dadachova, Ekaterina; Feldmesser, Marta] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Patterson, Thomas F.] S Texas Vet Healthcare Syst, San Antonio, TX USA.
[Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Dufresne, Simon F.] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada.
[Li, Xinming] China Med Univ, Shenyang, Peoples R China.
RP Dufresne, SF (reprint author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
EM kmarr4@jhmi.edu
RI Dadachova, Ekaterina/I-7838-2013; Datta, Kausik/A-2879-2016
OI Datta, Kausik/0000-0001-8666-143X
FU Johns Hopkins Accelerated Translational Incubator Pilot (ATIP) program;
National Institutes of Health [AI065745, AI060507]; National Institute
of Allergy and Infectious Disease [AI30041]; Hopital
Maisonneuve-Rosemont and Universite de Montreal
FX This work was supported by the Johns Hopkins Accelerated Translational
Incubator Pilot (ATIP) program grant to JFS; National Institutes of
Health [R21 grant AI065745 to MF, grant AI060507 to ED and National
Institute of Allergy and Infectious Disease N01 Contract AI30041 to
TFP]; and Hopital Maisonneuve-Rosemont and Universite de Montreal
[fellowship grant to SFD]. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 52
TC 12
Z9 14
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 10
PY 2012
VL 7
IS 8
AR e42736
DI 10.1371/journal.pone.0042736
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 986XO
UT WOS:000307380900063
PM 22900046
ER
PT J
AU Prasad, R
Vaid, M
Katiyar, SK
AF Prasad, Ram
Vaid, Mudit
Katiyar, Santosh K.
TI Grape Proanthocyanidin Inhibit Pancreatic Cancer Cell Growth In Vitro
and In Vivo through Induction of Apoptosis and by Targeting the PI3K/Akt
Pathway
SO PLOS ONE
LA English
DT Article
ID SKH-1 HAIRLESS MICE; ACTIVATED AKT; CARCINOMA-CELLS; CYCLE CONTROL;
BCL-2 FAMILY; EXPRESSION; PROTEIN; DEATH; PHOSPHORYLATION; KINASES
AB Pancreatic cancer is an aggressive malignancy that is frequently diagnosed at an advanced stage with poor prognosis. Here, we report the chemotherapeutic effects of bioactive proanthocyanidins from grape seeds (GSPs) as assessed using In Vitro and In Vivo models. Treatment of human pancreatic cancer cells (Miapaca-2, PANC-1 and AsPC-1) with GSPs In Vitro reduced cell viability and increased G2/M phase arrest of the cell cycle leading to induction of apoptosis in a dose- and time-dependent manner. The GSPs-induced apoptosis of pancreatic cancer cells was associated with a decrease in the levels of Bcl-2 and Bcl-xl and an increase in the levels of Bax and activated caspase-3. Treatment of Miapaca-2 and PANC-1 cells with GSPs also decreased the levels of phosphatidylinositol-3-kinase (PI3K) and phosphorylation of Akt at ser(473). siRNA knockdown of PI3K from pancreatic cancer cells also reduced the phosphorylation of Akt. Further, dietary administration of GSPs (0.5%, w/w) as a supplemented AIN76A control diet significantly inhibited the growth of Miapaca-2 pancreatic tumor xenografts grown subcutaneously in athymic nude mice, which was associated with: (i) inhibition of cell proliferation, (ii) induction of apoptosis of tumor cells, (iii) increased expression of Bax, reduced expression of anti-apoptotic proteins and activation of caspase-3-positive cells, and (iv) decreased expression of PI3K and p-Akt in tumor xenograft tissues. Together, these results suggest that GSPs may have a potential chemotherapeutic effect on pancreatic cancer cell growth.
C1 [Prasad, Ram; Vaid, Mudit; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
RP Prasad, R (reprint author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU Veterans Administration Merit Review Award
FX This work was supported by funds from the Veterans Administration Merit
Review Award (SKK). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 36
TC 31
Z9 36
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 8
PY 2012
VL 7
IS 8
AR e43064
DI 10.1371/journal.pone.0043064
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 986GX
UT WOS:000307331100082
PM 22905202
ER
PT J
AU Denberg, TD
Humphrey, LL
Shekelle, P
Qaseem, A
AF Denberg, Thomas D.
Humphrey, Linda L.
Shekelle, Paul
Qaseem, Amir
TI Screening for Colorectal Cancer RESPONSE
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Denberg, Thomas D.] Harvard Vanguard Med Associates & Atrius Hlth, Auburndale, MA 02466 USA.
[Humphrey, Linda L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Shekelle, Paul] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
[Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA.
RP Denberg, TD (reprint author), Harvard Vanguard Med Associates & Atrius Hlth, Auburndale, MA 02466 USA.
NR 1
TC 0
Z9 0
U1 1
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD AUG 7
PY 2012
VL 157
IS 3
BP 218
EP 219
DI 10.7326/0003-4819-157-3-201208070-00020
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 992PB
UT WOS:000307789900014
ER
PT J
AU St John, MA
Wang, G
Luo, J
Dohadwala, M
Hu, D
Lin, Y
Dennis, M
Lee, JM
Elashoff, D
Lawhon, T
Zaknoen, SL
Burrows, FJ
Dubinett, SM
AF St John, M. A.
Wang, G.
Luo, J.
Dohadwala, M.
Hu, D.
Lin, Y.
Dennis, M.
Lee, J. M.
Elashoff, D.
Lawhon, T.
Zaknoen, S. L.
Burrows, F. J.
Dubinett, S. M.
TI Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial
malignancies
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE EMT; PGT; 15-PGDH; HNSCC; metastasis; COX-2 inhibitor
ID SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; LUNG-CANCER; PHASE-II;
HEAD; NECK; CYCLOOXYGENASE-2; DEHYDROGENASE; COMBINATION; INHIBITION
AB BACKGROUND: Despite focused research in conventional therapies and considerable advances in the understanding of the molecular carcinogenesis of head and neck squamous cell carcinoma (HNSCC), the 5-year survival rate for patients with advanced disease remains similar to 15-20%. The major causes of HNSCC-related deaths are cervical node and distant metastasis. E-cadherin has a key role in epithelial intercellular adhesion and its downregulation is a hallmark of epithelial-mesenchymal transition (EMT), which is associated with invasion, metastasis, and poor prognosis. Epithelial-mesenchymal transition is the major mechanism responsible for mediating invasiveness and metastasis of epithelial cancers. Recently, we reported the role of E-cadherin transcriptional repressors in the inflammation-induced promotion of EMT in HNSCC, which is mediated by COX-2. These findings suggest that therapies targeting the cyclooxygenase pathway may diminish the propensity for tumour metastasis in HNSCC by blocking the PGE2-mediated induction of E-cadherin transcriptional repressors.
METHODS: Herein, we evaluate the efficacy of the COX-2 inhibitor, apricoxib, in HNSCC cell lines. Apricoxib is effective in preventing tumour cell growth in three-dimensional, and anchorage-independent growth assays, as well as decreasing the capacity for tumour cell migration.
RESULTS: Herein, we evaluate the efficacy of the COX-2 inhibitor, apricoxib, in HNSCC cell lines. Apricoxib is effective in preventing tumour cell growth in three-dimensional, and anchorage-independent growth assays, as well as decreasing the capacity for tumour cell migration. Treatment of HNSCC cells with apricoxib also causes greater upregulation of E-cadherin and Muc1 expression and downregulation of vimentin, as compared with celecoxib treatment. This has significant implications for targeted chemoprevention and anti-cancer therapy because E-cadherin expression has been implicated as a marker of sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor and other therapies. We show for the first time the molecular mechanisms underlying the efficacy of apricoxib in HNSCC cells.
CONCLUSION: In addition to reversing EMT via inhibition of COX-2, apricoxib upregulates 15-prostaglandin dehydrogenase and the prostaglandin transporter, thereby reducing the levels of active PGE2 by both suppressing its synthesis and increasing its catabolism. These findings have significant implications for metastasis and tumour progression in HNSCC. British Journal of Cancer (2012) 107, 707-712. doi:10.1038/bjc.2012.203 www.bjcancer.com Published online 24 July 2012 (C) 2012 Cancer Research UK
C1 [St John, M. A.; Hu, D.; Dennis, M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, Los Angeles, CA 90095 USA.
[Wang, G.; Luo, J.; Dohadwala, M.; Lee, J. M.; Dubinett, S. M.] Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA 90095 USA.
[Wang, G.; Luo, J.; Dohadwala, M.; Lin, Y.; Lee, J. M.; Elashoff, D.; Dubinett, S. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Wang, G.; Luo, J.; Dohadwala, M.; Lin, Y.; Lee, J. M.; Elashoff, D.; Dubinett, S. M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA.
[Dohadwala, M.; Dubinett, S. M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Lawhon, T.; Zaknoen, S. L.; Burrows, F. J.] Tragara Pharmaceut, San Diego, CA 92130 USA.
RP St John, MA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, 10833 Le Conte Ave,CHS 62-132, Los Angeles, CA 90095 USA.
EM MStJohn@mednet.ucla.edu
RI lin, yuan/E-6062-2011
FU NCATS NIH HHS [UL1 TR000124]
NR 26
TC 2
Z9 2
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD AUG 7
PY 2012
VL 107
IS 4
BP 707
EP 712
DI 10.1038/bjc.2012.203
PG 6
WC Oncology
SC Oncology
GA 992IY
UT WOS:000307770300019
PM 22828609
ER
PT J
AU Capo-Ramos, DE
Gao, Y
Lubin, JH
Check, DP
Goldin, LR
Pesatori, AC
Consonni, D
Bertazzi, PA
Saxon, AJ
Bergen, AW
Caporaso, NE
Landi, MT
AF Capo-Ramos, David E.
Gao, Ying
Lubin, Jay H.
Check, David P.
Goldin, Lynn R.
Pesatori, Angela C.
Consonni, Dario
Bertazzi, Pier Alberto
Saxon, Andrew J.
Bergen, Andrew W.
Caporaso, Neil E.
Landi, Maria Teresa
TI Mood Disorders and Risk of Lung Cancer in the EAGLE Case-Control Study
and in the US Veterans Affairs Inpatient Cohort
SO PLOS ONE
LA English
DT Article
ID BIPOLAR DISORDER; MAJOR DEPRESSION; RECORD-LINKAGE; SEROTONIN; GENETICS;
SMOKING; ANTIDEPRESSANTS; SCHIZOPHRENIA; ENVIRONMENT; POPULATION
AB Background: Mood disorders may affect lung cancer risk. We evaluated this hypothesis in two large studies.
Methodology/Principal Findings: We examined 1,939 lung cancer cases and 2,102 controls from the Environment And Genetics in Lung cancer Etiology (EAGLE) case-control study conducted in Italy (2002-2005), and 82,945 inpatients with a lung cancer diagnosis and 3,586,299 person-years without a lung cancer diagnosis in the U. S. Veterans Affairs Inpatient Cohort (VA study), composed of veterans with a VA hospital admission (1969-1996). In EAGLE, we calculated odds ratios (ORs) and 95% confidence intervals (CI), with extensive adjustment for tobacco smoking and multiple lifestyle factors. In the VA study, we estimated lung cancer relative risks (RRs) and 95% CIs with time-dependent Poisson regression, adjusting for attained age, calendar year, hospital visits, time within the study, and related previous medical diagnoses. In EAGLE, we found decreased lung cancer risk in subjects with a personal history of mood disorders (OR: 0.59, 95% CI: 0.44-0.79, based on 121 lung cancer incident cases and 192 controls) and family history of mood disorders (OR: 0.62, 95% CI: 0.50-0.77, based on 223 lung cancer cases and 345 controls). The VA study analyses yielded similar results (RR: 0.74, 95% CI: 0.71-0.77, based on 2,304 incident lung cancer cases and 177,267 non-cancer person-years) in men with discharge diagnoses for mood disorders. History of mood disorders was associated with nicotine dependence, alcohol and substance use and psychometric scales of depressive and anxiety symptoms in controls for these studies.
Conclusions/Significance: The consistent finding of a relationship between mood disorders and lung cancer risk across two large studies calls for further research into the complex interplay of risk factors associated with these two widespread and debilitating diseases. Although we adjusted for smoking effects in EAGLE, residual confounding of the results by smoking cannot be ruled out.
C1 [Capo-Ramos, David E.; Gao, Ying; Lubin, Jay H.; Check, David P.; Goldin, Lynn R.; Caporaso, Neil E.; Landi, Maria Teresa] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Pesatori, Angela C.; Consonni, Dario; Bertazzi, Pier Alberto] Univ Milan, Epidemiol Res Ctr, EPOCA, Milan, Italy.
[Pesatori, Angela C.; Consonni, Dario; Bertazzi, Pier Alberto] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Epidemiol Unit, Milan, Italy.
[Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Saxon, Andrew J.] Addict Psychiat Residency Program, Seattle, WA USA.
[Saxon, Andrew J.] Univ Washington, Seattle, WA 98195 USA.
[Bergen, Andrew W.] SRI Int, Ctr Hlth Sci, Mol Genet Program, Menlo Pk, CA 94025 USA.
RP Capo-Ramos, DE (reprint author), Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
EM landim@mail.nih.gov
RI Consonni, Dario/K-7943-2016; bertazzi, pietro alberto/D-5039-2017
OI Consonni, Dario/0000-0002-8935-3843; bertazzi, pietro
alberto/0000-0003-3475-2449; Bergen, Andrew/0000-0002-1237-7644;
pesatori, angela/0000-0002-0261-3252
FU National Institutes of Health, National Cancer Institute (Division of
Cancer Epidemiology and Genetics); Region of Lombardy, Milan, Italy
(Environmental Epidemiology Program); Center of Excellence in Substance
Abuse Treatment and Education at VA Puget Sound Health Care System; NIH
[U01DA020830, RC2DA028793]
FX Funding for this study was provided by the Intramural Research Program
of the National Institutes of Health, National Cancer Institute
(Division of Cancer Epidemiology and Genetics) and by the Region of
Lombardy, Milan, Italy (Environmental Epidemiology Program). Dr. Saxon
is supported by the Center of Excellence in Substance Abuse Treatment
and Education at VA Puget Sound Health Care System. Dr. Bergen is
supported by NIH grants U01DA020830 and RC2DA028793. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 44
TC 1
Z9 1
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 7
PY 2012
VL 7
IS 8
AR e42945
DI 10.1371/journal.pone.0042945
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 987SL
UT WOS:000307437900063
PM 22880133
ER
PT J
AU Milanesi, A
Lee, JW
Li, ZH
Da Sacco, S
Villani, V
Cervantes, V
Perin, L
Yu, JS
AF Milanesi, Anna
Lee, Jang-Won
Li, Zhenhua
Da Sacco, Stefano
Villani, Valentina
Cervantes, Vanessa
Perin, Laura
Yu, John S.
TI beta-Cell Regeneration Mediated by Human Bone Marrow Mesenchymal Stem
Cells
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INSULIN-PRODUCING CELLS; PROTEIN-KINASE-B;
IN-VIVO; STROMAL CELLS; PANCREATIC-ISLETS; DIABETIC MICE; FACTOR-A;
DIFFERENTIATION; EXPRESSION
AB Bone marrow mesenchymal stem cells (BMSCs) have been shown to ameliorate diabetes in animal models. The mechanism, however, remains largely unknown. An unanswered question is whether BMSCs are able to differentiate into beta-cells in vivo, or whether BMSCs are able to mediate recovery and/or regeneration of endogenous beta-cells. Here we examined these questions by testing the ability of hBMSCs genetically modified to transiently express vascular endothelial growth factor (VEGF) or pancreatic-duodenal homeobox 1 (PDX1) to reverse diabetes and whether these cells were differentiated into beta-cells or mediated recovery through alternative mechanisms. Human BMSCs expressing VEGF and PDX1 reversed hyperglycemia in more than half of the diabetic mice and induced overall improved survival and weight maintenance in all mice. Recovery was sustained only in the mice treated with hBMSCs-VEGF. However, de novo beta-cell differentiation from human cells was observed in mice in both cases, treated with either hBMSCs-VEGF or hBMSCs-PDX1, confirmed by detectable level of serum human insulin. Sustained reversion of diabetes mediated by hBMSCs-VEGF was secondary to endogenous beta-cell regeneration and correlated with activation of the insulin/IGF receptor signaling pathway involved in maintaining beta-cell mass and function. Our study demonstrated the possible benefit of hBMSCs for the treatment of insulin-dependent diabetes and gives new insight into the mechanism of beta-cell recovery after injury mediated by hBMSC therapy.
C1 [Milanesi, Anna] Cedars Sinai Med Ctr, Div Endocrinol, Los Angeles, CA 90048 USA.
[Milanesi, Anna] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Lee, Jang-Won; Li, Zhenhua; Cervantes, Vanessa; Yu, John S.] Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA.
[Da Sacco, Stefano; Villani, Valentina; Perin, Laura] Univ So Calif, Dept Urol, Childrens Hosp Los Angeles, Los Angeles, CA USA.
RP Milanesi, A (reprint author), Cedars Sinai Med Ctr, Div Endocrinol, Los Angeles, CA 90048 USA.
EM john.yu@cshs.org
RI Da Sacco, Stefano/G-6346-2011
FU Endocrine Fellow Foundation; Cedars-Sinai Clinical Scholar Program
FX Funding source: Endocrine Fellow Foundation, and Cedars-Sinai Clinical
Scholar Program. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 55
TC 21
Z9 22
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 7
PY 2012
VL 7
IS 8
AR e42177
DI 10.1371/journal.pone.0042177
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 987SL
UT WOS:000307437900023
PM 22879915
ER
PT J
AU Dey, N
Ghosh-Choudhury, N
Kasinath, BS
Choudhury, GG
AF Dey, Nirmalya
Ghosh-Choudhury, Nandini
Kasinath, Balakuntalam S.
Choudhury, Goutam Ghosh
TI TGF beta-Stimulated MicroRNA-21 Utilizes PTEN to Orchestrate AKT/mTORC1
Signaling for Mesangial Cell Hypertrophy and Matrix Expansion
SO PLOS ONE
LA English
DT Article
ID MESSENGER-RNA TRANSLATION; GROWTH-FACTOR-BETA; PLASMINOGEN-ACTIVATOR
INHIBITOR-1; PROMOTES RENAL FIBROSIS; CHRONIC KIDNEY-DISEASE;
SMOOTH-MUSCLE-CELLS; DIABETIC-NEPHROPATHY; MAMMALIAN TARGET; HIGH
GLUCOSE; AKT KINASE
AB Transforming growth factor-beta (TGF beta) promotes glomerular hypertrophy and matrix expansion, leading to glomerulosclerosis. MicroRNAs are well suited to promote fibrosis because they can repress gene expression, which negatively regulate the fibrotic process. Recent cellular and animal studies have revealed enhanced expression of microRNA, miR-21, in renal cells in response to TGF beta. Specific miR-21 targets downstream of TGF beta receptor activation that control cell hypertrophy and matrix protein expression have not been studied. Using 3'UTR-driven luciferase reporter, we identified the tumor suppressor protein PTEN as a target of TGF beta-stimulated miR-21 in glomerular mesangial cells. Expression of miR-21 Sponge, which quenches endogenous miR-21 levels, reversed TGF beta-induced suppression of PTEN. Additionally, miR-21 Sponge inhibited TGF beta-stimulated phosphorylation of Akt kinase, resulting in attenuation of phosphorylation of its substrate GSK3 beta. Tuberin and PRAS40, two other Akt substrates, and endogenous inhibitors of mTORC1, regulate mesangial cell hypertrophy. Neutralization of endogenous miR-21 abrogated TGF beta-stimulated phosphorylation of tuberin and PRAS40, leading to inhibition of phosphorylation of S6 kinase, mTOR and 4EBP-1. Moreover, downregulation of miR-21 significantly suppressed TGF beta-induced protein synthesis and hypertrophy, which were reversed by siRNA-targeted inhibition of PTEN expression. Similarly, expression of constitutively active Akt kinase reversed the miR-21 Sponge-mediated inhibition of TGF beta-induced protein synthesis and hypertrophy. Furthermore, expression of constitutively active mTORC1 prevented the miR-21 Sponge-induced suppression of mesangial cell protein synthesis and hypertrophy by TGF beta. Finally, we show that miR-21 Sponge inhibited TGF beta-stimulated fibronectin and collagen expression. Suppression of PTEN expression and expression of both constitutively active Akt kinase and mTORC1 independently reversed this miR-21-mediated inhibition of TGF beta-induced fibronectin and collagen expression. Our results uncover an essential role of TGF beta-induced expression of miR-21, which targets PTEN to initiate a non-canonical signaling circuit involving Akt/mTORC1 axis for mesangial cell hypertrophy and matrix protein synthesis.
C1 [Dey, Nirmalya; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
[Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Vet Adm Res, San Antonio, TX USA.
RP Dey, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
EM choudhuryg@uthscsa.edu
FU National Institutes of Health (NIH) [RO1 DK50190, RO1 AR 52425, RO1 DK
077295, RC2A 036613]; VA (Veterans Administration) Research Service
Merit Review grant; Juvenile Diabetes Research Foundation [1-2008-185];
VA Senior Research Career Scientist Award; VA Merit Review; Cancer
Therapy and Research Center, San Antonio, Texas
FX National Institutes of Health (NIH) RO1 DK50190 grant to GGC supported
this work. Part of this work was also supported by VA (Veterans
Administration) Research Service Merit Review grant to GGC. GGC is also
supported by Juvenile Diabetes Research Foundation 1-2008-185 grants and
is recipient of VA Senior Research Career Scientist Award. NGC is
supported by VA Merit Review, NIH RO1 AR 52425 grants and Ronald P.
Williams Orthopedic Oncology Developmental Research Award from Cancer
Therapy and Research Center, San Antonio, Texas. BSK is supported by NIH
RO1 DK 077295, NIH RC2A 036613 and VA Merit Review Award. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 102
TC 46
Z9 53
U1 1
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 3
PY 2012
VL 7
IS 8
AR e42316
DI 10.1371/journal.pone.0042316
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 985QT
UT WOS:000307284100066
PM 22879939
ER
PT J
AU Zarraga, IGE
Dougherty, CM
MacMurdy, KS
Raitt, MH
AF Zarraga, Ignatius Gerardo E.
Dougherty, Cynthia M.
MacMurdy, Karen S.
Raitt, Merritt H.
TI The Effect of Spironolactone on Ventricular Tachyarrhythmias in Patients
With Implantable Cardioverter-Defibrillators
SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
LA English
DT Article
DE antiarrhythmia agents; cardioversion; defibrillation; spironolactone;
tachyarrhythmias
ID RANDOMIZED ALDACTONE EVALUATION; CONGESTIVE-HEART-FAILURE;
MYOCARDIAL-INFARCTION; SHOCKS; CARDIOMYOPATHY; MORTALITY; PREVENTS;
THERAPY
AB Background-Previous studies have suggested that aldosterone blockade can reduce the incidence of ventricular tachycardia (VT) or ventricular fibrillation (VF) in patients with heart failure. The SPIronolactone to Reduce ICD Therapy (SPIRIT) trial was designed to test the hypothesis that spironolactone reduces the incidence of VT/VF in patients with implantable cardioverter-defibrillators (ICDs) who are at moderately high risk for recurrent VT/VF.
Methods and Results-Ninety patients who had ICDs who were at moderately high risk for recurrent VT/VF and who were not candidates for spironolactone by current heart failure guidelines were randomized to receive spironolactone 25 mg daily or placebo in a double-blind fashion. All patients had previously received ICD therapy (shock or antitachycardia pacing) for VT/VF within 2 years of randomization or an ICD for secondary prevention of VT/VF within 6 months of randomization. The primary end point was time to first recurrence of VT/VF requiring ICD therapy. After a median follow-up of 35 months, the Kaplan-Meier probability estimates for VT/VF requiring ICD therapy were 68.7% in the placebo group and 84.7% in the spironolactone group. Compared with placebo, spironolactone was associated with a similar risk of VT/VF (hazard ratio, 1.01; 95% CI, 0.64-1.83; P=0.71). There was no significant difference between the median times to first VT/VF recurrence requiring ICD therapy in the 2 groups.
Conclusions-In patients with ICDs who were at moderately high risk for recurrent VT/VF on account of a recent VT/VF event that was either sustained or treated by the ICD and who were not candidates for spironolactone by current heart failure guidelines, spironolactone did not delay the first recurrence of VT/VF or reduce the risk of recurrent VT/VF. (Circ Arrhythm Electrophysiol. 2012;5:739-747.)
C1 [Zarraga, Ignatius Gerardo E.; MacMurdy, Karen S.; Raitt, Merritt H.] Portland VA Med Ctr, Div Cardiol, Portland, OR 97239 USA.
[Zarraga, Ignatius Gerardo E.; MacMurdy, Karen S.; Raitt, Merritt H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Dougherty, Cynthia M.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
RP Zarraga, IGE (reprint author), Portland VA Med Ctr, Div Cardiol, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM Ignatius.Zarraga@va.gov
OI Raitt, Merritt/0000-0001-5638-7732
FU Department of Defense; Veterans Administration
FX This work was supported by a grant from the Department of Defense and
the Veterans Administration.
NR 24
TC 3
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3149
J9 CIRC-ARRHYTHMIA ELEC
JI Circ.-Arrhythmia Electrophysiol.
PD AUG
PY 2012
VL 5
IS 4
BP 739
EP 747
DI 10.1161/CIRCEP.112.970566
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 071IE
UT WOS:000313584500022
PM 22773022
ER
PT J
AU Segal, AD
Zelik, KE
Klute, GK
Morgenroth, DC
Hahn, ME
Orendurff, MS
Adamczyk, PG
Collins, SH
Kuo, AD
Czerniecki, JM
AF Segal, Ava D.
Zelik, Karl E.
Klute, Glenn K.
Morgenroth, David C.
Hahn, Michael E.
Orendurff, Michael S.
Adamczyk, Peter G.
Collins, Steven H.
Kuo, Arthur D.
Czerniecki, Joseph M.
TI The effects of a controlled energy storage and return prototype
prosthetic foot on transtibial amputee ambulation
SO HUMAN MOVEMENT SCIENCE
LA English
DT Article
DE Prosthesis; Amputation; Metabolic cost; Biomechanics; Rehabilitation
ID BELOW-KNEE AMPUTEES; POWERED ANKLE EXOSKELETONS; LOWER-LIMB AMPUTATION;
TO-STEP TRANSITIONS; HUMAN WALKING; MECHANICAL WORK; METABOLIC COST;
BIOMECHANICAL ANALYSIS; SOUND LIMB; GAIT
AB The lack of functional ankle musculature in lower limb amputees contributes to the reduced prosthetic ankle push-off, compensations at other joints and more energetically costly gait commonly observed in comparison to non-amputees. A variety of energy storing and return prosthetic feet have been developed to address these issues but have not been shown to sufficiently improve amputee biomechanics and energetic cost, perhaps because the timing and magnitude of energy return is not controlled. The goal of this study was to examine how a prototype microprocessor-controlled prosthetic foot designed to store some of the energy during loading and return it during push-off affects amputee gait. Unilateral transtibial amputees wore the Controlled Energy Storage and Return prosthetic foot (CESR), a conventional foot (CONV), and their previously prescribed foot (PRES) in random order. Three-dimensional gait analysis and net oxygen consumption were collected as participants walked at constant speed. The CESR foot demonstrated increased energy storage during early stance, increased prosthetic foot peak push-off power and work, increased prosthetic limb center of mass (COM) push-off work and decreased intact limb COM collision work compared to CONV and PRES. The biological contribution of the positive COM work for CESR was reduced compared to CONV and PRES. However, the net metabolic cost for CESR did not change compared to CONV and increased compared to PRES, which may partially reflect the greater weight, lack of individualized size and stiffness and relatively less familiarity for CESR and CONV. Controlled energy storage and return enhanced prosthetic push-off, but requires further design modifications to improve amputee walking economy. Published by Elsevier B.V.
C1 [Segal, Ava D.; Klute, Glenn K.; Morgenroth, David C.; Hahn, Michael E.; Orendurff, Michael S.; Czerniecki, Joseph M.] VA Puget Sound Hlth Care Syst, RR&D Ctr, Dept Vet Affairs, Seattle, WA 98108 USA.
[Klute, Glenn K.; Hahn, Michael E.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA.
[Klute, Glenn K.] Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA.
[Morgenroth, David C.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Zelik, Karl E.; Adamczyk, Peter G.; Collins, Steven H.; Kuo, Arthur D.] Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA.
[Adamczyk, Peter G.; Collins, Steven H.] Intelligent Prosthet Syst LLC, Ann Arbor, MI USA.
RP Czerniecki, JM (reprint author), VA Puget Sound Hlth Care Syst, RR&D Ctr, Dept Vet Affairs, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM joseph.czerniecki@med.va.gov
RI Kuo, Arthur/L-3359-2013; Adamczyk, Peter/P-5928-2014
OI Kuo, Arthur/0000-0001-5233-9709; Adamczyk, Peter/0000-0001-5374-7691;
Morgenroth, David/0000-0002-0226-7775; Collins,
Steve/0000-0002-3997-3374
FU NICHD NIH HHS [HD055706, R44 HD055706]
NR 49
TC 19
Z9 19
U1 1
U2 47
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-9457
EI 1872-7646
J9 HUM MOVEMENT SCI
JI Hum. Mov. Sci.
PD AUG
PY 2012
VL 31
IS 4
BP 918
EP 931
DI 10.1016/j.humov.2011.08.005
PG 14
WC Neurosciences; Psychology; Psychology, Experimental; Sport Sciences
SC Neurosciences & Neurology; Psychology; Sport Sciences
GA 063BV
UT WOS:000312971800014
PM 22100728
ER
PT J
AU Royall, DR
Palmer, RF
Petrovitch, H
Ross, GW
Masaki, K
White, LR
AF Royall, Donald R.
Palmer, Raymond F.
Petrovitch, Helen
Ross, G. Webster
Masaki, Kamal
White, Lon R.
TI Modeling regional vulnerability to Alzheimer pathology
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Old age; Neuropathology; Alzheimer's disease
ID MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLES; DEMENTIA SEVERITY;
SPATIAL-PATTERNS; BRAIN PATHOLOGY; SENILE PLAQUES; DISEASE; AGE; AD;
CRITERIA
AB Latent growth curve (LGC) models estimate change over time in a cohort's serially obtained measurements. We have applied LGC techniques to a spatial distribution of Alzheimer's disease (AD) pathology using autopsy data from 435 participants in the Honolulu-Asia Aging Study. Neurofibrillary tangle (NFT) and neuritic plaques (NP) were distributed across differently ordered sets of anatomical regions. The gradient of spatial change in neuritic plaque (dNP), was significantly associated with that of neurofibrillary tangle (dNFT), but weakly and inversely (r = -0.12; p < 0.001). Both dNFT and dNP correlated significantly and inversely with Braak stage. Sixty-one percent of the variance in Braak stage was explained by dNFT independent of covariates. Only dNFT was significantly associated with longitudinal change in cognition. Only dNP was associated with apolipoprotein (APOE) e4 burden. This is the first application of LGC models to spatially-ordered data. The result is a quantification of the interindividual variation in the interregional vulnerability to Alzheimer's disease lesions. (C) 2012 Published by Elsevier Inc.
C1 [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78284 USA.
[Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78284 USA.
[Royall, Donald R.; Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78284 USA.
[Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div GRECC, San Antonio, TX USA.
[Petrovitch, Helen] Pacific Hlth Res & Educ Inst, Honolulu, HI USA.
[Ross, G. Webster] Honolulu Dept Vet Affairs, Honolulu, HI USA.
[Masaki, Kamal; White, Lon R.] John A Burns Sch Med Kakaako, Dept Geriatr Med, Honolulu, HI USA.
[Masaki, Kamal; White, Lon R.] HonoluluKuakini Med Ctr, Kuakini Med Ctr, Honolulu, HI USA.
RP Royall, DR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.
EM royall@uthscsa.edu
FU National Institute of Neurological Disorders and Stroke (National
Institutes of Health, USA) [NSO48123-01]; Julia and Van Buren Parr
professorship in Aging and Geriatric Psychiatry
FX DRR, RFP, and LRW were funded by National Institute of Neurological
Disorders and Stroke (National Institutes of Health, USA), Grant No.
NSO48123-01. DRR is supported by the Julia and Van Buren Parr
professorship in Aging and Geriatric Psychiatry. HAAS neuropathological
data were entirely generated by a team of 4 expert neuropathologists
under leadership of Dr. William Markesbery (deceased), with the
oversight of LRW, the HAAS Principal Investigator. Other members of the
team were Dr. John Hardman (deceased), Dr. James Nelson (retired), and
Dr. Daron Davis (who left the study for a clinical practice in 2001).
NR 41
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD AUG
PY 2012
VL 33
IS 8
BP 1556
EP 1563
DI 10.1016/j.neurobiolaging.2011.05.028
PG 8
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 969QN
UT WOS:000306070800006
PM 21803455
ER
PT J
AU Bhattacharya, A
Bokov, A
Muller, FL
Jernigan, AL
Maslin, K
Diaz, V
Richardson, A
Van Remmen, H
AF Bhattacharya, Arunabh
Bokov, Alex
Muller, Florian L.
Jernigan, Amanda L.
Maslin, Keith
Diaz, Vivian
Richardson, Arlan
Van Remmen, Holly
TI Dietary restriction but not rapamycin extends disease onset and survival
of the H46R/H48Q mouse model of ALS
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Dietary-restriction; Rapamycin; H46R/H48Q; G93A; ALS
ID GENETICALLY HETEROGENEOUS MICE; AMYOTROPHIC-LATERAL-SCLEROSIS;
MOTOR-NEURON DEGENERATION; LIFE-SPAN; CALORIC RESTRICTION; G93A MOUSE;
PROGRESSION; EXTENSION; TOXICITY; MTOR
AB Dietary restriction (DR) and rapamycin (Rapa) have been shown to increase the lifespan of a variety of organisms leading to the speculation that these interventions increase lifespan through related mechanisms. However, both these interventions have a detrimental effect in the G93A mutant mouse model of amyotrophic lateral sclerosis (ALS). Our previous work indicated that different ALS SOD1 mutant mouse models differ in disease pathogenesis; therefore in this study we measured the effect of DR and Rapa in a second ALS mutant mouse model (the H46R/H48Q mutant). Interestingly, in mice expressing this mutant SOD1 protein, DR significantly delays disease onset and extends lifespan, while Rapa has no effect. These findings suggest that: (1) the effect of DR in ALS is not mediated through pathways common with Rapa, (2) the deleterious effect of DR and Rapa in the G93A ALS mouse model may not be universal to disease caused by all SOD1 mutations, and (3) the results reinforce our previous conclusions that the pathogenic mechanisms in G93A and H46R/H48Q mice are distinct. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Bhattacharya, Arunabh; Jernigan, Amanda L.; Maslin, Keith; Diaz, Vivian; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Bhattacharya, Arunabh; Muller, Florian L.; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA.
[Bokov, Alex; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA.
[Richardson, Arlan; Van Remmen, Holly] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA.
EM vanremmen@uthscsa.edu
FU Muscular Dystrophy Association [MDA 10047]
FX This work was supported by the Muscular Dystrophy Association (Grant MDA
10047 to HVR). We thank Dr. David Borchelt for kindly providing the
H46R/H48Q mutant mice.
NR 21
TC 21
Z9 21
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD AUG
PY 2012
VL 33
IS 8
BP 1829
EP 1832
DI 10.1016/j.neurobiolaging.2011.06.002
PG 4
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 969QN
UT WOS:000306070800032
PM 21763036
ER
PT J
AU Koontz, AM
Worobey, LA
Rice, IM
Collinger, JL
Boninger, ML
AF Koontz, Alicia M.
Worobey, Lynn A.
Rice, Ian M.
Collinger, Jennifer L.
Boninger, Michael L.
TI Comparison Between Overground and Dynamometer Manual Wheelchair
Propulsion
SO JOURNAL OF APPLIED BIOMECHANICS
LA English
DT Article
DE biomechanics; kinetics; spinal cord injury
ID SPINAL-CORD-INJURY; PUSHRIM FORCES; BIOMECHANICS; ERGOMETER; KINETICS;
TERRAIN; WALKING; LEVEL
AB Laboratory-based simulators afford many advantages for studying physiology and biomechanics; however, they may not perfectly mimic wheelchair propulsion over natural surfaces. The goal of this study was to compare kinetic and temporal parameters between propulsion overground on a tile surface and on a dynamometer. Twenty-four experienced manual wheelchair users propelled at a self-selected speed on smooth, level tile and a dynamometer while kinetic data were collected using an instrumented wheel. A Pearson correlation test was used to examine the relationship between propulsion variables obtained on the dynamometer and the overground condition. Ensemble resultant force and moment curves were compared using cross-correlation and qualitative analysis of curve shape. User biomechanics were correlated (R ranging from 0.41 to 0.83) between surfaces. Overall, findings suggest that although the dynamometer does not perfectly emulate overground propulsion, wheelchair users were consistent with the direction and amount of force applied, the time peak force was reached, push angle, and their stroke frequency between conditions.
C1 [Koontz, Alicia M.; Worobey, Lynn A.; Rice, Ian M.; Collinger, Jennifer L.; Boninger, Michael L.] US Dept Vet Affairs, Human Engn Res Labs, Rehabil Res & Dev Ctr, Pittsburgh, PA USA.
[Koontz, Alicia M.; Worobey, Lynn A.; Collinger, Jennifer L.; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
[Koontz, Alicia M.; Rice, Ian M.; Collinger, Jennifer L.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Koontz, Alicia M.; Worobey, Lynn A.; Rice, Ian M.; Collinger, Jennifer L.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Koontz, AM (reprint author), US Dept Vet Affairs, Human Engn Res Labs, Rehabil Res & Dev Ctr, Pittsburgh, PA USA.
OI Worobey, Lynn/0000-0001-8795-6061; Boninger, Michael/0000-0001-6966-919X
FU National Institutes of Health [1 R03 HD049735-01A1]; Department of
Veterans Affairs [B6252R]; Human Engineering Research Laboratories, VA
Pittsburgh Healthcare System
FX This material is based in part upon work supported by the National
Institutes of Health (Grant Number: 1 R03 HD049735-01A1) and by the
Department of Veterans Affairs (Project Number: B6252R). The study
sponsors had no involvement in study design, collection, analysis, and
interpretation of data, writing of the manuscript, or decision to submit
the manuscript for publication. This material is the result of work
supported with resources and the use of facilities at the Human
Engineering Research Laboratories, VA Pittsburgh Healthcare System. The
contents of this article do not represent the views of the Department of
Veterans Affairs or the United States Government.
NR 27
TC 6
Z9 6
U1 1
U2 6
PU HUMAN KINETICS PUBL INC
PI CHAMPAIGN
PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA
SN 1065-8483
J9 J APPL BIOMECH
JI J. Appl. Biomech.
PD AUG
PY 2012
VL 28
IS 4
BP 412
EP 419
PG 8
WC Engineering, Biomedical; Sport Sciences
SC Engineering; Sport Sciences
GA 017DC
UT WOS:000309569300007
PM 22085811
ER
PT J
AU Gonzalez, L
Chen, A
Lin, PH
Pisimisis, G
Barshes, NR
Bechara, CF
Kougias, P
AF Gonzalez, L.
Chen, A.
Lin, P. H.
Pisimisis, G.
Barshes, N. R.
Bechara, C. F.
Kougias, P.
TI Latest recanalization techniques for complex superficial femoral artery
occlusions
SO JOURNAL OF CARDIOVASCULAR SURGERY
LA English
DT Article
DE Femoral artery; Coronary occlusion; Surgical procedures, minimally
invasive
ID SINGLE-CENTER EXPERIENCE; TRUE LUMEN REENTRY; CONTROLLED BLUNT
MICRODISSECTION; SUBINTIMAL ANGIOPLASTY; OUTBACK CATHETER; DEVICE;
DISSECTION
AB Complex, long segment lesions of the superficial femoral artery (SFA) are common, occurring in 40% of patients with peripheral vascular disease. In particular, chronic total occlusions (CTOs) continue to pose a challenge in the endovascular management of SFA disease. Several conventional wire and catheter based techniques have been described including subintimal recanalization and retrograde techniques. In addition, advances in endovascular technology have led to the development of a series of new devices aimed specifically at facilitating the crossing of long segment SFA occlusions or establishing re-entry of the true lumen. Here we present an overview of the minimally invasive techniques used to recanalize CTOs of the SFA and the latest specialized devices available for both recanalization and re-entry, as well as a summary of the literature supporting their application.
C1 [Pisimisis, G.; Barshes, N. R.; Bechara, C. F.; Kougias, P.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
[Gonzalez, L.; Chen, A.; Lin, P. H.; Pisimisis, G.; Barshes, N. R.; Bechara, C. F.; Kougias, P.] Baylor Coll Med, Houston, TX 77030 USA.
RP Kougias, P (reprint author), Houston VAMC, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,OCL-112, Houston, TX 77030 USA.
EM pkougias@bcm.eclu
NR 19
TC 2
Z9 3
U1 0
U2 2
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0021-9509
J9 J CARDIOVASC SURG
JI J. Cardiovasc. Surg.
PD AUG
PY 2012
VL 53
IS 4
BP 487
EP 494
PG 8
WC Cardiac & Cardiovascular Systems; Surgery; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology; Surgery
GA 017EI
UT WOS:000309572500010
PM 22854529
ER
PT J
AU Khitri, MR
Mills, MD
Ying, GS
Davidson, SL
Quinn, GE
AF Khitri, Monica R.
Mills, Monte D.
Ying, Gui-Shuang
Davidson, Stefanie L.
Quinn, Graham E.
TI Visual acuity outcomes in pediatric glaucomas
SO JOURNAL OF AAPOS
LA English
DT Article
ID CHILDHOOD GLAUCOMA; GRATING ACUITY; CHILDREN; CATARACT
AB PURPOSE To evaluate and compare the visual acuity prognosis in the various pediatric glaucoma subtypes and to determine risk factors for vision loss.
METHODS The medical records of pediatric glaucoma patients from 2000 to 2010 at Children's Hospital of Philadelphia were retrospectively reviewed. Visual acuities, surgeries, glaucoma subtype, and etiology of vision impairment were recorded. Univariate and multivariate analyses were performed to determine the risk factors for visual impairment.
RESULTS A total of 133 eyes (36.8% primary congenital glaucoma, 28.6% aphakic glaucoma, 12.0% glaucoma associated with anterior segment dysgenesis, 12.0% Sturge-Weber glaucoma) of 88 patients were included. At last follow-up (median length, 5 years), 46.6% eyes achieved excellent (>= 20/70) visual acuity. Of the glaucoma subtypes, primary congenital glaucoma conferred the best visual prognosis, with 69.4% eyes with excellent (>= 20/70) visual acuity at final follow-up. Factors most associated with visual impairment (<20/200) were unilateral disease, multiple surgeries, poor vision at diagnosis, and other ocular comorbidities. The most common primary etiology for vision impairment was amblyopia (54.9%).
CONCLUSIONS Patients with glaucoma early in life appear to have a better visual acuity prognosis than previously reported, with those with primary congenital glaucoma faring better than other glaucoma subtypes. Recognition of risk factors for visual impairment can better guide clinical management and counseling of patients. (J AAPOS 2012;16:376-381)
C1 [Khitri, Monica R.; Mills, Monte D.; Ying, Gui-Shuang; Davidson, Stefanie L.; Quinn, Graham E.] Childrens Hosp Philadelphia, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
RP Khitri, MR (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM monica.ralli@gmail.com
NR 14
TC 8
Z9 8
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1091-8531
J9 J AAPOS
JI J. AAPOS
PD AUG
PY 2012
VL 16
IS 4
BP 376
EP 381
DI 10.1016/j.jaapos.2012.05.007
PG 6
WC Ophthalmology; Pediatrics
SC Ophthalmology; Pediatrics
GA 016FT
UT WOS:000309503600014
PM 22929453
ER
PT J
AU Padula, AM
Pressman, AR
Vittinghoff, E
Grady, D
Neuhaus, J
Ackerson, L
Rudd, P
Avins, AL
AF Padula, Amy M.
Pressman, Alice R.
Vittinghoff, Eric
Grady, Deborah
Neuhaus, John
Ackerson, Lynn
Rudd, Peter
Avins, Andrew L.
TI Placebo Adherence and Mortality in the Heart and Estrogen/Progestin
Replacement Study
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Adherence; Double-blind clinical trials; Placebo
ID MYOCARDIAL-INFARCTION; TRIAL; ASSOCIATION; SURVIVAL; THERAPY; WOMEN;
DEATH; RISK
AB BACKGROUND: Analyses from double-blind randomized trials have reported lower mortality among participants who were more adherent to placebo compared with those who were less adherent. We explored this phenomenon by analyzing data from the placebo arm of the Heart and Estrogen/Progestin Replacement Study (HERS), a randomized, double-blind, placebo-controlled trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Our primary aim was to measure and explain the association between adherence to placebo and total mortality among the placebo-allocated participants in the HERS. Secondary aims included assessment of the association between placebo adherence and cause-specific morbidity and mortality.
METHODS: Participants with "higher placebo adherence" were defined as having taken at least 75% of their placebo study medication during each individual's participation in the study, whereas those with "lower placebo adherence" took less than 75%. The primary outcome was in-study all-cause mortality.
RESULTS: More adherent participants had significantly lower total mortality compared with less adherent participants (hazard ratio, 0.52; 95% confidence interval, 0.29-0.93). Adjusting for available confounders did not change the magnitude or significance of the estimates. Analyses revealed that the association of higher adherence and mortality might be explained, in part, by time-dependent confounding.
CONCLUSIONS: Analyses of the HERS data support a strong association between adherence to placebo study medication and mortality. Although probably not due to simple confounding by healthy lifestyle factors, the underlying mechanism for the association remains unclear. Further analyses of this association are necessary to explain this observation. (C) 2012 Elsevier Inc. All rights reserved. center dot The American Journal of Medicine (2012) 125, 804-810
C1 [Padula, Amy M.; Rudd, Peter] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.
[Padula, Amy M.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
[Pressman, Alice R.; Ackerson, Lynn; Avins, Andrew L.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Vittinghoff, Eric; Neuhaus, John; Avins, Andrew L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Grady, Deborah; Avins, Andrew L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Grady, Deborah; Avins, Andrew L.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Padula, AM (reprint author), Stanford Univ, Sch Med, Dept Med, Off Bldg,1265 Welsh Rd, Stanford, CA 94305 USA.
EM ampadula@stanford.edu
FU National Heart, Lung, and Blood Institute [R01 HL081195]; Wyeth-Ayerst
Research
FX Supported by a grant from the National Heart, Lung, and Blood Institute
(R01 HL081195). The HERS was conducted and supported by Wyeth-Ayerst
Research. The manuscript does not necessarily reflect the opinions or
views of the HERS investigators or Wyeth-Ayerst Research.
NR 13
TC 4
Z9 5
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD AUG
PY 2012
VL 125
IS 8
BP 804
EP 810
DI 10.1016/j.amjmed.2012.02.014
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 978LE
UT WOS:000306741300025
PM 22840666
ER
PT J
AU Hutchens, MP
Fujiyoshi, T
Komers, R
Herson, PS
Anderson, S
AF Hutchens, Michael P.
Fujiyoshi, Tetsuhiro
Komers, Radko
Herson, Paco S.
Anderson, Sharon
TI Estrogen protects renal endothelial barrier function from
ischemia-reperfusion in vitro and in vivo
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE ischemia-reperfusion injury; renal ischemia; acute renal failure; acute
kidney injury; oxygen-glucose deprivation; cardiac arrest;
cardiopulmonary resuscitation; gender; sex; estrogen; estradiol
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; CRITICALLY-ILL PATIENTS; HEAT-SHOCK
PROTEINS; ACUTE KIDNEY INJURY; CARDIOPULMONARY-RESUSCITATION;
REPLACEMENT THERAPY; SIZE-SELECTIVITY; SERUM CREATININE; RECEPTOR-ALPHA;
CARDIAC-ARREST
AB Hutchens MP, Fujiyoshi T, Komers R, Herson PS, Anderson S. Estrogen protects renal endothelial barrier function from ischemia-reperfusion in vitro and in vivo. Am J Physiol Renal Physiol 303:F377-F385, 2012. First published May 23, 2012; doi:10.1152/ajprenal.00354.2011.-Emerging evidence suggests that renal endothelial function may be altered in ischemia-reperfusion injury. Acute kidney injury is sexually dimorphic, and estrogen protects renal tubular function after experimental ischemic injury. This study tested the hypothesis that during ischemia-reperfusion, estrogen alters glomerular endothelial function to prevent hyperpermeability. Glomerular endothelial cells were exposed to 8-h oxygen-glucose deprivation (OGD) followed by 4- and 8-h reoxygenation-glucose repletion. After 4-h reoxygenation-glucose repletion, transendothelial permeability to Ficoll-70 was reduced, and transendothelial resistance increased, by 17 beta-estradiol vs. vehicle treatment during OGD (OGD-vehicle: 91.0 +/- 11.8%, OGD-estrogen: 102.6 +/- 10.8%, P < 0.05). This effect was reversed by coadministration of G protein-coupled receptor 30 (GPR30) antagonist G15 with 17 beta-estradiol (OGD-estrogen-G15: 89.5 +/- 6.9, P < 0.05 compared with 17 beta-estradiol). To provide preliminary confirmation of this result in vivo, Ficoll-70 was administered to mice 24 h after cardiac arrest and cardiopulmonary resuscitation (CA/CPR). Blood urea nitrogen (BUN) and serum creatinine (SCr) in these mice were elevated within 12 h following CA/CPR and reduced at 24 h by pretreatment with 17 beta-estradiol (BUN/SCr 17 beta-estradiol: 34 +/- 19/0.2 +/- 0.1 vehicle: 92 +/- 49/0.5 +/- 0.3, n = 8-12, P < 0.05). Glomerular sieving of Ficoll 70 was increased by CA/CPR within 2 h of injury and 17 beta-estradiol treatment (theta; 17 beta-estradiol: 0.74 +/- 0.26 vs. vehicle: 1.05 +/- 0.53, n = 14-15, P < 0.05). These results suggest that estrogen reduces postischemic glomerular endothelial hyperpermeability at least in part through GPR30 and that estrogen may regulate post CA/CPR glomerular permeability in a similar fashion in vivo.
C1 [Hutchens, Michael P.; Fujiyoshi, Tetsuhiro; Herson, Paco S.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
[Komers, Radko; Anderson, Sharon] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Dept Internal Med, Portland, OR 97239 USA.
[Anderson, Sharon] Portland VA Med Ctr, Med Serv, Portland, OR USA.
RP Hutchens, MP (reprint author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, HRC 5N,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM hutchenm@ohsu.edu
OI Hutchens, Michael/0000-0001-8583-1812
FU NIDDK [DK090754-01]
FX This work was supported in part by NIDDK Grant DK090754-01 (to M. P.
Hutchens).
NR 48
TC 28
Z9 28
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD AUG
PY 2012
VL 303
IS 3
BP F377
EP F385
DI 10.1152/ajprenal.00354.2011
PG 9
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 984ZA
UT WOS:000307231300009
PM 22622457
ER
PT J
AU Bouhaddou, O
Cromwell, T
Davis, M
Maulden, S
Hsing, N
Carlson, D
Cockle, J
Hoang, C
Fischetti, L
AF Bouhaddou, Omar
Cromwell, Tim
Davis, Mike
Maulden, Sarah
Hsing, Nelson
Carlson, David
Cockle, Jennifer
Hoang, Catherine
Fischetti, Linda
TI Translating standards into practice: Experience and lessons learned at
the Department of Veterans Affairs
SO JOURNAL OF BIOMEDICAL INFORMATICS
LA English
DT Article
DE Standards adoption; Reference implementation; Standards Life Cycle;
Interoperability; Likelihood of Adoption Scale; Health information
technology
AB The increased need for interoperable electronic health records in health care organizations underscores the importance of standards. The US Department of Veterans Affairs (VA) has a long history of developing and adopting various types of health care data standards. The authors present in detail their experience in this domain. A formal organization within VA is responsible for helping to develop and implement standards. This group has produced a Standards Life Cycle (SLC) process endorsed by VA key business and information technology (IT) stakeholders. It coordinates the identification, description, and implementation of standards aligned with VA business requirements. In this paper, we review the adoption of four standards in the categories of security and privacy, terminology, health information exchange, and modeling tools; emphasizing the implementation approach used in each. In our experience, adoption is facilitated by internal staff with expertise in standards development and adoption. Use of processes such as an SLC and tools such as an enterprise requirement repository help formally track and ensure that IT development and acquisition incorporate these standards. An organization should adopt standards that are aligned with its business priorities and favor those that are more readily implementable. To assist with this final point, we offer a standard "Likelihood of Adoption Scale," which changes as standards specifications evolve from PDF documents only, to PDF documents with construction and testing tools, to fully functional reference implementations. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Bouhaddou, Omar; Cromwell, Tim; Davis, Mike; Maulden, Sarah; Hsing, Nelson; Carlson, David; Cockle, Jennifer; Hoang, Catherine; Fischetti, Linda] US Dept Vet Affairs, Washington, DC USA.
RP Bouhaddou, O (reprint author), POB 3351, Rancho Santa Fe, CA 92067 USA.
EM omar.bouhaddou@va.gov
NR 19
TC 6
Z9 6
U1 2
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1532-0464
J9 J BIOMED INFORM
JI J. Biomed. Inform.
PD AUG
PY 2012
VL 45
IS 4
SI SI
BP 813
EP 823
DI 10.1016/j.jbi.2012.01.003
PG 11
WC Computer Science, Interdisciplinary Applications; Medical Informatics
SC Computer Science; Medical Informatics
GA 998RN
UT WOS:000308258200023
PM 22285982
ER
PT J
AU Mostaghel, EA
Lin, DW
Amory, JK
Wright, JL
Marck, BT
Nelson, PS
Matsumoto, AM
Bremner, WJ
Page, ST
AF Mostaghel, Elahe A.
Lin, Daniel W.
Amory, John K.
Wright, Jonathan L.
Marck, Brett T.
Nelson, Peter S.
Matsumoto, Alvin M.
Bremner, William J.
Page, Stephanie T.
TI Impact of Male Hormonal Contraception on Prostate Androgens and Androgen
Action in Healthy Men: A Randomized, Controlled Trial
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID TESTOSTERONE REPLACEMENT; ORAL TESTOSTERONE; OLDER MEN; CANCER;
FINASTERIDE; CASTRATION; TISSUE; HYPERPLASIA; DUTASTERIDE;
DIHYDROTESTOSTERONE
AB Context: Male hormonal contraception (MHC) combines hypothalamic-pituitary-gonadal axis blockade with exogenous androgen delivery to maintain extragonadal androgen end-organ effects. Concern exists that MHC may adversely impact prostate health.
Objective: The objective of the study was to determine the molecular impact of MHC on intraprostatic androgen concentrations and androgen action.
Design: This was a single-blind, randomized, placebo-controlled study.
Setting: The study was conducted at an academic medical center.
Participants: 32 healthy men aged 25-55 yr participated in the study.
Intervention: Interventions included placebo, daily transdermal testosterone (T) (T-gel), T-gel + depomedroxyprogesterone acetate (T+DMPA), or T-gel + dutasteride daily (T+D) for 12 wk, and prostate biopsy during treatment wk 10.
Main Outcome Measures: Serum and prostate androgen concentrations and prostate epithelial-cell gene expression were measured.
Results: Thirty men completed the study. Serum T levels were significantly increased in T-gel and T+D groups compared with baseline (P < 0.05) but were decreased with the addition of DMPA. Intraprostatic androgens were no different from placebo with T-gel treatment. Addition of DMPA to T resulted in 40% lower intraprostatic dihydrotestosterone (DHT) concentration (P = 0.0273 vs. placebo), whereas combining dutasteride with T resulted in a 90% decrease in intraprostatic DHT (P = 0.0012), 11-fold increased intraprostatic T (P = 0.0011), and 7-fold increased intraprostatic androstenedione (P = 0.0011). Significant differences in global or androgen-regulated prostate epithelial-cell gene expression were not observed. Androgen-regulated gene expression correlated with epithelial-cell androgen receptor and prostatic DHT in placebo, T-gel, and T+DMPA arms and with T and androstenedione levels in the T+D arm.
Conclusions: MHC regimens do not markedly alter gene expression in benign prostate epithelium, suggesting they may not alter risk of prostate disease. Longer-term studies examining the impact of MHC on prostate health are needed. (J Clin Endocrinol Metab 97: 2809-2817, 2012)
C1 [Page, Stephanie T.] Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA.
[Mostaghel, Elahe A.; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol & Clin Res, Seattle, WA 98109 USA.
[Lin, Daniel W.; Wright, Jonathan L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Lin, Daniel W.; Wright, Jonathan L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
[Marck, Brett T.; Matsumoto, Alvin M.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Marck, Brett T.; Matsumoto, Alvin M.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA.
RP Page, ST (reprint author), Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Dept Med, Box 357138,1959 NE Pacific St, Seattle, WA 98195 USA.
EM page@u.washington.edu
FU National Institutes of Health through National Institute of Aging Grants
[K23-AG027238, RO1-AG037603A]; Eunice Kennedy Shriver National Institute
of Child Health and Human Development Grant [U54-HD-42454]; National
Cancer Institute Grant [K23 CA122820-01]; Pacific Northwest Prostate
Cancer SPORE Grant [P50-CA097186]; Damon Runyon-Genentech Clinical
Investigator Award [CI-40-08]; Prostate Cancer Foundation;
GlaxoSmithKline; Abbott Pharmaceuticals
FX This work was supported by the National Institutes of Health through
National Institute of Aging Grants K23-AG027238 and RO1-AG037603A, the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development Grant U54-HD-42454, the National Cancer Institute Grant K23
CA122820-01, and the Pacific Northwest Prostate Cancer SPORE Grant
P50-CA097186 E.A.M. was also supported by a Damon Runyon-Genentech
Clinical Investigator Award CI-40-08 and the Prostate Cancer Foundation.
NR 34
TC 9
Z9 9
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD AUG
PY 2012
VL 97
IS 8
BP 2809
EP 2817
DI 10.1210/jc.2012-1536
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 987ZI
UT WOS:000307457400066
PM 22659250
ER
PT J
AU Sevick, MA
Korytkowski, M
Stone, RA
Piraino, B
Ren, DX
Sereika, S
Wang, YY
Steenkiste, A
Burke, LE
AF Sevick, Mary Ann
Korytkowski, Mary
Stone, Roslyn A.
Piraino, Beth
Ren, Dianxu
Sereika, Susan
Wang, Yuanyuan
Steenkiste, Ann
Burke, Lora E.
TI Biophysiologic Outcomes of the Enhancing Adherence in Type 2 Diabetes
(ENHANCE) Trial
SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS
LA English
DT Article
DE Diabetes mellitus, type 2; Chronic kidney disease; Computers, hand-held;
Personal digital assistant; Randomized clinical trial
ID GLOMERULAR-FILTRATION-RATE; GLYCEMIC CONTROL; GLUCOSE; METAANALYSIS
AB Background Behavioral research to improve lifestyle in broadly defined populations of patients with type 2 diabetes is limited.
Objective We evaluated a behavioral intervention featuring technology-based self-monitoring on biophysiologic outcomes of glycemic control and markers of cardiovascular risk
Design In this single-site, randomized clinical trial, participants were stratified by good and poor glycemic control (glycated hemoglobin <8% or >= 8%) and absence or presence of kidney disease, (estimated glomerular filtration rate >= 60 or <60 mL/min) and randomized within strata. Measurements were obtained at 0, 3, and 6 months.
Participants/setting Self-referred, community-dwelling adults with type 2 diabetes mellitus.
Intervention The intervention group received Social Cognitive Theory-based counseling paired with technology-based self-monitoring, and results were compared with an attention control group.
Main outcome measures Glycated hemoglobin, fasting serum glucose, lipid levels, blood pressure, weight, body mass index, and waist circumference were evaluated.
Statistical analyses performed Mean differences within and between randomization groups were compared over time. Intervention effects over time were estimated using random intercept models.
Results Two hundred ninety-six subjects were randomized, 256(86.5%) completed 3-month and 246 (83.1%) completed 6-month assessments. Glycated hemoglobin was reduced in the intervention group by 0.5% at 3 months and 0.6% at 6 months (P<0.001 for each), and the control group by 0.3% (P<0.001) at 3 months and 0.2% (P<0.05) at 6 months; but between-group differences were not significant. In those with baseline glycated hemoglobin >= 8% and estimated glomerular filtration rate >= 60 mL/min, glycated hemoglobin was reduced in the intervention group by 1.5% at 3 months and 1.8% at 6 months (P<0.001 for each), and the control group by 0.9% (P<0.001) at 3 months and 0.8% (P<0.05) at 6 months; but between-group differences were not significant. In random intercept models, the estimated reduction in glycated hemoglobin of 0.29% was not significant.
Conclusions Two behavioral approaches to improving general lifestyle management in individuals with type 2 diabetes mellitus were effective in improving glycemic control, but no significant between-group differences were observed. J Acad Nutr Diet. 2012;112:1147-1157.
C1 [Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Ctr Res & Promot, Pittsburgh, PA 15213 USA.
[Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Pittsburgh, PA 15213 USA.
[Sevick, Mary Ann; Korytkowski, Mary] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.
[Stone, Roslyn A.; Burke, Lora E.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Ren, Dianxu; Burke, Lora E.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15213 USA.
[Wang, Yuanyuan] INC Res, Philadelphia, PA USA.
[Steenkiste, Ann] Vet Res Fdn Pittsburgh, Pittsburgh, PA USA.
RP Sevick, MA (reprint author), VA Pittsburgh Healthcare Syst, Ctr Res & Promot, Suite 600,230 McKee Pl, Pittsburgh, PA 15213 USA.
EM sevick@pitt.edu
OI Piraino, Beth/0000-0001-5061-0841
FU National Institutes of Health; National Institutes of Health/National
Institute of Nursing Research [NR-R01008792]; National Institutes of
Health/National Center for Research Resources [CTSA-UL1-RR024153,
GCRC-M01-RR000056]
FX M. Korytkowski serves as a consultant to Eli Lilly and Company, and also
serves as a grant reviewer to Pfizer, Inc. M. A. Sevick and L. E. Burke
have received grants from the National Institutes of Health to carry out
separate protocols involving self-management interventions involving
PDA-based self-monitoring. None of the other authors reported any
financial conflicts of interest.; This work was supported by the
following grants: National Institutes of Health/National Institute of
Nursing Research no. NR-R01008792, National Institutes of
Health/National Center for Research Resources no. CTSA-UL1-RR024153, and
National Institutes of Health/National Center for Research Resources no.
GCRC-M01-RR000056. Clinical trials.gov identifier: NCT00222846. The
sponsors initially approved the study concept and protocol, required
regular updates regarding protocol accrual and data safety and
monitoring, and provided funds to the participating organization. The
sponsor did not have any role in the analysis or interpretation of data
or in the preparation, review, or approval of the manuscript.
NR 21
TC 9
Z9 9
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-2672
J9 J ACAD NUTR DIET
JI J. Acad. Nutr. Diet.
PD AUG
PY 2012
VL 112
IS 8
BP 1147
EP 1157
DI 10.1016/j.jand.2012.05.008
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 986CJ
UT WOS:000307318100006
PM 22818724
ER
PT J
AU Brown, AK
Mandelkern, MA
Farahi, J
Robertson, C
Ghahremani, DG
Sumerel, B
Moallem, N
London, ED
AF Brown, Amira K.
Mandelkern, Mark A.
Farahi, Judah
Robertson, Chelsea
Ghahremani, Dara G.
Sumerel, Brittany
Moallem, Nathasha
London, Edythe D.
TI Sex differences in striatal dopamine D-2/D-3 receptor availability in
smokers and non-smokers
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE D-2 receptors; dopamine; [F-18]fallypride; nicotine dependence; PET; sex
differences
ID REFERENCE TISSUE MODEL; TRANSPORTER AVAILABILITY; NICOTINE DEPENDENCE;
BRAIN; REGISTRATION; F-18-FALLYPRIDE; SPECT
AB In previous research, nicotine-dependent men exhibited lower putamen D-2/D-3 dopamine-receptor availability than non-smokers (Fehr et al. 2008), but parallel assessments were not performed in women. Women and men (19 light smokers, 18 non-smokers) were tested for differences due to sex and smoking in striatal D-2/D-3 dopamine-receptor availability, using positron emission tomography with [F-18]fallypride. Receptor availability was determined using a reference region method, in striatal volumes and in whole-brain, voxel-wise analysis. Significant sex x smoking interactions were observed in the caudate nuclei and putamen. Post-hoc t tests showed that male smokers had significantly lower D-2/D-3 dopamine-receptor availability than female smokers (-17% caudate, -21% putamen) and male non-smokers (-15% caudate, -16% putamen). Female smokers did not differ from non-smokers. Whole-brain analysis demonstrated no statistically significant voxels or clusters. These results suggest that low receptor availability may confer vulnerability to nicotine dependence or that smoking selectively affects D-2/D-3 receptor down-regulation in men but not women.
C1 [London, Edythe D.] Univ Calif Los Angeles, Semel Inst Neurosci & Biobehav Sci, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90045 USA.
[Brown, Amira K.; Mandelkern, Mark A.; Farahi, Judah] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Mandelkern, Mark A.] UC Irvine, Dept Phys, Irvine, CA USA.
[Robertson, Chelsea; London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90045 USA.
[London, Edythe D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90045 USA.
RP London, ED (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Biobehav Sci, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,Rm C8-831, Los Angeles, CA 90045 USA.
EM elondon@mednet.ucla.edu
FU NIH [R01 DA020726, R01 DA015179, P20 DA022539]; Marjorie Green Family
Trust; UCLA
FX This research was supported by NIH grants R01 DA020726, R01 DA015179 and
P20 DA022539. Additional funding was provided by endowments from the
Thomas P. and Katherine K. Pike Chair in Addiction Studies and the
Marjorie Green Family Trust. The authors thank Dr Buyean Lee and Shruthi
Chakrapani for data acquisition, Ms Julia Keighley for assisting with
data organization and Dr Babak Ardekani for technical assistance with
the ART image registration software library.; Dr Edythe London has
tobacco-related research other than that reported here, supported by a
contract between Philip Morris USA and UCLA. The authors have no other
potential conflicts of interest.
NR 24
TC 32
Z9 32
U1 0
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1461-1457
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD AUG
PY 2012
VL 15
IS 7
BP 989
EP 994
DI 10.1017/S1461145711001957
PG 6
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 984KB
UT WOS:000307187400012
PM 22243762
ER
PT J
AU Gallun, FJ
Diedesch, AC
Beasley, R
AF Gallun, Frederick J.
Diedesch, Anna C.
Beasley, Robertson
TI Impacts of age on memory for auditory intensity
SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
LA English
DT Article
ID ATTENTIONAL BLINK; INFORMATIONAL MASKING; TEMPORAL DISCRIMINATION;
VISUAL-ATTENTION; DELAYED MASKING; TONAL PATTERNS; COMPONENTS;
SEQUENCES; SPEECH; IDENTIFICATION
AB It is hypothesized that older listeners are more likely than younger listeners to be impaired when asked to make intensity judgments about target tones embedded in rapidly presented auditory sequences. This study examined this hypothesis by asking listeners ranging in age from 19 to 74 yr to make judgments of intensity based on narrowband noise bursts varying in frequency and intensity. In two experiments, listeners made intensity judgments of target bursts alone or embedded in sequences of bursts. In the first experiment, one of four fixed sequences was presented and had to be identified. In the second experiment, pre- or post-trial bursts acted as cues that identified the frequency of the target burst in the sequence. In both experiments, intensity discrimination thresholds for single bursts were good predictors of performance with sequences and were little affected by age. Significant negative relationships between age and accuracy were observed when single sequences had to be identified or a post-trial cue was used, but no age effects were apparent when a pre-trial cue was used. These data are interpreted as being consistent with previous suggestions that the aging process results in a decline in auditory memory capacity and/or internally generated selective attention. [http://dx.doi.org/10.1121/1.4731235]
C1 [Gallun, Frederick J.; Diedesch, Anna C.; Beasley, Robertson] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res NCRAR, Portland, OR 97239 USA.
[Gallun, Frederick J.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97239 USA.
RP Gallun, FJ (reprint author), Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res NCRAR, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM Frederick.Gallun@va.gov
RI Gallun, Frederick/G-3792-2012
OI Gallun, Frederick/0000-0002-4145-2199
FU Department of Veterans Affairs, Veterans Health Administration,
Rehabilitation Research and Development Service (VA RR&D Career
Development II Award) [C4963W]; NIH/NIDCD [R03 DC08395]
FX This work was supported by the Department of Veterans Affairs, Veterans
Health Administration, Rehabilitation Research and Development Service
(VA RR&D Career Development II Award C4963W to F.J.G.) and by NIH/NIDCD
(R03 DC08395 to F.J.G.). Facilities and equipment support was also
provided by the VA RR&D National Center for Rehabilitative Auditory
Research. The authors are extremely grateful to Marjorie Leek for help
with the sensitivity analysis, to Stephen Fausti for guidance, to
Matthew Marble, Kelly Reavis, Marc Caldwell, and Erin Connor for help
with data collection, to Marilyn Dille and Julia Fitzer for discussions
of design issues, and of course to our listeners. Two anonymous
reviewers gave very helpful comments on previous versions of the
manuscript and one of the anonymous reviewers provided an especially
useful analysis of the Eguchi and Hirsh (1969) method of calculating
listener sensitivity, the core insights of which are described in the
Appendix. The opinions and assertions presented are private views of the
authors and are not to be construed as official or as necessarily
reflecting the views of the Department of Veterans Affairs.
NR 40
TC 0
Z9 0
U1 0
U2 4
PU ACOUSTICAL SOC AMER AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0001-4966
EI 1520-8524
J9 J ACOUST SOC AM
JI J. Acoust. Soc. Am.
PD AUG
PY 2012
VL 132
IS 2
BP 944
EP 956
DI 10.1121/1.4731235
PG 13
WC Acoustics; Audiology & Speech-Language Pathology
SC Acoustics; Audiology & Speech-Language Pathology
GA 010FD
UT WOS:000309079200053
PM 22894216
ER
PT J
AU Hershman, JM
Valente, W
Saji, M
AF Hershman, Jerome M.
Valente, William
Saji, Motoyasu
TI Leonard D. Kohn, 1935-2012 In Memoriam
SO THYROID
LA English
DT Biographical-Item
C1 [Hershman, Jerome M.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Endocrinol, Los Angeles, CA USA.
[Hershman, Jerome M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Valente, William] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
[Valente, William] Interthyr Res Fdn, Baltimore, MD USA.
[Saji, Motoyasu] Ohio State Univ, Dept Internal Med, Div Endocrinol, Columbus, OH 43210 USA.
RP Hershman, JM (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jhershmn@ucla.edu
NR 1
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
J9 THYROID
JI Thyroid
PD AUG
PY 2012
VL 22
IS 8
BP 863
EP 864
DI 10.1089/thy.2012.2208.obit
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 984KK
UT WOS:000307188300018
ER
PT J
AU Lutz, CT
Quinn, LS
AF Lutz, Charles T.
Quinn, LeBris S.
TI Sarcopenia, obesity, and natural killer cell immune senescence in aging:
Altered cytokine levels as a common mechanism
SO AGING-US
LA English
DT Review
DE Skeletal muscle; adipose tissue; Sarcopenia; obesity; immunity; natural
killer lymphocytes; aging
ID IL-15 RECEPTOR-ALPHA; TUMOR-NECROSIS-FACTOR; HUMAN NK CELLS;
ADIPOSE-TISSUE; IN-VIVO; SKELETAL-MUSCLE; GROWTH-FACTOR; TNF-ALPHA;
INTERLEUKIN-15 RECEPTOR; METABOLIC SYNDROME
AB Human aging is characterized by both physical and physiological frailty. A key feature of frailty, sarcopenia is the age-associated decline in skeletal muscle mass, strength, and endurance that characterize even the healthy elderly. Increases in adiposity, particularly in visceral adipose tissue, are almost universal in aging individuals and can contribute to sarcopenia and insulin resistance by increasing levels of inflammatory cytokines known collectively as adipokines. Aging also is associated with declines in adaptive and innate immunity, known as immune senescence, which are risk factors for cancer and all-cause mortality. The cytokine interleukin-15 (IL-15) is highly expressed in skeletal muscle tissue and declines in aging rodent models. IL-15 inhibits fat deposition and insulin resistance, is anabolic for skeletal muscle in certain situations, and is required for the development and survival of natural killer (NK) lymphocytes. We review the effect that adipokines and myokines have on NK cells, with special emphasis on IL-15. We posit that increased adipokine and decreased IL-15 levels during aging constitute a common mechanism for sarcopenia, obesity, and immune senescence.
C1 [Lutz, Charles T.] Univ Kentucky, Dept Pathol & Lab Med, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA.
[Lutz, Charles T.] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA.
[Quinn, LeBris S.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Quinn, LeBris S.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
[Quinn, LeBris S.] Seattle Inst Biomed & Clin Res, Seattle, WA 98108 USA.
RP Lutz, CT (reprint author), Univ Kentucky, Dept Pathol & Lab Med, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA.
EM ctlutz2@uky.edu
FU NIH [AI50656, AG040542]; National Center for Advancing Translational
Sciences [UL1TR000117]; Department of Veterans Affairs [BX001026]
FX Supported by NIH AI50656, AG040542, and the National Center for
Advancing Translational Sciences, UL1TR000117 (CTL) and Merit Review
#BX001026 from the Department of Veterans Affairs (LSQ), and use of
resources and facilities at VA Puget Sound Health Care System. We thank
Craig Horbinski, Michael Cibull, and Ahmad Al-Attar for help with
figures and Charlotte Peterson for insightful discussions.
NR 140
TC 50
Z9 54
U1 1
U2 17
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD AUG
PY 2012
VL 4
IS 8
BP 535
EP 546
PG 12
WC Cell Biology
SC Cell Biology
GA 002ZX
UT WOS:000308579000004
PM 22935594
ER
PT J
AU Trivedi, RB
Bryson, CL
Udris, E
Au, DH
AF Trivedi, Ranak B.
Bryson, Chris L.
Udris, Edmunds
Au, David H.
TI The Influence of Informal Caregivers on Adherence in COPD Patients
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Article
DE Self-management; Chronic illness; Dyads
ID SMOKING-CESSATION INTERVENTION; OBSTRUCTIVE PULMONARY-DISEASE;
QUALITY-OF-LIFE; MEDICAL-TREATMENT; CLINICAL-TRIAL; UNITED-STATES; LUNG
HEALTH; METAANALYSIS; MORTALITY; SUPPORT
AB Background Contributions of informal caregivers to adherence among chronic obstructive pulmonary disease (COPD) patients remain understudied.
Purpose This study aims to evaluate the association between caregiver presence and adherence to medical recommendations among COPD patients.
Methods Three hundred and seventy-four COPD patients were asked whether they had a caregiver. Medication adherence was assessed using pharmacy refill data. Smoking status was based on patient self-report. One-way ANOVAs and chi-square analyses were performed controlling for age and number of illnesses.
Results Compared with the "no caregiver" group, antihypertensive medications adherence was higher in the "spousal caregiver" (0.68 vs. 0.81; 95% CI=0.04 and 0.22) and "non-spousal caregiver" (0.68 vs. 0.80; 95% CI=0.03 and 0.22) groups; long-acting beta agonist adherence was higher in the "spousal caregiver" group (0.60 vs. 0.80; 95% CI=0.05 and 0.43). Patients in the "spousal caregiver" group had fewer current smokers compared with the "no caregiver" (chi(2)=16.08; p<0.001) and "non-spousal caregiver" (chi(2)=05.07; p<0.05) groups; those in the "non-spousal caregiver" group reported fewer smokers than the "no caregiver" group (chi(2)=4.54; p<0.05).
Conclusions Caregivers, especially spouses, may improve adherence in COPD. Future interventions may target patients without caregivers to optimize COPD management.
C1 [Trivedi, Ranak B.] Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA.
[Trivedi, Ranak B.; Bryson, Chris L.; Udris, Edmunds; Au, David H.] VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev HSR&D, Ctr Excellence, Seattle, WA USA.
[Bryson, Chris L.; Au, David H.] Univ Washington, Dept Med, Seattle, WA 98101 USA.
RP Trivedi, RB (reprint author), Univ Washington, Dept Hlth Serv, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM ranak.trivedi@va.gov
NR 29
TC 22
Z9 23
U1 4
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD AUG
PY 2012
VL 44
IS 1
BP 66
EP 72
DI 10.1007/s12160-012-9355-8
PG 7
WC Psychology, Multidisciplinary
SC Psychology
GA 006MG
UT WOS:000308822700010
PM 22422104
ER
PT J
AU Jones, DL
Bhanegaonkar, AJ
Billings, AA
Kriska, AM
Irrgang, JJ
Crossett, LS
Kwoh, CK
AF Jones, Dina L.
Bhanegaonkar, Abhijeet J.
Billings, Anthony A.
Kriska, Andrea M.
Irrgang, James J.
Crossett, Lawrence S.
Kwoh, C. Kent
TI Differences Between Actual and Expected Leisure Activities After Total
Knee Arthroplasty for Osteoarthritis
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article
DE leisure activities; total knee arthroplasty; osteoarthritis; physical
activity; expectations
ID TOTAL JOINT REPLACEMENT; HEALTH SURVEY SF-36; TOTAL HIP-ARTHROPLASTY;
QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; SELF-EFFICACY; PATIENTS
EXPECTATIONS; PATIENT EXPECTATIONS; OUTCOMES; QUESTIONNAIRE
AB This prospective cohort study determined the type, frequency, intensity, and duration of actual vs expected leisure activity among a cohort undergoing total knee arthroplasty. Data on actual and expected participation in 36 leisure activities were collected preoperatively and at 12 months in 90 patients with knee osteoarthritis. Despite high expectations, there were statistically and clinically significant differences between actual and expected activity at 12 months suggesting that expectations may not have been fulfilled. The differences were equivalent to walking 14 less miles per week than expected, which is more than the amount of activity recommended in national physical activity guidelines. Perhaps an educational intervention could be implemented to help patients establish appropriate and realistic leisure activity expectations before surgery.
C1 [Jones, Dina L.] W Virginia Univ, Sch Med, Dept Orthopaed, Hlth Sci Ctr S, Morgantown, WV 26506 USA.
[Jones, Dina L.] W Virginia Univ, Div Phys Therapy, Sch Med, Hlth Sci Ctr S, Morgantown, WV 26506 USA.
[Bhanegaonkar, Abhijeet J.] W Virginia Univ, Dept Pharmaceut Syst & Policy, Sch Pharm, Morgantown, WV 26506 USA.
[Billings, Anthony A.] W Virginia Univ, Dept Stat, Eberly Coll Arts & Sci, Morgantown, WV 26506 USA.
[Kriska, Andrea M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Irrgang, James J.; Crossett, Lawrence S.] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA.
[Kwoh, C. Kent] Univ Pittsburgh, Div Rheumatol & Clin Immunol, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Jones, DL (reprint author), W Virginia Univ, Sch Med, Dept Orthopaed, Hlth Sci Ctr S, POB 9196,1 Med Ctr Dr,Room 3603A, Morgantown, WV 26506 USA.
OI Kriska, Andrea/0000-0002-3522-0869
FU American College of Rheumatology Research and Education Foundation
FX This study was funded by a grant from the American College of
Rheumatology Research and Education Foundation.
NR 49
TC 9
Z9 9
U1 2
U2 7
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD AUG
PY 2012
VL 27
IS 7
BP 1289
EP 1296
DI 10.1016/j.arth.2011.10.030
PG 8
WC Orthopedics
SC Orthopedics
GA 986CF
UT WOS:000307317100006
PM 22480521
ER
PT J
AU Loewenstein, G
Volpp, KG
Asch, DA
AF Loewenstein, George
Volpp, Kevin G.
Asch, David A.
TI Incentives in Health: Different Prescriptions for Physicians and
Patients EDITORIAL COMMENT
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
AB Financial incentives in health care are different for physicians and patients. For physicians, financial incentives involve methods of payment for their services. For patients, incentives involve the structuring of health insurance coverage, co-payments, and deductibles. It is often assumed that individuals act according to conventional economic principles and respond directly to changes in incentives in a rational manner. However, in many instances, neither physicians nor patients act rationally. This lack of rationality among patients can be related to the lack of information or to actions that are contrary to their own best interests such as overeating, failure to take medication, or not wearing seatbelts. Rationality is dependent on individual psychological or personality differences, as well as differences in education or income. Whether a medical decision is economically rational or irrational is influenced by differences among individuals in knowledge about alternatives, prior experience in similar decision making, availability of rapid feedback on the consequences of decisions, and the ability to make thoughtful dispassionate decisions or rapid decisions when emotionally stressed.
Rationality is highly relevant to the discussion of the role of incentives in medicine for reducing widespread overuse of low-value services. Compared to physicians paid on a capitated basis, there is a tendency among physicians paid for specific procedures to recommend these procedures more frequently. Improvement in the value of health care spending in the US health care system will require moving away from payment systems that contribute to overuse of high-cost, low-value services, in large part, by exploiting the rationality of physicians.
The primary focus of efforts to address overuse of low-value services should be physicians rather than patients. Insurance payments to physicians for services of low value should be reduced. Coupling lower payment to physicians for low-value services with higher payment for high-value services that are underused could offset the adverse financial effects of this approach. Broad-based physician incentive schemes, such as capitated payment or fee for service, can lead to unintended consequences-too much care with fee-for-service medicine and too little with capitation-that have little regard to value.
Financial incentives for patients using health care services involve substantially different issues than for physicians. Patients receive relatively little useful feedback about the quality of their medical decisions. The behavior of ill and emotionally vulnerable patients can be less than perfectly rational, and it is difficult for them to balance the costs and benefits of alternative tests or treatments in a rational, dispassionate fashion. Patients play a significant role in cost sharing programs. The role of patient cost sharing is different for acute and chronic illnesses. Acutely ill patients are poor targets of cost-sharing incentive programs. Unlike the acutely ill, patients with chronic conditions, who have prior experience in making similar decisions, can make a dispassionate evaluation of costs and benefits and are more appropriate targets of higher cost sharing for low-value services.
It is hoped that financial incentives can change patient behavior (ie, lifestyle changes), thereby improving health care outcomes. There are only limited data on how much measured indicators of health outcomes resulting from changes in patient behaviors can be modified through use of premium-based health incentives. With financial incentives, the intended goals of improved health care at lower cost, while minimizing unintended consequences, can only be achieved through the design and implementation of programs that consider the individual response of patients and physicians to incentives and how they respond in different circumstances.
C1 [Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
Univ Penn, Wharton Sch, Penn CMU Roybal P30 Ctr Behav Econ & Hlth, Philadelphia, PA 19104 USA.
Univ Penn, Wharton Sch, Leonard Davis Inst Ctr Hlth Incent & Behav Econom, Philadelphia, PA 19104 USA.
Univ Penn, Wharton Sch, Dept Med, Philadelphia, PA 19104 USA.
Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA.
RP Loewenstein, G (reprint author), Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
NR 0
TC 0
Z9 0
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7828
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD AUG
PY 2012
VL 67
IS 8
BP 464
EP 465
DI 10.1097/01.ogx.0000419560.63610.67
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 005LG
UT WOS:000308751300006
ER
PT J
AU Wheeler, JM
Guthrie, CR
Kraemer, BC
AF Wheeler, Jeanna M.
Guthrie, Chris R.
Kraemer, Brian C.
TI Potential neuroprotective strategies against tauopathy
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article
DE autophagy; mammalian suppressor of tau pathology 2 (MSUT2);
neurodegeneration; neuroprotection; tau; tauopathy
ID TAU-INDUCED NEUROTOXICITY; CAENORHABDITIS-ELEGANS; NEUROFIBRILLARY
TANGLES; FRONTOTEMPORAL DEMENTIA; ALZHEIMERS-DISEASE; FTDP-17 MUTATIONS;
IN-VITRO; EXON 10; PROTEIN; AGGREGATION
AB Tauopathies are neurodegenerative diseases, including AD (Alzheimer's disease) and FTLD-T (tau-positive frontotemporal lobar degeneration), with shared pathology presenting as accumulation of detergent-insoluble hyperphosphorylated tau deposits in the central nervous system. The currently available treatments for AD address only some of the symptoms, and do not significantly alter the progression of the disease, namely the development of protein aggregates and loss of functional neurons. The development of effective treatments for various tauopathies will require the identification of common mechanisms of tau neurotoxicity, and pathways that can be modulated to protect against neurodegeneration. Model organisms, such as Caenorhabditis elegans, provide methods for identifying novel genes and pathways that are involved in tau pathology and may be exploited for treatment of various tauopathies. In the present paper, we summarize data regarding characterization of MSUT2 (mammalian suppressor of tau pathology 2), a protein identified in a C. elegans tauopathy model and subsequently shown to modify tau toxicity in mammalian cell culture via the effects on autophagy pathways. MSUT2 represents a potential drug target for prevention of tau-related neurodegeneration.
C1 [Wheeler, Jeanna M.; Guthrie, Chris R.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA.
[Wheeler, Jeanna M.; Guthrie, Chris R.; Kraemer, Brian C.] Univ Washington, Dept Med, Div Gerontol, Seattle, WA 98195 USA.
[Wheeler, Jeanna M.; Guthrie, Chris R.; Kraemer, Brian C.] Univ Washington, Dept Med, Div Geriatr Med, Seattle, WA 98195 USA.
RP Kraemer, BC (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Ctr Geriatr Res Educ & Clin, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM kraemerb@u.washington.edu
FU Department of Veterans Affairs Merit Review Grant; National Institute of
Neurological Disorders and Stroke [R01NS064131]
FX This work was supported by a Department of Veterans Affairs Merit Review
Grant and by the National Institute of Neurological Disorders and Stroke
[grant number R01NS064131] (to B.C.K.).
NR 47
TC 1
Z9 1
U1 0
U2 9
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0300-5127
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD AUG
PY 2012
VL 40
BP 656
EP 660
DI 10.1042/BST20120017
PN 4
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 987QH
UT WOS:000307431700011
PM 22817711
ER
PT J
AU Tanaka, M
Bailey, JN
Bai, DS
Ishikawa-Brush, Y
Delgado-Escueta, AV
Olsen, RW
AF Tanaka, Miyabi
Bailey, Julia N.
Bai, Dongsheng
Ishikawa-Brush, Yumiko
Delgado-Escueta, Antonio V.
Olsen, Richard W.
TI Effects on promoter activity of common SNPs in 5 ' region of GABRB3 exon
1A
SO EPILEPSIA
LA English
DT Article
DE Luciferase activity; rs20317; rs4906902; Epigenetic modulator REST;
Childhood absence epilepsy
ID CHILDHOOD ABSENCE EPILEPSY; GABA(A) RECEPTOR; TARGET GENES; REST;
SUBUNIT; GENOME; IDENTIFICATION; DISORDERS; REPRESSOR; ELEMENT
AB Purpose: The beta 3 subunit of the c-aminobutyric acid type A receptors (GABA(A)-Rs) is an essential component of GABA(A)-Rs in fetal, perinatal, and adult mammalian brain. Various transcripts of the beta 3 subunit gene (GABRB3) produce various proteins with different N-termini. Rare variants in this N-terminus (exon 1A and exon 2) of GABRB3 protein segregate in affected family members of two multigeneration-multiplex families with remitting childhood absence epilepsy (rCAE), suggesting GABRB3 is a major Mendelian epilepsy gene for rare families with CAE. Therefore, the N-terminus of GABRB3 could be important for GABRB3 regulation in development, and its alteration could produce rCAE. Herein we determine if single nucleotide polymorphisms (SNPs) within the 1,148-bp region upstream from exon 1A influence the expression of GABRB3.
Methods: We studied luciferase reporter expression for promoter activity, 1,148-bp upstream from exon 1A, using human embryonic kidney 293 cells. We generated constructs of the promoter region and compared different SNP haplotypes in 48 patients with rCAE. Next, we compared frequencies of rs20317, located in the core promoter region, and rs4906902, located in the enhancer region between 48 patients with rCAE and >500 healthy controls matched for ethnicity and ancestral origin.
Key Findings: Highest luciferase expression occurred 230-bp upstream of exon 1A. The construct that excluded this region lost luciferase activity. Therefore, this region contains the core promoter of exon 1A. Allele C but not allele G (rs20317) significantly increased luciferase expression activity. Allele C creates binding motifs for cMYB and EGR-3. Longer constructs overlapping this region have a binding motif for REST (RE1-silencing transcription factor), a critical epigenetic modulator for neuronal genes. REST represses expression of neuronal genes in nonneuronal tissues, resulting in reduced luciferase expression activity. Even in the suppressed condition, the longer construct enhanced luciferase expression activity of the shorter construct, which excluded the distal end containing rs4906902. However, allele frequencies of rs20317 and rs4906902 were not significantly associated with 48 rCAE patients in comparison to >500 controls matched for ethnicity and ancestral origin.
Significance: Common SNPs in the promoter region increase luciferase expression activity. An epigenetic modulator, REST, specifically alters expression of GABRB3 exon 1A transcripts, suggesting epigenetic regulation by REST dominantly controls the expression of GABRB3 variant 2 transcript in early life GABA(A) signaling. Abnormal epigenetic regulation could be involved in absence seizures.
C1 [Tanaka, Miyabi; Olsen, Richard W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
[Tanaka, Miyabi; Bailey, Julia N.; Bai, Dongsheng; Delgado-Escueta, Antonio V.] Vet Affairs Greater Los Angeles Healthcare Syst, Genom Lab, Neurol & Res Serv, Los Angeles, CA USA.
[Bailey, Julia N.] Univ Calif Los Angeles, Dept Epidemiol, Sch Publ Hlth, Los Angeles, CA 90095 USA.
[Bai, Dongsheng; Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Ishikawa-Brush, Yumiko] Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, San Francisco, CA 94143 USA.
RP Olsen, RW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
EM escueta@ucla.edu; rolsen@mednet.ucla.edu
OI Delgado-Escueta, Antonio V./0000-0002-1581-6999
FU National Institutes of Health [NS35985]; National Institutes of Health
NINDS [NS055057]; Veterans Administration Merit Review Grant
FX We thank all CAE patients and their families for their cooperation,
GENESS site neurologists and staff for their help, Ziwei Chen for
helpful advice, the J Huang laboratory, and Computational Sciences
Group, UCLA Pharmacology Dept, for their cooperation. This work was
supported by National Institutes of Health Grant NS35985 to RWO; by
National Institutes of Health NINDS Grant NS055057 to AVDE, and a
Veterans Administration Merit Review Grant to AVDE.
NR 21
TC 7
Z9 8
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD AUG
PY 2012
VL 53
IS 8
BP 1450
EP 1456
DI 10.1111/j.1528-1167.2012.03572.x
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 001EI
UT WOS:000308442800026
PM 22765836
ER
PT J
AU Xiu, MH
Chen, DC
Wang, D
Zhang, K
Dong, AL
Tang, W
Zhang, FX
Liu, LJ
Liu, JH
Liu, HB
Yang, FD
Kosten, TR
Zhang, XY
AF Xiu, Mei Hong
Chen, Da Chun
Wang, Dong
Zhang, Kui
Dong, AiLing
Tang, Wei
Zhang, Feixue
Liu, Lian Jing
Liu, Jia Hong
Liu, Hai Bo
Yang, Fu De
Kosten, Thomas R.
Zhang, Xiang Yang
TI Elevated interleukin-18 serum levels in chronic schizophrenia:
Association with psychopathology
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Schizophrenia; Interleukin; Cytokines; Immune
ID CYTOTOXIC T-LYMPHOCYTES; CYTOKINE ALTERATIONS; IL-18; AUTOIMMUNITY;
PATHOGENESIS; RISPERIDONE; INDUCTION; INFECTION; DISEASES; PLASMA
AB Background: Schizophrenia is associated with various abnormalities in the immune system including elevated levels of Interleukin-18 (IL-18), a potent inflammatory cytokine in T-helper 1 (Th1) responses. The aim of this study was to assess the clinical significance of serum IL-18 levels in various stages of schizophrenia.
Methods: We measured serum IL-18 levels using a sandwich enzyme-linked immunosorbent assay (ELISA) from 78 never-medicated first-episode schizophrenia, 79 medicated chronic schizophrenia and 78 healthy control subjects. The symptoms of schizophrenia were assessed by the Positive and Negative Syndrome Scale (PANSS).
Results: The chronic patients had significantly greater serum IL-18 levels than both first-episode patients and controls. Serum IL-18 was also positively correlated with the PANSS general psychopathology subscore in chronic schizophrenic patients.
Conclusions: Our results showed elevated IL-18 pathway activity may be involved in the psychopathology of schizophrenia. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Xiu, Mei Hong; Chen, Da Chun; Liu, Hai Bo; Yang, Fu De; Kosten, Thomas R.; Zhang, Xiang Yang] Peking Univ, Beijing HuiLongGuan Hosp, Psychiat Res Ctr, Beijing 100871, Peoples R China.
[Wang, Dong; Zhang, Kui; Dong, AiLing] JingQu Hosp, Dept Psychiat, Weihai, Shandong, Peoples R China.
[Tang, Wei; Zhang, Feixue; Liu, Lian Jing; Liu, Jia Hong] Kangning Hosp, Dept Psychiat, Wenzhou, Zhejiang, Peoples R China.
[Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP Kosten, TR (reprint author), VA Med Ctr, Res Bldg 110,Room 229,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM kosten@bcm.edu; xyzhang@bcm.edu
FU National Natural Science Foundation of China [81000509]; Beijing
Municipal Excellent Talents Foundation [2010D003034000032]; Stanley
Medical Research Institute [03T-459, 05T-726]; United States National
Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639]
FX This study was funded by National Natural Science Foundation of China
(81000509), and Beijing Municipal Excellent Talents Foundation
(2010D003034000032), and the Stanley Medical Research Institute (03T-459
and 05T-726), and the United States National Institute of Health
K05-DA0454, P50-DA18827 and U01-MH79639. These sources had no further
role in study design; in the collection, analysis and interpretation of
data; in the writing of the report; and in the decision to submit the
paper for publication.
NR 44
TC 20
Z9 20
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD AUG
PY 2012
VL 46
IS 8
BP 1093
EP 1098
DI 10.1016/j.jpsychires.2012.04.026
PG 6
WC Psychiatry
SC Psychiatry
GA 980AF
UT WOS:000306865300018
PM 22647522
ER
PT J
AU Brizendine, KD
Baddley, JW
Pappas, PG
Leon, KJ
Rodriguez, JM
AF Brizendine, K. D.
Baddley, J. W.
Pappas, P. G.
Leon, K. J.
Rodriguez, J. M.
TI Fatal Burkholderia gladioli infection misidentified as Empedobacter
brevis in a lung transplant recipient with cystic fibrosis
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE Burkholderia gladioli; Burkholderia; Empedobacter brevis; cystic
fibrosis; lung transplantation
ID PSEUDOMONAS-CEPACIA; SURVIVAL; PATIENT; COMPLEX
AB Data describing the risk of lung transplantation (LT), clinical features, and outcomes of patients with cystic fibrosis (CF) infected with Burkholderia gladioli are limited. Herein, we report a case of disseminated B. gladioli infection characterized by bacteremia, necrotizing pneumonia, lung abscess, and empyema in a lung transplant recipient with CF, highlight the importance of accurate microbiological identification, and review published outcomes of LT in CF patients infected with B. gladioli, which include cases of pneumonia, tracheobronchitis, bacteremia, and abscesses, and demonstrate an all-cause 1-year mortality of approximately 23%, often after combined medical and surgical treatment.
C1 [Brizendine, K. D.; Baddley, J. W.; Pappas, P. G.; Rodriguez, J. M.] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA.
[Baddley, J. W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Leon, K. J.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Dept Med, Birmingham, AL 35294 USA.
RP Rodriguez, JM (reprint author), Univ Alabama Birmingham, Div Infect Dis, Dept Med, Tinsley Harrison Tower 229,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM mrodri2@uab.edu
NR 20
TC 1
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD AUG
PY 2012
VL 14
IS 4
BP E13
EP E18
DI 10.1111/j.1399-3062.2012.00726.x
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 991VT
UT WOS:000307731800003
PM 22429703
ER
PT J
AU Singh, JA
Lewallen, DG
AF Singh, Jasvinder A.
Lewallen, David G.
TI Peptic ulcer disease and heart disease are associated with
periprosthetic fractures after total hip replacement
SO ACTA ORTHOPAEDICA
LA English
DT Article
ID TOTAL KNEE ARTHROPLASTY; PROTON PUMP INHIBITORS; FEMORAL FRACTURES;
RISK; REVISION; REGISTER; COMORBIDITY; MORBIDITY; MORTALITY; PREDICT
AB Background and purpose There have been no published studies assessing the possible association of medical comorbidities with periprosthetic fracture risk. We therefore assessed whether medical comorbidity is associated with risk of periprosthetic fractures after total hip replacement (THR).
Material and methods We used prospectively collected data from 1989-2008 in the Mayo Clinic Total Joint Registry for 2 cohorts: primary THR and revision THR. The main variables of interest were Deyo-Charlson comorbidities at the time of surgery. Outcome of interest was p ostoperative periprosthetic fracture at postoperative day 1 onwards. Multivariable Cox regression models were additionally adjusted for age, sex, body mass index, American Society of Anesthesiology (ASA) class, and operative diagnosis.
Results We identified 14,065 primary THRs and 6,281 revision THRs with mean follow-up times of 6.3 and 5.6 years, respectively. There were 305 postoperative periprosthetic fractures in the primary THR cohort and 330 in the revision THR cohort. In patients who underwent primary THR, 2 comorbidities were associated with higher risk of periprosthetic fracture: peptic ulcer disease with adjusted hazard ratio of 1.5 (95% CI: 1.1-2.2) and heart disease with adjusted hazard ratio of 1.7 (CI: 1.2-2.4). In patients with revision THR, peptic ulcer disease was associated with a higher adjusted risk of periprosthetic fracture, 1.6 (CI: 1.1-2.3).
Interpretation Peptic ulcer disease and heart disease in primary THR patients and peptic ulcer disease in revision THR patients were associated with higher postoperative periprosthetic fracture risk. Further studies are needed to understand whether disease severity or specific medications used for treatment, or both, are responsible for this association. This may allow identification of modifiable factors.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA.
[Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Mayo Clinic Orthopedic Surgery research funds; Birmingham VA Medical
Center, Alabama; NIH (Mayo Clinic Center for Clinical and Translational
Research) [1 KL2 RR024151-01]; URL Pharmaceuticals; Savient; Takeda;
Novartis; Zimmer; DePuy; Stryker
FX We thank Scott Harmsen and Matthew Jensen at the Mayo Clinic for
assistance in data programming and data analysis. This work was
supported through an NIH Clinical Translational Science Award (1 KL2
RR024151-01; Mayo Clinic Center for Clinical and Translational
Research), by Mayo Clinic Orthopedic Surgery research funds, and by the
Birmingham VA Medical Center, Alabama (resources and use of
facilities).; There are no financial conflicts relating directly to this
study. JA has received speaker honoraria from Abbott; research and
travel grants from Takeda, Savient, Wyeth and Amgen; and consultant fees
from URL Pharmaceuticals, Savient, Takeda, and Novartis. DGL has
received royalties/speaker fees from Zimmer, has been a paid consultant
to Zimmer, and has received institutional research funds from DePuy,
Stryker, and Zimmer. None of the sources of funding (NIH, Mayo Clinic,
Birmingham VA) had any role in the design or conduct of the study, data
analysis, interpretation of the results, or preparation of the
manuscript for publication.
NR 37
TC 3
Z9 4
U1 0
U2 3
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 1745-3674
J9 ACTA ORTHOP
JI Acta Orthop.
PD AUG
PY 2012
VL 83
IS 4
BP 353
EP 359
DI 10.3109/17453674.2012.717844
PG 7
WC Orthopedics
SC Orthopedics
GA 993HO
UT WOS:000307848600007
PM 22900908
ER
PT J
AU Thorpe, JM
Thorpe, CT
Kennelty, KA
Gellad, WF
Schulz, R
AF Thorpe, Joshua M.
Thorpe, Carolyn T.
Kennelty, Korey A.
Gellad, Walid F.
Schulz, Richard
TI The Impact of Family Caregivers on Potentially Inappropriate Medication
Use in Noninstitutionalized Older Adults With Dementia
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Article
DE care quality; dementia; inappropriate medications; informal caregivers
ID RANDOMIZED CONTROLLED-TRIAL; BEERS CRITERIA; COMMUNITY; HOME;
PRESCRIPTION; CARE; HOSPITALIZATION; POLYPHARMACY; DISORDERS; FRAMEWORK
AB Background: The risk of potentially inappropriate medication (PIM), both prescription and over-the-counter, use in dementia patients is high. Informal caregivers often facilitate patients' use of medications, but the effect of caregiver factors on PIM use has not been a focus of previous research.
Objective: The aim of this study was to examine PIM use in dementia patients and caregivers and identify caregiver risk factors for PIM use in dementia patients.
Methods: We conducted a secondary data analysis of the baseline wave of the Resources for Enhancing Alzheimer's Caregiver's Health study. The sample comprised 566 persons with dementia aged 65 and older and their coresiding family caregiver. PIM was defined using the 2003 Beers criteria and was examined in both dementia patients and their caregivers. Caregiver and patient risk factors included a range of sociodemographic and health variables.
Results: In dementia patients, 33% were taking at least 1 PIM, and 39% of their caregivers were also taking a PIM. In fully adjusted models, the following caregiver factors were associated with an increased risk of dementia patient PIM use: caregiver's own PIM use, spouse caregivers, Hispanic caregivers, and greater number of years that the caregiver has lived in the United States. Increased caregiver age was associated with a decreased risk of PIM use in patients.
Conclusions: PIM use may be higher in dementia patients and their informal caregivers compared with the general older adult population. Further, patterns of medication use in 1 member of the dyad may influence PIM risk in the other dyad member. These results suggest that interventions to increase appropriate medication use in dementia patients and their caregivers should target both members of the dyad and target over-the-counter agents along with prescription medications. (Am J Geriatr Pharmacother. 2012;10:230-241) Published by Elsevier HS Journals, Inc.
C1 [Thorpe, Joshua M.; Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA.
[Thorpe, Joshua M.; Thorpe, Carolyn T.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Kennelty, Korey A.] Univ Wisconsin, Madison Sch Pharm, Div Social & Adm Sci, Madison, WI USA.
[Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med Gen Med, Pittsburgh, PA USA.
[Gellad, Walid F.] RAND Corp, Pittsburgh, PA USA.
[Schulz, Richard] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Schulz, Richard] Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15260 USA.
RP Thorpe, JM (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, 916 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA.
EM jmthorpe@pitt.edu; ctthorpe@pitt.edu
RI Thorpe, Joshua/C-1188-2013
FU National Institute on Aging, National Institutes of Health; Veterans
Affairs Career Development Award [CDA 09-207]; Health Innovation
Program; Community-Academic Partnerships core of the University of
Wisconsin Institute for Clinical and Translational Research (UW ICTR);
Clinical and Translational Science Award (CTSA) program of the National
Center for Research Resources, National Institutes of Health [1UL1
RR025011]
FX This study was supported by grant R03AG029995 from the National
Institute on Aging, National Institutes of Health, and a Veterans
Affairs Career Development Award (CDA 09-207). Additional support was
provided by the Health Innovation Program and the Community-Academic
Partnerships core of the University of Wisconsin Institute for Clinical
and Translational Research (UW ICTR), grant 1UL1 RR025011 from the
Clinical and Translational Science Award (CTSA) program of the National
Center for Research Resources, National Institutes of Health. The views
expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States government. No funding source had a role in
the design, methods, subject recruitment, data collection, analysis, or
preparation of the manuscript. The authors have indicated that they have
no other conflicts of interest regarding the content of this article.
NR 53
TC 14
Z9 14
U1 7
U2 14
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD AUG
PY 2012
VL 10
IS 4
BP 230
EP 241
DI 10.1016/j.amjopharm.2012.05.001
PG 12
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 992QV
UT WOS:000307795700002
PM 22683399
ER
PT J
AU Gray, KM
Carpenter, MJ
Baker, NL
DeSantis, SM
Kryway, E
Hartwell, KJ
McRae-Clark, AL
Brady, KT
AF Gray, Kevin M.
Carpenter, Matthew J.
Baker, Nathaniel L.
DeSantis, Stacia M.
Kryway, Elisabeth
Hartwell, Karen J.
McRae-Clark, Aimee L.
Brady, Kathleen T.
TI A Double-Blind Randomized Controlled Trial of N-Acetylcysteine in
Cannabis-Dependent Adolescents
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PLACEBO-CONTROLLED TRIAL;
YOUTH TREATMENT CYT; CONTINGENCY MANAGEMENT; MAIN FINDINGS; DRUG;
RELIABILITY; MEDICATIONS; ADDICTIONS; CESSATION
AB Objective: Preclinical findings suggest that the over-the-counter supplement N-acetylcysteine (NAC), via glutamate modulation in the nucleus accumbens, holds promise as a pharmacotherapy for substance dependence. The authors investigated NAC as a novel cannabis cessation treatment in adolescents, a vulnerable group for whom existing treatments have shown limited efficacy.
Method: In an 8-week double-blind randomized placebo-controlled trial, treatment-seeking cannabis-dependent adolescents (ages 15-21 years; N=116) received NAC (1200 mg) or placebo twice daily as well as a contingency management intervention and brief (< 10 minutes) weekly cessation counseling. The primary efficacy measure was the odds of negative weekly urine cannabinoid test results during treatment among participants receiving NAC compared with those receiving placebo, in an intent-to-treat analysis. The primary tolerability measure was frequency of adverse events, compared by treatment group.
Results: Participants receiving NAC had more than twice the odds, compared with those receiving placebo, of having negative urine cannabinoid test results during treatment (odds ratio=2.4, 95% CI=1.1-5.2). Exploratory secondary abstinence outcomes favored NAC but were not statistically significant. NAC was well tolerated, with minimal adverse events.
Conclusions: This is the first randomized controlled trial of pharmacotherapy for cannabis dependence in any age group to yield a positive primary cessation outcome in an intent-to-treat analysis. Findings support NAC as a pharmacotherapy to complement psychosocial treatment for cannabis dependence in adolescents.
C1 [Gray, Kevin M.] Med Univ S Carolina, Hollings Canc Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC USA.
Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Gray, KM (reprint author), Med Univ S Carolina, Hollings Canc Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
EM graykm@musc.edu
RI McRae-Clark, Aimee/I-3341-2013
OI McRae-Clark, Aimee/0000-0002-9774-318X
FU Merck; Supernus Pharmaceuticals; Pfizer; Shire Pharmaceuticals;
GlaxoSmithKline; National Institute on Drug Abuse (NIDA) [R01DA026777];
National Center for Research Resources [UL1RR029882]; NIDA [K23DA020482]
FX Dr. Gray has received research funding from Merck and Supernus
Pharmaceuticals. Dr. Hartwell has received research funding from Pfizer.
Dr. McRae-Clark has received research funding from Shire
Pharmaceuticals. Dr. Brady has received research funding from
GlaxoSmithKline. The other authors report no financial relationships
with commercial interests.; Supported by National Institute on Drug
Abuse (NIDA) grant R01DA026777, via the American Recovery and
Reinvestment Act of 2009. Administrative and technical support was
provided by National Center for Research Resources grant UL1RR029882.
Dr. Carpenter's effort was supported by NIDA grant K23DA020482.
NR 40
TC 64
Z9 67
U1 7
U2 19
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD AUG
PY 2012
VL 169
IS 8
BP 805
EP 812
DI 10.1176/appi.ajp.2012.12010055
PG 8
WC Psychiatry
SC Psychiatry
GA 980JH
UT WOS:000306888900008
PM 22706327
ER
PT J
AU Vizueta, N
Rudie, JD
Townsend, JD
Torrisi, S
Moody, TD
Bookheimer, SY
Altshuler, LL
AF Vizueta, Nathalie
Rudie, Jeffrey D.
Townsend, Jennifer D.
Torrisi, Salvatore
Moody, Teena D.
Bookheimer, Susan Y.
Altshuler, Lori L.
TI Regional fMRI Hypoactivation and Altered Functional Connectivity During
Emotion Processing in Nonmedicated Depressed Patients With Bipolar II
Disorder
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID VOXEL-BASED METAANALYSIS; FACIAL EXPRESSIONS; AMYGDALA ACTIVATION;
RATING-SCALE; RESPONSES; MANIA; FACES; STATE; RECOGNITION; TRAIT
AB Objective: Although the amygdala and ventrolateral prefrontal cortex have been implicated in the pathophysiology of bipolar I disorder, the neural mechanisms underlying bipolar II disorder remain unknown. The authors examined neural activity in response to negative emotional faces during an emotion perception task that reliably activates emotion regulatory regions.
Method: Twenty-one nonmedicated depressed bipolar II patients and 21 healthy comparison subjects underwent functional MRI (fMRI) while performing an emotional face-matching task. Within- and between-group whole-brain fMRI activation and seed-based connectivity analyses were conducted.
Results: In depressed bipolar II patients, random-effects between-group fMRI analyses revealed a significant reduction in activation in several regions, including the left and right ventrolateral prefrontal cortices (Brodmann's area [BA] 47) and the right amygdala, a priori regions of interest. Additionally, bipolar patients exhibited significantly reduced negative functional connectivity between the right amygdala and the right orbitofrontal cortex (BA 10) as well as the right dorsolateral prefrontal cortex (BA 46) relative to healthy comparison subjects.
Conclusions: These findings suggest that bipolar II depression is characterized by reduced regional orbitofrontal and limbic activation and altered connectivity in a fronto-temporal circuit implicated in working memory and emotional learning. While the amygdala hypoactivation observed in bipolar II depression is opposite to the direction seen in bipolar I mania and may therefore be state dependent, the observed orbitofrontal cortex hypoactivation is consistent with findings in bipolar I depression, mania, and euthymia, suggesting a physiologic trait marker of the disorder.
C1 [Vizueta, Nathalie] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Ahmanson Lovelace Brain Mapping Ctr, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Neurosci Interdept Program, Los Angeles, CA 90095 USA.
W Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
RP Vizueta, N (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
EM vizuetan@gmail.com
FU NIMH [K24 MH-01848, T32 MH-17140]; University of California, Los
Angeles, Integrative Study Center in Mood Disorders; National Center for
Research Resources [RR12169, RR13642, RR00865]; Ahmanson Foundation;
Brain Mapping Medical Research Organization; Brain Mapping Support
Foundation; Capital Group Companies Charitable Foundation; Jennifer
Jones-Simon Foundation; Northstar Fund; Pierson-Lovelace Foundation;
Robson Family; Tamkin Foundation; Northern Piedmont Community Foundation
FX Supported by NIMH grants (K24 MH-01848, T32 MH-17140) and a fellowship
from the University of California, Los Angeles, Integrative Study Center
in Mood Disorders to Dr. Vizueta; by grants from the National Center for
Research Resources (RR12169, RR13642, and RR00865); and by the Ahmanson
Foundation, the Brain Mapping Medical Research Organization, the Brain
Mapping Support Foundation, the Capital Group Companies Charitable
Foundation, the Jennifer Jones-Simon Foundation, the Northstar Fund, the
Pierson-Lovelace Foundation, the Robson Family, the Tamkin Foundation,
and the William M. and Linda R. Dietel Philanthropic Fund at the
Northern Piedmont Community Foundation.
NR 46
TC 43
Z9 44
U1 1
U2 13
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD AUG
PY 2012
VL 169
IS 8
BP 831
EP 840
DI 10.1176/appi.ajp.2012.11030349
PG 10
WC Psychiatry
SC Psychiatry
GA 980JH
UT WOS:000306888900011
PM 22773540
ER
PT J
AU Matsunaga, J
Coutinho, ML
AF Matsunaga, James
Coutinho, Mariana L.
TI Positive Regulation of Leptospira interrogans kdp Expression by KdpE as
Demonstrated with a Novel beta-Galactosidase Reporter in Leptospira
biflexa
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GENE-EXPRESSION; OUTER-MEMBRANE;
SPIROCHETE; INACTIVATION; MUTAGENESIS; CONSTRUCTION; PATHOGENESIS;
VIRULENCE
AB Leptospirosis is a potentially deadly zoonotic disease that afflicts humans and animals. Leptospira interrogans, the predominant agent of leptospirosis, encounters diverse conditions as it proceeds through its life cycle, which includes stages inside and outside the host. Unfortunately, the number of genetic tools available for examining the regulation of gene expression in L. interrogans is limited. Consequently, little is known about the genetic circuits that control gene expression in Leptospira. To better understand the regulation of leptospiral gene expression, the L. interrogans kdp locus, encoding homologs of the P-type ATPase KdpABC potassium transporter with their KdpD sensors and KdpE response regulators, was selected for analysis. We showed that a kdpE mutation in L. interrogans prevented the increase in kdpABC mRNA levels observed in the wild-type L interrogans strain when external potassium levels were low. To confirm that KdpE was a positive regulator of kdpABC transcription, we developed a novel approach for constructing chromosomal genetic fusions to the endogenous bgaL (beta-galactosidase) gene of the nonpathogen Leptospira biflexa. We demonstrated positive regulation of a kdpA'-bgaL fusion in L. biflexa by the L. interrogans KdpE response regulator. A control lipL32'-bgaL fusion was not regulated by KdpE. These results demonstrate the utility of genetic fusions to the bgaL gene of L. biflexa for examining leptospiral gene regulation.
C1 [Matsunaga, James; Coutinho, Mariana L.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
[Matsunaga, James; Coutinho, Mariana L.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Coutinho, Mariana L.] Univ Fed Pelotas, Ctr Biotecnol, Pelotas, Brazil.
RP Matsunaga, J (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
EM jamesm@ucla.edu
RI Coutinho, Mariana/J-9024-2012
FU VA Medical Research Funds
FX This study was supported by VA Medical Research Funds (to J.M.).
NR 44
TC 8
Z9 8
U1 1
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD AUG
PY 2012
VL 78
IS 16
BP 5699
EP 5707
DI 10.1128/AEM.00713-12
PG 9
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 983SR
UT WOS:000307139500028
PM 22685146
ER
PT J
AU Malandraki, GA
Kaufman, A
Hind, J
Ennis, S
Gangnon, R
Waclawik, A
Robbins, J
AF Malandraki, Georgia A.
Kaufman, Andrew
Hind, Jacqueline
Ennis, Stephanie
Gangnon, Ronald
Waclawik, Andrew
Robbins, JoAnne
TI The Effects of Lingual Intervention in a Patient With Inclusion Body
Myositis and Sjogren's Syndrome: A Longitudinal Case Study
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Inclusion body myositis; Longitudinal studies; Neuromuscular diseases;
Rehabilitation; Swallowing
ID IDIOPATHIC INFLAMMATORY MYOPATHIES; PENETRATION-ASPIRATION SCALE; ORAL
MANIFESTATIONS; OLDER-ADULTS; DYSPHAGIA; EXERCISE; STRENGTH; MUSCLE
AB Objective: To report the 5-year course of a patient's swallowing disorder in the context of progressive neuromuscular disease and the effectiveness of a lingual strengthening treatment program.
Design: This is a case report that describes a lingual treatment protocol that was repeated 3 times over a 5-year period with and without maintenance periods.
Setting: The study was completed in 2 settings an outpatient swallowing clinic at an acute care hospital and the patient's home.
Participant: The subject was a 77-year-old woman who was diagnosed with inclusion body myositis and Sjogren's syndrome.
Intervention: The patient participated in an intensive 8-week lingual strengthening protocol 3 times (at years 1, 4, and 5) and a subsequent maintenance program twice (at years 4 and 5).
Main Outcome Measures: Three outcome measures were collected during the study: (I) lingual manometric pressures at the anterior and posterior tongue, measured by using a lingual manometric device, (2) airway invasion measured by using an 8-point Penetration-Aspiration Scale, and (3) clearance of the bolus measured by using a 3-point residue scale.
Result: Isometric lingual strengthening was effective in maintaining posterior tongue lingual pressure and Penetration-Aspiration Scale scores during the treatment periods. Residue scale scores did not significantly change during treatment.
Conclusions: We conclude that, in this patient, lingual strengthening slowed the progression of disease-related lingual strength loss and extended functional swallowing performance. Thus, this type of intervention may hold promise as an effective swallowing treatment option for patients with neurodegenerative inflammatory diseases such as inclusion body myositis and Sjogren's syndrome.
C1 [Malandraki, Georgia A.] Columbia Univ, Dept Biobehav Sci, Teachers Coll, Program Speech & Language Pathol, New York, NY 10027 USA.
[Malandraki, Georgia A.; Hind, Jacqueline; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
[Malandraki, Georgia A.; Hind, Jacqueline; Robbins, JoAnne] Univ Wisconsin, Dept Med, Madison, WI USA.
[Gangnon, Ronald] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA.
[Gangnon, Ronald] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA.
[Waclawik, Andrew] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA.
[Kaufman, Andrew] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Bethesda, MD USA.
[Ennis, Stephanie] Univ Washington, Seattle, WA 98195 USA.
RP Malandraki, GA (reprint author), Columbia Univ, Dept Biobehav Sci, Teachers Coll, Program Speech & Language Pathol, 1052A Thorndike Hall,525 W 120th St, New York, NY 10027 USA.
EM malandraki@tc.columbia.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Rehabilitation Research and Development
Service
FX Supported in part by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Rehabilitation
Research and Development Service.
NR 37
TC 6
Z9 6
U1 0
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD AUG
PY 2012
VL 93
IS 8
BP 1469
EP 1475
DI 10.1016/j.apmr.2012.02.010
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 983XJ
UT WOS:000307151700028
PM 22480545
ER
PT J
AU Blum, MA
Ibrahim, SA
AF Blum, Marissa A.
Ibrahim, Said A.
TI Race/Ethnicity and Use of Elective Joint Replacement in the Management
of End-Stage Knee/Hip Osteoarthritis A Review of the Literature
SO CLINICS IN GERIATRIC MEDICINE
LA English
DT Review
DE Disparity; Joint arthroplasty; Osteoarthritis; Race/ethnicity
ID TOTAL HIP-ARTHROPLASTY; STATES MEDICARE POPULATION; UNITED-STATES;
RACIAL DISPARITIES; AFRICAN-AMERICANS; DECISION-MAKING; HEALTH-SERVICES;
ETHNIC-DIFFERENCES; NATIONAL-HEALTH; OLDER PATIENTS
AB Osteoarthritis is the most prevalent form of arthritis for which elective knee and hip joint replacement are effective treatment options in the management of end-stage disease. There are marked racial disparities in the utilization of joint arthroplasty. This article reviews the rationale for understanding this disparity, the evidence base that supports the disparity, and some known potential explanations, as well as additional data on racial disparities emerging in research on postarthroplasty outcomes and quality of care. The article concludes with a call for more research examining patient, provider and system-level factors that underlie these disparities.
C1 [Blum, Marissa A.] Temple Univ, Sch Med, Div Rheumatol, Philadelphia, PA 19140 USA.
[Ibrahim, Said A.] Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA 19104 USA.
[Ibrahim, Said A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
RP Blum, MA (reprint author), Temple Univ, Sch Med, Div Rheumatol, 3322 N Broad St,Suite 205, Philadelphia, PA 19140 USA.
EM Marissa.blum@tuhs.temple.edu
NR 71
TC 8
Z9 8
U1 3
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0690
J9 CLIN GERIATR MED
JI Clin. Geriatr. Med.
PD AUG
PY 2012
VL 28
IS 3
BP 521
EP +
DI 10.1016/j.cger.2012.05.002
PG 13
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 998VG
UT WOS:000308267900011
PM 22840312
ER
PT J
AU Wilson, BZ
Anzueto, A
Restrepo, MI
Pugh, MJV
Mortensen, EM
AF Wilson, Bryan Z.
Anzueto, Antonio
Restrepo, Marcos I.
Pugh, Mary Jo V.
Mortensen, Eric M.
TI Comparison of two guideline-concordant antimicrobial combinations in
elderly patients hospitalized with severe community-acquired pneumonia
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE antimicrobial therapy; length of stay; mortality; pneumonia
ID BACTEREMIC PNEUMOCOCCAL PNEUMONIA; INITIAL EMPIRIC THERAPY; MACROLIDE
ANTIBIOTICS; CLINICAL-OUTCOMES; COMORBIDITY INDEX; MEDICAL OUTCOMES;
BETA-LACTAM; MORTALITY; IMPACT; VALIDATION
AB Objective: Two of the guideline-concordant therapies for severe community-acquired pneumonia are either a beta-lactam and fluoroquinolone or beta-lactam and macrolide. However it is unclear if there is a benefit for one vs. the other for elderly patients with severe community-acquired pneumonia.
Design: A retrospective population-based cohort study of patients with community-acquired pneumonia.
Setting: Patients admitted to an intensive care unit of any Department of Veterans Affairs hospital during 5-yr period.
Patients: We included only those patients >65 yrs of age admitted to the intensive care unit with community-acquired pneumonia who received either beta-lactam +fluoroquinolone or beta-lactam + macrolide antibiotic therapy for pneumonia.
Intervention: Not applicable.
Measurements: We used multilevel regression models to examine the effect of beta-lactam + fluoroquinolone vs. beta-lactam + macrolide on each of the outcomes after adjusting for potential confounders using propensity scores.
Main Results: The cohort consisted of 1,989 patients: 98.5% male and a mean age of 74 yrs. For treatment, 44% of subjects received beta-lactam + fluoroquinolone and 56% received beta-lactam + macrolide. Unadjusted 30-day mortality was 27% for beta-lactam + fluoroquinolone and 24% for beta-lactam + macrolide (p = .11). In the multilevel models, the use of beta-lactam + fluoroquinolone was not significantly associated with 30-day mortality (odds ratio 1.05, 95% confidence interval 0.85-1.30). However, the use of beta-lactam + fluoroquinolone was significantly associated with increased mean length of stay (incidence rate ratio 1.30, 95% confidence interval 1.27-1.33).
Conclusions: We found no significant difference for 30-day mortality but did demonstrate an association with increase in length of stay associated with the use of beta-lactam + fluoroquinolone. Randomized controlled trials are needed to determine the most effective antibiotics regimes for patients with severe pneumonia. (Crit Care Med 2012; 40:2310-2314)
C1 [Anzueto, Antonio; Restrepo, Marcos I.; Pugh, Mary Jo V.; Mortensen, Eric M.] VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, San Antonio, TX 78229 USA.
[Anzueto, Antonio; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Wilson, Bryan Z.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
RP Mortensen, EM (reprint author), VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX USA.
EM Eric.Mortensen@UTSouthwestern.edu
RI Restrepo, Marcos/H-4442-2014
OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563
FU National Institute of Nursing Research [R01NR010828]; National Heart,
Lung, and Blood Institute [K23HL096054]; National Institute of Health
[K23HL096054]
FX The project described was supported by Grant Number R01NR010828 from the
National Institute of Nursing Research. Dr. Restrepo is supported by
grant K23HL096054 from the National Heart, Lung, and Blood Institute.
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of
Nursing Research or the National Institutes of Health. Dr. Marcos I.
Restrepo participated in advisory boards for Theravan, Forest
Laboratories, Johnson and Johnson, and Novartis and was a consultant for
Trius, Theravan and Pfizer (Wyeth). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the Department of Veterans Affairs and National
Institutes of Health. This material is the result of work supported with
resources and the use of facilities at the South Texas Veterans Health
Care System. The funding agencies had no role in conducting the study,
or role in the preparation, review, or approval of the manuscript.; Drs.
Restrepo and Mortensen received funding from the National Institute of
Health K23HL096054. The remaining authors have not disclosed any
potential conflicts of interest.
NR 37
TC 15
Z9 16
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD AUG
PY 2012
VL 40
IS 8
BP 2310
EP 2314
DI 10.1097/CCM.0b013e31825151a8
PG 5
WC Critical Care Medicine
SC General & Internal Medicine
GA 976SM
UT WOS:000306604900006
PM 22622401
ER
PT J
AU Laghi, F
AF Laghi, Franco
TI Proteasome inhibition and ventilator-induced diaphragmatic dysfunction:
Is the glass half full or half empty?
SO CRITICAL CARE MEDICINE
LA English
DT Editorial Material
DE diaphragm weakness; diaphragmatic function; mechanical ventilation;
oxidative stress; proteasome; proteolysis; respiratory muscles; weaning
failure
ID MECHANICAL VENTILATION; ATROPHY; RATS; PROTEOLYSIS
C1 [Laghi, Franco] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA.
[Laghi, Franco] Loyola Univ, Maywood, IL 60153 USA.
RP Laghi, F (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.
NR 18
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD AUG
PY 2012
VL 40
IS 8
BP 2525
EP 2526
DI 10.1097/CCM.0b013e318258ebc5
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA 976SM
UT WOS:000306604900050
PM 22809936
ER
PT J
AU Hu, XM
Zhang, MJ
Leak, RK
Gan, Y
Li, PY
Gao, YQ
Chen, J
AF Hu, Xiaoming
Zhang, Meijuan
Leak, Rehana K.
Gan, Yu
Li, Peiying
Gao, Yanqin
Chen, Jun
TI Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Cell penetrating peptide; TAT protein transduction domains; blood brain
barrier; stroke; neuroprotection
ID CELL-PENETRATING PEPTIDE; FOCAL CEREBRAL-ISCHEMIA; VECTOR-MEDIATED
STRATEGY; ARGININE-RICH PEPTIDES; TAT-FUSION PROTEINS; KINASE-C-DELTA;
POLY(BUTYL CYANOACRYLATE) NANOPARTICLES; HUMAN IMMUNODEFICIENCY VIRUS;
MEMBRANE-PERMEABLE PEPTIDES; NEURONAL PRECURSOR CELLS
AB Stroke is a devastating disease with few therapeutic options. Despite our growing understanding of the critical mechanistic events in post-stroke brain injury, the clinical translation of these findings has been less effective. A monumental hurdle to the field has been the inability of many systemically applied therapies to efficiently cross the blood brain barrier (BBB) and enter brain cells. Over the last two decades, however, significant technological achievements have overcome this obstacle to facilitate central nervous system (CNS) drug delivery. Noninvasive drug carriers, especially cell penetrating peptide (CPP) show great potential to deliver neurotherapeutics across the BBB for the treatment of ischemic brain injury. This review begins with a brief introduction to the BBB in relation to drug delivery and then provides an overview of the development of drug carriers for neurotherapeutics, with a focus on CPP-mediated transduction. We discuss recent advances and limitations in this field, as well as mechanisms underlying CPP-mediated brain targeting. We also summarize the application of CPPs in stroke research. Continuing modifications and improvements of CPPs are expected to enhance both their feasibility in clinical stroke management and their specificity towards particular cell types.
C1 [Hu, Xiaoming; Zhang, Meijuan; Gan, Yu; Li, Peiying; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
[Hu, Xiaoming; Zhang, Meijuan; Gan, Yu; Li, Peiying; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.
[Hu, Xiaoming; Gan, Yu; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China.
[Hu, Xiaoming; Gan, Yu; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China.
[Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA.
[Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.
RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
EM yqgao@shmu.edu.cn; chenj2@upmc.edu
RI Gao, Yanqin/I-6790-2016
OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417
FU American Heart Association [10POST4150028]; National Institutes of
Health/NINDS Grants [NS36736, NS43802, NS56118, NS45048]; Chinese
Natural Science Foundation grants [30670642, 30870794, 81020108021]
FX XIAOMING HU is supported by a grant (10POST4150028) from the American
Heart Association. JUN CHEN is supported by National Institutes of
Health/NINDS Grants NS36736, NS43802, NS56118, and NS45048. YANQIN GAO
is supported by Chinese Natural Science Foundation grants 30670642,
30870794, and 81020108021. We thank Pat Strickler for excellent
secretarial support.
NR 188
TC 4
Z9 4
U1 0
U2 37
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD AUG
PY 2012
VL 18
IS 25
BP 3704
EP 3720
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 993OR
UT WOS:000307869600012
PM 22574984
ER
PT J
AU Wajnberg, A
Hwang, U
Torres, L
Yang, S
AF Wajnberg, Ania
Hwang, Ula
Torres, Lucille
Yang, Samuel
TI CHARACTERISTICS OF FREQUENT GERIATRIC USERS OF AN URBAN EMERGENCY
DEPARTMENT
SO JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the Society-for-Academic-Emergency-Medicine
CY MAY 13-17, 2009
CL New Orleans, LA
SP Soc Acad Emergency Med
DE geriatrics; ED overcrowding; access to care; primary care
ID PRIMARY-CARE; ELDERLY-PATIENTS; BARRIERS; VISITS; ACCESS
AB Background: As the population ages, it is projected that older adults will increase emergency department (ED) utilization and contribute to ED crowding. Older patients are at risk of decreased health-related quality of life after an ED visit. Characteristics of older adults that frequently use the ED have not been well studied, and prior studies have shown that lack of access to primary care may influence ED utilization. Objective: Determine factors associated with frequent Emergency Department (ED) utilization by older adults. Methods: Retrospective chart review of all patients >= 65 years of age seen in an urban ED between December 2007 and September 2008. A prospective telephone survey was done of "frequent" (>= 4 ED visits over a 6-month period) geriatric users. "Frequent" and "infrequent" geriatric ED users were compared using chi-squared and t-test. Survey results are univariate descriptive statistics. Results: There were 8520 ED visits of adults >= 65 years of age analyzed, of which 5718 were unique patients. Of these, 268 (5%) were frequent ED users. Frequent geriatric ED users were more likely to be Black or Hispanic and were considered less urgent at triage. Of the 59 surveyed frequent users of the ED, 95% reported having a usual source of care, though only 36% contacted their outpatient provider before a visit to the ED. Conclusion: Frequent geriatric users of the ED were considered less urgent at triage, and although most identified themselves as having a primary care provider in the community, many did not contact them before going to the ED. (C) 2012 Elsevier Inc.
C1 [Wajnberg, Ania; Torres, Lucille; Yang, Samuel] Mt Sinai Sch Med, Dept Gen Internal Med, Mt Sinai Visiting Doctors Program, New York, NY 10029 USA.
[Hwang, Ula; Torres, Lucille; Yang, Samuel] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA.
[Hwang, Ula] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA.
[Hwang, Ula] James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA.
RP Wajnberg, A (reprint author), Mt Sinai Sch Med, Dept Gen Internal Med, Mt Sinai Visiting Doctors Program, 1 Gustave L Levy Pl,Box 1216, New York, NY 10029 USA.
FU NIA NIH HHS [K24 AG022345]
NR 20
TC 9
Z9 9
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0736-4679
J9 J EMERG MED
JI J. Emerg. Med.
PD AUG
PY 2012
VL 43
IS 2
BP 376
EP 381
DI 10.1016/j.jemermed.2011.06.056
PG 6
WC Emergency Medicine
SC Emergency Medicine
GA 994HC
UT WOS:000307920500034
PM 22040771
ER
PT J
AU Gierach, GL
Ichikawa, L
Kerlikowske, K
Brinton, LA
Farhat, GN
Vacek, PM
Weaver, DL
Schairer, C
Taplin, SH
Sherman, ME
AF Gierach, Gretchen L.
Ichikawa, Laura
Kerlikowske, Karla
Brinton, Louise A.
Farhat, Ghada N.
Vacek, Pamela M.
Weaver, Donald L.
Schairer, Catherine
Taplin, Stephen H.
Sherman, Mark E.
TI Relationship Between Mammographic Density and Breast Cancer Death in the
Breast Cancer Surveillance Consortium
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID PARENCHYMAL PATTERNS; TUMOR CHARACTERISTICS; POSTMENOPAUSAL WOMEN;
SUBSEQUENT RISK; ASSOCIATION; FEATURES; MENOPAUSE; ACCURACY; SURVIVAL;
MARKERS
AB Women with elevated mammographic density have an increased risk of developing breast cancer. However, among women diagnosed with breast cancer, it is unclear whether higher density portends reduced survival, independent of other factors.
We evaluated relationships between mammographic density and risk of death from breast cancer and all causes within the US Breast Cancer Surveillance Consortium. We studied 9232 women diagnosed with primary invasive breast carcinoma during 19962005, with a mean follow-up of 6.6 years. Mammographic density was assessed using the Breast Imaging Reporting and Data System (BI-RADS) density classification. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by Cox proportional hazards regression; women with scattered fibroglandular densities (BI-RADS 2) were the referent group. All statistical tests were two-sided.
A total of 1795 women died, of whom 889 died of breast cancer. In multivariable analyses (adjusted for site, age at and year of diagnosis, American Joint Committee on Cancer stage, body mass index, mode of detection, treatment, and income), high density (BI-RADS 4) was not related to risk of death from breast cancer (HR = 0.92, 95% CI = 0.71 to 1.19) or death from all causes (HR = 0.83, 95% CI = 0.68 to 1.02). Analyses stratified by stage and other prognostic factors yielded similar results, except for an increased risk of breast cancer death among women with low density (BI-RADS 1) who were either obese (HR = 2.02, 95% CI = 1.37 to 2.97) or had tumors of at least 2.0cm (HR = 1.55, 95% CI = 1.14 to 2.09).
High mammographic breast density was not associated with risk of death from breast cancer or death from any cause after accounting for other patient and tumor characteristics. Thus, risk factors for the development of breast cancer may not necessarily be the same as factors influencing the risk of death after breast cancer has developed.
C1 [Gierach, Gretchen L.; Brinton, Louise A.; Sherman, Mark E.] NCI, Hormonal & Reprod Epidemiol Branch, NIH, Rockville, MD USA.
[Schairer, Catherine] NCI, Biostat Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA.
[Taplin, Stephen H.] NCI, Proc Care Res Branch, Behav Res Program, Div Canc Control & Populat Sci,NIH, Rockville, MD USA.
[Ichikawa, Laura] Grp Hlth Res Inst, Seattle, WA USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Gen Internal Med Sect, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Farhat, Ghada N.] Univ Balamand, Beirut, Lebanon.
[Vacek, Pamela M.] Univ Vermont, Coll Med, Dept Med Biostat, Burlington, VT USA.
[Weaver, Donald L.] Vermont Canc Ctr, Burlington, VT USA.
[Weaver, Donald L.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA.
RP Gierach, GL (reprint author), 6120 Execut Blvd,Ste 550,Rm 5016, Rockville, MD 20852 USA.
EM gierachg@mail.nih.gov
RI Brinton, Louise/G-7486-2015; Gierach, Gretchen/E-1817-2016
OI Brinton, Louise/0000-0003-3853-8562; Gierach,
Gretchen/0000-0002-0165-5522
FU National Institutes of Health, National Cancer Institute (NCI); NCI
[U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976,
U01CA63731, U01CA70040, HHSN261201100031C]
FX This work was supported (in part) by the Intramural Research Program of
the National Institutes of Health, National Cancer Institute (NCI), and
the NCI-funded Breast Cancer Surveillance Consortium (U01CA63740 to KK,
U01CA86076 to DM, U01CA86082 to TO, U01CA63736 to GC, U01CA70013 to BG,
U01CA69976 to RR, U01CA63731 to DB, U01CA70040 to BY, and
HHSN261201100031C to DM).
NR 32
TC 55
Z9 55
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD AUG
PY 2012
VL 104
IS 16
BP 1218
EP 1227
DI 10.1093/jnci/djs327
PG 10
WC Oncology
SC Oncology
GA 998JO
UT WOS:000308234100006
PM 22911616
ER
PT J
AU Brasky, TM
Baik, CS
Slatore, CG
Potter, JD
White, E
AF Brasky, Theodore M.
Baik, Christina S.
Slatore, Christopher G.
Potter, John D.
White, Emily
TI Non-steroidal anti-inflammatory drugs and small cell lung cancer risk in
the VITAL study
SO LUNG CANCER
LA English
DT Article
DE Aspirin; Ibuprofen; NSAID; Small cell lung cancer
ID SEX-DIFFERENCES; WOMENS HEALTH; ASPIRIN USE; EXPRESSION; COHORT;
METAANALYSIS; ASSOCIATION; SMOKING; USERS; MEN
AB Few studies have examined the association between non-steroidal anti-inflammatory drug (NSAID) use and risk of small cell lung cancer (SCLC); among them, findings are mixed. Recently, we found that use of NSAIDs was differentially associated with lung cancer risk by histology. Here, we examine, more comprehensively, the association between individual NSAIDs and SCLC risk. 75,546 residents of western Washington State, ages 50-76, completed a baseline questionnaire in 2000-2002 and reported on their use of individual NSAIDs over the past 10 years. NSAID use was categorized as non-users, low (<4 days/week or <4 years), and high (>= 4 days/week and >= 4 years). 111 SCLC were identified through linkage to a population-based cancer registry. Multivariable-adjusted Cox proportional hazards models including strong adjustment for smoking were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI). Compared to non-use, high use of regular-strength aspirin was associated with an elevated risk of SCLC (HR 1.78,95% CI: 1.05-3.02; P-trend = 0.03). Findings for low-dose aspirin were elevated but did not reach statistical significance. Use of non-aspirin NSAIDs was not associated with SCLC risk. Our findings provide further indication of heterogeneity in the association between aspirin and lung cancer morphologies. Large, prospective studies with comprehensive assessments of NSAID use and smoking history and data on both men and women, are needed in order to better understand the association between use of aspirin and SCLC. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Brasky, Theodore M.; Baik, Christina S.; Potter, John D.; White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA.
[Brasky, Theodore M.] Ohio State Univ, James Comprehens Canc Ctr, Dept Canc Prevent & Control, Columbus, OH 43210 USA.
[Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR USA.
[Slatore, Christopher G.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
RP Brasky, TM (reprint author), Fred Hutchinson Canc Res Ctr, Canc Prevent Program, 1100 Fairview Ave N,M4-B402, Seattle, WA 98109 USA.
EM tbrasky@fhcrc.org
OI Potter, John/0000-0001-5439-1500; Slatore,
Christopher/0000-0003-0958-8122
FU National Institutes of Health [R25-CA094880, K05-CA154337]; VA HSRD
Career Development Awards
FX This work is supported by National Institutes of Health grants
R25-CA094880 (National Cancer Institute) and K05-CA154337 (National
Cancer Institute and Office of Dietary Supplements). Dr. Slatore is a
recipient of a VA HSRD Career Development Awards and is supported by
resources from the Portland VA Medical Center. The Department of
Veterans Affairs did not have a role in the conduct of the study, in the
collection, management, analysis, or interpretation of data, or in the
preparation of the manuscript. The views expressed in this article are
those of the authors and do not necessarily represent the views of the
Department of Veterans Affairs or the US Government.
NR 26
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0169-5002
J9 LUNG CANCER
JI Lung Cancer
PD AUG
PY 2012
VL 77
IS 2
BP 260
EP 264
DI 10.1016/j.lungcan.2012.04.015
PG 5
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 982IM
UT WOS:000307036500004
PM 22608142
ER
PT J
AU Voils, CI
Coffman, CJ
Edelman, D
Maciejewski, ML
Grubber, JM
Sadeghpour, A
Cho, A
McKenzie, J
Blanpain, F
Scheuner, M
Sandelowski, M
Gallagher, MP
Ginsburg, GS
Yancy, WS
AF Voils, Corrine I.
Coffman, Cynthia J.
Edelman, David
Maciejewski, Matthew L.
Grubber, Janet M.
Sadeghpour, Azita
Cho, Alex
McKenzie, Jamiyla
Blanpain, Francoise
Scheuner, Maren
Sandelowski, Margarete
Gallagher, M. Patrick
Ginsburg, Geoffrey S.
Yancy, William S., Jr.
TI Examining the impact of genetic testing for type 2 diabetes on health
behaviors: study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE Genetic testing; Type II diabetes; Weight loss
ID LOW-CARBOHYDRATE DIET; WEIGHT-LOSS; SELF-EFFICACY; RISK; PREVENTION;
QUESTIONNAIRE; INTERVENTION; RELIABILITY; PROGRESSION; NUMERACY
AB Background: We describe the study design, procedures, and development of the risk counseling protocol used in a randomized controlled trial to evaluate the impact of genetic testing for diabetes mellitus (DM) on psychological, health behavior, and clinical outcomes.
Methods/Design: Eligible patients are aged 21 to 65 years with body mass index (BMI) >= 27 kg/m(2) and no prior diagnosis of DM. At baseline, conventional DM risk factors are assessed, and blood is drawn for possible genetic testing. Participants are randomized to receive conventional risk counseling for DM with eye disease counseling or with genetic test results. The counseling protocol was pilot tested to identify an acceptable graphical format for conveying risk estimates and match the length of the eye disease to genetic counseling. Risk estimates are presented with a vertical bar graph denoting risk level with colors and descriptors. After receiving either genetic counseling regarding risk for DM or control counseling on eye disease, brief lifestyle counseling for prevention of DM is provided to all participants.
Discussion: A standardized risk counseling protocol is being used in a randomized trial of 600 participants. Results of this trial will inform policy about whether risk counseling should include genetic counseling.
C1 [Voils, Corrine I.; Coffman, Cynthia J.; Edelman, David; Maciejewski, Matthew L.; Grubber, Janet M.; Sadeghpour, Azita; McKenzie, Jamiyla; Gallagher, M. Patrick; Yancy, William S., Jr.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Voils, Corrine I.; Edelman, David; Maciejewski, Matthew L.; Yancy, William S., Jr.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Coffman, Cynthia J.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA.
[Cho, Alex; Ginsburg, Geoffrey S.] Duke Univ, Med Ctr, Inst Genom Sci & Policy, Durham, NC USA.
[Blanpain, Francoise] Duke Univ, Med Ctr, Clin Mol Diagnost Lab, Durham, NC USA.
[Scheuner, Maren] VA Greater Los Angeles Healthcare Syst, Div Med Genet, Los Angeles, CA USA.
[Scheuner, Maren] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Sandelowski, Margarete] Univ N Carolina, Sch Nursing, Chapel Hill, NC USA.
[Voils, Corrine I.] Vet Affairs Med Ctr 152, Durham, NC 27705 USA.
RP Voils, CI (reprint author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
EM corrine.voils@dm.duke.edu
OI Edelman, David/0000-0001-7112-6151; Voils, Corrine/0000-0003-1913-663X
FU Department of Veterans Affairs (DVA) Health Services Research and
Development (HSRD) service [IIR 09-039]; Career Scientist Award from DVA
HSRD [RCS 10-391]
FX This research was supported by a grant from the Department of Veterans
Affairs (DVA) Health Services Research and Development (HSR&D) service
(IIR 09-039). Dr. Maciejewski was supported by a Career Scientist Award
from DVA HSR&D (RCS 10-391). The views expressed in this article are
those of the authors and do not necessarily represent the views of the
DVA. We express our deepest gratitude to Tamika Brown and Cherisa
Williams for their assistance with data collection, to Jennifer Hoff for
development of the study database, and to Karen Nicely, MS for delivery
of genetic counseling. Dr. Sadeghpour is now at Duke University Medical
Center. Ms. Blanpain is now at Pathgroup in Nashville, TN. Dr. Gallagher
is now at Altisource Solutions in Winston-Salem, NC.
NR 35
TC 6
Z9 6
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD AUG 1
PY 2012
VL 13
AR 121
DI 10.1186/1745-6215-13-121
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 992YN
UT WOS:000307817600001
PM 22852560
ER
PT J
AU Shaw, LJ
Weintraub, WS
Maron, DJ
Hartigan, PM
Hachamovitch, R
Min, JK
Dada, M
Mancini, GBJ
Hayes, SW
O'Rourke, RA
Spertus, JA
Kostuk, W
Gosselin, G
Chaitman, BR
Knudtson, M
Friedman, J
Slomka, P
Germano, G
Bates, ER
Teo, KK
Boden, WE
Berman, DS
AF Shaw, Leslee J.
Weintraub, William S.
Maron, David J.
Hartigan, Pamela M.
Hachamovitch, Rory
Min, James K.
Dada, Marcin
Mancini, G. B. John
Hayes, Sean W.
O'Rourke, Robert A.
Spertus, John A.
Kostuk, William
Gosselin, Gilbert
Chaitman, Bernard R.
Knudtson, Merill
Friedman, John
Slomka, Piotr
Germano, Guido
Bates, Eric R.
Teo, Koon K.
Boden, William E.
Berman, Daniel S.
TI Baseline stress myocardial perfusion imaging results and outcomes in
patients with stable ischemic heart disease randomized to optimal
medical therapy with or without percutaneous coronary intervention
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID EMISSION COMPUTED-TOMOGRAPHY; EVALUATION COURAGE TRIAL; UTILIZING
REVASCULARIZATION; ARTERY-DISEASE; HIGH-RISK; STRATEGIES; PCI;
MANAGEMENT; INFARCTION; BENEFIT
AB Background The COURAGE trial reported similar clinical outcomes for patients with stable ischemic heart disease (SIHD) receiving optimal medical therapy (OMT) with or without percutaneous coronary intervention (PCI). The current post hoc substudy analysis examined the relationship between baseline stress myocardial ischemia and clinical outcomes based on randomized treatment assignment.
Methods A total of 1,381 randomized patients (OMT n = 699, PCI + OMT n = 682) underwent baseline stress myocardial perfusion single-photon emission computed tomographic imaging. Site investigators interpreted the extent of ischemia by the number of ischemic segments using a 6-segment myocardial model. Patients were divided into those with no to mild (<3 ischemic segments) and moderate to severe ischemia (>= 3 ischemic segments). Cox proportional hazards models were calculated to assess time to the primary end point of death or myocardial infarction.
Results At baseline, moderate to severe ischemia occurred in more than one-quarter of patients (n = 468), and the incidence was comparable in both treatment groups (P = .36). The primary end point, death or myocardial infarction, was similar in the OMT and PCI + OMT treatment groups for no to mild (18% and 19%, P = .92) and moderate to severe ischemia (19% and 22%, P = .53, interaction P value = .65). There was no gradient increase in events for the overall cohort with the extent of ischemia.
Conclusions From the COURAGE trial post hoc substudy, the extent of site-defined ischemia did not predict adverse events and did not alter treatment effectiveness. Currently, evidence supports equipoise as to whether the extent and severity of ischemia impact on therapeutic effectiveness. (Am Heart J 2012; 164: 243-50.)
C1 [Shaw, Leslee J.] Emory Univ, Emory Clin Cardiovasc Res Inst, Sch Med, Atlanta, GA 30306 USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA.
[Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Hartigan, Pamela M.] VA Connecticut Healthcare Syst, VA Cooperat Studies Program, Coordinating Ctr, West Haven, CT USA.
[Hachamovitch, Rory] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Min, James K.; Hayes, Sean W.; Friedman, John; Slomka, Piotr; Germano, Guido] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Dada, Marcin] Hartford Hosp, Hartford, CT 06115 USA.
[Mancini, G. B. John] Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada.
[O'Rourke, Robert A.] S Texas Vet HCS, San Antonio, TX USA.
[Spertus, John A.] Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA.
[Kostuk, William] London Hlth Sci Ctr, London, ON, Canada.
[Gosselin, Gilbert] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Chaitman, Bernard R.] St Louis Univ, St Louis, MO 63103 USA.
[Knudtson, Merill] Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada.
[Bates, Eric R.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Teo, Koon K.] McMaster Univ, Hamilton, ON, Canada.
[Boden, William E.] SUNY Buffalo, Buffalo Gen Hosp, Western New York VA Healthcare Network, Buffalo, NY 14260 USA.
RP Shaw, LJ (reprint author), Emory Univ, Emory Clin Cardiovasc Res Inst, Sch Med, Room 529,1462 Clifton Rd NE, Atlanta, GA 30306 USA.
EM leslee.shaw@emory.edu
FU Astellas Healthcare; Lantheus Medical Imaging; Cooperative Studies
Program of the Department of Veterans Affairs Office of Research and
Development; Canadian Institute of Health Research-Institute for
Circulatory and Respiratory Health
FX Partial funding for this substudy was provided by Astellas Healthcare
and Lantheus Medical Imaging. Drs Shaw and Berman have declared a
conflict for substudy 0 with grant support to the Department of
Veterans' Affairs, Astellas Healthcare, and Lantheus Medical Imaging. No
other authors have any conflicts to disclose.; Supported by the
Cooperative Studies Program of the Department of Veterans Affairs Office
of Research and Development and Canadian Institute of Health
Research-Institute for Circulatory and Respiratory Health. Additional
support for this nuclear substudy was provided by Astellas Healthcare
and Lantheus Imaging in the form of unrestricted research grants to the
Department of Veterans Affairs.
NR 29
TC 70
Z9 74
U1 1
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD AUG
PY 2012
VL 164
IS 2
BP 243
EP 250
DI 10.1016/j.ahj.2012.05.018
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 991AR
UT WOS:000307673700018
PM 22877811
ER
PT J
AU Kimmel, SE
Troxel, AB
Loewenstein, G
Brensinger, CM
Jaskowiak, J
Doshi, JA
Laskin, M
Volpp, K
AF Kimmel, Stephen E.
Troxel, Andrea B.
Loewenstein, George
Brensinger, Colleen M.
Jaskowiak, Jane
Doshi, Jalpa A.
Laskin, Mitchell
Volpp, Kevin
TI Randomized trial of lottery-based incentives to improve warfarin
adherence
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID PAY-FOR-PERFORMANCE; IN-RANGE; PATIENT ADHERENCE; RISK-FACTORS; CARE;
ANTICOAGULATION; MEDICATION; QUALITY
AB Background Poor adherence to medications is a major cause of morbidity and inadequate drug effectiveness. Efforts to improve adherence have typically been either ineffective or too complex to implement in clinical practice. Lottery-based incentive interventions could be a scalable approach to improving adherence.
Methods This was a randomized, controlled clinical trial of a daily lottery-based incentive in patients on warfarin stratified by baseline international normalized ratio (INR). The trial randomized 100 patients to either a lottery-based incentive or no lottery intervention. Main outcome was out-of-range INRs.
Results Over 6 months, the overall percentage of out-of-range INRs did not differ between the 2 arms (mean 23.0% in lottery arm and 25.9% in control arm, adjusted odds ratio [OR] 0.93, 95% CI 0.62-1.41). However, among the a priori subgroup with a baseline INR below therapeutic range, there was a significant reduction in out-of-range INR in the lottery arm versus the control arm (adjusted OR 0.39, 95% CI 0.25-0.62), whereas there was no such effect among those with therapeutic INRs at baseline (adjusted OR 1.26, 95% CI, 0.76-2.09, P value for interaction = .0016). Among those with low INR at baseline, there was a nonsignificant 49% reduction in the odds of nonadherence with the intervention (OR 0.51, 95% CI 0.23-1.14
). Conclusions Although a lottery-based intervention was not associated with a significant improvement in anticoagulation control among all study participants, it improved control among an a priori group of patients at higher risk for poor adherence. (Am Heart J 2012; 164: 268-74.)
C1 [Kimmel, Stephen E.; Troxel, Andrea B.; Brensinger, Colleen M.; Jaskowiak, Jane] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Kimmel, Stephen E.; Doshi, Jalpa A.; Volpp, Kevin] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Kimmel, Stephen E.; Troxel, Andrea B.; Loewenstein, George; Doshi, Jalpa A.; Volpp, Kevin] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA.
[Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA.
[Laskin, Mitchell] Hosp Univ Penn, Dept Pharm Serv, Philadelphia, PA 19104 USA.
[Volpp, Kevin] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA.
[Volpp, Kevin] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
RP Kimmel, SE (reprint author), Univ Penn, Sch Med, Dept Biostat & Epidemiol, 717 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM stevek@mail.med.upenn.edu
OI Troxel, Andrea/0000-0002-1393-3075
FU Aetna Foundation
FX The study was funded by the Aetna Foundation who had no role in the
design of the study; execution of the study; analysis, interpretation,
and writing of the manuscript; or decision to submit the manuscript for
publication. Aetna also did not have access to the data. All authors had
access to the data.
NR 19
TC 28
Z9 28
U1 0
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD AUG
PY 2012
VL 164
IS 2
BP 268
EP 274
DI 10.1016/j.ahj.2012.05.005
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 991AR
UT WOS:000307673700021
PM 22877814
ER
PT J
AU Hiramoto, JS
Katz, R
Peralta, CA
Ix, JH
Fried, L
Cushman, M
Siscovick, D
Palmas, W
Sarnak, M
Shlipak, MG
AF Hiramoto, Jade S.
Katz, Ronit
Peralta, Carmen A.
Ix, Joachim H.
Fried, Linda
Cushman, Mary
Siscovick, David
Palmas, Walter
Sarnak, Mark
Shlipak, Michael G.
TI Inflammation and Coagulation Markers and Kidney Function Decline: The
Multi-Ethnic Study of Atherosclerosis (MESA)
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Kidney function; inflammation; coagulation markers
ID C-REACTIVE PROTEIN; SERUM CYSTATIN-C; RENAL-FUNCTION; FACTOR-VIII;
VENOUS THROMBOEMBOLISM; PLASMA-CONCENTRATION; OLDER-ADULTS; RISK-FACTOR;
DISEASE; INTERLEUKIN-6
AB Background: The strength and direction of the associations between inflammation and coagulation biomarkers with kidney disease onset and progression remain unclear, especially in a population-based setting.
Study Design: Prospective observational study.
Setting & Participants: 4,966 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with a cystatin C-based estimate of glomerular filtration rate (eGFR(cys)) >60 mL/min/1.73 m(2) and at least one follow-up measurement of kidney function. All participants were free of cardiovascular disease at entry.
Predictor: We evaluated the associations of C-reactive protein (CRP), interleukin 6 (IL-6), fibrinogen, factor VIII, and D-dimer levels with kidney function decrease.
Outcomes & Measurements: Kidney function decrease was assessed primarily by repeated measurements of eGFR(cys) over 5 years. Rapid decrease in kidney function was defined as eGFR decrease >3 mL/min/1.73 m(2) per year. Incident low eGFR was defined as the onset of eGFR(cys) <60 mL/min/1.73 m(2) at any follow-up examination and eGFR(cys) decrease >= 1 mL/min/1.73 m(2) per year.
Results: Mean age was 60 years, 39% were white, 52% were women, and 11% had diabetes. Mean eGFR(cys) was 96 mL/min/1.73 m(2) and 7% had albuminuria. Median follow-up was 4.77 years. Higher factor VIII levels (per 1 standard deviation [SD] of biomarker) had the strongest association with kidney function decrease (beta = -0.25; 95% CI, -0.38 to -0.12; P < 0.001), followed by IL-6 (beta = -0.16; 95% CI, -0.29 to -0.03; P = 0.01), CRP (beta = -0.09; 95% CI, -0.22 to 0.03; P = 0.1), and fibrinogen levels (beta = -0.09; 95% CI, -0.22 to 0.04; P = 0.2). Each 1-SD higher concentration of IL-6 (OR, 1.15; 95% CI, 1.07-1.23), factor VIII (OR, 1.11; 95% CI, 1.03-1.18), and CRP (OR, 1.09; 95% CI, 1.02-1.16) at baseline was associated significantly with rapid kidney function decrease. Only IL-6 level was associated significantly with incident low eGFR (OR, 1.09; 95% CI, 1.00-1.19).
Limitations: Observational study design and absence of measured GFR.
Conclusions: Inflammation and coagulation biomarkers are associated with decreasing kidney function in ambulatory adults without established cardiovascular disease or chronic kidney disease. Am J Kidney Dis. 60(2):225-232. (C) 2012 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Hiramoto, Jade S.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
[Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Ix, Joachim H.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA.
[Fried, Linda] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA.
[Fried, Linda] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA.
[Fried, Linda] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Cushman, Mary] Univ Vermont, Dept Med, Thrombosis & Hemostasis Program, Burlington, VT USA.
[Siscovick, David] Univ Washington, Dept Epidemiol & Biostat, Seattle, WA 98195 USA.
[Palmas, Walter] Columbia Univ, Dept Med, New York, NY USA.
[Sarnak, Mark] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA.
[Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA.
RP Hiramoto, JS (reprint author), UCSF Vasc Surg, 400 Parnassus Ave,A-581,Box 0222, San Francisco, CA 94143 USA.
EM jade.hiramoto@ucsfmedctr.org
FU National Institutes of Health (NIH)/National Center for Research
Resources/OD UCSF-CTSI [KL2 RR024130]; NIH/National Institute of
Diabetes and Digestive and Kidney Diseases [R01 DK066488-01]; American
Heart Association (AHA) [0640012N]
FX This publication was supported by National Institutes of Health
(NIH)/National Center for Research Resources/OD UCSF-CTSI grant KL2
RR024130 (Dr Hiramoto), NIH/National Institute of Diabetes and Digestive
and Kidney Diseases/R01 DK066488-01 (Dr Shlipak), and American Heart
Association (AHA) Established Investigator Award 0640012N (Dr Shlipak).
Its contents are the responsibility of the authors and do not
necessarily represent the official views of the NIH or AHA.
NR 45
TC 29
Z9 29
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD AUG
PY 2012
VL 60
IS 2
BP 225
EP 232
DI 10.1053/j.ajkd.2012.02.335
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 974ZW
UT WOS:000306477200010
PM 22560844
ER
PT J
AU Vijayan, A
Palevsky, PM
AF Vijayan, Anitha
Palevsky, Paul M.
TI In Reply to 'Renal Replacement Therapy Dosing in Acute Kidney Injury'
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Letter
ID CRITICALLY-ILL PATIENTS
C1 [Vijayan, Anitha] Washington Univ, St Louis, MO 63130 USA.
[Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Palevsky, Paul M.] Univ Pittsburgh, Pittsburgh, PA USA.
RP Vijayan, A (reprint author), Washington Univ, St Louis, MO 63130 USA.
OI Palevsky, Paul/0000-0002-7334-5400
NR 4
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD AUG
PY 2012
VL 60
IS 2
BP 328
EP 329
DI 10.1053/j.ajkd.2012.05.015
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 974ZW
UT WOS:000306477200026
ER
PT J
AU Valente, AJ
Yoshida, T
Murthy, SN
Sakamuri, SSVP
Katsuyama, M
Clark, RA
Delafontaine, P
Chandrasekar, B
AF Valente, Anthony J.
Yoshida, Tadashi
Murthy, Subramanyam N.
Sakamuri, Siva S. V. P.
Katsuyama, Masato
Clark, Robert A.
Delafontaine, Patrice
Chandrasekar, Bysani
TI Angiotensin II enhances AT(1)-Nox1 binding and stimulates arterial
smooth muscle cell migration and proliferation through AT(1), Nox1, and
interleukin-18
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE renin-angiotensin-aldosterone system; mitogenesis; migration;
atherosclerosis; restenosis; angiotensin II type 1 receptor
ID NF-KAPPA-B; NADPH OXIDASE; MATRIX METALLOPROTEINASES; NEOINTIMAL
FORMATION; INDUCED HYPERTENSION; SIGNALING PATHWAYS; OXIDATIVE STRESS;
TYPE-1 RECEPTOR; GENE-EXPRESSION; CROSS-TALK
AB Valente AJ, Yoshida T, Murthy SN, Sakamuri SS, Katsuyama M, Clark RA, Delafontaine P, Chandrasekar B. Angiotensin II enhances AT(1)-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT(1), Nox1, and interleukin18. Am J Physiol Heart Circ Physiol 303: H282-H296, 2012. First published May 25, 2012; doi:10.1152/ajpheart.00231.2012.-The redox- sensitive transcription factors NF-kappa B and activator protein-1 (AP-1) are critical mediators of ANG II signaling. The promitogenic and promigratory factor interleukin (IL)-18 is an NF-kappa B- and AP-1-responsive gene. Therefore, we investigated whether ANG II-mediated smooth muscle cell (SMC) migration and proliferation involve IL-18. ANG II induced rat carotid artery SMC migration and proliferation and IL-18 and metalloproteinase (MMP)-9 expression via ANG II type 1 (AT1) receptor. ANG II-induced superoxide generation, NF-kappa B and AP-1 activation, and IL-18 and MMP-9 induction were all markedly attenuated by losartan, diphenyleneiodonium chloride (DPI), and Nox1 knockdown. Similar to ANG II, addition of IL-18 also induced superoxide generation, activated NF-kappa B and AP-1, and stimulated SMC migration and proliferation, in part via Nox1, and both ANG II and IL-18 induced NOX1 transcription in an AP-1-dependent manner. AT1 physically associates with Nox1 in SMC, and ANG II enhanced this binding. Interestingly, exogenous IL-18 neither induced AT1 binding to Nox1 nor enhanced the ANG II-induced increase in AT(1)/Nox1 binding. Importantly, IL-18 knockdown, or pretreatment with IL-18 neutralizing antibodies, or IL-18 binding protein, all attenuated the migratory and mitogenic effects of ANG II. Continuous infusion of ANG II for 7 days induced carotid artery hyperplasia in rats via AT1 and was associated with increased AT(1)/Nox1 binding (despite lower AT1 levels); increased DPI-inhibitable superoxide production; increased phospho-IKK beta, JNK, p65, and c-Jun; and induction of IL-18 and MMP-9 in endothelium-denuded carotid arteries. These results indicate that IL-18 amplifies the ANG II-induced, redox-dependent inflammatory cascades by activating similar promitogenic and promigratory signal transduction pathways. The ANG II/Nox1/IL-18 pathway may be critical in hyperplastic vascular diseases, including atherosclerosis and restenosis.
C1 [Yoshida, Tadashi; Sakamuri, Siva S. V. P.; Delafontaine, Patrice; Chandrasekar, Bysani] Tulane Univ, Inst Heart & Vasc, Sch Med, New Orleans, LA 70112 USA.
[Valente, Anthony J.; Clark, Robert A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Valente, Anthony J.; Clark, Robert A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Katsuyama, Masato] Kyoto Prefectural Univ Med, Radioisotope Ctr, Kamigyo Ku, Kyoto, Japan.
[Chandrasekar, Bysani] SE Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA USA.
RP Chandrasekar, B (reprint author), Tulane Univ, Inst Heart & Vasc, Sch Med, 1430 Tulane Ave,SL 48, New Orleans, LA 70112 USA.
OI Delafontaine, Patrice/0000-0003-3744-3617; Yoshida,
Tadashi/0000-0002-4544-1497
FU Veterans Affairs Office of Research; Development-Biomedical Laboratory
Research; Development Service Award [1IO1BX000246]; National Heart,
Lung, and Blood Institute [HL-86787, HL-70241, HL-80682]
FX This work was supported by the Veterans Affairs Office of Research and
Development-Biomedical Laboratory Research and Development Service Award
1IO1BX000246 and National Heart, Lung, and Blood Institute Grant
HL-86787 to BC. P. Delafontaine is supported by National Heart, Lung,
and Blood Institute Grants HL-70241 and HL-80682.
NR 52
TC 35
Z9 37
U1 1
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD AUG
PY 2012
VL 303
IS 3
BP H282
EP H296
DI 10.1152/ajpheart.00231.2012
PG 15
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA 984ZG
UT WOS:000307231900004
PM 22636674
ER
PT J
AU Freytes, CO
Zhang, MJ
Carreras, J
Burns, LJ
Gale, RP
Isola, L
Perales, MA
Seftel, M
Vose, JM
Miller, AM
Gibson, J
Gross, TG
Rowlings, PA
Inwards, DJ
Pavlovsky, S
Martino, R
Marks, DI
Hale, GA
Smith, SM
Schouten, HC
Slavin, S
Klumpp, TR
Lazarus, HM
van Besien, K
Hari, PN
AF Freytes, Cesar O.
Zhang, Mei-Jie
Carreras, Jeanette
Burns, Linda J.
Gale, Robert Peter
Isola, Luis
Perales, Miguel-Angel
Seftel, Matthew
Vose, Julie M.
Miller, Alan M.
Gibson, John
Gross, Thomas G.
Rowlings, Philip A.
Inwards, David J.
Pavlovsky, Santiago
Martino, Rodrigo
Marks, David I.
Hale, Gregory A.
Smith, Sonali M.
Schouten, Harry C.
Slavin, Simon
Klumpp, Thomas R.
Lazarus, Hillard M.
van Besien, Koen
Hari, Parameswaran N.
TI Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin
Lymphoma after Autologous Transplantation Failure
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Allogeneic; Relapse; Reduced-intensity
ID STEM-CELL TRANSPLANTATION; PROGRESSIVE DISEASE; REGISTRY; BLOOD;
MALIGNANCIES; RELAPSE; THERAPY; EXPERIENCE; REMISSION
AB We studied the outcome of allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning regimens (reduced-intensity conditioning and nonmyeloablative) in patients with non-Hodgkin lymphoma who relapsed after autologous hematopoietic stem cell transplantation. Nonrelapse mortality, lymphoma progression/relapse, progression-free survival (PFS), and overall survival were analyzed in 263 patients with non-Hodgkin lymphoma. All 263 patients had relapsed after a previous autologous hematopoietic stem cell transplantation and then had undergone allogeneic hematopoietic stem cell transplantation from a related (n = 26) or unrelated (n = 237) donor after reduced-intensity conditioning (n = 128) or nonmyeloablative (n = 135) and were reported to the Center for International Blood and Marrow Transplant Research between 1996 and 2006. The median follow-up of survivors was 68 months (range, 3-111 months). Three-year nonrelapse mortality was 44% (95% confidence interval [CI], 37%-50%). Lymphoma progression/relapse at 3 years was 35% (95% CI, 29%-41%). Three-year probabilities of PFS and overall survival were 21% (95% CI, 16%-27%) and 32% (95% CI, 27%-38%), respectively. Superior Karnofsky Performance Score, longer interval between transplantations, total body irradiation-based conditioning regimen, and lymphoma remission at transplantation were correlated with improved PFS. Allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning is associated with significant nonrelapse mortality but can result in long-term PFS. We describe a quantitative risk model based on pretransplantation risk factors to identify those patients likely to benefit from this approach. Biol Blood Marrow Transplant 18: 1255-1264 (2012) (C) 2012 American Society for Blood and Marrow Transplantation
C1 [Zhang, Mei-Jie; Carreras, Jeanette; Hari, Parameswaran N.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Burns, Linda J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA.
[Gale, Robert Peter] Celgene Corp, Summit, NJ USA.
[Isola, Luis] Mt Sinai Hosp, New York, NY 10029 USA.
[Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Seftel, Matthew] Univ Manitoba, Winnipeg, MB, Canada.
[Vose, Julie M.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Miller, Alan M.] Baylor Univ, Med Ctr, Dallas, TX USA.
[Gibson, John] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia.
[Gross, Thomas G.] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH 43210 USA.
[Rowlings, Philip A.] Calvary Mater Hosp, Waratah, Australia.
[Inwards, David J.] Mayo Clin, Rochester, MN USA.
[Pavlovsky, Santiago] Fundaleu, Buenos Aires, DF, Argentina.
[Martino, Rodrigo] Hosp Santa Creu & Sant Pau, Barcelona, Spain.
[Marks, David I.] Bristol Childrens Hosp, Bristol, Avon, England.
[Hale, Gregory A.] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA.
[Smith, Sonali M.; van Besien, Koen] Univ Chicago Hosp, Chicago, IL 60637 USA.
[Schouten, Harry C.] Univ Hosp Maastricht, Maastricht, Netherlands.
[Slavin, Simon] Hadassah Med Ctr, Tel Aviv, Israel.
[Klumpp, Thomas R.] Temple Univ, BMT Program, Philadelphia, PA 19122 USA.
[Lazarus, Hillard M.] Univ Hosp Cleveland, Case Med Ctr, Cleveland, OH 44106 USA.
RP Hari, PN (reprint author), Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, POB 26509, Milwaukee, WI 53226 USA.
EM phari@mcw.edu
RI van Besien, Koen/G-4221-2012
OI van Besien, Koen/0000-0002-8164-6211; PERALES,
MIGUEL-ANGEL/0000-0002-5910-4571; Hari, Parameswaran/0000-0002-8800-297X
FU National Cancer Institute, Public Health Service [U24-CA76518]; National
Heart, Lung and Blood Institute; National Institute of Allergy and
Infectious Diseases; National Cancer Institute [5U01HL069294]; Health
Resources and Services Administration [HHSH234200637015C]; Office of
Naval Research [N00014-06-1-0704, N00014-08-1-0058]; Allos; Amgen;
Angioblast; Ariad; Be the Match Foundation; Blue Cross and Blue Shield
Association; Buchanan Family Foundation; CaridianBCT; Celgene;
CellGenix; Children's Leukemia Research Association; Fresenius-Biotech
North America, Gamida Cell Teva Joint Venture; Genentech; Genzyme;
GlaxoSmithKline; Kiadis Pharma; Leukemia and Lymphoma Society; Medical
College of Wisconsin; Millennium Pharmaceuticals; Milliman USA; Miltenyi
Biotec, National Marrow Donor Program; Optum Healthcare Solutions;
Otsuka America Pharmaceutical; Seattle Genetics; Sigma-Tau
Pharmaceuticals; Soligenix; Swedish Orphan Biovitrum; THERAKOS;
Well-point
FX The CIBMTR is supported by Public Health Service Grant/Cooperative
Agreement U24-CA76518 from the National Cancer Institute, National
Heart, Lung and Blood Institute, and National Institute of Allergy and
Infectious Diseases; Grant/Cooperative Agreement 5U01HL069294 from the
National Cancer Institute and National Heart, Lung and Blood Institute;
Contract HHSH234200637015C with the Health Resources and Services
Administration; Grants N00014-06-1-0704 and N00014-08-1-0058 from the
Office of Naval Research; and grants from Allos, Amgen, Angioblast,
anonymous donation to the Medical College of Wisconsin, Ariad, Be the
Match Foundation, Blue Cross and Blue Shield Association, Buchanan
Family Foundation, CaridianBCT, Celgene, CellGenix, Children's Leukemia
Research Association, Fresenius-Biotech North America, Gamida Cell Teva
Joint Venture, Genentech, Genzyme, GlaxoSmithKline, Kiadis Pharma,
Leukemia and Lymphoma Society, Medical College of Wisconsin, Millennium
Pharmaceuticals, Milliman USA, Miltenyi Biotec, National Marrow Donor
Program, Optum Healthcare Solutions, Otsuka America Pharmaceutical,
Seattle Genetics, Sigma-Tau Pharmaceuticals, Soligenix, Swedish Orphan
Biovitrum, THERAKOS, and Well-point. The views expressed in this article
do not reflect the official policy or position of the National
Institutes of Health, Department of the Navy, Department of Defense, or
any other agency of the US Government. The authors have no conflicts of
interest to disclose.
NR 29
TC 15
Z9 15
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD AUG
PY 2012
VL 18
IS 8
BP 1255
EP 1264
DI 10.1016/j.bbmt.2011.12.581
PG 10
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 982KB
UT WOS:000307040800015
PM 22198543
ER
PT J
AU Cheng, G
AF Cheng, G.
TI The diagnostic value of FDG-PET cannot be judged by iliac bone marrow
biopsy
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Letter
ID POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKINS-LYMPHOMA; MALIGNANT-LYMPHOMA;
INVOLVEMENT; UTILITY
C1 Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA.
RP Cheng, G (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM gangcheng99@yahoo.com
NR 17
TC 2
Z9 2
U1 0
U2 2
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0007-1285
J9 BRIT J RADIOL
JI Br. J. Radiol.
PD AUG
PY 2012
VL 85
IS 1016
BP 1204
EP 1205
DI 10.1259/bjr/61638269
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 988OK
UT WOS:000307500200057
PM 22815418
ER
PT J
AU Li, G
De La Garza, B
Shih, YYI
Muir, ER
Duong, TQ
AF Li, Guang
De La Garza, Bryan
Shih, Yen-Yu I.
Muir, Eric R.
Duong, Timothy Q.
TI Layer-specific blood-flow MRI of retinitis pigmentosa in RCS rats
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE retinal degeneration; retinitis pigmentosa; arterial spin labeling;
blood flow; retina; choroid
ID OPTICAL COHERENCE TOMOGRAPHY; MANGANESE-ENHANCED MRI; HEREDITARY RETINAL
DEGENERATION; OXYGEN-METABOLISM; ABYSSINIAN CATS; OCULAR FUNDUS; MOUSE
RETINA; MUTATIONS; PERFUSION; GENE
AB The Royal College of Surgeons (RCS) rat is an established animal model of retinitis pigmentosa, a family of inherited retinal diseases which starts with loss of peripheral vision and progresses to eventual blindness. Blood flow (BF), an important physiological parameter, is intricately coupled to metabolic function under normal physiological conditions and is perturbed in many neurological and retinal diseases. This study reports non-invasive high-resolution MRI (44 x 44 x 600 pm) to image quantitative retinal and choroidal BF and layer-specific retinal thicknesses in RCS rat retinas at different stages of retinal degeneration compared with age-matched controls. The unique ability to separate retinal and choroidal BF was made possible by the depth-resolved MRI technique. RBF decreased with progressive retinal degeneration, but ChBF did not change in RCS rats up to post-natal day 90. We concluded that choroidal and retinal circulations have different susceptibility to progressive retinal degeneration in RCS rats. Layer-specific retinal thickness became progressively thinner and was corroborated by histological analysis in the same animals. MRI can detect progressive anatomical and BF changes during retinal degeneration with laminar resolution. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Li, Guang; De La Garza, Bryan; Shih, Yen-Yu I.; Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Li, Guang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Li, Guang/C-9539-2011; Muir,
Eric/H-8830-2013
OI Li, Guang/0000-0002-7648-0464; Shih, Yen-Yu Ian/0000-0001-6529-911X
FU NIH/NEI [R01 EY014211, EY018855]; MERIT Award from the Department of
Veterans Affairs; Clinical Translational Science Award Supplement
(parent grant) [UL1RR025767]
FX Grant support: This work was supported in part by the NIH/NEI (R01
EY014211 and EY018855), and a MERIT Award from the Department of
Veterans Affairs, and a Clinical Translational Science Award Supplement
(parent grant UL1RR025767).
NR 58
TC 13
Z9 13
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2012
VL 101
BP 90
EP 96
DI 10.1016/j.exer.2012.06.006
PG 7
WC Ophthalmology
SC Ophthalmology
GA 984QE
UT WOS:000307205300012
PM 22721720
ER
PT J
AU Wen, HY
Schumacher, HR
Li, XF
Gu, JR
Ma, L
Wei, H
Yokogawa, N
Shiroto, K
Baker, JF
Dinnella, J
Ogdie, A
AF Wen, Hongyan
Schumacher, H. Ralph
Li, Xiaofeng
Gu, Jieruo
Ma, Li
Wei, Hua
Yokogawa, Naoto
Shiroto, Katsuaki
Baker, Joshua F.
Dinnella, Janet
Ogdie, Alexis
TI Comparison of expectations of physicians and patients with rheumatoid
arthritis for rheumatology clinic visits: a pilot, multicenter,
international study
SO INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
LA English
DT Article
DE clinical aspects; drug treatment; education; rehabilitation; rheumatoid
arthritis
ID DISEASE-ACTIVITY; DEPRESSION; COMMUNICATION; OUTCOMES; PARTICIPATION;
PREVALENCE; DISORDERS; SYMPTOM
AB Aim To describe and compare expectations of patients with rheumatoid arthritis (RA) and their physicians with regard to what is most important to achieve during a rheumatology clinic visit. Methods Subjects were RA patients enrolled in four centers from China, one from Japan and one from the USA, and rheumatologists at those centers. The questionnaires were provided at clinics and patients were asked to list their three top priorities for the rheumatology clinic visit. Physicians were contacted separately and asked to give three general expectations, not for specific visits. We classified clinical expectations into a series of 24 terms for patients and 17 for physicians. We compared physicians' to patients' responses, compared expectations among centers in China, Japan and the USA, and evaluated relationships between patients' responses and age, gender, nationality, disease duration and DAS-28 (Disease Activity Score-28). Results Patients' clinical expectations for visits focused primarily on control of pain (63.7%), improvement of function (49.3%) and discussion of effects of medication (38.1%). Physicians also included control of pain (59.5%), but also emphasized inquiry about drug side-effects (47.8%) and objective assessment of disease activity (41.4%). We found no differences related to patients' gender, disease duration and DAS-28, but there were some differences related to age and nationality. Conclusion We found some agreement and some discordance of clinical expectations between RA patients and physicians. There appear to be some different expectations in different countries. Findings from this pilot survey may help physicians consider patients' expectations in planning rheumatology clinic visits and may lead to further hypothesis-driven studies.
C1 [Schumacher, H. Ralph] Philadelphia Vet Affairs Med Ctr, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA.
[Wen, Hongyan; Schumacher, H. Ralph; Baker, Joshua F.; Dinnella, Janet; Ogdie, Alexis] Univ Penn, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA.
[Wen, Hongyan; Li, Xiaofeng] Shanxi Med Univ, Hosp 2, Taiyuan, Shanxi Province, Peoples R China.
[Gu, Jieruo] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510275, Guangdong, Peoples R China.
[Ma, Li] China Japan Friendship Hosp, Beijing, Peoples R China.
[Wei, Hua] No Jiangsu Peoples Hosp, Yangzhou, Jiangsu, Peoples R China.
[Yokogawa, Naoto; Shiroto, Katsuaki] Tokyo Metropolitan Tama Med Ctr, Sect Rheumatol 2 8 29, Tokyo, Japan.
RP Schumacher, HR (reprint author), Philadelphia Vet Affairs Med Ctr, Dept Med, Div Rheumatol, 151K Univ & Woodland Aves, Philadelphia, PA 19104 USA.
EM schumacr@mail.med.upenn.edu
OI Ogdie, Alexis/0000-0002-4639-0775
NR 29
TC 9
Z9 10
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1756-1841
J9 INT J RHEUM DIS
JI Int. J. Rheum. Dis.
PD AUG
PY 2012
VL 15
IS 4
BP 380
EP 389
DI 10.1111/j.1756-185X.2012.01752.x
PG 10
WC Rheumatology
SC Rheumatology
GA 989OK
UT WOS:000307569600014
PM 22898218
ER
PT J
AU Groessl, EJ
Liu, L
Ho, SB
Kanwal, F
Gifford, AL
Asch, SM
AF Groessl, Erik J.
Liu, Lin
Ho, Samuel B.
Kanwal, Fasiha
Gifford, Allen L.
Asch, Steven M.
TI National patterns and predictors of liver biopsy use for management of
hepatitis C
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Hepatitis C; Liver biopsy; Guidelines
ID GENOTYPE 1 INFECTION; VIRUS-INFECTION; AMINOTRANSFERASE LEVELS; PLUS
RIBAVIRIN; UNITED-STATES; HEALTH-CARE; VETERANS; HCV; CARRIERS;
PEGINTERFERON
AB Background & Aims: Liver biopsy remains the standard, recommended method for assessing liver damage associated with chronic hepatitis C (HCV) infection. However, there is considerable debate about how liver biopsy should best be used, especially with the advent of more efficacious antiviral therapies. To identify the factors that influence the use of liver biopsy for HCV patients, we describe variations in liver biopsy use at the delivery system and patient level in a national VA sample.
Methods: We analyzed VA HCV registry data for 171,893 VA patients with confirmed chronic HCV. Delivery system characteristics included geographic region and specialist time. Patient characteristics included antiviral treatment indicators, contraindications, volume of healthcare visits, and demographic variables. Logistic regression was used to explore correlates of biopsy use.
Results: Liver biopsy use in the VA system increased from 1997 to 2003 but began declining in 2004. Rates of liver biopsy from 2004 to 2006 varied by VA region, ranging from 5% to 18%. Treatment contraindications and laboratory tests were significantly associated with more biopsies. Demographic variables (higher age, lower BMI, race/ethnicity, and less% service connected disability) were associated with fewer biopsies. Regional variability remained significant independent of volume of care and specialist time.
Conclusions: Liver biopsy rates in the VA system have variability that seems unrelated to clinical need. New antiviral therapies and non-invasive assessment techniques may create additional uncertainty for the role of liver biopsy, perhaps explaining its decline in recent years. The availability of more effective antiviral therapies may also affect biopsy rates in the future. Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.
C1 [Groessl, Erik J.; Ho, Samuel B.] VA San Diego Healthcare Syst, La Jolla, CA 92161 USA.
[Groessl, Erik J.; Liu, Lin; Ho, Samuel B.] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Gifford, Allen L.] Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA.
[Gifford, Allen L.] Boston Univ, Boston, MA 02215 USA.
[Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Asch, Steven M.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Kanwal, Fasiha] VA St Louis, St Louis, MO USA.
[Kanwal, Fasiha] Washington Univ, St Louis, MO 63130 USA.
RP Groessl, EJ (reprint author), VA San Diego Healthcare Syst, 3550 La Jolla Village Dr,Mail Code 111 N-1, La Jolla, CA 92161 USA.
EM egroessl@ucsd.edu
FU VA HSRD [SHP - 08-203]
FX VA HSR&D, Project SHP - 08-203.
NR 36
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD AUG
PY 2012
VL 57
IS 2
BP 252
EP 259
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 991EW
UT WOS:000307685300008
PM 22521358
ER
PT J
AU Ishaque, B
Zayed, MA
Miller, J
Nguyen, D
Kaji, AH
Lee, JT
O'Connell, J
de Virgilio, C
AF Ishaque, Brandon
Zayed, Mohamed A.
Miller, Jessica
Nguyen, David
Kaji, Amy H.
Lee, Jason T.
O'Connell, Jessica
de Virgilio, Christian
TI Ethnic differences in arm vein diameter and arteriovenous fistula
creation rates in men undergoing hemodialysis access
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT 26th Annual Meeting of the Western-Vascular-Surgical-Society
CY SEP 17-20, 2011
CL Lihue, HI
SP Western Vasc Surg Soc
ID PREOPERATIVE NONINVASIVE EVALUATION; 1ST-TIME DIALYSIS ACCESS; VASCULAR
ACCESS; AUTOLOGOUS FISTULAS; NATURAL-HISTORY; INCREASING USE; KDOQI ERA;
MATURATION; FAILURE; IMPACT
AB Objective: The National Kidney Foundation recommends that arteriovenous fistulas (AVFs) be placed in at least 65% of hemodialysis patients. Some studies suggest that African American patients are less likely to receive a first-time AVF than patients of other ethnicities, although the reason for this disparity is unclear. The purpose of our study is to determine (1) whether there are ethnic differences in AVF creation, (2) whether this may be related to differences in vein diameters, and (3) whether AVF patency rates are similar between African American and non-African American male patients.
Methods: Consecutive male patients undergoing first-time hemodialysis access from 2006 to 2010 at two institutions were retrospectively reviewed. Data collected included age, ethnicity, weight, height, body mass index, diabetes, hypertension, congestive heart failure, smoking history, intravenous drug abuse, need for temporary access placement, and preoperative venous ultrasound measurements. Categoric variables were compared using chi(2) analysis, and the Wilcoxon rank-sum test was used to compare continuous variables.
Results: Of 249 male patients identified, 95 were African American. Median age in African American and non-African American patients was 63 years. Hypertension and hyperlipidemia were statistically significantly greater in African American patients. The need for temporary access before hemoaccess was similar between the cohorts. African American patients demonstrated significantly smaller median basilic and cephalic vein diameters at most measured sites. Overall, 221 of 249 (88.8%) underwent AVF first. An AV graft was created in 17.9% of African American patients vs in only 7.1% of non-African Americans (odds ratio, 2.8; 95% confidence interval, 1.3-6.4; P = .009). The difference between median vein diameters used for autologous fistula creation in African American and non-African American patients was not significant. There was no significant difference in the primary patency (80.8% vs 76.2%; P = .4), primary functional patency (73.1% vs 69.2%; P = .5), or secondary functional patency rates (91.0% vs 96.5%; P = .1). Average primary fistula survival time was 257 days in African American and 256 in non-African American patients (P = .2).
Conclusions: African American patients are less likely than non-African American patients to undergo AVF during first-time hemodialysis access surgery. This ethnic discrepancy appears to be due to smaller arm vein diameters in African American patients. In African American patients with appropriate vein diameters who do undergo AVF, primary and functional patencies are equivalent to non-African American patients. (J Vasc Surg 2012;56:424-32.)
C1 [de Virgilio, Christian] Harbor UCLA Med Ctr, Dept Surg, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA.
[Ishaque, Brandon; Miller, Jessica; Nguyen, David; O'Connell, Jessica; de Virgilio, Christian] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Zayed, Mohamed A.; Lee, Jason T.] Stanford Univ, Med Ctr, Dept Vasc Surg, Stanford, CA 94305 USA.
[Kaji, Amy H.] Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA.
[O'Connell, Jessica; de Virgilio, Christian] W Los Angeles Vet Affairs Hosp, Div Vasc Surg, Los Angeles, CA USA.
RP de Virgilio, C (reprint author), Harbor UCLA Med Ctr, Dept Surg, Los Angeles Biomed Res Inst, 1000 W Carson St, Torrance, CA 90509 USA.
EM cdevirgilio@labiomed.org
NR 27
TC 8
Z9 8
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD AUG
PY 2012
VL 56
IS 2
BP 424
EP 432
DI 10.1016/j.jvs.2012.01.029
PG 9
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 984AS
UT WOS:000307160400020
PM 22551911
ER
PT J
AU Heinrich, MC
Marino-Enriquez, A
Presnell, A
Donsky, RS
Griffith, DJ
McKinley, A
Patterson, J
Taguchi, T
Liang, CW
Fletcher, JA
AF Heinrich, Michael C.
Marino-Enriquez, Adrian
Presnell, Ajia
Donsky, Rachel S.
Griffith, Diana J.
McKinley, Arin
Patterson, Janice
Taguchi, Takahiro
Liang, Cher-Wei
Fletcher, Jonathan A.
TI Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant
Gastrointestinal Stromal Tumors
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID CHRONIC MYELOID-LEUKEMIA; DIAGNOSED CHRONIC-PHASE; FACTOR-RECEPTOR-BETA;
IMATINIB MESYLATE; IN-VITRO; KIT; MUTANTS; MECHANISMS; SUNITINIB;
FREQUENCY
AB Sorafenib has substantial clinical activity as third-or fourth-line treatment of imatinib-and sunitinib-resistant gastrointestinal stromal tumors (GIST). Because sorafenib targets both angiogenesis-related kinases (VEGFR) and the pathogenetic kinases found in GIST (KIT or PDGFRA), the molecular basis for sorafenib efficacy in this setting remains unknown. We sought to determine the spectrum of activity of sorafenib against different mutant kinases associated with drug-sensitive and drug-resistant GIST. We compared the activity of imatinib and sorafenib against transiently expressed mutant forms of KIT and PDGFRA, including various secondary mutations that have been identified in imatinib-resistant or sunitinib-resistant GISTs. We also examined these drugs against four GIST cell lines, three of which are imatinib resistant. In our in vitro studies, we determined that sorafenib inhibited imatinib-resistant mutations in exons encoding the ATP/drug-binding pocket and in exons encoding the activation loop, with the exception of substitutions at KIT codon D816 and PDGFRA codon 842. Notably our data indicate that sorafenib is more effective than imatinib or sunitinib for inhibiting the kinase activity of drug-resistant KIT mutants (as assessed by biochemical IC50). We hypothesize that a major determinant of the efficacy of sorafenib for treatment of advanced GIST is the activity of this agent against KIT or PDGFRA-mutant kinases. These results have implications for the further development of treatments for drug-resistant GIST. Mol Cancer Ther; 11(8); 1770-80. (C) 2012 AACR.
C1 [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Med, Div Hematol Oncol, Portland, OR 97239 USA.
[Heinrich, Michael C.; Presnell, Ajia; Griffith, Diana J.; McKinley, Arin; Patterson, Janice] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Portland, OR 97239 USA.
[Marino-Enriquez, Adrian; Donsky, Rachel S.; Liang, Cher-Wei; Fletcher, Jonathan A.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Marino-Enriquez, Adrian; Donsky, Rachel S.; Liang, Cher-Wei; Fletcher, Jonathan A.] Harvard Univ, Sch Med, Boston, MA USA.
[Taguchi, Takahiro] Kochi Univ, Kochi 780, Japan.
RP Heinrich, MC (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Med, Div Hematol Oncol, R&D-19 3710,US Vet Hosp Rd, Portland, OR 97239 USA.
EM Heinrich@ohsu.edu
OI Patterson, Janice/0000-0002-8969-2933; LIANG,
CHER-WEI/0000-0001-8903-6082
FU Veterans Affairs Merit Review Grant; Life Raft Group; GIST Cancer
Research Fund; GI SPORE [1P50CA127003]; BP Lester Foundation; Virginia
and Daniel K. Ludwig Trust for Cancer Research; Fundacion Alfonso Martin
Escudero; Cathay General Hospital Research Fund; Novartis; AROG;
Imclone; Ariad
FX M.C. Heinrich is a recipient of commercial research grant from Novartis,
AROG, Imclone, and Ariad; has received honoraria from Speakers Bureau of
Novartis and has ownership interest (including patents) from
MolecularMD. He is also a consultant and advisory board member of
Novartis.; This work was supported in part from funding from a Veterans
Affairs Merit Review Grant (M. C. Heinrich), the Life Raft Group (M. C.
Heinrich, J. A. Fletcher), the GIST Cancer Research Fund (M. C.
Heinrich, J. A. Fletcher), GI SPORE 1P50CA127003 (J. A. Fletcher), BP
Lester Foundation (M. C. Heinrich), the Virginia and Daniel K. Ludwig
Trust for Cancer Research (J. A. Fletcher), Fundacion Alfonso Martin
Escudero (A. Marino-Enriquez), and Cathay General Hospital Research Fund
(C.-W. Liang).
NR 34
TC 23
Z9 23
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD AUG
PY 2012
VL 11
IS 8
BP 1770
EP 1780
DI 10.1158/1535-7163.MCT-12-0223
PG 11
WC Oncology
SC Oncology
GA 995PG
UT WOS:000308022100016
PM 22665524
ER
PT J
AU Pekary, AE
Sattin, A
AF Pekary, A. Eugene
Sattin, Albert
TI Rapid modulation of TRH and TRH-like peptide release in rat brain and
peripheral tissues by ghrelin and 3-TRP-ghrelin
SO PEPTIDES
LA English
DT Article
DE Ghrelin; TRH-like peptides; Rat; Limbic system
ID HORMONE TRH; MESSENGER-RNA; FOOD-INTAKE; SECRETION; RECEPTOR;
STIMULATION; MECHANISM; BEHAVIOR; SYSTEM; LEPTIN
AB Ghrelin is not only a modulator of feeding and energy expenditure but also regulates reproductive functions, CNS development and mood. Obesity and major depression are growing public health concerns which may derive, in part, from dysregulation of ghrelin feedback at brain regions regulating feeding and mood. We and others have previously reported that thyrotropin-releasing hormone (TRH, pGlu-His-Pro-NH2) and TRH-like peptides (pGIu-X-Pro-NH2, where "X" can be any amino acid residue) have neuroprotective, antidepressant, anti-epileptic, analeptic, anti-ataxic, and anorectic properties. For this reason male Sprague-Dawley rats were injected ip with 0.1 mg/kg rat ghrelin or 0.9 mg/kg 3-Trp-rat ghrelin. Twelve brain regions: cerebellum, medulla oblongata, anterior cingulate, posterior cingulate, frontal cortex, nucleus accumbens, hypothalamus, entorhinal cortex, hippocampus, striatum, amygdala, piriform cortex and 5 peripheral tissues (adrenals, testes, epididymis, pancreas and prostate) were analyzed. Rapid and profound decreases in TRH and TRH-like peptide levels (increased release) occurred throughout brain and peripheral tissues following ip ghrelin. Because ghrelin is rapidly deacylated in vivo we also studied 3-Trp-ghrelin which cannot be deacylated. Significant increases in TRH and TRH-like peptide levels following 3-Trp-ghrelin, relative to those after ghrelin were observed in all brain regions except posterior cingulate and all peripheral tissues except prostate and testis. The rapid stimulation of TRH and TRH-like peptide release by ghrelin in contrast with the inhibition of such release by 3-Trp-TRH is consistent with TRH and TRH-like peptides modulating the downstream effects of both ghrelin and unacylated ghrelin. Published by Elsevier Inc.
C1 [Pekary, A. Eugene; Sattin, Albert] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
[Sattin, Albert] VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA.
[Pekary, A. Eugene] VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA.
[Sattin, Albert] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA.
[Sattin, Albert] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
[Pekary, A. Eugene] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
RP Pekary, AE (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM Eugene.Pekary@va.gov
FU Department of Veterans Affairs Medical Research funds; Pekary Trust
FX This work was supported by the Department of Veterans Affairs Medical
Research funds (AEP and AS) and the Pekary Trust.
NR 74
TC 6
Z9 6
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
J9 PEPTIDES
JI Peptides
PD AUG
PY 2012
VL 36
IS 2
BP 157
EP 167
DI 10.1016/j.peptides.2012.04.021
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 983YR
UT WOS:000307155100002
PM 22634385
ER
PT J
AU Zivin, K
Ilgen, MA
Pfeiffer, PN
Welsh, DE
McCarthy, J
Valenstein, M
Miller, EM
Islam, K
Kales, HC
AF Zivin, Kara
Ilgen, Mark A.
Pfeiffer, Paul Nelson
Welsh, Deborah E.
McCarthy, John
Valenstein, Marcia
Miller, Erin M.
Islam, Khairul
Kales, Helen C.
TI Early Mortality and Years of Potential Life Lost Among Veterans Affairs
Patients With Depression
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID SUICIDE MORTALITY; RISK-FACTOR; ILLNESS; CARE
AB Objective: Substantial literature documents excess and early mortality among individuals with serious mental illness, but there are relatively few data about mortality and depression. Methods: During fiscal year 2007, data from the U.S. Department of Veterans Affairs and the National Death Index were used to calculate mean age of death and years of potential life lost (YPLL) associated with 13 causes of death among veterans with (N=701,659) or without (N=4,245,193) depression. Results: Compared with nondepressed patients, depressed patients died younger (71.1 versus 75.9) and had more YPLL (13.4 versus 10.2) as a result of both natural and unnatural causes. Depending on the cause of death, depressed patients died between 2.5 and 8.7 years earlier and had 1.5 to 6.1 YPLL compared with nondepressed patients. Conclusions: These findings have important implications for clinical practice, given that improved quality of care may be needed to reduce early mortality among depressed VA patients. (Psychiatric Services 63:823-826, 2012; doi: 10.1176/appi.ps.201100317)
C1 [Zivin, Kara; Ilgen, Mark A.; Pfeiffer, Paul Nelson; Welsh, Deborah E.; McCarthy, John; Valenstein, Marcia; Miller, Erin M.; Kales, Helen C.] US Dept Vet Affairs, Natl Serious Mental Illness Treatment Res & Evalu, Ann Arbor, MI 48109 USA.
[Zivin, Kara; Ilgen, Mark A.; Pfeiffer, Paul Nelson; Welsh, Deborah E.; McCarthy, John; Valenstein, Marcia; Miller, Erin M.; Kales, Helen C.] US Dept Vet Affairs, Hlth Serv Res & Dev Ctr Clin Management Res, Ann Arbor, MI 48109 USA.
[Zivin, Kara; Ilgen, Mark A.; Pfeiffer, Paul Nelson; McCarthy, John; Valenstein, Marcia; Miller, Erin M.; Islam, Khairul; Kales, Helen C.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
RP Zivin, K (reprint author), US Dept Vet Affairs, Natl Serious Mental Illness Treatment Res & Evalu, N Campus Res Complex,2800 Plymouth Rd,Bldg 14, Ann Arbor, MI 48109 USA.
EM kzivin@umich.edu
FU U.S. Department of Veterans Affairs Health Services Research and
Development Service [IIR 10-176-3, CD2 07-206-1, CDA 10-036-1]
FX This study was funded by grants IIR 10-176-3, CD2 07-206-1, and CDA
10-036-1 from the U.S. Department of Veterans Affairs Health Services
Research and Development Service.
NR 14
TC 10
Z9 10
U1 1
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD AUG
PY 2012
VL 63
IS 8
BP 823
EP 826
DI 10.1176/appi.ps.201100317
PG 4
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 984PX
UT WOS:000307204600015
PM 22854727
ER
PT J
AU Eaddy, AC
Cummings, BS
Mchowat, J
Schnellmann, RG
AF Eaddy, Andre C.
Cummings, Brian S.
Mchowat, Jane
Schnellmann, Rick G.
TI The Role of Endoplasmic Reticulum Ca2+-Independent Phospholipase
A(2)gamma in Oxidant-Induced Lipid Peroxidation, Ca2+ Release, and Renal
Cell Death
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE lipid peroxidation; phospholipase A(2); Ca2+ release; necrotic cell
death
ID ELECTROSPRAY MASS-SPECTROMETRY; OXIDATIVE STRESS; A(2) ENZYMES;
FATTY-ACIDS; IDENTIFICATION; INJURY; PERMEABILITY; IPLA(2)GAMMA;
SUPERFAMILY; METABOLISM
AB Oxidant-induced lipid peroxidation and cell death are major components of ischemia/reperfusion and toxicant injury. Our previous studies showed that renal proximal tubular cells (RPTCs) express Ca2+-independent phospholipase A(2)gamma (iPLA(2)gamma) in endoplasmic reticulum (ER) and mitochondria and that iPLA(2)gamma is cyto-protective. Our present studies reveal the role of ER-iPLA(2)gamma in oxidant-induced ER lipid peroxidation, Ca2+ release, and cell death. Oxidant tert-butyl hydroperoxide (TBHP) caused ER lipid peroxidation and Ca2+ release in isolated rabbit kidney cortex microsomes. ER-iPLA(2)gamma inhibition, using bromoenol lactone (BEL), potentiated both oxidant-induced ER lipid peroxidation and Ca2+ release. Assessment of fatty acids using electrospray ionization-mass spectrometry revealed that ER-iPLA(2)gamma mediates the TBHP-induced release of arachidonic acid (20:4), linoleic acid (18:2), and their oxidized forms (18:2-OH, 18:2-OOH, 20:4-OH, 20:4-OOH, 20:4-(OH)(3). iPLA(2)gamma inhibition also accelerated oxidant-induced ER Ca2+ release in RPTC. Depletion of ER Ca2+ stores in RPTC with thapsigargin, an ER Ca2+ pump inhibitor, prior to TBHP exposure reduced necrotic cell death and blocked the potentiation of TBHP-induced necrotic cell death by BEL. Together, these data provide strong evidence that ER-iPLA(2)gamma protects renal cells from oxidant-induced necrotic cell death by releasing unsaturated and/or oxidized fatty acids from ER membranes, thereby preserving ER membrane integrity and preventing ER Ca2+ release.
C1 [Eaddy, Andre C.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, Charleston, SC 29425 USA.
[Cummings, Brian S.] Univ Georgia, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.
[Mchowat, Jane] St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA.
[Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, 280 Calhoun St,MSC140, Charleston, SC 29425 USA.
EM schnell@musc.edu
FU National Institutes of Health (NIH) [DK-62028]; Biomedical Laboratory
Research and Development Program of the Department of Veterans Affairs;
Southern Regional Educational Board Predoctoral Scholarship; National
Institute of Environmental Health Sciences (NIEHS), NIH [T32 ESO12878,
F30 ES015964]; NIH [C06 RR-015455]
FX This research was supported by National Institutes of Health (NIH) Grant
DK-62028 and by the Biomedical Laboratory Research and Development
Program of the Department of Veterans Affairs to R.G.S. A.C.E. was
supported by a Southern Regional Educational Board Predoctoral
Scholarship, a training grant from the National Institute of
Environmental Health Sciences (NIEHS), NIH (T32 ESO12878), and an
Individual National Research Service Award Fellowship (F30 ES015964)
from NIEHS, NIH. The Medical University of South Carolina animal
facilities were funded by NIH Grant C06 RR-015455.
NR 32
TC 4
Z9 5
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
J9 TOXICOL SCI
JI Toxicol. Sci.
PD AUG
PY 2012
VL 128
IS 2
BP 544
EP 552
DI 10.1093/toxsci/kfs175
PG 9
WC Toxicology
SC Toxicology
GA 991JY
UT WOS:000307698500023
PM 22584685
ER
PT J
AU Braquehais, MD
Picouto, MD
Casas, M
Sher, L
AF Dolores Braquehais, Maria
Dolores Picouto, Maria
Casas, Miquel
Sher, Leo
TI Hypothalamic-pituitary-adrenal axis dysfunction as a neurobiological
correlate of emotion dysregulation in adolescent suicide
SO WORLD JOURNAL OF PEDIATRICS
LA English
DT Review
DE adolescence; hypothalamic-pituitary-adrenal axis; suicide
ID DEXAMETHASONE-SUPPRESSION TEST; POSTTRAUMATIC-STRESS-DISORDER; SALIVARY
CORTISOL; PSYCHIATRIC-SYMPTOMS; ANXIETY DISORDER; HEALTHY CONTROLS;
YOUNG-ADULTS; CHILDHOOD; CHILDREN; DEPRESSION
AB Biological markers of vulnerability for current or future risk of suicide in adolescents could be important adjuncts to the treatment and prevention of this phenomenon.
We conducted a PubMed search of all English-language articles published between January 1990 and June 2011 using the following search terms: ("hypothalamic-pituitary-adrenal" OR "HPA") AND ("adolescence" OR "adolescent" OR "teenager") AND ("depression" OR "major depressive disorder" OR "suicidal behavior" OR "suicidal ideation" OR "suicidal thoughts" OR "deliberate self-harm" OR "suicidal attempt" OR "suicide").
HPA axis activity can be examined using different methods that do not have the same biological interpretation. An abnormal HPA axis functioning together with an anomalous interaction between HPA mechanisms and other systems such as the serotonergic system may be one of the neurobiological correlates of emotion dysregulation (ED). ED may play an important role in adolescent suicidal behavior. Some psychopathological conditions such as depression or childhood psychological trauma that increase suicidal risk in adolescents are also associated with HPA axis dysregulation. ED, a personality trait, can also be viewed as a predisposing factor that augments the vulnerability to suffer from psychiatric conditions.
Correlating HPA axis dysfunction with psychological factors such as ED could lead to a better understanding of the role of HPA abnormalities in adolescent suicide and may enhance preventive and treatment strategies.
C1 [Dolores Braquehais, Maria; Casas, Miquel] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Psychiat & Legal Med, Barcelona 08035, Spain.
[Dolores Picouto, Maria] Univ Barcelona, St Joan de Deu Hosp, Dept Child & Adolescent Psychiat & Psychol, Barcelona, Spain.
[Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, James J Peters Vet Adm Med Ctr, New York, NY USA.
RP Braquehais, MD (reprint author), Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Psychiat & Legal Med, Pg Vall Hebron 119-129, Barcelona 08035, Spain.
EM mdbraquehais@vhebron.net
FU Department of Health of the Government of Catalonia (Generalitat de
Catalonia), Spain; Department of Health of the Generalitat of Catalonia
FX The work of Dr. Maria Dolores Braquehais and Prof. Miquel Casas was
partly supported by a grant from the Department of Health of the
Government of Catalonia (Generalitat de Catalonia), Spain.; The work of
Dr. Braquehais and Dr. Casas was partly supported by a grant of the
Department of Health of the Generalitat of Catalonia.
NR 90
TC 7
Z9 7
U1 2
U2 13
PU ZHEJIANG UNIV SCH MEDICINE
PI HANGZHOU
PA CHILDRENS HOSPITAL, 57 ZHUGAN XIANG, HANGZHOU, 310003, PEOPLES R CHINA
SN 1708-8569
J9 WORLD J PEDIATR
JI World Journal of Pediatrics
PD AUG
PY 2012
VL 8
IS 3
BP 197
EP 206
DI 10.1007/s12519-012-0358-0
PG 10
WC Pediatrics
SC Pediatrics
GA 988RE
UT WOS:000307507400001
PM 22886191
ER
PT J
AU Garrett-Mayer, E
Wagner, CL
Hollis, BW
Kindy, MS
Gattoni-Celli, S
AF Garrett-Mayer, Elizabeth
Wagner, Carol L.
Hollis, Bruce W.
Kindy, Mark S.
Gattoni-Celli, Sebastiano
TI Vitamin D-3 supplementation (4000 IU/d for 1 y) eliminates differences
in circulating 25-hydroxyvitamin D between African American and white
Men
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; CARDIOVASCULAR HEALTH; US POPULATION;
DISPARITIES; SAFETY
AB Background: African Americans suffer disproportionately from diabetes and cardiovascular disease and are significantly more likely to have suboptimal concentrations of circulating 25-hydroxyvitamin D [25(OH)D]. The results of epidemiologic and observational studies suggest that there is a link between vitamin D deficiency and the risk of cardiometabolic disorders, which underscores the importance of maintaining healthy concentrations of 25(OH)D.
Objective: The objective was to investigate whether daily supplementation with 4000 IU vitamin D-3 for 1 y would eliminate any disparities in circulating concentrations of 25(OH)D between African American and white men.
Design: Serum concentrations of 25(OH)D were measured every 2 mo in 47 subjects who received a daily oral dose of 4000 IU vitamin D3 for I y.
Results: More than 90% of African Americans had serum concentrations of 25(OH)D <32 ng/mL, and approximately two-thirds had serum concentrations <20 ng/mL. Furthermore, there were significant disparities in serum concentrations of 25(OH)D between African American and white men. Supplementation with 4000 IU/d for 1 y eliminated any significant differences in circulating concentrations of 25(OH)D between African American and white men.
Conclusion: The results of this clinical study show the feasibility and efficacy of this approach in the elimination of hypovitaminosis D, which is a widespread health disparity among African Americans. This trial was registered at clinicaltrials.gov as NCT01045109. Am J Clin Num 2012:96:332-6.
C1 [Garrett-Mayer, Elizabeth] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Wagner, Carol L.; Hollis, Bruce W.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Gattoni-Celli, Sebastiano] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA.
[Kindy, Mark S.; Gattoni-Celli, Sebastiano] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Gattoni-Celli, S (reprint author), Strom Thurmond Biomed Res Bldg,Room 338C,114 Doug, Charleston, SC 29403 USA.
EM gattonis@musc.edu
FU Gateway for Cancer Research; Health Services Research and Development
Program of the Department of Veterans Affairs; South Carolina Clinical
and Translational Research Institute; Biostatistics Shared Resource of
the Hollings Cancer Center at the Medical University of South Carolina
FX Supported in part by grants from the Gateway for Cancer Research, the
Health Services Research and Development Program of the Department of
Veterans Affairs, the South Carolina Clinical and Translational Research
Institute, and the Biostatistics Shared Resource of the Hollings Cancer
Center at the Medical University of South Carolina.
NR 32
TC 18
Z9 18
U1 0
U2 1
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD AUG
PY 2012
VL 96
IS 2
BP 332
EP 336
DI 10.3945/ajcn.112.034256
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 978TW
UT WOS:000306769700016
PM 22760568
ER
PT J
AU Williams, BA
Stern, MF
Mellow, J
Safer, M
Greifinger, RB
AF Williams, Brie A.
Stern, Marc F.
Mellow, Jeff
Safer, Meredith
Greifinger, Robert B.
TI Aging in Correctional Custody: Setting a Policy Agenda for Older
Prisoner Health Care
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID PALLIATIVE CARE; ALZHEIMERS-DISEASE; ELDERLY PERSONS; INMATES;
COMMUNITY; DEMENTIA; RELEASE; STATE; RISK; COMORBIDITIES
AB An exponential rise in the number of older prisoners is creating new and costly challenges for the criminal justice system, state economies, and communities to which older former prisoners return. We convened a meeting of 29 national experts in correctional health care, academic medicine, nursing, and civil rights to identify knowledge gaps and to propose a policy agenda to improve the care of older prisoners. The group identified 9 priority areas to be addressed: definition of the older prisoner, correctional staff training, definition of functional impairment in prison, recognition and assessment of dementia, recognition of the special needs of older women prisoners, geriatric housing units, issues for older adults upon release, medical early release, and prison-based palliative medicine programs. (Am J Public Health. 2012;102:1475-1481. doi:10.2105/AJPH.2012.300704)
C1 [Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94117 USA.
[Williams, Brie A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA.
[Stern, Marc F.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Mellow, Jeff] CUNY John Jay Coll Criminal Justice, Dept Criminal Justice, New York, NY USA.
[Greifinger, Robert B.] CUNY John Jay Coll Criminal Justice, Ctr Evaluat & Res, New York, NY USA.
[Safer, Meredith] Liberian Minist Hlth & Social Welf, US Agcy Int Dev, Monrovia, Liberia.
RP Williams, BA (reprint author), Univ Calif San Francisco, Div Geriatr, Dept Med, 3333 Calif St,Suite 380, San Francisco, CA 94117 USA.
EM brie.williams@ucsf.edu
FU National Institute of Aging [K23AG033102]; Jacob and Valeria Langeloth
Foundation; University of California, San Francisco Hartford Center of
Excellence; Langeloth Foundation Leadership Symposia in Correctional
Health Care
FX B. A. Williams is supported by the National Institute of Aging (grant
K23AG033102), the Jacob and Valeria Langeloth Foundation, and the
University of California, San Francisco Hartford Center of Excellence.
This study and J. Mellow and R. B. Greifinger were also supported by a
grant from the Langeloth Foundation Leadership Symposia in Correctional
Health Care.
NR 60
TC 31
Z9 31
U1 3
U2 28
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD AUG
PY 2012
VL 102
IS 8
BP 1475
EP 1481
DI 10.2105/AJPH.2012.300704
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 981AO
UT WOS:000306937900009
PM 22698042
ER
PT J
AU Ponnusamy, S
Selvam, SP
Mehrotra, S
Kawamori, T
Snider, AJ
Obeid, LM
Shao, Y
Sabbadini, R
Ogretmen, B
AF Ponnusamy, Suriyan
Selvam, Shanmugam Panneer
Mehrotra, Shikhar
Kawamori, Toshihiko
Snider, Ashley J.
Obeid, Lina M.
Shao, Yuan
Sabbadini, Roger
Ogretmen, Besim
TI Communication between host organism and cancer cells is transduced by
systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to
regulate tumour metastasis
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE lung metastasis; sphingolipids; sphingomab; sphingosine kinase 1;
sphingosine 1-phosphate
ID MYELOID-LEUKEMIA CELLS; IMATINIB-INDUCED APOPTOSIS; PROTEIN-COUPLED
RECEPTOR; BREAST-CANCER; OVARIAN-CANCER; LUNG-CANCER;
SPHINGOSINE-1-PHOSPHATE; BRMS1; MIGRATION; SURVIVAL
AB Mechanisms by which cancer cells communicate with the host organism to regulate lung colonization/metastasis are unclear. We show that this communication occurs via sphingosine 1-phosphate (S1P) generated systemically by sphingosine kinase 1 (SK1), rather than via tumour-derived S1P. Modulation of systemic, but not tumour SK1, prevented S1P elevation, and inhibited TRAMP-induced prostate cancer growth in TRAMP+/+SK1-/- mice, or lung metastasis of multiple cancer cells in SK1-/- animals. Genetic loss of SK1 activated a master metastasis suppressor, Brms1 (breast carcinoma metastasis suppressor 1), via modulation of S1P receptor 2 (S1PR2) in cancer cells. Alterations of S1PR2 using pharmacologic and genetic tools enhanced Brms1. Moreover, Brms1 in S1PR2-/- MEFs was modulated by serum S1P alterations. Accordingly, ectopic Brms1 in MB49 bladder cancer cells suppressed lung metastasis, and stable knockdown of Brms1 prevented this process. Importantly, inhibition of systemic S1P signalling using a novel anti-S1P monoclonal antibody (mAb), Sphingomab, attenuated lung metastasis, which was prevented by Brms1 knockdown in MB49 cells. Thus, these data suggest that systemic SK1/S1P regulates metastatic potential via regulation of tumour S1PR2/Brms1 axis.
C1 [Ponnusamy, Suriyan; Selvam, Shanmugam Panneer; Ogretmen, Besim] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Ponnusamy, Suriyan; Selvam, Shanmugam Panneer; Mehrotra, Shikhar; Kawamori, Toshihiko; Snider, Ashley J.; Obeid, Lina M.; Shao, Yuan; Ogretmen, Besim] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
[Mehrotra, Shikhar] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
[Kawamori, Toshihiko; Shao, Yuan] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Snider, Ashley J.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Snider, Ashley J.; Obeid, Lina M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Sabbadini, Roger] Lpath Inc, San Diego, CA USA.
RP Ogretmen, B (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
EM ogretmen@musc.edu
OI obeid, lina/0000-0002-0734-0847
FU National Institutes of Health [CA088932, DE016572, CA097165];
Biogen/IDEC, Inc. (San Diego, CA); CTSA/SCTR (MUSC); NIH [C06 RR015455,
P30 CA138313]
FX We thank Dr. Jennifer G. Schnellmann (Medical University of South
Carolina, MUSC, Charleston, SC) for her editorial review. We also thank
Dr. Yusuf A. Hannun (MUSC) for helpful discussions. SK1-/-
and S1PR2-/- mice were kindly provided to us by Dr. Richard
L. Proia (National Institute of Diabetes and Digestive and Kidney
Disease, National Institutes of Health, Bethesda, MD). This work was
supported by research grants obtained from the National Institutes of
Health (CA088932, DE016572 and CA097165 to BO), Biogen/IDEC, Inc. (San
Diego, CA) and CTSA/SCTR (MUSC). The core facilities utilized for animal
studies, lipidomics and imaging were constructed using support from NIH
(C06 RR015455, or P30 CA138313).
NR 51
TC 51
Z9 53
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD AUG
PY 2012
VL 4
IS 8
BP 761
EP 775
DI 10.1002/emmm.201200244
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 983LL
UT WOS:000307120700011
PM 22707406
ER
PT J
AU Ditre, JW
Oliver, JA
Myrick, H
Henderson, S
Saladin, ME
Drobes, DJ
AF Ditre, Joseph W.
Oliver, Jason A.
Myrick, Hugh
Henderson, Scott
Saladin, Michael E.
Drobes, David J.
TI Effects of Divalproex on Smoking Cue Reactivity and Cessation Outcomes
Among Smokers Achieving Initial Abstinence
SO EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Article
DE smoking; cessation; craving; cue reactivity; divalproex
ID BRAIN REWARD AREAS; TOBACCO DEPENDENCE; SELF-QUITTERS; NICOTINE;
RELAPSE; WITHDRAWAL; CIGARETTE; ALCOHOL; URGES; PHARMACOTHERAPY
AB Divalproex, a GABA agonist, may be a useful agent in the treatment of tobacco dependence. Cue reactivity assessment paradigms are ideally suited to explore basic mechanisms underlying the pharmacological effects of medications that purport to have efficacy for smoking cessation. Our primary goal in the current study was to examine the effects of divalproex on in-treatment reactivity to smoking-relevant and affective cues, and to determine if these reactions were predictive of posttreatment smoking behavior. There were 120 nicotine dependent smokers enrolled in an 8-week double-blind clinical trial and randomly assigned to either divalproex or placebo conditions. Of these, 72 smokers (60% female) who achieved a minimal level of abstinence underwent an in-treatment cue reactivity assessment. Contrary to expectations, divalproex was associated with greater craving and arousal during smoking cue presentation. Divalproex also inhibited cardiovascular response to pleasant cues. Although no significant differences in cessation-related outcomes between divalproex- and placebo-treated participants were observed, cue-elicited craving to smoke predicted end-of-treatment and posttreatment smoking rates. These findings suggest that in-treatment cue reactivity assessment may proactively and dynamically inform ongoing treatment as well as provide a tool for screening potential medications for smoking cessation.
C1 [Ditre, Joseph W.] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA.
[Oliver, Jason A.; Drobes, David J.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA.
[Oliver, Jason A.; Drobes, David J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Drobes, David J.] Univ S Florida, Dept Oncol Sci, Tampa, FL USA.
[Myrick, Hugh; Henderson, Scott] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Myrick, Hugh; Henderson, Scott; Saladin, Michael E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA.
RP Drobes, DJ (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Tobacco Res & Intervent Program, 4115 E Fowler Ave, Tampa, FL 33617 USA.
EM david.drobes@moffitt.org
FU Abbott Pharmaceutical
FX This study was supported by a grant from Abbott Pharmaceutical, who had
no role in the study beyond financial support. All authors made
substantive contributions and approved the manuscript. There are no
conflicts of interest to report. We thank Cynthia Myers, Laura Juliano,
Suzanne Wise, and Beth Platz for their assistance in conducting the
study and preparing the manuscript.
NR 57
TC 8
Z9 8
U1 1
U2 4
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1064-1297
J9 EXP CLIN PSYCHOPHARM
JI Exp. Clin. Psychopharmacol.
PD AUG
PY 2012
VL 20
IS 4
BP 293
EP 301
DI 10.1037/a0027789
PG 9
WC Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy;
Psychiatry
SC Psychology; Pharmacology & Pharmacy; Psychiatry
GA 986CZ
UT WOS:000307319700006
PM 22468897
ER
PT J
AU Lee, SE
Lee, EH
Park, H
Sung, JY
Lee, HW
Kang, SY
Seo, S
Kim, BH
Lee, H
Seo, AN
Ahn, G
Choi, YL
AF Lee, Seung Eun
Lee, Eun Hee
Park, Heejung
Sung, Ji-Youn
Lee, Hyoun Wook
Kang, So Young
Seo, Sungwook
Kim, Byung Heon
Lee, Hyojin
Seo, An Na
Ahn, Geunghwan
Choi, Yoon-La
TI The diagnostic utility of the GNAS mutation in patients with fibrous
dysplasia: meta-analysis of 168 sporadic cases
SO HUMAN PATHOLOGY
LA English
DT Article
DE Fibrous dysplasia; GNAS; Mutation
ID MCCUNE-ALBRIGHT-SYNDROME; ACTIVATING G(S)ALPHA MUTATION; STIMULATORY
G-PROTEIN; ALPHA-SUBUNIT; BONE; GENE; LESIONS; CELLS
AB GNAS mutations have been implicated in the development of fibrous dysplasia and multiple endocrinopathies of the Albright-McCune syndrome. To investigate the diagnostic utility of GNAS mutations in patients with fibrous dysplasia, we performed mutational analyses of histologically confirmed fibrous dysplasia and conducted a meta-analysis of the literature. We collected 48 cases of fibrous dysplasia from 3 institutions from 2002 to 2011 and performed polymerase chain reaction and direct bidirectional sequencing of exons 8 and 9 of GNAS using paraffin-embedded tissues. We searched MEDLINE, PubMed, and the KoreaMed databases from 1997 to 2011 and included an additional 155 cases of fibrous dysplasia from 8 representative studies to conduct a meta-analysis. In our sample, 28 (58.3%) of 48 cases showed point mutations of codon 201 at exon 8. Twenty-five cases had a substitution of arginine at codon 201 for histidine (p.R201H), and 3 cases had a substitution for cysteine (p.R201C). One case had a new mutation at codon 224 (p.V224A). The incidence of GNAS mutations was significantly greater in cases that involved long bones than in cases that involved flat bones (P = .017) and was higher in polyostotic cases than in monostotic cases (P = .067). In meta-analysis, 9 studies and 203 patients were included. The overall positive rate of GNAS mutation in fibrous dysplasia was 71.9% (146/203). The major types of mutations were missense mutations such as R201H (66.4%) and R201C (30.8%). As a result, the detection of GNAS mutation could be a valuable adjunct to conventional histopathologic diagnosis of fibrous dysplasia. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Lee, Seung Eun; Sung, Ji-Youn; Kang, So Young; Choi, Yoon-La] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul 135710, South Korea.
[Lee, Eun Hee; Lee, Hyoun Wook; Kim, Byung Heon] Sungkyunkwan Univ, Samsung Changwon Hosp, Sch Med, Dept Pathol, Chang Won 630732, South Korea.
[Park, Heejung] Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea.
[Seo, Sungwook] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Orthoped Surg, Seoul 135710, South Korea.
[Lee, Hyojin] Natl Police Hosp, Seoul 138708, South Korea.
[Seo, An Na] Kyungpook Natl Univ, Sch Med, Dept Pathol, Taegu 700721, South Korea.
[Ahn, Geunghwan] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Pathol, San Francisco, CA 94121 USA.
[Choi, Yoon-La] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Inst Refractory Canc Res, Seoul 135710, South Korea.
RP Choi, YL (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Irwon Ro 81, Seoul 135710, South Korea.
EM ylachoi@skku.edu
RI Sung, Ji-Youn/I-5016-2013
OI Sung, Ji-Youn/0000-0002-6607-2117
FU Ministry for Health and Welfare Affairs [A092255]; National Research
Foundation [NRF-M1AXA002-2010-0029795]; Ministry of Education, Science,
and Technology, South Korea
FX Grant support: This work was supported by a grant (A092255) from the
Korea Healthcare Technology R&D Project, Ministry for Health and Welfare
Affairs, and by the Global Frontier (NRF-M1AXA002-2010-0029795) grant of
National Research Foundation funded by the Ministry of Education,
Science, and Technology, South Korea.
NR 22
TC 22
Z9 24
U1 0
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD AUG
PY 2012
VL 43
IS 8
BP 1234
EP 1242
DI 10.1016/j.humpath.2011.09.012
PG 9
WC Pathology
SC Pathology
GA 981OX
UT WOS:000306979800011
PM 22245114
ER
PT J
AU Foland-Ross, LC
Brooks, JO
Mintz, J
Bartzokis, G
Townsend, J
Thompson, PM
Altshuler, LL
AF Foland-Ross, Lara C.
Brooks, John O., III
Mintz, Jim
Bartzokis, George
Townsend, Jennifer
Thompson, Paul M.
Altshuler, Lori L.
TI Mood-state effects on amygdala volume in bipolar disorder
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Bipolar disorder; Depression; Magnetic resonance imaging; MRI; Amygdala
ID TEMPORAL-LOBE STRUCTURES; RATING-SCALE; DEPRESSION; MANIA;
SCHIZOPHRENIA; MRI; MATTER; CORTEX
AB Background: Prior structural neuroimaging studies of the amygdala in patients with bipolar disorder have reported higher or lower volumes, or no difference relative to healthy controls. These inconsistent findings may have resulted from combining subjects in different mood states. The prefrontal cortex has recently been reported to have a lower volume in depressed versus euthymic bipolar patients. Here we examined whether similar mood state-dependent volumetric differences are detectable in the amygdala.
Methods: Forty subjects, including 28 with bipolar disorder type I (12 depressed and 16 euthymic), and 12 healthy comparison subjects were scanned on a 3 T magnetic resonance image (MRI) scanner. Amygdala volumes were manually traced and compared across subject groups, adjusting for sex and total brain volume.
Results: Statistical analyses found a significant effect of mood state and hemisphere on amygdala volume. Subsequent comparisons revealed that amygdala volumes were significantly lower in the depressed bipolar group compared to both the euthymic bipolar (p =0.005) and healthy control (p = 0.043) groups.
Limitations: Our study was cross-sectional and some patients were medicated.
Conclusions: Our results suggest that mood state influences amygdala volume in subjects with bipolar disorder. Future studies that replicate these findings in unmedicated patient samples scanned longitudinally are needed. Published by Elsevier B.V.
C1 [Altshuler, Lori L.] Univ Calif Los Angeles, Mood Disorders Res Program, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Foland-Ross, Lara C.; Thompson, Paul M.] Univ Calif Los Angeles, Lab Neuro Imaging, Dept Neurol, Sch Med, Los Angeles, CA 90095 USA.
[Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Altshuler, Lori L.] W Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
RP Altshuler, LL (reprint author), Univ Calif Los Angeles, Mood Disorders Res Program, Semel Inst Neurosci & Human Behav, 300 Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA.
EM laltshuler@mednet.ucla.edu
RI Bartzokis, George/K-2409-2013
FU National Institutes of Health [MH078556, MH075944, MH001848, EB001561,
RR019771]; National Institute on Aging [AG016570]; National Association
for Research on Schizophrenia and Affective Disorders (NARSAD); Brain
Mapping Medical Research Organization; Brain Mapping Support Foundation;
Pierson-Lovelace Foundation; Ahmanson Foundation; William M. and Linda
R. Dietel Philanthropic Fund at the Northern Piedmont Community
Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital
Group Companies Charitable Foundation; Robson Family and Northstar Fund;
National Center for Research Resources [RR012169, RR013642, RR000865];
Abbott Laboratories; Pfizer Inc.
FX Funding for this study was provided by the National Institutes of Health
[MH078556 (LCFR), MH075944 (LLA), MH001848 (LEA) EB001561 (PMT),
RR019771 (PMT)]. The National Institute on Aging provided additional
support for algorithm development (AG016570). For their generous
support, the authors also thank the National Association for Research on
Schizophrenia and Affective Disorders (NARSAD), the Brain Mapping
Medical Research Organization, the Brain Mapping Support Foundation, the
Pierson-Lovelace Foundation, the Ahmanson Foundation, the William M. and
Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community
Foundation, the Tamkin Foundation, the Jennifer Jones-Simon Foundation,
the Capital Group Companies Charitable Foundation, the Robson Family and
Northstar Fund and the National Center for Research Resources (RR012169,
RR013642 and RR000865). The study design was peer-reviewed by the
National Institutes of Health. Funding sources had no further role in
study design; in the collection, analysis and interpretation of data; in
the writing of the report; and in the decision to submit the paper for
publication.; Dr. Altshuler has received past (and potential future)
funding from Abbott Laboratories (research support and consulting
honoraria); Forest Laboratories (consulting and speakers bureau
honoraria); GlaxoSmithKline (speakers bureau honoraria); and no past,
but potential future honoraria from Astra-Zeneca (speakers bureau) and
Merck and Co. (consulting). Dr. Brooks has received funding from Pfizer
Inc. (research support), Merck (speakers bureau), and Sunovion (speakers
bureau).
NR 25
TC 14
Z9 14
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD AUG
PY 2012
VL 139
IS 3
BP 298
EP 301
DI 10.1016/j.jad.2012.03.003
PG 4
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 981QM
UT WOS:000306984500012
PM 22521854
ER
PT J
AU Ishibashi, K
Robertson, C
London, E
Mandelkern, M
AF Ishibashi, Kenji
Robertson, Chelsea
London, Edythe
Mandelkern, Mark
TI Is the cerebellum the best reference region for a PET study with
[F-18]-fallypride?
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Ishibashi, Kenji] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Ishibashi, Kenji] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA.
[Ishibashi, Kenji; Mandelkern, Mark] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Robertson, Chelsea; London, Edythe] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA.
[Mandelkern, Mark] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
NR 3
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S178
EP S179
PG 2
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000187
ER
PT J
AU Ishibashi, K
Robertson, C
Brown, A
Morgan, A
Farahi, J
Mandelkern, M
Sabb, F
Cannon, T
London, E
AF Ishibashi, Kenji
Robertson, Chelsea
Brown, Amira
Morgan, Andrew
Farahi, Judah
Mandelkern, Mark
Sabb, Fred
Cannon, Tyrone
London, Edythe
TI Differential roles of dopamine D1-and D2-like receptors in impulsivity:
a preliminary PET study
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Ishibashi, Kenji; Brown, Amira; Morgan, Andrew; Sabb, Fred; Cannon, Tyrone; London, Edythe] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Ishibashi, Kenji; Brown, Amira; Morgan, Andrew; Sabb, Fred; Cannon, Tyrone; London, Edythe] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA.
[Ishibashi, Kenji; Morgan, Andrew; Farahi, Judah; Mandelkern, Mark] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Robertson, Chelsea] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA.
[Mandelkern, Mark] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
[Cannon, Tyrone] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
NR 3
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S82
EP S83
PG 2
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000080
ER
PT J
AU Robertson, C
Ishibashi, K
Brown, A
Morgan, A
Ghahremani, D
Congdon, E
Farahi, J
Mandelkern, M
Cannon, T
Sabb, F
London, E
AF Robertson, Chelsea
Ishibashi, Kenji
Brown, Amira
Morgan, Andrew
Ghahremani, Dara
Congdon, Eliza
Farahi, Judah
Mandelkern, Mark
Cannon, Tyrone
Sabb, Fred
London, Edythe
TI Relationships of D1-and D2-like receptor availability and response
inhibition in the stop-signal task: a preliminary PET study
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Robertson, Chelsea; London, Edythe] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA.
[Ishibashi, Kenji; Brown, Amira; Morgan, Andrew; Ghahremani, Dara; Congdon, Eliza; Cannon, Tyrone; Sabb, Fred; London, Edythe] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Ishibashi, Kenji; Brown, Amira; Morgan, Andrew; Ghahremani, Dara; Congdon, Eliza; Cannon, Tyrone; Sabb, Fred; London, Edythe] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA.
[Morgan, Andrew; Farahi, Judah; Mandelkern, Mark] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Mandelkern, Mark] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
[London, Edythe] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
[Cannon, Tyrone] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S14
EP S15
PG 2
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000003
ER
PT J
AU Chinman, M
Hannah, G
McCarthy, S
AF Chinman, Matthew
Hannah, Gordon
McCarthy, Sharon
TI Lessons Learned from a Quality Improvement Intervention with Homeless
Veteran Services
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Quality improvement; homeless people; veterans; evidence-based practice;
capacity building
ID CRITICAL TIME INTERVENTION; SUPPORTED EMPLOYMENT; IMPLEMENTATION;
OUTCOMES; PROGRAM; DIFFUSION; DISSEMINATION; PREDICTORS; DISCHARGE;
MATTERS
AB Homeless veterans are a vulnerable population, with high mortality and morbidity rates. Evidence-based practices for homelessness have been challenging to implement. This study engaged staff members from three VA homeless programs to improve their quality using Getting-To-Outcomes (GTO), a model and intervention of trainings and technical assistance that builds practitioner capacity to plan, implement, and self-evaluate evidence-based practices. Primarily used in community-based, non-VA settings, this study piloted GTO in VA by creating a GTO project within each homeless program and one across all three. The feasibility and acceptability of GTO in VA is examined using the results of the projects, time spent on GTO, and data from focus groups and interviews. With staff members averaging 33 minutes per week on GTO, each team made significant programmatic changes. Homeless staff stated GTO was helpful, and that high levels of communication, staff member commitment to the program, and technical assistance were critical.
C1 [Chinman, Matthew; Hannah, Gordon; McCarthy, Sharon] VA Pittsburgh Healthcare Syst, MIRECC, VISN 4, Pittsburgh, PA 15206 USA.
RP Chinman, M (reprint author), VA Pittsburgh Healthcare Syst, MIRECC, VISN 4, 7180 Highland Dr 151-R, Pittsburgh, PA 15206 USA.
EM chinman@rand.org
NR 39
TC 3
Z9 3
U1 2
U2 12
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD AUG
PY 2012
VL 23
IS 3
SU S
BP 210
EP 224
PG 15
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 987JR
UT WOS:000307413700019
PM 22864498
ER
PT J
AU Sher, L
AF Sher, Leo
TI Mind and Brain: A Critical Appraisal of Cognitive Neuroscience
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Book Review
C1 [Sher, Leo] Mt Sinai Sch Med, New York, NY 10029 USA.
[Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA.
RP Sher, L (reprint author), Mt Sinai Sch Med, New York, NY 10029 USA.
NR 1
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD AUG
PY 2012
VL 200
IS 8
BP 735
EP 736
DI 10.1097/NMD.0b013e31826143cf
PG 2
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 983NJ
UT WOS:000307125700017
ER
PT J
AU Markun, LC
Starr, PA
Air, EL
Marks, WJ
Volz, MM
Ostrem, JL
AF Markun, Leslie C.
Starr, Philip A.
Air, Ellen L.
Marks, William J., Jr.
Volz, Monica M.
Ostrem, Jill L.
TI Shorter Disease Duration Correlates With Improved Long-term Deep Brain
Stimulation Outcomes in Young-Onset DYT1 Dystonia
SO NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; DYT1 dystonia; Globus pallidus; Pediatrics
ID GLOBUS-PALLIDUS INTERNUS; PRIMARY GENERALIZED DYSTONIA; TORSION
DYSTONIA; FOLLOW-UP; EFFICACY
AB BACKGROUND: Treatment with deep brain stimulation (DBS) of the globus pallidus internus in children with DYT1 primary torsion dystonia is highly effective; however, individual response to stimulation is variable, and a greater understanding of predictors of long-term outcome is needed.
OBJECTIVE: To report the long-term outcomes of subjects with young-onset DYT1 primary torsion dystonia treated with bilateral globus pallidus DBS.
METHODS: Fourteen subjects (7 male, 7 female) treated consecutively from 2000 to 2010 at our center were included in this retrospective study. The Burke-Fahn-Marsden Dystonia Rating Scale was performed at baseline and at 1, 2, and up to 6 years postoperatively.
RESULTS: Pallidal DBS was well tolerated and highly effective, with mean Burke-Fahn-Marsden Dystonia Rating Scale movement scores improving from baseline by 61.5% (P < .001) at 1 year, 64.4% (P < .001) at 2 years, and 70.3% (P < .001) at the final follow-up visit (mean, 32 months; range, 7-77 months). Disability scores also improved significantly. Multiple linear regression analysis revealed a significant influence of duration of disease as a predictor of percent improvement in Burke-Fahn-Marsden Dystonia Rating Scale movement score at long-term follow-up (duration of disease, P < .05). Subjects with fixed orthopedic deformities (4) had less improvement in these regions. Location of the active DBS electrode used at final follow-up visit was not predictive of clinical outcome.
CONCLUSION: Our findings highlight the sustained benefit from DBS and the importance of early referral for DBS in children with medically refractory DYT1 primary torsion dystonia, which can lead to improved long-term benefits.
C1 [Markun, Leslie C.; Marks, William J., Jr.; Volz, Monica M.; Ostrem, Jill L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
[Markun, Leslie C.; Starr, Philip A.; Marks, William J., Jr.; Volz, Monica M.; Ostrem, Jill L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Air, Ellen L.] Univ Cincinnati, Dept Neurol Surg, Cincinnati, OH USA.
RP Ostrem, JL (reprint author), UCSF Mt Zion, Dept Neurol, Box 1838,1635 Divisadero St,5th Floor,Ste 520-530, San Francisco, CA 94115 USA.
EM Jill.Ostrem@ucsf.edu
NR 21
TC 26
Z9 27
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD AUG
PY 2012
VL 71
IS 2
BP 325
EP 330
DI 10.1227/NEU.0b013e318258e21b
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 983HB
UT WOS:000307109301022
PM 22811083
ER
PT J
AU Carmody, TP
McFall, M
Saxon, AJ
Malte, CA
Chow, B
Joseph, AM
Beckham, JC
Cook, JW
AF Carmody, Timothy P.
McFall, Miles
Saxon, Andrew J.
Malte, Carol A.
Chow, Bruce
Joseph, Anne M.
Beckham, Jean C.
Cook, Jessica W.
TI Smoking Outcome Expectancies in Military Veteran Smokers With
Posttraumatic Stress Disorder
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID CONSEQUENCES QUESTIONNAIRE-ADULT; ADMINISTERED PTSD SCALE;
MENTAL-HEALTH-CARE; NEGATIVE AFFECT; NICOTINE DEPENDENCE;
CIGARETTE-SMOKING; SELF-EFFICACY; MOTIVATION; CESSATION; RELAPSE
AB Introduction: Smoking outcome expectancies were investigated in treatment-seeking military Veteran smokers with post-traumatic stress disorder (PTSD). The investigation of smoking outcome expectancies may enhance our understanding of the relationship between PTSD and cigarette smoking.
Methods: Participants were 943 military Veterans with a diagnosis of PTSD who were current smokers enrolled in a randomized multisite effectiveness trial to test whether the integration of smoking cessation treatment into mental health care (integrated care) improves prolonged abstinence rates compared with referral to specialized smoking cessation clinics (usual care). Using confirmatory factor analysis (CFA), we evaluated the conceptual model of smoking outcome expectancies measured on the Smoking Consequences Questionnaire Adult (SCQ-A) version. The Kraemer method of mediation analysis was used to investigate the role of smoking outcome expectancies in mediating relationships between PTSD symptoms and smoking behavior, tobacco dependence, and abstinence self-efficacy.
Results: The CFA supported the 10-factor structure of the SCQ-A in smokers with PTSD. Relationships between measures of PTSD symptoms and tobacco dependence were mediated by the smoking outcome expectancy regarding negative affect reduction. This same smoking outcome expectancy mediated relationships between PTSD symptoms and smoking abstinence self-efficacy.
Conclusions: The findings support the use of the SCQ-A as a valid measure of smoking outcome expectancies in military Veteran smokers with PTSD. Moreover, they suggest that smoking outcome expectancies may play an important role in explaining the relationship between PTSD and cigarette smoking.
C1 [Carmody, Timothy P.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Carmody, Timothy P.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[McFall, Miles; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Malte, Carol A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA USA.
[Chow, Bruce] VA Palo Alto Hlth Care Syst, Vet Affairs Cooperat Studies Program, Palo Alto, CA USA.
[Joseph, Anne M.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Beckham, Jean C.] Durham Vet Affairs Med Ctr, Vet Affairs Mid Atlantic Reg Mental Illness Res E, Durham, NC USA.
[Beckham, Jean C.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
[Cook, Jessica W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
RP Carmody, TP (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM timothy.carmody@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development Cooperative Studies Program [519]
FX This work was supported by the Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development Cooperative
Studies Program, Study #519.
NR 51
TC 11
Z9 11
U1 6
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD AUG
PY 2012
VL 14
IS 8
BP 919
EP 926
DI 10.1093/ntr/ntr304
PG 8
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA 987PX
UT WOS:000307430700005
PM 22271610
ER
PT J
AU Udoetuk, JD
Dai, Y
Ying, GS
Daniel, E
Gangaputra, S
Rosenbaum, JT
Suhler, EB
Thorne, JE
Foster, CS
Jabs, DA
Levy-Clarke, GA
Nussenblatt, RB
Kempen, JH
AF Udoetuk, Joshua D.
Dai, Yang
Ying, Gui-Shuang
Daniel, Ebenezer
Gangaputra, Sapna
Rosenbaum, James T.
Suhler, Eric B.
Thorne, Jennifer E.
Foster, C. Stephen
Jabs, Douglas A.
Levy-Clarke, Grace A.
Nussenblatt, Robert B.
Kempen, John H.
CA Systemic Immunosuppressive Therapy
TI Risk of Corticosteroid-Induced Hyperglycemia Requiring Medical Therapy
among Patients with Inflammatory Eye Diseases
SO OPHTHALMOLOGY
LA English
DT Article
ID INDUCED DIABETES-MELLITUS; PREVALENCE; GLUCOCORTICOIDS; MANAGEMENT;
UVEITIS
AB Objective: To identify the incidence and risk factors for corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases.
Design: Retrospective cohort study.
Participants: Patients with ocular inflammation followed at 5 United States tertiary centers that initially were neither diabetic nor taking hypoglycemic medications.
Methods: Eligible patients who used oral corticosteroids during follow-up were identified and followed longitudinally for initiation of hypoglycemic medication over 1 year after beginning corticosteroids. The remaining eligible patients were followed for 1 year after their initial visit. Survival analysis was used to calculate the risk of hyperglycemia requiring medical therapy and to identify potential risk factors.
Main Outcome Measures: Initiation of hypoglycemic medications.
Results: Among 2073 non-diabetic patients treated with oral corticosteroids, 25 (1.21%) initiated hypoglycemic therapy compared with 5 of 2666 patients (0.19%) not treated with oral corticosteroids (relative risk [RR], 4.39; 95% confidence interval [CI], 1.68-11.5). The RR tended to be higher in association with higher initial doses (for initial doses <40 mg of prednisone per day: RR, 3.23; 95% CI, 1.08-9.64; for initial prednisone dose >= 40 mg/d: RR, 5.51; 95% CI, 2.01-15.1). Other risk factors for the initiation of hypoglycemic therapy included older age (RR [per each additional 10 years], 1.46; 95% CI, 1.15-1.85; P = 0.002) and African-American race (RR, 2.94; 95% CI, 1.34-6.43; P = 0.007).
Conclusions: These results suggest that the absolute risk of corticosteroid-induced hyperglycemia that is detected and treated with hypoglycemic therapy in the tertiary ocular inflammation setting is low (an excess cumulative risk on the order of 1% within 1 year), although on a relative scale it is approximately 4.4-fold higher than in patients not treated with oral corticosteroids. Older age and African-American race also were risk factors. Physicians who use systemic corticosteroids for ocular inflammatory diseases should be aware of this risk, and should consider surveillance for hyperglycemia among high-risk patients. However, given the low absolute risk, routine laboratory monitoring or referral for monitoring may not be necessary for low-risk patients.
Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:1569-1574 (C) 2012 by the American Academy of Ophthalmology.
C1 [Kempen, John H.] Univ Penn, Sch Med, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, Philadelphia, PA 19104 USA.
[Udoetuk, Joshua D.; Dai, Yang; Ying, Gui-Shuang; Daniel, Ebenezer; Kempen, John H.] Univ Penn, Ocular Inflammat Serv, Philadelphia, PA 19104 USA.
[Ying, Gui-Shuang; Kempen, John H.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Udoetuk, Joshua D.] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA.
[Daniel, Ebenezer; Gangaputra, Sapna] Univ Wisconsin, Dept Ophthalmol, Fundus Photograph Reading Ctr, Madison, WI USA.
[Gangaputra, Sapna; Thorne, Jennifer E.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA.
[Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA.
[Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA.
[Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
[Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA.
[Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Jabs, Douglas A.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA.
[Jabs, Douglas A.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD 20892 USA.
RP Kempen, JH (reprint author), Univ Penn, Sch Med, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM john.kempen@uphs.upenn.edu
OI Daniel, Ebenezer/0000-0002-2027-2316
FU National Eye Institute [EY014943]; Research to Prevent Blindness; Paul
and Evanina Mackall Foundation; R.P.B. James S. Adams Special Scholar
Award; R.P.B. Harrington Special Scholar Award; Department of Veterans'
Affairs
FX Supported primarily by National Eye Institute Grant EY014943 (J.H.K.).
Additional support was provided by Research to Prevent Blindness and the
Paul and Evanina Mackall Foundation. J.H.K. was an R.P.B. James S. Adams
Special Scholar Award recipient, J.E.T. was an R.P.B. Harrington Special
Scholar Award recipient, and D.A.J. and J.T.R. were Research to Prevent
Blindness Senior Scientific Investigator Award recipients during the
course of the study. G. A. L.-C. was previously supported by and R.B.N.
continues to be supported by intramural funds of the National Eye
Institute. E. B. S. receives support from the Department of Veterans'
Affairs. None of the sponsors had any role in the design and conduct of
the report; collection, management, analysis, and interpretation of the
data; or in the preparation, review, and approval of this manuscript.
NR 13
TC 5
Z9 5
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2012
VL 119
IS 8
BP 1569
EP 1574
DI 10.1016/j.ophtha.2012.01.043
PG 6
WC Ophthalmology
SC Ophthalmology
GA 982YA
UT WOS:000307080100012
PM 22484116
ER
PT J
AU Liu, Q
Rehman, H
Krishnasamy, Y
Haque, K
Schnellmann, RG
Lemasters, JJ
Zhong, Z
AF Liu, Q.
Rehman, H.
Krishnasamy, Y.
Haque, K.
Schnellmann, R. G.
Lemasters, J. J.
Zhong, Z.
TI Amphiregulin Stimulates Liver Regeneration After Small-for-Size Mouse
Liver Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Growth factor; liver graft survival; liver regeneration; liver
transplantation; living donor transplantation; small-for-size syndrome
ID MITOCHONDRIAL PERMEABILITY TRANSITION; GROWTH-FACTOR-ALPHA;
N-TERMINAL-KINASE; RAT-LIVER; CYCLIN D1; GENE-EXPRESSION; FACTOR
RECEPTOR; GRAFT INJURY; IN-VIVO; MICE
AB This study investigated whether amphiregulin (AR), a ligand of the epidermal growth factor receptor (EGFR), improves liver regeneration after small-for-size liver transplantation. Livers of male C57BL/6 mice were reduced to similar to 50% and similar to 30% of original sizes and transplanted. After transplantation, AR and AR mRNA increased in 50% but not in 30% grafts. 5-Bromodeoxyuridine (BrdU) labeling, proliferating cell nuclear antigen (PCNA) expression and mitotic index increased substantially in 50% but not 30% grafts. Hyperbilirubinemia and hypoalbuminemia occurred and survival decreased after transplantation of 30% but not 50% grafts. AR neutralizing antibody blunted regeneration in 50% grafts whereas AR injection (5 mu g/mouse, iv) stimulated liver regeneration, improved liver function and increased survival after transplantation of 30% grafts. Phosphorylation of EGFR and its downstream signaling molecules Akt, mTOR, p70S6K, ERK and JNK increased markedly in 50% but not 30% grafts. AR stimulated EGFR phosphorylation and its downstream signaling pathways. EGFR inhibitor PD153035 suppressed regeneration of 50% grafts and largely abrogated stimulation of regeneration of 30% grafts by AR. AR also increased cyclin D1 and cyclin E expression in 30% grafts. Together, liver regeneration is suppressed in small-for-size grafts, as least in part, due to decreased AR formation. AR supplementation could be a promising therapy to stimulate regeneration of partial liver grafts.
C1 [Liu, Q.; Rehman, H.; Krishnasamy, Y.; Haque, K.; Schnellmann, R. G.; Lemasters, J. J.; Zhong, Z.] Med Univ S Carolina, Dept Pharmaceut, Charleston, SC 29425 USA.
[Liu, Q.; Rehman, H.; Krishnasamy, Y.; Haque, K.; Schnellmann, R. G.; Lemasters, J. J.; Zhong, Z.] Med Univ S Carolina, Dept Biomed Sci, Charleston, SC 29425 USA.
[Liu, Q.] Dalian Med Univ, Affiliated Hosp 2, Dept Gen Surg, Dalian, Peoples R China.
[Schnellmann, R. G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Lemasters, J. J.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Lemasters, J. J.; Zhong, Z.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
RP Zhong, Z (reprint author), Med Univ S Carolina, Dept Pharmaceut, Charleston, SC 29425 USA.
EM zhong@musc.edu
FU National Institutes of Health [DK70844, DK70844S1, DK084632, DK037034]
FX This study was supported, in part, by Grants DK70844, DK70844S1,
DK084632 and DK037034 from the National Institutes of Health.
NR 64
TC 10
Z9 11
U1 2
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD AUG
PY 2012
VL 12
IS 8
BP 2052
EP 2061
DI 10.1111/j.1600-6143.2012.04069.x
PG 10
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 980OT
UT WOS:000306903400014
PM 22694592
ER
PT J
AU Petri, M
Orbai, AM
Alarcon, GS
Gordon, C
Merrill, JT
Fortin, PR
Bruce, IN
Isenberg, D
Wallace, DJ
Nived, O
Sturfelt, G
Ramsey-Goldman, R
Bae, SC
Hanly, JG
Sanchez-Guerrero, J
Clarke, A
Aranow, C
Manzi, S
Urowitz, M
Gladman, D
Kalunian, K
Costner, M
Werth, VP
Zoma, A
Bernatsky, S
Ruiz-Irastorza, G
Khamashta, MA
Jacobsen, S
Buyon, JP
Maddison, P
Dooley, MA
van Vollenhoven, RF
Ginzler, E
Stoll, T
Peschken, C
Jorizzo, JL
Callen, JP
Lim, SS
Fessler, BJ
Inanc, M
Kamen, DL
Rahman, A
Steinsson, K
Franks, AG
Sigler, L
Hameed, S
Fang, H
Pham, N
Brey, R
Weisman, MH
McGwin, G
Magder, LS
AF Petri, Michelle
Orbai, Ana-Maria
Alarcon, Graciela S.
Gordon, Caroline
Merrill, Joan T.
Fortin, Paul R.
Bruce, Ian N.
Isenberg, David
Wallace, Daniel J.
Nived, Ola
Sturfelt, Gunnar
Ramsey-Goldman, Rosalind
Bae, Sang-Cheol
Hanly, John G.
Sanchez-Guerrero, Jorge
Clarke, Ann
Aranow, Cynthia
Manzi, Susan
Urowitz, Murray
Gladman, Dafna
Kalunian, Kenneth
Costner, Melissa
Werth, Victoria P.
Zoma, Asad
Bernatsky, Sasha
Ruiz-Irastorza, Guillermo
Khamashta, Munther A.
Jacobsen, Soren
Buyon, Jill P.
Maddison, Peter
Dooley, Mary Anne
van vollenhoven, Ronald F.
Ginzler, Ellen
Stoll, Thomas
Peschken, Christine
Jorizzo, Joseph L.
Callen, Jeffrey P.
Lim, S. Sam
Fessler, Barri J.
Inanc, Murat
Kamen, Diane L.
Rahman, Anisur
Steinsson, Kristjan
Franks, Andrew G., Jr.
Sigler, Lisa
Hameed, Suhail
Fang, Hong
Ngoc Pham
Brey, Robin
Weisman, Michael H.
McGwin, Gerald, Jr.
Magder, Laurence S.
TI Derivation and validation of the systemic lupus international
collaborating clinics classification criteria for systemic lupus
erythematosus
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID RHEUMATISM-ASSOCIATION CRITERIA; OF-RHEUMATOLOGY CRITERIA; WEIGHTED
CRITERIA; REVISED CRITERIA; ANTIBODIES; NEPHRITIS; ARTHRITIS
AB Objective The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE. Methods The classification criteria were derived from a set of 702 expert-rated patient scenarios. Recursive partitioning was used to derive an initial rule that was simplified and refined based on SLICC physician consensus. The SLICC group validated the classification criteria in a new validation sample of 690 new expert-rated patient scenarios. Results Seventeen criteria were identified. In the derivation set, the SLICC classification criteria resulted in fewer misclassifications compared with the current ACR classification criteria (49 versus 70; P = 0.0082) and had greater sensitivity (94% versus 86%; P < 0.0001) and equal specificity (92% versus 93%; P = 0.39). In the validation set, the SLICC classification criteria resulted in fewer misclassifications compared with the current ACR classification criteria (62 versus 74; P = 0.24) and had greater sensitivity (97% versus 83%; P < 0.0001) but lower specificity (84% versus 96%; P < 0.0001). Conclusion The new SLICC classification criteria performed well in a large set of patient scenarios rated by experts. According to the SLICC rule for the classification of SLE, the patient must satisfy at least 4 criteria, including at least one clinical criterion and one immunologic criterion OR the patient must have biopsy-proven lupus nephritis in the presence of antinuclear antibodies or antidouble-stranded DNA antibodies.
C1 [Petri, Michelle] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
[Alarcon, Graciela S.; Fessler, Barri J.; McGwin, Gerald, Jr.] Univ Alabama Birmingham, Birmingham, AL USA.
[Gordon, Caroline] Univ Birmingham, Birmingham, W Midlands, England.
[Merrill, Joan T.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Fortin, Paul R.] Univ Laval, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada.
[Bruce, Ian N.] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
[Bruce, Ian N.] Univ Manchester, Manchester, Lancs, England.
[Isenberg, David; Rahman, Anisur] UCL, London, England.
[Wallace, Daniel J.; Weisman, Michael H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Wallace, Daniel J.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Nived, Ola; Sturfelt, Gunnar] Univ Lund Hosp, S-22185 Lund, Sweden.
[Ramsey-Goldman, Rosalind] Northwestern Univ, Chicago, IL 60611 USA.
[Bae, Sang-Cheol] Hanyang Univ Hosp Rheumat Dis, Seoul, South Korea.
[Hanly, John G.] Dalhousie Univ, Halifax, NS, Canada.
[Hanly, John G.] Capital Hlth, Halifax, NS, Canada.
[Sanchez-Guerrero, Jorge] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Sanchez-Guerrero, Jorge] Univ Hlth Network, Toronto, ON, Canada.
[Clarke, Ann; Bernatsky, Sasha] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
[Aranow, Cynthia] Feinstein Inst Med Res, Manhasset, NY USA.
[Manzi, Susan] Allegheny Singer Res Inst, Pittsburgh, PA 15212 USA.
[Manzi, Susan] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA.
[Urowitz, Murray; Gladman, Dafna] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada.
[Urowitz, Murray; Gladman, Dafna] Univ Toronto, Toronto, ON, Canada.
[Kalunian, Kenneth] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Costner, Melissa] N Dallas Dermatol Associates, Dallas, TX USA.
[Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Werth, Victoria P.] Univ Penn, Philadelphia, PA 19104 USA.
[Zoma, Asad] Lanarkshire Ctr Rheumatol, E Kilbride, Lanark, Scotland.
[Zoma, Asad] Hairmyres Hosp, E Kilbride, Lanark, Scotland.
[Ruiz-Irastorza, Guillermo] Hosp Univ Cruces, Baracaldo, Spain.
[Ruiz-Irastorza, Guillermo] Univ Basque Country, Baracaldo, Spain.
[Khamashta, Munther A.] Rayne Inst, London, England.
[Khamashta, Munther A.] St Thomas Hosp, London, England.
[Jacobsen, Soren] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark.
[Buyon, Jill P.; Franks, Andrew G., Jr.] NYU, New York, NY USA.
[Maddison, Peter] Ysbyty Gwynedd, Bangor, Gwynedd, Wales.
[Dooley, Mary Anne] Univ N Carolina, Chapel Hill, NC USA.
[van vollenhoven, Ronald F.] Karolinska Univ Hosp, Stockholm, Sweden.
[Ginzler, Ellen] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA.
[Stoll, Thomas] Kantonsspital Schaffhausen, Schaffhausen, Switzerland.
[Peschken, Christine] Univ Manitoba, Winnipeg, MB, Canada.
[Jorizzo, Joseph L.] Wake Forest Univ, Winston Salem, NC 27109 USA.
[Callen, Jeffrey P.] Univ Louisville, Louisville, KY 40292 USA.
[Lim, S. Sam] Emory Univ, Atlanta, GA 30322 USA.
[Inanc, Murat] Istanbul Univ, Istanbul, Turkey.
[Kamen, Diane L.] Med Univ S Carolina, Charleston, SC USA.
[Steinsson, Kristjan] Landspitali Univ Hosp, Reykjavik, Iceland.
[Brey, Robin] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Magder, Laurence S.] Univ Maryland, Baltimore, MD 21201 USA.
RP Petri, M (reprint author), Johns Hopkins Univ, Sch Med, 1830 E Monument St,Suite 7500, Baltimore, MD 21205 USA.
EM mpetri@jhmi.edu
RI inanc, murat/I-3444-2012; Ruiz-Irastorza, Guillermo/P-7058-2014; ,
Ivan/D-6804-2012
OI Ruiz-Irastorza, Guillermo/0000-0001-7788-1043; Peschken,
Christine/0000-0002-4269-5213; Isenberg, David/0000-0001-9514-2455; ,
Ivan/0000-0002-3108-058X; Franks, Andrew/0000-0001-5427-6369; Bruce,
Ian/0000-0003-3047-500X
FU NIH (National Institute of Arthritis and Musculoskeletal and Skin
Diseases) [R01-AR-043727]; Lupus Foundation of America; Human Genome
Sciences; NIH [T32-AR-048522]; GlaxoSmithKline; Roche; Abbott; MSD;
Pfizer; UCB Pharma; Amgen; LEO Pharma; Warner Chilcott
FX Supported by the NIH (National Institute of Arthritis and
Musculoskeletal and Skin Diseases grant R01-AR-043727), the Lupus
Foundation of America, and Human Genome Sciences (unrestricted research
grant). Dr. Orbai's work was supported by the NIH (grant
T32-AR-048522).; Dr. Fortin has received consulting fees, speaking fees,
and/or honoraria from GlaxoSmithKline (less than $10,000). Dr. Bruce has
received consulting fees, speaking fees, and/or honoraria from Human
Genome Sciences, GlaxoSmithKline, and Roche (less than $10,000 each).
Dr. Nived has received speaking fees from GlaxoSmithKline (less than
$10,000). Dr. van Vollenhoven has received honoraria from Abbott,
GlaxoSmithKline, MSD, Pfizer, Roche, and UCB Pharma (less than $10,000
each) and research support from Abbott, GlaxoSmithKline, MSD, Pfizer,
Roche, and UCB Pharma. Dr. Jorizzo has received consulting fees,
speaking fees, and/or honoraria from Amgen, LEO Pharma, and Warner
Chilcott (less than $10,000 each).
NR 33
TC 476
Z9 533
U1 7
U2 36
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD AUG
PY 2012
VL 64
IS 8
BP 2677
EP 2686
DI 10.1002/art.34473
PG 10
WC Rheumatology
SC Rheumatology
GA 980PX
UT WOS:000306906500028
PM 22553077
ER
PT J
AU Zhao, KQ
Cowan, AT
Lee, RJ
Goldstein, N
Droguett, K
Chen, B
Zheng, CQ
Villalon, M
Palmer, JN
Kreindler, JL
Cohen, NA
AF Zhao, Ke-Qing
Cowan, Andrew T.
Lee, Robert J.
Goldstein, Natalia
Droguett, Karla
Chen, Bei
Zheng, Chunquan
Villalon, Manuel
Palmer, James N.
Kreindler, James L.
Cohen, Noam A.
TI Molecular modulation of airway epithelial ciliary response to sneezing
SO FASEB JOURNAL
LA English
DT Article
DE chronic rhinosinusitis; mucociliary clearance; ATP; calcium
ID BEAT FREQUENCY; EXTRACELLULAR ATP; CHRONIC RHINOSINUSITIS; MUCOCILIARY
TRANSPORT; INTRACELLULAR CALCIUM; PROTEIN-KINASE; CA2+ RELEASE; CELLS;
STIMULATION; RECEPTOR
AB Our purpose was to evaluate the effect of the mechanical force of a sneeze on sinonasal cilia function and determine the molecular mechanism responsible for eliciting the ciliary response to a sneeze. A novel model was developed to deliver a stimulation simulating a sneeze (55 mmHg for 50 ms) at 26 degrees C to the apical surface of mouse and human nasal epithelial cells. Ciliary beating was visualized, and changes in ciliary beat frequency (CBF) were determined. To interrogate the molecular cascades driving sneeze-induced changes of CBF, pharmacologic manipulation of intra- and extracellular calcium, purinergic, PKA, and nitric oxide (NO) signaling were performed. CBF rapidly increases by >= 150% in response to a sneeze, which is dependent on the release of adenosine triphosphate (ATP), calcium influx, and PKA activation. Furthermore, apical release of ATP is independent of calcium influx, but calcium influx and subsequent increase in CBF are dependent on the ATP release. Lastly, we observed a blunted ciliary response in surgical specimens derived from patients with chronic rhinosinusitis compared to control patients. Apical ATP release with subsequent calcium mobilization and PKA activation are involved in sinonasal ciliary response to sneezing, which is blunted in patients with upper-airway disease.-Zhao, K.-Q., Cowan, A. T., Lee, R. J., Goldstein, N., Droguett, K., Chen, B., Zheng, C., Villalon, M., Palmer, J. N., Kreindler, J. L., Cohen, N. A. Molecular modulation of airway epithelial ciliary response to sneezing. FASEB J. 26, 3178-3187 (2012). www.fasebj.org
C1 [Zhao, Ke-Qing; Lee, Robert J.; Goldstein, Natalia; Chen, Bei; Palmer, James N.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
[Zhao, Ke-Qing; Zheng, Chunquan] Fudan Univ, Dept Otorhinolaryngol Head & Neck Surg, Sch Shanghai Med, Eye & Ear Nose & Throat Hosp, Shanghai 200433, Peoples R China.
[Cowan, Andrew T.] Temple Univ, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19122 USA.
[Droguett, Karla; Villalon, Manuel] Pontificia Univ Catolica Chile, Dept Physiol, Santiago, Chile.
[Goldstein, Natalia] Pontificia Univ Catolica Chile, Dept Med Sci, Santiago, Chile.
[Kreindler, James L.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Kreindler, James L.] Univ Penn, Dept Pediat, Sch Med, Philadelphia, PA 19104 USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA.
RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA.
EM cohenn@uphs.upenn.edu
OI Cohen, Noam/0000-0002-9462-3932; Lee, Robert/0000-0001-5826-6686
FU Flight Attendant Medical Research Institute (FAMRI) Clinical Innovator
Award (CIA) grant [082478]; Fondo Nacional de Desarrollo Cientifico y
Tecnologico (FONDECYT) grant [1080679]; Proyecto Anillo ACT-79; Comision
Nacional de Investigacion Cientifica y Tecnologica (CONICYT) grant
[24090041]
FX Financial support for these experiments was provided by Flight Attendant
Medical Research Institute (FAMRI) Clinical Innovator Award (CIA) grant
082478 to N.A.C., Fondo Nacional de Desarrollo Cientifico y Tecnologico
(FONDECYT) grant 1080679 to M.V., Proyecto Anillo ACT-79 to K.D., and
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
grant 24090041 to M.V.
NR 58
TC 10
Z9 10
U1 0
U2 8
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD AUG
PY 2012
VL 26
IS 8
BP 3178
EP 3187
DI 10.1096/fj.11-202184
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 984BI
UT WOS:000307162800009
PM 22516297
ER
PT J
AU Zhou, XH
Ma, YB
AF Zhou XiaoHua
Ma YunBei
TI BATE curve in assessment of clinical utility of predictive biomarkers
SO SCIENCE CHINA-MATHEMATICS
LA English
DT Article
DE predictive biomarker; cutoff points; interaction; BATE curve;
time-to-event outcome
ID CONFIDENCE BANDS; TRIAL DESIGNS; SURVIVAL-DATA; COX MODEL; REGRESSION;
VALIDATION; SUBSETS
AB In this paper, for time-to-event data, we propose a new statistical framework for casual inference in evaluating clinical utility of predictive biomarkers and in selecting an optimal treatment for a particular patient. This new casual framework is based on a new concept, called Biomarker Adjusted Treatment Effect (BATE) curve. The BATE curve can be used for assessing clinical utility of a predictive biomarker, for designing a subsequent confirmation trial, and for guiding clinical practice. We then propose semi-parametric methods for estimating the BATE curves of biomarkers and establish asymptotic results of the proposed estimators for the BATE curves. We also conduct extensive simulation studies to evaluate finite-sample properties of the proposed estimation methods. Finally, we illustrate the application of the proposed method in a real-world data set.
C1 [Zhou XiaoHua] VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA 98198 USA.
[Zhou XiaoHua] Univ Washington, Dept Biostat, Seattle, WA 98198 USA.
[Zhou XiaoHua] Peking Univ, Beijing Int Ctr Math Res, Beijing 100871, Peoples R China.
[Ma YunBei] Princeton Univ, Dept Operat Res & Financial Engn, Princeton, NJ 08540 USA.
[Ma YunBei] SW Univ Finance & Econ, Sch Stat, Chengdu 611130, Peoples R China.
RP Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA 98198 USA.
EM azhou@u.washington.edu; jamie82.ma@gmail.com
FU Department of Veterans Affairs Medical Center, Seattle, WA; Department
of Veterans Affairs, Veterans Health Administration, Health Services
Research and Development Service [XVA 61-036]; [RCS OS-196]
FX This work was supported by a Core Investigator, Research Career
Scientist (Grant No. RCS OS-196), Biostatistics Unit Director at the
Northwest HSR&D Center of Excellence, Department of Veterans Affairs
Medical Center, Seattle, WA and Department of Veterans Affairs, Veterans
Health Administration, Health Services Research and Development Service,
project (Grant No. XVA 61-036). The views expressed in this article are
those of the authors, and do not necessarily represent the views of the
Department of Veterans Affairs. The authors are grateful to Dr. Yi Li
for the data analyzed in the paper. We would also like to thank an
associated editor and two reviewers for their valuable comments and
suggestions, which have helped us to improve the paper.
NR 19
TC 1
Z9 1
U1 2
U2 9
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1674-7283
J9 SCI CHINA MATH
JI Sci. China-Math.
PD AUG
PY 2012
VL 55
IS 8
BP 1529
EP 1552
DI 10.1007/s11425-012-4473-0
PG 24
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 985OX
UT WOS:000307277600002
ER
PT J
AU Biteker, M
Ilhan, E
Biteker, G
Duman, D
Bozkurt, B
AF Biteker, Murat
Ilhan, Erkan
Biteker, Gul
Duman, Dursun
Bozkurt, Biykem
TI Delayed recovery in peripartum cardiomyopathy: an indication for
long-term follow-up and sustained therapy
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Peripartum cardiomyopathy; Late recovery; Treatment
ID ECHOCARDIOGRAPHY; RECOMMENDATIONS; PREDICTORS; PROGNOSIS; SOCIETY; HEART
AB Persistence of left ventricular (LV) systolic dysfunction after 6 months of diagnosis is believed to be a marker of an irreversible cardiomyopathy in peripartum cardiomyopathy (PPCM). We sought to determine the length of time required for recovery of LV systolic function (LVSF) in patients with PPCM.
Forty-two consecutive women with PPCM were enrolled in this prospective study. The minimum required time of follow-up for inclusion was 30 months. Each patient underwent transthoracic echocardiography, and plasma brain natriuretic peptide (BNP) and C-reactive protein measurement at admission, and every 3 months. Early recovery was defined as normalization of LVSF at 6 months post-diagnosis. Delayed recovery was defined if the length of time required for recovery of LVSF was longer than 6 months. Persistent left ventricular dysfunction (PLVD) was defined as an ejection fraction of 50 at the end of follow-up. Twenty patients (47.6) recovered completely, 10 died (23.8), and 12 (28.6) had PLVD. Average time to complete recovery was 19.3 months after initial diagnosis (342 months). Early recovery was observed only in six patients (30), whereas delayed recovery was observed in 14 out of 20 patients (70). Patients with complete recovery were more likely to have a higher LV ejection fraction and smaller LV end-systolic dimensions at baseline.
Full recovery of LVSF in PPCM patients often requires longer than 6 months.
C1 [Biteker, Murat; Duman, Dursun] Haydarpasa Numune Educ & Res Hosp, Dept Cardiol, Istanbul, Turkey.
[Ilhan, Erkan] Siyami Ersek Cardiovasc Surg Ctr, Dept Cardiol, Istanbul, Turkey.
[Biteker, Gul] Ortaca Yucelen Hosp, Dept Obstet & Gynecol, Istanbul, Turkey.
[Bozkurt, Biykem] Baylor Coll Med, Dept Med, Cardiol Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Bozkurt, Biykem] Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA.
RP Biteker, M (reprint author), 4-7 Cevizli Kartal, Istanbul, Turkey.
EM murbit2@yahoo.com
NR 19
TC 25
Z9 27
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD AUG
PY 2012
VL 14
IS 8
BP 895
EP 901
DI 10.1093/eurjhf/hfs070
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 980WM
UT WOS:000306924900006
PM 22588321
ER
PT J
AU Costanzo, MR
Heywood, JT
Massie, BM
Iwashita, J
Henderson, L
Mamatsashvili, M
Sisakian, H
Hayrapetyan, H
Sager, P
van Veldhuisen, DJ
Albrecht, D
AF Costanzo, Maria Rosa
Heywood, J. Thomas
Massie, Barry M.
Iwashita, Julie
Henderson, Lee
Mamatsashvili, Merab
Sisakian, Hamayak
Hayrapetyan, Hamlet
Sager, Philip
van Veldhuisen, Dirk J.
Albrecht, Detlef
TI A double-blind, randomized, parallel, placebo-controlled study examining
the effect of cross-linked polyelectrolyte in heart failure patients
with chronic kidney disease
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Heart failure; Chronic kidney disease; Cross-linked polyelectrolyte;
Potassium
ID LEFT-VENTRICULAR DYSFUNCTION; EUROPEAN-SOCIETY; 6-MINUTE WALK;
MORTALITY; OUTCOMES; ADHERE; ASSOCIATION; CARDIOLOGY; MORBIDITY;
STATEMENT
AB This double-blind, randomized, parallel, placebo-controlled investigation evaluated the effects of cross-linked polyelectrolyte (CLP) on serum potassium and measures of congestion in patients with heart failure (HF) and chronic kidney disease (CKD).
The primary endpoint was change in serum potassium over time. Exploratory endpoints included: weight, physician and patient assessment of exertional dyspnoea, effect on N-terminal pro brain natriuretic peptide (NT-proBNP) levels, New York Heart Association (NYHA) classification, 6 min walk test (6MWT), and quality of life by Kansas City Cardiomyopathy Questionnaire (KCCQ). Serum potassium was similar in CLP (n 59) and placebo (n 52) groups throughout the 8-week study. Weight loss was greater in the CLP than in the placebo group at Weeks 1 (P 0.014) and 2 (P 0.004), and this trend continued until the end of the study. After 8 weeks, by physician assessment, the percentage of patients experiencing marked or disabling dyspnoea tended to be lower in the CLP than in the placebo group (7.3 vs. 23.9, P 0.128). Fewer patients in the CLP than in the placebo group had NT-proBNP levels 1000 pg/mL at Week 4 (P 0.039) and Week 8 (P 0.065). The proportion of patients improving by at least one NYHA functional class over the study was higher in the CLP than in the placebo group (48.8 vs. 17.4; P 0.002). Effects on 6MWT at Week 8 (p 0.072) and quality of life (overall KCCQ score) at Week 4 (p 0.005) and 8 (P 0.062) all favoured the CLP cohort. Four treatment-unrelated deaths occurred in the CLP group and none in the placebo group (P 0.056).
In advanced, symptomatic HF with CKD, CLP is associated with beneficial clinical effects without significant serum potassium changes.
Trial registration: NCT01265524.
C1 [Costanzo, Maria Rosa] Edward Heart Hosp, Midwest Heart Fdn, Naperville, IL 60566 USA.
[Heywood, J. Thomas] Scripps Clin, La Jolla, CA 92037 USA.
[Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Iwashita, Julie; Henderson, Lee; Albrecht, Detlef] Sorbent Therapeut Inc, Sunnyvale, CA USA.
[Mamatsashvili, Merab] Adapti Angiocardiol Clin, Tbilisi, Rep of Georgia.
[Sisakian, Hamayak] Yerevan State Med Univ, Yerevan, Armenia.
[Hayrapetyan, Hamlet] Erebouni Med Ctr, Yerevan, Armenia.
[Sager, Philip] Sager Consulting Experts Inc, San Francisco, CA USA.
[van Veldhuisen, Dirk J.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
RP Costanzo, MR (reprint author), Edward Heart Hosp, Midwest Heart Fdn, POB 3226, Naperville, IL 60566 USA.
EM mariarosa.costanzo@advocatehealth.com
RI van Veldhuisen, Dirk Jan/E-8967-2014
FU Sorbent Therapeutics, Inc.
FX Sorbent Therapeutics, Inc.
NR 30
TC 11
Z9 11
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD AUG
PY 2012
VL 14
IS 8
BP 922
EP 930
DI 10.1093/eurjhf/hfs074
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 980WM
UT WOS:000306924900010
PM 22613585
ER
PT J
AU Rice, TR
Sher, L
AF Rice, Timothy R.
Sher, Leo
TI Educating non-mental healthcare providers about suicide-risk assessment
in adolescents
SO NEUROPSYCHIATRY
LA English
DT Editorial Material
ID PSYCHOLOGICAL DISTRESS; EMERGENCY-DEPARTMENT; GENERAL-PRACTITIONERS;
PEDIATRIC RESIDENTS; YOUTH SUICIDE; IDEATION; COMPLAINTS; BEHAVIOR
C1 [Rice, Timothy R.; Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Rice, Timothy R.; Sher, Leo] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA.
RP Rice, TR (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1425 Madison Ave,Box 1230, New York, NY 10029 USA.
EM timothy.rice@mssm.edu
NR 31
TC 0
Z9 0
U1 1
U2 4
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-2008
EI 1758-2016
J9 NEUROPSYCHIATRY-LOND
JI Neuropsychiatry
PD AUG
PY 2012
VL 2
IS 4
BP 267
EP 270
DI 10.2217/NPY.12.33
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 980JF
UT WOS:000306888700002
ER
PT J
AU Cooper, RA
Grindle, GG
Vazquez, JJ
Xu, J
Wang, H
Candiotti, J
Chung, C
Salatin, B
Houston, E
Kelleher, A
Cooper, R
Teodorski, E
Beach, S
AF Cooper, Rory A.
Grindle, G. G.
Vazquez, J. J.
Xu, J.
Wang, H.
Candiotti, J.
Chung, C.
Salatin, B.
Houston, E.
Kelleher, A.
Cooper, R.
Teodorski, E.
Beach, S.
TI Personal Mobility and Manipulation Appliance-Design, Development, and
Initial Testing
SO PROCEEDINGS OF THE IEEE
LA English
DT Article
DE Electric powered wheelchair (EPW); manipulation; people with
disabilities; rehabilitation; robotics
ID ASSISTIVE TECHNOLOGY; WHEELCHAIR; REHABILITATION; ROBOT; USERS
AB The ability to perform activities of daily living and mobility-related activities of daily living are substantial indicators of one's ability to live at home and to participate in one's community. Technologies to assist with mobility and manipulation are among the most important tools that clinicians can provide to people with disabilities to promote independence and community participation. For people with severe disabilities involving both the upper and lower extremities, there are few systems that provide practical and coordinated assistance with mobility and manipulation tasks. The personal mobility and manipulation appliance (PerMMA) was created in response to goals set forth by a team of clinicians and people with disabilities.
C1 [Cooper, Rory A.; Grindle, G. G.; Vazquez, J. J.; Wang, H.; Candiotti, J.; Salatin, B.; Kelleher, A.; Cooper, R.; Teodorski, E.] Dept Vet Affairs, Human Engn Res Labs, Rehabil Res & Dev Serv, Pittsburgh, PA 15206 USA.
[Cooper, Rory A.; Grindle, G. G.; Vazquez, J. J.; Xu, J.; Wang, H.; Candiotti, J.; Chung, C.; Salatin, B.; Houston, E.; Kelleher, A.; Cooper, R.; Teodorski, E.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA.
[Xu, J.; Chung, C.; Houston, E.] VA Pittsburgh Healthcare Syst, Rehabil Res & Dev Serv, Dept Vet Affairs VA, Human Engn Res Labs, Pittsburgh, PA 15206 USA.
[Beach, S.] Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15260 USA.
RP Cooper, RA (reprint author), Dept Vet Affairs, Human Engn Res Labs, Rehabil Res & Dev Serv, Pittsburgh, PA 15206 USA.
EM RCOOPER@pitt.edu
RI Wang, Hongwu/J-6133-2013
OI Wang, Hongwu/0000-0002-6567-9144
FU NSF-ERC Quality of Life Technology [EEC-0540865]; VA Rehabilitation
Research & Development Center [B6789C]
FX This work was supported in part by the NSF-ERC Quality of Life
Technology (EEC-0540865) and the VA Rehabilitation Research &
Development Center (B6789C). The contents of this paper do not represent
the views of the Department of Veterans Affairs or the United States
Government.
NR 12
TC 10
Z9 10
U1 0
U2 7
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9219
J9 P IEEE
JI Proc. IEEE
PD AUG
PY 2012
VL 100
IS 8
SI SI
BP 2505
EP 2511
DI 10.1109/JPROC.2012.2200537
PG 7
WC Engineering, Electrical & Electronic
SC Engineering
GA 976NV
UT WOS:000306592500010
ER
PT J
AU Bartels, CM
Kind, AJH
Thorpe, CT
Everett, CM
Cook, RJ
McBride, PE
Smith, MA
AF Bartels, Christie M.
Kind, Amy J. H.
Thorpe, Carolyn T.
Everett, Christine M.
Cook, Rachel J.
McBride, Patrick E.
Smith, Maureen A.
TI Lipid Testing in Patients with Rheumatoid Arthritis and Key
Cardiovascular-Related Comorbidities: A Medicare Analysis
SO SEMINARS IN ARTHRITIS AND RHEUMATISM
LA English
DT Review
DE rheumatoid arthritis; cardiovascular disease; prevention and control;
preventive medicine; cholesterol
ID QUALITY-OF-CARE; POSITIVE PREDICTIVE-VALUE; ADMINISTRATIVE DATA;
ORTHOPEDIC-SURGERY; CLAIMS; RISK; MANAGEMENT; RECOMMENDATIONS;
ASSOCIATION; SENSITIVITY
AB Objective: For patients with rheumatoid arthritis (RA) and comorbid cardiovascular disease (CVD), diabetes, or hyperlipidemia, annual lipid testing is recommended to reduce morbidity and mortality from comorbidities. Given trends encouraging complex patients to receive care in "medical homes," we examined associations between regularly seeing a primary care provider (PCP) and lipid testing in RA patients with cardiovascular-related comorbidities.
Methods: We performed a retrospective cohort study examining a 5% random USA Medicare sample (2004-06) of beneficiaries over 65 years old with RA and concomitant CVD, diabetes, or hyperlipidemia (n = 16,893). We examined the relationship between receiving lipid testing in 2006 and having at least 1 PCP visit per year in 2004, 2005, and 2006 using multivariate regression.
Results: Ninety percent of patients had prevalent CVD; 46% had diabetes, and 64% had hyperlipidemia. However, annual lipid testing was only performed in 63% of these RA patients. Thirty percent of patients saw a PCP less than once per year, despite frequent visits (mean >9) with other providers. Patients without at least 1 annual PCP visit were 16% less likely to have lipid testing. Increased age, complexity scores, hospitalization, and large town residence predicted decreased lipid testing.
Conclusions: Despite comorbid CVD, diabetes, or hyperlipidemia, 30% of Medicare RA patients saw a PCP less than once per year, and 1 in 3 lacked annual lipid testing. Findings support advocating primary care visits at least once per year. Remaining gaps in lipid testing suggest the need for additional strategies to improve lipid testing in at-risk RA patients. (C) 2012 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 42:9-16
C1 [Bartels, Christie M.] Univ Wisconsin, Rheumatol Sect, Dept Med, Sch Med & Publ Hlth, Madison, WI USA.
[Kind, Amy J. H.; Everett, Christine M.] Univ Wisconsin, Dept Med, Div Geriatr, Sch Med & Publ Hlth, Madison, WI USA.
[Kind, Amy J. H.] William S Middleton Hosp, GRECC, US Dept Vet Affairs, Madison, WI USA.
[Thorpe, Carolyn T.] Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA.
[Thorpe, Carolyn T.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA.
[Cook, Rachel J.] Univ Wisconsin, Dept Med, Hematol Oncol Sect, Sch Med & Publ Hlth, Madison, WI USA.
[McBride, Patrick E.] Univ Wisconsin, Dept Med, Cardiovasc Div, Sch Med & Publ Hlth, Madison, WI USA.
[Smith, Maureen A.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI USA.
[Smith, Maureen A.] Univ Wisconsin, Dept Family Med, Sch Med & Publ Hlth, Madison, WI USA.
[Smith, Maureen A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA.
RP Bartels, CM (reprint author), 1685 Highland Ave,Room 4132, Madison, WI 53705 USA.
EM cb4@medicine.wisc.edu
FU University of Wisconsin Institute for Clinical and Translational
Research; National Center for Research Resources, National Institutes of
Health [1UL1RR025011]
FX This project was supported by a training grant and partnership with the
Health Innovation Program and the Community-Academic Partnerships core
of the University of Wisconsin Institute for Clinical and Translational
Research (UW-ICTR). Grant 1UL1RR025011 from the Clinical and
Translational Science Award (CTSA) program of the National Center for
Research Resources, National Institutes of Health. Additional support
was provided by the UW School of Medicine and Public Health from the
Wisconsin Partnership Program. The authors have no potential conflicts
of interest. The Health Innovation Program assisted with data management
and manuscript preparation.
NR 38
TC 13
Z9 13
U1 1
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0049-0172
EI 1532-866X
J9 SEMIN ARTHRITIS RHEU
JI Semin. Arthritis Rheum.
PD AUG
PY 2012
VL 42
IS 1
BP 9
EP 16
DI 10.1016/j.semarthrit.2012.01.005
PG 8
WC Rheumatology
SC Rheumatology
GA 982GF
UT WOS:000307030300002
PM 22424813
ER
PT J
AU Byers, AL
Covinsky, KE
Barnes, DE
Yaffe, K
AF Byers, Amy L.
Covinsky, Kenneth E.
Barnes, Deborah E.
Yaffe, Kristine
TI Dysthymia and Depression Increase Risk of Dementia and Mortality Among
Older Veterans
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Dementia; depression; dysthymia; mortality
ID MILD COGNITIVE IMPAIRMENT; CARDIOVASCULAR HEALTH; LATE-LIFE;
ALZHEIMERS-DISEASE; VASCULAR-DISEASE; ELDERLY PERSONS; SYMPTOMS;
ASSOCIATION; WOMEN; DECLINE
AB Objective: To determine whether less severe depression spectrum diagnoses such as dysthymia, as well as depression, are associated with risk of developing dementia and mortality in a "real-world" setting. Design: Retrospective cohort study conducted using the Department of Veterans Affairs (VA) National Patient Care Database (1997-2007). Setting: VA medical centers in the United States. Participants: A total of 281,540 veterans aged 55 years and older without dementia at study baseline (1997-2000). Measurements: Depression status and incident dementia were ascertained from International Classification of Diseases, Ninth Revision codes during study baseline (1997-2000) and follow-up (2001-2007), respectively. Mortality was ascertained by time of death dates in the VA Vital Status File. Results: Ten percent of veterans had baseline diagnosis of depression and nearly 1% had dysthymia. The unadjusted incidence of dementia was 11.2% in veterans with depression, 10.2% with dysthymia and 6.4% with neither. After adjusting for demographics and comorbidities, patients diagnosed with dysthymia or depression were twice as likely to develop incident dementia compared with those with no dysthymia/depression (adjusted dysthymia hazard ratio [HR]: 1.96, 95% confidence interval [CI]: 1.71-2.25; and depression HR: 2.18, 95% CI: 2.08-2.28). Dysthymia and depression also were associated with increased risk of death (31.6% dysthymia and 32.9% depression versus 28.5% neither; adjusted dysthymia HR: 1.41, 95% CI: 1.31-1.53; and depression HR: 1.47, 95% CI: 1.43-1.51). Conclusions: Findings suggest that older adults with dysthymia or depression need to be monitored closely for adverse outcomes. Future studies should determine whether treatment of depression spectrum disorders may reduce risk of these outcomes. (Am J Geriatr Psychiatry 2012; 20:664-672)
C1 [Byers, Amy L.; Covinsky, Kenneth E.; Barnes, Deborah E.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Byers, Amy L.; Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Byers, AL (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116H, San Francisco, CA 94121 USA.
EM Amy.Byers@ucsf.edu
FU Department of Defense [W81XWH-05-2-0094]; National Institute of Mental
Health [K01 MH079093]; National Institute on Aging [AG031155, AG029812];
NARSAD
FX This work was supported by the Department of Defense (W81XWH-05-2-0094
[KY]) and the National Institute of Mental Health (K01 MH079093 [ALB]).
Drs. Yaffe and Covinsky are supported in part by K24 Midcareer
Investigator Awards from the National Institute on Aging (AG031155 [KY]
and AG029812 [KEC]). Dr. Barnes was supported in part by NARSAD.
NR 40
TC 32
Z9 35
U1 4
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2012
VL 20
IS 8
BP 664
EP 672
DI 10.1097/JGP.0b013e31822001c1
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 977UX
UT WOS:000306691400004
PM 21597358
ER
PT J
AU Schneider, B
Ercoli, L
Siddarth, P
Lavretsky, H
AF Schneider, Brooke
Ercoli, Linda
Siddarth, Prabha
Lavretsky, Helen
TI Vascular Burden and Cognitive Functioning in Depressed Older Adults
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Cerebrovascular risk factors; cognitive impairment; geriatric
depression; vascular disease
ID LATE-LIFE DEPRESSION; PRIMARY-CARE PATIENTS; SUBCORTICAL ISCHEMIC
DEPRESSION; CEREBROVASCULAR RISK-FACTORS; EXECUTIVE DYSFUNCTION;
GERIATRIC DEPRESSION; NEUROPSYCHIATRIC SYMPTOMS; CARDIOVASCULAR HEALTH;
RATING-SCALE; IMPAIRMENT
AB Background: Vascular burden is known to contribute to geriatric depression and cognitive impairment. The objective of our study was to evaluate the relationship between vascular burden and pattern of cognitive impairment in older adults with depression. Methods: Ninety-four community-dwelling older adults (mean age = 70.8 years; SD = 7.63) diagnosed with major depression were recruited to participate in the tai chi complementary use study aimed to improve antidepressant response to an antidepressant medication. All participants received comprehensive evaluations of depression, apathy, and vascular risk factors, and completed a battery of cognitive measures of memory, cognitive control, verbal fluency, and attention. Results: The severity of vascular burden was significantly correlated with depression severity and impaired performance on measures of cognitive control (i.e., inhibition/mental flexibility), and attention, but not memory or verbal fluency. Neither the severity of comorbid apathy nor medical illness burden was related to cognitive impairment. Conclusions: Vascular burden in older depressed adults contributes to cognitive impairment, particularly in domains of attention and cognitive control. Our findings suggest that aggressive treatment of vascular risk factors may reduce risk for further cognitive decline in depressed older adults. (Am J Geriatr Psychiatry 2012; 20:673-681)
C1 [Lavretsky, Helen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Schneider, Brooke] Greater Los Angeles VA Healthcare Ctr, Psychol Serv, Los Angeles, CA USA.
RP Lavretsky, H (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,C9-948A, Los Angeles, CA 90095 USA.
EM hlavrets@ucla.edu
RI Lavretsky, Helen/M-5711-2015
OI Lavretsky, Helen/0000-0001-9990-5085
FU NIH [MH077650, MH086481, AT003480]; Forest Research Institute;
Alzheimer's Prevention Research Foundation
FX This work was supported by the NIH grants MH077650, MH086481, and
AT003480 to Dr. Lavretsky. Research grants from the Forest Research
Institute; Alzheimer's Prevention Research Foundation.
NR 65
TC 4
Z9 4
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2012
VL 20
IS 8
BP 673
EP 681
DI 10.1097/JGP.0b013e31822ccd64
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 977UX
UT WOS:000306691400005
PM 21857219
ER
PT J
AU Brenes, GA
Miller, ME
Williamson, JD
McCall, WV
Knudson, M
Stanley, MA
AF Brenes, Gretchen A.
Miller, Michael E.
Williamson, Jeff D.
McCall, W. Vaughn
Knudson, Mark
Stanley, Melinda A.
TI A Randomized Controlled Trial of Telephone-Delivered
Cognitive-Behavioral Therapy for Late-Life Anxiety Disorders
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Anxiety; cognitive-behavioral therapy; elderly; generalized anxiety
disorder; panic disorder; telephone-delivered psychotherapy
ID WORKING ALLIANCE INVENTORY; OLDER-ADULTS; PRIMARY-CARE; PSYCHOMETRIC
PROPERTIES; MENTAL-DISORDERS; HEALTH SURVEY; SHORT-FORM; VALIDATION;
DEPRESSION; STATE
AB Objectives: Older adults face a number of barriers to receiving psychotherapy, such as a lack of transportation and access to providers. One way to overcome such barriers is to provide treatment by telephone. The purpose of this study was to examine the effects of cognitive behavioral therapy delivered by telephone (CBT-T) to older adults diagnosed with an anxiety disorder. Design: Randomized controlled trial. Setting: Participants' homes. Participants: Sixty participants age 60 and older with a diagnosis of generalized anxiety disorder, panic disorder, or anxiety disorder not otherwise specified. Intervention: CBT-T versus information-only comparison. Measurements: Coprimary outcomes included worry (Penn State Worry Questionnaire) and general anxiety (State Trait Anxiety Inventory). Secondary outcomes included clinician-rated anxiety (Hamilton Anxiety Rating Scale), anxiety sensitivity (Anxiety Sensitivity Index), depressive symptoms (Beck Depression Inventory), quality of life (SF-36), and sleep (Insomnia Severity Index). Assessments were completed prior to randomization, immediately upon completion of treatment, and 6 months after completing treatment. Results: CBT-T was superior to information-only in reducing general anxiety (ES = 0.71), worry (ES = 0.61), anxiety sensitivity (ES = 0.85), and insomnia (ES = 0.82) at the posttreatment assessment; however, only the reductions in worry were maintained by the 6-month follow-up assessment (ES = 0.80). Conclusions: These results suggest that CBT-T may be efficacious in reducing anxiety and worry in older adults, but additional sessions may be needed to maintain these effects. (Am J Geriatr Psychiatry 2012; 20:707-716)
C1 [Brenes, Gretchen A.; McCall, W. Vaughn] Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC 27157 USA.
[Miller, Michael E.] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Winston Salem, NC 27157 USA.
[Williamson, Jeff D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Gerontol & Geriatr Med, Winston Salem, NC 27157 USA.
[Knudson, Mark] Wake Forest Univ, Bowman Gray Sch Med, Dept Family & Community Med, Winston Salem, NC 27157 USA.
[Stanley, Melinda A.] Houston Ctr Qual Care & Utilizat Studies, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
RP Brenes, GA (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM gbrenes@wfubmc.edu
FU National Institute of Mental Health [MH65281, MH53932]; Wake Forest
University Claude D. Pepper Older Americans Independence Center
[P30-AG21332]; VA HSR&D Houston Center of Excellence [HFP90-020]
FX This research was supported by National Institute of Mental Health Grant
MH65281 to Gretchen A. Brenes, Wake Forest University Claude D. Pepper
Older Americans Independence Center (P30-AG21332), and National
Institute of Mental Health Grant MH53932 to Melinda A. Stanley. It was
also partly supported by the VA HSR&D Houston Center of Excellence
(HFP90-020). The content is solely the responsibility of the authors and
does not necessarily represent the official views of the NIMH, the NIH,
the Department of Veterans Affairs or Baylor College of Medicine. The
NIMH had no role in the design and conduct of the study; the collection,
management, analysis and interpretation of the data; or the preparation,
review or approval of the manuscript.
NR 39
TC 19
Z9 19
U1 4
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2012
VL 20
IS 8
BP 707
EP 716
DI 10.1097/JGP.0b013e31822ccd3e
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 977UX
UT WOS:000306691400009
PM 22828172
ER
PT J
AU Bakaeen, FG
Sethi, G
Wagner, TH
Kelly, R
Lee, K
Upadhyay, A
Thai, H
Juneman, E
Goldman, S
Holman, WL
AF Bakaeen, Faisal G.
Sethi, Gulshan
Wagner, Todd H.
Kelly, Rosemary
Lee, Kelvin
Upadhyay, Anjali
Hoang Thai
Juneman, Elizabeth
Goldman, Steven
Holman, William L.
TI Coronary Artery Bypass Graft Patency: Residents Versus Attending
Surgeons
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Proceedings Paper
CT Late-Breaking Clinical Trial Abstract Session on Congenital Heart
Surgery at the 48th Annual Meeting of the Society-of-Thoracic-Surgeons /
Surgical Motion Picture Session
CY JAN 28-FEB 01, 2012
CL Fort Lauderdale, FL
SP Soc Thorac Surg
ID VOLUME-OUTCOME RELATIONSHIP; TRAIN RESIDENTS; IMPACT; EXPERIENCE; LEVEL;
SAFE
AB Background. Data are limited regarding the patency of coronary artery bypass grafts performed by residents versus attending surgeons.
Methods. We analyzed data from a multicenter, randomized Veterans Affairs Cooperative Study in which the left internal mammary artery was used preferentially to graft the left anterior descending coronary artery, and the best remaining coronary vessel received (per random assignment) either a radial artery or a saphenous vein graft. The study vessel's 1-year graft patency was the primary outcome measure. Secondary outcomes included operative times, operative morbidity, mortality, repeat revascularization, cost, angina symptoms, and quality of life. Multivariate analyses were used to compare patient outcomes for residents versus attendings.
Results. Residents were designated as primary surgeons in 23% of cases (167 of 725). Among the 531 patients who had a 1-year angiogram, study graft patency rates for resident cases (n = 122) and attending cases (n = 409) were not significantly different (86% versus 90%, p = 0.22). Residents' cases had longer perfusion time (119 versus 105 minutes, p < 0.0001) and cross-clamp time (84 versus 68 minutes, p < 0.0001). After risk adjustment, all outcome measures did not differ between the two groups, and there was no apparent interaction effect between resident/attending designation and radial artery versus saphenous vein use or on-pump versus off-pump approach.
Conclusions. Surgeons in training perform coronary artery bypass surgery without compromising graft patency or patient outcomes. Ongoing evaluation of residents' performance and surgical outcomes is needed, given the major changes that are occurring in residency training. (Ann Thorac Surg 2012;94:482-8) (c) 2012 by The Society of Thoracic Surgeons
C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
St Lukes Episcopal Hosp, Texas Heart Inst, Div Cardiovasc Surg, Houston, TX USA.
Univ Arizona, Hlth Sci Ctr, Dept Cardiothorac Surg, Tucson, AZ USA.
Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
Univ Minnesota Hosp, Dept Cardiovasc Surg, Minneapolis, MN USA.
So Arizona Vet Affairs Hlth Care Syst, Tucson, AZ USA.
Univ Arizona, Tucson, AZ USA.
Univ Alabama Birmingham, Div Cardiothorac Surg, Birmingham, AL USA.
RP Bakaeen, FG (reprint author), Michael E DeBakey VAMC, Dept Cardiothorac Surg, OCL 112,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM fbakaeen@bcm.edu
NR 25
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD AUG
PY 2012
VL 94
IS 2
BP 482
EP 488
DI 10.1016/j.athoracsur.2012.04.039
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 977YA
UT WOS:000306700100031
PM 22698772
ER
PT J
AU Sarkar, U
Bonacum, D
Strull, W
Spitzmueller, C
Jin, N
Lopez, A
Giardina, TD
Meyer, AND
Singh, H
AF Sarkar, Urmimala
Bonacum, Doug
Strull, William
Spitzmueller, Christiane
Jin, Nancy
Lopez, Andrea
Giardina, Traber Davis
Meyer, Ashley N. D.
Singh, Hardeep
TI Challenges of making a diagnosis in the outpatient setting: a multi-site
survey of primary care physicians
SO BMJ QUALITY & SAFETY
LA English
DT Article
ID ADVERSE EVENTS; MALPRACTICE CLAIMS; FOLLOW-UP; MEDICAL-RECORDS; ERRORS;
NEGLIGENT; REFORM; SAFETY
AB Background: Although misdiagnosis in the outpatient setting leads to significant patient harm and wasted resources, it is not well studied. The authors surveyed primary care physicians (PCPs) about barriers to timely diagnosis in the outpatient setting and assessed their perceptions of diagnostic difficulty.
Methods: Surveys of PCPs practicing in an integrated health system across 10 geographically dispersed states in 2005. The survey elicited information on key cognitive failures (including in clinical knowledge or judgement) for a specific case, and solicited strategies for reducing diagnostic delays. Content analysis was used to categorise cognitive failures and strategies for improvement. The authors examined the extent and predictors of diagnostic difficulty, defined as reporting >5% patients difficult to diagnose.
Results: Of 1817 physicians surveyed, 1054 (58%) responded; 848 (80%) respondents primarily practiced in outpatient settings and had an assigned patient panel (inclusion sample). Inadequate knowledge (19.9%) was the most commonly reported cognitive factor. Half reported >5% of their patients were difficult to diagnose; more experienced physicians reported less diagnostic difficulty. In adjusted analyses, problems with information processing (information availability and time to review it) and the referral process were associated with greater diagnostic difficulty. Strategies for improvement most commonly involved workload issues (panel size, non-visit tasks).
Conclusions: PCPs report a variety of reasons for diagnostic difficulties in primary care practice. In this study, knowledge gaps appear to be a prominent concern. Interventions that address these gaps as well as practice level issues such as time to process diagnostic information and better subspecialty input may reduce diagnostic difficulties in primary care.
C1 [Sarkar, Urmimala; Jin, Nancy; Lopez, Andrea] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Sarkar, Urmimala; Jin, Nancy; Lopez, Andrea] Univ Calif San Francisco, San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94143 USA.
[Strull, William] Kaiser Permanente, Permanente Federat, Oakland, CA USA.
[Spitzmueller, Christiane] Univ Houston, Houston, TX USA.
[Giardina, Traber Davis; Meyer, Ashley N. D.; Singh, Hardeep] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA.
[Giardina, Traber Davis; Meyer, Ashley N. D.; Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
RP Sarkar, U (reprint author), Univ Calif San Francisco, Dept Med, SFGH Div Gen Internal Med, Ward 13, Box 1364,1001 Potrero,Bldg 10,Floor 3, San Francisco, CA 94143 USA.
EM usarkar@medsfgh.ucsf.edu
OI Davis Giardina, Traber/0000-0002-9184-6524; Meyer,
Ashley/0000-0001-7993-8584
FU Agency for Healthcare Research and Quality [K08 HS017594]; NIH
[K23CA125585]; Houston VA HSR&D Center of Excellence [HFP90-020]
FX Dr Sarkar is supported by the Agency for Healthcare Research and Quality
K08 HS017594. Dr. Singh is supported by an NIH K23 career development
award (K23CA125585), and in part by the Houston VA HSR&D Center of
Excellence (HFP90-020). Manuscript contents are solely the
responsibility of the authors and do not necessarily represent the
official views of the NIH or any of the other funders. None of the
funders had any role in design and conduct of the study; collection,
management, analysis or interpretation of the data; or preparation,
review or approval of the manuscript.
NR 30
TC 17
Z9 17
U1 2
U2 6
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD AUG
PY 2012
VL 21
IS 8
BP 641
EP 648
DI 10.1136/bmjqs-2011-000541
PG 8
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 977IH
UT WOS:000306649700005
PM 22626738
ER
PT J
AU Greenbaum, CJ
Beam, CA
Boulware, D
Gitelman, SE
Gottlieb, PA
Herold, KC
Lachin, JM
McGee, P
Palmer, JP
Pescovitz, MD
Krause-Steinrauf, H
Skyler, JS
Sosenko, JM
AF Greenbaum, Carla J.
Beam, Craig A.
Boulware, David
Gitelman, Stephen E.
Gottlieb, Peter A.
Herold, Kevan C.
Lachin, John M.
McGee, Paula
Palmer, Jerry P.
Pescovitz, Mark D.
Krause-Steinrauf, Heidi
Skyler, Jay S.
Sosenko, Jay M.
CA Type 1 Diabet TrialNet Study Grp
TI Fall in C-Peptide During First 2 Years From Diagnosis Evidence of at
Least Two Distinct Phases From Composite Type 1 Diabetes Trial Net Data
SO DIABETES
LA English
DT Article
ID BETA-CELL FUNCTION; ANTI-CD3 MONOCLONAL-ANTIBODY; NATURAL-HISTORY;
TOLERANCE-TEST; DOUBLE-BLIND; ONSET; INSULIN; MELLITUS; THERAPY; RISK
AB Interpretation of clinical trials to alter the decline in beta-cell function after diagnosis of type 1 diabetes depends on a robust understanding of the natural history of disease. Combining data from the Type 1 Diabetes TrialNet studies, we describe the natural history of beta-cell function from shortly after diagnosis through 2 years post study randomization, assess the degree of variability between patients, and investigate factors that may be related to C-peptide preservation or loss. We found that 93% of individuals have detectable C-peptide 2 years from diagnosis. In 11% of subjects, there was no significant fall from baseline by 2 years. There was a biphasic decline in C-peptide; the C-peptide slope was -0.0245 pmol/mL/month (95% CI -0.0271 to -0.0215) through the first 12 months and -0.0079 (-0.0113 to -0.0050) from 12 to 24 months (P < 0.001). This pattern of fall in C-peptide over time has implications for understanding trial results in which effects of therapy are most pronounced early and raises the possibility that there are time-dependent differences in pathophysiology. The robust data on the C-peptide obtained under clinical trial conditions should be used in planning and interpretation of clinical trials. Diabetes 61:2066-2073, 2012
C1 [Greenbaum, Carla J.] Benaroya Res Inst, Seattle, WA USA.
[Beam, Craig A.; Boulware, David] Univ S Florida, Dept Pediat, Tampa, FL 33620 USA.
[Gitelman, Stephen E.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
[Gottlieb, Peter A.] Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Aurora, CO USA.
[Herold, Kevan C.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA.
[Lachin, John M.; McGee, Paula; Krause-Steinrauf, Heidi] George Washington Univ, Ctr Biostat, Washington, DC USA.
[Palmer, Jerry P.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Palmer, Jerry P.] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
[Pescovitz, Mark D.] Indiana Univ, Dept Surg, Indianapolis, IN 46204 USA.
[Pescovitz, Mark D.] Indiana Univ, Dept Microbiol & Immunol, Indianapolis, IN 46204 USA.
[Skyler, Jay S.; Sosenko, Jay M.] Univ Miami, Diabet Res Inst, Miami, FL USA.
RP Greenbaum, CJ (reprint author), Benaroya Res Inst, Seattle, WA USA.
EM cjgreen@benaroyaresearch.org
RI Skyler, Jay/F-4211-2016
OI Lachin, John/0000-0001-9838-2841; Gallagher, Mary/0000-0002-5844-2309
FU National Institutes of Health (NIH) through the National Institute of
Diabetes and Digestive and Kidney Diseases; National Institute of
Allergy and Infectious Diseases; Eunice Kennedy Shriver National
Institute of Child Health and Human Development [U01-DK-061010,
U01-DK-061016, U01-DK-061034, U01-DK-061036, U01-DK-061040,
U01-DK-061041, U01-DK-061042, U01-DK-061055, U01-DK-061058,
U01-DK-084565, U01-DK-085453, U01-DK-085461, U01-DK-085463,
U01-DK-085466, U01-DK-085499, U01-DK-085505, U01-DK-085509,
HHSN267200800019C]; National Center for Research Resources
[UL1-RR-024131, UL1-RR-024139, UL1-RR-024153, UL1-RR-024975,
UL1-RR-024982, UL1-RR-025744, UL1-RR-025761, UL1-RR-025780,
UL1-RR-029890, UL1-RR-031986]; General Clinical Research Center Award
[M01-RR-00400]; Juvenile Diabetes Research Foundation International
(JDRF); American Diabetes Association (ADA)
FX The sponsor of the trial was the Type 1 Diabetes Trial Net Study Group.
Type I Diabetes Trial Net Study Group is a clinical trials network
funded by the National Institutes of Health (NIH) through the National
Institute of Diabetes and Digestive and Kidney Diseases, the National
Institute of Allergy and Infectious Diseases, and the Eunice Kennedy
Shriver National Institute of Child Health and Human Development,
through Cooperative Agreements U01-DK-061010, U01-DK-061016,
U01-DK-061034, U01-DK-061036, U01-DK-061040, U01-DK-061041,
U01-DK-061042, U01-DK-061055, U01-DK-061058, U01-DK-084565,
U01-DK-085453, U01-DK-085461, U01-DK-085463, U01-DK-085466,
U01-DK-085499, U01-DK-085505, U01-DK-085509, and Contract
HHSN267200800019C, the National Center for Research Resources, through
Clinical Translational Science Awards UL1-RR-024131, UL1-RR-024139,
UL1-RR-024153, UL1-RR-024975, UL1-RR-024982, UL1-RR-025744,
UL1-RR-025761, UL1-RR-025780, UL1-RR-029890, UL1-RR-031986, and General
Clinical Research Center Award M01-RR-00400, the Juvenile Diabetes
Research Foundation International (JDRF), and the American Diabetes
Association (ADA).
NR 33
TC 86
Z9 87
U1 2
U2 5
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD AUG
PY 2012
VL 61
IS 8
BP 2066
EP 2073
DI 10.2337/db11-1538
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 980KC
UT WOS:000306891100022
PM 22688329
ER
PT J
AU Hornsby, PJ
AF Hornsby, Peter J.
TI Adrenarche: a cell biological perspective
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Review
ID EMBRYONIC STEM-CELLS; ADRENOCORTICAL-CELLS; STEROIDOGENIC CELLS;
ZONA-RETICULARIS; DEHYDROEPIANDROSTERONE-SULFATE; ANDROGEN PRODUCTION;
MESENCHYMAL CELLS; SONIC HEDGEHOG; IN-VIVO; DIFFERENTIATION
AB Adrenarche is a cell biological and endocrinological puzzle. The differentiation of the zona reticularis in childhood in humans requires special techniques for study because it is confined to humans and possibly a small number of other primates. Despite the rapid progress in the definition of adrenocortical stem/progenitor cells in the mouse, the factors that cause the differentiation of adrenocortical cells into zonal cell types have not been identified. There are, however, many candidates in the Wnt, Hedgehog, and other families of signaling molecules. A suitable system for identifying authentic stem cells, capable of differentiation into all zones, has yet to be developed. It is proposed here that the in vitro differentiation of pluripotent cells, combined with appropriate in vitro and in vivo methods for validating authentic adrenocortical stem cells, is a promising approach to solving these questions. Journal of Endocrinology (2012) 214, 113-119
C1 [Hornsby, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA.
[Hornsby, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Hornsby, Peter J.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Hornsby, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM hornsby@uthscsa.edu
NR 53
TC 4
Z9 4
U1 0
U2 3
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 0022-0795
J9 J ENDOCRINOL
JI J. Endocrinol.
PD AUG
PY 2012
VL 214
IS 2
BP 113
EP 119
DI 10.1530/JOE-12-0022
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 976CR
UT WOS:000306558600002
PM 22573830
ER
PT J
AU Germain, A
Richardson, R
Moul, D
Mammen, O
Haas, G
Forman, S
Rode, N
Begley, A
Nofzinger, E
AF Germain, Anne
Richardson, Robin
Moul, Douglas
Mammen, Oommen
Haas, Gretchen
Forman, Steven
Rode, Noelle
Begley, Amy
Nofzinger, Eric
TI Response to Dr. Mommersteeg and colleagues on Germain et al.,
"Placebo-controlled comparison of prazosin and cognitive-behavioral
treatments for sleep disturbances in US Military Veterans"
SO JOURNAL OF PSYCHOSOMATIC RESEARCH
LA English
DT Letter
ID QUALITY INDEX ADDENDUM; INSOMNIA; PTSD
C1 [Germain, Anne] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
Cleveland Clin Fdn, Sleep Disorders Ctr, Neurol Inst, Cleveland, OH 44195 USA.
VA Pittsburgh Healthcare Syst, MIRECC VSN4, Pittsburgh, PA USA.
RP Germain, A (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
EM germax@upmc.edu
NR 10
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3999
J9 J PSYCHOSOM RES
JI J. Psychosomat. Res.
PD AUG
PY 2012
VL 73
IS 2
BP 154
EP 155
DI 10.1016/j.jpsychores.2012.05.004
PG 2
WC Psychiatry
SC Psychiatry
GA 977BZ
UT WOS:000306632700014
ER
PT J
AU Little, EC
Wang, CD
Watson, PM
Watson, DK
Cole, DJ
Camp, ER
AF Little, Elizabeth C.
Wang, Cindy
Watson, Patricia M.
Watson, Dennis K.
Cole, David J.
Camp, E. Ramsay
TI Novel Immunocompetent Murine Models Representing Advanced Local and
Metastatic Pancreatic Cancer
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE pancreatic cancer; murine model; gemcitabine
ID IN-VIVO; TUMOR BURDEN; ANTITUMOR IMMUNITY; MOUSE MODELS; CELLS; MICE;
GEMCITABINE; INDUCTION; SURVIVAL; GROWTH
AB Background. The development of novel therapeutics for pancreatic cancer has been hindered by a lack of relevant preclinical models. The purpose of this study was to evaluate the clinical relevancy of two pancreatic cancer models using standard-of-care therapeutic agent gemcitabine.
Materials and Methods. Murine Panc02 cells were injected directly into the spleen or pancreas of C57BL/6 mice to respectively create models of metastatic and locally advanced pancreatic cancer. Beginning 7 d post-Panc02 injection, treated mice received 20 mg/kg gemcitabine i.p. every 3 d. Animals were sacrificed when the untreated mice became moribund and tumor/liver weight used to assess tumor burden.
Results. Untreated mice became moribund 22 d after pancreatic Panc02 injection. Gross analysis revealed localized pancreatic tumors weighing 1.063 g. Intrasplenic Panc02 injection produced extensive liver metastasis by d 15 when the untreated mice first became moribund. Liver weights at this time averaged 3.6 g compared with the average non-tumor-bearing weight of 1.23 g. Gemcitabine therapy resulted in a 54% decrease in localized pancreatic tumor weight and 62.5% decrease in metastatic liver weight. Additionally, gemcitabine therapy extended animal survival to 20.5 d compared with 18.0 d average for the untreated mice.
Conclusions. We describe two models depicting both locally advanced and metastatic pancreatic cancer in immunocompetent mice. In efforts to establish baseline therapeutic efficacy, we determined that gemcitabine reduces tumor burden in both models and enhances survival in the metastatic model. These clinically relevant models provide valuable tools to evaluate novel therapeutics in pancreatic cancer. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Wang, Cindy; Cole, David J.; Camp, E. Ramsay] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
[Watson, Patricia M.; Watson, Dennis K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Little, Elizabeth C.; Cole, David J.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Watson, Dennis K.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Little, Elizabeth C.; Wang, Cindy; Watson, Patricia M.; Watson, Dennis K.; Cole, David J.; Camp, E. Ramsay] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
[Camp, E. Ramsay] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, 25 Courtenay Dr,Room 7018,MSC795, Charleston, SC 29425 USA.
EM campe@musc.edu
FU National Institutes of Health [5R01CA123159-05, 1K08CA142904]
FX The authors thank Dr. Michael Rosol at the Small Animal Imaging Core
Facility at MUSC for his assistance with bioluminescence imaging. This
research was supported by the National Institutes of Health,
5R01CA123159-05 (DJC, DKW) and 1K08CA142904 (ERC).
NR 28
TC 8
Z9 9
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD AUG
PY 2012
VL 176
IS 2
BP 359
EP 366
DI 10.1016/j.jss.2011.10.025
PG 8
WC Surgery
SC Surgery
GA 975EC
UT WOS:000306488700007
PM 22221605
ER
PT J
AU Davidson, BP
Giraud, GD
AF Davidson, Brian P.
Giraud, George D.
TI Left Ventricular Function and the Systemic Arterial Vasculature:
Remembering What We Have Learned
SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
LA English
DT Editorial Material
ID PRESERVED EJECTION FRACTION; HEART-FAILURE; FILLING PRESSURE; INTACT
HEART; FORCE; LOAD
C1 [Giraud, George D.] Portland VA Med Ctr, Cardiol Sect, Portland, OR 97207 USA.
Oregon Hlth & Sci Univ, Dept Med, Div Cardiovasc Med, Portland, OR USA.
RP Giraud, GD (reprint author), Portland VA Med Ctr, Cardiol Sect, P3Card,POB 1034, Portland, OR 97207 USA.
EM giraudg@ohsu.edu
FU NHLBI NIH HHS [R01 HL102763, T32HL094294, T32 HL094294, R21 HL093617];
NICHD NIH HHS [P01 HD034430, P01 HD 34430]
NR 22
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0894-7317
J9 J AM SOC ECHOCARDIOG
JI J. Am. Soc. Echocardiogr.
PD AUG
PY 2012
VL 25
IS 8
BP 891
EP 894
DI 10.1016/j.echo.2012.06.020
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 977KJ
UT WOS:000306657900014
PM 22824174
ER
PT J
AU Schittone, SA
Dionne, KR
Tyler, KL
Clarke, P
AF Schittone, Stephanie A.
Dionne, Kalen R.
Tyler, Kenneth L.
Clarke, Penny
TI Activation of Innate Immune Responses in the Central Nervous System
during Reovirus Myelitis
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TOLL-LIKE RECEPTOR; ACUTE FLACCID PARALYSIS; ASTROCYTIC METABOLIC
PHENOTYPE; INTERFERON-STIMULATED GENES; THEILERS VIRUS-INFECTION;
NECROSIS-FACTOR-ALPHA; SPINAL-CORD; NEURODEGENERATIVE DISEASES;
MAMMALIAN REOVIRUS; ANIMAL-MODELS
AB Reovirus infection of the murine spinal cord (SC) was used as a model system to investigate innate immune responses during viral myelitis, including the activation of glia (microglia and astrocytes) and interferon (IFN) signaling and increased expression of inflammatory mediators. Reovirus myelitis was associated with the pronounced activation of SC glia, as evidenced by characteristic changes in cellular morphology and increased expression of astrocyte and microglia-specific proteins. Expression of inflammatory mediators known to be released by activated glia, including interleukin-1 beta (IL-1 beta), tumor necrosis factor alpha (TNF-alpha), chemokine (C-C motif) ligand 5 (CCL 5), chemokine (C-X-C motif) ligand 10 (CXCL10), and gamma interferon (IFN-gamma), was also significantly upregulated in the SC of reovirus-infected animals compared to mock-infected controls. Reovirus infection of the mouse SC was also associated with increased expression of genes involved in IFN signaling, including IFN-stimulated genes (ISG). Further, reovirus infection of mice deficient in the expression of the IFN-alpha/beta receptor (IFNAR(-/-)) resulted in accelerated mortality, demonstrating that IFN signaling is protective during reovirus myelitis. Experiments performed in ex vivo SC slice cultures (SCSC) confirmed that resident SC cells contribute to the production of at least some of these inflammatory mediators and ISG during reovirus infection. Microglia, but not astrocytes, were still activated, and glia-associated inflammatory mediators were still produced in reovirus-infected INFAR(-/-) mice, demonstrating that IFN signaling is not absolutely required for these neuroinflammatory responses. Our results suggest that activated glia and inflammatory mediators contribute to a local microenvironment that is deleterious to neuronal survival.
C1 [Schittone, Stephanie A.; Dionne, Kalen R.; Tyler, Kenneth L.; Clarke, Penny] Univ Colorado, Dept Neurol, Aurora, CO 80045 USA.
[Schittone, Stephanie A.; Tyler, Kenneth L.] Univ Colorado, Dept Microbiol, Aurora, CO USA.
[Dionne, Kalen R.; Tyler, Kenneth L.] Univ Colorado, Dept Neurosci, Aurora, CO USA.
[Tyler, Kenneth L.] Univ Colorado, Dept Med, Aurora, CO USA.
[Dionne, Kalen R.; Tyler, Kenneth L.] Univ Colorado, Med Scientist Training Program, Aurora, CO USA.
[Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Clarke, P (reprint author), Univ Colorado, Dept Neurol, Anshutz Med Campus, Aurora, CO 80045 USA.
EM Penny.Clarke@ucdenver.edu
OI Tyler, Kenneth/0000-0003-3294-5888
FU NIH [R01 NS076512, F31 NS06258303, F30 NS071630, T32 GM008497]; VA merit
grant; NIH/NCRR Colorado CTSI [UL1 RR025780]
FX This publication was supported by NIH grants R01 NS076512 (K.L.T.), F31
NS06258303 (S.A.S.), F30 NS071630 (K.R.D.), and T32 GM008497 (K.R.D.)
and by a VA merit grant (K.L.T.). K.L.T. is supported by the
Reuler-Lewin Family Professorship. The Advanced Microscopy Core at the
Division of Renal Disease and Hypertension, University of Colorado
School of Medicine is funded by NIH/NCRR Colorado CTSI grant number UL1
RR025780.
NR 80
TC 6
Z9 7
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD AUG
PY 2012
VL 86
IS 15
BP 8107
EP 8118
DI 10.1128/JVI.00171-12
PG 12
WC Virology
SC Virology
GA 976VE
UT WOS:000306614400035
PM 22623770
ER
PT J
AU Bhattacharya, D
Ansari, IH
Mehle, A
Striker, R
AF Bhattacharya, Dipankar
Ansari, Israrul H.
Mehle, Andrew
Striker, Rob
TI Fluorescence Resonance Energy Transfer-Based Intracellular Assay for the
Conformation of Hepatitis C Virus Drug Target NS5A
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NONSTRUCTURAL PROTEIN 5A; MEMBRANE ANCHOR; RNA REPLICATION; LIVING
CELLS; DOMAIN 3; IDENTIFICATION; CYCLOPHILINS; INHIBITOR; SUBSTRATE;
DYNAMICS
AB Nonstructural protein 5A (NS5A) is essential for hepatitis C virus (HCV) replication and assembly and is a critical drug target. Biochemical data suggest large parts of NS5A are unfolded as an isolated protein, but little is known about its folded state in the cell. We used fluorescence resonance energy transfer (FRET) to probe whether or not different regions of NS5A are in close proximity within the cell. Twenty-three separate reporter constructs were created by inserting one or more fluorophores into different positions throughout the three domains of NS5A. FRET efficiency was maximal when donor and acceptor fluorophores were positioned next to each other but also could be observed when the two fluorophores flanked NS5A domain I or domain 3. Informatic and biochemical analysis suggests that large portions of the carboxy terminus of NS5A are in an unfolded and disordered state. Quercetin, a natural product known to disrupt NS5A function in cells, specifically disrupted a conformationally specific domain 3 FRET signal. Intermolecular FRET indicated that the NS5A amino termini, but not other regions, are in close proximity in multimeric complexes. Overall, this assay provides a new window on the intracellular conformation(s) of NS5A and how the conformation changes in response to cellular and viral components of the replication and assembly complex as well as antiviral drugs.
C1 [Striker, Rob] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Bhattacharya, Dipankar; Ansari, Israrul H.; Striker, Rob] Univ Wisconsin, Dept Med, Madison, WI USA.
[Mehle, Andrew] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA.
RP Striker, R (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
EM rtstriker@wisc.edu
FU American Cancer Society [07-077-01]; Office of Research and Development,
Biomedical Laboratory R&D Service, Department of Veterans Affairs;
[R00GM088484]
FX This work was supported by the American Cancer Society Research Scholar
Grant (07-077-01) to R.S., by the Office of Research and Development,
Biomedical Laboratory R&D Service, Department of Veterans Affairs, and
by R00GM088484 to A.M.
NR 38
TC 6
Z9 6
U1 2
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD AUG
PY 2012
VL 86
IS 15
BP 8277
EP 8286
DI 10.1128/JVI.00645-12
PG 10
WC Virology
SC Virology
GA 976VE
UT WOS:000306614400050
PM 22623794
ER
PT J
AU Shamsi, KS
Pierce, A
Ashton, AS
Halade, DG
Richardson, A
Espinoza, SE
AF Shamsi, Kinza S.
Pierce, Anson
Ashton, Aaron S.
Halade, Dipti G.
Richardson, Arlan
Espinoza, Sara E.
TI Proteomic Screening of Glycoproteins in Human Plasma for Frailty
Biomarkers
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE Proteomics; Frailty
ID HUMAN SERUM; AFFINITY-CHROMATOGRAPHY; ALZHEIMERS-DISEASE;
MASS-SPECTROMETRY; OLDER-ADULTS; INFLAMMATION; COAGULATION;
GLYCOSYLATION; ACTIVATION; AMERICAN
AB The application of proteomics methodology for analyzing human blood samples is of increasing importance as a noninvasive method for understanding, detecting, and monitoring disease. In particular, glycoproteomic analysis may be useful in the study of age-related diseases and syndromes, such as frailty. This study demonstrates the use of methodology for isolating plasma glycoproteins using lectins, comparing the glycoproteome by frailty status using two-dimensional polyacrylamide gel electrophoresis and identifying glycoproteins using mass spectrometry. In a pilot study, we found seven glycoproteins to differ by at least twofold in prefrail compared with nonfrail older adults, including haptoglobin, transferrin, and fibrinogen, consistent with known inflammatory and hematologic changes associated with frailty. Enzyme-linked immunosorbent assay analysis found that plasma transferrin concentration was increased in frail and prefrail older adults compared with nonfrail, confirming our proteomic findings. This work provides evidence for using a reproducible methodology for conducting clinical proteomic comparative studies of age-related diseases.
C1 [Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Div Geriatr Gerontol & Palliat Med, Dept Med, San Antonio, TX 78229 USA.
[Shamsi, Kinza S.; Ashton, Aaron S.; Richardson, Arlan; Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Pierce, Anson] Univ Texas Galveston, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77550 USA.
[Halade, Dipti G.; Richardson, Arlan; Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Halade, Dipti G.; Richardson, Arlan; Espinoza, Sara E.] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
RP Espinoza, SE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Div Geriatr Gerontol & Palliat Med, Dept Med, 7703 Floyd Curl Dr,Mail Code 7875, San Antonio, TX 78229 USA.
EM espinozas2@uthscsa.edu
RI Pierce, Anson/D-1079-2012
OI Pierce, Anson/0000-0002-1383-0180
FU Veterans Affairs Research & Development (VISN 17 New Investigator Award)
[10N17]; San Antonio Area Foundation; Biomedical Research Foundation of
South Texas; University Research Council of the University of Texas
Health Science Center at San Antonio; National Center for Research
Resources [KL2 RR025766]
FX This work was supported by Veterans Affairs Research & Development (VISN
17 New Investigator Award, #10N17), the San Antonio Area Foundation, the
Biomedical Research Foundation of South Texas, The University Research
Council of the University of Texas Health Science Center at San Antonio,
and The Clinical and Translational Science Award (KL2 RR025766) from the
National Center for Research Resources.
NR 36
TC 9
Z9 10
U1 1
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD AUG
PY 2012
VL 67
IS 8
BP 853
EP 864
DI 10.1093/gerona/glr224
PG 12
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 977CE
UT WOS:000306633200005
PM 22219522
ER
PT J
AU Marcum, ZA
Pugh, MJV
Amuan, ME
Aspinall, SL
Handler, SM
Ruby, CM
Hanlon, JT
AF Marcum, Zachary A.
Pugh, Mary Jo V.
Amuan, Megan E.
Aspinall, Sherrie L.
Handler, Steven M.
Ruby, Christine M.
Hanlon, Joseph T.
TI Prevalence of Potentially Preventable Unplanned Hospitalizations Caused
by Therapeutic Failures and Adverse Drug Withdrawal Events Among Older
Veterans
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE Drug-related problems; Hospitalizations; Veterans
ID DISCONTINUING MEDICATIONS; CARE; QUALITY; POPULATION; ADMISSIONS;
MORTALITY; INDICATOR; PEOPLE; RISK
AB Background. Studies of drug-related hospitalizations have focused on adverse drug reactions, but few data are available on therapeutic failures (TFs) and adverse drug withdrawal events (ADWEs) leading to hospitalization among community-dwelling older adults. Thus, we sought to describe the prevalence of unplanned hospitalizations caused by TFs and ADWEs. In addition, we evaluated factors associated with these events in a nationally representative sample of older Veterans.
Methods. This study included 678 randomly selected unplanned hospitalizations of older (age >= 65 years) Veterans between December 1, 2003, and November 9, 2006. The main outcomes were hospitalizations caused by a TF and/or an ADWE as determined by a pair of health professionals from review of medication charts and application of the Therapeutic Failure Questionnaire and/or Naranjo ADWE algorithm, respectively. Preventability (ie, medication error) of the admission was also assessed.
Results. Thirty-four TFs and eight ADWEs involving 54 drugs were associated with 40 (5.9%) Veterans' hospitalizations; of these admissions, 90.0% (36/40) were rated as potentially preventable mostly due to medication nonadherence and suboptimal prescribing. The most common TFs that occurred were heart failure exacerbations (n = 8), coronary heart disease symptoms (n = 6), tachyarrhythmias (n = 3), and chronic obstructive pulmonary disease exacerbations (n = 3). Half (4/8) of the ADWEs that occurred were cardiovascular in nature. Multivariable logistic regression modeling indicated that black Veterans (adjusted odds ratio 2.92, 95% CI 1.25-6.80) were significantly more likely to experience a TF-related admission compared with white Veterans.
Conclusions. TF-related unplanned hospitalizations occur more frequently than ADWE-related admissions among older Veterans. Almost all TFs and/or ADWEs are potentially preventable.
C1 [Marcum, Zachary A.; Handler, Steven M.; Ruby, Christine M.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med Geriatr, Dept Med, Pittsburgh, PA 15213 USA.
[Marcum, Zachary A.; Aspinall, Sherrie L.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Pugh, Mary Jo V.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr & Gerontol, San Antonio, TX 78229 USA.
[Amuan, Megan E.] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Aspinall, Sherrie L.; Ruby, Christine M.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA.
[Aspinall, Sherrie L.] Vet Affairs Ctr Medicat Safety, Hines, IL USA.
[Handler, Steven M.] Univ Pittsburgh, Sch Med Biomed Informat, Dept Med, Pittsburgh, PA 15213 USA.
RP Marcum, ZA (reprint author), Univ Pittsburgh, Sch Med, Dept Med Geriatr, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA.
EM zam12@pitt.edu
OI Handler, Steven/0000-0002-3940-3224
FU VA Health Services Research and Development Service [IIR-06-062];
National Institute on Aging [R01AG027017, P30AG024827, T32 AG021885,
K07AG033174, R01AG034056]; National Institute of Mental Health [R34
MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency
for Healthcare Research and Quality [R01 HS017695, R01HS018721];
National Institutes of Health, National Institute on Aging
[N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]
FX This work was supported by a VA Health Services Research and Development
Service grant (IIR-06-062). Study investigators were also supported by
National Institute on Aging grants and contracts (R01AG027017 and
P30AG024827, T32 AG021885, K07AG033174, and R01AG034056), a National
Institute of Mental Health) grant (R34 MH082682), a National Institute
of Nursing Research grant (R01 NR010135), and an Agency for Healthcare
Research and Quality grant (R01 HS017695 and R01HS018721). This research
was also supported in part by the Intramural Research program of the
National Institutes of Health, National Institute on Aging
(N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106).
NR 35
TC 20
Z9 20
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD AUG
PY 2012
VL 67
IS 8
BP 867
EP 874
DI 10.1093/gerona/gls001
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 977CE
UT WOS:000306633200006
PM 22389461
ER
PT J
AU Horan, WP
Foti, D
Hajcak, G
Wynn, JK
Green, MF
AF Horan, W. P.
Foti, D.
Hajcak, G.
Wynn, J. K.
Green, M. F.
TI Impaired neural response to internal but not external feedback in
schizophrenia
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE Error-related negativity; event-related potential (ERP); feedback
negativity; reward sensitivity; schizophrenia
ID PSYCHIATRIC RATING-SCALE; STRIATAL REWARD PREDICTION; CINGULATE CORTEX
ACTIVITY; ERROR-RELATED NEGATIVITY; QUALITY-ASSURANCE; BRAIN ACTIVITY;
DYSFUNCTION; ACTIVATION; SENSITIVITY; PERFORMANCE
AB Background. Accurate monitoring and integration of both internal and external feedback is crucial for guiding current and future behavior. These aspects of performance monitoring are commonly indexed by two event-related potential (ERP) components: error-related negativity (ERN) and feedback negativity (FN). The ERN indexes internal response monitoring and is sensitive to the commission of erroneous versus correct responses, and the FN indexes external feedback monitoring of positive versus negative outcomes. Although individuals with schizophrenia consistently demonstrate a diminished ERN, the integrity of the FN has received minimal consideration.
Method. The current research sought to clarify the scope of feedback processing impairments in schizophrenia in two studies: study 1 examined the ERN elicited in a flanker task in 16 out-patients and 14 healthy controls; study 2 examined the EN on a simple monetary gambling task in expanded samples of 35 out-patients and 33 healthy controls.
Results. Study 1 replicated prior reports of an impaired ERN in schizophrenia. By contrast, patients and controls demonstrated comparable FN differentiation between reward and non-reward feedback in study 2.
Conclusions. The differential pattern across tasks suggests that basic sensitivity to external feedback indicating reward versus non-reward is intact in schizophrenia, at least under the relatively simple task conditions used in this study. Further efforts to specify intact and impaired reward-processing subcomponents in schizophrenia may help to shed light on the diminished motivation and goal-seeking behavior that are commonly seen in this disorder.
C1 [Horan, W. P.; Wynn, J. K.; Green, M. F.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Foti, D.; Hajcak, G.] SUNY Stony Brook, Stony Brook, NY 11794 USA.
RP Horan, WP (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM horan@ucla.edu
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
FU NARSAD Young Investigator Award; NIMH [MH043292, MH065707]
FX Funding for this project came from a NARSAD Young Investigator Award (to
W.P.H.) and NIMH grants MH043292 and MH065707 (to M.F.G.)
NR 51
TC 20
Z9 20
U1 2
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
EI 1469-8978
J9 PSYCHOL MED
JI Psychol. Med.
PD AUG
PY 2012
VL 42
IS 8
BP 1637
EP 1647
DI 10.1017/S0033291711002819
PG 11
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 980JS
UT WOS:000306890100007
PM 22152069
ER
PT J
AU Marconescu, P
Graviss, EA
Musher, DM
AF Marconescu, Praveena
Graviss, Edward A.
Musher, Daniel M.
TI Rates of killing of methicillin-resistant Staphylococcus aureus by
ceftaroline, daptomycin, and telavancin compared to that of vancomycin
SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID IN-VITRO ACTIVITY; BACTEREMIA; INTERMEDIATE; STRAINS; IMPACT
AB Treatment failure of methicillin-resistant Staphylococcus aureus (MRSA) remains an important concern. In order to investigate new MRSA treatment modalities, we used standard time-kill assays to determine the in vitro killing rate of 22 strains of MRSA by vancomycin, telavancin, daptomycin, and ceftaroline. Studies were carried out with 7-10-times the minimum bactericidal concentrations of each antibiotic in broth culture for 24 h, with subculture at 4, 8, and 24 h. We found that killing by ceftaroline closely paralleled that of vancomycin. Telavancin killed bacteria significantly more slowly, whereas daptomycin killed significantly more rapidly.
C1 [Marconescu, Praveena; Musher, Daniel M.] ME DeBakey Vet Affairs Med Ctr, Houston, TX 77040 USA.
[Marconescu, Praveena] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA.
[Graviss, Edward A.; Musher, Daniel M.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA.
[Graviss, Edward A.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Graviss, Edward A.] Methodist Hosp, Res Inst, Dept Pathol & Genom Med, Houston, TX 77030 USA.
[Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
RP Musher, DM (reprint author), ME DeBakey Vet Affairs Med Ctr, 2002 Holcombe, Houston, TX 77040 USA.
EM daniel.musher@va.gov
NR 10
TC 11
Z9 11
U1 1
U2 8
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0036-5548
J9 SCAND J INFECT DIS
JI Scand. J. Infect. Dis.
PD AUG
PY 2012
VL 44
IS 8
BP 620
EP 622
DI 10.3109/00365548.2012.669843
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 976EL
UT WOS:000306563500011
PM 22668202
ER
PT J
AU Ma, Y
Shurin, GV
Gutkin, DW
Shurin, MR
AF Ma, Yang
Shurin, Galina V.
Gutkin, Dmitriy W.
Shurin, Michael R.
TI Tumor associated regulatory dendritic cells
SO SEMINARS IN CANCER BIOLOGY
LA English
DT Review
DE Dendritic cells; Cancer; Immunosuppression; Immune escape; Tolerance;
Immune regulatory cells
ID EXPRESSING INDOLEAMINE 2,3-DIOXYGENASE; ANTITUMOR IMMUNE-RESPONSES;
DRAINING LYMPH-NODES; CD4(+) T-CELLS; IN-VIVO; BREAST-CANCER; CUTTING
EDGE; MULTIPLE-MYELOMA; OVARIAN-CANCER; LUNG-CANCER
AB Immune effector and regulatory cells in the tumor microenvironment are key factors in tumor development and progression as the pathogenesis of cancer vitally depends on the multifaceted interactions between various microenvironmental stimuli provided by tumor-associated immune cells. Immune regulatory cells participate in all stages of cancer development from the induction of genomic instability to the maintenance of intratumoral angiogenesis, proliferation and spreading of malignant cells, and formation of premetastatic niches in distal tissues. Dendritic cells in the tumor microenvironment serve as a double-edged sword and, in addition to initiating potent anti-tumor immune responses, may mediate genomic damage, support neovascularization, block anti-tumor immunity and stimulate cancerous cell growth and spreading. Regulatory dendritic cells in cancer may directly and indirectly maintain antigen-specific and non-specific T cell unresponsiveness by controlling T cell polarization, MDSC and Treg differentiation and activity, and affecting specific microenvironmental conditions in premalignant niches. Understanding the mechanisms involved in regulatory dendritic cell polarization and operation and revealing pharmacological means for harnessing these pathways will provide additional opportunities for modifying the tumor microenvironment and improving the efficacy of different therapeutic approaches to cancer. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Ma, Yang; Shurin, Galina V.; Shurin, Michael R.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15261 USA.
[Gutkin, Dmitriy W.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Shurin, Michael R.] Univ Pittsburgh, Med Ctr, Dept Immunol, Pittsburgh, PA USA.
RP Shurin, MR (reprint author), Univ Pittsburgh, Med Ctr, Dept Pathol, 5735 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM shurinmr@upmc.edu
FU NCI NIH HHS [R01 CA154369, R01 CA154369-01A1]
NR 150
TC 34
Z9 40
U1 2
U2 31
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1044-579X
J9 SEMIN CANCER BIOL
JI Semin. Cancer Biol.
PD AUG
PY 2012
VL 22
IS 4
BP 298
EP 306
DI 10.1016/j.semcancer.2012.02.010
PG 9
WC Oncology
SC Oncology
GA 978FF
UT WOS:000306725300005
PM 22414911
ER
PT J
AU Salovich, JM
Vinson, PN
Sheffler, DJ
Lamsal, A
Utley, TJ
Blobaum, AL
Bridges, TM
Le, U
Jones, CK
Wood, MR
Daniels, JS
Conn, PJ
Niswender, CM
Lindsley, CW
Hopkins, CR
AF Salovich, James M.
Vinson, Paige N.
Sheffler, Douglas J.
Lamsal, Atin
Utley, Thomas J.
Blobaum, Anna L.
Bridges, Thomas M.
Le, Uyen
Jones, Carrie K.
Wood, Michael R.
Daniels, J. Scott
Conn, P. Jeffrey
Niswender, Colleen M.
Lindsley, Craig W.
Hopkins, Corey R.
TI Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide,
ML293, as a novel, selective and brain penetrant positive allosteric
modulator of the muscarinic 4 (M-4) receptor
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Positive allosteric modulator; M-4; ML293; CNS penetration; Muscarinic
receptor 4
ID CENTRAL-NERVOUS-SYSTEM; ACETYLCHOLINE-RECEPTORS; KNOCKOUT MICE
AB Herein we describe the discovery and development of a novel class of M-4 positive allosteric modulators, culminating in the discovery of ML293. ML293 exhibited modest potency at the human M4 receptor (EC50 = 1.3 mu M) and excellent efficacy as noted by the 14.6-fold leftward shift of the agonist concentration-response curve. ML293 was also selective versus the other muscarinic subtypes and displayed excellent in vivo PK properties in rat with low IV clearance (11.6 mL/min/kg) and excellent brain exposure (PO PBL, 10 mg/kg at 1 h, [Brain] = 10.3 mu M, B: P = 0.85). (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Salovich, James M.; Vinson, Paige N.; Sheffler, Douglas J.; Lamsal, Atin; Utley, Thomas J.; Blobaum, Anna L.; Bridges, Thomas M.; Le, Uyen; Jones, Carrie K.; Wood, Michael R.; Daniels, J. Scott; Conn, P. Jeffrey; Niswender, Colleen M.; Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
[Wood, Michael R.; Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA.
[Salovich, James M.; Vinson, Paige N.; Sheffler, Douglas J.; Lamsal, Atin; Utley, Thomas J.; Blobaum, Anna L.; Bridges, Thomas M.; Le, Uyen; Jones, Carrie K.; Wood, Michael R.; Daniels, J. Scott; Conn, P. Jeffrey; Niswender, Colleen M.; Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA.
[Salovich, James M.; Vinson, Paige N.; Sheffler, Douglas J.; Lamsal, Atin; Utley, Thomas J.; Blobaum, Anna L.; Bridges, Thomas M.; Le, Uyen; Jones, Carrie K.; Wood, Michael R.; Daniels, J. Scott; Conn, P. Jeffrey; Niswender, Colleen M.; Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Specialized Chem Ctr Probe Dev MLPCN, Nashville, TN 37232 USA.
[Jones, Carrie K.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37232 USA.
RP Hopkins, CR (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
EM corey.r.hopkins@vanderbilt.edu
FU NIMH NIH HHS [U19 MH097056, U54 MH084659, U54MH084659, R01 MH073676, U01
MH087965]
NR 15
TC 12
Z9 12
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 1
PY 2012
VL 22
IS 15
BP 5084
EP 5088
DI 10.1016/j.bmcl.2012.05.109
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 975BG
UT WOS:000306481100034
PM 22738637
ER
PT J
AU Teodorescu, M
Polomis, DA
Teodorescu, MC
Gangnon, RE
Peterson, AG
Consens, FB
Chervin, RD
Jarjour, NN
AF Teodorescu, Mihaela
Polomis, David A.
Teodorescu, Mihai C.
Gangnon, Ronald E.
Peterson, Andrea G.
Consens, Flavia B.
Chervin, Ronald D.
Jarjour, Nizar N.
TI Association of Obstructive Sleep Apnea Risk or Diagnosis with Daytime
Asthma in Adults
SO JOURNAL OF ASTHMA
LA English
DT Article
DE asthma; asthma control; obstructive sleep apnea; obstructive sleep apnea
risk; sleep
ID POSITIVE AIRWAY PRESSURE; HYPOXIA SUPPRESSES; NOCTURNAL ASTHMA; INDUCED
SPUTUM; DISEASE; QUESTIONNAIRE; INFLAMMATION; POPULATION; REFLUX; MODEL
AB Objective. Obstructive sleep apnea (OSA) worsens nocturnal asthma, but its potential impact on daytime asthma remains largely unassessed. We investigated whether the sleep disorder is associated with daytime, in addition to nighttime, asthma symptoms. Methods. Asthma patients at tertiary-care centers completed the Sleep Apnea scale of the Sleep Disorders Questionnaire (SA-SDQ), and an asthma control questionnaire. SA-SDQ scores >= 36 for males and >= 32 for females defined high OSA risk. Medical records were reviewed for established diagnosis of OSA and continuous positive airway pressure (CPAP) use. Results. Among 752 asthma patients, high OSA risk was associated similarly with persistent daytime and nighttime asthma symptoms (p < .0001 for each). A diagnosis of OSA was robustly associated with persistent daytime (p < .0001) in addition to nighttime (p = .0008) asthma symptoms. In regression models that included obesity and other known asthma aggravators, high OSA risk retained associations with persistent daytime (odds ratio [OR] = 1.96 [95% confidence interval [CI] = 1.31-2.94]) and nighttime (1.97 [1.32-2.94]) asthma symptoms. Diagnosed OSA retained an association with persistent daytime (2.08 [1.13-3.82]) but not with nighttime (1.48 [0.82-2.69]) asthma symptoms. CPAP use was associated with lower likelihood of persistent daytime symptoms (0.46 [0.23-0.94]). Conclusions. Questionnaire-defined OSA risk and historical diagnosis were each associated with persistent daytime asthma symptoms, to an extent that matched or exceeded associations with nighttime asthma symptoms. Unrecognized OSA may be a reason for persistent asthma symptoms during the day as well as the night.
C1 [Teodorescu, Mihaela; Polomis, David A.; Peterson, Andrea G.; Jarjour, Nizar N.] Univ Wisconsin, Sch Med & Publ Hlth, Sect Allergy Pulm & Crit Care Med, Madison, WI 53792 USA.
[Teodorescu, Mihaela; Teodorescu, Mihai C.] William S Middleton Mem Vet Adm Med Ctr, Med Serv, Madison, WI USA.
[Teodorescu, Mihai C.] Univ Wisconsin, Sch Med & Publ Hlth, Sect Geriatr & Gerontol, Madison, WI 53792 USA.
[Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat & Populat Hlth Sci, Madison, WI 53792 USA.
[Consens, Flavia B.; Chervin, Ronald D.] Univ Michigan Hlth Syst, Dept Neurol, Ann Arbor, MI USA.
[Consens, Flavia B.; Chervin, Ronald D.] Univ Michigan Hlth Syst, Sleep Disorders Ctr, Ann Arbor, MI USA.
RP Teodorescu, M (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Sect Allergy Pulm & Crit Care Med, K4-910 CSC 9988,600 Highland Ave, Madison, WI 53792 USA.
EM mt3@medicine.wisc.edu
FU National Institutes of Health [T32 NS007222, MO1 RR00042, 1UL1RR025011];
University of Wisconsin School of Medicine and Public Health, Medical
Education and Research Committee-New Investigator Award; University of
Wisconsin School of Medicine and Public Health Department of Medicine;
University of Michigan Department of Neurology Training Grant [T32
NS007222]; General Clinical Research Center [MO1 RR00042]; University of
Wisconsin School of Medicine and Public Health; Medical Education and
Research Committee-New Investigator Award; Department of Medicine;
Clinical and Translational Science Award (CTSA) program of the National
Center for Research Resources, National Institutes of Health
[1UL1RR025011]; William S. Middleton Memorial Veteran's Hospital,
Madison, Wisconsin; National Institutes of Health; Fox Foundation;
GlaxoSmithKline (GSK); Bristol Meyer Squib
FX Received funding support from the National Institutes of Health (nos.
T32 NS007222, MO1 RR00042, and 1UL1RR025011); the University of
Wisconsin School of Medicine and Public Health, Medical Education and
Research Committee-New Investigator Award; and the University of
Wisconsin School of Medicine and Public Health Department of Medicine.
Additional resources from the William S. Middleton Memorial Veteran's
Hospital, Madison, Wisconsin.; Funding support for this study was from
the University of Michigan Department of Neurology Training Grant (T32
NS007222) and General Clinical Research Center (MO1 RR00042); the
University of Wisconsin School of Medicine and Public Health, Medical
Education and Research Committee-New Investigator Award, Department of
Medicine, and 1UL1RR025011 from the Clinical and Translational Science
Award (CTSA) program of the National Center for Research Resources,
National Institutes of Health; and the William S. Middleton Memorial
Veteran's Hospital, Madison, Wisconsin.; Dr R.D. Chervin has received
research support from the National Institutes of Health and Fox
Foundation and has served on the advisory boards for Pavad Medical,
not-for-profit Sweet Dreamzzz, and the NHLBI (Sleep Disorders Research
Advisory Board). Chervin is a section editor for UpToDate, Inc.;
received support for educational purposes from Philips Respironics, Inc.
and Fisher Paykel, Inc.; and has consulted for Arena Pharmaceuticals,
Proctor & Gamble, and Zansors. Chervin serves on the Board of Directors
of the American Academy of Sleep Medicine and the International
Pediatric Sleep Association and is named in University of Michigan
patents for algorithms and devices to facilitate diagnosis and treatment
of sleep disorders.; Dr N.N. Jarjour received funding support from the
National Institutes of Health, GlaxoSmithKline (GSK), and Bristol Meyer
Squib, and received honorarium <$5000 from the Saudi Thoracic Society
for a GSK-supported continuing medical education program.
NR 49
TC 17
Z9 20
U1 1
U2 6
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0277-0903
EI 1532-4303
J9 J ASTHMA
JI J. Asthma
PD AUG
PY 2012
VL 49
IS 6
BP 620
EP 628
DI 10.3109/02770903.2012.689408
PG 9
WC Allergy; Respiratory System
SC Allergy; Respiratory System
GA 974IH
UT WOS:000306426300011
PM 22742082
ER
PT J
AU Ferrer, RA
Klein, WMP
Zajac, LE
Land, SR
Ling, BS
AF Ferrer, Rebecca A.
Klein, William M. P.
Zajac, Laura E.
Land, Stephanie R.
Ling, Bruce S.
TI An affective booster moderates the effect of gain- and loss-framed
messages on behavioral intentions for colorectal cancer screening
SO JOURNAL OF BEHAVIORAL MEDICINE
LA English
DT Article
DE Message framing; Anticipated emotion; Anticipatory emotion; Colorectal
cancer screening
ID RISK PERCEPTIONS; HEALTH BEHAVIOR; ANTICIPATED REGRET; DECISION-MAKING;
INFLUENZA VACCINATION; FEAR APPEALS; BREAST; WORRY; MAMMOGRAPHY;
PREVENTION
AB Previous research has demonstrated that loss-framed messages are more effective than gain-framed messages in motivating detection behaviors such as screening. The present study examined whether affective context moderates the degree to which message frame is associated with behavioral intentions to engage in colorectal cancer screening. In particular, we buttressed a framing manipulation with an "affective booster" to increase anticipated and anticipatory emotions associated with the framed messages. Consistent with previous research, we found that loss-framed messages are more effective in increasing intentions to screen. However, we found that among individuals who received gain-framed messages (but not loss-framed messages), the affective booster increased message persuasiveness. This effect on intentions was partially mediated by self-efficacy for engaging in screening. This study indicates that in the presence of emotional boosters, loss-framed messages may lose their advantage over gain-framed messages in motivating detection behaviors, and that self-efficacy may partially explain these effects.
C1 [Ferrer, Rebecca A.; Klein, William M. P.] NCI, Behav Res Program, Div Canc Control & Populat Sci, Rockville, MD 20852 USA.
[Klein, William M. P.; Zajac, Laura E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
[Land, Stephanie R.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
[Ling, Bruce S.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Ferrer, RA (reprint author), NCI, Behav Res Program, Div Canc Control & Populat Sci, 6130 Execut Blvd,Room 4083, Rockville, MD 20852 USA.
EM ferrerra@mail.nih.gov
NR 63
TC 8
Z9 8
U1 4
U2 27
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0160-7715
J9 J BEHAV MED
JI J. Behav. Med.
PD AUG
PY 2012
VL 35
IS 4
BP 452
EP 461
DI 10.1007/s10865-011-9371-3
PG 10
WC Psychology, Clinical
SC Psychology
GA 974KS
UT WOS:000306434500009
PM 21850516
ER
PT J
AU Hunt, KJ
Gebregziabher, M
Egede, LE
AF Hunt, Kelly J.
Gebregziabher, Mulugeta
Egede, Leonard E.
TI Racial and Ethnic Differences in Cardio-Metabolic Risk in Individuals
with Undiagnosed Diabetes: National Health and Nutrition Examination
Survey 1999-2008
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE undiagnosed diabetes; disparities; cardio-metabolic risk; HbA1c
ID IMPAIRED GLUCOSE-TOLERANCE; CARDIOVASCULAR-DISEASE; FASTING GLUCOSE;
CORONARY-DISEASE; US POPULATION; ADULTS; PREVALENCE; MELLITUS; BLACK;
MEN
AB Although early recognition and treatment of diabetes may be essential to prevent complications, roughly one-fifth of diabetes remains undiagnosed.
Examine cardio-metabolic risk factors and their control in non-Hispanic white (NHW), non-Hispanic black (NHB) and Mexican American (MA) individuals with undiagnosed diabetes.
Nationally representative cross-sectional study of participants in the National Health and Nutrition Examination Survey (NHANES) continuous cycles conducted 1999 through 2008.
Of 22,621 non-pregnant individuals aged a parts per thousand yen20 years, 2521 had diagnosed diabetes. Of the remaining 20,100 individuals, 17,963 had HbA1c measured, 551 of whom were classified as having undiagnosed diabetes and comprise the study population.
Undiagnosed diabetes was defined as HbA1c a parts per thousand yenaEuro parts per thousand 6.5% without a self-report of physician diagnosed diabetes. Cardio-metabolic risk factor control was examined using regression methods for complex survey data.
Among individuals with undiagnosed diabetes, mean HbA1c level was 7.7% (95% CI: 7.5, 7.9), 19.3% (95% CI: 14.2, 24.3) smoked, 59.7% (95% CI: 54.5, 64.8%) had hypertension and 96.5% (95% CI: 94.6, 98.4%) had dyslipidemia. Lipid profiles were remarkably different across racial-ethnic groups: NHB had the highest LDL- and HDL-cholesterol, but the lowest triglycerides, while MA had the highest triglycerides and the lowest LDL-cholesterol. After adjusting for age, sex, NHANES examination cycle and use of either blood pressure or lipid medication, the odds of having blood pressure a parts per thousand yen130/80 mmHg was higher in NHB [1.92 (95% CI: 1.09, 3.55)] than NHW, while the odds of having LDL-cholesterol > 100 mg/dl was higher in NHW[2.93 (95% CI: 1.37, 6.24)] and NHB[3.34 (95% CI: 1.08, 10.3)] than MA.
In a nationally representative sample of individuals with undiagnosed diabetes, cardio-metabolic risk factor levels were high across all racial/ethnic groups, but NHB and MA had poorer control compared to NHW. Interventions that target identification of diabetes and treatment of cardio-metabolic risk factors are needed.
C1 [Hunt, Kelly J.; Gebregziabher, Mulugeta] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Hunt, Kelly J.; Gebregziabher, Mulugeta; Egede, Leonard E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Hunt, KJ (reprint author), Med Univ S Carolina, Div Biostat & Epidemiol, 135 Cannon St,Suite 302,POB 250835, Charleston, SC 29425 USA.
EM huntke@musc.edu
OI Gebregziabher, Mulugeta/0000-0002-4826-481X
FU Office of Research and Development; Department of Veterans Affairs;
Ralph H. Johnson VAMC; VA HSRD REAP [IIR-06-219]; National Center on
Minority Health and Health Disparities [R01-MD004251]
FX This material is based upon work supported in part by the Office of
Research and Development, Department of Veterans Affairs, and the Ralph
H. Johnson VAMC. Further support is provided through VA HSR&D REAP Award
(grant #IIR-06-219) as well as the National Center on Minority Health
and Health Disparities (R01-MD004251). The funding agency did not
participate in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; and preparation,
review, or approval of the manuscript.
NR 40
TC 11
Z9 11
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD AUG
PY 2012
VL 27
IS 8
BP 893
EP 900
DI 10.1007/s11606-012-2023-7
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 974LB
UT WOS:000306435500004
PM 22415867
ER
PT J
AU Zhang, Z
Xie, DW
Kurichi, JE
Streim, J
Zhang, GY
Stineman, MG
AF Zhang, Zi
Xie, Dawei
Kurichi, Jibby E.
Streim, Joel
Zhang, Guangyu
Stineman, Margaret G.
TI Mortality Predictive Indexes for the Community-Dwelling Elderly US
Population
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE mortality; prediction; score system; community; instrumental activities
of daily living.
ID NURSING-HOME RESIDENTS; QUALITY-OF-LIFE; OLDER-ADULTS; INSTRUMENTAL
ACTIVITIES; COGNITIVE IMPAIRMENT; FUNCTIONAL STATUS; METHODOLOGICAL
STANDARDS; HOSPITAL DISCHARGE; ADVANCED DEMENTIA; PHYSICAL FUNCTION
AB Few predictive indexes for long-term mortality have been developed for community-dwelling elderly populations. Parsimonious predictive indexes are important decision-making tools for clinicians, policy makers, and epidemiologists.
To develop 1-, 5-, and 10-year mortality predictive indexes for nationally representative community-dwelling elderly people.
Cohort study.
The Second Longitudinal Study of Aging (LSOA II).
Nationally representative civilian community-dwelling persons at least 70 years old. We randomly selected 60% of the sample for prediction development and used the remaining 40% for validation.
Sociodemographics, impairments, and medical diagnoses were collected from the LSOA II baseline interviews. Instrumental activities of daily living (IADLs) stages were derived to measure functional status. All-cause mortality was obtained from the LSOA II Linked Mortality Public-use File.
The analyses included 7,373 sample persons with complete data, among which mortality rates were 3.7%, 23.3%, and 49.8% for 1, 5, and 10 years, respectively. Four, eight, and ten predictors were identified for 1-, 5-, and 10-year mortality, respectively, in multiple logistic regression models to create three predictive indexes. Age, sex, coronary artery disease, and IADL stages were the most essential predictors for all three indexes. C-statistics of the three indexes were 0.72, 0.74, and 0.75 in the development cohort and 0.72, 0.72, and 0.74 in the validation cohort for 1-, 5-, and 10-year mortality, respectively. Five risk groups were defined based on the scores.
The 1-, 5-, and 10-year mortality indexes include parsimonious predictor sets maximizing ease of mortality prediction in community settings. Thus, they may provide valuable information for prognosis of elderly patients and guide the comparison of alternative interventions. Including IADL stage as a predictor yields simplified mortality prediction when detailed disease information is not available.
C1 [Zhang, Zi; Xie, Dawei; Kurichi, Jibby E.; Stineman, Margaret G.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Streim, Joel] Univ Penn, Dept Psychiat, Perelman Sch Med, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA.
[Streim, Joel] Philadelphia Vet Affairs Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA.
[Zhang, Guangyu] Univ Maryland, Dept Epidemiol & Biostat, College Pk, MD 20742 USA.
[Stineman, Margaret G.] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Stineman, MG (reprint author), Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, 904 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM mstinema@exchange.upenn.edu
FU National Institutes of Health [AG032420-01A1]
FX The research for this manuscript was supported by the National
Institutes of Health (AG032420-01A1). There are no personal conflicts of
interest of any of the authors, and no authors reported disclosures
beyond the funding source. The opinions and conclusions of the authors
are not necessarily those of the sponsoring agency or of the NCHS who is
responsible only for provision of the data.
NR 57
TC 9
Z9 9
U1 3
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD AUG
PY 2012
VL 27
IS 8
BP 901
EP 910
DI 10.1007/s11606-012-2027-3
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 974LB
UT WOS:000306435500005
PM 22422075
ER
PT J
AU Momplaisir, F
Long, JA
Badolato, G
Brady, KA
AF Momplaisir, Florence
Long, Judith A.
Badolato, Gia
Brady, Kathleen A.
TI The Role of Primary Care Physicians in Improving Colorectal Cancer
Screening in Patients with HIV
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE colorectal cancer screening; HIV; primary care; infectious diseases
specialists; model of care
ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; ADULTS; SPECIALIZATION;
DEATH; OLDER; AIDS
AB As HIV positive patients live longer, they become susceptible to the development of non-AIDS defining malignancies. Little is known about routine cancer screening practices in that population and the factors associated with cancer screening.
Evaluate 1) the proportion of patients with HIV who had any type of colorectal cancer (CRC) screening and 2) whether having a primary care physician (PCP) or seeking care in an integrated care practice is associated with higher CRC screening.
A cross-sectional chart abstraction study of patients with HIV enrolled in the Philadelphia Medical Monitoring Project (MMP).
MMP participants age 50 and older.
CRC screening defined as having a documented colonoscopy, sigmoidoscopy, barium enema, or fecal occult blood test after the age of 50.
Out of 123 chart abstractions performed, 115 had a complete clinical record from MMP. The majority of the population was male (71.3%), Black/Hispanic (73.8%) and between the age of 50 and 59 (71.3%). 45.2% of patients did not have a PCP. The overall proportion of patients who received CRC screening was 46.9%. Having a documented PCP was the only factor strongly associated with CRC screening. Rates of screening were 66.7% among those with a PCP versus 28.5% among those without a PCP (chi(2) p < 0.001). After adjusting for race, socioeconomic status, substance and alcohol abuse, the odds of getting CRC screening in those with a PCP was 4.59 (95% CI 2.01-10.48, p < 0.001). The type of practice where patients were enrolled into care was not associated with CRC screening.
Having a PCP significantly increases the likelihood of receiving CRC screening in patients with HIV. Competency in addressing primary care needs in HIV clinics will only become more important as patients with HIV age.
C1 [Momplaisir, Florence; Long, Judith A.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Long, Judith A.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Badolato, Gia; Brady, Kathleen A.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
RP Momplaisir, F (reprint author), Univ Penn, Div Gen Internal Med, Perelman Sch Med, 423 Guardian Dr,13th Floor,Blockley Hall, Philadelphia, PA 19104 USA.
EM fmo@mail.med.upenn.edu
FU Philadelphia Department of Public Health [U62 PS001608-01]; Centers for
Disease Control and Prevention [U62 PS001608-01]
FX Supported by funding by a cooperative agreement between the Philadelphia
Department of Public Health and the Centers for Disease Control and
Prevention (grant # U62 PS001608-01).
NR 14
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD AUG
PY 2012
VL 27
IS 8
BP 940
EP 944
DI 10.1007/s11606-012-2010-z
PG 5
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 974LB
UT WOS:000306435500010
PM 22370768
ER
PT J
AU Navathe, AS
Volpp, KG
Konetzka, RT
Press, MJ
Zhu, JS
Chen, W
Lindrooth, RC
AF Navathe, Amol S.
Volpp, Kevin G.
Konetzka, R. Tamara
Press, Matthew J.
Zhu, Jingsan
Chen, Wei
Lindrooth, Richard C.
TI A Longitudinal Analysis of the Impact of Hospital Service Line
Profitability on the Likelihood of Readmission
SO MEDICAL CARE RESEARCH AND REVIEW
LA English
DT Article
DE quality of care; Medicare; payment reform; intensity of services;
service line profitability; readmission rates
ID DUTY HOUR REFORM; BALANCED BUDGET ACT; LENGTH-OF-STAY; ADMINISTRATIVE
DATA; MEDICARE BENEFICIARIES; COMORBIDITY MEASURES; PROSPECTIVE PAYMENT;
STAFFING DECISIONS; COMPETING RISKS; COX REGRESSION
AB Quality of care may be linked to the profitability of admissions in addition to level of reimbursement. Prior policy reforms reduced payments that differentially affected the average profitability of various admission types. The authors estimated a Cox competing risks model, controlling for the simultaneous risk of mortality post discharge, to determine whether the average profitability of hospital service lines to which a patient was admitted was associated with the likelihood of readmission within 30 days. The sample included 12,705,933 Medicare Fee for Service discharges from 2,438 general acute care hospitals during 1997, 2001, and 2005. There was no evidence of an association between changes in average service line profitability and changes in readmission risk, even when controlling for risk of mortality. These findings are reassuring in that the profitability of patients' admissions did not affect readmission rates, and together with other evidence may suggest that readmissions are not an unambiguous quality indicator for in-hospital care.
C1 [Navathe, Amol S.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19146 USA.
[Navathe, Amol S.] Dept Hlth & Human Serv, Washington, DC USA.
[Navathe, Amol S.] Harvard Univ, Sch Med, Boston, MA USA.
[Volpp, Kevin G.; Chen, Wei] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Konetzka, R. Tamara] Univ Chicago, Chicago, IL 60637 USA.
[Press, Matthew J.] Weill Cornell Med Coll, New York, NY USA.
[Lindrooth, Richard C.] Univ Colorado Denver, Aurora, CO USA.
RP Navathe, AS (reprint author), Univ Penn, Wharton Sch, Dept Hlth Care Management, 3641 Locust Walk,Room 202, Philadelphia, PA 19146 USA.
EM amol@wharton.upenn.edu
RI Lindrooth, Richard/J-8607-2012
OI Lindrooth, Richard/0000-0001-9538-9749
FU Robert Wood Johnson Foundation's Health Care Financing and Organization
program
FX This research was funded, in part, by a grant from the Robert Wood
Johnson Foundation's Health Care Financing and Organization program.
NR 45
TC 3
Z9 3
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-5587
J9 MED CARE RES REV
JI Med. Care Res. Rev.
PD AUG
PY 2012
VL 69
IS 4
BP 414
EP 431
DI 10.1177/1077558712441085
PG 18
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 976TW
UT WOS:000306609400003
PM 22466577
ER
PT J
AU Frazier-Wood, AC
Garvey, WT
Dall, T
Honigberg, R
Pourfarzib, R
AF Frazier-Wood, Alexis C.
Garvey, W. Timothy
Dall, Tara
Honigberg, Robert
Pourfarzib, Ray
TI Opportunities for Using Lipoprotein Subclass Profile by Nuclear Magnetic
Resonance Spectroscopy in Assessing Insulin Resistance and Diabetes
Prediction
SO METABOLIC SYNDROME AND RELATED DISORDERS
LA English
DT Review
ID HOMEOSTASIS MODEL ASSESSMENT; LOW-DENSITY LIPOPROTEINS; PARTICLE-SIZE;
METABOLIC SYNDROME; FASTING GLUCOSE; GLOBAL BURDEN; UNITED-STATES;
FOLLOW-UP; RISK; ATHEROSCLEROSIS
AB The incidence of type 2 diabetes mellitus (T2DM) has reached epidemic levels, and current trends indicate that its prevalence will continue to rise. The development of T2DM can be delayed by several years, and may even be prevented, by identifying individuals at risk for T2DM and treating them with lifestyle modification and/or pharmacological therapies. There are a number of methods available for assessing the insulin resistance (IR) that characterizes, and is the precursor to, T2DM. However, current clinical methods for assessing IR, based on measures of plasma glucose and/or insulin are either laborious and time-consuming or show a low specificity. IR manifests its earliest measurable abnormalities through changes in lipoproteins, and thus we propose that by examining lipoprotein subclass profile, it may be possible to alert physicians and patients to a heightened risk of developing diabetes. This will allow us to institute appropriate lifestyle changes and treatment potentially to delay the onset or possibly prevent the progression to diabetes.
C1 [Frazier-Wood, Alexis C.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
[Frazier-Wood, Alexis C.] Univ Alabama Birmingham, Sect Stat Genet, Birmingham, AL 35294 USA.
[Frazier-Wood, Alexis C.] Univ Alabama Birmingham, Off Energet, Birmingham, AL 35294 USA.
[Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Honigberg, Robert; Pourfarzib, Ray] LipoScience Inc, Raleigh, NC USA.
RP Frazier-Wood, AC (reprint author), Univ Alabama Birmingham, Dept Epidemiol, RPHB 230P, Birmingham, AL 35294 USA.
EM lekkiwood@gmail.com
RI Frazier-Wood, Alexis (Lekki)/B-8053-2010
OI Frazier-Wood, Alexis (Lekki)/0000-0001-7616-2119
FU National Institutes of Health (NIH) [DK-038764, DK-083562]; Merit Review
program of the Department of Veterans Affairs; UAB Diabetes Research and
Training Center [P60DK079626]; NIH National Heart, Lung, and Blood
Institute grant [U01HL072524-04]
FX The authors acknowledge research support from the National Institutes of
Health (NIH; DK-038764, DK-083562) and the Merit Review program of the
Department of Veterans Affairs. We also gratefully acknowledge the
support of the UAB Diabetes Research and Training Center (P60DK079626).
Dr. Frazier-Wood is supported by NIH National Heart, Lung, and Blood
Institute grant U01HL072524-04.
NR 37
TC 6
Z9 6
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-4196
J9 METAB SYNDR RELAT D
JI Metab. Syndr. Relat. Disord.
PD AUG
PY 2012
VL 10
IS 4
BP 244
EP 251
DI 10.1089/met.2011.0148
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 976OR
UT WOS:000306594700002
PM 22533466
ER
PT J
AU Wilkinson, JE
Burmeister, L
Brooks, SV
Chan, CC
Friedline, S
Harrison, DE
Hejtmancik, JF
Nadon, N
Strong, R
Wood, LK
Woodward, MA
Miller, RA
AF Wilkinson, John E.
Burmeister, Lisa
Brooks, Susan V.
Chan, Chi-Chao
Friedline, Sabrina
Harrison, David E.
Hejtmancik, James F.
Nadon, Nancy
Strong, Randy
Wood, Lauren K.
Woodward, Maria A.
Miller, Richard A.
TI Rapamycin slows aging in mice
SO AGING CELL
LA English
DT Article
DE interventions; longevity pathology; TOR
ID AMES DWARF MICE; GENETICALLY HETEROGENEOUS MICE; LIFE-SPAN EXTENSION;
SIGNALING PATHWAY; CELL-CYCLE; TOR; TARGET; CANCER; AGE; RESTRICTION
AB Rapamycin increases lifespan in mice, but whether this represents merely inhibition of lethal neoplastic diseases, or an overall slowing in multiple aspects of aging is currently unclear. We report here that many forms of age-dependent change, including alterations in heart, liver, adrenal glands, endometrium, and tendon, as well as age-dependent decline in spontaneous activity, occur more slowly in rapamycin-treated mice, suggesting strongly that rapamycin retards multiple aspects of aging in mice, in addition to any beneficial effects it may have on neoplastic disease. We also note, however, that mice treated with rapamycin starting at 9 months of age have significantly higher incidence of testicular degeneration and cataracts; harmful effects of this kind will guide further studies on timing, dosage, and tissue-specific actions of rapamycin relevant to the development of clinically useful inhibitors of TOR action.
C1 [Wilkinson, John E.; Burmeister, Lisa; Friedline, Sabrina; Miller, Richard A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
[Burmeister, Lisa; Friedline, Sabrina; Miller, Richard A.] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA.
[Wilkinson, John E.] Univ Michigan, Unit Lab Anim Med, Ann Arbor, MI 48109 USA.
[Brooks, Susan V.; Wood, Lauren K.] Univ Michigan, Dept Mol & Integrat Physiol & Biomed Engn, Ann Arbor, MI 48109 USA.
[Chan, Chi-Chao] NEI, Histol Core, NIH, Bethesda, MD 20892 USA.
[Harrison, David E.] Jackson Lab, Bar Harbor, ME 04609 USA.
[Hejtmancik, James F.] NEI, Ophthalm Genet & Visual Funct Branch, NIH, Bethesda, MD 20892 USA.
[Nadon, Nancy] NIA, Div Aging Biol, Bethesda, MD 20892 USA.
[Woodward, Maria A.] Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Strong, Randy] S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78229 USA.
[Strong, Randy] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Miller, RA (reprint author), Univ Michigan, Dept Pathol, BSRB Room 3001,Box 2200,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.
EM millerr@umich.edu
OI Zaseck, Lauren/0000-0002-8604-0032
FU [AG022303]; [AG007996]; [AG013283]
FX This work was supported by grants AG022303, AG007996, and AG013283. We
thank Vivian Diaz, Lynn Winkleman, and Mike Astle for expert technical
assistance.
NR 35
TC 211
Z9 216
U1 2
U2 38
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
J9 AGING CELL
JI Aging Cell
PD AUG
PY 2012
VL 11
IS 4
BP 675
EP 682
DI 10.1111/j.1474-9726.2012.00832.x
PG 8
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 973ZY
UT WOS:000306400600014
PM 22587563
ER
PT J
AU Riegel, B
Ratcliffe, SJ
Sayers, SL
Potashnik, S
Buck, HG
Jurkovitz, C
Fontana, S
Weaver, TE
Weintraub, WS
Goldberg, LR
AF Riegel, Barbara
Ratcliffe, Sarah J.
Sayers, Steven L.
Potashnik, Sheryl
Buck, Harleah G.
Jurkovitz, Claudine
Fontana, Sarah
Weaver, Terri E.
Weintraub, William S.
Goldberg, Lee R.
TI Determinants of Excessive Daytime Sleepiness and Fatigue in Adults With
Heart Failure
SO CLINICAL NURSING RESEARCH
LA English
DT Article
DE fatigue; physical activity; exercise; diuretics; functional class;
excessive daytime sleepiness; heart failure
ID RANDOMIZED CONTROLLED-TRIAL; MODERATE-INTENSITY EXERCISE;
QUALITY-OF-LIFE; OLDER-ADULTS; WAKEFULNESS TEST; APNEA SYNDROME;
RISK-FACTORS; CONSEQUENCES; DISORDERS; HEALTH
AB Little is known about excessive daytime sleepiness (EDS) in heart failure (HF). The aim of this cross-sectional descriptive study was to describe the prevalence of EDS and factors associated with it in HF. A secondary purpose was to explore the correlates of fatigue. We enrolled a consecutive sample of 280 adults with a confirmed diagnosis of chronic HF from three outpatient settings in the northeastern United States. Patients with major depressive illness were excluded. Clinical, sociodemographic, behavioral, and perceptual factors were explored as possible correlates of EDS. Using an Epworth Sleepiness Scale score > 10, the prevalence of EDS was 23.6%. Significant determinants of EDS were worse sleep quality (p = .048), worse functional class (p = .004), not taking a diuretic (p = .005), and lack of physical activity (p = .04). Only sleep quality was associated with fatigue (p < .001). Sleep-disordered breathing was not significantly associated with EDS or with fatigue. These factors may be amenable to intervention.
C1 [Riegel, Barbara] Univ Penn, Sch Nursing, Biobehav Res Ctr, Philadelphia, PA 19104 USA.
[Sayers, Steven L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Ratcliffe, Sarah J.; Sayers, Steven L.; Goldberg, Lee R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Buck, Harleah G.] Penn State Univ, Sch Nursing, University Pk, PA 16802 USA.
[Jurkovitz, Claudine; Weintraub, William S.] Christiana Care Hlth Syst, Christiana Care Ctr Outcomes Res, Newark, DE USA.
[Weaver, Terri E.] Univ Illinois, Coll Nursing, Chicago, IL USA.
[Fontana, Sarah] Univ Penn, Heart Failure & Transplant Ctr, Philadelphia, PA 19104 USA.
[Goldberg, Lee R.] Univ Penn, Med Ctr, Heart Lung Transplant Program, Philadelphia, PA 19104 USA.
RP Riegel, B (reprint author), Univ Penn, Sch Nursing, Biobehav Res Ctr, 418 Curie Blvd, Philadelphia, PA 19104 USA.
EM briegel@nursing.upenn.edu
OI Goldberg, Lee/0000-0002-7906-9638
FU National Heart, Lung & Blood Institute [RO1 HL084394-01A1]; Philadelphia
Veterans Affairs Medical Center; VISN 4 Mental Illness Research,
Education, and Clinical Center (MIREC)
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
funded by a grant from the National Heart, Lung & Blood Institute (RO1
HL084394-01A1) and by the Philadelphia Veterans Affairs Medical Center,
VISN 4 Mental Illness Research, Education, and Clinical Center (MIREC).
NR 65
TC 11
Z9 12
U1 0
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1054-7738
J9 CLIN NURS RES
JI Clin. Nurs. Res.
PD AUG
PY 2012
VL 21
IS 3
BP 271
EP 293
DI 10.1177/1054773811419842
PG 23
WC Nursing
SC Nursing
GA 973QL
UT WOS:000306374800004
PM 21878581
ER
PT J
AU Alexander, KA
Coleman, CL
Deatrick, JA
Jemmott, LS
AF Alexander, Kamila A.
Coleman, Christopher L.
Deatrick, Janet A.
Jemmott, Loretta S.
TI Moving beyond safe sex to women-controlled safe sex: a concept analysis
SO JOURNAL OF ADVANCED NURSING
LA English
DT Article
DE concept analysis; gender equity; HIV; AIDS; sexuality; sexually
transmitted infections; unintended pregnancy; women-controlled safe sex
ID FEMALE-CONDOM USE; RANDOMIZED CONTROLLED-TRIAL; RISK-REDUCTION
HIERARCHY; FAMILY-PLANNING CLINICS; HIV PREVENTION METHODS; URBAN US
WOMEN; VAGINAL MICROBICIDE; BARRIER METHODS; DIAPHRAGM USERS;
UNITED-STATES
AB alexander k.a., coleman c.l., deatrick j.a. & jemmott l.s. (2011) Moving beyond safe sex to women-controlled safe sex: a concept analysis. Journal of Advanced Nursing68(6), 18581869. Abstract Aim. This paper is a report of a conceptual analysis of women-controlled safe sex. Background. Women bear disproportionate burdens from sexually related health compromising outcomes. Imbalanced societal gender and power positions contribute to high morbidities. The expression, women-controlled safe sex, aims to empower women to gain control of their sexual lives. Few researchers focus on contextualized socio-cultural definitions of sexual safety among women. Data sources. The sample included scientific literature from Scopus, CINAHL, PubMed, PsychINFO and Sociological Abstracts. Papers were published 20002010. Review methods. Critical analyses of literature about women-controlled safe sex were performed in May 2011 using Rodgers evolutionary concept analysis methods. The search focused on social and cultural influences on sexual practices aimed at increasing womens control over their sexual safety. Results. The analysis uncovered five attributes of women-controlled safe sex: technology; access to choices; women at-risk; condom migration panic; and communication. Three antecedents included: male partner influence; body awareness; and self-efficacy. Consequences were categorized as positive or negative. Nine surrogate terms included: empowerment; gender power; female-controlled sexual barrier method; microbicides; diaphragm; sexual negotiation and communication; female condom; women-initiated disease transmission prevention; and spermicides. Finally, a consensus definition was identified: a socio-culturally influenced multi-level process for initiating sexual safety by women deemed at-risk for sexually related dangers, usually sexually transmitted infections and/or HIV/AIDS. Conclusion. This concept analysis described current significance, uses, and applications of women-controlled safe sex in the scientific literature. The authors clarified its limited nature and conclude that additional conceptual refinement in nursing is necessary to influence womens health.
C1 [Alexander, Kamila A.; Deatrick, Janet A.; Jemmott, Loretta S.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
RP Alexander, KA (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
EM kamilaa@nursing.upenn.edu
FU NINR/NIH [T32NR007100, F31NR013121]
FX This work was supported by NINR/NIH Ruth L. Kirschstein NRSA Predoctoral
Fellowship and Research Training to Promote Health in Vulnerable
Populations (T32NR007100) and Award Number F31NR013121 (PI: Alexander).
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of
Nursing Research or the National Institutes of Health.
NR 77
TC 3
Z9 3
U1 2
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-2402
J9 J ADV NURS
JI J. Adv. Nurs.
PD AUG
PY 2012
VL 68
IS 8
BP 1858
EP 1869
DI 10.1111/j.1365-2648.2011.05881.x
PG 12
WC Nursing
SC Nursing
GA 972IX
UT WOS:000306271900018
PM 22111843
ER
PT J
AU Hirschmann, JV
Raugi, GJ
AF Hirschmann, Jan V.
Raugi, Gregory J.
TI Lower limb cellulitis and its mimics Part II. Conditions that simulate
lower limb cellulitis
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE carcinoma erysipeloides; dependent rubor; eczema; erythromelalgia; gout;
hereditary periodic fevers; lymphedema; necrotizing soft tissue
infections; venous disease
ID SERUM URIC-ACID; NECROTIZING FASCIITIS; PERIODIC SYNDROME;
ERYTHROMELALGIA; CARCINOMA; LIPODERMATOSCLEROSIS; ERYTHERMALGIA;
MANAGEMENT; MORTALITY; RISK
AB Several common conditions can mimic cellulitis, creating a potential for misdiagnosis and incorrect management. The most common disorders mistaken for lower limb cellulitis include venous eczema, lipodermatosclerosis, irritant dermatitis, and lymphedema. The dermatologist is often consulted when a patient has failed to respond to therapy, and a thorough knowledge of the differential diagnosis is essential. This article focuses on entities that can mimic cellulitis, with an emphasis of elements of the history and physical examination that can help to distinguish between lower limb cellulitis and its simulators. (J Am Acad Dermatol 2012; 67: 177. e1-9.)
C1 [Raugi, Gregory J.] VA Puget Sound Hlth Care Syst, Dermatol 111D, Dept Dermatol, Seattle, WA 98108 USA.
Univ Washington, Sch Med, Seattle, WA USA.
RP Raugi, GJ (reprint author), VA Puget Sound Hlth Care Syst, Dermatol 111D, Dept Dermatol, 1660 Columbian Way S, Seattle, WA 98108 USA.
EM gregory.raugi@va.gov
NR 35
TC 2
Z9 2
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD AUG
PY 2012
VL 67
IS 2
AR 177.e1
DI 10.1016/j.jaad.2012.03.023
PG 9
WC Dermatology
SC Dermatology
GA 973OD
UT WOS:000306368600011
PM 22794816
ER
PT J
AU Sundara-Rajan, K
Bestick, A
Rowe, GI
Klute, GK
Ledoux, WR
Wang, HC
Mamishev, AV
AF Sundara-Rajan, K.
Bestick, A.
Rowe, G. I.
Klute, G. K.
Ledoux, W. R.
Wang, H. C.
Mamishev, A. V.
TI An interfacial stress sensor for biomechanical applications
SO MEASUREMENT SCIENCE AND TECHNOLOGY
LA English
DT Article
DE biomechanical interfaces; prosthesis; capacitive sensor; interfacial
stress; pressure; sensor fabrication; shear stress
ID PROSTHETIC SOCKET INTERFACE; TIBIAL AMPUTEE SUBJECTS; SHEAR STRESSES;
PLANTAR SHEAR; RESIDUAL LIMB; PRESSURES; AMBULATION; SUCTION; FOOT; TIME
AB This paper presents a capacitive sensor that measures interfacial forces in prostheses and is promising for other biomedical applications. These sensors can be integrated into prosthetic devices to measure both normal and shear stress simultaneously, allowing for the study of prosthetic limb fit, and ultimately for the ability to better adapt prosthetics to individual users. A sensing cell with a 1.0 cm(2) spatial resolution and a measurement range of 0-220 kPa of shear and 0-2 MPa of pressure was constructed. The cell was load tested and found to be capable of isolating the applied shear and pressure forces. This paper discusses the construction of the prototype, the mechanical and electrode design, fabrication and characterization. The work presented is aimed at creating a class of adaptive prosthetic interfaces using a capacitive sensor.
C1 [Sundara-Rajan, K.; Bestick, A.; Rowe, G. I.; Mamishev, A. V.] Univ Washington, Dept Elect Engn, Sensors Energy & Automat Lab, Seattle, WA 98195 USA.
[Klute, G. K.; Ledoux, W. R.] VA Puget Sound Hlth Care Syst, Ctr Excellence Limb Loss Prevent & Prosthet Engn, Seattle, WA USA.
[Klute, G. K.; Ledoux, W. R.; Wang, H. C.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA.
[Ledoux, W. R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA.
RP Sundara-Rajan, K (reprint author), Univ Washington, Dept Elect Engn, Sensors Energy & Automat Lab, Seattle, WA 98195 USA.
EM kishore@u.washington.edu
RI Ledoux, William/K-6815-2015
OI Ledoux, William/0000-0003-4982-7714
FU US National Institute of Health [R21HD052109-02]; Department of Veterans
Affairs [A4843C]; Washington NASA Space Grant scholarships
FX The authors would like to thank Dan Hemmons, Anthony Simon, John
Thomson, Michael Fassbind and Shruti Pai for their help with sensor
fabrication and the force measurement systems used in the experiments
reported in this paper, and also STREAM Tools [47] for the guide to
formatting documents in Word, and Meagan Schuver, Kenneth Yuen and Aaron
Zielinski for editing. This work was supported in part by the US
National Institute of Health under Grant R21HD052109-02, the Department
of Veterans Affairs Grant A4843C and the Washington NASA Space Grant
scholarships.
NR 47
TC 7
Z9 7
U1 0
U2 21
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0957-0233
EI 1361-6501
J9 MEAS SCI TECHNOL
JI Meas. Sci. Technol.
PD AUG
PY 2012
VL 23
IS 8
AR 085701
DI 10.1088/0957-0233/23/8/085701
PG 10
WC Engineering, Multidisciplinary; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA 973NJ
UT WOS:000306366600053
ER
PT J
AU Yoon, J
Yano, EM
Altman, L
Cordasco, KM
Stockdale, SE
Chow, A
Barnett, PG
Rubenstein, LV
AF Yoon, Jean
Yano, Elizabeth M.
Altman, Lisa
Cordasco, Kristina M.
Stockdale, Susan E.
Chow, Adam
Barnett, Paul G.
Rubenstein, Lisa V.
TI Reducing Costs of Acute Care for Ambulatory Care-sensitive Medical
Conditions The Central Roles of Comorbid Mental Illness
SO MEDICAL CARE
LA English
DT Article
DE mental health; primary care; avoidable admissions; ED visits
ID HEALTH-CARE; PREVENTABLE HOSPITALIZATIONS; VETERANS-AFFAIRS;
COLLABORATIVE CARE; DEPRESSION; DISORDERS; BENEFICIARIES; QUALITY;
ACCESS; IMPACT
AB Background: New patient-centered models of ambulatory care aim to substitute better primary care for preventable acute care within existing primary care practices. This study aims to identify whether mental illness and other characteristics of primary care patients are related to risk for an acute event for an ambulatory care-sensitive condition (ACSC).
Methods: We conducted a 2-year, longitudinal analysis comparing ambulatory care-sensitive admissions and emergency department (ED) visits for a cohort of 18,526 primary care patients followed in 5 veterans affairs (VA) primary care sites. We compared rates, risks, and costs of ACSC-related acute events during a follow-up year for patients with and without mental illness seen during the previous year in primary care.
Results: The 12-month rate of ACSC admissions was 31.7 admissions per 1000 patients with mental health diagnoses compared with 21.0 admissions per 1000 patients without (P=0.0009). The ACSC-associated ED visit rate was also significantly higher (P<0.0001). In adjusted analyses controlling for demographics, chronic disease, illness severity, and prior ambulatory care, those with depression or drug use disorders had higher odds of receiving ACSC-related acute care (odds ratio=1.10, 95% confidence interval: 1.03, 1.17 for depression; odds ratio=1.48, 95% confidence interval: 1.05, 1.99 for drug use disorders). Costs per admission and ED visit were similar across patient groups. Higher medication use and lower medication regimen complexity were significantly associated with decreased risk for ACSC events.
Conclusions: Prior mental health diagnoses and medication use were independent risk factors for ACSC-related acute care. These risk factors require focused attention if the full benefits of new primary care models are to be achieved.
C1 [Yoon, Jean; Chow, Adam; Barnett, Paul G.] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA 94025 USA.
[Yano, Elizabeth M.; Cordasco, Kristina M.; Stockdale, Susan E.; Rubenstein, Lisa V.] VA Greater Los Angeles, Ctr Excellence Study Healthcare Provider Behav, North Hills, CA USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Altman, Lisa] VA Greater Los Angeles, Dept Ambulatory Care, North Hills, CA USA.
[Cordasco, Kristina M.; Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Cordasco, Kristina M.; Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA.
[Barnett, Paul G.] Stanford Univ, Hlth Res & Policy Dept, Stanford, CA 94305 USA.
RP Yoon, J (reprint author), VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA.
EM jean.yoon@va.gov
FU Department of Veteran Affairs, Veterans Health Administration, Patient
Care Services, the VA Improvement and Assessment Laboratory [XVA 65-018]
FX The authors declare no conflict of interest. Funding for this study was
provided by the Department of Veteran Affairs, Veterans Health
Administration, Patient Care Services, the VA Improvement and Assessment
Laboratory (Project XVA 65-018).
NR 47
TC 19
Z9 19
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD AUG
PY 2012
VL 50
IS 8
BP 705
EP 713
DI 10.1097/MLR.0b013e31824e3379
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 973KX
UT WOS:000306360100013
PM 22437618
ER
PT J
AU Doba, N
Tokuda, Y
Goldstein, NE
Kushiro, T
Hinohara, S
AF Doba, Nobutaka
Tokuda, Yasuharu
Goldstein, Nathan E.
Kushiro, Toshio
Hinohara, Shigeaki
TI A pilot trial to predict frailty syndrome: The Japanese Health Research
Volunteer Study
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE Frailty; Prediction; Gait speed; Pulse pressure; Cognitive deficits;
Hearing deficits
ID COMPREHENSIVE GERIATRIC ASSESSMENT; ANDROGEN-DEPRIVATION THERAPY;
DWELLING OLDER-PEOPLE; IANA TASK-FORCE; BODY-COMPOSITION;
PROSTATE-CANCER; GAIT SPEED; DISEASE; MANAGEMENT; PROMOTION
AB Most definitions of frailty utilize US populations in their development. The concept of frailty has not been well studied in Japan, which has the largest percentage of older patients ( per capita) in the world. We created a 5-year prospective cohort study of community-dwelling older Japanese adults. Participants were not frail at baseline, based on our definition adapted from the Canadian Study for Health and Aging Clinical Frailty Scale. Participants underwent a comprehensive geriatric assessment (CGA) at baseline, and final assessments were either in person or via mailed survey. We enrolled 407 individuals (184 men, mean age 78 +/- 4 years; 223 women, mean age 77 +/- 4 years). Sixty-five participants met criteria for frailty by the end of the study. In univariate analyses, eighteen separate parameters were associated with frailty, some of which included: age, gender, handgrip, timed walk, systolic blood pressure, pulse pressure, cognitive status, living alone, and hearing deficits. In multivariate analyses, the following elements remained associated with frailty: timed walk, pulse pressure, cognition deficits and hearing deficits. We established cut-off points for timed walk (5 m/3 s) and pulse pressure (60 mm Hg). We then created a simple additive score for these four factors (present = 1; absent = 0). A score of 0 had a 93% negative predictive value for frailty while a score of 4 had a 70% positive predictive value. While further study is needed, this work creates an easy-to-administer tool that may be generalizable to other populations. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Doba, Nobutaka] Sasakawa Kinen Kaikan, Life Planning Ctr Fdn, Div Res & Educ, Minato Ku, Tokyo 1080073, Japan.
[Tokuda, Yasuharu] Univ Tsukuba, Mito Kyodo Gen Hosp, Dept Med, Mito, Ibaraki 3100015, Japan.
[Goldstein, Nathan E.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Goldstein, Nathan E.] James J Peters VA Med Ctr Bronx, Bronx, NY USA.
[Kushiro, Toshio] Nihon Univ, Sch Med, Ctr Hlth Evaluat & Promot, Chiyoda Ku, Tokyo 1010062, Japan.
[Hinohara, Shigeaki] Sasakawa Kinen Kaikan, Life Planning Ctr Fdn, Minato Ku, Tokyo 1080073, Japan.
RP Doba, N (reprint author), Sasakawa Kinen Kaikan, Life Planning Ctr Fdn, Div Res & Educ, Minato Ku, 11th Floor,12-12,Mita 3 Chome, Tokyo 1080073, Japan.
EM doba@krd.biglobe.ne.jp; yasuharu.tokuda@gmail.com;
Nathan.goldstein@mssm.edu; Kushiro@med.nihon-u.ac.jp;
shosler@mrj.biglobe.ne.jp
FU Life Planning Center
FX The research reported in this paper was supported by the institutional
research fund from the Life Planning Center, a not-for-profit
organization. The authors have no conflict of interest to disclose. We
thank all the participants who joined the study as well as the members
of the study committee. Also we express our gratitude to other research
members at the LPC for their professional and technical assistance.
NR 43
TC 15
Z9 16
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
J9 EXP GERONTOL
JI Exp. Gerontol.
PD AUG
PY 2012
VL 47
IS 8
BP 638
EP 643
DI 10.1016/j.exger.2012.05.016
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 970CU
UT WOS:000306106500014
PM 22664579
ER
PT J
AU Rose, AJ
Petrakis, BA
Callahan, P
Mambourg, S
Patel, D
Hylek, EM
Bokhour, BG
AF Rose, Adam J.
Petrakis, Beth Ann
Callahan, Patricia
Mambourg, Scott
Patel, Dimple
Hylek, Elaine M.
Bokhour, Barbara G.
TI Organizational Characteristics of High- and Low-Performing
Anticoagulation Clinics in the Veterans Health Administration
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Qualitative research; quality of health care; anticoagulants;
pharmacists; organization and administration
ID VITAMIN-K ANTAGONISTS; THERAPY; WARFARIN; QUALITY
AB Objective Anticoagulation clinics (ACCs) can improve anticoagulation control and prevent adverse events. However, ACCs vary widely in their performance on anticoagulation control. Our objective was to compare the organization and management of top-performing with that of bottom-performing ACCs. Data Sources/Study Setting Three high outlier and three low outlier ACCs in the Veterans Health Administration (VA). Study Design Site visits with qualitative data collection and analysis. Data Collection/Extraction Methods We conducted semi-structured interviews with ACC staff regarding work flow, staffing, organization, and quality assurance efforts. We also observed ACC operations and collected documents, such as the clinic protocol. We used grounded thematic analysis to examine site-level factors associated with high and low outlier status. Principal Findings High outlier sites were characterized by (1) adequate (pharmacist) staffing and effective use of (nonpharmacist) support personnel; (2) innovation to standardize clinical practice around evidence-based guidelines; (3) the presence of a quality champion for the ACC; (4) higher staff qualifications; (5) a climate of ongoing group learning; and (6) internal efforts to measure performance. Although high outliers had all of these features, no low outlier had more than two of them. Conclusions The top-performing ACCs in the VA system shared six relatively recognizable characteristics. Efforts to improve performance should focus on these domains.
C1 [Rose, Adam J.; Petrakis, Beth Ann; Hylek, Elaine M.; Bokhour, Barbara G.] Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA.
[Rose, Adam J.; Hylek, Elaine M.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA.
[Rose, Adam J.; Petrakis, Beth Ann; Callahan, Patricia; Mambourg, Scott; Patel, Dimple; Hylek, Elaine M.; Bokhour, Barbara G.] US Dept Vet Affairs, Washington, DC USA.
[Bokhour, Barbara G.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
RP Rose, AJ (reprint author), Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, 200 Springs Rd,Bldg 70, Bedford, MA 01730 USA.
EM adamrose@bu.edu
OI Bokhour, Barbara/0000-0001-8238-0745
FU VA Stroke Quality Enhancement Research Initiative (QUERI) [RRP-10-054];
VA HSR&D Career Development Award [CDA-2-08-017]
FX This study was funded by the VA Stroke Quality Enhancement Research
Initiative (QUERI), Project RRP-10-054. Dr. Rose is supported by a VA
HSR&D Career Development Award (CDA-2-08-017). The authors thank Russell
Buono, Mitchell Finkel, Elizabeth Goy, and Anthony Vo for their help
collecting the data. The authors thank Steve Spear, Rani Elwy, Dan
Berlowitz, Arlene Ash, and Vicky Parker for their helpful comments on
the manuscript. The authors thank all the interviewees for
participating.
NR 19
TC 15
Z9 15
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD AUG
PY 2012
VL 47
IS 4
BP 1541
EP 1560
DI 10.1111/j.1475-6773.2011.01377.x
PG 20
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 970OL
UT WOS:000306141500009
PM 22299722
ER
PT J
AU Kaplan, RC
Landay, AL
Hodis, HN
Gange, SJ
Norris, PJ
Young, M
Anastos, K
Tien, PC
Xue, XN
Lazar, J
Parrinello, CM
Benning, L
Tracy, RP
AF Kaplan, Robert C.
Landay, Alan L.
Hodis, Howard N.
Gange, Stephen J.
Norris, Philip J.
Young, Mary
Anastos, Kathryn
Tien, Phyllis C.
Xue, Xiaonan
Lazar, Jason
Parrinello, Christina M.
Benning, Lorie
Tracy, Russell P.
TI Potential Cardiovascular Disease Risk Markers Among HIV-Infected Women
Initiating Antiretroviral Treatment
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE antiretroviral therapy; cardiovascular diseases; cytokines; hemostasis;
HIV; inflammation
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; INTIMA-MEDIA THICKNESS;
T-CELL-ACTIVATION; INTERAGENCY HIV; CAROTID-ARTERY; COAGULATION
BIOMARKERS; THERAPY EXPOSURE; SOLUBLE CD14; COHORT; ATHEROSCLEROSIS
AB Background: Inflammation and hemostasis perturbation may be involved in vascular complications of HIV infection. We examined atherogenic biomarkers and subclinical atherosclerosis in HIV-infected adults before and after beginning highly active antiretroviral therapy (HAART).
Methods: In the Women's Interagency HIV Study, 127 HIV-infected women studied pre and post HAART were matched to HIV-uninfected controls. Six semiannual measurements of soluble CD14, tumor necrosis factor (TNF) alfa, soluble interleukin (IL) 2 receptor, IL-6, IL-10, monocyte chemoattractant protein 1, D-dimer, and fibrinogen were obtained. Carotid artery intima-media thickness was measured by B-mode ultrasound.
Results: Relative to HIV-uninfected controls, HAART-naive HIVinfected women had elevated levels of soluble CD14 (1945 vs 1662 ng/mL, Wilcoxon signed rank P < 0.0001), TNF-alpha (6.3 vs 3.4 pg/mL, P < 0.0001), soluble IL-2 receptor (1587 vs 949 pg/mL, P < 0.0001), IL-10 (3.3 vs 1.9 pg/mL, P < 0.0001), monocyte chemo-attractant protein 1 (190 vs 163 pg/mL, P, 0.0001), and D-dimer (0.43 vs 0.31 mu g/mL, P < 0.01). Elevated biomarker levels declined after HAART. Although most biomarkers normalized to HIV-uninfected levels, in women on effective HAART, TNF-alpha levels remained elevated compared with HIV-uninfected women (+ 0.8 pg/mL, P = 0.0002). Higher post-HAART levels of soluble IL-2 receptor (P = 0.02), IL-6 (P = 0.05), and D-dimer (P = 0.03) were associated with increased carotid artery intima-media thickness.
Conclusions: Untreated HIV infection is associated with abnormal hemostasis (eg, D-dimer), proatherogenic (eg, TNF-alpha), and antiatherogenic (eg, IL-10) inflammatory markers. HAART reduces most inflammatory mediators to HIV-uninfected levels. Increased inflammation and hemostasis are associated with subclinical atherosclerosis in recently treated women. These findings have potential implications for long-term risk of cardiovascular disease in HIV-infected patients, even with effective therapy.
C1 [Kaplan, Robert C.; Anastos, Kathryn; Xue, Xiaonan; Parrinello, Christina M.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA.
[Landay, Alan L.] Rush Univ, Med Ctr, Dept Immunol Microbiol, Chicago, IL USA.
[Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA 90089 USA.
[Gange, Stephen J.; Benning, Lorie] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Norris, Philip J.] Univ Calif San Francisco, Dept Lab Med, Blood Syst Res Inst, San Francisco, CA 94143 USA.
[Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA.
[Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Lazar, Jason] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA.
[Tracy, Russell P.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA.
[Tracy, Russell P.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
RP Kaplan, RC (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, 1300 Morris Pk Ave,Belfer 1306C, Bronx, NY 10461 USA.
EM Robert.kaplan@einstein.yu.edu
OI Gange, Stephen/0000-0001-7842-512X
FU National Institutes of Health; National Institute of Allergy and
Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994,
UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver
National Institute of Child Health and Human Development [UO1-HD-32632];
National Cancer Institute; National Institute on Drug Abuse; National
Institute on Deafness and Other Communication Disorders; National Center
for Research Resources (UCSF-CTSI) [UL1 RR024131]; National Heart, Lung
and Blood Institute [1R01HL095140, 1R01HL083760]; University of
Washington's CVD and Metabolic Complications of HIV/AIDS Data
Coordinating Center [5R01HL095126]
FX Supported by the National Institutes of Health. The Women's Interagency
HIV Study is funded by the National Institute of Allergy and Infectious
Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989,
UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver
National Institute of Child Health and Human Development (UO1-HD-32632).
The study was cofunded by the National Cancer Institute, the National
Institute on Drug Abuse, and the National Institute on Deafness and
Other Communication Disorders. Funding was also provided by the National
Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131).
Additional cofunding was provided by the National Heart, Lung and Blood
Institute (1R01HL095140, 1R01HL083760 to R.C.K.). Partial funding for
laboratory work and assistance with general study coordination was
provided by the University of Washington's CVD and Metabolic
Complications of HIV/AIDS Data Coordinating Center (5R01HL095126).
NR 36
TC 25
Z9 26
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2012
VL 60
IS 4
BP 359
EP 368
DI 10.1097/QAI.0b013e31825b03be
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 971YF
UT WOS:000306242300010
PM 22592585
ER
PT J
AU Medapalli, RK
Parikh, CR
Gordon, K
Brown, ST
Butt, AA
Gibert, CL
Rimland, D
Rodriguez-Barradas, MC
Chang, CCH
Justice, AC
He, JCJ
Wyatt, CM
AF Medapalli, Raj K.
Parikh, Chirag R.
Gordon, Kirsha
Brown, Sheldon T.
Butt, Adeel A.
Gibert, Cynthia L.
Rimland, David
Rodriguez-Barradas, Maria C.
Chang, Chung-Chou H.
Justice, Amy C.
He, John Cijiang
Wyatt, Christina M.
TI Comorbid Diabetes and the Risk of Progressive Chronic Kidney Disease in
HIV-Infected Adults: Data From the Veterans Aging Cohort Study
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE non-AIDS complications; HIV; chronic kidney disease; diabetes; risk
factors
ID GLOMERULAR-FILTRATION-RATE; CORONARY-HEART-DISEASE; ANTIRETROVIRAL
THERAPY; DATA-COLLECTION; ADVERSE EVENTS; HEPATITIS-C; MELLITUS; RATES
AB Introduction: Approximately, 15% of HIV-infected individuals have comorbid diabetes. Studies suggest that HIV and diabetes have an additive effect on chronic kidney disease (CKD) progression; however, this observation may be confounded by differences in traditional CKD risk factors.
Methods: We studied a national cohort of HIV-infected and matched HIV-uninfected individuals who received care through the Veterans Healthcare Administration. Subjects were divided into 4 groups based on baseline HIV and diabetes status, and the rate of progression to an estimated glomerular filtration rate (eGFR) <45 mL/min/ 1.73m(2) was compared using Cox-proportional hazards modeling to adjust for CKD risk factors.
Results: About 31,072 veterans with baseline eGFR >= 45 mL/min/1.73m(2) (10,626 with HIV only, 5088 with diabetes only, and 1796 with both) were followed for a median of 5 years. Mean baseline eGFR was 94 mL/min/1.73m(2), and 7% progressed to an eGFR < 45 mL/min/1.73m(2). Compared with those without HIV or diabetes, the relative rate of progression was increased in individuals with diabetes only [adjusted hazard ratio (HR) 2.48; 95% confidence interval (CI): 2.19 to 2.80], HIV only [HR: 2.80, 95% CI: 2.50 to 3.15], and both HIV and diabetes [HR: 4.47, 95% CI: 3.87 to 5.17].
Discussion: Compared with patients with only HIV or diabetes, patients with both diagnoses are at significantly increased risk of progressive CKD even after adjusting for traditional CKD risk factors. Future studies should evaluate the relative contribution of complex comorbidities and accompanying polypharmacy to the risk of CKD in HIV-infected individuals and prospectively investigate the use of cART, glycemic control, and adjunctive therapy to delay CKD progression.
C1 [Medapalli, Raj K.; He, John Cijiang; Wyatt, Christina M.] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA.
[Parikh, Chirag R.] Yale Univ, Dept Med, Nephrol Sect, New Haven, CT 06520 USA.
[Parikh, Chirag R.; Gordon, Kirsha] W Haven VA Med Ctr, Clin Epidemiol Res Ctr, West Haven, CT USA.
[Brown, Sheldon T.] James J Peters VA Med Ctr, Dept Med, Div Infect Dis, Bronx, NY USA.
[Brown, Sheldon T.] Mt Sinai Sch Med, Dept Med, Div Infect Dis, New York, NY 10029 USA.
[Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Dept Med, Div Infect Dis, Pittsburgh, PA USA.
[Butt, Adeel A.] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA USA.
[Butt, Adeel A.] Dept Med, Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates.
[Gibert, Cynthia L.] VA Med Ctr, Dept Med, Div Infect Dis, Washington, DC USA.
[Gibert, Cynthia L.] George Washington Univ, Med Ctr, Dept Med, Div Infect Dis, Washington, DC 20037 USA.
[Rimland, David] VA Med Ctr, Dept Med, Div Infect Dis, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Dept Med, Infect Dis Sect, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA.
[Justice, Amy C.] W Haven VA Med Ctr, Dept Med, New Haven, CT USA.
[He, John Cijiang] James J Peters VA Med Ctr, Dept Med, Div Nephrol, Bronx, NY USA.
RP Wyatt, CM (reprint author), Mt Sinai Sch Med, Dept Med, Div Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA.
EM christina.wyatt@mssm.edu
FU National Institutes of Health, National Institute of Alcohol and Alcohol
Abuse [U01 AA13566]; Office of Research and Development, Department of
Veterans Affairs; National Institute of Diabetes and Digestive and
Kidney Disease [P01DK056492, R01DK088541, R01DK078897, K23DK077568]
FX The Veterans Aging Cohort Study is supported by the National Institutes
of Health, National Institute of Alcohol and Alcohol Abuse (U01 AA13566)
and by the Office of Research and Development, Department of Veterans
Affairs. This work was also supported in part by the National Institute
of Diabetes and Digestive and Kidney Disease (P01DK056492, R01DK088541,
R01DK078897, and K23DK077568).
NR 22
TC 24
Z9 24
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2012
VL 60
IS 4
BP 393
EP 399
DI 10.1097/QAI.0b013e31825b70d9
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 971YF
UT WOS:000306242300014
PM 22592587
ER
PT J
AU Abraham, BP
Mehta, S
El-Serag, HB
AF Abraham, Bincy P.
Mehta, Seema
El-Serag, Hashem B.
TI Natural History of Pediatric-onset Inflammatory Bowel Disease A
Systematic Review
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Review
DE natural history; pediatric IBD; long-term risk; growth failure; disease
reclassification; disease extension; hospitalization; cancer; death
ID POPULATION-BASED COHORT; 10 YEARS OLD; CROHNS-DISEASE;
ULCERATIVE-COLITIS; GROWTH FAILURE; CLINICAL-FEATURES; ADULT LIFE;
FOLLOW-UP; CHILDREN; PROGNOSIS
AB Background/Aims: There has been no systematic review of natural history studies of pediatric-onset inflammatory bowel disease (IBD). We conducted a systematic review focused on understanding the long-term risks of growth failure, disease reclassification and extension, hospitalizations, cancer and death among patients with childhood IBD.
Methods: PubMed searches and subsequent data abstraction were performed by 2 independent investigators. Studies published full in english with a 5-year minimum average follow-up in at least 30 patients with IBD onset before age 18 years.
Results: We evaluated 41 total studies (only 2 population-based studies) with 3505 Crohn's disease (CD) patients, 2071 ulcerative colitis (UC) patients, and 461 indeterminate colitis (IC). Growth failure was reported in CD (10% and 56%) more often than UC (0% to 10%) or non-IBD controls. Improvements in growth occurred after surgical resection in patients with CD. There was an increase in disease reclassification over time from UC and indeterminate colitis diagnosis to CD diagnosis. Patients with CD had higher number of hospitalizations and hospital days per year in comparison with UC patients in most studies. The reported surgery rates in CD ranged between 10% and 72%; the colectomy rates in UC ranged between 0% and 50%. Cancers were reported in 6 CD patients during a total 18,270 patient-years (PY) follow-up, and 8 UC patients in 18,115 PY. Deaths directly related to IBD were 63 during 39,719 PY.
Conclusions: Childhood-onset IBD patients had growth failure reported in patients with CD more often than those with UC, had a reclassification of disease type to CD over time. Higher rates of surgery and hospitalizations were found with CD than with UC. The risk of cancer and death is low in this population.
C1 [Abraham, Bincy P.; Mehta, Seema; El-Serag, Hashem B.] Texas Childrens Hosp, Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Abraham, BP (reprint author), 1709 Dryden St,Suite 800, Houston, TX 77030 USA.
EM bincya@bcm.edu
FU Houston VA HSR&D Center of Excellence [HFP90-020]; NIH/National
Institute of Diabetes and Digestive and Kidney Disease, Center [P30
DK56338]
FX Supported by Houston VA HSR&D Center of Excellence (HFP90-020) and
NIH/National Institute of Diabetes and Digestive and Kidney Disease,
Center Grant P30 DK56338.
NR 58
TC 40
Z9 43
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0192-0790
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD AUG
PY 2012
VL 46
IS 7
BP 581
EP 589
DI 10.1097/MCG.0b013e318247c32f
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 972OY
UT WOS:000306287600010
PM 22772738
ER
PT J
AU Demetriou, SK
Ona-Vu, K
Teichert, AE
Cleaver, JE
Bikle, DD
Oh, DH
AF Demetriou, Stephanie K.
Ona-Vu, Katherine
Teichert, Arnaud E.
Cleaver, James E.
Bikle, Daniel D.
Oh, Dennis H.
TI Vitamin D Receptor Mediates DNA Repair and Is UV Inducible in Intact
Epidermis but Not in Cultured Keratinocytes
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Letter
ID MOUSE SKIN; DOSE UVB; GENE; SUSCEPTIBILITY; EXPRESSION; PROTEIN; MICE
C1 [Demetriou, Stephanie K.; Ona-Vu, Katherine; Oh, Dennis H.] San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA 94121 USA.
[Demetriou, Stephanie K.; Ona-Vu, Katherine; Cleaver, James E.; Bikle, Daniel D.; Oh, Dennis H.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Teichert, Arnaud E.; Bikle, Daniel D.] San Francisco VA Med Ctr, Endocrine Unit, San Francisco, CA USA.
[Bikle, Daniel D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Demetriou, SK (reprint author), San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA 94121 USA.
EM ohd@derm.ucsf.edu
FU BLRD VA [I01 BX001066]; NIAMS NIH HHS [R01AR050023, R01 AR050023, R01
AR050023-05]
NR 15
TC 18
Z9 18
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD AUG
PY 2012
VL 132
IS 8
BP 2097
EP 2100
DI 10.1038/jid.2012.107
PG 4
WC Dermatology
SC Dermatology
GA 974CT
UT WOS:000306408100024
PM 22495177
ER
PT J
AU Hirschmann, JV
Raugi, GJ
AF Hirschmann, Jan V.
Raugi, Gregory J.
TI Lower limb cellulitis and its mimics Part I. Lower limb cellulitis
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE beta-hemolytic streptococci; Cryptococcus neoformans; Gram-negative
bacilli; lower limb cellulitis; Staphylococcus aureus; Streptococcus
pneumoniae
ID SOFT-TISSUE INFECTIONS; LOWER-EXTREMITY CELLULITIS;
FINE-NEEDLE-ASPIRATION; BETA-HEMOLYTIC STREPTOCOCCI; RANDOMIZED
CONTROLLED-TRIAL; GRAM-NEGATIVE CELLULITIS; CORONARY-BYPASS SURGERY;
ACUTE LEG CELLULITIS; RECURRENT ERYSIPELAS; RISK-FACTORS
AB An aging population and obesity have both contributed to a rising incidence of lower limb cellulitis; the most important predisposing factors include older age, obesity, venous insufficiency, saphenous venectomy, and edema. Streptococci are the most commonly implicated pathogen, and often reside in the interdigital toes spaces. Any disruption of the skin surface can allow the organism to invade. Effective management requires an appropriate antibiotic and attention to the predisposing factors. This article summarizes the epidemiology and treatment of this common infection. (J Am Acad Dermatol 2012; 67: 163. e1-12.)
C1 [Raugi, Gregory J.] VA Puget Sound Hlth Care Syst, Dermatol 111D, Dept Dermatol, Seattle, WA 98108 USA.
Univ Washington, Sch Med, Seattle, WA USA.
RP Raugi, GJ (reprint author), VA Puget Sound Hlth Care Syst, Dermatol 111D, Dept Dermatol, 1660 Columbian Way S, Seattle, WA 98108 USA.
EM gregory.raugi@va.gov
NR 111
TC 0
Z9 1
U1 2
U2 11
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD AUG
PY 2012
VL 67
IS 2
AR 163.e1
DI 10.1016/j.jaad.2012.03.024
PG 12
WC Dermatology
SC Dermatology
GA 973OD
UT WOS:000306368600010
PM 22794815
ER
PT J
AU Hawkins, EJ
Grossbard, J
Benbow, J
Nacev, V
Kivlahan, DR
AF Hawkins, Eric J.
Grossbard, Joel
Benbow, Jim
Nacev, Vladimir
Kivlahan, Daniel R.
TI Evidence-Based Screening, Diagnosis, and Treatment of Substance Use
Disorders Among Veterans and Military Service Personnel
SO MILITARY MEDICINE
LA English
DT Article
AB Substance use disorders (SUDs) are among the most common and costly conditions in veterans and active duty military personnel, adversely affecting their health and occupational and personal functioning. The pervasive burden of SUD has been a continuing concern for the Department of Veterans Affairs (VA) and Department of Defense (DoD), particularly as large numbers of service members return from Operations Enduring and Iraqi Freedom. The VA and DoD have prioritized implementation of evidence-based practices and treatment services to enhance the recognition and management of SUD in general medical and SUD specialty-care settings. This article summarizes the clinical practice guidelines for identifying, diagnosing, and treating SUD in VA and DoD general medical and SUD specialty-care settings, highlights evidence-based pharmacotherapy and psychosocial interventions for managing SUD, and describes barriers to successful treatment of veterans and service members at risk for SUD in VA and DoD health care systems.
C1 [Hawkins, Eric J.; Grossbard, Joel; Benbow, Jim; Kivlahan, Daniel R.] VA Puget Sound Healthcare Syst, Ctr Excellence Substance Abuse Treatment & Educ, Hlth Serv Res & Dev, Seattle, WA 98108 USA.
[Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Nacev, Vladimir] Def Ctr Excellence Psychol Hlth & Traumat Brain I, Resilience & Prevent Directorate, Silver Spring, MD 20910 USA.
RP Hawkins, EJ (reprint author), VA Puget Sound Healthcare Syst, Ctr Excellence Substance Abuse Treatment & Educ, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA.
NR 75
TC 9
Z9 9
U1 2
U2 5
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD AUG
PY 2012
VL 177
IS 8
SU S
SI SI
BP 29
EP 38
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA V33OB
UT WOS:000209027000006
PM 22953439
ER
PT J
AU Tollison, SJ
Henderson, RC
Baer, JS
Saxon, AJ
AF Tollison, Sean J.
Henderson, Ryan C.
Baer, Johns S.
Saxon, Andrew J.
TI Next Steps in Addressing the Prevention, Screening, and Treatment of
Substance Use Disorder in Active Duty and Veteran Operation Enduring
Freedom and Operation Iraqi Freedom Populations
SO MILITARY MEDICINE
LA English
DT Article
AB The two articles presented previously in this volume provide state-of-the-art reviews of the etiology, epidemiology, screening and treatment of substance use disorder (SUD). This article identifies next steps in research and development for understanding and treating SUD in Operation Enduring Freedom/Operation Iraqi Freedom service members and veterans. Four promising areas are reviewed: advances in psychopharmacological treatment of SUD, innovations in behavioral treatments, the use of technological advances for the screening and treatment of SUD, and integration of treatment services. Future directions are explored and suggestions for research, development and implementation of each of these trends are discussed.
C1 [Tollison, Sean J.; Henderson, Ryan C.; Baer, Johns S.; Saxon, Andrew J.] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA 98108 USA.
RP Tollison, SJ (reprint author), VA Puget Sound Hlth Care Syst, CESATE, 1660 South Columbian Way, Seattle, WA 98108 USA.
FU Center of Excellence in Substance Abuse Treatment and Education at VA
Puget Sound Health Care System; Research and Development Service,
Department of Veterans Affairs
FX This work was supported by the Center of Excellence in Substance Abuse
Treatment and Education at VA Puget Sound Health Care System and by the
Research and Development Service, Department of Veterans Affairs.
NR 68
TC 1
Z9 1
U1 2
U2 3
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD AUG
PY 2012
VL 177
IS 8
SU S
SI SI
BP 39
EP 46
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA V33OB
UT WOS:000209027000007
PM 22953440
ER
PT J
AU Zhang, XY
Chen, DC
Xiu, MH
Tang, W
Zhang, FX
Liu, LJ
Chen, YL
Liu, JH
Yao, JK
Kosten, TA
Kosten, TR
AF Zhang, Xiang Yang
Chen, Da Chun
Xiu, Mei Hong
Tang, Wei
Zhang, Feixue
Liu, LianJing
Chen, Yuanling
Liu, JiaHong
Yao, Jeffrey K.
Kosten, Therese A.
Kosten, Thomas R.
TI Plasma total antioxidant status and cognitive impairments in
schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Cognition; Oxidative stress; Psychopathology
ID SUPEROXIDE DISMUTASE/CATALASE MIMETICS; BRAIN OXIDATIVE STRESS;
FREE-RADICAL PATHOLOGY; AGE-RELATED-CHANGES; NEUROPSYCHOLOGICAL
PROFILES; THERAPEUTIC IMPLICATIONS; REPEATABLE BATTERY;
TARDIVE-DYSKINESIA; LIPID-PEROXIDATION; DIFFERENT FORMS
AB Oxidative stress-induced damage to neurons may contribute to cognitive deficits during aging and in neurodegenerative disorders. Schizophrenia has a range of cognitive deficits that may evolve from oxidative stress, and this study examines this association of oxidative stress with cognitive deficits in schizophrenia. We recruited 296 chronic schizophrenia patients and 181 healthy control subjects and examined the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and plasma total antioxidant status (TAS) in both groups. Schizophrenia symptoms were assessed using the positive and negative syndrome scale (PANSS). Our results showed that TAS levels were significantly lower in patients than controls (179.6 +/- 81.0 U/ml vs. 194.8 +/- 46.0 U/ml, p<0.05). Cognitive scores on the RBANS and nearly all of its five subscales (all p<0.001) except for the Visuospatial/Constructional index (p>0.05) were significantly lower in schizophrenia patients than normal controls. For the patients, TAS was inversely associated with some domains of cognitive deficits in schizophrenia, such as Attention and Immediate Memory. Our findings suggest that oxidative stress may be involved in the pathophysiology of schizophrenia, and its associated cognitive impairment. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zhang, Xiang Yang; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Zhang, Xiang Yang; Chen, Da Chun; Xiu, Mei Hong; Kosten, Thomas R.] Beijing Hui Long Guan Hosp, Psychiat Res Ctr, Beijing, Peoples R China.
[Tang, Wei; Zhang, Feixue; Liu, LianJing; Chen, Yuanling; Liu, JiaHong] Kangning Hosp, Dept Psychiat, Wenzhou, Zhejiang, Peoples R China.
[Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Yao, Jeffrey K.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu; kosten@bcm.edu
FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of
Veterans Affairs; VISN 16; Mental Illness Research, Education and
Clinical Center (MIRECC), United States National Institute of Health
[K05-DA0454, P50-DA18827, U01-MH79639]
FX Funding for this study was provided by grants from the Stanley Medical
Research Institute (03T-459 and 05T-726), and the Department of Veterans
Affairs, VA Senior Research Career Scientist Award (JKY), VISN 16,
Mental Illness Research, Education and Clinical Center (MIRECC), United
States National Institute of Health K05-DA0454, P50-DA18827 and
U01-MH79639. These sources had no further role in study design; in the
collection, analysis and interpretation of data; in the writing of the
report; and in the decision to submit the paper for publication. The
contents of this article do not represent the views of the VA or the
United States Government.
NR 71
TC 27
Z9 28
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD AUG
PY 2012
VL 139
IS 1-3
BP 66
EP 72
DI 10.1016/j.schres.2012.04.009
PG 7
WC Psychiatry
SC Psychiatry
GA 970JO
UT WOS:000306124400011
PM 22555016
ER
PT J
AU Lin, YC
Wynn, JK
Hellemann, G
Green, MF
AF Lin, Yu-chung
Wynn, Jonathan K.
Hellemann, Gerhard
Green, Michael F.
TI Factor structure of emotional intelligence in schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; MSCEIT; Emotional intelligence; Factor analysis
ID PSYCHIATRIC RATING-SCALE; QUALITY-ASSURANCE; SOCIAL COGNITION
AB Social cognition, which includes emotional intelligence, is impaired in schizophrenia. The Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) is a widely-used assessment of emotional intelligence, with a four-factor structure in healthy individual. However, a recent factor analysis in schizophrenia patients revealed a two-factor structure of the MSCEIT. The current study aimed to replicate this finding in a larger, more diverse, schizophrenia sample (n=194). Our findings revealed an identical two-factor structure as in the previously-reported study, indicating that emotional intelligence is organized in a different manner in schizophrenia than it is in healthy controls. Published by Elsevier B.V.
C1 [Wynn, Jonathan K.; Green, Michael F.] MIRECC, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Wynn, Jonathan K.; Hellemann, Gerhard; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
[Lin, Yu-chung] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan.
RP Wynn, JK (reprint author), MIRECC, VA Greater Los Angeles Healthcare Syst, Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jkwynn@ucla.edu
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
FU National Institute of Mental Health [MH043292]
FX Funding for this study was provided by the National Institute of Mental
Health grant MH043292 to Michael F. Green. The funding agency had no
further role in the analysis or interpretation of data, in writing the
report, or in the decision to submit the paper for publication.
NR 19
TC 9
Z9 10
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
EI 1573-2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD AUG
PY 2012
VL 139
IS 1-3
BP 78
EP 81
DI 10.1016/j.schres.2012.04.013
PG 4
WC Psychiatry
SC Psychiatry
GA 970JO
UT WOS:000306124400013
PM 22584064
ER
PT J
AU Holman, KM
Wolff, M
Sena, AC
Martin, DH
Behets, F
Van Damme, K
Leone, P
McNeil, L
Gehrig, ML
Hook, EW
AF Holman, Katherine M.
Wolff, Mark
Sena, Arlene C.
Martin, David H.
Behets, Frieda
Van Damme, Kathleen
Leone, Peter
McNeil, Linda
Gehrig, Meredyth L.
Hook, Edward W., III
TI Rapid Plasma Reagin Titer Variation in the 2 Weeks After Syphilis
Therapy
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
AB Background: Serologic tests for syphilis results at the time of diagnosis are the basis for evaluating response to syphilis therapy. After treatment, however, serologic tests for syphilis titers may continue to increase for several weeks. We evaluated rapid plasma reagin (RPR) titer variation during the 14 days after therapy using data from a recent large, prospective randomized controlled trial.
Methods: Prospectively enrolled participants in North America and Madagascar with primary, secondary, or early latent syphilis were randomly assigned to penicillin, doxycycline (in the case of penicillin allergy), or azithromycin treatment. Blood for RPR analysis was drawn at days 0, 7, and 14 posttreatment. All RPR titers were determined simultaneously at a central laboratory.
Results: Four hundred and seventy patients had data available for at least 2 of 3 RPR measurements. Overall, 20% of patients showed a titer increase of at least 1 dilution in the 14 days after therapy. The greatest proportion of titer increases following therapy was observed in patients with primary syphilis. Comparing outcome of therapy using the initial (day 0) RPR titer versus the maximal RPR titer (during 14 days) resulted in outcome reclassification in 2.98% of participants.
Conclusions: Despite the fact that about 20% of early syphilis patients had increases in RPR titers immediately after treatment, these changes rarely influenced assessment of therapeutic outcome. Only 3% of patients treated would have been reclassified.
C1 [Holman, Katherine M.; Hook, Edward W., III] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA.
[Holman, Katherine M.] Birmingham VA Med Ctr, Dept Qual Management, Birmingham, AL USA.
[Wolff, Mark; Gehrig, Meredyth L.] Emmes Corp, Rockville, MD USA.
[Sena, Arlene C.; Behets, Frieda; Leone, Peter] Univ N Carolina, Dept Med, Div Infect Dis, Chapel Hill, NC USA.
[Martin, David H.] Louisiana State Univ, Div Infect Dis, Dept Med, Baton Rouge, LA 70803 USA.
[Behets, Frieda; Van Damme, Kathleen] Univ N Carolina Madagascar, Dept Med, Antananarivo, Madagascar.
[Behets, Frieda; Van Damme, Kathleen] Univ N Carolina Madagascar, Dept Epidemiol, Antananarivo, Madagascar.
[McNeil, Linda] Family Hlth Int, Res Triangle Pk, NC 27709 USA.
RP Holman, KM (reprint author), Univ Alabama Birmingham, Div Infect Dis, Dept Med, 1900 Univ Blvd,THT 229, Birmingham, AL 35294 USA.
EM holmkm@uab.edu; ehook@uab.edu
FU National Institute of Allergy and Infectious Diseases at the National
Institutes of Health [N01 A1 75329]; STI Clinical Trials Group [HHSN
26620040073C]; GSK; Abbott Diagnostics; Norvartis; Trinity Diagnostics;
GenProbe; Becton-Dickinson; Roche Molecular Diagnostics; Siemens
Diagnostics
FX Supported by the National Institute of Allergy and Infectious Diseases
at the National Institutes of Health (grant number N01 A1 75329, Myron
Cohen, MD, PI) and the STI Clinical Trials Group (grant number HHSN
26620040073C, Edward W. Hook, III, MD, PI).; K.H., M. W., A. S., F. B.,
K. V. D, L. M., and M. G. declare no conflict of interest. D. M. is a
share holder in Merck and has been a consultant to Cempra Pharma. P. L.
has received research funding from GSK, Abbott Diagnostics, Norvartis
and Trinity Diagnostics and has been on the speakers' bureaus for GSK,
Norvartis and Abbott Diagnostics. E. W. has received research funding
from GenProbe, Becton-Dickinson, Roche Molecular Diagnostics, Siemens
Diagnostics, and has been on the speakers' bureaus for GSK, Norvartis
and Abbott Diagnostics.
NR 7
TC 5
Z9 5
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-5717
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD AUG
PY 2012
VL 39
IS 8
BP 645
EP 647
DI 10.1097/OLQ.0b013e3182536574
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 974FA
UT WOS:000306414300013
PM 22801348
ER
PT J
AU Kargi, AY
Merriam, GR
AF Kargi, Atil Y.
Merriam, George R.
TI Testing for growth hormone deficiency in adults: doing without growth
hormone-releasing hormone
SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
LA English
DT Review
DE growth hormone; growth hormone deficiency; growth hormone stimulation
testing
ID INSULIN TOLERANCE-TEST; GLUCAGON STIMULATION TEST; BONE-MINERAL DENSITY;
IGF-I LEVELS; GH-DEFICIENCY; (GH)-RELEASING HORMONE; REPLACEMENT
THERAPY; PITUITARY DISEASE; CUTOFF LIMITS; PLUS ARGININE
AB Purpose of review
This article summarizes recent advances in testing for growth hormone deficiency (GHD) in adults, focusing on critical appraisal of existing growth hormone (GH) provocative tests as well as newer tests in development.
Recent findings
The diagnosis of GHD can be challenging and often requires the use of GH provocative testing. The most widely validated of these is insulin-induced hypoglycemia (ITT), which requires close supervision and has significant contraindications and side-effects. The arginine-growth hormone-releasing hormone (GHRH) test had become widely used as a safe and accurate alternative to the ITT, but GHRH is currently unavailable for clinical use in the USA. On the basis of review of recent literature we recommend that in the absence of GHRH, glucagon stimulation testing should be the preferred alternative to ITT. Several synthetic GH secretagogues that mimic the gastric peptide ghrelin are currently in development and may become available for use in the diagnosis of GHD in the near future. Other GH provocative tests suitable for use in children lack adequate specificity for the diagnosis of GHD in adults.
Summary
Due to the current unavailability of the arginine-GHRH test in the USA, when ITT is contraindicated or impractical we recommend the glucagon stimulation testing as the GH provocative test of choice. There remains a need for a simple, safe and accurate test for the diagnosis of GHD.
C1 [Kargi, Atil Y.] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Miami, FL 33136 USA.
[Merriam, George R.] Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, VA Puget Sound Hlth Care Syst, Seattle, WA 98493 USA.
RP Merriam, GR (reprint author), VA Puget Sound Healthcare Syst A 151, Seattle, WA 98493 USA.
EM merriam@uw.edu
FU Ardana Biosciences; Aeterna Zentaris
FX A.Y.K. has nothing to disclose. G. R. M. received research grant support
from Ardana Biosciences and from Aeterna Zentaris.
NR 62
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1752-296X
EI 1752-2978
J9 CURR OPIN ENDOCRINOL
JI Curr. Opin. Endocrinol. Diabetes Obes.
PD AUG
PY 2012
VL 19
IS 4
BP 300
EP 305
DI 10.1097/MED.0b013e32835430da
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 970FX
UT WOS:000306114600008
PM 22596248
ER
EF